<SEC-DOCUMENT>0001564590-21-010726.txt : 20210304
<SEC-HEADER>0001564590-21-010726.hdr.sgml : 20210304
<ACCEPTANCE-DATETIME>20210304072625
ACCESSION NUMBER:		0001564590-21-010726
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210304
DATE AS OF CHANGE:		20210304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dyne Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001818794
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				364883909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39509
		FILM NUMBER:		21712573

	BUSINESS ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(781) 786-8230

	MAIL ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dyn-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> (Mark&#160;One) </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number:&#160;<font style="color:#000000;">001-39509</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:22pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Dyne Therapeutics, Inc.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Delaware</font></p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">36-4883909</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">830 Winter Street</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Waltham, Massachusetts</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">02451</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="color:#000000;">(781) 786-8230</font> </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:3pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Common Stock, $0.0001 par value per share</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DYN</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Nasdaq Global Select Market</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None </font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:2.35pt;">
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<font style="font-size:8.5pt;font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, there was no public market for the Registrant&#8217;s common stock. The Registrant&#8217;s common stock began trading on the Nasdaq Global Select Market on September 17, 2020. The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on <font style="Background-color:#FFFFFF;color:#000000;">Nasdaq Global Select Market</font><font style="Background-color:#FFFFFF;color:#000000;font-size:9pt;"> </font>on February 26, 2021, was $552,278,064. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February 26, 2021 was 51,457,555. </p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2021 Annual Meeting of Stockholders within 120 days of the end of the Registrant&#8217;s fiscal year ended December&#160;31, 2020. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">PART I</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">PART&#160;II</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:underline;">PART&#160;III</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:underline;">PART&#160;IV</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note Regarding Forward-Looking Statements and Industry Data</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements within the meaning of the U.S. Private Securities Litigation Reform Act and Section 21E of the Securities Exchange Act of 1934, as amended, other than statements of historical fact, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the initiation, timing, progress and results of our research and development programs and preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the anticipated timing of the submission of investigational new drug applications, or INDs, for any product candidates we develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the impact of the ongoing&#160;COVID-19&#160;pandemic and our response to it;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period over which we believe our cash, cash equivalents and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our plans to develop and, if approved, subsequently commercialize any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the timing of and our ability to submit applications for, obtain and maintain regulatory approvals for any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the potential advantages of our FORCE platform;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our estimates regarding the potential addressable patient populations for our programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our commercialization, marketing and manufacturing capabilities and strategy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our intellectual property position and our expectations regarding our ability to obtain and maintain intellectual property protection;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the impact of government laws and regulations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or become available;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">developments and expectations regarding developments and projections relating to our competitors and our industry;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our ability to establish and maintain collaborations or obtain additional funding; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Moreover, we operate in a competitive and rapidly changing environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments we may make or enter into.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Annual Report on Form 10-K and the documents that we have filed or incorporated by reference as exhibits to this Annual Report on Form 10-K with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as our own estimates of the prevalence of certain diseases and conditions. The market data used in this Annual Report on Form 10-K involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the patient population with the potential to benefit from treatment with any product candidates we may develop include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;">Risk Factor Summary</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to a number of risks that, if realized, could materially affect our business, prospects, operating results and financial condition. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. These risks include, but are not limited to, the following:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">we are very early in our development efforts. We have not initiated&#160;IND-enabling&#160;studies or identified any product candidates for clinical development, and as a result it will be many years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">we may encounter substantial delays in commencement, enrollment or completion of our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our approach to the discovery and development of product candidates based on our FORCE platform is unproven, and we may not be successful in our efforts to identify, discover or develop potential product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">if any product candidates we may develop cause undesirable side effects or have other unexpected adverse properties, such side effects or properties could delay or prevent regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">we rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research, preclinical and clinical testing, and these third parties may not perform satisfactorily;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">we face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">our rights to develop and commercialize any product candidates are subject and may in the future be subject, in part, to the terms and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under current or future intellectual property license agreements or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">if we or our licensors are unable to obtain, maintain and defend patent and other intellectual property protection for any product candidates or technology, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully develop and commercialize any product candidates we may develop or our technology may be adversely affected due to such competition; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the&#160;COVID-19&#160;pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation of our planned clinical trial or future clinical trials, disrupt regulatory activities, or have other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, which could negatively impact our operations.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><a name="PART_I"></a>PART I</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. We are utilizing our proprietary FORCE platform to overcome the current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases. Our proprietary FORCE platform therapeutics consist of an oligonucleotide payload that we rationally design to target the genetic basis of the disease we are seeking to treat, a clinically validated linker and an antigen-binding fragment, or Fab, that we attach to the payload using the linker. With our FORCE platform, we have the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. We leverage this modularity to focus on muscle diseases with high unmet need, with etiologic targets and with clear translational potential from preclinical disease models to well-defined clinical development and regulatory pathways. Using our FORCE platform, we are assembling a broad portfolio of muscle disease therapeutics, including our lead programs in myotonic dystrophy type 1, or DM1, Duchenne muscular dystrophy, or DMD, and facioscapulohumeral dystrophy, or FSHD. In addition, we plan to expand our portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases, including some with larger patient populations. Our programs are currently all in the preclinical stage. We expect to submit investigational new drug, or IND, applications to the U.S. Food and Drug Administration, or FDA, for product candidates in each of our DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oligonucleotide therapeutics are a genetic medicine modality that, using nucleic acids, specifically aims to correct the function of disease-causing genes by either degrading the target gene or modifying expression of a target protein. While some oligonucleotide therapeutics have been approved, the development of oligonucleotide therapeutics has been limited by challenges in the delivery of the oligonucleotide to the tissue that requires therapy. To overcome these limitations, our FORCE platform utilizes the importance of Transferrin 1 receptor, or TfR1, in muscle biology as the foundation of our novel approach of linking therapeutic payloads to our TfR1-binding Fab to deliver targeted therapeutics for muscle diseases. TfR1, which is highly expressed on the surface of muscle cells, is required for iron transport into muscle cells, and evidence to date suggests that there are no other proteins that can substitute for TfR1 function. We believe our FORCE platform may provide several advantages, including targeted delivery to muscle tissue, extended durability, redosable administration and potent targeting of the genetic basis of disease to stop or reverse disease progression.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our approach </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have designed our proprietary FORCE platform using our deep knowledge of muscle biology and oligonucleotide therapeutics. We have demonstrated&#160;proof-of-concept&#160;of our FORCE platform in multiple&#160;<font style="font-style:italic;">in vitro</font>&#160;and&#160;<font style="font-style:italic;">in vivo</font>&#160;studies. In murine and&#160;non-human&#160;primate studies, we have delivered antisense oligonucleotides, or ASOs, and phosphorodiamidate morpholino oligomers, or PMOs, to genetic targets within muscle tissue and observed durable, disease-modifying, functional benefit in preclinical models of disease. For instance, in our DM1 program, we observed almost complete reversal of myotonia after a single dose in the&#160;HSA-LR&#160;mouse DM1&#160;model and reductions in levels of DMPK in wild-type, or WT, mice for up to 12 weeks after a single dose, and in our DMD program, we observed increased muscle function four weeks after a single dose in the mdx mouse DMD model that mirrored levels of muscle function in a control cohort of healthy, wild-type mice.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our therapeutics consist of three essential components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that we attach to our Fab using the linker.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Proprietary antibody (Fab)</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary Fabs are engineered to bind to TfR1 to enable targeted delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscle. A Fab is the region of an antibody that binds to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">antigens. We selected a Fab antibody over monoclonal antibodies, or mAbs, due to its potential significant advantages when targeting TfR1 to enable muscle delivery, including enhanced tissue penetration, increased tolerability due to lower protein load and reduced risk of immune system activation due to the lack of the Fc domain on the Fab. The Fc domain is the portion of an antibody that interacts with the immune system. To identify the proprietary Fab we plan to use in our product candidates, we generated and screened proprietary antibodies for selectivity to TfR1 in order to enhance muscle specificity and for binding to TfR1 without interfering with the receptor&#8217;s function of transporting iron into cells. These proprietary antibodies were also screened to minimize competition with transferrin binding and interference of iron uptake in targeted muscle cells.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Clinically validated linker</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The role of the linker is to connect, or conjugate, the Fab and the oligonucleotide payload. As a result, it is critical that the linker maintain stability in serum and provide release kinetics that favor sufficient payload accumulation in the targeted muscle cell. We have selected the&#160;Val-Cit&#160;linker as the linker for our FORCE platform based on its clinically validated safety and efficacy in approved products, its serum stability and its endosomal release attributes. Additionally, our linker and conjugation chemistry allow us to optimize the ratio of payload molecules attached to the Fab for each type of payload. We believe that our linker and conjugation chemistry will enable us to rapidly design, produce and screen molecules to enable new muscle disease programs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Optimized payload</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With our FORCE platform, we have the flexibility to deploy different types of therapeutic payloads with specific mechanisms of action that modify target functions. Using this modularity, we rationally select the therapeutic payload for each program to match the biology of the target, with the aim of addressing the genetic basis of disease and stopping or reversing disease progression.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Advantages of our FORCE platform </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our FORCE platform is designed to deliver disease-modifying therapeutics for a broad portfolio of serious muscle diseases. We believe that our FORCE platform may provide the following potential advantages:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Targeted delivery to muscle tissue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Potent targeting of the genetic basis of disease to stop or reverse disease progression;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Enhanced tolerability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Extended durability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Redosable administration;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Well-established and scalable manufacturing; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Accelerated and efficient development enabled by use of a single Fab and linker across all of our programs.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are building a pipeline of programs to address genetically-driven muscle diseases with high unmet need with etiologic targets. Our initial focus is on DM1, DMD and FSHD with potential pipeline expansion opportunities in additional rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases. In selecting diseases to target with our FORCE platform, we seek diseases with clear translational potential from preclinical disease models to well-defined clinical development and regulatory pathways. We have global commercial rights to all of our programs.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000001.jpg" title="" alt="" style="width:484px;height:208px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">DM1 program overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our DM1 program is focused on the development of a potentially disease-modifying treatment for DM1. DM1 is a monogenic, autosomal dominant, progressive disease that affects skeletal, cardiac and smooth muscle, resulting in significant physical, cognitive and behavioral impairments and disability. There are currently no disease-modifying therapies to treat DM1 that are approved or in clinical development. DM1 is caused by an abnormal CTG triplet repeat expansion in a region of the DMPK gene and it is estimated to have a genetic prevalence of 1 in 2,500 to 1 in 8,000 people in the United States and Europe, affecting over 40,000 people in the United States and over 74,000 people in Europe. Our program candidates consist of a proprietary TfR1-binding Fab conjugated using our linker to an ASO that is designed to address the genetic basis of DM1 by reducing the levels of mutant DMPK RNA in the nucleus, releasing splicing proteins, allowing normal mRNA processing and translation of normal proteins, and potentially stopping or reversing disease. In preclinical studies, we have observed reduction of nuclear foci and correction of splicing in DM1 patient cells, reduction of toxic human nuclear DMPK in a DM1 mouse model developed by us, reversal of myotonia after a single dose in a separate DM1 mouse disease model which demonstrates a DM1 phenotype, durability of response up to 12 weeks in WT mice and enhanced muscle distribution as evidenced by reduced levels of cytoplasmic WT DMPK RNA in&#160;non-human&#160;primates. We expect to submit an IND to the FDA for a product candidate in our DM1 program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">DMD program overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our DMD program is focused on the development of potentially disease-modifying treatments for DMD. DMD is a&#160;monogenic,&#160;X-linked&#160;disease&#160;caused by mutations in the gene that encodes for the dystrophin protein. In patients with DMD, mutations in the dystrophin gene lead to certain exons being misread resulting in the loss of function of the dystrophin protein, muscle cell death and progressive loss of muscle function. We estimate that DMD occurs in approximately one in every 3,500 to 5,000 live male births and that the patient population is approximately 12,000 to 15,000 in the United States and approximately 25,000 in Europe. We are developing program candidates to address the genetic basis of DMD by delivering a PMO to muscle tissue to promote the skipping of specific DMD exons in the nucleus, allowing muscle cells to create a more complete, functional dystrophin protein and potentially stop or reverse disease progression. In&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">in vitro</font><font style="Background-color:#FFFFFF;">&#160;and&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">in vivo</font><font style="Background-color:#FFFFFF;">&#160;preclinical studies, our PMOs when conjugated to a Fab targeting TfR1 have shown increased exon skipping, increased dystrophin expression, reduced muscle </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">damage and increased muscle function. We are seeking to build a DMD franchise by initially focusing on the development of a therapeutic for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44. We expect to submit an IND to the FDA for a product candidate in </font><font style="Background-color:#FFFFFF;">our Exon 51 skipping program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">FSHD program overview<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our FSHD program is focused on the development of a potentially disease-modifying therapy for FSHD. FSHD is an autosomal dominant muscular dystrophy characterized by progressive skeletal muscle loss, resulting in significant physical impairments and disability. FSHD is caused by aberrant expression of the double homeobox 4, or DUX4, gene in muscle tissue, which leads to death of muscle and replacement by fat. There are no approved treatments for FSHD. We estimate the patient population is between 16,000 and 38,000 in the United&#160;States and approximately 35,000 in Europe. Our FSHD program candidates consist of our proprietary TfR1-binding Fab conjugated using our linker to an ASO that is designed to address the genetic basis of FSHD by reducing DUX4 expression in muscle tissue. In preclinical studies, we observed that administration of our proprietary ASO conjugated to a Fab targeting TfR1 reduced expression of key DUX4 biomarkers in FSHD patient myotubes. We expect to submit an IND to the FDA for a product candidate in our FSHD program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Discovery programs overview<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We intend to utilize our FORCE platform to expand our portfolio by pursuing the development of programs in additional indications, including additional rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases. By rationally selecting therapeutic payloads to conjugate with our proprietary Fab and linker, we believe we can develop product candidates to address the genetic basis of additional muscle diseases. We have completed screening and identified potent ASO and siRNA payloads against a number of cardiac and metabolic targets. In addition to our muscle disease portfolio, we believe there is an opportunity to leverage our TfR1 antibody expertise to develop novel antibodies that cross the blood-brain barrier and deliver therapeutics to the central nervous system, or CNS, tissue through systemic intravenous administration.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our strategy </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our goal is to become the leading muscle disease company by advancing innovative life-transforming therapeutics for genetically driven diseases. To accomplish this, we intend to continue building a team that shares our commitment to patients, to continue to enhance our platform and to advance our pipeline. The key elements of our strategy are to:</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Arial;">Advance our lead programs&#160;in DM1, DMD and FSHD to clinical&#160;proof-of-concept&#160;and approval to offer meaningful benefit to patients.</font><font style="Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Arial;">&#160;We are developing our lead programs for the treatment of DM1, DMD and FSHD. By applying our FORCE platform, we are able to optimize product candidates for each indication based on extensive preclinical data, including disease-specific models and biomarkers, thus enhancing the probability of clinical success of our programs. Our immediate focus is on our programs for DM1 and DMD followed by our program for FSHD, and we expect to submit INDs to the FDA for product candidates in each of our DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022. We intend to conduct our clinical studies in a genetically-defined patient population and to leverage learnings from other therapeutics in clinical development or approved by the FDA to inform the clinical and regulatory pathways for&#160;our programs. We believe&#160;our DM1, DMD and FSHD programs have the potential to stop or reverse the progression of the disease and offer meaningful benefit to patients in need.</font><font style="font-size:10pt;font-family:Arial;color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Establish a DMD franchise by expanding our DMD program to reach additional DMD patient populations.</font><font style="font-size:10pt;font-family:Arial;color:#000000;">&#160;We are developing our DMD program to treat the genetic basis of DMD. Approximately 80% of patients with DMD have mutations amenable to exon skipping in the </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;font-family:Arial;color:#000000;">nucleus. Exons 51, 53, 45 and 44 represent nearly half of the total mutations observed in DMD that are amenable to exon skipping. We are seeking to build a DMD franchise by initially focusing on the development of a therapeutic for patients with mutations amenable to skipping Exon 51, to </font><font style="font-size:10pt;font-family:Arial;color:#000000;">be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exons 53, 45 and 44.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Expand our pipeline of therapeutics for muscle diseases to fully exploit the potential of our proprietary FORCE platform.</font><font style="font-size:10pt;font-family:Arial;color:#000000;">&#160;Our FORCE platform leverages the pivotal role played by TfR1 in muscle biology as the foundation of our novel approach of linking therapeutic payloads to TfR1-targeted Fabs to deliver precision therapeutics for muscle diseases. We believe there are many muscle diseases with significant unmet need and we aim to expand our portfolio by pursuing additional programs where our FORCE platform could improve clinical efficacy relative to current therapeutic approaches. We have completed screening and identified potent ASO and siRNA payloads against a number of cardiac and metabolic targets. In addition to our muscle disease portfolio, we believe there is an opportunity to leverage our TfR1 antibody expertise to develop novel antibodies that cross the blood-brain barrier and deliver therapeutics to CNS tissue through systemic intravenous administration.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Selectively enter into strategic collaborations to maximize the value of our pipeline and our proprietary FORCE platform.</font><font style="font-size:10pt;font-family:Arial;color:#000000;">&#160;Given the potential of our platform to generate novel product candidates addressing a wide variety of muscle diseases, we may opportunistically enter into strategic collaborations around certain targets, programs or muscle tissues. We may seek strategic collaborations where we believe we can utilize our FORCE platform to enhance delivery of third-party payloads to muscle tissue. We may also explore collaboration arrangements to commercialize any product candidates where we believe the resources and expertise of the third party could be beneficial. These collaborations could advance and accelerate our programs to maximize their market potential and expand our FORCE platform capabilities.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;font-family:Arial;color:#000000;">Build a sustainable leadership position in muscle diseases with a deep connection to patients, caregivers, the research community and physicians.</font><font style="font-size:10pt;font-family:Arial;color:#000000;">&#160;We have global commercial rights to all of our programs and intend to build a fully integrated biotechnology company and independently pursue the development and commercialization of our lead programs. Our mission is to expand our portfolio into a wide range of muscle diseases and become a leader in this area by advancing life-transforming therapeutics for patients with serious muscle diseases. To achieve this, we plan to continue to evaluate and invest in enhancing our platform and technologies that may accelerate the development of our therapeutics, to build out our capabilities to commercialize our therapeutics on our own and to cultivate a strong network with patient advocacy groups and thought leaders.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our culture and team </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a patient-focused culture that drives our shared mission of developing life-transforming therapeutics for patients with serious muscle diseases. Our shared definition of success is simple: we do what we say we are going to do. We keep our commitments to patients, employees and Dyne stakeholders. We endeavor to act with integrity and transparency.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management team is led by Joshua Brumm, our President and Chief Executive Officer, who brings over 15 years of leadership experience with life sciences companies; Romesh Subramanian, Ph.D., our Chief Scientific Officer and Founder, who is an expert in nucleic acid, antibody and peptide therapeutic development as well as delivery platforms with 20 years of experience across pharmaceutical and biotechnology companies; Susanna High, our Chief Operating Officer, who has more than two decades of experience leading corporate strategy, <font style="Background-color:#FFFFFF;">portfolio management, business planning and operations for biotechnology companies; and Oxana Beskrovnaya, Ph.D., our Senior Vice President, Head of Research, who has extensive experience in musculoskeletal and renal research. Our organization is comprised of 47 talented individuals with significant experience across discovery, preclinical research, manufacturing, clinical development and operations. We have also established scientific and clinical advisory boards comprised of leading experts in the fields of muscle disease drug discovery and development and nucleic </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">acid therapeutics, who share our mission of delivering disease-modifying therapeutics for patients with serious muscle diseases.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Genetic medicines background </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Overview </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person&#8217;s genetic material, or genome, consists of deoxyribonucleic acid, or DNA, in sequences of genetic code called genes. A genetic disease is caused by a change, or a mutation, in an individual&#8217;s DNA sequence. Genetic diseases can be caused by a mutation in a single gene, known as a monogenic disorder, or by mutations in multiple genes, known as a multifactorial inheritance disorder. Current estimates suggest that there are more than 10,000 monogenic diseases. Many of these are rare muscle diseases, affecting thousands of patients worldwide, such as DM1, DMD and FSHD. There are also a number of more prevalent genetic muscle diseases, including many types of cardiac disease.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genetic medicines are designed to correct disease-causing dysfunction at the genetic level and include multiple therapeutic modalities, such as oligonucleotide therapeutics, including ASOs and siRNAs, viral gene therapy and small molecules. Significant progress has been made in the field of genetic medicine over the last decade as a number of genetic medicines have been approved or are in clinical development. However, the nature and fundamental limitations of these genetic medicines, such as poor tissue specificity, reduced efficacy, unknown durability and immunogenicity, make them poorly suited to effectively address the majority of genetic muscle diseases.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Viral gene therapy, in which viral vectors are employed to deliver therapeutic genes to defective cells or tissues, has made significant progress in the past decade. The most advanced method for systemic administration is adeno-associated virus, or AAV, gene therapy, which has demonstrated durable transduction of cells in several organ systems, with long-lasting expression&#160;in&#160;non-dividing&#160;cells.&#160;Several AAV gene therapy products have been approved, including LUXTURNA&#160;(voretigene&#160;neparvovec-rzyl)&#160;for&#160;the treatment of biallelic RPE65 mutation-associated retinal dystrophy, a rare inherited blindness disorder, and ZOLGENSMA (onasemnogene abeparvovec-xioi) for spinal muscular atrophy, and a number of AAV gene therapy products are in clinical development for muscle diseases, including microdystrophin gene therapy candidates for DMD.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, current AAV gene therapy has significant limitations, including:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Limited durability: AAV gene therapies, which are administered in a single dose, have shown limited durability. This limited durability is problematic because following a single dose of AAV, antibodies are induced against the AAV capsid, the protein shell of the virus used for delivery, with the result that the therapy cannot be re-administered after the first dose.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Pre-existing immunity: Up to half of patients have antibodies against AAV due to naturally acquired infections. These antibodies prevent them from receiving AAV gene therapy due to pre-existing AAV immunity to the capsid encapsulating the transgene.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Variable safety profile: Multiple clinical trials have reported significant adverse events associated with systemic administration of AAV to treat muscle diseases, particularly at higher doses.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Limited payload capacity: AAV constructs are limited to 4.7 kb in length, restricting both the size of genes and complexity of regulatory sequences that can be delivered. For example, AAV payload capacity prevents the delivery of the full dystrophin gene. As a result, AAV gene therapies being developed for DMD use a microdystrophin, a smaller, less complete version of the dystrophin protein, as the therapeutic payload.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Off-target, multi-tissue delivery: Due to the inherent nature of AAVs, off-target delivery to unintended tissues and cell-types can lead to adverse events.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">Limited manufacturing scale: The production systems for AAV gene therapies are limited in scale to 2,000 liters per batch or less. In general, the high doses required by AAV gene therapies and the low productivity of these systems combine to limit treatment to rare disease populations at a higher cost relative to other treatment modalities.&#160;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Evolution of oligonucleotide therapeutics </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oligonucleotide therapeutics are a genetic medicine modality that, using nucleic acids, specifically aims to correct the function of disease-causing genes by either degrading the disease-causing gene or modifying expression of a gene or a protein. Oligonucleotides are rationally designed genetic medicines which have demonstrated clinical benefit and been approved for marketing in multiple diseases, such as spinal muscular atrophy, elevated cholesterol and hereditary transthyretin-mediated amyloidosis. Oligonucleotides are designed based on genomic data, using Watson-Crick base pairing rules, to bind to and decrease or modify the expression of specific disease-causing RNA or proteins which ultimately results in disease modification.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oligonucleotide therapeutics include single-stranded nucleic acids, known as antisense oligonucleotides or ASOs, as well as double-stranded nucleic acids, known as small interfering RNA, or siRNAs. The ASOs are generally less than 30 nucleobases in length. ASOs can have either charged nucleobases or uncharged bases. ASOs with uncharged bases are referred to as phosphorodiamidate morpholinos oligomers, or PMOs. The charged nucleobases impart an overall negative charge to ASOs that enhances their ability to cross membranes and enter into cells without the assistance of a delivery formulation. Once inside the cell, the charged ASOs can degrade RNA if they are gapmers, which have a DNA region in the center flanked by RNA wings, by recruiting the RNAseH1 enzyme to cleave heteroduplexes of DNA and RNA. ASOs can also alter splicing or exon skipping if they are&#160;non-gapmers.&#160;ASOs are functional in the nucleus and the cytoplasm. In contrast, a PMO is neutral in charge and unable to enter into cells without a delivery enhancement. PMOs are capable of exon skipping and are functional in the nucleus. In addition to ASOs and PMOs, siRNAs are a third type of oligonucleotide therapy which are generally less than 23 nucleobases in length and are a negatively charged duplex molecule comprised of a guide strand and a passenger strand. In order to modulate RNA or protein expressions, siRNAs need to be loaded into an&#160;RNA-induced&#160;silencing complex which is generally present in the cytoplasm but not the nucleus.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While some oligonucleotide therapeutics have been approved, the development of oligonucleotide therapeutics has been limited by challenges in the delivery of the oligonucleotide to the tissue that requires therapy. These challenges have been particularly evident in the delivery of oligonucleotides to muscle tissue. Unconjugated, or naked, oligonucleotides bind&#160;non-specifically&#160;to plasma proteins which increases their plasma half-life and circulation time through filtering organs such as the liver and kidney, leading the oligonucleotides to accumulate primarily in the liver and kidney, and resulting in increased toxicity in these organs. As a result, many oligonucleotide therapeutics are limited to organs where direct delivery to the target organ can be an effective approach, such as intravitreal administration in the retina or intrathecal administration in the central nervous system. There have been efforts to enhance delivery of siRNAs to tissue by utilizing lipid nanoparticles, or LNPs, and other encapsulation vehicles. Although these approaches can increase the effectiveness of an siRNA therapeutic, they are largely limited to filtering organs such as the liver and kidney and increase the safety risk of the therapeutic. Despite these limitations, both naked ASOs and encapsulated siRNAs have been approved and commercialized.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent efforts using targeted delivery of ASOs or siRNAs have demonstrated that conjugation to a delivery moiety can effectively deliver these compounds to target tissues and provide significant health benefits to patients. For instance, third-party developers have leveraged proteins on cell surfaces to enhance the delivery of oligonucleotides using a process called receptor-mediated uptake. These developers have conjugated sugar molecules referred to as GalNAcs to oligonucleotides in order to engage asiaglycoprotein, or ASGPR, a transporter protein expressed primarily on the surface of liver cells, and facilitate intracellular delivery of oligonucleotide therapeutics, resulting in increased target engagement as compared to naked oligonucleotides. The emerging preclinical and clinical data around the GalNAc-ASGPR approach and recent FDA approval of GIVLAARI (givosiran) and OXLUMO (lumasiran), which use this approach, supports receptor-mediated uptake as a delivery strategy for oligonucleotide therapeutics.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to increase the uptake of oligonucleotides, third-party developers have also used antibody conjugates as a means of delivering oligonucleotides into cells. Antibodies are&#160;naturally occurring&#160;proteins&#160;produced by the immune system that first identify and then neutralize or clear antigens, such as bacteria, viruses and other substances, by selectively binding to these foreign substances. Antibodies can be engineered&#160;for desired characteristics, such as&#160;high selectivity and high affinity for their target cell surface proteins and antibody format, such as mAb or Fab, in order to facilitate the delivery of oligonucleotide therapeutics into those cells. The use of engineered antibodies as a conjugate to oligonucleotide therapeutics is being studied for the delivery of oligonucleotides to muscle tissue and tumors.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developers have sought to use the TfR1 receptor, which is highly expressed on the surface of muscle cells, to deliver oligonucleotides to muscle tissue. TfR1 is required for iron transport into muscle cells, and evidence to date suggests that there are no other proteins that can substitute for TfR1 function. For instance, in third-party studies, a conditional&#160;knock-out&#160;of TfR1 in cardiac muscle was lethal in mice, and a conditional&#160;knock-out&#160;of TfR1 in skeletal muscle resulted in significant metabolic imbalance in mice. These studies provide evidence that TfR1 is critical for muscle function. However, we believe that previous efforts to develop muscle disease therapeutics based on TfR1-mediated delivery have been unsuccessful because receptor-mediated uptake requires the optimization of each component of the conjugate molecule (the antibody, the linker and the oligonucleotide), which has not yet been achieved.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our FORCE platform utilizes the importance of TfR1 in muscle biology as the foundation of our novel approach of linking therapeutic payloads to TfR1-targeted Fabs to deliver targeted therapeutics for muscle diseases.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our approach </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are using our proprietary FORCE platform to develop targeted, life-transforming therapeutics for serious muscle diseases. We have designed our proprietary FORCE platform using our deep knowledge of muscle biology and oligonucleotide therapeutics with the goal of overcoming the current limitations of muscle tissue delivery and advancing modern oligonucleotide therapeutics for muscle diseases. Our therapeutics consist of three essential components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that we attach to our Fab using the linker. We engineered our proprietary Fab to bind to TfR1 to enable targeted delivery to skeletal, cardiac and smooth muscle. We selected the linker for our platform based on its clinically validated safety and efficacy in approved products, its serum stability and its ability to release the therapeutic payload within the muscle cell. Finally, we attach the Fab and linker to a therapeutic payload that can be an ASO, siRNA, PMO or small molecule that we rationally select to target the genetic basis of disease to potentially stop or reverse disease progression.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have demonstrated&#160;proof-of-concept&#160;of our FORCE platform in multiple&#160;<font style="font-style:italic;">in vitro</font>&#160;and&#160;<font style="font-style:italic;">in vivo</font>&#160;studies. In murine and&#160;non-human&#160;primate (NHP) studies, we have delivered ASOs and PMOs to genetic targets within muscle tissue and observed durable, disease-modifying, functional benefit in preclinical models of disease. For <font style="Background-color:#FFFFFF;">instance, in our DM1 program, we observed almost complete reversal of myotonia after a single dose in the&#160;HSA-LR&#160;mouse DM1 model, reduction of toxic human nuclear DMPK in a hTfR1/DMSXL DM1 mouse model developed by us and reductions in levels of DMPK in WT mice for up to 12 weeks after a single dose, and in our DMD program, we observed increased muscle function four weeks after a single dose in the mdx mouse DMD model that mirrored levels of muscle function in a control cohort of healthy, wild-type mice.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following graphic illustrates the three components of our therapeutics: </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE platform </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000002.jpg" title="" alt="" style="width:239px;height:465px;"></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Proprietary antibody (Fab) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our proprietary Fabs are engineered to bind to TfR1 to enable targeted delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscle. A Fab is the region of an antibody that binds to antigens. Although we have engineered a number of Fabs, we plan to use the same Fab to target TfR1 across all of our muscle programs. We chose to develop our programs using a Fab rather than using mAbs because we believe Fabs provide the following potential significant advantages:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Potential advantages of Fabs targeting TfR1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000003.jpg" title="" alt="" style="width:615px;height:320px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To identify the proprietary Fab we plan to use in our product candidates, we generated and screened proprietary antibodies for selectivity to TfR1 in order to enhance muscle specificity and for binding to TfR1 without interfering with the receptor&#8217;s function of transporting iron into cells. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Clinically validated linker </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The role of the linker is to connect the Fab and the oligonucleotide therapy. As a result, it is critical that the linker maintain stability in serum and provide release kinetics that favor sufficient payload accumulation in the targeted muscle cell. We have selected the&#160;Val-Cit&#160;linker for our FORCE platform based on its clinically validated safety and efficacy in approved products, its serum stability and its endosomal release attributes. As shown in the figure below, serum stability of our linker was comparable across multiple species, showing at least 75% stability measured at 72 hours after intravenous dosing.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Serum stability of linker &gt;75% at 72 hours </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000004.jpg" title="" alt="" style="width:432px;height:218px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We believe that serum stability is necessary to enable systemic intravenous administration, stability of the conjugated oligonucleotide in the bloodstream, delivery to muscle tissue and internalization of the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">therapeutic payload in the muscle cells. In preclinical studies, our&#160;Val-Cit&#160;linker facilitated precise conjugation of multiple types of payloads to our proprietary Fabs, including ASOs, siRNAs and PMOs. This flexibility enables us to rationally select the appropriate type of payload to address the genetic basis of each muscle disease. Additionally, our linker and conjugation chemistry allow us to optimize the ratio of payload molecules attached to each Fab for each type of payload. We believe that our linker and conjugation chemistry will enable us to rapidly design, produce and screen molecules to enable new muscle disease programs.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Optimized payload </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">With our FORCE platform, we have the flexibility to deploy different types of therapeutic payloads with specific mechanisms of action that modify target functions. Using this modularity, we rationally select the therapeutic payload for each program to match the biology of the target, with the aim of addressing the genetic basis of disease and stopping or reversing disease progression. For instance, in our DM1 program, where the genetic driver of DM1 is mutant DMPK&#160;pre-mRNA&#160;located in the nucleus, we have determined to use an ASO because ASOs have advantages in degrading RNA in the nucleus when compared to siRNAs. In the case of our DMD program, we are utilizing an exon skipping PMO payload with the goal of enhancing dystrophin expression. In the case of certain cardiac and metabolic programs where the genetic targets are focused in the cytoplasm, we have engineered proprietary siRNA payloads to reduce the expression of these cytoplasmic targets.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Advantages of our FORCE platform </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are using our FORCE platform to develop disease-modifying therapeutics for a broad portfolio of serious muscle diseases. We believe that these therapeutics may provide the following potential advantages:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Arial;">Targeted delivery to muscle tissue:</font><font style="font-family:Arial;">&nbsp;&nbsp; Using our FORCE platform, we are designing our oligonucleotide therapeutics to leverage TfR1 expression on skeletal, cardiac and smooth muscle cells to deliver muscle-targeted therapeutics to benefit patients with serious muscle disease.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Arial;">Potent targeting of the genetic basis of disease:</font><font style="font-family:Arial;">&nbsp;&nbsp; The flexibility of our FORCE platform allows us to deploy different types of payloads with specific mechanisms of action to modify target function. This enables us to rationally select payloads that match the biology of the target, with the aim of addressing the genetic basis of disease and stopping or reversing disease progression.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Arial;">Enhanced tolerability:</font><font style="font-family:Arial;">&nbsp;&nbsp; We engineered our Fabs to enhance the tolerability of oligonucleotide therapeutics by limiting systemic drug exposure through targeted delivery of potent therapeutic payloads to muscle tissue. Additionally, we engineered our Fabs to minimize competition with transferrin binding and interference of iron uptake in targeted muscle cells.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Arial;">Extended durability:</font><font style="font-family:Arial;">&nbsp;&nbsp; Our program candidates have demonstrated in preclinical studies the ability to deliver oligonucleotides to muscle cells at concentrations that we believe could produce prolonged disease-modifying pharmacodynamic effects. We believe that the potential durability of our program candidates may enable less frequent dosing of patients.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Arial;">Redosable administration:</font><font style="font-family:Arial;">&nbsp;&nbsp; Our program candidates are engineered to be redosable, not just administered one time, which may enable individualized patient titration to reach the desired level of therapeutic expression and to potentially maintain efficacy throughout a patient&#8217;s life.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Arial;">Well-established and scalable manufacturing:</font><font style="font-family:Arial;">&nbsp;&nbsp; Our program candidates can be manufactured using well-established and scalable methods for manufacturing antibodies, linkers and oligonucleotides. In addition, we expect our manufacturing costs will be reduced by our use of the same Fab and linker in each product candidate we develop.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Arial;">Accelerated and efficient development:</font><font style="font-family:Arial;">&nbsp;&nbsp; We believe our use of a single Fab and linker across all of our programs reduces the development risk and cost of each product candidate and enables us to more quickly expand our portfolio of programs through either internally or externally developed payloads as the focus of our development will remain with the selection and optimization of each program-specific therapeutic payload.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our mission is to develop life-transforming medicines for patients with serious muscle diseases. We are creating a pipeline of programs to address diseases with high unmet need with etiologic targets. Our initial focus is on DM1, DMD and FSHD with potential pipeline expansion opportunities in additional rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases. In selecting diseases to target with our FORCE platform, we seek diseases with clear translational potential from preclinical disease models to well-defined clinical development and regulatory pathways, and where we believe that we would be able to commercialize any products that we develop and are approved with an efficient, targeted sales force. We have global commercial rights to all of our programs.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000005.jpg" title="" alt="" style="width:484px;height:208px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Myotonic dystrophy type 1 (DM1) </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are developing program candidates under our DM1 program to address the genetic basis of DM1 by targeting the toxic nuclear DMPK RNA that causes the disease. Our DM1 program is designed to deliver an ASO to muscle tissue to reduce the accumulation of DMPK&#160;pre-mRNA&#160;in the nucleus, release splicing proteins and potentially stop or reverse disease progression. In&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">in vitro&#160;</font><font style="Background-color:#FFFFFF;">and</font><font style="font-style:italic;Background-color:#FFFFFF;">&#160;in vivo</font><font style="Background-color:#FFFFFF;">&#160;preclinical studies, our ASOs when conjugated to Fabs targeting TfR1 have shown reduction in nuclear foci, correction of splicing changes, reversal of myotonia, which is a neuromuscular condition in which the relaxation of a muscle is impaired, and enhanced muscle distribution as evidenced by reduced levels of cytoplasmic wild type, or WT, DMPK RNA. We anticipate submitting an IND to the FDA for a product candidate in our DM1 program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Disease overview and prevalence </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DM1 is a monogenic, autosomal dominant, progressive disease that primarily affects skeletal, cardiac and smooth muscles. DM1 patients can suffer from various manifestations of the disease including myotonia, muscle weakness, cardiac arrhythmias, respiratory problems, fatigue, cardiac abnormalities, gastrointestinal, or GI, complications, early cataracts and cognitive and behavioral impairment.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DM1 is caused by an abnormal expansion in a region of the DMPK gene. Specifically, DM1 is caused by an increase in the number of CTG triplet repeats found in the 3&#8217;&#160;non-coding&#160;region of the DMPK gene. The number of repeats ranges from up to approximately 35 in healthy individuals to many thousands in DM1 patients. The higher than normal number of triplet repeats form large hairpin loops that entrap the DMPK&#160;pre-mRNA&#160;in the nucleus and impart toxic activity, referred to as a toxic&#160;gain-of-function&#160;mutation. The mutant DMPK&#160;pre-mRNA&#160;sequesters in the nucleus, forming nuclear foci that bind splicing proteins. This inhibits the ability of splicing proteins to perform their normal function in the nucleus of guiding&#160;pre-mRNA&#160;processing of gene transcripts from many other genes. As a result, multiple&#160;pre-mRNAs&#160;that encode key proteins are&#160;mis-spliced.&#160;This&#160;mis-splicing&#160;in the nucleus results in the translation of atypical proteins which ultimately cause the clinical presentation of DM1. When nuclear DMPK levels are reduced, the nuclear foci that bind splicing proteins are diminished, releasing splicing proteins, allowing normal mRNA processing and translation of normal proteins, and potentially stopping or reversing disease progression. This disease process is illustrated below:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">DM1: Genetic basis and clinical presentation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000006.jpg" title="" alt="" style="width:570px;height:155px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">DM1 is estimated to have a genetic prevalence of 1 in 2,500 to 1 in 8,000 people in the United States and Europe, affecting over 40,000 people in the United States and over 74,000 people in Europe. However, we believe that the patient population is currently underdiagnosed due to lack of available therapies as is observed for other rare diseases. DM1 is highly variable with respect to disease severity, presentation and age of onset. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are advancing our own efforts to better characterize the actual DM1 patient population through a natural history study that we are sponsoring. We believe that the introduction of new therapies for DM1 will cause the diagnosis rate to improve, resulting in an increase in the overall prevalence estimates for the disease. Based on age of onset and severity of symptoms, DM1 is typically categorized into four overlapping phenotypes: late-onset; classical (adult-onset); childhood; and congenital (cDM1):</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Overview of DM1 phenotypes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:28.8%;"></td>
<td style="width:26.94%;"></td>
<td style="width:23.15%;"></td>
<td style="width:21.1%;"></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 2.25pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style=" border-top:solid 2.25pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style=" border-top:solid 2.25pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style=" border-top:solid 2.25pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Phenotype</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical presentation</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated % of DM1&#160;patients</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age of onset</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Late-onset</p></td>
<td valign="bottom"  style="padding-left:7.2pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Myotonia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Muscle weakness</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Cataracts</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10%</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40 - 70 years</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classical (Adult-onset)</p></td>
<td valign="bottom"  style="padding-left:7.2pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Muscle weakness and wasting</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Myotonia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Cardiac conduction abnormalities</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Respiratory insufficiency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Fatigue/Excessive daytime sleepiness</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;GI disturbance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Cataracts</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Early teens - 50 years</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Childhood</p></td>
<td valign="bottom"  style="padding-left:7.2pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Psychological problems</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Low IQ</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Incontinence</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15%</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 10 years</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congenital (cDM1)</p></td>
<td valign="bottom"  style="padding-left:7.2pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Infantile hypotonia</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Severe generalized weakness</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Respiratory deficits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Intellectual disability</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Classic signs present in adults</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10%</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Birth</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;margin-left:-7.5pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">All DM1 phenotypes, except the late-onset form, are associated with high levels of disease burden and premature mortality. The clinical course of DM1 is progressive, and may become extremely disabling, especially when more generalized limb weakness and respiratory muscle involvement develops. Systemic manifestations such as fatigue, GI complications, cataracts and excessive daytime sleepiness greatly impact a patient&#8217;s quality of life. As a result, DM1 leads to physical impairment, activity limitations and decreased participation in social activities and work. Excluding congenital DM1 deaths, life expectancy ranges from 45 years to 60 years. Approximately 80% of early mortality is caused by cardiorespiratory complications. Respiratory failure due to muscle weakness (especially diaphragmatic weakness) causes at least 50% of early mortality, and cardiac abnormalities, including sudden death, account for approximately 30% of early mortality.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Current approaches and limitations </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">There are currently no disease-modifying therapies to treat DM1 that are approved or in clinical development, and treatment is focused largely on symptom management or palliative therapies. There are a number of product candidates in development, including product candidates in late stage clinical development that also are focused on symptom management or palliative therapies and do not target toxic nuclear DMPK RNA, which is the genetic basis of the disease. There remains a high unmet medical need for new disease-modifying therapies.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Our approach </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our program is designed to address the genetic basis of DM1 by targeting the toxic nuclear DMPK RNA that is the cause of the disease. We are developing program candidates linking our proprietary Fab to a proprietary ASO to address the genetic basis of DM1 by reducing the levels of mutant DMPK RNA in the nucleus, thereby releasing splicing proteins, allowing normal mRNA processing and translation of normal proteins, and potentially stopping or reversing disease progression. We expect that the proprietary ASO will be a gapmer oligonucleotide that is designed to translocate to the nucleus, bind its complementary sequence on the DMPK RNA, recruit RNAseH1 to degrade DMPK RNA and thus reduce toxic nuclear DMPK RNA. We have chosen to develop our program candidates for DM1 with an ASO because single-stranded ASOs preferentially target nuclear RNAs, which is essential for degradation of toxic nuclear DMPK RNA.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Another company previously attempted to develop a naked ASO to treat DM1 but discontinued its program due to challenges related to delivery. Specifically, the program was unable to reach the oligonucleotide muscle tissue concentration required to reduce nuclear DMPK levels, correct splicing abnormalities and address the clinical presentation. The other company believed there was a need to focus on more potent delivery to muscle. We believe that our FORCE platform has the potential to overcome the limitations faced by the other company and address the genetic basis of DM1 by achieving enhanced delivery of therapeutic ASOs to muscle.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical data </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are conducting preclinical studies of our ASOs conjugated to Fabs targeting TfR1 in DM1 patient cells and in the&#160;HSA-LR&#160;DM1 mouse model, which are disease models in which toxic RNA is observed. In&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">in vitro</font><font style="Background-color:#FFFFFF;">&#160;and&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">in vivo</font><font style="Background-color:#FFFFFF;">&#160;preclinical studies, our conjugated ASOs have shown reduction of nuclear foci, correction of splicing changes and reversal of myotonia in disease models, reduction of toxic human nuclear DMPK in a hTfR1/DMSXL DM1 mouse model developed by us, as well as enhanced muscle distribution as evidenced by reduced levels of cytoplasmic WT DMPK RNA. We believe these data support the potential for our oligonucleotide therapy to be a disease-modifying therapy for patients with DM1.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Reduction of nuclear foci </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In preclinical studies in DM1 patient cells that contained toxic nuclear DMPK RNA, we observed that administration of an ASO conjugated to a Fab targeting TfR1 resulted in reduction of nuclear foci. In DM1, the higher than normal number of CUG repeats form large hairpin loops that remain trapped in the nucleus, forming nuclear foci that bind splicing proteins and inhibit the ability of splicing proteins to perform their normal function. When toxic nuclear DMPK levels are reduced, the nuclear foci are </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">diminished, releasing splicing proteins, allowing restoration of normal mRNA processing, and potentially stopping or reversing disease progression. As illustrated in the figure below, in this study in DM1 patient cells, a single dose of conjugated ASO (shown as Dyne in the figure below) reduced nuclear DMPK foci as determined through a fluorescence in situ hybridization (FISH) analysis. The reduced nuclear DMPK foci are indicated by the reduction in red punctate staining in the figure below for Dyne as compared to a saline control (shown as PBS). We believe the approximately 40% reduction in nuclear foci observed in this study supports the potential for our approach to advance a disease-modifying therapy for patients with DM1.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE targeted nuclear DMPK and reduced nuclear foci in DM1 patient cells </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000007.jpg" title="" alt="" style="width:476px;height:230px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.61%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Correction of splicing </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In preclinical studies in DM1 patient cells that contained toxic nuclear DMPK RNA, we observed that administration of an ASO conjugated to a Fab targeting TfR1 resulted in correction of splicing of downstream RNAs such as Bridging Integrator Protein 1, or BIN1. Toxic DMPK RNA in the nucleus binds splicing proteins, inhibiting splicing protein function, and thereby reducing Exon 11 in BIN1 RNA. As illustrated in the figure below, in this study in DM1 patient cells, a single dose of the conjugated ASO (shown as Dyne in the figure) resulted in a statistically significant increase (p &lt; 0.001) in Exon 11 inclusion compared to saline (shown as PBS), indicating that our conjugated ASO had reduced toxic DMPK RNA in the nucleus, causing the release of splicing proteins and the correction of BIN1 splicing. A&#160;p-value&#160;is a conventional statistical method for measuring the statistical significance of study results. A&#160;p-value&#160;of less than 0.05 is generally considered to represent statistical significance, meaning that there is a less than 5% likelihood that the observed results occurred by chance.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE targeted nuclear DMPK and corrected BIN1 splicing in DM1 patient cells </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000008.jpg" title="" alt="" style="width:427px;height:308px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.92%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.92%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*** P &lt; 0.001 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also observed correction of splicing in the&#160;HSA-LR&#160;DM1 mouse model. The&#160;HSA-LR&#160;DM1 mouse model is a well-validated model of DM1 that exhibits pathologies that are very similar to human DM1 patients. This model accumulates toxic RNA with triplet repeats within the nucleus and sequesters proteins responsible for splicing such as Muscleblind-like Protein, or MBNL, thus causing&#160;mis-splicing&#160;of multiple RNAs such as CLCN1 (chloride channel) and Atp2a1 (calcium channel), among others. This&#160;mis-splicing&#160;causes the mice to exhibit myotonia, which is a hallmark of the DM1 clinical presentation in humans.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In blinded preclinical studies, single doses of one of our ASOs conjugated to a Fab targeting TfR1 delivered intravenously demonstrated dose-dependent correction of splicing in multiple RNAs and multiple muscles and was well tolerated by&#160;HSA-LR&#160;mice. In these studies, we tested the ability of the conjugated ASO to correct splicing in more than 30 different RNAs that are critical for contraction and relaxation of muscle in&#160;HSA-LR&#160;mice and observed dose-dependent correction of splicing. In DM1, significant RNA&#160;mis-splicing&#160;of these RNAs reduces muscle function.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first figure below presents the data from these studies with respect to the Atp2a1 RNA, which encodes a calcium channel and contributes to muscle contraction and relaxation. The&#160;X-axis&#160;in the figure below represents splice derangement with 1.00 on the right side of the figure representing severe&#160;mis-splicing&#160;and 0.00 on the left side of the figure representing a normal or WT splice pattern. Hence, progression from right to left on the&#160;X-axis&#160;in the figure represents a correction of splicing. The&#160;Y-axis&#160;of the figure below represents the percent of the gene spliced in, or PSI. Severe&#160;mis-splicing&#160;of Atp2a1 is caused by the lack of Exon 22 inclusion in the Atp2a1 RNA as reflected in a PS1 close to 0.00, while WT splicing reflects near complete inclusion of Exon 22 as reflected in a PSI close to 1.00. Accordingly, the blue dots in the figure indicate a&#160;near-WT&#160;splicing pattern and&#160;near-WT&#160;Exon 22 inclusion. As the figure shows, our conjugated ASO (shown as Dyne) corrected splicing of Atp2a1 in a dose-dependent manner in the gastrocnemius muscle. Two doses were administered in this study in order to evaluate dose dependence.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The second figure below presents the same data from these studies with respect to the more than 30 different RNAs that were tested, showing similar dose-dependent correction of splicing for all of the tested </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">RNAs in gastrocnemius muscle. For some of these RNAs, correction of splicing toward WT reflects an increase in PSI, like Atp2a1 RNA in the first figure below, and for others it reflects a decrease in PSI.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE dose-dependently corrected Atp2a1 splicing in HSA-LR DM1 mouse model </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000009.jpg" title="" alt="" style="width:312px;height:316px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE dose-dependently corrected splicing in multiple RNAs in HSA-LR DM1 mouse model </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000010.jpg" title="" alt="" style="width:603px;height:322px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In addition to the dose-dependent changes shown in the gastrocnemius muscle, we also observed similar dose-dependent correction of splicing across the same panel of RNAs in the quadriceps and tibialis anterior muscles. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The figure below presents the levels of splicing derangement observed for saline and different doses of one of our conjugated ASOs, presented on a composite basis across the more than 30 RNAs that we tested in each muscle type.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE dose-dependently corrected splicing in multiple muscles in HSA-LR DM1 mouse model </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000011.jpg" title="" alt="" style="width:438px;height:266px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.61%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Reversal of myotonia </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In addition to these reductions in splicing derangement across multiple genes and muscles in the&#160;HSA-LR&#160;model, we observed in the&#160;HSA-LR&#160;model disease modification and almost complete reversal of myotonia after a single dose (20&#160;mg/kg) of one of our ASOs conjugated to a Fab targeting TfR1. As shown in the figure below, we evaluated the severity of myotonia on a four-point scale 14 days following dosing with saline (PBS), naked ASO and the conjugated ASO, with grade 0 representing no myotonia, grade 1 representing myotonic discharge as measured by electromyography (EMG) in less than 50% of needle insertions, grade 2 representing myotonic discharge in greater than 50% of needle insertions and grade 3 representing myotonic discharge with nearly every needle insertion. We conducted this evaluation in quadriceps, gastrocnemius and tibialis anterior muscles.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Single dose of FORCE reversed myotonia in HSA-LR DM1 mouse model </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000012.jpg" title="" alt="" style="width:392px;height:354px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in a third-party study of a naked ASO conducted in the same&#160;HSA-LR&#160;model by the company that discontinued its program due to delivery challenges, reductions in myotonia were observed after one month following eight 25&#160;mg/kg doses of a naked ASO administered biweekly for a total dose of 200&#160;mg/kg.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the correction of splicing and reduction of myotonia we observed in our studies show that the intravenously administered ASO conjugated to a Fab was internalized into multiple muscles, enabling the ASO payload to enter the nucleus and degrade toxic DMPK RNA, thereby releasing splicing proteins to correct splicing of multiple RNAs and reverse myotonia.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reduction of toxic human nuclear DMPK in a DM1 mouse disease model</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed an innovative hTfR1/DMSXL mouse model designed to evaluate pharmacodynamics and accelerate the advancement of our DM1 program. This model was designed with two key characteristics:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">it expresses a human TfR1, or hTfR1, rather than the murine TfR1 expressed in WT mice, enabling uptake of human TfR1-targeting Fabs; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">it expresses murine WT DMPK and toxic human nuclear DMPK that represents a severe DM1 phenotype with more than 1,000 CTG repeats.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;These characteristics enable us to evaluate the ability of our lead DM1 candidate to reduce toxic human nuclear DMPK RNA. This hTfR1/DMSXL mouse model is illustrated below.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Overview of hTfR1/DMSXL DM1 mouse model</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000013.jpg" title="" alt="" style="width:606px;height:298px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In a preclinical study using the hTfR1/DMSXL mouse model, as shown below, we observed that two doses of an ASO conjugated to a Fab targeting human TfR1 resulted in significant reductions after 14 days in toxic human nuclear DMPK RNA in the tibialis anterior, gastrocnemius, heart and diaphragm muscles. In the study, our candidate was well tolerated.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE reduced toxic human nuclear DMPK RNA in multiple muscles in hTfR1/DMSXL DM1 mouse model</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000014.jpg" title="" alt="" style="width:423px;height:307px;"></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:39.31%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">** P &lt; 0.01</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:39.31%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">*** P &lt; 0.001</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:39.31%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">**** P &lt; 0.0001</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Separately, in a third-party study of a naked ASO conducted in a DMSXL mouse model, after 44 days and significantly more and higher doses of the naked ASO, the naked ASO achieved toxic human nuclear DMPK knockdown at levels comparable to what we observed after 14 days in our study in the hTfR1/DMSXL mouse model.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Enhanced muscle distribution </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While oligonucleotides are rationally designed genetic medicines, the current limitations with respect to delivery of oligonucleotides to muscle tissue present a significant limitation to advancing modern oligonucleotide therapeutics for muscle diseases. We have designed our FORCE platform to overcome these limitations. In preclinical studies, we observed that a single intravenous dose of one of our ASOs conjugated to a Fab targeting TfR1 was able to deliver its DMPK-targeted ASO payload to skeletal, cardiac and smooth muscle cells in mice and&#160;non-human&#160;primates and decrease WT DMPK RNA in the cytoplasm of different muscle cells.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have observed dose-dependent and long-lasting reductions in the levels of DMPK in WT mice. In preclinical studies shown in the figures below, one of our ASOs when conjugated to a Fab targeting TfR1 resulted in a dose-dependent reduction in levels of cytoplasmic WT DMPK RNA that was greater than the reductions observed with the naked ASO. In this study we also evaluated our ASO conjugated to a Fab &#8220;scramble control&#8221; which does not bind to any known murine cell receptor in the gastrocnemius, soleus, heart and diaphragm muscles, at two dose levels, to demonstrate the advantage of leveraging TfR1 to deliver oligonucleotides to muscle. The percentages in the green boxes reflect the amount by which DMPK RNA decreased with the conjugated ASO compared to saline (PBS) administration.<font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE dose-dependently decreased DMPK RNA </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000015.jpg" title="" alt="" style="width:464px;height:307px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dose A: low dose </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dose B: high dose </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;* P &lt; 0.05 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;** P &lt; 0.01 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*** P &lt; 0.001 </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also observed results in preclinical studies important to our efforts to develop redosable, titratable and durable therapeutics under our FORCE platform. Specifically, we observed durability of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">response up to 12 weeks in the tibialis anterior muscle and other muscles after a single dose in WT mice. In addition, repeat doses in WT mice were well tolerated and resulted in increased reductions in cytoplasmic WT DMPK RNA as compared to single doses.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also developed a distinct hTfR1 mouse model which expresses a human TfR1, rather than the murine TfR1 expressed in WT mice, and cytoplasmic WT DMPK. In preclinical studies using the hTfR1 mouse model, as shown below, we observed that two doses of an ASO conjugated to a Fab targeting human TfR1 resulted in significant reductions in cytoplasmic WT DMPK RNA in the tibialis anterior, gastrocnemius, heart and diaphragm muscles.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE decreased WT DMPK RNA in hTfR1 mouse model </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000016.jpg" title="" alt="" style="width:464px;height:292px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">** P &lt; 0.01 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">**** P &lt; 0.0001 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We also are evaluating our DM1 program in&#160;non-human&#160;primates. Currently there are no known DM1 disease models in&#160;non-human&#160;primates. As a result, any therapeutic candidate that reduces DMPK RNA expression in&#160;non-human&#160;primates is a result of targeting cytoplasmic WT DMPK RNA and not reflective of disease modification, which would require targeting toxic DMPK RNA in the nucleus. Consequently, we utilize&#160;non-human&#160;primate studies to evaluate muscle delivery, pharmacokinetics and tolerability of our FORCE platform. As shown in the figure below, in studies in&#160;non-human&#160;primates, a single intravenous dose of one of our ASOs when conjugated to a Fab targeting TfR1 reduced cytoplasmic DMPK RNA in multiple skeletal, cardiac and smooth muscles. In addition, and also as shown in the figure below, our conjugated ASO produced greater reductions, or knockdown (KD), in DMPK RNA than an equivalent dose of the naked ASO. Furthermore, our conjugated ASO produced less knockdown in DMPK RNA in&#160;non-muscle&#160;tissues, including kidney, liver and spleen tissues, as compared to a naked ASO, which we believe indicates specificity of our conjugated ASO for muscle tissue. Treatment with our conjugated ASO in these&#160;non-human&#160;primates was well tolerated with no clinically meaningful changes in hematology, serum biochemistry, platelet numbers, iron homeostasis, or kidney or liver function.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE significantly decreased cytoplasmic DMPK RNA in non-human primate skeletal, cardiac and smooth muscle </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000017.jpg" title="" alt="" style="width:487px;height:766px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Next steps </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our preclinical studies, we have observed targeting of mutant DMPK RNA in the nucleus, reduction of nuclear foci and splicing correction of key genes in DM1 patient cells, dose-dependent correction of splicing and reversal of myotonia after a single dose in the&#160;HSA-LR&#160;mouse DM1 model, reduction of toxic human nuclear DMPK in a hTfR1/DMSXL DM1 mouse model developed by us, durability of DMPK RNA knockdown up to 12 weeks, enhanced DMPK RNA knockdown with repeat dosing in WT and hTfr1 mice and enhanced delivery of DMPK-targeting ASO payload to murine and&#160;non-human&#160;primate skeletal, cardiac and smooth muscle tissue.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these results, we plan to conduct&#160;IND-enabling&#160;safety studies in&#160;non-human&#160;primates and anticipate submitting an IND to the FDA for a product candidate in our DM1 program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Duchenne muscular dystrophy (DMD) </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are developing program candidates under our DMD program to address the genetic basis of DMD by delivering a PMO to muscle tissue to promote the skipping of specific DMD exons in the nucleus, allowing muscle cells to create a more complete, functional dystrophin protein and to potentially stop or reverse disease progression. We believe that PMOs, with their preferential targeting of nuclear mechanisms, are the best payload to address nuclear exon skipping. In&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">in vitro&#160;</font><font style="Background-color:#FFFFFF;">and</font><font style="font-style:italic;Background-color:#FFFFFF;">&#160;in vivo</font><font style="Background-color:#FFFFFF;">&#160;preclinical studies, our PMOs when conjugated to a Fab targeting TfR1 have shown increased exon skipping, increased dystrophin expression, reduced muscle damage and increased muscle function. We are seeking to build a DMD franchise by initially focusing on the development of a therapeutic for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44. We expect to submit an IND to the FDA for a product candidate in our Exon 51 skipping program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Disease overview and prevalence </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DMD is a&#160;monogenic,&#160;X-linked,&#160;disease&#160;caused by mutations in the gene that encodes for the dystrophin protein. Dystrophin protein is essential to maintain the structural integrity and normal function of muscle cells for walking, breathing and cardiac function. In patients with DMD, mutations in the dystrophin gene lead to certain exons being misread, resulting in the loss of function of the dystrophin protein. The reduction or absence of dystrophin leads to damage to muscle cell membranes, resulting in muscle cell death and progressive loss of muscle function.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DMD symptoms typically begin to manifest with weakness and progressive loss of muscle function beginning in the first few years of life. Young boys experience progressive muscle wasting and have difficulty standing up, climbing stairs, running, breathing and performing daily functions. As the disease progresses the severity of damage to skeletal and cardiac muscles results in patients experiencing total loss of ambulation in the&#160;pre-teenage&#160;or early teenage years. Progressive loss of upper extremity function is often observed in the&#160;mid-to-late&#160;teens followed by respiratory and/or cardiac failure, resulting in death before the age of 30.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that DMD occurs in approximately one in every 3,500 to 5,000 live male births and that approximately 12,000 to 15,000 patients in the United States, and approximately 25,000 patients in Europe, have DMD. Approximately 80% of patients with DMD have DMD mutations amenable to exon skipping in the nucleus. Exons 51, 53, 45 and 44 represent nearly half of the total mutations observed in DMD that are amenable to exon skipping, as illustrated in the figure below.<font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Overview of DMD exons amenable to skipping </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000018.jpg" title="" alt="" style="width:442px;height:190px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Current approaches and limitations </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. There are four&#160;FDA-approved&#160;naked&#160;PMO-based&#160;oligonucleotide&#160;therapies, each addressing a specific mutation: EXONDYS 51 (eteplirsen), which is approved for the treatment of DMD patients amenable to Exon 51 skipping, VYONDYS 53 (golodirsen), which is approved for the treatment of DMD patients amenable to Exon 53 skipping, VILTEPSO (vitolarsen), which is approved for the treatment of DMD patients amenable to Exon 53 skipping and AMONDYS 45 (casimersen), which is approved for the treatment of DMD patients amenable to EXON 45 skipping. However, each of the drugs requires weekly intravenous infusions. Eteplirsen, golodirsen and casimersen have demonstrated a less than 1% mean increase in dystrophin in clinical trials and vitolarsen has demonstrated an approximately 3% increase in dystrophin in clinical trials. The&#160;FDA-approved&#160;labels for all four drugs state that a clinical benefit has not yet been established and that continued approval may be contingent upon the verification of such clinical benefit in confirmatory clinical trials. In Europe, the European Medicines Agency has rejected an application for approval of eteplirsen citing insufficient evidence of clinical benefit. In addition, a fourth drug, TRANSLARNA (ataluren), has only been conditionally approved in the European Union, Iceland and South Korea&#160;for&#160;non-sense&#160;mutations&#160;in DMD in ambulatory patients aged five years and older. Each of these approved products seeks to address DMD through the exon skipping approach we are pursuing, but we believe their limited efficacy is due to poor muscle uptake and biodistribution. There are a number of product candidates in development, including product candidates in late stage clinical development, which seek to address DMD through the exon skipping approach we are pursuing, including naked oligonucleotides, targeted oligonucleotides and PMOs conjugated to charged peptides, as well as product candidates that seek to address DMD through gene editing and gene replacement with viral gene therapies and with other approaches. We believe that each of these approaches currently have significant limitations, and that there continues to be a high unmet medical need for new disease-modifying therapies.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Our approach </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our DMD program is designed to address the genetic basis of DMD by promoting the skipping of specific DMD exons in the nucleus, allowing muscle cells to create more complete, functional dystrophin protein. Under our DMD program, we are developing program candidates for intravenous infusion that incorporate a Fab targeting TfR1 conjugated to a PMO designed to promote the skipping of specific DMD exons in the nucleus. Existing clinical data generated by others supports the benefits of utilizing a single stranded ASO or PMO to skip the faulty exon in the nucleus of DMD patient cells. We believe the Fab targeting TfR1 allows for more efficient delivery of a PMO to skeletal, cardiac and smooth muscle cells, creating an opportunity to increase dystrophin expression, enable less frequent dosing and provide greater clinical benefit compared to current therapeutic approaches. We plan to develop our program candidates for DMD with a PMO, initially for Exon 51 and in the future for other exon mutations including Exons 53, 45 </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">and 44. We have identified potential PMOs for mutations amenable to skipping Exons 51, 53 and 45 and plan to identify PMOs for mutations amenable to skipping Exon&#160;44.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical data </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are conducting preclinical studies of our PMOs conjugated to Fabs targeting TfR1 in human DMD cell lines and in mouse models of DMD. In&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">in vitro</font><font style="Background-color:#FFFFFF;">&#160;and&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">in vivo</font><font style="Background-color:#FFFFFF;">&#160;preclinical studies, these PMOs when conjugated to a Fab targeting TfR1 have shown increased exon skipping, increased dystrophin expression, reduced muscle damage and increased muscle function. We believe these data support the potential for our oligonucleotide therapy to be a disease-modifying therapy for patients with DMD.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Increased exon skipping </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We evaluated a candidate Exon&#160;51-targeting&#160;PMO conjugated to a Fab targeting TfR1 in human DMD myotubes, a type of muscle cell, with a mutation amenable to Exon 51 skipping. We observed that treatment with the conjugated PMO resulted in a 50% increase in exon skipping as compared to a 25% increase in exon skipping following treatment with an equimolar dose of the naked PMO (p=0.001), as illustrated in the figure below.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE increased exon skipping in human DMD myotubes with exon 51 mutation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000019.jpg" title="" alt="" style="width:410px;height:280px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.62%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.62%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style:italic;">*** P &lt; 0.001</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In studies in the mdx mouse DMD model, a validated and widely accepted mouse model in DMD which has a mutation in Exon 23, we observed that single intravenous doses of an Exon&#160;23-targeting&#160;PMO conjugated to a Fab targeting TfR1 which we refer to as FORCE-M23D, achieved effective, dose-dependent exon skipping in multiple muscles, including in the quadriceps, diaphragm and cardiac muscles, 14 days following treatment, as illustrated in the figure below.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE achieved effective exon skipping in mdx mouse DMD model </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000020.jpg" title="" alt="" style="width:457px;height:164px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Levels of exon skipping of FORCE-M23D in this study were also higher than levels of exon skipping observed in third-party studies of a naked PMO or a stereopure ASO in the same mdx mouse model.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Increased dystrophin expression </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In the same mdx mouse DMD model, we observed that the exon skipping promoted by a Exon&#160;23-targeting&#160;PMO when conjugated to a Fab targeting TfR1 resulted in dose-dependent production of dystrophin protein in the quadriceps muscle, as illustrated in the western blot (top) and bar graph (bottom) below. Levels of dystrophin expression in this study were also higher than levels of dystrophin expression observed in a third-party study of a naked PMO in the same mdx mouse model. In this study, we utilized Alpha-Actinin as a control protein.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE dose-dependently increased dystrophin expression in mdx mouse DMD model quadriceps muscle </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000021.jpg" title="" alt="" style="width:450px;height:124px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000022.jpg" title="" alt="" style="width:347px;height:310px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We also observed in the mdx mouse DMD model that a single dose of FORCE-M23D restored dystrophin expression to the muscle cell membrane based on immunohistochemistry in the quadricep. In addition, FORCE-M23D restored more dystrophin compared to an equivalent dose of the naked PMO which we refer to as naked M23D, as indicated by the greater purple shading in the figure for FORCE-M23D as compared to naked M23D and a saline control.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Dystrophin expression in quadriceps muscle </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000023.jpg" title="" alt="" style="width:452px;height:100px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We believe localization of dystrophin to the muscle cell membrane is critical to restore muscle cell structural integrity and function in patients with DMD and that these data show more effective PMO delivery to muscle when using our conjugated PMO as compared to the naked PMO.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Reduced muscle damage </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In DMD patients, the reduction of muscle cell structural integrity leads to muscle cell membrane damage and the leakage of creatine kinase (CK), an enzyme normally found inside muscle cells, into serum. As a result, the presence of creatine kinase in serum is utilized as a biomarker for muscle damage in DMD. In preclinical studies in the mdx mouse DMD model, we observed that levels of creatine kinase decreased significantly more in mice treated with a single dose of FORCE-M23D when measured two and four weeks following dosing compared to mice treated with naked M23D, as illustrated in the figure below.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Single dose of FORCE significantly reduced serum creatine kinase in mdx mouse DMD model </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000024.jpg" title="" alt="" style="width:442px;height:188px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.62%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.62%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;**** P &lt; 0.0001 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Increased muscle function </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In additional preclinical studies in the mdx mouse DMD model, we observed that a single dose of FORCE-M23D demonstrated a functional benefit in multiple standardized assessments conducted in blinded conditions. In a hind limb fatigue challenge, mice treated with a single dose of FORCE-M23D performed significantly better than those treated with naked M23D two weeks following treatment. In addition, the performance of the mdx mice treated with FORCE-M23D was statistically equivalent to the performance of a control cohort of healthy, wild-type mice treated with saline, as illustrated in the figure below.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Single dose of FORCE demonstrated functional benefit in mdx mouse DMD model: hind limb fatigue challenge </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000025.jpg" title="" alt="" style="width:388px;height:336px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:31.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:31.38%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">** P &lt; 0.01<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:31.38%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">*** P &lt; 0.001 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:31.38%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">NS: not statistically significant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In the home cage running wheel study, the distance traveled by mice is measured over a&#160;24-hour&#160;period. In this functional assessment, mdx mice treated with a single dose of FORCE-M23D performed better than those treated with naked M23D four weeks following treatment, with the performance of the mdx mice treated with FORCE-M23D mirroring the performance of a control cohort of healthy, wild-type mice treated with saline, as illustrated in the figure below. In this study, the mice were subjected to both light and dark periods to simulate the course of a day, and activity was higher during dark periods reflecting the nocturnal nature of mice.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Single dose of FORCE demonstrated functional benefit in mdx mouse DMD model: home cage running wheel </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000026.jpg" title="" alt="" style="width:427px;height:254px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We believe the results from these preclinical studies are consistent with improvements in both skeletal and cardiac muscle function resulting from targeted delivery of PMOs in muscle tissue, enhanced exon skipping, increased dystrophin expression and improved muscle health.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Next steps </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are seeking to build a DMD franchise by initially focusing on the development of a therapeutic for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exons 53, 45 and 44. We plan to conduct&#160;IND-enabling&#160;safety studies in&#160;non-human&#160;primates and anticipate submitting an IND to the FDA for a product candidate in our Exon 51 skipping program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Facioscapulohumeral Dystrophy (FSHD) </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are developing program candidates under our FSHD program that are designed to address the genetic basis of FSHD by reducing DUX4 expression in muscle tissue. We exclusively licensed from the University of Mons, or UMONS, intellectual property covering multiple ASOs that have been shown to potently target DUX4 in preclinical studies. We anticipate submitting an IND to the FDA for a product candidate in our FSHD program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Disease overview and prevalence </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FSHD is one of the most common muscular dystrophies and affects both sexes equally, with onset typically in teens and young adults. FSHD is characterized by progressive skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms and trunk and progresses to weakness </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in muscles in lower extremities and the pelvic girdle. Skeletal muscle weakness results in significant physical limitations, including progressive loss of facial muscles that can cause an inability to smile or communicate, difficulty using arms for activities of daily living and difficulty getting out of bed, with many patients ultimately becoming dependent upon the use of a wheelchair for daily mobility activities. We estimate that the patient population is between 16,000 and 38,000 in the United States and approximately 35,000 in Europe. We believe that there may be additional patients who are not formally diagnosed due to a perceived difficulty of obtaining a diagnosis and the fact that there are no approved treatments. Approximately&#160;two-thirds&#160;of cases are familial-inherited in an autosomal dominant fashion and&#160;one-third&#160;of cases occur randomly or as a result of environmental factors. FSHD affects all ethnic groups with similar incidence and prevalence.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FSHD is caused by aberrant expression of the DUX4 gene in muscle resulting in inappropriate presence of the DUX4 protein, a transcription factor causing the expression of other genes. Normally, DUX4-driven gene expression is limited to early embryonic development, after which time the DUX4 gene is silenced. In patients with FSHD, a genetic mutation causes expression of DUX4 protein to continue after embryonic development. The DUX4 protein regulates the expression of multiple genes encoding other proteins, some of which are toxic to muscle. Evidence of aberrant expression of DUX4 and the genes it activates, including ZSCAN4, MBD3L2, and TRIM43, is a major molecular signature that distinguishes muscles affected by FSHD from healthy muscle. The aberrant expression of DUX4 in FSHD results in muscle death and replacement by fat, which leads to the progressive muscle weakness and disability which characterize the disease, as shown in the figure below.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FSHD: genetic basis and disease process </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000027.jpg" title="" alt="" style="width:482px;height:160px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Current approaches and limitations </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">There are currently no approved therapies for FSHD, and patients are treated with pain management and physical therapy. There are a number of product candidates in clinical development, including losmapimod, a p38 MAPK inhibitor that is intended to modulate DUX4 expression and is being evaluated in a Phase 2 clinical trial. To aid in the development of therapies for FSHD, we are sponsoring an ongoing natural history study seeking to validate new clinical outcome assessments and evaluate physiological biomarkers to support the design and implementation of future clinical trials.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Our approach </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are developing program candidates under our FSHD program that are designed to address the genetic basis of FSHD by reducing DUX4 expression in muscle tissue. We exclusively licensed from UMONS intellectual </font>property covering multiple&#160;DUX-targeting&#160;ASOs that have been shown to potently target DUX4 in preclinical studies. We are currently evaluating these ASOs conjugated to a Fab targeting TfR1 in patient-derived FSHD myotubes.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the figure below, we administered to patient-derived myotubes an ASO conjugated to a Fab targeting TfR1, which we refer to as FORCE-FM10, and naked FM10 and observed reduced DUX4-associated gene expression, as measured by the mRNA transcribed by three genes that are known to be only expressed following DUX4 activation, MBD3L2, TRIM43 and ZSCAN4. In addition, IC50 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">concentrations for the conjugated FM10 were up to 9.6 times lower than those observed for naked FM10, indicating that conjugated FORCE-FM10 was up to 9.6 times more potent than naked FM10. IC50 concentration is a measure of the potency of a substance that indicates how much of the substance is needed to inhibit a biological process.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FORCE-FM10 suppressed expression of key DUX4 biomarkers in FSHD patient myotubes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gtinntqqusay000028.jpg" title="" alt="" style="width:482px;height:214px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Next steps </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We plan to conduct&#160;IND-enabling&#160;safety studies in&#160;non-human&#160;primates and anticipate submitting an IND to the FDA for a product candidate in our FSHD program as one of the three INDs we expect to submit between the fourth quarter of 2021 and the fourth quarter of 2022.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Discovery programs </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to expand our FORCE portfolio by pursuing programs in additional indications, including additional rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases. By rationally selecting therapeutic payloads to conjugate with our proprietary Fab and linker, we plan to develop product candidates to address the genetic basis of additional muscle diseases. In selecting these payloads, we plan to prioritize ASOs for indications driven by nuclear genetic targets and siRNAs for indications driven by cytoplasmic targets. We have completed screening and identified potent ASO and siRNA payloads against a number of cardiac and metabolic targets. We may selectively establish strategic collaborations for certain of these programs where we believe we could benefit from the resources or capabilities of other biopharmaceutical companies. We may also seek strategic collaborations where we believe we can utilize our FORCE platform to enhance delivery of third-party payloads to muscle tissue.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our muscle disease portfolio, we believe there is an opportunity to leverage our TfR1 antibody expertise to develop novel antibodies that cross the blood-brain barrier and deliver therapeutics to CNS tissue through systemic intravenous administration. These antibodies will likely have different characteristics, such as TfR1 affinity, than the antibodies we have optimized for muscle delivery.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate manufacturing facilities. We currently rely on third-party contract manufacturing organizations, or CMOs, and suppliers for the Fab antibodies, linker and oligonucleotide payloads that comprise our program candidates and the conjugation of these components. We plan to use third-party CMOs to support&#160;our&#160;IND-enabling&#160;studies&#160;and to fully supply our clinical trials and commercial activities, but may also seek to eventually establish our own manufacturing facility for long-term commercial supply. As we scale manufacturing, we intend to continue to expand and strengthen our network of CMOs. We believe there are multiple sources for all of the materials required for the manufacture of our product candidates, as well as multiple CMOs who could assemble the antibody, linker and payload that comprise our program candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing is subject to extensive regulations that impose procedural and documentation requirements. These regulations govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our CMOs are required to comply with these regulations and are assessed through regular monitoring and formal audits. Our third-party manufacturers are required to manufacture any product candidates we develop under current Good Manufacturing Practice, or cGMP, requirements and other applicable laws and regulations.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have personnel with extensive technical, manufacturing, analytical and quality experience to oversee all contracted manufacturing and testing activities. We have established a CMC Advisory Board to support our manufacturing personnel.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect our proprietary technology, inventions, improvements, platforms, program candidates, product candidates and components thereof, their methods of use and processes for their manufacture that we believe are important to our business, including by obtaining, maintaining, defending and enforcing patent and other intellectual property rights for the foregoing in the United States and in foreign jurisdictions. We also rely on trade secrets and confidentiality agreements to protect our confidential information&#160;and&#160;know-how&#160;and&#160;other aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future commercial success depends in part on our ability to:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">obtain, maintain, enforce and defend patent and other intellectual property rights for our important technology, inventions and know-how;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">preserve the confidentiality of our trade secrets and other confidential information;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">obtain and maintain licenses to use and exploit intellectual property owned or controlled by third parties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">operate without infringing, misappropriating or otherwise violating any valid and enforceable patents and other intellectual property rights of third parties; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;">defend against challenges and assertions by third parties challenging the validity or enforceability of our intellectual property rights, or our rights in our intellectual property, or asserting that the operation of our business infringes, misappropriates or otherwise violates their intellectual property rights.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 2, 2021, we owned 36 patent application families related to our business, comprised of 40 U.S. provisional patent applications, 10 pending U.S. non-provisional patent applications, 14 pending Patent Cooperation Treaty, or PCT, patent applications, and 75 pending foreign patent applications in Australia, Canada, Europe, Eurasia, India, Israel, Japan, South Korea, Mexico, Singapore, and South Africa, and we exclusively licensed one patent family, comprised of two issued U.S. patents, two pending U.S. patent applications and one issued European patent that has been validated in Belgium, Switzerland, Germany, Denmark, Spain, France, the United Kingdom, Ireland, Italy, the Netherlands and Sweden. None of our pending PCT patent applications has entered the national stage. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our owned and licensed patent estate covers various aspects of our programs and technology, including our FORCE platform, proprietary antibodies, oligonucleotide conjugates, methods of treatment and aspects of manufacturing. Any U.S. or foreign patents issued from national stage filings of our PCT patent applications and any U.S. patents issued&#160;from&#160;non-provisional&#160;applications&#160;we may file in connection with our provisional patent applications would be scheduled to expire on various dates from 2039 through 2041, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity and other governmental fees. Further details on certain segments of our patent portfolio are included below.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">FORCE platform</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to our FORCE platform, as of March 2, 2021, <font style="color:#000000;">we owned four pending PCT patent applications, nineteen pending U.S. provisional patent applications, one pending U.S. non-provisional patent application, and eleven pending foreign patent applications in Australia, Canada, Europe, Eurasia, India, Israel, Japan, South Korea, Mexico, Singapore, and South Africa. </font> These applications relate to various aspects of our FORCE platform including proprietary antibodies, oligonucleotide conjugates, methods of manufacture and methods of treatment. Any patents issued from these applications are expected to expire from 2039 to 2041; however, patent term extension may be available.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">DM1 program</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to our DM1 program, as of March 2, 2021, we owned two pending PCT patent applications, seven pending U.S. provisional patent applications, one pending U.S. non-provisional patent application, and eleven pending foreign patent applications in Australia, Canada, Europe, Eurasia, India, Israel, Japan, South Korea, Mexico, Singapore, and South Africa. These applications relate to composition of matter and methods of treating disease involving our FORCE platform in the context of DM1. Any patents issued from these applications are expected to expire from 2039 to 2041; however, patent term extension may be available.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">DMD program</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to our DMD program, as of March 2, 2021, we owned one pending PCT patent application, five pending U.S. provisional patent applications, one pending US non-provisional patent application, and eleven pending foreign patent applications in Australia, Canada, Europe, Eurasia, India, Israel, Japan, South Korea, Mexico, Singapore, and South Africa. These applications relate to composition of matter and methods of treating disease involving our FORCE platform in the context of DMD. Any patents issued from these applications are expected to expire in 2039 and 2041; however, patent term extension may be available.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">FSHD program</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to our FSHD Program, as of March 2, 2021, we owned one pending PCT patent application, five pending U.S. provisional patent applications, one pending US non-provisional patent application, and eleven pending foreign patent applications in Australia, Canada, Europe, Eurasia, India, Israel, Japan, South Korea, Mexico, Singapore, and South Africa. These applications relate to composition of matter and methods of treating disease involving our FORCE platform in the context of FSHD. Any patents issued from these applications are expected to expire in 2039 and 2041; however, patent term extension may be available. We also&#160;in-license&#160;a patent family from UMONS comprised of two issued U.S. patents, two pending U.S. patent applications and one issued European patent that has been validated in Belgium, Switzerland, Germany, Denmark, Spain, France, the United Kingdom, Ireland, Italy, the Netherlands and Sweden. The issued patents expire in 2031; however, a patent term extension may be available.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Discovery programs</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to our discovery programs, as of March 2, 2021, we owned five pending PCT patent applications, one pending US non-provisional patent application, and one European patent application. These applications relate to composition of matter and methods of treating disease involving our FORCE platform in the context of a variety of additional rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases. Any patents issued from these applications are expected to expire in 2039 and 2041; however, patent term extension may be available.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent prosecution</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A PCT patent application is not eligible to become an issued patent until, among other things, we file one or more national stage patent applications in the jurisdictions in which we seek patent protection and do so within prescribed timelines of the PCT application&#8217;s priority date. These prescribed timelines are generally 30 months, 31 months or 32 months, depending on the jurisdiction. If we do not timely file any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">national stage patent applications, we may lose our priority date with respect to our PCT patent </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">application and any potential patent protection on the inventions disclosed in such PCT patent application.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, a provisional patent application is not eligible to become an issued patent. A provisional patent application may serve as a priority filing for a&#160;non-provisional&#160;patent application we file within 12 months of such provisional patent application. If we do not timely file&#160;non-provisional&#160;patent applications, we may lose our priority date with respect to our existing provisional patent applications and any potential patent protection on the inventions disclosed in our provisional patent applications.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we intend to timely file additional provisional patent applications and national stage and&#160;non-provisional&#160;patent applications relating to our PCT patent applications, we cannot predict whether any of our patent applications will result in the issuance of patents. If we do not successfully obtain patent protection, or if the scope of the patent protection we or our licensors obtain with respect to our product candidates or technology is insufficient, we will be unable to use patent protection to prevent others from using our technology or from developing or commercializing technology and products similar or identical to ours or other similar competing products and technologies. Our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our technology, inventions and improvements, either directly or indirectly, will depend in part on our success in obtaining, maintaining, defending and enforcing patent claims that cover our technology, inventions and improvements.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. The protection afforded by a patent varies on a&#160;product-by-product&#160;basis, from&#160;jurisdiction-to-jurisdiction,&#160;and depends upon many factors, including the type of patent, the scope of its coverage, the availability of patent term adjustments and regulatory-related patent term extensions, the availability of legal remedies in a particular jurisdiction and the validity and enforceability of the patent. Patent laws and related enforcement in various jurisdictions outside of the United States are uncertain and may not protect our rights to the same extent as the laws of the United States. Changes in the patent laws and rules, whether by legislation, judicial decisions or regulatory interpretation, in the United States and other jurisdictions may have uncertain affects that could improve or diminish our ability to protect our inventions and obtain, maintain, defend and enforce our patent rights, and could therefore affect the value of our business in uncertain ways.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The area of patent and other intellectual property rights in biotechnology is evolving and has many risks and uncertainties, and third parties may have blocking patents and other intellectual property that could be used to prevent us from commercializing our platform and product candidates and practicing our proprietary technology. Our patent rights may be challenged, narrowed, circumvented, invalidated or ruled unenforceable, which could limit our ability to stop third parties from marketing and commercializing related platforms or product candidates or limit the term of patents that cover our platform and any product candidates. In addition, the rights granted under any issued patents may not provide us with protection or competitive advantages against third parties with similar technology, and third parties may independently develop similar technologies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any competitive advantage provided by the patent. For this and other risks related to our proprietary technology, inventions, improvements, platforms and product candidates and intellectual property rights related to the foregoing, please see the section entitled &#8220;Risk factors&#8212;Risks related to our intellectual property.&#8221;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent term</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the laws of the jurisdictions in which they are obtained. In most jurisdictions in which we file, the patent term is 20&#160;years from the earliest date of filing of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">first&#160;non-provisional&#160;patent&#160;application to which the patent claims priority. However, the term of U.S. </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents may be extended or adjusted for delays incurred due to compliance with FDA requirements or by delays encountered during prosecution that are caused by the United States Patent and Trademark Office, or the USPTO. For example, in the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, for up to five years beyond the normal expiration date of the patent. Patent term extension cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. During the period of extension, if granted, the scope of exclusivity is limited to the approved product for approved uses. Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. For more information on patent term extensions, see </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1. </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Business&#8212;Government regulation&#8212;Patent term restoration and extension&#8221;</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in this Annual Report on Form 10-K.</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In the future, if and when any product candidates we may develop receive FDA approval, we expect to apply for patent term extensions on issued patents covering those product candidates. Moreover, we intend to seek patent term adjustments and extensions for any of our issued patents in any jurisdiction where such adjustments and extensions are available. However, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such adjustments and extensions should be granted, and even if granted, the length of such adjustments and extensions.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Trade secrets </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In addition to patent protection, we also rely on trade secrets,&#160;know-how,&#160;unpatented technology and other proprietary information to strengthen our competitive position. We currently, and may continue in the future continue to, rely on third parties to assist us in developing and manufacturing our products. Accordingly, we must, at times, share trade secrets,&#160;know-how,&#160;unpatented technology and other proprietary information, including those related to our platform, with them. We may in the future also enter into research and development collaborations with third parties that may require us to share trade secrets,&#160;know-how,&#160;unpatented technology and other proprietary information under the terms of research and development partnerships or similar agreements. Nonetheless, we take steps to protect and preserve our trade secrets and other confidential and proprietary information and prevent the unauthorized disclosure of the foregoing, including by entering into&#160;non-disclosure&#160;and invention assignment agreements with parties who have access to our trade secrets or other confidential and proprietary information, such as employees, consultants, outside scientific collaborators, contract research and manufacturing organizations, sponsored researchers and other advisors, at the commencement of their employment, consulting or other relationships with us. In addition, we take other appropriate precautions, such as maintaining physical security of our premises and physical and electronic security of our information technology systems, to guard against any misappropriation or </font>unauthorized disclosure of our trade secrets and other confidential and proprietary information by third parties.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite these efforts, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or other confidential or proprietary information. In addition, we cannot provide any assurances that all of the&#160;foregoing&#160;non-disclosure&#160;and&#160;invention assignment agreements have been duly executed, and any of the counterparties to such agreements may breach them and disclose our trade secrets and other confidential and proprietary information. Although we have confidence in the measures we take to protect and preserve our trade secrets and other confidential and proprietary information, they may be inadequate, our agreements or security measures may be breached, and we may not have adequate remedies for such breaches. Moreover, to the extent that our employees, contractors, consultants, collaborators and advisors use intellectual property owned by others in their work for us, disputes may arise as to our rights in&#160;any&#160;know-how&#160;or&#160;inventions arising out of such work. For more information, please see the section entitled &#8220;Risk factors&#8212;Risks related to our intellectual property.&#8221;<font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">License agreement with the University of Mons </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, we entered into a license agreement with UMONS, or the UMONS Agreement, pursuant to which UMONS granted to us an exclusive, worldwide license to certain patents and patent applications related to oligonucleotides for our FSHD program and a&#160;non-exclusive,&#160;worldwide license to existing, related&#160;know-how.&#160;Each of the issued patents licensed to us under the UMONS Agreement is scheduled to expire in 2031. The licenses under the UMONS Agreement confer on us the right to research, develop and commercialize products, which we refer to as licensed products, and to practice processes, in each case, covered by the licensed patents and existing, related&#160;know-how.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UMONS Agreement, we are obligated to use commercially reasonable efforts to develop at least one licensed product and, to the extent regulatory approval is obtained in such jurisdictions, to commercialize at least one licensed product in the United States and the United Kingdom or a member country of the European Union. Unless terminated earlier, the UMONS Agreement will remain in effect until the last to expire of the licensed patent rights on a licensed&#160;product-by-licensed&#160;product and&#160;country-by-country&#160;basis. UMONS may terminate the UMONS Agreement in the event of a material breach by us and our failure to cure such breach within a specified time period. We may voluntarily terminate the UMONS Agreement with prior notice to UMONS.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our entry into the UMONS Agreement, we paid UMONS an upfront payment of&#160;&#8364;50,000. We also agreed to make milestone payments to UMONS upon the achievement of specified development and regulatory milestones up to a maximum aggregate total of&#160;&#8364;400,000 for the first licensed product to achieve such milestones and up to a maximum aggregate total of&#160;&#8364;200,000 for each subsequent licensed product to achieve each such milestones, as well as a low single-digit percentage royalty on net sales of licensed products by us, our affiliates and sublicensees. These royalty obligations continue on a licensed&#160;product-by-licensed&#160;product and&#160;country-by-country&#160;basis until the expiration of the last licensed patent rights covering such licensed product in such country. In addition, if we sublicense rights under the UMONS Agreement, we are required to pay a low double-digit percentage of the sublicense revenue to UMONS. Additionally, if we choose to file, prosecute or maintain any patents included in the licensed patent rights under the UMONS Agreement, we will be required to bear the full cost and expenses of preparing, filing, prosecuting and maintaining any such patents.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and biopharmaceutical industries generally, and the muscle disease field specifically, are characterized by rapid evolution of technologies, sharp competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our technology, development experience and scientific knowledge in the field of muscle diseases, oligonucleotide therapeutics and manufacturing provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no approved therapies to treat the underlying cause of DM1. Product candidates currently in development to treat DM1 include: tideglusib, a GSK3-&#223; inhibitor in late-stage clinical development by AMO Pharma Ltd. for the congenital phenotype of DM1;&#160;AT466, which is&#160;an&#160;AAV-antisense&#160;candidate&#160;in preclinical development by Audentes Therapeutics, Inc.; an antibody linked siRNA in preclinical development by Avidity Biosciences, Inc.; gene editing treatments in preclinical development by Vertex Pharmaceuticals, Inc., or Vertex; an&#160;RNA-targeting&#160;gene therapy in preclinical development by Locana, Inc.; small molecules interacting with RNA in preclinical development by Expansion Therapeutics, Inc. and therapeutics based on biomolecular condensate biology in preclinical development by Dewpoint Therapeutics, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is an&#160;FDA-approved&#160;corticosteroid marketed by PTC Therapeutics, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc., or PTC. In addition, there are </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">four</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;FDA-approved&#160;exon skipping drugs: EXONDYS 51 (eteplirsen)</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> VYONDYS 53 (golodirsen)</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and AMONDYS 45 (casimersen)</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which are naked PMOs approved for the treatment of DMD patients amenable to Exon&#160;51</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Exon&#160;53</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Exon 45</font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> skipping, respectively, and are marketed by Sarepta Therapeutics, Inc., or Sarepta, and VILTEPSO (vitolarsen), a naked PMO approved for the treatment of DMD patients amenable to Exon 53 skipping, which is marketed by Nippon Shinyaku Co. Ltd. Companies focused on developing treatments for DMD that target dystrophin mechanisms, as does our DMD program, include Sarepta&#160;with&#160;SRP-5051,&#160;a&#160;peptide-linked PMO currently being evaluated in a Phase&#160;2 clinical trial for patients amenable to Exon&#160;51 skipping, Wave Life Sciences Ltd. with&#160;WVE-N531,&#160;a stereopure oligonucleotide in preclinical development for patients amenable to Exon&#160;53 skipping, PTC with ataluren, a small molecule targeting nonsense mutations in a Phase&#160;3 clinical trial, and Avidity Biosciences, Inc., which is in preclinical development with an antibody oligonucleotide conjugate that targets dystrophin production. In addition, several companies are developing gene therapies to treat DMD, including Milo Biotechnology (AAV1-FS344), Pfizer&#160;Inc.&#160;(PF-06939926),&#160;Sarepta&#160;(SRP-9001&#160;and&#160;Galgt2 gene therapy program), Solid Biosciences&#160;Inc.&#160;(SGT-001)&#160;and REGENXBIO Inc. Gene editing treatments that are in preclinical development are also being pursued by Vertex and Sarepta. We are also aware of several companies&#160;targeting&#160;non-dystrophin&#160;mechanisms&#160;for the treatment of DMD.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no therapies to treat the underlying cause of FSHD. Products currently in development to treat FSHD include: creatine monohydrate, a supplement that enhances muscle performance, which is being evaluated in a Phase 2 clinical trial by Murdoch Children&#8217;s Research Institute, and losmapimod, a p38 MAPK inhibitor that may modulate DUX4 expression, which is being evaluated in a Phase 2 clinical trial by Fulcrum Therapeutics Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies working to develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Aro Biotherapeutics, Arrowhead Therapeutics, Avidity Biosciences, Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, NeuBase Therapeutics, Inc. and Sarepta, as well as gene therapy and gene editing approaches.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, either independently or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than we are in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval for treatments and achieving widespread market acceptance. Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than products we may develop. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of other drugs. The key competitive factors affecting the successful of all any products we may develop are likely to be their efficacy, safety, convenience, price and availability of reimbursement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Government regulation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Government authorities in the United States, at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing,&#160;post-approval&#160;monitoring and reporting and import and export of pharmaceutical products, including biological products. The </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Licensure and regulation of biologics in the United States </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, any product candidates we may develop would be regulated as biological products, or biologics, under the Public Health Service Act, or PHSA, and the Federal Food, Drug and Cosmetic Act, or FDCA, and their implementing regulations and guidance. The failure to comply with the applicable U.S. requirements at any time during the product development process, including preclinical testing, clinical testing, the approval process, or&#160;post-approval&#160;process, may subject an applicant to delays in the conduct of the study, regulatory review and approval and/or administrative or judicial sanctions. These sanctions may include, but are not limited to, the FDA&#8217;s refusal to allow an applicant to proceed with clinical testing, refusal to approve pending applications, license suspension, or revocation, withdrawal of an approval, warning letters, adverse publicity, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines and civil or criminal investigations and penalties brought by the FDA or the Department of Justice, or DOJ, and other governmental entities, including state agencies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An applicant seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA&#8217;s Good Laboratory Practices, or GLP regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">performance of adequate and&#160;well-controlled&#160;human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance with current Good Clinical Practices, or GCP; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">preparation and submission to the FDA of a BLA for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">review of the product by an FDA advisory committee, where appropriate or if applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">payment of user Prescription Drug User Fee Act, or PDUFA, securing FDA approval of the BLA and licensure of the new biologic product; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">compliance with any&#160;post-approval&#160;requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and any&#160;post-approval&#160;studies or other post-marketing commitments required by the FDA. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical studies and investigational new drug application </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biologic product candidate in humans, including an antibody, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin or recommence.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or <font style="Background-color:#FFFFFF;">questions either during this&#160;initial&#160;30-day&#160;period,&#160;or at any time during the IND review process, it may choose to impose a partial or complete clinical hold. Clinical holds are imposed by the FDA whenever there is concern for patient safety, may be a result of new data, findings, or developments in clinical, preclinical and/or chemistry, manufacturing and controls or where there&#160;is&#160;non-compliance&#160;with&#160;regulatory requirements. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could cause significant delays or difficulties in completing our planned clinical trial or future clinical trials in a timely manner.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Expanded access to an investigational drug for treatment use </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on&#160;a&#160;case-by-case&#160;basis&#160;for: individual patients (single-patient IND applications for treatment in emergency settings and&#160;non-emergency&#160;settings);&#160;intermediate-size&#160;patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Although these requirements were rolled out over time, they have now come into full effect. This provision requires drug and biologic companies to make publicly available their policies for expanded access for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individual patient access to products intended for serious diseases. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 trial; or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, on May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Human clinical trials in support of a BLA </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in order to use the trial as support for an IND or application for marketing approval. Specifically, the FDA requires that such trials be conducted in accordance with GCP, including review and approval by an independent ethics committee and informed consent from participants. The GCP requirements encompass both ethical and data integrity standards for clinical trials. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled&#160;in&#160;non-IND&#160;foreign&#160;clinical trials, as well as the quality and integrity of the resulting data. They further help ensure&#160;that&#160;non-IND&#160;foreign&#160;trials are conducted in a manner comparable to that required for clinical trials in the United States.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB. This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB has access. Finally, research activities involving infectious agents, hazardous chemicals, recombinant DNA and genetically altered organisms and agents may be subject to review and approval of an Institutional Biosafety Committee, or IBC, in accordance with NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">Phase&#160;1</font><font style="font-size:10pt;font-family:Arial;color:#000000;">&#160;&#160;&#160;&#160;clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy subjects or patients. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">Phase&#160;2</font><font style="font-size:10pt;font-family:Arial;color:#000000;">&#160;&#160;&#160;&#160;clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase&#160;2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase&#160;3 clinical trials. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;font-family:Arial;color:#000000;">Phase&#160;3</font><font style="font-size:10pt;font-family:Arial;color:#000000;">&#160;&#160;&#160;&#160;clinical trials proceed if the Phase&#160;2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase&#160;3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A&#160;well-controlled,&#160;statistically robust Phase&#160;3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase&#160;3 studies are referred to as &#8220;pivotal.&#8221; </font></p></td></tr></table></div>
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety and effectiveness after approval. Such&#160;post-approval&#160;trials are typically referred to as Phase&#160;4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase&#160;4 clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting Phase&#160;4 clinical trials could result in withdrawal of approval for products.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act of 2003, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, FDA will meet early in the development process to discuss pediatric study plans with sponsors and FDA must meet with sponsors by no later than&#160;the&#160;end-of-phase&#160;1&#160;meeting for serious or life-threatening diseases and by no later than 90 days after FDA&#8217;s receipt of the study plan.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in the Food and Drug Administration Safety and Innovation Act. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about applicable clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Compliance with cGMP requirements </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes </font>and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a&#160;&#8220;risk-based&#160;schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Review and approval of a BLA </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of product candidate development, preclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject to an application user fee, which for federal fiscal year 2021 is $2,875,842 for an application requiring clinical data. The sponsor of a licensed BLA is also subject to an annual program fee, which for fiscal year 2021 is $336,432. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has 60&#160;days after submission of the application to conduct an initial review to determine whether to accept it for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission has been accepted for filing, the FDA begins&#160;an&#160;in-depth&#160;review&#160;of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond to the applicant, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the applicant otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent, and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of preclinical and clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the application is not approved, the FDA will issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a complete response letter may submit to the FDA information that represents a complete response to the issues identified by the FDA. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such resubmissions are classified under PDUFA as either Class&#160;1 or Class&#160;2. The classification of a resubmission is based on the information submitted by an applicant in response to an action letter. Under </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the goals and policies agreed to by the FDA under PDUFA, the FDA has two months to review a Class&#160;1 resubmission and six months to review a Class&#160;2 resubmission. The FDA will not approve an application until issues identified in the complete response letter have been addressed.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may also refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA approves a new product, it may limit the approved indication(s) for use of the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may call for&#160;post-approval&#160;studies, including Phase&#160;4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of&#160;post-market&#160;studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Fast track, breakthrough therapy, priority review and regenerative medicine advanced therapy designations </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or&#160;life-threatening&#160;disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation, priority review designation and regenerative medicine advanced therapy, or RMAT, designation. These designations are not mutually exclusive, and a product candidate may qualify for one or more of these programs. While these programs are intended to expedite product development and approval, they do not alter the standards for FDA approval.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, the FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or&#160;life-threatening&#160;disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.<font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second, in 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act. This law established a new regulatory scheme allowing for expedited review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or&#160;life-threatening&#160;disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a&#160;cross-disciplinary&#160;project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. Breakthrough designation may be rescinded if a product no longer meets the qualifying criteria.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third, the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on&#160;a&#160;case-by-case&#160;basis,&#160;whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a&#160;treatment-limiting&#160;product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months. Priority designation may be rescinded if a product no longer meets the qualifying criteria.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With passage of the Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative medicine advanced therapies. A product is eligible for RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative medicine advanced therapy designation include early interactions with FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review, and accelerated approval based on surrogate or intermediate endpoints. RMAT designation may be rescinded if a product no longer meets the qualifying criteria.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Accelerated approval pathway </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may grant accelerated approval to a product for a serious or&#160;life-threatening&#160;condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional&#160;post-approval&#160;confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous&#160;post-marketing&#160;compliance requirements, including the completion of Phase&#160;4 or&#160;post-approval&#160;clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required&#160;post-approval&#160;studies, confirm a clinical benefit during&#160;post-marketing studies or dissemination of false or misleading promotional materials would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Post-approval&#160;regulation </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular&#160;post-approval&#160;regulatory requirements as well as any&#160;post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to <font style="Background-color:#FFFFFF;">the approved labeling to add new safety information; imposition of&#160;post- market&#160;studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">fines, warning letters or holds on&#160;post-approval&#160;clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">product recall, seizure or detention, or refusal to permit the import or export of products; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Although healthcare providers may prescribe products for uses not described in the drug&#8217;s labeling, known&#160;as&#160;off-label&#160;uses,&#160;in their professional judgment, drug manufacturers are prohibited from soliciting, encouraging or promoting unapproved uses of a product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion&#160;of&#160;off-label&#160;uses,&#160;and a company that is found to have improperly&#160;promoted&#160;off-label&#160;uses&#160;may be subject to significant liability.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for&#160;direct-to-consumer&#160;advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such&#160;off-label&#160;uses because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of&#160;off-label&#160;uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional,&#160;non-misleading&#160;communication&#160;regarding&#160;off-label&#160;information,&#160;such as distributing scientific or medical journal information.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a company is found to have&#160;promoted&#160;off-label&#160;uses,&#160;it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Orphan drug designation </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more </font>than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file&#160;a complete request for designation.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Pediatric exclusivity is another type&#160;of&#160;non-patent&#160;marketing&#160;exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including&#160;the&#160;non-patent&#160;and&#160;orphan exclusivity.&#160;This&#160;six-month&#160;exclusivity&#160;may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six months.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Biosimilars and exclusivity </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or, collectively, the ACA, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA. The BPCIA established a regulatory scheme </font>authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an&#160;existing&#160;FDA-licensed&#160;&#8220;reference&#160;product.&#8221; As of January&#160;1, 2021, the FDA has approved 29 biosimilar products for use in the United States. No interchangeable biosimilars, however, have been approved. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Additional guidances are expected to be finalized by the FDA in the near term. Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12&#160;years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and&#160;well-controlled&#160;clinical trials to demonstrate the safety, purity </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the passage of the BPCIA, many states have passed laws or amendments to laws, including laws governing pharmacy practices, which are state-regulated, to regulate the use of biosimilars.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Federal and state data privacy and security laws </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, the U.S. Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 or HITECH, and their regulations, including the final omnibus rule published on January&#160;25, 2013, also imposes certain obligations on the business associates of covered entities and their subcontractors that obtain protected health information in providing services to or on behalf of covered entities. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to our business. In addition to possible federal administrative, civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Accordingly, state attorneys general have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. New laws and regulations governing privacy and security may be adopted in the future as well.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January&#160;1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways&#160;to&#160;opt-out&#160;of&#160;certain sales of personal information, and allow for a new cause of action for data breaches. Additionally, effective starting on January&#160;1, 2023, the California Privacy Rights Act, or CPRA, will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of&#160;non-compliance&#160;with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates we may develop, once approved, are sold in a foreign country, we may be subject to similar foreign laws.<font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Patent term restoration and extension </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the&#160;Hatch-Waxman&#160;Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is&#160;typically&#160;one-half&#160;the&#160;time between the effective date of the IND involving human beings and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&#160;years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Regulation and procedures governing approval of medicinal products in the European Union </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and&#160;well-controlled&#160;clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Clinical trial approval </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted, or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the applicant may only start a clinical trial at a specific site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the member states and further detailed in applicable guidance documents.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, but it has not yet become effective. It will overhaul the current system of approvals for clinical trials in the European Union. Specifically, the new legislation, which will be directly applicable in all member states, aims at simplifying and streamlining the approval of clinical trials in the European Union. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure via a single-entry point and strictly defined deadlines for the assessment of clinical trial applications. On January&#160;1, 2020, the website of the European Commission reported that the implementation of the new Clinical Trials Regulation was dependent on the development of a fully functional clinical trials portal and database, which would be confirmed by an independent audit, and that the new legislation would come into effect six months after the European Commission publishes a notice of this confirmation. In late 2020, the EMA indicated that it plans to focus on the findings of a system audit; improving the usability, quality and stability of the clinical trial information system; and knowledge transfer to prepare users and their organizations for the new </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical trial system. The EMA has indicated that the system will go live in December 2021. Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the European Union at the EudraCT website: https://eudract.ema.europa.eu.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">PRIME designation in the European Union </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and&#160;medium-sized&#160;enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#8217;s Committee level. A&#160;kick-off&#160;meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Marketing authorization </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain a marketing authorization for a product under the European Union regulatory system, an applicant must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in European Union Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, an applicant must demonstrate compliance with all measures included in&#160;an&#160;EMA-approved&#160;Pediatric&#160;Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a&#160;product-specific&#160;waiver, class waiver or a deferral for one or more of the measures included in the PIP.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. Pursuant to Regulation (EC) No.&#160;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. Manufacturers must demonstrate the quality, safety and efficacy of their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting an initial assessment of a product. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210&#160;days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210&#160;days will be reduced to 150&#160;days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.<font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Regulatory data protection in the European Union </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In the European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application for a period of eight years. During the additional&#160;two-year&#160;period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall&#160;ten-year&#160;period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Patent term extensions in the European Union and other jurisdictions </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The European Union also provides for patent term extension through Supplementary Protection Certificates, or SPCs. The rules and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained. Although SPCs are available throughout the European Union, sponsors must apply on&#160;a&#160;country-by-country&#160;basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Periods of authorization and renewals </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the European Union market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Regulatory requirements after marketing authorization </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization&#160;studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products, including&#160;industry-sponsored&#160;continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83EC, as amended.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Orphan drug designation and exclusivity </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Regulation (EC) No 141/2000 and Regulation (EC) No.&#160;847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1)&#160;a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2)&#160;a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without </font>incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to&#160;a&#160;ten-year&#160;period&#160;of market exclusivity. During this market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Brexit and the regulatory framework in the United Kingdom </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the European Union on January&#160;31, 2020. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom withdrew from the European Union, effective December&#160;31, 2020. On December&#160;24, 2020, the United Kingdom and the European Union entered into a Trade and Cooperation Agreement. The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the Trade and Cooperation Agreement or otherwise, would prevent pharmaceutical companies from commercializing any product candidates in the United Kingdom and/or the European Union and restrict their ability to generate revenue and achieve and sustain profitability. It remains to be seen how the new arrangement will be implemented and operate.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, while the GDPR continues to apply in the United Kingdom in substantially unvaried form under the UK GDPR and is complemented by the United Kingdom Data Protection Act of 2018, which achieved Royal Assent on May&#160;23, 2018 and remains effective in the United Kingdom in amended form, it is still unclear whether transfers of data from the EEA to the United Kingdom will remain lawful under GDPR. As noted above, the Trade and Cooperation Agreement provides for a transitional period during which the United Kingdom will be treated like a European Union member state in relation to processing and transfers of personal data for four months from January&#160;1, 2021. This may be extended by two further months. After such period, the United Kingdom will be a &#8220;third country&#8221; under the GDPR unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the United Kingdom. The United Kingdom has already determined that it considers all of the EU 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the EU/EEA remain unaffected. We may, however, incur liabilities, expenses, costs and other operational losses under GDPR and applicable European Union Member States and the United Kingdom privacy laws in connection with any measures we take to comply with them.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">General Data Protection Regulation </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection, use, disclosure, transfer or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the GDPR, which became effective on </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May&#160;25, 2018. </font><font style="color:#000000;">The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to&#160;&#8364;20&#160;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information on these matters and the GDPR, please see the section entitled &#8220;Risk Factors&#8212;Risks related to regulatory approval and other regulatory and legal compliance matters&#8212;We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition, results of operations or prospects.&#8221;<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Coverage, pricing and reimbursement </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on&#160;third-party&#160;payers to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates we may develop are approved, sales of such product candidates will depend, in part, on the extent to which&#160;third-party&#160;payers, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payer will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved.&#160;Third-party&#160;payers are increasingly challenging the prices charged, examining the medical necessity, and reviewing the&#160;cost-effectiveness&#160;of medical products and services and imposing controls to manage costs.&#160;Third-party&#160;payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a&#160;third-party&#160;payer not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payer&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#8217;s determination to provide coverage for a product does not assure that other payers will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payer to payer.&#160;Third-party&#160;reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing&#160;cost-containment&#160;programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and&#160;cost-containment&#160;measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and&#160;third-party&#160;reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain approval in the future to market in the United States any product candidates we may develop, we may be required to provide discounts or rebates under government healthcare programs or to certain</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government and private purchasers in order to obtain coverage under federal healthcare programs such as Medicaid. Participation in such programs may require us to track and report certain drug prices. We may be subject to fines and other penalties if we fail to report such prices accurately.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, ensuring adequate coverage and payment for any product candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the&#160;cost-effectiveness&#160;of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage&#160;between&#160;low-priced&#160;and&#160;high-priced&#160;member&#160;states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical <font style="Background-color:#FFFFFF;">products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Healthcare law and regulation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Healthcare providers and&#160;third-party&#160;payers play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party&#160;payers and customers are subject to broadly applicable fraud and abuse,&#160;anti-kickback, false claims laws, reporting of payments to physicians and teaching hospitals and patient privacy laws and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">the U.S. federal&#160;Anti-Kickback&#160;Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">the federal civil and criminal false claims laws, including the civil False Claims Act, false statement laws and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">the federal regulations relating to pricing and submission of pricing information for government programs, including penalties for knowingly and intentionally overcharging 340b eligible entities and the submission of false or fraudulent pricing information to government entities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">HIPAA, as amended by HITECH, and their respective implementing regulations, including the final omnibus rule published in January 2013, which impose obligations, including mandatory contractual terms, on certain covered healthcare providers, health plans and healthcare clearinghouses, as well as their respective business associates that perform services for them, that involve the use, or disclosure of, individually identifiable health information, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">the Foreign Corrupt Practices Act, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to&#160;non-U.S.&#160;officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians, as defined to include doctors, dentists, optometrists, podiatrists and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made during the previous year to other healthcare providers, such as physician assistants and nurse practitioners; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">analogous state and foreign laws and regulations, such as state&#160;anti-kickback&#160;and false claims laws, which may apply to healthcare items or services that are reimbursed by&#160;non-governmental&#160;third-party&#160;payers, including private insurers. </font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers, drug pricing or marketing expenditures. In addition, certain state and local laws require drug manufacturers to register pharmaceutical sales representatives. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, imprisonment, integrity oversight and reporting obligations and the curtailment or restructuring of our operations.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Healthcare reform </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government healthcare programs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since enactment of the ACA, there have been, and continue to be, numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing legal and constitutional challenges in the U.S. Supreme Court. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what affect further changes to the ACA would have on our business.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the Trump Administration&#8217;s budget proposal for fiscal year 2021 includes a $135&#160;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower&#160;out-of-pocket&#160;drug costs for patients, and increase patient access to lower cost generic and biosimilar drugs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More recently, President Trump has issued five executive orders that are intended to lower the costs of prescription drug products. Several of these orders are reflected in recently promulgated regulations, and one of these regulations is currently subject to a nationwide preliminary injunction. It remains to be seen whether these orders and resulting regulations will remain in force in the Biden Administration.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the <font style="Background-color:#FFFFFF;">future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for any product candidates we may develop or additional pricing pressures.</font><font style="color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Employees and human capital</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January&#160;31,&#160;2021, we had 47 full-time employees, including a total of 15 employees with M.D. or Ph.D. degrees. Of these full-time employees, 35 employees are engaged in research and development. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Our corporate information</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the laws of the state of Delaware on December 1, 2017 under the name Dyne Therapeutics, Inc. Our principal executive offices are located at 830 Winter Street, Waltham, Massachusetts 02451 and our telephone number is (781) 786-8230.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. The service marks and trademarks that we own include the marks Dyne Therapeutics&#8482; and FORCE&#8482;. Other trademarks, service marks and trade names appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K are listed without the &#174; and &#8482; symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Available information</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file reports and other information with the Securities and Exchange Commission, or SEC, as required by the Securities Exchange Act of 1934, as amended, or the Exchange Act. You can review our electronically filed reports and other information that we file with the SEC on the SEC&#8217;s website at http://www.sec.gov.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our website address is https://www.dyne-tx.com. We make available free of charge through our website our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investors &amp; Media,&#8221; as a source of information about us.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing references to our website are not intended to, nor shall they be deemed to, incorporate information on our website into this Annual Report on Form 10-K by reference. We have included our website address in this Annual Report on Form 10-K as an inactive textual reference.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63670445"></a><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Risk Factors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K including our consolidated financial statements and the related notes thereto in evaluating our company. The risks described below are not the only risks facing our company. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could cause our business, prospects, operating results and financial condition to suffer materially.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our financial position and need for additional capital</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception, have no products approved for sale and we expect to incur losses for the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have incurred significant operating losses. Our net losses were $14.9 million for the year ended December 31, 2019 and $59.4 million for the year ended December 31, 2020. As of December 31, 2020, we had an accumulated deficit of $79.2 million. To date, we have financed our operations with the proceeds raised from the sale of equity securities and borrowings under a loan and security agreement. We have devoted substantially all of our financial resources and efforts to research and development. We are still in the early stages of development of our programs, have not initiated investigational new drug, or IND, -enabling studies or identified a product candidate for clinical development and have not commenced or completed clinical development. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">continue our current research programs and conduct additional research programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">advance any product candidates we identify through our research programs into IND-enabling studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="page26"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">expand the capabilities of our proprietary FORCE platform;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">seek marketing approvals for any product candidates that successfully complete clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">obtain, expand, maintain, defend and enforce our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">hire additional clinical, regulatory and scientific personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">establish manufacturing sources for any product candidate we may develop, including the Fab antibody, Val-cit linker and therapeutic payload that will comprise the product candidate, and secure supply chain capacity to provide sufficient quantities for preclinical and clinical development and commercial supply;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and future commercialization efforts, as well as to support our operations as a public company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval of, and are successful in commercializing, one or more of any product candidates we may develop, we will continue to incur substantial research and development and other costs to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We have never generated revenue from product sales and may never achieve or maintain profitability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not initiated IND-enabling studies, identified any product candidates for clinical development or initiated clinical development of any product candidate and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in developing, obtaining the necessary regulatory approvals for and eventually commercializing a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including:</p>
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">identifying product candidates and completing preclinical and clinical development of any product candidates we may identify;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">obtaining regulatory approval for any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">manufacturing, marketing and selling any products for which we may obtain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">achieving market acceptance of any products for which we obtain regulatory approval as a viable treatment option; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">satisfying any post-marketing requirements.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. We are currently only in the preclinical stage of our research programs. Because of the numerous risks and uncertainties associated with product development, we are unable to accurately estimate or know the nature, timing or costs of the efforts that will be necessary to complete the preclinical and clinical development and commercialization of any product candidate we may develop or when, or if, we will be able to generate revenues or achieve profitability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are successful in obtaining regulatory approval to market one or more of our products, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page27"></a><a name="page27"></a>We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate preclinical testing and clinical trials of, arrange for the manufacturing of, and potentially seek marketing approval for any product candidates we may develop. In addition, if we obtain marketing approval for any product candidates we may develop, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed, on attractive terms or at all, we may be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had cash, cash equivalents and marketable securities of $345.3 million. In addition, in January 2021 we issued and sold an aggregate of 6,000,000 shares of our common stock at a public offering price of $28.00 per share, resulting in net proceeds to us of $153.7 million, after deducting underwriting discounts and commissions and offering expenses payable by us. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2024. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect and could be forced to seek additional funding sooner than planned.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the identification of additional research programs and product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the scope, progress, costs and results of preclinical and clinical development for any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the scope, costs, timing and outcome of regulatory review of any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the cost and timing of manufacturing activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the costs and scope of the continued development of our FORCE platform;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the costs and timing of preparing, filing and prosecuting applications for patents, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including claims of infringement, misappropriation or other violations of third-party intellectual property;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidates we may develop for which we receive marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the costs of satisfying any post-marketing requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the revenue, if any, received from commercial sales of product candidates we may develop for which we receive marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the costs of operational, financial and management information systems and associated personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the associated costs in connection with any acquisition of in-licensed products, intellectual property and technologies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Arial;color:#000000;">the costs of operating as a public company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully identify and develop product candidates and those are approved, we may not achieve commercial success. Our commercial revenues, if any, may not be sufficient to sustain our operations. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our operations. We cannot be certain that additional funding will be available on acceptable terms, when needed or at all. We have no committed source of additional capital and, if we are unable to raise additional capital in sufficient amounts, when needed or on terms acceptable to us, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate we may develop, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. We could be required to seek collaborators for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates we may develop at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product candidates we may develop in markets where we otherwise would seek to pursue </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development or commercialization ourselves. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page28"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Any debt financing or preferred equity financing, if available, may involve, agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we may be required to delay, limit, reduce or eliminate some or all of our research and development programs, pipeline expansion or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations in 2017, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting research activities and filing and prosecuting patent applications. All of our research programs are still in the research or preclinical stage of development, and their risk of failure is high. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain marketing approvals, manufacture product for clinical trials or on a commercial scale or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions our stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult to evaluate our technology and industry and predict our future performance. Our limited history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research focus to a company capable of conducting development activities and then to a company supporting commercial activities. We may not be successful in such transitions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be subject to limitations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future; thus, we do not know whether or when we will generate taxable income necessary to utilize our net operating losses, or NOLs, or research and development tax credit carryforwards. As of December 31, 2020, we had federal NOL carryforwards of $69.1 million and state NOL carryforwards of $68.9 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and pre-change research and development tax credit carryforwards to offset post-change income or taxes. We have not conducted a study to assess whether any such ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future through subsequent changes in our stock ownership (which may be outside our control). As a result, if, and to the extent that, we earn net taxable income, our ability to use our NOL carryforwards and research and development tax credit carryforwards to offset such taxable income may be subject to limitations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page29"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise become unavailable to offset future income tax liabilities. As described below in &#8220;Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,&#8221; legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, includes changes to U.S. federal tax rates and the rules governing NOL carryforwards that may significantly impact our ability to utilize our NOLs to offset taxable income in the future. In addition, state NOLs generated in one state cannot be used to offset income generated in another state. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to discovery and development</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We are very early in our development efforts. We have not initiated IND-enabling studies or identified any product candidates for clinical development, and as a result it will be years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are very early in our development efforts and have invested our research efforts to date in developing our platform. We have a portfolio of programs that are in early stages of preclinical development and have not yet initiated IND-enabling studies or identified any product candidates for clinical development. We may never advance any product candidates to clinical-stage development. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencing clinical trials in the United States is subject to acceptance by the U.S. Food and Drug Administration, or FDA, of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or we are required to satisfy other FDA requests prior to commencing clinical trials, the start of our first clinical trials may be delayed. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialization of any product candidates we may develop will require preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the European Medicines Agency, or EMA; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of product candidates we may identify and develop will depend on many factors, including the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any product candidates we may develop;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">successful enrollment and completion of clinical trials, including under the FDA&#8217;s current Good Clinical Practices, or cGCPs, current Good Laboratory Practices, or cGLPs, and any additional regulatory requirements from foreign regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">positive results from our future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">receipt of marketing approvals from applicable regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">commercial launch of any product candidates we may develop, if approved, whether alone or in collaboration with others;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">acceptance of the benefits and use of our product candidates we may develop, including method of administration, if and when approved, by patients, the medical community and third-party payers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><a name="page30"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="page30"></a>effective competition with other therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates we may develop following approval; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishment and maintenance of healthcare coverage and adequate reimbursement by payers.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates we may develop, which would materially harm our business. If we are unable to advance our product candidates to clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter substantial delays in commencement, enrollment or completion of our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk of failure in developing product candidates is high. It is impossible to predict when or if any product candidate would prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efficacy of product candidates in humans. We have not yet conducted a clinical trial of any product candidate. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our INDs and other regulatory filings. We cannot be certain of the timely identification of a product candidate or the completion or outcome of our preclinical testing and studies and cannot predict whether the FDA will accept our proposed clinical programs or whether the outcome of our preclinical testing and studies will ultimately support the further development of any product candidates. Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. As a result, we cannot be sure that we will be able to submit INDs for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs will result in the FDA allowing clinical trials to begin.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other events that may prevent successful or timely completion of clinical development include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in reaching a consensus with regulatory authorities on trial design;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CLROs, and clinical trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in opening clinical trial sites or obtaining required institutional review board, or IRB, or independent ethics committee approval, or the equivalent review groups for sites outside the United States, at each clinical trial site;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">negative or inconclusive results observed in clinical trials, including failure to demonstrate statistical significance, which could lead us, or cause regulators to require us, to conduct additional clinical trials or abandon product development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure by us, any CLROs we engage or any other third parties to adhere to clinical trial requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure to perform in accordance with the FDA&#8217;s cGCPs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure by physicians to adhere to delivery protocols leading to variable results;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in the testing, validation, manufacturing and delivery of any product candidates we may develop to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure of our third-party contractors to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner, or at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">clinical trial sites or patients dropping out of a trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">occurrence of serious adverse events associated with a product candidate in development by another company, which are viewed to outweigh its potential benefits, and which may negatively impact the perception of our product due to a similarity in technology or approach;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in the legal or regulatory regimes domestically or internationally related to patient rights and privacy; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">lack of adequate funding to continue the clinical trial.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully complete preclinical studies and clinical trials could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to any product candidates we may develop, we may need to conduct additional studies or trials to bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize any product candidates we may develop or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize any product candidates we may develop and may harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if the results of future clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with any product candidates we may develop, we may:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">be delayed in obtaining marketing approval for product candidates, if at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtain approval for indications or patient populations that are not as broad as intended or desired;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">be subject to changes in the way the product is administered;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">be subject to the addition of labeling statements, such as warnings or contraindications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">be sued; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">experience damage to our reputation.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, each of the conditions for which we plan to develop product candidates are rare genetic diseases with limited patient pools from which to draw for clinical trials. Further, because it can be difficult to diagnose these diseases in the absence of a genetic screen, we may have difficulty finding patients who are eligible to participate in our studies. The eligibility criteria of our clinical trials will further limit the pool of available study participants. Additionally, the process of finding and diagnosing patients may prove costly. The treating physicians in our clinical trials may also use their medical discretion in advising patients enrolled in our clinical trials to withdraw from our studies to try alternative therapies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our approach to the discovery and development of product candidates based on our FORCE platform is unproven, and we may not be successful in our efforts to identify, discover or develop potential product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page32"></a>The success of our business depends upon our ability to identify, develop and commercialize products based on our proprietary FORCE platform. Our therapeutics consist of three essential components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that we attach to our Fab <a name="page32"></a>using the linker. The Fab is engineered to bind to TfR1 to enable targeted delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscle. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our product development programs are still in the research or preclinical stage of development and our approach to treating muscle disease is unproven. Our research programs may fail to identify potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates and our potential product candidates may be shown to have harmful side effects in preclinical <font style="font-style:italic;">in vitro</font> experiments or animal model studies. In addition, our potential product candidates may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable or unlikely to receive marketing approval. Further, because all of our development programs are based on our FORCE platform, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have not initiated any IND-enabling studies, identified any product candidates for clinical development or successfully developed any product candidate and our ability to identify and develop a product candidate may never materialize. The process by which we identify and disclose product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors. In addition:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may not be able to assemble sufficient resources to acquire or discover product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">potential product candidates we develop may nevertheless be covered by third parties&#8217; patents or other intellectual property rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">potential product candidates may not be effective in treating their targeted diseases or disorders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the regulatory pathway for a potential product candidate may be too complex and difficult to navigate successfully or economically.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to identify and discover suitable product candidates for clinical development, this would adversely impact our business strategy and our financial position and share price and could potentially cause us to cease operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in the early stage of research in the development of our platform and programs and have not initiated any IND-enabling studies or identified any product candidates for clinical development. As a result, our belief in the capabilities of our platform is based on early research and preclinical studies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, the results of preclinical studies may not be predictive of the results of later preclinical studies or clinical trials, and the results of any early-stage clinical trials may not be predictive of the results of later clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our future clinical trials may not ultimately be successful or support further clinical </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development of any product candidates we may develop. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of operations.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our ability to complete clinical trials may be adversely impacted.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying and qualifying patients to participate in clinical trials of any product candidates we may develop is critical to our success. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by factors including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">perceived risks and benefits of novel unproven approaches;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">size of the patient population, in particular for rare diseases such as the diseases on which we are initially focused, and process for identifying patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><a name="page33"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">design of the trial protocol;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">eligibility and exclusion criteria;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">perceived risks and benefits of the product candidate under study;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">availability of competing therapies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">severity of the disease or disorder under investigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">proximity and availability of clinical trial sites for prospective patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">ability to obtain and maintain patient consent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">risk that enrolled patients will drop out before completion of the trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">patient referral practices of physicians; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">ability to monitor patients adequately during and after treatment.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we rely on and expect to continue to rely on contract research organizations, or CROs, CLROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining patients in our clinical trials. Many of the patients who end up receiving placebo may perceive that they are not receiving the product candidate being tested, and they may decide to withdraw from our clinical trials to pursue other alternative therapies rather than continue the trial with the perception that they are receiving placebo. If we have difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, we may need to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If any product candidates we may develop cause undesirable side effects or have other unexpected adverse properties, such side effects or properties could delay or prevent regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not evaluated any product candidates in human clinical trials. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that our technologies will not cause undesirable side effects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although other oligonucleotide therapeutics have received regulatory approval, our approach, which combines oligonucleotides with a Fab, is a novel approach to oligonucleotide therapy. As a result, there is uncertainty as to the safety profile of product candidates we may develop compared to more well-established classes of therapies, or oligonucleotide therapeutics on their own. Moreover, there have been only a limited number of clinical trials involving the use of conjugated oligonucleotide therapeutics and none involving the proprietary technology used in our FORCE platform.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidates we develop are associated with serious adverse events, undesirable side effects or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further clinical development of the product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page34"></a><a name="page34"></a>If in the future we are unable to demonstrate that such side effects were caused by factors others than our product candidates, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates for any or all targeted indications. Even if we are able to demonstrate that any future serious adverse events are not product-related and regulatory authorities do not order us to cease further development of our product candidates, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular program, product candidate or indication and fail to capitalize on programs, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and expect to focus on product candidates that we identify for specific indications among many potential options. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential, or we may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Any such event could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit commercialization of any product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will face an inherent risk of clinical trial and product liability exposure related to the testing of any product candidates we may develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no product candidates in clinical trials or that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">decreased demand for any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">injury to our reputation and significant negative media attention;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">withdrawal of clinical trial participants;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">significant costs to defend any related litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">substantial monetary awards to trial participants or patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">loss of revenue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reduced resources of our management to pursue our business strategy; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the inability to commercialize any product candidates we may develop.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to increase our insurance coverage if we commence clinical trials or if we commence commercialization of any product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our dependence on third parties</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect to independently conduct all aspects of our product manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to many of these items, including contract manufacturing organizations, or CMOs, for the manufacturing of any product candidates we test in preclinical or clinical development, as well as CROs for the conduct of our animal testing and research and CLROs for the conduct of our planned clinical trials. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page35"></a><a name="page35"></a>Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols. Moreover, the FDA requires us to comply with cGCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we or any of our CLROs or other third parties, including trial sites, fail to comply with applicable cGCPs, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with cGCP regulations. In addition, our clinical trials must be conducted with product produced under conditions that comply with the FDA&#8217;s current Good Manufacturing Practices. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we intend to design the clinical trials for any product candidates we may develop, CLROs will conduct some or all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">have staffing difficulties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">fail to comply with contractual obligations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">experience regulatory compliance issues;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">undergo changes in priorities or become financially distressed; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">form relationships with other entities, some of which may be our competitors.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. In addition, any third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical programs. If the CROs, CLROs and other third parties do not perform preclinical studies and future clinical trials in a satisfactory manner, if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, or if they breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of any product candidates we may develop may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs, CLROs and other third parties, we could be required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the preclinical studies and clinical trials required to support future IND submissions and approval of any product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We currently depend on a small number of third-party suppliers for the manufacture of the Fabs, linker and oligonucleotide payloads that we are evaluating in our research programs. The loss of these or future third-party suppliers, or their inability provide us with sufficient supply, could harm our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page36"></a>We do not own or operate manufacturing facilities and have no current plans to develop our own clinical or commercial-scale manufacturing capabilities. We rely on a small number of third-party suppliers for the manufacture of the Fabs, linker and oligonucleotide payloads that we are evaluating in our research programs. We expect to continue to depend on third-party suppliers for the manufacture of any product candidates we advance into preclinical and clinical development, as well as for commercial manufacture if those product candidates receive marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA and any comparable foreign regulatory authority pursuant to inspections that will be conducted after we submit an NDA to the FDA or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page36"></a>any comparable filing to a foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities.</font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate we may develop will consist of a proprietary Fab conjugated with the oligonucleotide therapy. Our Fab is manufactured by starting with cells which are stored in a cell bank. If we lose multiple cell banks, our manufacturing will be adversely impacted by the need to replace the cell banks.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any comparable foreign regulatory authority does not approve these facilities for the manufacture of any product candidates we may develop or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market any product candidates we may develop, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also seek to eventually establish our own manufacturing facility for the long-term commercial supply of any product candidates we may develop and which receive regulatory approval. If we determine to establish our own manufacturing facility and manufacture our products on our own, we will need to obtain the resources and expertise in order to build such manufacturing capabilities and to conduct such manufacturing operations. In addition, our conduct of such manufacturing operations will be subject to the extensive regulations and operational risks to which our third-party suppliers are subject. If we are not successful in building these capabilities or complying with the regulations or otherwise operating our manufacturing function, our commercial supply could be disrupted and our business could be materially harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our or a third party&#8217;s failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with cGMP could adversely affect our business in a number of ways, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an inability to initiate preclinical studies or clinical trials of product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in submitting regulatory applications, or receiving marketing approvals, for product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">requirements to cease development or to recall batches of product candidates; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">in the event of approval to market and commercialize any product, an inability to meet commercial demands for the product.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to manufacturing agreements with a number of third-party manufacturers. We may be unable to maintain these agreements or establish any additional agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to maintain or establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">breach of the manufacturing agreement by the third party;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure to manufacture according to our specifications;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failure to manufacture according to our schedule or at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">misappropriation of our proprietary information, including our trade secrets and know-how; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may compete with third parties for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have arrangements in place for redundant supply or a second source for all required raw materials. If our existing or future third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in supply. An alternative manufacturer would need to be qualified through a biologics license application, or BLA, supplement which could result in further delay. The regulatory agencies may also require additional studies or trials if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page37"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon third parties for the manufacture of any product candidates we develop may adversely affect our development programs and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may from time to time be dependent on single-source suppliers for some of the components and materials used in the product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may from time to time depend on single-source suppliers for some of the components and materials used in any product candidates we may develop. For instance, we currently use a single supplier for each of our Fab, linker and payloads. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods could expose us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have to switch to a replacement supplier, the manufacture and delivery of any product candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational medicines.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may enter into collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek third-party collaborators for the research, development and commercialization of certain of the product candidates we may develop. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations involving our research programs or any product candidates we may develop pose numerous risks to us, including the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators would have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may not pursue development and commercialization of any product candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may delay programs, preclinical studies or clinical trials, provide insufficient funding for programs, preclinical studies or clinical trials, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with any product candidates we may develop if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><a name="page38"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may be acquired by a third party having competitive products or different priorities, causing the emphasis on our product development or commercialization program under such collaboration to be delayed, diminished or terminated;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of any product candidates we may develop or that result in costly litigation or arbitration that diverts management attention and resources;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may lose certain valuable rights under certain circumstances, including if we undergo a change of control;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates we may develop; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our collaborations do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this &#8220;Risk Factors&#8221; section apply to the activities of our collaborators.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If conflicts arise between us and our potential collaborators, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If conflicts arise between us and our potential collaborators, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Our collaborators may develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that are the subject of these collaborations with us. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our future collaborators could also become our competitors. Our collaborators could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, fail to devote sufficient resources to the development and commercialization of products, or merge with or be acquired by a third party who may do any of these things. Any of these developments could harm our product development efforts.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development and research programs and the potential commercialization of any product candidates we may develop will require substantial additional cash to fund expenses. For some of the product candidates we may develop, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page39"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, the EMA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities, or increase our own expenditures on the development of the product candidate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on third-party vendors to provide certain licenses, products and services and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We engage a number of third-party suppliers and service providers to supply critical goods and services, such as contract research services, contract manufacturing services and IT services. Disruptions to the business, financial stability or operations of these suppliers and service providers, including due to strikes, labor disputes or other disruptions to the workforce, for instance, if, as a result of COVID-19, employees are not able to come to work, or to their willingness and ability to produce or deliver such products or provide such services in a manner that satisfies the requirements put forth by the authorities, or in a manner that satisfies our own requirements, could affect our ability to develop and market our future product candidates on a timely basis. If these suppliers and service providers were unable or unwilling to continue to provide their products or services in the manner expected, or at all, we could encounter difficulty finding alternative suppliers. Even if we are able to secure appropriate alternative suppliers in a timely manner, costs for such products or services could increase significantly. Any of these events could adversely affect our results of operations and our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to commercialization</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new drug products is highly competitive. We face competition with respect to any product candidates that we may develop from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of many of the disorders for which we are conducting research programs. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our product candidates or that would render any product candidates that we may develop obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page40"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to face competition from existing products and product candidates in development for each of our programs. There are currently no approved therapies to treat the underlying cause of DM1. Product candidates currently in development to treat DM1 include: tideglusib, a GSK3-&#223; inhibitor in late-stage clinical development by AMO Pharma Ltd. for the congenital phenotype of DM1; AT466, which is an AAV-antisense candidate in preclinical development by Audentes Therapeutics, Inc.; an antibody linked siRNA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in preclinical development by Avidity Biosciences, Inc.; gene editing treatments in preclinical development by Vertex Pharmaceuticals, Inc., or Vertex; an RNA-targeting gene therapy in preclinical development by Locana, Inc.; small molecules interacting with RNA in preclinical development by Expansion Therapeutics, Inc.; and therapeutics based on biomolecular condensate biology in preclinical development by Dewpoint Therapeutics, Inc.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is an FDA-approved corticosteroid marketed by PTC Therapeutics, Inc., or PTC. In addition, there are four FDA-approved exon skipping drugs: EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen) and AMONDYS 45 (casimersen), which are naked PMOs approved for the treatment of DMD patients amenable to Exon 51, Exon 53 and Exon 45 skipping, respectively, and are marketed by Sarepta Therapeutics, Inc., or Sarepta, and VILTEPSO (vitolarsen), a naked PMO approved for the treatment of DMD patients amenable to Exon 53 skipping, which is marketed by Nippon Shinyaku Co. Ltd. Companies focused on developing treatments for DMD that target dystrophin mechanisms, as does our DMD program, include Sarepta with SRP-5051, a peptide-linked PMO currently being evaluated in a Phase 2 clinical trial for patients amenable to Exon 51 skipping, Wave Life Sciences Ltd. with WVE-N531, a stereopure oligonucleotide in preclinical development for patients amenable to Exon 53 skipping, PTC with ataluren, a small molecule targeting nonsense mutations in a Phase 3 clinical trial, and Avidity Biosciences, Inc., which is in preclinical development with an antibody oligonucleotide conjugate that targets dystrophin production. In addition, several companies are developing gene therapies to treat DMD, including Milo Biotechnology (AAV1-FS344), Pfizer Inc. (PF-06939926), Sarepta (SRP-9001 and Galgt2 gene therapy program), Solid Biosciences Inc. (SGT-001) and REGENXBIO Inc. Gene editing treatments that are in preclinical development are also being pursued by Vertex and Sarepta. We are also aware of several companies targeting non-dystrophin mechanisms for the treatment of DMD.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no therapies to treat the underlying cause of FSHD. Products currently in development to treat FSHD include: creatine monohydrate, a supplement that enhances muscle performance, which is being evaluated in a Phase 2 clinical trial by Murdoch Children&#8217;s Research Institute, and losmapimod, a p38 MAPK inhibitor that may modulate DUX4 expression, which is being evaluated in a Phase 2 clinical trial by Fulcrum Therapeutics Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies working to develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Aro Biotherapeutics, Arrowhead Therapeutics, Avidity Biosciences, Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, NeuBase Therapeutics, Inc.&nbsp;&nbsp;and Sarepta, as well as gene therapy and gene editing approaches.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we compete or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page41"></a>If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products or technological approaches may make any products we develop, or our FORCE platform, obsolete or noncompetitive before we recover the expense of developing and commercializing our </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page41"></a>product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Even if any product candidate that we may develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidate we may develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payers and others in the medical community. Sales of medical products depend in part on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost-effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost-effective as compared with competing treatments. Efforts to educate the medical community and third-party payers on the benefits of any product candidates we may develop may require significant resources and may not be successful. If any product candidates we may develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the efficacy and safety of such product candidates as demonstrated in clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the potential advantages and limitations compared to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the effectiveness of sales and marketing efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost of treatment in relation to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the clinical indications for which the product is approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the convenience and ease of administration compared to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the strength of marketing and distribution support;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing of market introduction of competitive products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the availability of third-party coverage and adequate reimbursement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the prevalence and severity of any side effects; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any restrictions on the use of our products, if approved, together with other medications.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If the market opportunities for any product candidates we develop are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because the target patient populations of our programs are small, and the addressable patient population even smaller, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus our research and product development on treatments for rare diseases. Given the small number of patients who have the diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these rare diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these diseases who have the potential to benefit from treatment with any product candidates we may develop, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research that we conducted, and may prove to be incorrect or contain errors. New studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our target patient populations are relatively small, and there is currently no standard of care treatment directed at some of our target indications, such as FSHD. As a result, the pricing and reimbursement of any product candidates we may develop, if approved, is uncertain, but must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell product candidates will be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page42"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our future product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial target platforms in our pipeline are indications with small patient populations. For product candidates that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such product candidates must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size. If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payers, the adoption of those product candidates and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that coverage and reimbursement by third-party payers will be essential for most patients to be able to afford these treatments. Accordingly, sales of our future product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payers. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement by government authorities for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, since CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. However, one payer&#8217;s determination to provide coverage for a product does not assure that other payers will also provide coverage for the drug product. Further, a payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement agencies in the European Union may be more conservative than CMS.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">usage of therapeutics such as any product candidates we may develop. In many countries, particularly the countries of the European Union, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay or might even prevent our commercial launch of the product, possibly for </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lengthy periods of time. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for product candidates. Accordingly, in markets outside the United States, the reimbursement for any product candidates we may develop may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payers, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for any product candidates we may develop. We expect to experience pricing pressures in connection with the sale of any product candidates we may develop due to the trend toward managed healthcare, the increasing influence of certain third-party payers, such as health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market. There have been instances in which third-party payers have refused to reimburse treatments for patients for whom the treatment is indicated in the FDA-approved product label. Even if we are successful in obtaining FDA approvals to commercialize our product candidates, we cannot guarantee that we will be able to secure reimbursement for all patients for whom treatment with our product candidates is indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page43"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to CMS and private payers, professional organizations such as the American Medical Association, can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payers contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing any product candidates we may develop if and when they are approved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may build a sales and marketing infrastructure to market some of the product candidates we may develop if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to commercialize our products on our own include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the inability of sales personnel to educate adequate numbers of physicians on the benefits of any future products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute any product candidates we may develop or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing any product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">The biologic product candidates for which we intend to seek approval may face competition sooner than anticipated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Amendment, or the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our biological products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page44"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a risk that any product candidates we may develop that are approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in a way that is similar to traditional generic substitution for nonbiological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our intellectual property</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Although we own and license a number of pending patent applications which have not yet issued as patents, we do not currently own any issued patents. We do, however, in-license two issued U.S. patents and one issued European patent relating to product candidates we may develop. If we or our licensors are unable to obtain, maintain and defend patent and other intellectual property protection for any product candidates or technology, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully develop and commercialize any product candidates we may develop or our technology may be adversely affected due to such competition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain patent and other intellectual property protection in the United States and other jurisdictions. We currently own and license patent applications relating to our FORCE platform technology, including our Fabs, oligonucleotide payloads and Fab-oligonucleotide conjugates, as well as aspects of our manufacturing and methods of treatment. We and our licensors have sought, and will seek, to protect our proprietary position by filing additional patent applications in the United States and abroad related to certain technologies and our platform that are important to our business. However, our patent portfolio is at an early stage and we currently do not own or exclusively license any issued patents in any jurisdiction other than two issued U.S. patents and one issued European patent which we exclusively license. Moreover, there can be no assurance as to whether or when our patent applications will issue as granted patents. Our ability to stop third parties from making, using, selling, marketing, offering to sell, importing and commercializing any product candidates we may develop and our technology is dependent upon the extent to which we have rights under valid and enforceable patents and other intellectual property that cover our platform and technology. If we are unable to secure, maintain, defend and enforce patents and other intellectual property with respect to any product candidates we may develop and technology, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our pending Patent Cooperation Treaty, or PCT, patent applications are not eligible to become issued patents until, among other things, we file a national stage patent application within 30 to 32 months, depending on the jurisdiction, from such application&#8217;s priority date in the jurisdictions in which we are seeking patent protection. Similarly, our pending provisional patent applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of such provisional patent application&#8217;s filing date. If we do not timely file such national stage patent applications or non-provisional patent applications, we may lose our priority date with respect to such PCT or provisional patent applications, respectively, and any patent protection on the inventions disclosed in such PCT or provisional patent applications, respectively. While we and our licensors intend to timely file national stage and non-provisional patent applications relating to our PCT and provisional patent applications, respectively, we cannot predict whether any such patent applications will result in the issuance of patents. If we or our licensors do not successfully obtain issued patents, or, if the scope of any patent protection we or our licensors obtain is not sufficiently broad, we will be unable to prevent others from using any product candidates we may develop or our technology or from developing or commercializing technology and products similar or identical to ours or other competing products and technologies. Any failure to obtain or maintain patent protection with respect to our product candidates or our FORCE platform would have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive, time-consuming and complex, and we and our licensors may not be able to file, prosecute, maintain, defend, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. We and our licensors may not be able to obtain, maintain or defend patents and patent applications due to the subject matter claimed in such patents and patent applications being in the public domain. It is also possible that we will fail to identify patentable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we would not </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be able to prevent any third party from using any of our technology that is in the public domain to compete with any product candidates we may develop.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page45"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of patent rights are highly uncertain. Our pending and future owned and licensed patent applications may not result in patents being issued which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and product or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all, and even if such patent applications do issue as patents, they may not issue in a form, or with a scope of claims, that will provide us with any meaningful protection, prevent others from competing with us or otherwise provide us with any competitive advantage. In addition, the scope of claims of an issued patent can be reinterpreted after issuance, and changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions may diminish the value of our patent rights or narrow the scope of our patent protection. Furthermore, our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties have developed technologies that may be related or competitive to our own technologies and product candidates and may have filed or may file patent applications, or may have obtained issued patents, claiming inventions that may overlap or conflict with those claimed in our owned or licensed patent applications or issued patents. We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates and technology. Publications of discoveries in the scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know for certain whether the inventors of our owned or licensed patents and patent applications were the first to make the inventions claimed in any owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. If a third party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or licensed patent applications may not issue as patents and even if issued, may be challenged and invalidated or ruled unenforceable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and other jurisdictions. For example, we may be subject to a third-party submission of prior art to the United States Patent and Trademark Office, or USPTO, challenging the validity of one or more claims of our owned or licensed patents. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of our owned or licensed pending patent applications. We may become involved in opposition, derivation, re-examination, <font style="font-style:italic;">inter partes</font> review, post-grant review or interference proceedings and similar proceedings in foreign jurisdictions (for example, opposition proceedings) challenging our owned or licensed patent rights. In addition, a third party may claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. An adverse result in any litigation or patent office proceeding could put one or more of our owned or licensed patents at risk of being invalidated, ruled unenforceable or interpreted narrowly and could allow third parties to commercialize products identical or similar to any product candidates we may develop and compete directly with us, without payment to us. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such challenges and proceedings may result in loss of patent rights, exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and any product candidates we may develop. Such challenges and proceedings may also result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Moreover, there could be public announcements of the results of hearings, motions or other interim proceedings or developments </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to such challenges and proceedings. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, patents have a limited lifespan. In the United States, the expiration of a patent is generally 20 years from the earliest date of filing of the first non-provisional patent application to which the patent claims priority. Patent term adjustments and extensions may be available; however, the overall term of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent and other intellectual property rights may not provide us with sufficient rights to exclude others from commercializing products similar or identical to our technology and any product candidates we may develop. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page46"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our rights to develop and commercialize any product candidates are subject and may in the future be subject, in part, to the terms and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under our current or future intellectual property license agreements or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are and expect to continue to be reliant upon third-party licensors for certain patent and other intellectual property rights that are important or necessary to the development of our technology and product candidates. For example, we rely on a license from the University of Mons, or UMONS, to certain patent rights and know-how of UMONS. Our license agreement with UMONS imposes, and we expect that any future license agreement will impose, specified diligence, milestone payment, royalty, commercialization, development and other obligations on us and require us to meet development timelines, or to exercise diligent or commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. For more information on the terms of the license agreement with UMONS, see Item 1. &#8220;Business&#8212;Intellectual Property&#8212;License Agreement with the University of Mons&#8221; in this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our licensors have, or may in the future have, the right to terminate a license if we materially breach the agreement and fail to cure such breach within a specified period or in the event we undergo certain bankruptcy events. In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements. If our license agreements are terminated, we may lose our rights to develop and commercialize product candidates and technology, lose patent protection, experience significant delays in the development and commercialization of our product candidates and technology, and incur liability for damages. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, our competitors or other third parties could have the freedom to seek regulatory approval of, and to market, products and technologies identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates and technology. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with any product candidates we may develop and our technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our or our licensors&#8217; ability to obtain, maintain and defend intellectual property and to enforce intellectual property rights against third parties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the extent to which our technology, product candidates and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the license agreement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the sublicensing of patent and other intellectual property rights under our license agreements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our diligence, development, regulatory, commercialization, financial or other obligations under the license agreement and what activities satisfy those diligence obligations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our partners; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the priority of invention of patented technology.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our license agreement with UMONS is, and future license agreements are likely to be, complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement. In addition, if disputes over intellectual property that we have licensed or any other dispute related to our license agreements prevent or impair our ability to maintain our current license agreements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and technology. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License agreements we may enter into in the future may be non-exclusive. Accordingly, third parties may also obtain non-exclusive licenses from such licensors with respect to the intellectual property licensed to us under such license agreements. Accordingly, these license agreements may not provide us with exclusive rights to use such licensed patent and other intellectual property rights, or may not provide us with exclusive rights to use such patent and other intellectual property rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and any product candidates we may develop in the future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page47"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, some of our in-licensed patent and other intellectual property rights may in the future be subject to third party interests such as co-ownership. If we are unable to obtain an exclusive license to such third-party co-owners&#8217; interest, in such patent and other intellectual property rights, such third-party co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We or our licensors may need the cooperation of any such co-owners of our licensed patent and other intellectual property rights in order to enforce them against third parties, and such cooperation may not be provided to us or our licensors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may not have complete control over the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. It is possible that our licensors&#8217; filing, prosecution and maintenance of the licensed patents and patent applications, enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, and accordingly, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to file, prosecute, maintain, enforce and defend such patents and patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our technology and any product candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors or other third parties from making, using and selling competing products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our owned and in-licensed patent rights may be subject to a reservation of rights by one or more third parties. When new technologies are developed with government funding, in order to secure ownership of patent rights related to the technologies, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. A failure to meet these obligations may lead to a loss of rights or the unenforceability of relevant patents or patent applications. In addition, the U.S. government may have certain rights in such patent rights, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology, which may include our confidential information, to third parties and to exercise march-in rights to use or allow third parties to use the technology that was developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we or our licensors failed to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such U.S. government-funded inventions may be subject to certain requirements to manufacture any product candidates we may develop embodying such inventions in the United States. Any of the foregoing could harm our business, financial condition, results of operations and prospects significantly.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, maintaining, enforcing and defending patents and other intellectual property rights on our technology and any product candidates we may develop in all jurisdictions throughout the world would be prohibitively expensive, and accordingly, our intellectual property rights in some jurisdictions outside the United States could be less extensive than those in the United States. In some cases, we or our licensors may not be able to obtain patent or other intellectual property protection for certain technology and product candidates outside the United States. In addition, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors may not be able to obtain issued patents or other intellectual property rights covering any product candidates we may develop and our technology in all jurisdictions outside the United States and, as a result, may not be able to prevent third parties from practicing our and our licensors&#8217; inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Third parties may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent or other intellectual property protection to develop their own products and, further, may export otherwise infringing, misappropriating or violating products to territories where we have patent or other intellectual property protection, but enforcement is not as strong as that in the United States. These products may compete with any product candidates we may develop and our technology and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page48"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain jurisdictions, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patent and other intellectual property rights or marketing of competing products in violation of our intellectual property rights generally. For example, an April 2019 report from the Office of the United States Trade Representative identified a number of countries, including China, Russia, Argentina, Chile and India, where challenges to the procurement and enforcement of patent rights have been reported. Proceedings to enforce our or our licensors&#8217; patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patent and other intellectual property rights at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many jurisdictions have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many jurisdictions limit the enforceability of patents against government agencies or government contractors. In these jurisdictions, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patent rights. We rely on our outside counsel and other professionals or our licensing partners to pay these fees due to the USPTO and non-U.S. government patent agencies. The USPTO and various non-U.S. government patent agencies also require compliance with several procedural, documentary and other similar provisions during the patent application process. We rely on our outside counsel and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment, loss of priority or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in obtaining necessary rights to product candidates we may develop through acquisitions and in-licenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have rights to certain intellectual property through licenses from third parties. Because our programs may require the use of additional intellectual property rights held by third parties, the growth of our business likely will depend, in part, on our ability to acquire, in-license or use these intellectual property rights. In addition, with respect to any patent or other intellectual property rights that we co-own with third parties, we may require exclusive licenses to such co-owners&#8217; interest in such patent or other intellectual property rights. However, we may be unable to secure such licenses or otherwise acquire or in-license any intellectual property rights related to compositions, methods of use, processes or other components from third parties that we identify as necessary for any product candidates we may develop and our technology on commercially reasonable terms, or at all. Even if we are able to in-license any such necessary intellectual property, it could be on non-exclusive terms, thereby giving our competitors and other third parties access to the same intellectual property licensed to us, and the applicable licensors could require us to make substantial licensing and royalty payments. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page49"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sometimes collaborate with non-profit and academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual property rights to third parties, potentially blocking our ability to pursue our research program and develop and commercialize our product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have licensed, we may be required to expend significant time and resources to redesign any product candidates we may develop or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Issued patents covering any product candidates we may develop could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our owned and licensed patent rights may be subject to priority, validity, inventorship and enforceability disputes. If we or our licensors are unsuccessful in any of these proceedings, such patent rights may be narrowed, invalidated or held unenforceable, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or we may be required to cease the development, manufacture and commercialization of one or more of our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or one of our licensors initiate legal proceedings against a third party to enforce a patent covering any of any product candidates we may develop or our technology, the defendant could counterclaim that the patent covering the product candidate or technology is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, interference proceedings, derivation proceedings, post grant review, <font style="font-style:italic;">inter</font> <font style="font-style:italic;">partes </font>review and equivalent proceedings such as opposition, invalidation and revocation proceedings in foreign jurisdictions. Such<font style="font-style:italic;"> </font>proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover any product candidates we may develop or our technology or prevent third parties from competing with any product candidates we may develop or our technology. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or technology. Such a loss of patent protection could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, contractors and other parties who have access to such technology and processes. However, we may not be able to prevent the unauthorized disclosure or use of </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our technical know-how or other trade secrets by the parties to these agreements. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breach or violate the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. As a result, we could lose our trade secrets and third parties could use our trade secrets to compete with any product candidates we may develop and our technology. Additionally, we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page50"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems; however, such systems and security measures may be breached, and we may not have adequate remedies for any breach.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors or other third parties. Competitors or third parties could purchase any product candidates we may develop or our technology and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our intellectual property rights or develop their own competitive technologies that fall outside the scope of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products, our business, financial condition, results of operations and prospects could be materially and adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could harm our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may become party to, or be threatened with, adversarial proceedings or litigation in which third parties may assert infringement, misappropriation or other violation claims against us, alleging that any product candidates we may develop, manufacturing methods, formulations or administration methods are covered by their patents. Given the vast number of patents and other intellectual property in our field of technology, we cannot be certain or guarantee that we do not infringe, misappropriate or otherwise violate patents or other intellectual property. Other companies and institutions have filed, and continue to file, patent applications that may be related to our technology and, more broadly, to gene therapy and related manufacturing methods. Some of these patent applications have already been allowed or issued and others may issue in the future. Since this area is competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. If a patent holder believes the manufacture, use, sale or importation of any product candidates we may develop or our technology infringes its patent, the patent holder may sue us even if we have licensed other patent rights for our technology.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of certain patents in the United States and other jurisdictions owned by third parties that claim subject matter that relates to our program candidates and the FORCE platform. Although we believe that these patents are invalid and/or not infringed, such third parties may assert these patents against us in litigation in the United States or other jurisdictions. The outcome of any such litigation is uncertain and, even if we prevail, the costs of such litigation could have a material adverse effect on our financial position, result in disclosure of our trade secrets, distract key personnel from the continued development of our business, and adversely affect our ability to enter or maintain commercial relationships with collaborators, clients or customers. If we are unsuccessful in such litigation, we could be prevented from commercializing products or could be required to take licenses from such third parties which may not be available on commercially reasonable terms, if at all.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that we have failed to identify relevant third-party patents or applications. Because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of any product candidates we may develop or our technology and we may not be aware of such patents. Furthermore, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential until a patent issues. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to any product candidates we may develop and our technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, any product candidates we may develop or the use of any product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page51"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize any product candidates we may develop or any other of our product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing any product candidates we may develop and our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing any product candidates we may develop or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation or other proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may challenge the validity and enforceability of our patent rights or those of our licensing partners, infringe, misappropriate or otherwise violate our or our licensors&#8217; patent and other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violation. Litigation and other proceedings in connection with any of the foregoing claims can be unpredictable, expensive and time consuming. Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our scientific, technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could adversely affect our ability to compete in the marketplace and could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or be required to obtain licenses to such intellectual property rights, which may not be available on commercially reasonable terms or at all. An inability to incorporate such intellectual property rights would harm our business and may prevent us from successfully commercializing any product candidates we may develop or at all. In addition, we may lose personnel as a result of such claims and any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize any product candidates we may develop and our technology, which would have a material adverse effect on our business, results of operations, financial condition and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our scientific and management personnel.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page52"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have pre-existing or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes about the ownership of intellectual property that we own may have a material adverse effect on our business, financial condition, results of operations and prospects.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we or our licensors may in the future be subject to claims by former employees, consultants or other third parties asserting an ownership right in our owned or licensed patent rights. An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, or could limit the duration of the patent protection covering our technology and any product candidates we may develop. Such challenges may also result in our inability to develop, manufacture or commercialize our technology and product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or licensed patent rights are threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future technology and product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop and our technology, one or more of our U.S. patents that we license or may own in the future may be eligible for limited patent term extension under Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patent and other intellectual property rights.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patent rights, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or technology. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patent rights, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use intellectual property that is important to any product candidates we may develop or our technology. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page54"></a><a name="page54"></a>We have filed trademark applications with the USPTO for our corporate name, logos and tagline. Our current and future trademark applications in the United States and other foreign jurisdictions may not be allowed or may be subsequently opposed. Once filed and registered, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">others may be able to make products that are similar to any product candidates we may develop but that are not covered by the intellectual property, including the claims of the patents, that we own or license currently or in the future;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or license currently or in the future;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our owned or licensed intellectual property rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">it is possible that our or our licensors&#8217; current or future pending patent applications will not lead to issued patents;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by third parties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">third parties might conduct research and development activities in jurisdictions where we do not have patent or other intellectual property rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may not develop additional proprietary technologies that are patentable;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the patents or other intellectual property rights of others may have an adverse effect on our business; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover our trade secrets or that our trade secrets will be misappropriated or disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we currently rely on certain third parties to manufacture all or part of our drug product and to perform quality testing, and because we collaborate with various organizations and academic institutions for the advancement of our product engine and pipeline, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements and other similar agreements with our collaborators, advisors, employees, consultants and contractors prior to beginning research or disclosing any proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors or other third parties, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets by third parties. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s or other third party&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page55"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to regulatory approval and other regulatory and legal compliance matters</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we may develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we may develop, and our ability to generate revenue will be materially impaired.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidates we may develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate we may develop will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CLROs to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety, purity and potency. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we may develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities, or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. Even if any product candidates we may develop demonstrate safety and efficacy in clinical trials, the regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agencies may not complete their review processes in a timely manner, or we may not be able to obtain </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we eventually complete clinical testing and receive approval of a BLA or foreign marketing application for any product candidates, the FDA or the applicable foreign regulatory agency may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the applicable foreign regulatory agency also may approve or authorize for marketing a product candidate for a more limited indication or patient population that we originally request, and the FDA or applicable foreign regulatory agency may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any of these restrictions or commitments could render an approved product not commercially viable, which would materially adversely impact our business and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining marketing approval or commercialization of our product candidates in the United States does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions. Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we may develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="page56"></a><a name="page56"></a>In order to market and sell any product candidates we may develop in the European Union and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any jurisdiction, which would materially impair our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the recent withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom withdrew from the European Union, effective December 31, 2020. On December 24, 2020, the United Kingdom and the European Union entered into a Trade and Cooperation Agreement. The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the Trade and Cooperation Agreement or otherwise, would prevent us from commercializing any product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability.&nbsp;&nbsp;If any of these outcomes occur, we may be forced to restrict or delay efforts to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seek regulatory approval in the United Kingdom and/or the European Union for any product candidates we may develop, which could significantly and materially harm our business.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure FDA approval of any product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidate we may develop is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical need for this condition, the sponsor may apply for FDA fast track designation. However, a fast track designation does not ensure that the product candidate will receive marketing approval or that approval will be granted within any particular timeframe. As a result, while we may seek and receive fast track designation for any product candidates we may develop, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Breakthrough or RMAT therapy designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of any product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidate we may develop is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development, the sponsor may apply for FDA breakthrough designation or a regenerative medicine advanced therapy, or RMAT, designation. However, neither a breakthrough designation nor an RMAT designation ensures that the product candidate will receive marketing approval or that approval will be granted within any particular timeframe. As a result, while we may seek and receive breakthrough or RMAT designation for any product candidates we may develop, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw breakthrough or RMAT designation if it believes that the designation is no longer supported by data from our clinical development program. Neither breakthrough nor RMAT designation alone guarantees qualification for the FDA&#8217;s priority review procedures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of any product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA determines that a product candidate we may develop offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for any product candidates we may develop. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate we may develop is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page57"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent regulatory authorities from approving other competing products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In particular, the concept of what constitutes the &#8220;same drug&#8221; for purposes of orphan drug exclusivity remains in flux in the context of gene therapies, and the FDA has issued recent draft guidance suggesting that it would not consider two genetic medicine products to be different drugs solely based on minor differences in the transgenes or vectors. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the Congress passed the FDA Reauthorization Act of 2017, or the FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we may develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate for which we obtain marketing approval, if ever, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The FDA typically advises that patients treated with genetic medicine undergo follow-up observations for potential adverse events for a 15-year period. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, assuming we, or any third parties we may collaborate with, receive marketing approval for one or more product candidates we may develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page58"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable regulatory requirements following approval of any product candidates we may develop, a regulatory agency may:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">issue a warning letter asserting that we are in violation of the law;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">seek an injunction or impose civil or criminal penalties or monetary fines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">suspend or withdraw regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">suspend any ongoing clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refuse to approve a pending BLA or supplements to a BLA submitted by us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">seize product; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refuse to allow us to enter into supply contracts, including government contracts.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we may develop and generate revenues.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Any product candidate we may develop for which we obtain marketing approval will be subject to restrictions, such as the laws and regulations prohibiting the promotion of off-label uses, or may need to be withdrawn from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other regulatory agencies impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we do not market our medicines for their approved indications, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice. Violation of the Federal Food, Product, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on such medicines, manufacturers or manufacturing processes;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on the labeling or marketing of a medicine;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on the distribution or use of a medicine;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">requirements to conduct post-marketing clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">receipt of warning or untitled letters;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">withdrawal of the medicines from the market;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refusal to approve pending applications or supplements to approved applications that we submit;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">recall of medicines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">fines, restitution or disgorgement of profits or revenue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">suspension or withdrawal of marketing approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">suspension of any ongoing clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refusal to permit the import or export of our medicines;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">product seizure; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">injunctions or the imposition of civil or criminal penalties.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we develop and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page59"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if any product candidates we may develop receive marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a communication plan to healthcare practitioners. Furthermore, if we or others later identify undesirable side effects caused by our product candidate, several potentially significant negative consequences could result, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory authorities may suspend or withdraw approvals of such product candidate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory authorities may require additional warnings on the label;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we could be sued and held liable for harm caused to patients; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our reputation may suffer.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We and our contract manufacturers are subject to significant regulation. The manufacturing facilities on which we rely may not continue to meet regulatory requirements, which could materially harm our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All entities involved in the preparation of product candidates for clinical trials or commercial sale, including any contract manufacturers, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturer must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s cGLP and cGMP regulations enforced through its facilities inspection program. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of any product candidates we may develop or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, FDA approval of the products will not be granted.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product, or revocation of a pre-existing approval. Any such consequence would severely harm our business, financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur significant costs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health, and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page60"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws, regulations and permitting requirements. These current or future laws, regulations and permitting requirements may impair our research, development or production efforts. Failure to comply with these laws, regulations and permitting requirements also may result in substantial fines, penalties or other sanctions or business disruption. Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could in turn have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our relationships with healthcare providers, physicians and third-party payers will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any product candidates that we develop for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the federal civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalty laws which can be enforced through civil whistleblower or qui tam actions, imposes civil and criminal penalties against individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other government payers that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><a name="page61"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">HIPAA, as further amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, which imposes certain requirements, including mandatory contractual terms, on covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the federal transparency requirements under the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services, or HHS, information related to payments and other transfers of value to physicians, as defined by such law, and teaching hospitals and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, and certain state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to drug pricing and payments to physicians and other healthcare providers or marketing expenditures and state and local laws that require the registration of sales representatives.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union Member States, such as the UK Bribery Act 2010. Violation of these laws could result in substantial fines and imprisonment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Liabilities they incur pursuant to these laws could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page62"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Legislative and regulatory changes may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of any product candidates we may develop, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA, which became law in 2010, contains provisions of importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any product candidates we may develop and that are approved for sale, the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expansion of federal healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">extension of manufacturers&#8217; Medicaid rebate liability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expansion of eligibility criteria for Medicaid programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program new requirements to report financial arrangements with physicians and teaching hospitals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, and other COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. In January 2013, the American Taxpayer Relief Act of 2012 became law, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page63"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since enactment of the ACA, there have been, and continue to be, numerous executive and legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Act, which was signed by President Trump on December 22, 2017, Congress effectively repealed the &#8220;individual mandate&#8221; by reducing the applicable penalty to zero dollars. The modification of this provision, which required most Americans to carry a minimal level of health insurance, became effective in 2019. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. Further, the Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Trump Administration also took executive actions to undermine or delay implementation of the ACA. During the Trump presidency, the president signed several executive orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One executive order directs federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers or manufacturers of pharmaceuticals or medical devices. Another executive order terminates the cost-sharing subsidies that reimburse insurers under the ACA. In addition, CMS proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. On November 10, 2020, the United States Supreme Court heard oral argument in this case and it is expected to issue a decision sometime this year. It is unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our potential products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States, and members of Congress and the executive branch have stated that they will address such costs through new legislative and administrative measures. To date, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the Trump Administration&#8217;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page64"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More recently, President Trump issued five executive orders intended to lower the costs of prescription drug products. Several of these orders are reflected in recently promulgated regulations, and one of these regulations is currently subject to a nationwide preliminary injunction. It remains to be seen whether these orders and resulting regulations will remain in force during the Biden Administration. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for any product candidates we may develop or additional pricing pressures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the demand for product candidates that we may identify, if we obtain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to receive or set a price that we believe is fair for our products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to generate revenue and achieve or maintain profitability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the level of taxes that we are required to pay; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the availability of capital.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page65"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, consultants and partners, and, if we commence clinical trials, our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page66"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing the provision of money or anything of value, directly or indirectly through parties, to any foreign official, official of a public international organization, or political party official or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with the FCPA and other anti-corruption laws potentially applicable to our business is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, compliance with the FCPA and other anti-corruption laws presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various U.S. export and sanctions laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of certain products and technical data relating to those products. Furthermore, such export and sanctions laws include restrictions or prohibitions on the sale or supply of certain products and services to United States embargoed countries or sanctioned countries, governments, persons and entities. Our expansion outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA and export and sanctions laws can result in significant civil and criminal penalties, imprisonment, the loss of export or import privileges, debarment, breach of contract and fraud litigation, reputational harm, and other consequences. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition, results of operations or prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to data privacy and protection laws, regulations, policies and contractual obligations that apply to the collection, transmission, storage and use of personal information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with laws and regulations governing personal information could result in enforcement actions against us, including fines, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the European Union General Data Protection Regulation (EU) 2016/679, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018; and continues to have effect in amended form in the United Kingdom by operation of the so-called &#8220;UK GDPR&#8221; (i.e., the GDPR as it continues to form part of law in the United Kingdom by virtue of section 3 of the European Union (Withdrawal) Act 2018, as amended (including by the various Data Protection, Privacy and Electronic Communications (Amendments etc) (EU Exit) Regulations)). The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, establishing a legal basis for processing, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data that requires the adoption of administrative, physical and technical safeguards to protect such information, providing notification of data breaches to appropriate data protection authorities or data subjects, establishing means for data subjects to exercise rights in relation to their personal data and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA and United Kingdom by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny for transfers of personal data from clinical trial sites located in the EEA and United Kingdom to the United&#160;States. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the United Kingdom, EEA and Switzerland to the United States, uncertainty about compliance with such data protection laws remains and such mechanisms may not be available or applicable with respect to the personal data processing activities necessary to research, develop and market our any product candidates we develop. For example, legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross-border data transfers, such as the EU-U.S. and Swiss-U.S. Privacy Shield Frameworks. Specifically, on July&#160;16, 2020, the Court of Justice of the European Union, or CEJU, invalidated Decision 2016/1250 on the adequacy of the protection provided by the EU-U.S. Privacy Shield Framework, in a case known colloquially as &#8220;Schrems&#160;II&#8221;. Following this decision, the Swiss Federal Data Protection and Information Commissioner, or the FDPIC, announced that the Swiss-U.S. Privacy Shield does not provide adequate safeguards for the purposes of personal data transfers from Switzerland to the United States. While the FDPIC does not have authority to invalidate the Swiss-U.S. Privacy Shield regime, the FDPIC&#8217;s announcement casts doubt on the viability of the Swiss-U.S. Privacy Shield as a future compliance mechanism for Swiss-U.S. data transfers. Following the decision in Schrems II, the United Kingdom government has also invalidated use of the EU-U.S. Privacy Shield as a mechanism for lawful transfers of personal data from the United Kingdom to the United States under the UK GDPR. The CJEU&#8217;s decision in Schrems II also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the United States or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in Schrems II, it made clear that reliance on those Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or applicable European law, the decision in Schrems II and subsequent draft guidance from the European Data Protection Board, or EDPB, would require the parties to that transfer to implement certain supplementary technical, organizational and/or contractual measures to rely on the Standard Contractual Clauses as a compliant &#8216;transfer mechanism.&#8217; However, the aforementioned draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to conclude that no combination of such measures could be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#8216;in the clear&#8217; to recipients in countries where the power granted to public authorities to access the transferred data goes beyond that which is &#8216;necessary and proportionate in a democratic society&#8217; &#8212; which may, following the CJEU&#8217;s conclusions in Schrems II on relevant powers of United States public </font><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities and commentary in that draft EDPB guidance, include the United States in certain circumstances (e.g., where Section 702 of the US Foreign Intelligence Surveillance Act applies). At present, there are few, if any, viable alternatives to the EU-U.S. Privacy Shield and the Standard Contractual Clauses. As such, if we are unable to implement a valid solution for personal data transfers from Europe, including, for example, obtaining individuals&#8217; explicit consent to transfer their personal data </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from Europe to the United States or other countries, we will face increased exposure to regulatory actions, substantial fines and injunctions against processing personal data from Europe. Inability to import personal data from the EEA, United Kingdom or Switzerland may also restrict our clinical trials activities in Europe; limit our ability to collaborate with contract research organizations as well as other service providers, contractors and other companies subject to European data protection laws; and require us to increase our data processing capabilities in Europe at significant expense. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20&#160;million Euros, whichever is greater, and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. Furthermore, following the United Kingdom&#8217;s withdrawal from the European Union on January&#160;31, 2020, pursuant to the transitional arrangements agreed to between the United Kingdom and European Union, the GDPR continued to have effect in law in the United Kingdom, and continued to do so until December&#160;31, 2020 as if the United Kingdom remained a Member State of the European Union for such purposes. Following December&#160;31, 2020, and the expiry of those transitional arrangements, the data protection obligations of the GDPR continue to apply to United Kingdom-related processing of personal data in substantially unvaried form under the UK GDPR. However, going forward, there will be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the United Kingdom and EEA. Furthermore, the relationship between the United Kingdom and the EEA in relation to certain aspects of data protection law remains unclear. For example, it is still unclear whether the transfer of data from the EEA to the United Kingdom will in the future remain lawful under the GDPR. For the meantime, under the post-Brexit Trade and Cooperation Agreement between the European Union and the United Kingdom, it has been agreed, that transfers of personal data to the United Kingdom from European Union Member States will not be treated as &#8220;restricted transfers&#8221; to a non-EEA country for a period of up to four months from January&#160;1, 2021, which may be extended by a further two months &#8212; such period, the adequacy assessment period. This will also apply to transfers to the United Kingdom from EEA Member States, assuming those Member States accede to the relevant provision of the Trade and Cooperation Agreement. Although the current maximum duration of the adequacy assessment period is six months it may end sooner, for example, in the event that the European Commission adopts an adequacy decision in respect of the United Kingdom, or the United Kingdom amends the UK GDPR and/or makes certain changes regarding data transfers under the UK GDPR or the Data Protection Act 2018 without the consent of the European Union (unless those amendments or decisions are made simply to keep relevant United Kingdom laws aligned with the European Union&#8217;s data protection regime). Unless the European Commission makes an &#8216;adequacy finding&#8217; in respect of the United Kingdom prior to the expiry of the adequacy assessment period, from that point onwards the United Kingdom will be an &#8216;inadequate third country&#8217; under the GDPR and transfers of data from the EEA to the United Kingdom will require a &#8216;transfer mechanism,&#8217; such as the European Commission&#8217;s Standard Contractual Clauses issued and approved from time-to-time. Additionally, the transposition of the GDPR into United Kingdom domestic law by way of the UK GDPR could expose us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. In addition to such parallel United Kingdom and European Union regimes, following the expiry of the post-Brexit transitional arrangements agreed between the United Kingdom and European Union, the United Kingdom Information Commissioner&#8217;s Office is not able to be our &#8216;lead supervisory authority&#8217; in respect of any &#8216;cross border processing&#8217; for the purposes of the GDPR. In the event that we are unable to, and/or do not, designate a lead supervisory authority in an EEA Member State, with effect from January&#160;1, 2021, we are not able to benefit from the GDPR&#8217;s &#8216;one stop shop&#8217; mechanism. Amongst other things, this would mean that, in the event of a violation of the GDPR affecting data subjects across the United Kingdom and the EEA, we could be investigated by, and ultimately fined by the United Kingdom Information Commissioner&#8217;s Office and the supervisory authority in each and every EEA member state where data </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subjects have been affected by such violation. Additionally, other countries have passed or are considering passing laws requiring local data residency and/or restricting the international transfer of data. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR and similar laws&#8217; requirements are rigorous and time intensive and require significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered or have been implemented at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which became effective on January&#160;1, 2020, requires companies that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, provides consumers with new data privacy rights, imposes new operational requirements for covered businesses, provides a private right of action for data breaches and creates a statutory damages framework. Additionally, effective starting on January&#160;1, 2023, the California Privacy Rights Act, or the CPRA, will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. Many other states are considering similar legislation, and a broad range of legislative measures also have been introduced at the federal level. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information, including certain laws that regulate the use and disclosure of personal health information. In particular, regulations promulgated pursuant to HIPAA, as amended by HITECH, establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. These provisions may be applicable to our business. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to properly protect the privacy and security of protected health information, we could be found to have violated these privacy and security laws and/or breached certain contracts with our business partners (including as a business associate). Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face significant civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any failure by our third-party collaborators, service providers, contractors or consultants to comply with applicable law, regulations or contractual obligations related to data privacy or security could result in proceedings against us by governmental entities or others. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with our published policies and other documentation, we may at times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees or vendors fail to comply with our published policies and documentation. Such failures can subject us to potential international, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Moreover, patients or subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that new and existing laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. If so, this could result in government-imposed fines, or penalties or orders requiring that we change our practices, which could adversely affect our business. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with federal, state and international laws regarding privacy and security of personal information could expose us to fines and penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines, penalties or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement actions, litigation and significant costs for remediation, reputational harm, diminished profits and earnings, additional reporting requirements and/or oversight, any of which could adversely affect our business, our results of operations or prospects. We also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business, financial condition, results of operations or prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to employee matters, managing growth and other operational matters</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive officers, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment offer letters with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page69"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success as a public company also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 47 full-time employees. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs and, if any product candidate we may develop receives marketing approval, sales, marketing, distribution and coverage and reimbursement capabilities. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a growing biotechnology company, we are actively pursuing new platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for, and fully understanding the regulatory and manufacturing pathways to, all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our product candidates, if approved, will depend in part on our ability to effectively manage the future development and expansion of our company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may acquire additional businesses, technologies or assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products or product candidates resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions, include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">diversion of management time and focus from operating our business to addressing acquisition integration challenges;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">coordination of research and development efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">retention of key employees from the acquired company;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><a name="page70"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in relationships with collaborators as a result of product acquisitions or strategic positioning resulting from the acquisition;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">cultural challenges associated with integrating employees from the acquired company into our organization;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities and other known liabilities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">unanticipated write-offs or charges; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to address these risks or other problems encountered in connection with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our internal information technology systems, or those of our vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data and other disruptions or compromise, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, trigger contractual and legal obligations, potentially exposing us to liability, reputational harm or otherwise adversely affecting our business and financial results.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we, our vendors, collaborators or other contractors or consultants, do so in a secure manner to maintain the availability, security, confidentiality, privacy and integrity of such confidential information.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, given the size and complexity of our internal information technology systems and those of our current and any future vendors, collaborators and other contractors and consultants, and the increasing amounts of confidential information that they maintain, such information technology systems are vulnerable to damage or interruption from computer viruses, computer hackers, malicious code, employee error, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures or other compromise. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we seek to protect our information technology systems from system failure, accident and security breach, our efforts may not be successful. If such an event were to occur, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary or confidential information or other disruptions. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with the investigation, remediation and potential notification of the breach to counterparties, data subjects, regulators or others could be material. In addition, our remediation efforts may not be successful. Moreover, if the information technology systems of our vendors, collaborators and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page71"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our or our vendors&#8217;, collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive position and reputation could be harmed and the further development and commercialization of our product candidates could be delayed. As a result of such an event, we may be in breach of our contractual obligations. Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain and could have a material adverse effect on our business, financial condition, results of operations or prospects. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our operations or those of the third parties upon whom we depend might be affected by the occurrence of a natural disaster, pandemic or other catastrophic event.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend on our employees, consultants, CMOs, CROs and CLROs, as well as regulatory agencies and other parties, for the continued operation of our business. While we maintain disaster recovery plans, they might not adequately protect us. Despite any precautions we take for natural disasters or other catastrophic events, these events, including terrorist attack, pandemics, hurricanes, fire, floods and ice and snowstorms, could result in significant disruptions to our research and development, preclinical studies, clinical trials, and, ultimately, commercialization of our products. Long-term disruptions in the infrastructure caused by events, such as natural disasters, the outbreak of war, the escalation of hostilities and acts of terrorism or other &#8216;&#8216;acts of God,&#8217;&#8217; particularly involving cities in which we have offices, manufacturing or clinical trial sites, could adversely affect our businesses. Although we carry business interruption insurance policies and typically have provisions in our contracts that protect us in certain events, our coverage might not respond or be adequate to compensate us for all losses that may occur. Any natural disaster or catastrophic event affecting us, our CMOs, CROs or CLROs, regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agencies or other parties with which we are engaged could have a significant negative impact on our operations and financial performance.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation of our planned clinical trial or future clinical trials, disrupt regulatory activities, or have other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption and may adversely impact economies worldwide, which could negatively impact our operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, emerged in China. Since then, COVID-19 has spread to multiple countries worldwide, including the United States. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The COVID-19 pandemic is causing many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border scrutiny and other measures. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The future progression of the outbreak and its effects on our business and operations are uncertain. We and our CMOs and CROs have experienced a reduction in the capacity to undertake research-scale production and to execute some preclinical studies, and we may face disruptions that affect our ability to initiate and complete preclinical studies, and disruptions in procuring items that are essential for our research and development activities, such as raw materials used in the manufacture of any product candidates we may develop, laboratory supplies used in our preclinical studies, or animals that are used for preclinical testing for which there are shortages because of ongoing efforts to address the outbreak. We and our CROs and CMOs may face disruptions related to our future IND-enabling studies and clinical trials arising from delays in preclinical studies, manufacturing disruptions, and the ability to obtain necessary IRB, IBC or other necessary site approvals, as well as other delays at clinical trial sites.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page72"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to the COVID-19 pandemic may also redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions. The pandemic has already caused significant disruptions in worldwide financial markets, and may continue to cause such disruptions, which may impact the volatility of our stock price and trading in our stock. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business, although for the reasons described above it has the potential to adversely affect our financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to ownership of our common stock and our status as a public company</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We do not know whether an active trading market will continue to develop or be sustained for our common stock and, as a result, it may be difficult for our stockholders to sell their shares of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock began trading on the Nasdaq Global Select Market on September 17, 2020. Prior to September 17, 2020, there was no public market for our common stock, and we cannot assure you that an active trading market for our shares will continue to develop or be sustained. As a result, it may be difficult for our stockholders to sell their shares without depressing the market price of our common stock, or at all.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for our stockholders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price has been, and is likely to continue to be, volatile. The stock market in general, and the market for smaller biopharmaceutical companies in particular, have experienced extreme price volatility </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and volume fluctuations that have often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their common stock at or above the price they paid for their shares. The market price for our common stock may be influenced by many factors, including:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">timing and results of, or developments in, preclinical studies and clinical trials of any product candidates we may develop or those of our competitors or potential collaborators;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">adverse regulatory decisions, including failure to receive marketing approvals for any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our success in commercializing any product candidates that may be approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the success of competitive products or technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory or legal developments in the United States and other countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the recruitment or departure of key personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the level of expenses related to any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the results of our efforts to discover, develop, acquire or in-license products, product candidates, technologies or data referencing rights, the costs of commercializing any such products and the costs of development of any such product candidates or technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">actual or anticipated changes in estimates as to our financial results, development timelines or recommendations by securities analysts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">variations in our financial results or the financial results of companies that are perceived to be similar to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">sales of our common stock by us, our executive officers, directors or principal stockholders or others;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in the structure of healthcare payment systems;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">market conditions in the pharmaceutical and biotechnology sectors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">general economic, industry, political and market conditions, including conditions resulting from the effects of the ongoing COVID-19 pandemic; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the other factors described in this &#8220;Risk Factors&#8221; section.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#8217;s attention and resources.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page73"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. We do not have control over these analysts. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analysts will provide favorable coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provide more favorable relative recommendations about our competitors, the price of our stock could decline. If </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the 2008 global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn resulting from the COVID-19 pandemic could result in a variety of risks to our business, including weakened demand for any product candidates we may develop. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could impair our ability to achieve our growth strategy, could harm our financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that our current or future service providers, manufacturers or other collaborators may not survive such difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. We cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our executive officers and directors and their affiliates, if they choose to act together, have the ability to significantly influence all matters submitted to stockholders for approval.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers and directors and their affiliates, in the aggregate, beneficially owned shares representing approximately 42.5% of our common stock as of January 31, 2020. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs, even though some of these persons or entities may have interests different than yours. For example, these stockholders, if they choose to act together, could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This concentration of ownership may:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delay, defer or prevent a merger, consolidation or sale of all or substantially all of our assets that may be desired by other stockholders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delay, defer or prevent a change in control transaction involving us that other stockholders may desire; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">entrench our management and board of directors.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management has broad discretion in the application of our cash, cash equivalents and marketable securities and could use such funds in ways that do not improve our results of operations or enhance the value of our common stock or in ways that our stockholders may not agree with. The failure by our management to apply these funds effectively could result in financial losses that could cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest these funds in a manner that does not produce income or that loses value.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page74"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock or impair our ability to raise capital through the sale of equity securities in the future. As of January 31, 2021, we had 51,457,177 shares of common stock outstanding which includes a total of 20,089,314 shares that we sold in our IPO and in our January 2021 offering of common stock, which may be resold in the public market without restriction, unless purchased by our affiliates. As of January 31, 2021, 31,367,863 shares of our common stock were restricted as a result of securities laws or lock-up agreements entered into in connection with our IPO and our recent offering of common stock, but will become eligible to be sold at various times after the expiration of the applicable lock-up periods. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the expiration of the lock-up agreements related to the IPO on March 16, 2021, an aggregate of 9,799,603 shares of common stock will become eligible for sale in the public market, subject to applicable securities laws. An additional 21,556,198 shares of common stock will remain subject to the lock-up agreements entered into in connection with our January 2021 offering of common stock, which will expire on April 20, 2021. J.P. Morgan Securities LLC and Jefferies LLC, in their sole discretion, may release some or all of the securities subject to these lock-up agreements at any time, which would allow for earlier sales of shares in the public market. All other outstanding shares of our common stock may be freely sold in the public market at any time, subject to applicable securities laws.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, holders of an aggregate of 8,687,435 shares of our common stock following the expiration of the lock-up agreements entered into in connection with our IPO, and holders of an additional 21,011,360 shares of our common stock and 196,890 shares of our common stock issuable upon exercise of outstanding options following the expiration of the lock-up agreements entered into in connection with our January 2021 offering of common stock, will have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also filed a registration statement on Form S-8 to register all of the shares of common stock that we were able to issue under our equity compensation plans as of December 31, 2020, and we intend to file a registration statement on Form S-8 to register an additional 2,272,345 shares of our common stock that became issuable under the 2020 Plan on January 1, 2021. Shares registered under these registration statements on Form S-8 can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates, vesting arrangements, exercise of options, and the lock-up agreements entered into in connection with our IPO and our recent offering of common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an EGC until December 31, 2025, although if the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of any June 30 before that time or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0 billion of non-convertible debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reduced disclosure obligations regarding executive compensation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after we no longer qualify as an emerging growth company, we may continue to qualify as a smaller reporting company, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. In addition, if we are a smaller reporting company with less than $100 million in annual revenue, we would not be required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to take advantage of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either irrevocably elect to &#8220;opt out&#8221; of such extended transition period or no longer qualify as an EGC. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="page75"></a>&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we are no longer an EGC or a smaller reporting company, we will incur significant legal, accounting and other expenses that we did not previously incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements and will make some activities more time-consuming and costly compared to when we were a private company. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified members of our board of directors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our filing of an Annual Report on Form 10-K with the SEC for the year ended December 31, 2021. However, while we remain an EGC or a smaller reporting company with less than $ 100 million in annual revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could harm our business and have a negative effect on the trading price of our stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an EGC under the JOBS Act or a smaller reporting company with less than $100 million in annual revenue, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. We could be an EGC for up to five years. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation, which could have a negative effect on the trading price of our stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"><a name="page76"></a>&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establish a classified board of directors such that only one of three classes of directors is elected each year;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">limit the manner in which stockholders can remove directors from our board of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">limit who may call stockholder meetings;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation or bylaws.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our restated certificate of incorporation designates the Court of Chancery of the State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any derivative action or proceeding brought on our behalf;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><a name="page77"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="page77"></a>any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find the either exclusive forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could materially adversely affect our business, financial condition and operating results.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Changes in patent law in the United States or worldwide could diminish the value of patents in general, thereby impairing our ability to protect any product candidates we may develop and our technology.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or interpretation of patent laws in the United States and worldwide, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of any owned or in-licensed patent applications and the maintenance, enforcement or defense of any current in-licensed issued patents and issued patents we may own or in-license in the future. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our in-licensed issued patents and issued patents we may own or in-license in the future, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim unpatentable even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to review patentability of our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. As one example, in the case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable simply because they have been isolated from surrounding material. Moreover, in 2012, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or correlation that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to patent-ineligible subject matter. Accordingly, in view of the guidance memo, there can be no assurance that claims in our patent rights covering any product candidates we may develop or our technology will be held by the USPTO or equivalent foreign patent offices or by courts in the United States or in foreign jurisdictions to cover patentable subject matter. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Changes in tax laws or regulations or in their implementation or interpretation may adversely affect our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business or financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, on December 22, 2017, the U.S. government enacted the Tax Act, which significantly reformed the Code. The Tax Act, among other things, contained significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for NOLs arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income and elimination of NOL carrybacks for losses arising in taxable years beginning after December 31, 2017 (though any such NOLs may be carried forward indefinitely), the imposition of a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, the elimination of U.S. tax on foreign earnings (subject to certain important exceptions), the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as part of Congress&#8217; response to the COVID-19 pandemic, the Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, and the CARES Act was enacted on March 27, 2020 and COVID relief provisions were included in the Consolidated Appropriations Act 2021, or CAA, wich was enacted on December 27, 2020. Each of these laws contains numerous tax provisions. In particular, the CARES Act retroactively and temporarily (for taxable years beginning before January 1, 2021) suspends application of the 80%-of-income limitation on the use of NOLs, which was enacted as part of the Tax Act. It also provides that NOLs arising in any taxable year beginning after December 31, 2017, and before January 1, 2021 are generally eligible to be carried back up to five years. The CARES Act also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30 to 50% of adjusted taxable income.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory guidance under the Tax Act, the FFCR Act, the CARES Act and the CAA is and continues to be forthcoming, and such guidance could ultimately increase or lessen impact of these laws on our business and financial condition. It is also possible that Congress will enact additional legislation in connection with the COVID-19 pandemic, some of which could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the FFCR Act, the CARES Act or the CAA.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our principal facilities consist of office and laboratory space. We occupy approximately 15,000 square feet of office and laboratory space in Waltham, Massachusetts under a sublease that currently expires in December 2021. Additionally, we have signed a lease that expires in January 2030 for approximately 68,000 square feet of office and laboratory space in Waltham, Massachusetts and plan to move into this space in the second half of 2021. We believe our facilities are adequate and suitable for our current needs and that should it be needed, suitable additional or alternative space will be available to accommodate our operations.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently subject to any material legal proceedings. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PAR</font><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T II</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;DYN&#8221; since September&#160;17, 2020. Prior to that date, there was no public trading market for our common stock.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Holders</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 31, 2021, we had 47 holders of record of our common stock. The actual number of stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our common stock since our inception. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under Equity Compensation Plans</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about our equity compensation plans is incorporated by reference herein to Item 12 Part III of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Issuances of Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020 and July 2020, we issued and sold an aggregate of 19,500,000 shares of our Series A preferred stock to four investors at a price per share of $1.00 in cash, for an aggregate purchase price of $19,500,000.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we issued and sold an aggregate of 41,159,724 shares of our Series B preferred stock to 19 investors at a price per share of $2.811 in cash, for an aggregate purchase price of approximately $115,699,984.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of our IPO, all of the outstanding shares of our Series A preferred stock and Series B preferred stock converted into shares of our common stock on a 0.3015-to-one basis (when rounded to the nearest ten-thousandth).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No underwriters were involved in the foregoing issuances of securities. These securities described above were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(a)(2) under the Securities Act and, in certain cases, Regulation D thereunder, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were affixed to the securities issued in these transactions. Each of the purchasers in these transactions was an accredited investor within the meaning of Rule 501 of Regulation D under the Securities Act. All purchasers received written disclosures that the securities </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option Grants and Exercises</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020 prior to the pricing of our IPO on September 16, 2020, we granted unregistered stock options to purchase an aggregate of 5,009,333  shares of common stock, with exercise prices ranging from $1.03 to $5.54 per share, to our employees, directors, advisors and consultants pursuant to our 2018 Stock Incentive Plan, or the 2018 Plan. During the year ended December 31, 2020 prior to the pricing of our IPO on September 16, 2020, 28,902 shares of common stock were issued upon the exercise of unregistered stock options granted pursuant to the 2018 Plan for aggregate consideration of $23,497.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuances of stock options and shares of common stock upon exercise thereof that are described above were deemed to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. The shares of common stock issued upon the exercise of stock options are deemed to be restricted securities for purposes of the Securities Act. On September 17, 2020, we filed a registration statement on Form S-8 under the Securities Act to register all of the shares of our common stock subject to outstanding stock options and all shares of our common stock otherwise issuable pursuant to our equity compensation plans.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of Proceeds from our Public Offering of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 21, 2020, we closed our IPO of our common stock pursuant to which we issued and sold 14,089,314 shares of our common stock, including 1,837,736 shares sold by us pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares at a price to the public of $19.00 per share for aggregate gross proceeds of $267.7 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the shares issued and sold in the IPO were registered under the Securities Act of 1933, as amended, pursuant to a Registration Statement on Form S-1 (File No. 333-248414), which was declared effective by the SEC on September 16, 2020. J.P. Morgan Securities LLC, Jefferies LLC, Piper Sandler &amp; Co. and Stifel, Nicolaus &amp; Company, Incorporated acted as joint book-running managers for our IPO.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63282970"></a><a name="_Hlk63282970"></a>We received aggregate net proceeds of approximately $246.4 million after deducting underwriting discounts and commissions and offering expenses payable by us. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we have used approximately $30.8 million of the net proceeds from the IPO for the continued research and development of our programs, continued development and enhancement of our proprietary FORCE platform and for working capital and other general corporate purposes. There has been no material change in our planned use of the net proceeds from the offering as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on September 17, 2020. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected Financial Data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information requested under this item.</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. We are utilizing our proprietary FORCE platform to overcome the current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases. Our proprietary FORCE platform therapeutics consist of an oligonucleotide payload that we rationally design to target the genetic basis of the disease we are seeking to treat, a clinically validated linker and an antigen-binding fragment, or Fab, that we attach to the payload using the linker. With our FORCE platform, we have the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. We leverage this modularity to focus on muscle diseases with high unmet need, with etiologic targets and with clear translational potential from preclinical disease models to well-defined clinical development and regulatory pathways. Using our FORCE platform, we are assembling a broad portfolio of muscle disease therapeutics, including our lead programs in myotonic dystrophy type 1, or DM1, Duchenne muscular dystrophy, or DMD, and facioscapulohumeral dystrophy, or FSHD. In addition, we plan to expand our portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases, including some with larger patient populations. Our programs are currently all in the preclinical stage. We expect to submit investigational new drug, or IND, applications to the U.S. Food and Drug Administration, or FDA, for product candidates in each of our DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated and commenced operations in 2017. Since our incorporation, we have devoted substantially all of our financial resources and efforts to organizing and staffing our company, business planning, raising capital, conducting research activities and filing and prosecuting patent applications. We do not have any products for sale and have not generated any revenue from product sales or otherwise. To date, we have principally raised capital through sales of equity securities and borrowings under a loan and security agreement, or our loan agreement, with a commercial bank. On September 21, 2020, we completed our initial public offering, or IPO, pursuant to which we issued and sold 14,089,314 shares of our common stock, including 1,837,736 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares. We received net proceeds of $246.4 million, after deducting underwriting discounts and commissions and offering expenses payable by us. On January 25, 2021, we completed a follow-on public offering, which we refer to as the January 2021 offering, pursuant to which we issued and sold 6,000,000 shares of our common stock. We received net proceeds of $157.3 million, after deducting underwriting discounts and commissions and offering expenses payable by us.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk63671181"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development&nbsp;&nbsp;and eventual commercialization of one or more product candidates we may develop. For the years ended </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019 and 2020, we reported net losses of $14.9 million and $</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.4</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, respectively. As of December 31, 2020, we had an accumulated deficit of $</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.2</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We expect that our expenses and capital expenditures will increase substantially in connection with our ongoing activities, particularly if and as we: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continue our current research programs and conduct additional research programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">advance any product candidates we identify through our research programs into IND-enabling studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expand the capabilities of our proprietary FORCE platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">seek marketing approvals for any product candidates that successfully complete clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtain, expand, maintain, defend and enforce our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">hire additional clinical, regulatory and scientific personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establish manufacturing sources for any product candidate we may develop, including the Fab antibody, Val-cit linker and therapeutic payload that will comprise the product candidate, and secure supply chain capacity to provide sufficient quantities for preclinical and clinical development and commercial supply; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and future commercialization efforts, as well as to support our operations as a public company. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for any product candidates we may develop. If we obtain regulatory approval for or otherwise commercialize any product candidates we may develop, we expect to incur significant expenses related to developing our commercialization capabilities to support product sales, marketing and distribution. Further, we expect to continue to incur additional costs associated with operating as a public company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed, on favorable terms, or at all. If we fail to raise capital or enter into such agreements or arrangements as and when needed, we may have to significantly delay, reduce or eliminate the development or future commercialization of one or more product candidates we may develop.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash, cash equivalents and marketable securities, including the net proceeds from the January 2021 offering, will enable us to fund our operating expenses and capital expenditures into the second half of 2024. We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong. We could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financing, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. See &#8220;&#8212;Liquidity and capital resources&#8221;</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Impact of COVID-19 on our business </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The worldwide COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay the initiation of our future clinical trials, disrupt regulatory activities or have other adverse effects on our business, results of operations, financial condition and prospects. In addition, the pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could adversely affect our business and operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not experienced material business disruptions, including with our vendors, or impairments of any of our assets as a result of the pandemic. We are following, and plan to continue to follow, recommendations from federal, state and local governments regarding workplace policies, practices and procedures. In March 2020, we implemented a remote working policy for many of our employees and began restricting non-essential travel, and on May&#160;18, 2020, when Massachusetts began its staged reopening plan, we began implementing a return-to-work plan, in accordance with the guidance and requirements of federal and state authorities. We expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners. We are continuing to monitor the potential impact of the pandemic, but we cannot be certain what the overall impact will be on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Components of our results of operations </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all. If our development efforts are successful and we commercialize products, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from product sales, as well as upfront, milestone and royalty payments from such collaboration or license agreements, or a combination thereof. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities and development of our programs. These expenses include: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">development and operation of our proprietary FORCE platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">employee-related expenses, including salaries, related benefits and stock-based compensation expense, for employees engaged in research and development functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expenses incurred in connection with our research programs, including under agreements with third parties, such as consultants and contract research organizations, or CROs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost of laboratory supplies and acquiring, developing and manufacturing materials for use in our research and preclinical studies, including under agreements with third parties, such as consultants and contract manufacturing organizations, or CMOs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">costs related to compliance with regulatory requirements. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our direct external research and development expenses consist of costs that include fees, reimbursed materials and other costs paid to consultants, contractors, CMOs and CROs in connection with our development and manufacturing activities. We do not allocate our research and development costs to specific programs because costs are deployed across multiple programs and our platform and, as such, are not separately classified. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we expect that our research and development expenses will increase substantially in connection with our preclinical and clinical development activities in the future as we advance our program candidates into IND-enabling studies and clinical trials. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any product candidates we may develop. The successful development of any product candidate is highly uncertain. This is due to the numerous risks and uncertainties associated with product development, including the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing and progress of preclinical and clinical development activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the number and scope of programs we decide to pursue and their regulatory paths to market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the need to raise funding to complete preclinical and clinical development of any product candidates we may develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to establish new licensing or collaboration arrangements and the progress of the development efforts of third parties with whom we may enter into such arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to maintain our current research and development programs and to establish new programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the successful initiation, enrollment and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the receipt and related terms of regulatory approvals from applicable regulatory authorities for any product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the availability of specialty raw materials for use in production of any product candidate we may develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishing agreements with third-party manufacturers for supply of product candidate components for our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the United States and internationally; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to protect our other rights in our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining and maintaining third-party insurance coverage and adequate reimbursement for any approved products. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of any product candidate we may develop could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidate we may develop. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of employee-related expenses, including salaries, related benefits and stock-based compensation, for employees in executive, finance, corporate and business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administrative consulting services; insurance costs; administrative travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our growth strategy and move into our new facility in the second half of 2021. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with our operations as a public company. In addition, if we obtain regulatory approval for a product candidate and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing and distribution activities. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Interest income </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on our cash, cash equivalents and marketable securities. We expect our interest income to increase as we invest the net proceeds received from our sale of Series A preferred stock and Series B preferred stock during 2020, the net proceeds from our IPO in September 2020 and the net proceeds from the January 2021 offering. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Interest expense </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense consisted of interest on borrowings under our loan agreement as well as amortization of debt discount and debt issuance costs. In October 2020, all outstanding borrowings under our loan agreement were repaid. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche obligations </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the stock purchase agreement that we entered into with purchasers of our Series A preferred stock in November 2018, we were contingently obligated to sell, and the purchasers were contingently obligated to purchase, additional shares of Series A preferred stock upon the achievement of specified milestones.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These contingent rights and obligations, which we refer to as the Tranche Rights, were legally detachable and separately exercisable from the Series A preferred stock. Therefore, we allocated the proceeds from the initial closing of the Series A preferred stock financing in November 2018 between the Tranche Rights (as a liability on the balance sheet) and the Series A preferred stock sold at the initial closing (within equity on the balance sheet). The Tranche Rights were subsequently remeasured at their fair value at the end of each reporting period, with changes in fair value recorded within other income (expense) on the statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the Tranche Rights ceased to be remeasured at fair value at the end of each reporting period. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Change in success fee obligation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our loan agreement required us to pay a success fee upon the occurrence of a specified liquidity event, as defined in the agreement, which included our recently completed IPO. At inception of the loan agreement, this contingent obligation was considered immaterial. The fair value of this liability was remeasured at each reporting date, with changes in fair value recorded as a component of other income (expense) on the statement of operations. Upon the closing of our IPO, the success fee was paid and the remaining liability was eliminated. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December 31, 2020, we had federal and state </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net operating loss carryforwards of $69.1 million and $68.9 million, respectively.&nbsp;&nbsp;The federal net operating loss carryforwards are indefinite lived and the state net operating loss carryforwards begin to expire in 2038. As of December 31, 2020, we also had federal and state research and development tax credit carryforwards $0.8 million and $0.4 million which begin to expire in 2039 and 2033, respectively.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. We have not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If we have experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of our common stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Results of operations </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comparison of the years ended December&#160;31, 2020 and 2019 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,160</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,447</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,786</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,661</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,826</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,821</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,647</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,826</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,821</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">290</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(234</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; tranche obligations</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,323</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,323</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in success fee obligation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(790</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,033</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,578</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses for the years ended December&#160;31, 2020 and 2019: </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel-related</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,056</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,239</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,817</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,699</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies and research materials</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,718</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,464</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(746</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External manufacturing and research</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,108</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,296</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,812</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting fees</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,719</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(517</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,310</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,200</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,040</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,160</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in personnel-related costs and stock-based compensation expense was primarily due to increased headcount in our research and development function. The increases in facility-related and other expenses and in costs for laboratory supplies and research materials were primarily due to the increased costs of supporting a larger group of research and development personnel and their research efforts. The increase in external manufacturing and research costs was primarily due to the development of our manufacturing process, increased research activity and the advancement of our programs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our general and administrative expenses for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel-related</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,153</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,976</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,892</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,879</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting fees</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,466</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,090</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,376</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related and other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,936</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">506</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,430</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total general and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,447</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,786</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,661</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in personnel-related costs and stock-based compensation expense was primarily the result of an increase in headcount in our general and administrative function. Professional and consulting fees increased primarily due to accounting, audit and legal services as well as costs associated with ongoing business activities and our preparations to operate as a public company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Interest income </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income for the years ended December&#160;31, 2020 and 2019 was $0.1 million and $0.3 million, respectively, due to interest earned on invested cash balances. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Interest expense </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense for the year ended December&#160;31, 2020 was $0.4 million <font style="Background-color:#FFFFFF;color:#000000;">due to interest incurred on outstanding borrowings under our loan agreement. We did not incur any interest expense in the prior year period.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche obligations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, we recorded other income of $1.3&#160;million from a decrease in the fair value of our preferred stock tranche obligations resulting from the decrease in the fair value of the underlying Series A preferred stock. The remaining liability was reclassified to permanent equity in September 2019, and the obligations were no longer required to be remeasured.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Change in success fee obligation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the success fee obligation included in our loan agreement increased during the year ended December&#160;31, 2020 by $0.5&#160;million. The obligation was settled in September 2020 and no longer requires recognition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Sources of liquidity </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we support our continued research activities and development of our programs and platform. We have not yet commercialized any product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. To date, we have funded our operations primarily with proceeds from sales of equity securities, borrowings under our loan agreement and, most recently, with proceeds from the sale of common stock in our IPO and the January 2021 offering. As of December 31, 2020 we had cash, cash equivalents and marketable securities of $345.3 million. On January 25, 2021, we completed a follow-on offering pursuant to which we issued and sold 6,000,000 shares of our common stock at a public offering price of $28.00 per share, resulting in net proceeds of $157.3 million, after deducting underwriting discounts and commissions and offering expenses payable by us. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash flows </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for each of the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,507</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,834</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,661</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380,689</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,989</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, operating activities used $46.5&#160;million of cash, due to our net loss of $59.4&#160;million, partially offset by non-cash charges of $7.8&#160;million and net cash provided by changes in our operating assets and liabilities of $5.1&#160;million. Net cash provided by changes in our operating assets and liabilities primarily consisted of a $8.6&#160;million increase in accounts payable and other liabilities, partially offset by a $3.5&#160;million increase in prepaid expenses and other current assets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, operating activities used $11.8&#160;million of cash, due to our net loss of $14.9&#160;million, partially offset by non-cash charges of $7.8&#160;million and net cash provided by changes in our operating assets and liabilities of $1.6&#160;million. Net cash provided by changes in our operating assets and liabilities primarily consisted of a $1.7&#160;million increase in accounts payable and other liabilities, partially offset by a $0.3&#160;million increase in prepaid expenses and other current assets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in our operating assets and liabilities during these periods were generally due to growth in our business, the advancement of our research programs and the timing of vendor invoices and payments. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Investing activities </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, net cash used in investing activities was $45.7&#160;million due primarily to the purchases of marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, net cash used in investing activities was $1.6&#160;million due to purchases of property and equipment during the period. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Financing activities </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, net cash provided by financing activities was $380.7&#160;million, consisting of $246.4 million in aggregate net proceeds from our IPO in March 2019, $134.8 million in net proceeds from issuance of Preferred Stock, and an offset of $0.5 million in the settlement of our success fee obligation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, net cash provided by financing activities was $20.0&#160;million, consisting solely of the proceeds from our issuance of Series A preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Funding requirements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our research programs into preclinical and clinical development and incur additional costs associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the identification of additional research programs and product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope, progress, costs and results of preclinical and clinical development of any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs, timing and outcome of regulatory review of any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in laws or regulations applicable to any product candidates we may develop, including but not limited to clinical trial requirements for approvals;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost and timing of obtaining materials to produce adequate product supply for any preclinical or clinical development of any product candidate we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidate we may develop for which we obtain marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the legal costs involved in prosecuting patent applications and enforcing patent claims and other intellectual property claims;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">additions or departures of key scientific or management personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to establish and maintain collaborations on favorable terms, if at all, as well as the costs and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs of operating as a public company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash, cash equivalents and marketable securities, including the net proceeds from the January 2021 offering, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2024. We expect that our liquidity will be sufficient to enable us to submit INDs in each of our DM1, DMD and FSHD programs and achieve proof-of-concept data readouts in our DM1, DMD and FSHD programs. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities,&#160;the&#160;ownership interest&#160;of our stockholders&#160;may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect&#160;the&#160;rights&#160;of holders of our&#160;common stock. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. We may be unable to raise additional funds or enter into such other agreements or arrangements when&#160;needed, on favorable terms, or at all. If we fail to raise capital or enter into such agreements other arrangements as and when needed, we may have to significantly delay, reduce or eliminate the development or future commercialization of one or more of our product candidates we may develop. See </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A. </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Risk factors&#8221; </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in this Annual Report on Form 10-K </font><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for additional risks associated with our substantial capital requirements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Contractual obligations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with CROs, CMOs and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancelable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation and in the case of certain arrangements with CROs and CMOs may include non-cancelable fees. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also entered into a license agreement with the University of Mons under which we are obligated to make specified milestone and royalty payments. The payment obligations under this agreement are contingent upon future events, such as our achievement of specified development, regulatory and commercial milestones, or generating product sales. We are unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. For additional information about our license agreement with the University of Mons and amounts that could become payable in the future under that agreement, see Item 1. &#8220;Business&#8212;Intellectual Property&#8212;License Agreement with the University of Mons&#8221; in this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we entered into a sublease agreement for a portion of our laboratory and office space. The term of the sublease commenced on July 1, 2019 and expires on December 31, 2021. Our lease payments for the remainder of the term of the sublease will be $0.1 million per month. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 4, 2020, we entered into a lease agreement for additional office and laboratory space. The lease has a term of 8.5 years, with lease payments that begin six months after the premises are ready for occupancy and will be $0.4 million per month, increasing up to $0.5 million during the term of the lease. We have two options to extend the term of the lease, each for a period of an additional five years. We expect the premises to be ready for occupancy in the second half of 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Critical accounting policies and significant judgments and estimates </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Accrued research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a&#160;pre-determined&#160;schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">vendors in connection with preclinical development activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">CROs and investigative sites in connection with research activities; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">CMOs in connection with the production of research materials. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure the expense recognized based on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage preclinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the achievement of specified milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in changes in estimates that increase or decrease amounts recognized in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure stock-based awards granted to employees and directors based on fair value on the date of the grant using the Black-Scholes option-pricing model for options. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. We use the straight-line method to record the expense of awards with service-based vesting conditions. We use the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing when achievement of the performance condition becomes probable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our IPO, there was no public market for our common stock, and consequently, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering third-party valuations of our common stock as well as our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. Since our IPO, we have determined the fair market value of our common stock using the closing price of our common stock as reported on the Nasdaq Global Select Market.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Off-balance&#160;sheet arrangements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any&#160;off-balance&#160;sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; in the accompanying notes to the consolidated financial statements for a discussion of recent accounting pronouncements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company and smaller reporting company status </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We may take advantage of these exemptions until we are no longer an &#8220;emerging growth company.&#8221; Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. We may take advantage of these exemptions until December 31, 2025 or until such earlier time that we are no longer an &#8220;emerging growth company.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 under the Exchange Act. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million as of the last business day of our most recently completed second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. </p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitati</font><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ve Disclosures About Market Risk. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company as defined by Rule 12b<font style="font-family:Cambria Math;">&#8209;</font>2 of the Exchange Act and are not required to provide the information required under this item. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required to be filed pursuant to this Item&#160;8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item&#160;15 of Part IV of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures. </p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, under the supervision and with the participation of our Chief Executive Officer and Vice President, Accounting &amp; Administration (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2020, our Chief Executive Officer and Vice President, Accounting &amp; Administration concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Exemption from Management&#8217;s Report on Internal Control over Financial Reporting<font style="font-style:normal;">&#160;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting<font style="font-style:normal;">&#160;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d&#8209;15(f) under the Exchange Act) that occurred during the three months ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART</font><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> III </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except to the extent provided below, the information required by this Item 10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders which we intend to file not later than 120 days after the end of our fiscal year ended December 31, 2020 and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a written code of business conduct and ethics that applies to our directors, officers, employees and designated agents, including our principal executive officer, principal financial officer, principal accounting officer, or persons performing similar functions. A current copy of the code is posted on the investor relations section of our website, which is located at http://www.dyne-tx.com. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.<font style="color:#000000;"> </font></p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PART</font><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> IV </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Consolidated Financial Statements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are included on pages F-1 through F-24 attached hereto and are filed as part of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_REDEEMABLE_CONVERTIBLE_PREFER"><font style="text-decoration:underline;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:normal;"></font>Financial Statement Schedules</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.62%;text-indent:-2.62%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Exhibits</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.62%;text-indent:-2.62%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.62%;text-indent:-2.62%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:9.49%;"></td>
<td style="width:0.22%;"></td>
<td style="width:90.29%;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;3.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520250237/d122515dex31.htm"><font style="text-decoration:underline;">Restated Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K, File No. 001-39509, filed September 21, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;3.2</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520250237/d122515dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of the registrant (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form 8-K, File No. 001-39509, filed September 21, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;4.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520242598/d920854dex41.htm"><font style="text-decoration:underline;">Specimen Stock Certificate evidencing the shares of common stock</font></a><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed September 10, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;4.2</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex42.htm"><font style="text-decoration:underline;">Amended and Restated Investors&#8217; Rights Agreement dated as of August&nbsp;&nbsp;7, 2020 by and among the registrant and the other parties thereto</font></a><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 4.2 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).<br /></font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&nbsp;&nbsp;4.3*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dyn-ex43_148.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Description of Securities Registered Under Section 12 of the Exchange Act</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.1#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520242598/d920854dex101.htm"><font style="text-decoration:underline;">2018 Stock Incentive Plan, as amended</font></a><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed September 10, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.2#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex102.htm"><font style="text-decoration:underline;">Form of Stock Option Agreement under 2018 Stock Incentive Plan</font></a><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.3#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex103.htm"><font style="text-decoration:underline;">Form of Restricted Stock Agreement under 2018 Stock Incentive Plan</font></a><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.3 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:9.49%;"></td>
<td style="width:0.22%;"></td>
<td style="width:90.29%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.4#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520242598/d920854dex104.htm"><font style="text-decoration:underline;">2020 Stock Incentive Plan</font></a><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to the registrant&#8217;s Registration Statement on&#160;Form S-1, File No. 333-248414, filed September&#160;10,&#160;2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.5#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex105.htm"><font style="text-decoration:underline;">Form of Stock Option Agreement under 2020 Stock Incentive Plan</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.6#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex106.htm"><font style="text-decoration:underline;">Form of Restricted Stock Agreement under 2020 Stock Incentive Plan</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.6 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.7#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex107.htm"><font style="text-decoration:underline;">Form of Restricted Stock Unit Agreement under 2020 Stock Incentive Plan</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.7 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.8#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520242598/d920854dex108.htm"><font style="text-decoration:underline;">2020 Employee Stock Purchase Plan</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to the registrant&#8217;s Registration Statement on&#160;Form S-1, File No. 333-248414, filed September 10, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.9</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex109.htm"><font style="text-decoration:underline;">Sublease Agreement, dated May 20, 2019, by and between Arrakis Therapeutics, Inc., as sublandlord, and the registrant, as subtenant</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.9 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.10#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1010.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between the registrant and each of its executive officers and directors</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.10 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.11</font><font style="color:#000000;">&#8224;</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001818794/000119312520230038/d920854dex1011.htm"><font style="text-decoration:underline;">License Agreement, dated as of April&#160;27, 2020, by and between the registrant and the University of Mons</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.11 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.12#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1013.htm"><font style="text-decoration:underline;">Offer letter, dated as of September 19, 2019, by and between the registrant and Joshua Brumm</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.13 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.13#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1014.htm"><font style="text-decoration:underline;">Offer letter, dated as of March 21, 2018, by and between the registrant and Romesh Subramanian</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.14 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.14#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1015.htm"><font style="text-decoration:underline;">Employment side letter, dated as of November 29, 2018, by and between the registrant and Romesh Subramanian</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.15 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.15#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1016.htm"><font style="text-decoration:underline;">Offer letter, dated as of December 21, 2018, by and between the registrant and Jonathan McNeill</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.16 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.16#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1017.htm"><font style="text-decoration:underline;">Offer letter, dated as of December 12, 2019, by and between the registrant and Oxana Beskrovnaya</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.17 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:9.49%;"></td>
<td style="width:0.22%;"></td>
<td style="width:90.29%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.17#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1018.htm"><font style="text-decoration:underline;">Offer letter, dated as of November 8, 2019, by and between the registrant and Richard Scalzo</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.18 to the registrant&#8217;s Registration Statement on Form S-1, File No.&nbsp;&nbsp;333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.18#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1019.htm"><font style="text-decoration:underline;">Offer letter, dated as of July 24, 2020, by and between the registrant and Susanna High</font></a><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to Exhibit 10.19 to the registrant&#8217;s Registration Statement on Form S-1, </font><font style="text-decoration:none;color:#auto;">File No. 333-248414, </font>filed <font style="color:#000000;">August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.19#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312520230038/d920854dex1020.htm"><font style="text-decoration:underline;">Executive Severance and Change in Control Benefits Plan</font></a><font style="text-decoration:none;"> (incorporated by reference to Exhibit 10.20 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-248414, filed August 25, 2020).</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.20</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1818794/000119312521010863/d55376dex1020.htm"><font style="text-decoration:underline;">Lease, by and between Dyne Therapeutics, Inc. and BP3-BOS1 1560 Trapelo Road LLC, dated as of December 4, 2020, as amended</font></a><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (incorporated by reference to </font><font style="text-decoration:none;color:#auto;">Exhibit 10.20 to the registrant&#8217;s Registration Statement on Form S-1, File No. 333-252194 filed January 19, 2021</font>).</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;10.21*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dyn-ex1021_147.htm"><font style="text-decoration:underline;">Offer letter, dated as of December 17, 2020, by and between the registrant and Wildon Farwell</font></a><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;21.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dyn-ex211_146.htm"><font style="text-decoration:underline;">Subsidiaries of the Registrant</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;23.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dyn-ex231_145.htm"><font style="text-decoration:underline;">Consent of Deloitte &amp; Touche LLP, independent registered public accounting firm.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;31.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dyn-ex311_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;31.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dyn-ex312_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;32.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dyn-ex321_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;32.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dyn-ex322_6.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:84.62%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.92%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Management contract or compensatory plan or arrangement filed in response to Item 15(a)(3) of the Instructions to the Annual Report on Form 10-K.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company Name</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 4, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joshua Brumm</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director (principal executive officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Joshua Brumm</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Scalzo</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Accounting and Administration and Treasurer (principal financial and accounting officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 4, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Richard Scalzo</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jason Rhodes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director and Chairman of the Board</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 4, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Jason Rhodes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ed Hurwitz</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 4, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Ed Hurwitz</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Dirk Kersten</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 4, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Dirk Kersten</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Lawrence Klein</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 4, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Lawrence Klein, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Lubner</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 4, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">David Lubner</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Catherine Stehman-Breen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 4, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Catherine Stehman-Breen, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Index to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="middle"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="middle"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="middle"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_REDEEMABLE_CONVERTIBLE_PREFER"><font style="text-decoration:underline;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="middle"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="middle"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of Independent R<a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>egistered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the stockholders and board of directors of Dyne Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the financial statements </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Dyne Therapeutics, Inc. and subsidiary (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended and the related notes to the financial statements (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for opinion </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulation of the Securities and Exchange Commission and the PCAOB. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:2.62%;text-indent:-2.62%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte&#160;&amp; Touche LLP </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:2.62%;text-indent:-2.62%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:2.62%;text-indent:-2.62%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021 </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Dyne Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="BALANCE_SHEETS"></a>Consolidated <a name="BALANCE_SHEETS"></a>Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,852</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,632</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349,087</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,759</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,946</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,486</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash and other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,301</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353,334</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,436</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,440</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,256</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,527</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,967</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,358</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,967</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 12)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (Note 7)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,429</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.0001 par value; 200,000,000 and 68,000,000 shares authorized at December 31, 2020 and 2019, respectively; 45,446,903 and 3,239,017 shares issued and 45,076,574 and 2,586,535 shares outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,572</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,352</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,183</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,367</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,036</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353,334</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Dyne Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_OPERATIONS"></a>Consolidated <a name="STATEMENTS_OPERATIONS"></a>Statements of Operations and Comprehensive Loss</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,447</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,786</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,826</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,647</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,826</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">290</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche obligations</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,323</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in success fee obligation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other (expense) income, net</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(790</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,033</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.13</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.08</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,395,955</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,442,872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized losses on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,464</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Dyne Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_REDEEMABLE_CONVERTIBLE_PREFER"></a>Consolidated Statements of Redeemable Convertible P<a name="STATEMENTS_REDEEMABLE_CONVERTIBLE_PREFER"></a>referred Stock and Stockholders&#8217; Equity (Deficit)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Redeemable Convertible Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other Comprehensive Loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2019</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500,000</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,061</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,110,404</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,887</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,879</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series A redeemable convertible preferred stock, net of issuance costs of $0.1 million</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,989</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of Tranche Right I</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,621</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of redeemable convertible preferred stock and preferred stock tranche obligations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,429</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,429</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,319</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476,131</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,429</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,586,535</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,352</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,036</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series A convertible preferred stock, net of issuance costs of $0.1 million</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,500,000</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,467</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,467</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B convertible preferred stock, net of issuance costs of $0.4 million</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,159,724</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,319</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,319</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common stock upon initial public offering</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,159,724</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(162,215</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,086,375</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,212</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon initial public offering, net of issuance costs of $2.6 million</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,089,314</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,387</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,388</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,197</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted shares</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">282,153</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,076,574</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,572</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,183</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,367</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Dyne Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_CASH_FLOWS"></a>Consolidated <a name="STATEMENTS_CASH_FLOWS"></a>Statements of Cash Flows</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; activities:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt discount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization (accretion) of premium (discount) on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value of preferred stock tranche obligations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,323</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in success fee obligation</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,455</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(284</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,508</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,834</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,161</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,647</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,661</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,647</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from initial public offering of common stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,388</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of success fee obligation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,786</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,989</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of debt, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,936</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayment of debt</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,000</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380,690</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,989</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, beginning of year</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,632</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,124</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, end of year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303,153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,632</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest and taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; information:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of preferred stock tranche obligation liability to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; permanent equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,319</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock to common stock</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,215</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of Tranche Right I</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Dyne Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_FINANCIAL_STATEMENTS"></a>Notes to Consolidated F<a name="NOTES_TO_FINANCIAL_STATEMENTS"></a>inancial Statements</p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of business and basis of presentation </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dyne Therapeutics, Inc. (the &#8220;Company&#8221;) is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases that was incorporated in Delaware on December 1, 2017 and has a principal place of business in Waltham, Massachusetts.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, fluctuations in operating results, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes, the impact of the COVID-19 pandemic and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of a product. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 21, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold 14,089,314 shares of its common stock, including 1,837,736 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $19.00 per share, resulting in net proceeds of $246.4 million, after deducting underwriting discounts and commissions and offering expenses. Upon the closing of the IPO, all of the Company&#8217;s then outstanding convertible preferred stock automatically converted into shares of common stock.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 25, 2021, the Company completed a follow-on public offering of common stock pursuant to which it issued and sold 6,000,000 shares of its common stock at a public offering price of $28.00 per share, resulting in net proceeds of $157.3 million, after deducting underwriting discounts and commissions and offering expenses. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations with proceeds from the sales of preferred stock and common stock, including the IPO completed in September 2020 and the follow-on offering completed in January 2021. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance of these consolidated financial statements.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To continue its development efforts, the Company will need to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements in order to fund its research and development and ongoing operating expenses. The Company may not be able to obtain financing on acceptable terms, when needed or at all, and the Company may not be able to enter into collaborations, strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Any collaborations, strategic alliances or licensing arrangements may require the Company to relinquish rights to certain of its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to obtain funding, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company could be forced to delay, limit, reduce or eliminate some or all of its research and development programs, pipeline expansion or future commercialization efforts or grant rights to develop and market product candidates, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.</font></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has not experienced material business disruptions, including with its vendors, as a result of the COVID-19 pandemic. In March 2020, the Company implemented a remote working policy for many of its employees and began restricting non-essential travel, and on May 18, 2020, when Massachusetts began its staged reopening plan, the Company began implementing a return-to-work plan, in accordance with the guidance and requirements of federal and state authorities. The Company expects to continue to take actions as may be required or recommended by government authorities or as it determines are in the best interests of its employees and other business partners. The Company is continuing to monitor the potential impact of the pandemic, but cannot be certain what the overall impact will be on its business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of significant accounting policies </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements reflect the operations of the Company and the Company&#8217;s wholly owned subsidiary, Dyne Therapeutics Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States of America. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentrations of credit risk and of significant suppliers</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company believes the depository institutions in which the cash and cash equivalents are held are of high-credit quality. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&#8217;s marketable securities as of December&#160;31, 2020 consisted of commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of any single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the development of its programs and future production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and cash equivalents </font></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash includes cash in readily available checking accounts and cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Restricted cash </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#8217;s leased facilities. Restricted cash totaled $2.3 million and $0.0 million at December 31, 2020 and 2019, respectively. These amounts are classified as restricted cash on the Company&#8217;s consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketable securities</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities as of December 31, 2020 consisted of commercial paper, certificates of deposit and corporate debt securities and are classified as available-for-sale and are reported at fair value. Unrealized losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#8220;other than temporary,&#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Deferred rent</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms.</p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnitures and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of life of lease or 10&nbsp;&nbsp;years</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Impairment of long-lived assets </font></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company has not recorded any impairment charges in the periods presented in these financial statements. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker is the chief executive officer (&#8220;CEO&#8221;). The CEO views the Company&#8217;s operations and manages the business as one operating segment. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are consumed or the services are performed. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and manufacturing contract costs and accruals</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent costs</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:8pt;margin-bottom:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</font></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;2&#8212;Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level&#160;2 inputs include the following: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">quoted prices for similar assets and liabilities in active markets; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">quoted prices for identical or similar assets or liabilities in markets that are not active; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">observable inputs other than quoted prices that are used in the valuation of the asset or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals); and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">inputs that are derived principally from or corroborated by observable market data by correlation or other means. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs for the assets or liability (i.e., supported by little or no market activity). Level&#160;3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, the Company does not allocate loss to participating securities because they have no contractual obligation to share in the losses of the Company. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net income loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss is computed by adjusting net loss to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </font></p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&#8217;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based awards at fair value, and measures fair value using the Black-Scholes option-pricing model. Stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period, on a straight-line basis for all time-vested awards. Forfeitures are recognized as they occur. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Success fee obligation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s loan and security agreement (the &#8220;Loan Agreement&#8221;) entered into in 2020 required the Company to pay a success fee of $0.5&#160;million upon the occurrence of a specified liquidity event, as described in the Loan Agreement, which included the Company&#8217;s IPO. The liability was initially deemed immaterial upon entering into the Loan Agreement and was subsequently remeasured to fair value at each reporting date. Following the completion of the IPO, the success fee of $0.5 million was paid in September 2020. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comprehensive loss </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended December&#160;31, 2020, the Company&#8217;s only element of other comprehensive loss was unrealized gains (losses) on marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Accounting pronouncements issued and not adopted </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The Company plans to adopt ASU 2016-02 on January 1, 2021 using the modified retrospective approach transition method as of the date of adoption such that prior periods will not be restated. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. The adoption of the new standard is expected to result in the recognition of material liabilities and right-of-use assets, however, the Company has not completed the assessment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3. </font><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities and f</font><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">air value measurements </font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities by security type at December&#160;31, 2020 consisted of the following:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,572</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,489</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have marketable securities as of December&#160;31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth by level, within the fair value hierarchy (see Note 2), the assets carried at fair value on a recurring basis for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,017</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,017</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,309</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,309</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,428</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,359</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207,787</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of U.S. government money market funds and commercial paper were determined by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. Certificates of deposit and corporate debt securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the years ended December&#160;31, 2020 and 2019, there were no transfers between Level 1, Level 2 and Level 3. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the scheduled maturity for the Company&#8217;s marketable securities at December 31, 2020:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing in one year or less</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,623</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing after one year through two years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,147</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing after two years</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,770</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no sales of marketable securities during the year ending December&#160;31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the preferred stock tranche obligations in connection with the unfunded tranches associated with the Series A Preferred Stock Purchase Agreement (see Note 7) was determined based on significant inputs not observable in the market, which represents a Level&#160;3 measurement within the fair </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value hierarchy. The fair value of the preferred stock tranche obligations was determined by considering as inputs the future value of the Series A Preferred Stock, the difference between the future value of the Series A Preferred Stock and the contract price, the number of shares underlying the contract, the probability of achieving the funding of the tranches, expected timing of the tranche closing and the discount rate. The future value of Series A Preferred Stock was estimated by calibrating, or backsolving, to the price of the Series A Preferred Stock as set forth in the Series A Preferred Stock Purchase Agreement. The contractual price of the shares to be issued in addition to the number of shares underlying the contract are both provided for by the Series A Preferred Stock Purchase Agreement. The probability of achieving the funding of the tranches and the expected timing of those closings were estimates made by the Company. The discount rate was equal to the risk-free rate for the estimated timing of each tranche closing. </font></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the liability recognized in connection with the contingent success fee associated with the Loan Agreement (see Note 6) was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the liability was determined using the probability-weighted expected return method (&#8220;PWERM&#8221;), which considered as inputs the probability of occurrence of a specified liquidity event, the expected timing of a liquidity event, the amount of the success fee and a risk-adjusted discount rate. The initial fair value of the liability was de minimis due to the low probability of the events probable of triggering payment. As of September 21, 2020, the closing date of the IPO, the event occurred and the probability increased to 100% and the discount rate was assessed to be 0%. Based on these inputs, the Company determined that the fair value of the derivative liability was $0.5 million as of September 21, 2020. Following the completion of the IPO, the success fee of $0.5 million was paid in September 2020. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a roll-forward of the aggregate fair values of the Company&#8217;s liabilities for which fair value is determined by Level&#160;3 inputs: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock Tranche Obligations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Success Fee Obligation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;January 1, 2019</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of Tranche Right I</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,323</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of Tranche Right II to equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,319</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial fair value of success fee obligation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of derivative instrument</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Financial instruments not recorded at fair value </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of cash, cash equivalents, accounts payable and accrued expenses that are reported on the balance sheets approximate their fair value due to the short-term nature of these assets and liabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">4. Property and equipment </font></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,744</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,705</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment&#8212;at cost</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,941</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(295</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment&#8212;net</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,946</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,486</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense totaled $0.7 million and $0.3&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">5. Accrued expenses and other current liabilities </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and benefits</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,105</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal services</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,782</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">484</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility costs</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,527</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">6. Debt financing </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 20, 2020, the Company entered into a Loan Agreement pursuant to which the lender made term loans to the Company in an aggregate principal amount of $10.0 million. Borrowings under the Loan Agreement were collateralized by substantially all of the Company&#8217;s assets, excluding intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on the outstanding loan balance accrued at a variable annual rate equal to the greater of (i) the lender&#8217;s prime rate plus 0.25% and (ii) 5.00%, and the Company was required to make interest-only payments on the loans on a monthly basis through August 2021. The outstanding borrowings were repaid in October 2020.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Loan Agreement, a success fee of $0.5 million was required in the event of a liquidation event, including an IPO. The success fee represented an embedded derivative which the Company bifurcated from the debt arrangement and carried at fair value. In September 2020, the Company completed its IPO and paid the success fee of $0.5 million. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">C</font><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">onvertible preferred stock </font></p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company issued Series A convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;) and Series B convertible preferred stock (the &#8220;Series B Preferred Stock&#8221;). Collectively the Series A Preferred Stock and the Series B Preferred Stock are referred to as the Preferred Stock. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO in September 2020, the Company&#8217;s Preferred Stock automatically converted into 28,086,375 shares of common stock.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Series A Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;29, 2018, the Company entered into the Series A Preferred Stock Purchase Agreement with its initial investors committing to purchase an aggregate of $50.0&#160;million in shares of Series A Preferred Stock. At the initial closing, 12,500,000 shares of Series A Preferred Stock were issued by the Company at a purchase price of $1.00 per share, for gross cash proceeds of $7.5&#160;million. Of the 12,500,000 shares issued, 5,000,000 shares were issued upon conversion of the then outstanding SAFEs, which had a fair value of $5.0&#160;million. In April 2019, the Company issued an additional 20,000,000 shares of Series A Preferred Stock under the terms of the Series A Preferred Stock Purchase Agreement at a purchase price of $1.00 per share for total gross proceeds of $20.0&#160;million. Issuance costs associated with each closing of the Series A Preferred Stock financing were $0.1&#160;million. On March&#160;18, 2020, the Company entered into a separate Series A Preferred Stock Purchase Agreement with an additional investor and issued 2,000,000 shares of Series A Preferred Stock at a purchase price $1.00 per share for gross cash proceeds of $2.0&#160;million. In July 2020, the Company issued and sold 17,500,000 shares of Series A Preferred Stock at a price of $1.00 per share, for gross proceeds of $17.5 million.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Series B Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company issued and sold 41,159,724 shares of Series B Preferred Stock at a price of $2.81 per share for gross proceeds of $115.7 million.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Tranche Rights</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in the terms of the November 2018 Series A Preferred Stock Purchase Agreement were certain rights (&#8220;Tranche Rights&#8221;) granted to the investors who purchased the Series A Preferred Stock purchased in November 2018. The Tranche Rights contingently obligated the investors to purchase, and the Company to sell, up to an aggregate of 37,500,000 shares of Series A Preferred Stock at $1.00 per share upon the satisfaction of specified research and development milestones by the Company. The Tranche Rights are also exercisable at the option of the holders of the Series A Preferred Stock. The Tranche Rights were divided into separate rights and obligations to purchase 20,000,000 shares (&#8220;Tranche Right I&#8221;) and 17,500,000 shares (&#8220;Tranche Right II&#8221;) based on the achievement of specified milestones for each tranche. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that the Tranche Rights met the definition of a freestanding financial instrument, as the Tranche Rights were legally detachable and separately exercisable from the Series A Preferred Stock. Therefore, the Company allocated the proceeds from the November 2018 issuance between the Tranche Rights and the Series A Preferred Stock. As the Series A Preferred Stock was redeemable upon a deemed liquidation event at the election of the holder-controlled Board, and therefore outside of the control of the Company, the Tranche Rights were initially classified as a liability and were initially recorded at their fair value of $3.4&#160;million. The Tranche Rights were then remeasured at fair value at each reporting period, with changes in fair value recorded in the statement of operations. The estimated fair value of the Tranche Rights was determined at each reporting date using a probability-weighted present value model that considers the probability of closing a tranche, the estimated future value of the Series A Preferred Stock to be issued at each closing, and the investment required at each closing. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, Tranche Right I was settled when the Company closed on the issuance of </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000,000</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares Series A Preferred Stock. The fair value of the Tranche Right I as of the closing date was reclassified from a liability to Series A Preferred Stock within equity. </font></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the size of the Board was increased from five to six members, including three independent members, which allowed the Company to conclude that the redemption rights of the holders of the Series A Preferred Stock was within the control of the Company. As a result, the Company concluded that Tranche Right II qualified for equity classification as of that date. The preferred stock tranche obligation liability, with a fair value of $6.3&#160;million, was reclassified into permanent equity and was no longer remeasured at fair value. In July 2020, Tranche Right II was settled when the Company closed on the issuance of 17,500,000 shares Series A Preferred Stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Preferred Stock had the followings rights and privileges: </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of the Preferred Stock were entitled to receive non-cumulative dividends when, as and if declared by the Board. The Company did not declare dividends on any class of preferred or common stock. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any liquidation, dissolution, or winding-up of the Company, which would include the sale of the Company, the Preferred Stock was senior to common stock. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Voting </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Preferred Stock were entitled to the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by each holder were then convertible. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Conversion </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Preferred Stock were able to convert, at any time, each share of Preferred Stock into shares of common stock at the stated conversion price. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">8. Equity </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company&#8217;s restated certificate of incorporation authorized the Company to issue 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had authorized 68,000,000 shares of common stock. The voting,<font style="Background-color:#FFFFFF;color:#000000;"> dividend and liquidation rights of the holders of the Company&#8217;s common stock was subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock as set forth above.</font> </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">9. Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2018 Stock incentive plan </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;) provided for the Company to sell or issue incentive stock options or nonqualified stock options, restricted stock, and other equity awards to employees, directors and consultants of the Company. The 2018 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of the board of directors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total number of shares of common stock authorized under the 2018 Plan was </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,267,252</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under the 2018 Plan, and the </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,928,487</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock remaining under the 2018 Plan became available for future issuance under the 2020 Plan.</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2020 Stock incentive plan </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020 the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2020 Plan (together with the 2018 Plan the &#8220;Plans&#8221;), which became effective on September 16, 2020. The 2020 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards to employees, directors, consultants and advisors of the Company. The 2020 Plan is administered by the Company&#8217;s board of directors or by a committee appointed by the board of directors. Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under the 2018 Plan. The number of shares initially reserved for issuance under the 2020 Plan was 4,884,233. The number of shares of common stock reserved for issuance under the 2020 Plan automatically increases on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030, in an amount equal to the lower of (1) 5% of the shares of common stock outstanding on such date and (2) an amount determined by the Company&#8217;s board of directors. On January 1, 2021, 2,272,345 shares were added to the shares reserved for issuance under the 2020 Plan in the first of these annual increases.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, 3,237,244 shares remained available for future issuance under the 2020 Plan. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020 the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;), which became effective September 16, 2020. The 2020 ESPP is administered by the Company&#8217;s board of directors or by a committee appointed by the board of directors. The 2020 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of 488,414 shares of common stock. The number of shares of common stock reserved for issuance under the 2020 ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030, in an amount equal to the lowest of (1) 1,953,656 shares of common stock, (2) 1% of the shares of common stock outstanding on such date, and (3) an amount determined by the board of directors. As of December&#160;31, 2020, no offering periods have commenced under the 2020 ESPP and 488,414 shares remained available for issuance.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock option valuation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company typically grants stock options at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time of grant. In the periods prior to the IPO, the fair value of the common stock was determined by the Board at each measurement date based on a variety of different factors, including the results obtained from independent third-party appraisals, the Company&#8217;s financial position and historical financial performance, the status of development of the Company&#8217;s programs, the current climate in the marketplace, the illiquid nature of the common stock, the effect of the rights and preferences of the preferred stockholders, and the prospects of a liquidity event, among others.&#160;&#160;In the periods following the IPO, the fair value is determined based upon the quoted price of the Company&#8217;s common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of options granted were as follows:</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75%</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74%</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% &#8212; 1.67%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46% &#8212; 2.50%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Stock option activity</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the option activity: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62634037"></a>Outstanding January 1, 2020</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311,303</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.93</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,252,967</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,197</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.93</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110,484</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.97</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,112</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable&#8212; December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,282</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested or expected to vest&#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2020</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.97</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,112</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of the options granted during the years ended December&#160;31, 2020 and 2019 was $4.50&#160;per share and $0.62 per share, respectively. As of December&#160;31, 2020 there was $20.3 million&#160;of unrecognized compensation expense, which the Company expects to recognize over&#160;a&#160;weighted-average&#160;period&#160;of&#160;2.71&#160;years. Additionally, as of December&#160;31, 2020, the Company has unrecognized compensation cost related to unvested stock-based awards with performance-based vesting conditions for which performance has not been deemed probable of $2.6 million.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Restricted stock units</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A restricted stock unit (&#8220;RSU&#8221;) represents the right to receive one share of common stock upon vesting of the RSU. The Company grants RSUs with service conditions that vest in four equal annual installments provided that the employee remains employed with the Company. The Company also grants RSUs with performance conditions that vest upon the achievement of specified milestones. The fair value of each RSU is based on the closing price of the Company&#8217;s common stock on the date of grant. A summary of the Company&#8217;s RSU activity and related information for the 2020 Plan for the year ended December&#160;31, 2020 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying RSUs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of January 1, 2020</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.60</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.60</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $7.7 million of unrecognized compensation costs &#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;related to unvested RSUs, which are expected to be recognized over a weighted-average period of 2.75 years. Additionally, as of December&#160;31, 2020, the Company has unrecognized compensation cost of $0.6 million related to unvested stock-based awards with performance-based vesting conditions for which performance has not been deemed probable.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Restricted common stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2018, the Company granted restricted common stock with service-based vesting conditions. Shares of unvested restricted common stock may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting conditions of each award. The grant date fair value of these shares was immaterial. The following table summarizes the Company&#8217;s restricted common stock award activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of Restricted&#160;Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of January 1, 2020</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,482</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(282,153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,329</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense in the following expense categories of its statements of operations: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,699</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,892</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">10. Income taxes </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no provision for income taxes because the Company has historically incurred net operating losses and maintains a full valuation allowance against its deferred tax assets. The reported amount of income tax expense/benefit for the years ended December&#160;31, 2020 and 2019 differs from the amount that would result from applying domestic federal statutory rates to pretax losses primarily because of changes in the valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax expense at statutory rate</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes&#8212;net of federal benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche obligations</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent differences</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal &amp; state R&amp;D credits</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets at December&#160;31, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended&#160;December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,349</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,858</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,848</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">612</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,942</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,634</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,899</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,607</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets (liabilities)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had federal and state net operating loss carryforwards of $69.1 million and $68.9 million, respectively.&nbsp;&nbsp;The federal net operating loss carryforwards are indefinite lived and the state net operating loss carryforwards begin to expire in 2038. As of December 31, 2020, the Company also had federal and state research and development tax credit carryforwards $0.8 million and $0.4 million, respectively, which begin to expire in 2039 and 2033, respectively.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and concluded that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2020 and 2019. The increase in the valuation allowance for deferred tax assets during the years ended December 31, 2020 and 2019 totaled $16.3 million and $4.2 million, respectively, and related primarily to the increase in net operating loss carryforwards. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to record estimated interest and penalties related to uncertain tax positions in income tax expense. The Company has no amounts recorded for any unrecognized tax positions, accrued interest or penalties as of December&#160;31, 2020 and 2019. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates, including the United States and the Commonwealth of Massachusetts. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#8217;s tax returns are open under statute from </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the present.</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">11. Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,395,955</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,442,872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.13</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.08</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311,303</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,329</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,482</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,798,298</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,195,273</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,762,083</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">12. Commitments and contingencies </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Operating leases </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a sublease agreement for laboratory and office space in Waltham, Massachusetts. The term of the sublease commenced on July&#160;1, 2019 and expires on December&#160;31, 2021.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into a lease agreement (the &#8220;Lease&#8221;), pursuant to which the Company will lease approximately 68,187 square feet of additional office and laboratory space located in Waltham, Massachusetts (the &#8220;Premises&#8221;). The Lease will have a term of eight years and six months that will commence when the Premises are ready for occupancy. The Company&#8217;s obligation for the payment of base rent for the Premises begins six months after the commencement date and will be $0.4 million per month, increasing up to $0.5 million during the term of the Lease. The Company has two options to extend the term of the Lease, each for a period of an additional five years. The Company expects the Premises to be ready for occupancy in the second half of 2021.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense for the years ended December&#160;31, 2020 and 2019 totaled $0.8&#160;million and $0.7&#160;million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under the non-cancelable operating leases consisted of the following as of December&#160;31, 2020: </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2021</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,603</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2023</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,741</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,883</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2025</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,672</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,728</p></td>
<td valign="bottom"  BGCOLOR="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Legal proceedings </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any such legal proceedings. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Other contractual obligations </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancelable by the Company upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancelable obligations of the service providers, up to the date of cancellation and in the case of certain arrangements may include non-cancelable fees. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has also entered into a license agreement (the &#8220;UMONS Agreement&#8221;) with the University of Mons (&#8220;UMONS&#8221;) in April 2020, pursuant to which UMONS granted to the Company an exclusive, worldwide license to certain patents and patent applications and a non-exclusive, worldwide license to existing, related know-how. Each of the issued patents licensed to the Company under the UMONS Agreement is scheduled to expire in 2031. The licenses under the UMONS Agreement confer on the Company the right to research, develop and commercialize products (&#8220;licensed products&#8221;), and to practice processes, in each case, covered by the licensed patents and existing, related know-how. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UMONS Agreement, the Company is obligated to use commercially reasonable efforts to develop at least one licensed product and, to the extent regulatory approval is obtained in such jurisdictions, to commercialize at least one licensed product in the United States and the United Kingdom or a member country of the European Union. Unless terminated earlier, the UMONS Agreement will remain in effect until the last to expire of the licensed patent rights on a licensed product-by-licensed product and country-by-country basis. UMONS may terminate the UMONS Agreement in the event of a material breach by the Company and the Company&#8217;s failure to cure such breach within a specified time period. The Company may voluntarily terminate the UMONS Agreement with prior notice to UMONS. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entry into the UMONS Agreement, the Company paid UMONS an upfront payment of &#8364;0.1 million. The Company also agreed to make milestone payments to UMONS upon the achievement of specified development and regulatory milestones up to a maximum aggregate total of &#8364;0.4 million for the first licensed product to achieve such milestones and up to a maximum aggregate total of &#8364;0.2 million for each subsequent licensed product to achieve each such milestones, as well as a low single-digit percentage royalty on net sales of licensed products by the Company, its affiliates and sublicensees. These royalty obligations continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the last licensed patent rights covering such licensed product in such country. In addition, if the Company sublicenses rights under the UMONS Agreement, the Company is required to pay a low double-digit percentage of the sublicense revenue to UMONS. Additionally, if the Company chooses to file, prosecute or maintain any patents included in the licensed patent rights under the UMONS Agreement, it will be required to bear the full cost and expenses of preparing, filing, prosecuting and maintaining any such patents. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> amounts have been accrued under this arrangement with respect to potential milestone payment obligations or royalty obligations given the uncertainty of achieving the specified milestones and commercial sales of any licensed products. </font></p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">13. Subsequent events </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020, subsequent events were evaluated through March 4, 2021, the date on which the audited consolidated financial statements were issued. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>dyn-ex43_148.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-ex43_148.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:6.11%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.11%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description of the common stock, par value $0.0001 per share, of Dyne Therapeutics, Inc. (&#8220;us,&#8221; &#8220;our,&#8221; &#8220;we&#8221; or the &#8220;Company&#8221;), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), summarizes certain information regarding our common stock in our restated certificate of incorporation, our amended and restated bylaws and applicable provisions of the Delaware corporate law (the &#8220;DGCL&#8221;), and is qualified by reference to our restated certificate of incorporation and amended and restated bylaws, which are incorporated by reference as Exhibit 3.1 and Exhibit 3.2, respectively, to the Annual Report on Form 10-K.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized Capital Stock</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.11%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. Our common stock is registered under Section 12(b) of the Exchange Act.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights<font style="font-style:normal;">. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends.<font style="font-style:normal;"> Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock that we may designate and issue in the future. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation and Dissolution.<font style="font-style:normal;"> In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Rights<font style="font-style:normal;">. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of our restated certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings, and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.11%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Delaware Business Combination Statute. <font style="font-style:normal;">We are subject to Section 203 of the DGCL. Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for three years following the date that the person became an interested stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">interested stockholder. A &#8220;business combination&#8221; includes, among other things, a merger or consolidation involving us and the &#8220;interested stockholder&#8221; and the sale of more than 10% of our assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.11%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Staggered Board; Removal of Directors<font style="font-style:normal;">. Our restated certificate of incorporation and our amended and restated bylaws divide our board of directors into three classes with staggered three-year terms. In addition, our restated certificate of incorporation and our amended and restated bylaws provide that directors may be removed only for cause and only by the affirmative vote of the holders of at least 75% of our shares of capital stock present in person or by proxy and entitled to vote. Under our restated certificate of incorporation and our amended and restated bylaws, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. Furthermore, our restated certificate of incorporation provides that the authorized number of directors may be changed only by the resolution of our board of directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. </font></p>
<p style="margin-top:16pt;margin-bottom:12pt;text-indent:6.11%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Super-majority Voting. <font style="font-style:normal;">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our amended and restated bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our restated certificate of incorporation described above.</font><font style="font-family:Arial;font-style:normal;color:#000000;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.11%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder Action; Special Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and Director Nominations. <font style="font-style:normal;">Our restated certificate of incorporation and our amended and restated bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our restated certificate of incorporation and our amended and restated bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called by our board of directors. In addition, our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for common stock because even if the third party acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. </font></p>
<p style="margin-top:16pt;margin-bottom:12pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Forum Selection.<font style="font-style:normal;"> Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of proceedings: (1)&#160;any derivative action or proceeding brought on behalf of our company, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (3)&#160;any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware, or (4)&#160;any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or amended and restated bylaws (in each case, as they may be amended from time to time) or </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ActiveUS 185218570</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:16pt;margin-bottom:12pt;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">governed by the internal affairs doctrine. These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&#160;22 of the Securities Act</font><font style="font-style:normal;"> of 1933, as amended (the &#8220;Securities Act&#8221;)</font><font style="font-style:normal;"> creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our </font><font style="font-style:normal;">restated </font><font style="font-style:normal;">certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.11%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.11%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ActiveUS 185218570</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>3
<FILENAME>dyn-ex1021_147.htm
<DESCRIPTION>EX-10.21
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-ex1021_147.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.21</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="geyphazaalhx000001.jpg" title="" alt="" style="width:240px;height:84px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wildon Farwell</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 17, 2020</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Wildon:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On behalf of Dyne Therapeutics, Inc. (the &#8220;Company&#8221;), I am pleased to offer you employment in the position of Chief Medical Officer.&nbsp;&nbsp;This letter summarizes the initial terms of your employment with the Company.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_2_1"></a><a name="_cp_text_1_2"></a><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Position</font><font style="color:#000000;">.&nbsp;&nbsp;You will be employed by the Company on a full-time basis, reporting to the Company&#8217;s President and Chief Executive Officer or his/her designee.&nbsp;&nbsp;You will work out of the Company&#8217;s office in Waltham, Massachusetts or at such other office as the Company<a name="_cp_text_2_1"></a><a name="_cp_text_1_2"></a> may designate. You agree to devote your full business time, best efforts, skill, knowledge, attention and energies to the advancement of the Company&#8217;s business and interests and to the performance of your duties and responsibilities as an employee of the Company, and shall not engage in any other employment, consulting or other business activity without the prior written consent of the Company.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Start Date</font><font style="color:#000000;">. </font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">Your employment will begin on March 1, 2021 (the &#8220;Start Date&#8221;).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Salary</font><font style="color:#000000;">. During your employment the Company will pay you a salary at the rate of $440,000 per year, payable in accordance with the regular payroll practices of the Company and subject to applicable deductions and withholdings. This salary will be subject to periodic review and adjustments at the Company&#8217;s discretion.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Annual Bonus</font><font style="color:#000000;">. Following the end of each fiscal year and provided you remain employed by the Company on the last day of such fiscal year, you will be eligible to receive an annual incentive bonus of up to forty percent (40%) of your cumulative regular earnings during that fiscal year.&nbsp;&nbsp;The actual bonus awarded for a fiscal year will be based on your performance and the Company&#8217;s performance that year against criteria to be established by the Company, both as determined by the Company in its sole discretion.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Signing Bonus</font><font style="color:#000000;">. In addition, upon the commencement of your employment with the Company, you shall become entitled to receive a bonus of $65,000, which will be paid in your first pay check.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Equity. </font><font style="color:#000000;"> Subject to the approval of the Board of Directors of the Company, and in consideration of your agreement in Section 8 to adhere to the non-competition provisions set forth in the Non-Competition Agreement (as defined below), the Company may grant to you an option (the &#8220;Option&#8221;) for the purchase of 250,000 shares of common stock of the Company at a price per share equal to the fair market value at the time of Board approval.&nbsp;&nbsp;Additionally, the Company may grant to you a restricted stock unit (the &#8220;RSU&#8221;) for 50,000 shares of common stock of the Company. The Option and RSU shall be subject to the terms of the Company&#8217;s 2020 Stock </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Incentive Plan (the &#8220;</font><font style="color:#000000;">20</font><font style="color:#000000;">20</font><font style="color:#000000;"> </font><font style="color:#000000;">Plan&#8221;) and other provisions set forth in a separate option</font><font style="color:#000000;"> and restricted stock unit</font><font style="color:#000000;"> agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Benefits.</font><font style="color:#000000;"> You may participate in the benefit programs offered by the Company to its employees from time to time, provided that you are eligible under (and subject to all provisions of) the plan documents that govern those programs.&nbsp;&nbsp;The Company does not offer a specific number of vacation days.&nbsp;&nbsp;Instead, the Company has an open policy of taking days off based on an employee&#8217;s reasonable discretion and prior approval from the employee&#8217;s manager.&nbsp;&nbsp;These benefits may be modified by the Company from time to time in its sole discretion.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Representation Regarding Other Obligations</font><font style="color:#000000;">.&nbsp;&nbsp;You will be required to sign, as a condition of your employment, a Non-Competition and Non-Solicitation Agreement (the &#8220;Non-Competition Agreement&#8221;) and an Invention and Non-Disclosure Agreement (collectively, with the Non-Competition Agreement, the &#8220; Restrictive Covenant Agreements&#8221;), copies of which are enclosed.&nbsp;&nbsp;You acknowledge that the Company&#8217;s agreement to grant you the equity grant provided in Section 6 is contingent upon your agreement to adhere to the non-competition provisions set forth in the Non-Competition Agreement, and that such consideration was mutually agreed upon by you and the Company and is fair and reasonable in exchange for your compliance with the non-competition obligations. You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter. You further represent that you have not used and will not use or disclose or induce the Company to use, any trade secret or other proprietary information or material of any previous employer or any other party.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Taxes</font><font style="color:#000000;">.&nbsp;&nbsp;All forms of compensation referred to in this letter are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.&nbsp;&nbsp;You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, that you are solely responsible for individual tax liabilities arising from your compensation and that you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Eligibility to Work.</font><font style="color:#000000;"> Your employment with the Company is conditioned on your eligibility to work in the United States and your providing to the Company satisfactory proof of identification and of authorization to work in the United States, in accordance with the Immigration and Control Act of 1986 within three days of your&nbsp;&nbsp;start date.&nbsp;&nbsp;Furthermore, you may need a work visa in order to be eligible to work in the United States.&nbsp;&nbsp;If that is the case, your employment will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company and maintaining such visa throughout your tenure with the Company, as it is Company policy to comply with all immigration laws and regulations.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Interpretation, Amendment and Enforcement</font><font style="color:#000000;">.&nbsp;&nbsp;This letter and the Restrictive Covenant Agreements constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.&nbsp;&nbsp;The terms of this letter and the resolution of any disputes as to the meaning, effect, performance or validity of this letter or arising out of, related to, or in any way connected with, this letter, your employment with the Company or any other relationship between you and the Company (the &#8220;Disputes&#8221;) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law.&nbsp;&nbsp;You and the Company submit to the exclusive personal jurisdiction of </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Other Terms.</font><font style="font-weight:bold;margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> Your employment with the Company will be on an &#8220;at will&#8221; basis.&nbsp;&nbsp;In other words, you or the Company may terminate your employment for any reason and at any time, with or without cause or notice.&nbsp;&nbsp;This letter shall not be construed as an agreement, either express or implied, to employ you for any stated term, and shall in no way alter the Company&#8217;s policy of employment at-will as defined by applicable law. Although your job duties, title, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time, the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and the Company.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, the Company confirms eligibility, based on employee&#8217;s position of Chief Medical Officer, for severance benefits offered to &#8216;Senior Executives&#8217; as set forth in the &#8216;Executive Severance and Change in Control Plan&#8217; filed as Exhibit 10.20 to the Company&#8217;s August 25<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>, 2020 Registration Statement on Form S-1. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Contingency.&nbsp;&nbsp;</font><font style="color:#000000;">This offer is subject to satisfactory background and reference checks, including our receiving at least two satisfactory professional references.</font><font style="font-weight:bold;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are excited about the prospect of having you join the Company.&nbsp;&nbsp;We look forward to receiving a response from you within one week acknowledging, by signing below, that you have accepted this offer of employment on the terms set forth herein, and by delivering signed copies of the Restrictive Covenant Agreements.&nbsp;&nbsp;If you do not accept this offer within one week, this offer will be deemed revoked.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very Truly Yours,</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">DYNE THERAPEUTICS, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joshua Brumm</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joshua Brumm</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:0.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:86.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I have read and accept this at-will employment offer on the terms set forth herein:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:48.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/</font>s/ Wildon Farwell</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:29.52%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18 December 2020</p></td>
<td valign="top"  style="width:14.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="top"  style="width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:43.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>dyn-ex211_146.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-ex211_146.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUBSIDIARIES<font style="font-weight:normal;"> </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:42.47%;"></td>
<td style="width:19.55%;"></td>
<td style="width:37.98%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Incorporation</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dyne Therapeutics Securities Corporation</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>dyn-ex231_145.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-ex231_145.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Exhibit 23.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in Registration Statement No. 333-248873 on Form S-8 of our report dated March 4, 2021, relating to the financial statements of Dyne Therapeutics, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &amp; Touche LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>dyn-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1 </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Joshua Brumm, hereby certify that: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Annual Report on Form&#160;10-K&#160;of Dyne Therapeutics, Inc.; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;for the registrant and have: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 4, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>dyn-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard Scalzo, hereby certify that: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Annual Report on Form&#160;10-K&#160;of Dyne Therapeutics, Inc.; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;for the registrant and have: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 4, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Scalzo</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Accounting and Administration and Treasurer</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>dyn-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO 18 U.S.C. SECTION 1350, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Joshua Brumm, certify pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Annual Report on Form&#160;10-K&#160;of Dyne Therapeutics, Inc. for the fiscal year ended December 31, 2020 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form&#160;10-K&#160;fairly presents, in all material respects, the financial condition and results of operations of Dyne Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joshua Brumm</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>dyn-ex322_6.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dyn-ex322_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO 18 U.S.C. SECTION 1350, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard Scalzo, certify pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Annual Report on Form&#160;10-K&#160;of Dyne Therapeutics, Inc. for the fiscal year ended December&#160;31, 2020 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form&#160;10-K&#160;fairly presents, in all material respects, the financial condition and results of operations of Dyne Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Scalzo</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Accounting and Administration and Treasurer</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 4, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gtinntqqusay000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /#!3@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#C?$/@6SUR8R31!B3FL,_"?3L?\>Z_I7IU% 'S6?"MNOBR:Q\OY$8
M"O;=$\,PZ9H9M(D"B0!B*A;P3 VMR:CYIW.V<5U:+LC5?0 4 >(Z7?-X9\<7
MK3JPB=MJG%>AZUXPL;72&E5\MM!PK9/2IO$7@ZUUQ.HB?KN4<UREM\* MR&E
MU&:1,_=8DB@"A\/].DOO$UYJCJ?+FY7(KV #"@>@JCI>E0:7:I#$J_*,9 ZU
M?H *\G^+?_'K)_NUZQ7D_P 6_P#CUD_W: .V\#_\BE8?[E=%7.^!_P#D4K#_
M '*Z*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\G^+?\ QZR?[M>L5Y/\6_\ CUD_W: .V\#_
M /(I6'^Y715SO@?_ )%*P_W*Z*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\G^+?_ !ZR?[M>
ML5Y/\6_^/63_ ': .V\#_P#(I6'^Y715SO@?_D4K#_<KHJ "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KR?XM_\>LG^[7K%>3_%O_CUD_W: .V\#_\ (I6'^Y715SO@?_D4K#_<
MKHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KR?XM_\>LG^[7K%>3_ !;_ ./63_=H [;P/_R*
M5A_N5T5<[X'_ .12L/\ <KHJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***CG<QP.ZC) XH )IDA3>Y 'N:CMKR*ZW>6RMMZX.:\
MT\6>+;V(O;31B.$?QBL#PGXPNK2:X2V_?^8W\1SB@#W+/%5!J$!E\O>N[.,9
MKBKKQ=JT%@96M5!/!K@4\7LFK"43$R[\[,\9H ]^JM<7L-LRK(Z@MTR<5Q=K
MXMU6XMA,+5<8KB/%7BZYN;^$W1\@QG@*<9H';N>XQ2K*@=2"#Z&GUY=X5\87
M]PL=M%$)(>SGK7IL+%X49A@D9- B2BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44UV"(6/0#)KSSQ'\3;72YS#:RH[@X(..
MM 'HM%>,_P#"WK\\B*+'T%'_  MW4/\ GC%^0H ]FHKS[P9X[NO$>J-:S1HJ
MA<\5Z#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D_Q;_P"/
M63_=KUBO*/BUC[+)G^[_ $H [7P/_P BE8?[E=%7.^"/^12L/]RNBH ****
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M0R Q2S$N3VH ]<7P)X? P+%*7_A!= _Y\4K)@^)^@O&"]XH/T%2_\+,\/_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH S-=D:/3)2G7:?Y5Y7\,;&UO=4U*:
MX56D2<[2?K7KU];BYM)(SW4@?E7A,DNH^!==ED$86":0L23VH ]^50JX XJA
MK%G;W=A*LZ@J1SFN$L_BSI;P SW*A^XXK(U_XIQW5L]MITBR.XP* *_@[%G\
M2[RUM^(%C& .G>O:5Y4&O*?AMH%T;_\ MN[C*R2K@_Y_&O5QTH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KR?XM_\>LG^[_2O6*\G^+?_'K)
M_N_TH [;P/\ \BE8?[E=%7.^!_\ D4K#_<KHJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTK!% STH&>4:[::EX*OH)ENV:.24+M'UKUW2=46[TI+@\809S]*\6\1^)/\
MA,=5AM+<AXHY5((^M>K36RZ3X2/ED_<4G/TH$>?:MJ&H>)_$L^FVL[QI$_)'
M0BK^J^ +^STTW-O>8E"@\=:C^',:W'BR^E89)&:]8N4#6Y4C(H \]^'WB*:X
MN9-,NG+2P#!+=Z])[5X9X=E-M\1M24< MBO8KO5[33H5:Y?:-H- &C7D_P 6
M_P#CUD_W?Z5VW_":Z+_S\?RKS;XF:]8:E;R"VEW$K0!Z3X'_ .12L/\ <KHJ
MYWP/_P BE8?[E=%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%1S3);Q&20X4=: )**YV;QMHL$AC>XPPZ]*C_P"$\T+_ )^?Y4 =
M-17,_P#">:%_S\_RH_X3S0O^?G^5 '345S/_  GFA?\ /S_*C_A/-"_Y^?Y4
M =-17,_\)YH7_/S_ "H_X3S0O^?G^5 '345S/_">:%_S\_RI#X]T%1DW/\J
M.GHKF1X]T$C(N?Y4?\)YH7_/S_*@#IJ*YG_A/-"_Y^?Y4?\ ">:%_P _/\J
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M*NA(2S(VSGVR*QO&'C6U\0)%9Z9()&+@$?6NO\$^')--T"2"=,&4[\?7G^M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 8G_"+Z9_SZQT?\(OIG_/K'6W10!B?\(OIG_/K'4D/AW3X) Z6Z CO6O10
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGQY_R*MS_ )[&NFKF
M?'G_ "*MS_GL: +?A3_D7[7_ '*VZQ/"G_(OVO\ N5MT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH *\G^+?_ !ZR?[O]*]8KR?XM_P#'K)_N_P!* .V\#_\
M(I6'^Y715SO@?_D4K#_<KHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO)_BW_QZR?[O]*]8KR?XM_\ 'K)_N_TH [;P/_R*5A_N5T5<[X'_ .12L/\
M<KHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?H/BRWL])@A;;E5Q6G_PF]K_ +/YUX[^)H_$T?4X![>1[%_PF]K_ +/YT?\
M";VO^S^=>._B:/Q-'U. ?6)'L7_";VO^S^='_";VO^S^=>._B:/Q-'U. ?6)
M'L7_  F]K_L_G1_PF]K_ +/YUX[^)H_$T?4X!]8D>Q?\)O:_[/YT?\)O:_[/
MYUX[^)H_$T?4X!]8D>Q?\)O:_P"S^='_  F]K_L_G7COXFC\31]3@'UB1[%_
MPF]K_L_G1_PF]K_L_G7COXFC\31]3@'UB1[%_P )O:_[/YT?\)O:_P"S^=>.
M_B:/Q-'U. ?6)'L7_";VO^S^='_";VO^S^=>._B:/Q-'U. ?6)'L7_";VO\
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MN=\#_P#(I6'^Y714 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_P@6A_\^_\ *@#+\(^.9_$6I-:R6GE +G-=W6-IGAC3=(N#-:1;7(QFMF@
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MKG? _P#R*5A_N5T5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %9VN?\@BX_W:T:SM<_Y!
M%Q_NU4?B0I;'A=__ ,?CU6JS?_\ 'X]5J]Q;'FO<****8@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOZMKLME%#/';!AB13P1FNT\&>%$\/V1#-OD<[B3US768&<TM !1110 4444
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MO_CUD_W?Z5ZQ7D_Q;_X]9/\ =_I0!VW@?_D4K#_<KHJYWP/_ ,BE8?[E=%0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6=KG_ ""+C_=K1K.US_D$7'^[51^)"EL>%W__
M !^/5:K-_P#\?CU6KW%L>:]PHHHIB"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.US_D$7'^[6C6=KG_ ""+
MC_=JH_$A2V/"[_\ X_'JM5F__P"/QZK5[BV/->X4444Q!1110 4444 %%%%
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MP-@I+/X3Z6D %Q;*TG<Y%8_B#X7):6[76FHD;1C(H ]2L(-/*">SAB4-T9%
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M&M+AD\Q+?#4 <C\/_#DMK*^I72%9IU^8'M7HO:FI&L:!%& .E.H *\G^+?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[
M7/\ D$7'^[6C6=KG_((N/]VJC\2%+8\+O_\ C\>JU6;_ /X_'JM7N+8\U[A1
M113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 58LO^/E/J*KU8LO\ CY3ZBD]A
MK<]YTG_D%V_^X*NU2TG_ )!=O_N"KM>%+=GI+8****0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH K7TS06SR*,E037!Z-\0;6\O
MY[343&C*Y500.:]"EC65"C#((P:\O\7_  _B+-?6!C@D'S$L1UH ]"CM-,O(
MA*EO RGOL%8^M:]HN@0,2L"2@?*-@KQZW\=ZEH&=.FN&D91C<G(JWHFBW_C2
M\^TW=W&\2M]QB,XH [3P=XNO/$'B:9#&!:[,JP_&O2ZPO#_AFQT.!1!"%<#!
M(K=H **** ,K6]*M]3M?+N&PH.:X]_#?AN-B&N%!SZ58^)6L7.GZ7$MHY21Y
M F1[D"O/+_P]XB@TM]0FNP5*[_S_ !H [DZ%X:')NU_*MKP_:Z/;OBRG#G/I
M7EUGX1\0:EH4>H17B;6!8CO@?C73_#6)QYJW#?O$D(Y[\T#1ZO1110(****
M"BBB@ HHHH **** "O)_BW_QZR?[O]*]8KR?XM_\>LG^[_2@#MO _P#R*5A_
MN5T5<[X'_P"12L/]RNBH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.US_D$7'^[6C6=K
MG_((N/\ =JH_$A2V/"[_ /X_'JM5F_\ ^/QZK5[BV/->X4444Q!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VN?\@B
MX_W:T:SM<_Y!%Q_NU4?B0I;'A=__ ,?CU6JS?_\ 'X]5J]Q;'FO<****8@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "K%E_P ?*?457JQ9?\?*?44GL-;GO.D_
M\@NW_P!P5=JEI/\ R"[?_<%7:\*6[/26P4444AA1110 4444 %%%% !1110
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M;:!]*L>"KFWB\"P^9*B_NVX+>U<GX<'VCQ2);88B64[L?6@9[%1110(****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %6++_CY3ZBJ]6++_CY3ZBD]AK<]YTG_ )!=O_N"
MKM4M)_Y!=O\ [@J[7A2W9Z2V"BBBD,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\[^*/_(,;_<KT2N;\5^'GUVU:)& RN.: .'^'?C+1
M]*\+V]M=7021>H_"G>.O&>C:EHT\5M=!W9, 5F+\'+Q1@3I^E!^#MXW!G3]*
M )_AQXNTC2=!@@N[D(ZCD?A74ZUX_P! N-)GBCO 69>!7'CX.7BC G3]*/\
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M4 =MX'_Y%*P_W*Z*N=\#_P#(I6'^Y714 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:Y
M_P @BX_W:T:SM<_Y!%Q_NU4?B0I;'A=__P ?CU6JS?\ _'X]5J]Q;'FO<***
M*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "K%E_Q\I]15>K%E_P ?*?44GL-;
MGO.D_P#(+M_]P5=JEI/_ ""[?_<%7:\*6[/26P4444AA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 48'I110 48'I110 4444 %<
M3XU\"V_BAUGD9Q(@P M=M10!X5_PANK^'W+65DLJ#NXS_2KEGK4=LP75[>&'
M'7""O9)C%L(D90/<URNLVWAHHS7*0.WIN% %/3IO#.HHIADC9C_L"NHT_3+.
MV :W50#SPN*\1U[48K>9H]&MF7!X,8S76?#B[UNX4F_>4KNX##'% 'JM%%%
M!1110 4444 %%%% !1110 5Y/\6_^/63_=_I7K%>3_%O_CUD_P!W^E ';>!_
M^12L/]RNBKG? _\ R*5A_N5T5 !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VN?\ ((N/
M]VM&L[7/^01<?[M5'XD*6QX7?_\ 'X]5JLW_ /Q^/5:O<6QYKW"BBBF(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JQ9?\?*?457JQ9?\ 'RGU%)[#6Y[SI/\
MR"[?_<%7:I:3_P @NW_W!5VO"ENSTEL%%%%(84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5!/=16PS*V!4]<QXPTV]OM.D-I,48+VH U/
M[?T__GM1_;^G_P#/:OFN=M>M]3-E+>.A!^\W%=3!X,\37$*RIJ;$,,\4 >U_
MV_I__/:C^W]/_P">U>,?\(-XH_Z"3_E1_P (-XH_Z"3_ )4 >W6VI6UV^V%]
MQJY7FG@/PYK.E:LTM_>-+&5P ?QKTN@;"N+\:>-4\-%8PRB1AD UVE>?^.O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.US_ )!%Q_NUHUG:
MY_R"+C_=JH_$A2V/"[__ (_'JM5F_P#^/QZK5[BV/->X4444Q!1110 4444
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M58DW,0!0 ^BLLZ[9JQ!E3CWI/[>L_P#GJGYT :M%97]O6?\ SU3\Z/[>L_\
MGJGYT :M%97]O6?_ #U3\Z/[>L_^>J?G0!JT5E?V]9_\]4_.C^WK/_GJGYT
M:M%97]O6?_/5/SIK>(;%?O3QCZM0!KT5DCQ!9'I,GYTO]O6?_/5/SH U:*RO
M[>L_^>J?G1_;UG_SU3\Z -6BLK^WK/\ YZI^=']O6?\ SU3\Z -6BLK^WK/_
M )ZI^=']O6?_ #U3\Z -6BLK^WK/_GJGYT^/6K65PJRH2?>@#2HI <@'UI:
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M'N*M5RGC*TOKJR9;.5T;;U6@"[]DTK^XG_?(I?LFE?W$_P"^17BW_".^*_\
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M#MO _P#R*5A_N5T5<[X'_P"12L/]RNBH **** "BBB@ HHHH **** "BBB@
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M#V_P/_R*5A_N5T5<[X'_ .12L/\ <KHJ "BBB@ HHHH **** "BBB@ HHHH
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M4=S71ZM\3+*ZTR:%43+#'6@#GOAL<?$*Z0=!'_C7N->#?"RX%UX]N9EZ&/\
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ME ':^!_^12L/]RNBKG? _P#R*5A_N5T5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7)^.?^/2V_ZZ#^8KK*Y/QS_P >EM_UT'\Q51W-L/\ Q$;.B?\
M'BOT%:=9FB?\>*_05IU)D]PHHHH$%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %9.M:!:ZW 8KH$J1CBM:B@#SO\
MX4]X>'\,E'_"GO#QZK)7HE% 'G0^#WAX=%D%+_PI_P /?W9*]$HH Y/PYX T
MGPU?-=V2L)",'-=9110 4444 %%%% !1110 4444 %%%% "!0.@ _"EHHH 0
M@'J :3RT_N+^5.HH **** "O)_BW_P >LG^[_2O6*\G^+?\ QZR?[O\ 2@#M
MO __ "*5A_N5T5<[X'_Y%*P_W*Z*@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBJ]Y=+:0&5\8'K0!8HKD9/'=C'(R%H\@XZTW_A/K#^]'^=
M '845Q__  GUA_>C_.C_ (3ZP_O1_G0!V%%<?_PGUA_>C_.C_A/K#^]'^= '
M845Q_P#PGUA_>C_.C_A/K#^]'^= '845Q_\ PGUA_>C_ #H_X3ZP_O1_G0!V
M%%<?_P )]8?WH_SH_P"$^L/[T?YT =A17'_\)]8?WH_SH_X3ZP_O1_G0!V%%
M<?\ \)]8?WH_SH_X3ZP_O1_G0!V%%<?_ ,)]8?WH_P Z/^$^L/[T?YT =A7)
M^.?^/2V_ZZ#^8J/_ (3ZP_O1_G7/^*?%UI?6\"HR?*X/!]Z<=S6@TJB;.]T3
M_CQ7Z"M.N"TSQO906JJ63@#O5W_A/K#^]'^=(S>YV%%<?_PGUA_>C_.C_A/K
M#^]'^= CL**X_P#X3ZP_O1_G1_PGUA_>C_.@#L**X_\ X3ZP_O1_G1_PGUA_
M>C_.@#L**X__ (3ZP_O1_G1_PGUA_>C_ #H ["BN/_X3ZP_O1_G1_P )]8?W
MH_SH ["BN/\ ^$^L/[T?YT?\)]8?WH_SH ["BN/_ .$^L/[T?YT?\)]8?WH_
MSH ["BN/_P"$^L/[T?YT?\)]8?WH_P Z .PHKC_^$^L/[T?YU+;^-[*XG2)6
M3+' YH ZNBFQN'0,.].H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K.US_D$7'^[6C6=KG_((N/\ =JH_$A2V/"[_ /X_'JM5F_\ ^/QZK5[B
MV/->X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %6++_CY3ZBJ]6++_CY3
MZBD]AK<]YTG_ )!=O_N"KM4M)_Y!=O\ [@J[7A2W9Z2V"BBBD,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***8TJ*0&8 GI0 ^BC.::[
M!$+'M0 ,ZJ,E@/QJ 7T!;;YBY^M>4^*];U#5_$$VC6#R1%.=Z'_/I6=_P@?B
M(1^<-:N<XSC/_P!:@#V\,K#((/T-+7E'@O7[ZRUQ]%OC)(8EYD?OU_PKU9&W
M(&]10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y/\6_^/63_
M '?Z5ZQ7D_Q;_P"/63_=_I0!VW@?_D4K#_<KHJYWP/\ \BE8?[E=%0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !6#XM_Y S_C6]6#XM_Y S_C
M0!\XW[-]OG^8_>]:K[F_O'\ZGO\ _C_G_P!ZJ] Q=S?WC^=&YO[Q_.DHH 7<
MW]X_G1N;^\?SI** %W-_>/YT;F_O'\Z2B@!=S?WC^=&YO[Q_.DHH 7<W]X_G
M1N;^\?SI** %W-_>/YT;F_O'\Z2B@!=S?WC^=&YO[Q_.DHH 7<W]X_G1N;^\
M?SI** %W-_>/YT;CZG\Z2B@!=S?WC^=&YO[Q_.DHH 7<W]X_G1N;^\?SI**
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M% !1110 4444 %8/BW_D#/\ C6]6#XM_Y S_ (T ?.%__P ?\_\ O57JQ?\
M_'_/_O57H&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:?A__ )#5I_UT
M%9E:?A__ )#5I_UT% 'TU9?\>J?[HJQ5>R_X]4_W15B@04444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6=KG_((N/]VM&L[7/^01<?[M5'XD*6QX
M7?\ _'X]5JLW_P#Q^/5:O<6QYKW"BBBF(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JQ9?\?*?457JQ9?\?*?44GL-;GO.D_\ (+M_]P5=JEI/_(+M_P#<%7:\
M*6[/26P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH *\G^+?_'K)_N_TKUBO)_BW_P >LG^[_2@#MO __(I6'^Y715SO@?\
MY%*P_P!RNBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\6_
M\@9_QK>K!\6_\@9_QH ^<+__ (_Y_P#>JO5B_P#^/^?_ 'JKT#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA?\ _'_/_O57JQ?_ /'_ #_[U5Z!A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6GX?_Y#5I_UT%9E:?A__D-6G_704 ?35E_QZI_NBK%5[+_CU3_=%6*!
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VN?\@BX_P!VM&L[
M7/\ D$7'^[51^)"EL>%W_P#Q^/5:K-__ ,?CU6KW%L>:]PHHHIB"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *L67_'RGU%5ZL67_'RGU%)[#6Y[SI/_(+M_P#<
M%7:I:3_R"[?_ '!5VO"ENSTEL%%%%(84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Y/\ %O\ X]9/]W^E>L5Y/\6_^/63_=_I0!VW
M@?\ Y%*P_P!RNBKG? __ "*5A_N5T5 !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %8/BW_ ) S_C6]6#XM_P"0,_XT ?.%_P#\?\_^]5>K%_\
M\?\ /_O57H&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:?A__D-6G_70
M5F5I^'_^0U:?]=!0!]-67_'JG^Z*L57LO^/5/]T58H$%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5G:Y_R"+C_ ':T:SM<_P"01<?[M5'XD*6Q
MX7?_ /'X]5JLW_\ Q^/5:O<6QYKW"BBBF(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JQ9?\?*?457JQ9?\?*?44GL-;GO.D_\@NW_ -P5=JEI/_(+M_\ <%7:
M\*6[/26P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>3_ !;_ ./6
M3_=_I7K%>3_%O_CUD_W?Z4 =MX'_ .12L/\ <KHJYWP/_P BE8?[E=%0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#XM_P"0,_XUO5@^+?\
MD#/^- 'SA?\ _'_/_O57JQ?_ /'_ #_[U5Z!A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6GX?_Y#5I_UT%9E:?A__D-6G_704 ?35E_QZI_NBK%5[+_C
MU3_=%6*!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VN?\@BX
M_P!VM&L[7/\ D$7'^[51^)"EL>%W_P#Q^/5:K-__ ,?CU6KW%L>:]PHHHIB"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *L67_'RGU%5ZL67_'RGU%)[#6Y[SI/
M_(+M_P#<%7:I:3_R"[?_ '!5VO"ENSTEL%%%%(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y/\ %O\ X]9/]W^E>L5Y1\6@/LTG
M^[_2@#M? _\ R*5A_N5T5<[X(_Y%*P_W*Z*@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "L'Q;_P @9_QK>K!\6?\ (&?\: /G"_\ ^/\ G_WJ
MKU9O_P#C_G_WC5:@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5I^'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D*,FF+,C' :@"2
MBBB@ KR?XM_\>LG^[_2O6*\G^+?_ !ZR?[O]* .V\#_\BE8?[E=%7.^!_P#D
M4K#_ '*Z*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'Q;_R
M!G_&MZL'Q;_R!G_&@#YPO_\ C_G_ -ZJ]6+_ /X_Y_\ >JO0,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *T_#_\ R&K3_KH*S*T_#_\ R&K3_KH* /IJ
MR_X]4_W15BJ]E_QZI_NBK% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "L[7/^01<?[M:-9VN?\@BX_P!VJC\2%+8\+O\ _C\>JU6;_P#X_'JM
M7N+8\U[A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 58LO^/E/J*KU8LO^
M/E/J*3V&MSWG2?\ D%V_^X*NU2TG_D%V_P#N"KM>%+=GI+8****0PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ I&(49-+6=K<YMM*EE!QB@#SGQ5XPOKG
M4VTS29629&PQP2*SKNV\;:1;?;IK\/$!DJHY_G4G@:U34/&E_/(-W<9KU>^M
M8Y[%HF0%<8Y% '->"O%0UJ 02DFX1?GS795XCX2N#8_$#4H5.$W8 KVH2*(U
M+'&0* )*\G^+?_'K)_N_TKU/[1%_>KRKXLR*]K)M.?EH [CP/_R*5A_N5T5<
MSX)FC7PG8@M_!70_:(_[U $M%1?:(O[U'VB+^]0!+147VB+^]1]HB_O4 2T5
M%]HB_O4?:(O[U $M%1?:(O[U'VB+^]0!+147VB+^]1]HB_O4 2T5%]HB_O4?
M:(O[U $M%1?:(O[U'VB+^]0!+147VB+^]1]HB_O4 2U@>+?^0,_XUM?:(O[U
M87BR:-M'<!O6@#YTO_\ C_G_ -ZJ]6+XC[?/_O57H&%%&:,T %%&:,T %%&:
M,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %
M%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:.* "M/P_P#\ANT_
MZZ"LS-:>@$#6K4_]-!0!]-67_'JG^Z*L53LYX_LJ?-_"*G^T1?WJ!$M%1?:(
MO[U'VB+^]0!+147VB+^]1]HB_O4 2T5%]HB_O4?:(O[U $M%1?:(O[U'VB+^
M]0!+147VB+^]1]HB_O4 2T5%]HB_O4?:(O[U $M%1?:(O[U'VB+^]0!+147V
MB+^]1]HB_O4 2UG:Y_R"+C_=JY]HB_O5GZW/&=(GPW\-5'XD*6QX??\ _'X]
M5JGOW7[8_-5MX]:]Q;'FO<=13=X]:-X]:8#J*;O'K1O'K0 ZBF[QZT;QZT .
MHIN\>M&\>M #J*;O'K1O'K0 ZBF[QZT;QZT .HIN\>M&\>M #J*;O'K1O'K0
M ZBF[QZT;QZT .HIN\>M&\>M #J*;O'K1O'K0 ZBF[QZT;QZT .HIN\>M&\>
MM #J*;O'K1O'K0 ZBF[QZT;QZT .HIN\>M&\>M #J*;O'K1O'K0 ZBF[QZT;
MQZT .JQ9?\?*?456WCUJ>S=?M*<]Q2>P+<][TG_D%V_^X*NUG:5/&-,M_F_@
M%7/M$7]ZO"ENSTEL2T5%]HB_O4?:(O[U(9+147VB+^]1]HB_O4 2T5%]HB_O
M4?:(O[U $M%1?:(O[U'VB+^]0!+147VB+^]1]HB_O4 2T5%]HB_O4?:(O[U
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M_P *XU[_ )ZK^7_UZ/\ A7&O?\]5_+_Z]?2?D1?\\T_*CR(O^>:?E0!\V?\
M"N->_P">J_E_]>C_ (5QKW_/5?R_^O7TGY$7_/-/RH\B+_GFGY4 ?-G_  KC
M7O\ GJOY?_7H_P"%<:]_SU7\O_KU])^1%_SS3\J/(B_YYI^5 'S9_P *XU[_
M )ZK^7_UZ/\ A7&O?\]5_+_Z]?2?D1?\\T_*CR(O^>:?E0!\V?\ "N->_P">
MJ_E_]>C_ (5QKW_/5?R_^O7TGY$7_/-/RH\B+_GFGY4 ?-G_  KC7O\ GJOY
M?_7H_P"%<:]_SU7\O_KU])^1%_SS3\J/(B_YYI^5 'S9_P *XU[_ )ZK^7_U
MZ/\ A7&O?\]5_+_Z]?2?D1?\\T_*CR(O^>:?E0!\V?\ "N->_P">J_E_]>C_
M (5QKW_/5?R_^O7TGY$7_/-/RH\B+_GFGY4 ?-G_  KC7O\ GJOY?_7H_P"%
M<:]_SU7\O_KU])^1%_SS3\J/(B_YYI^5 'S9_P *XU[_ )ZK^7_UZ/\ A7&O
M?\]5_+_Z]?2?D1?\\T_*CR(O^>:?E0!\V?\ "N->_P">J_E_]>C_ (5QKW_/
M5?R_^O7TGY$7_/-/RH\B+_GFGY4 ?-G_  KC7O\ GJOY?_7H_P"%<:]_SU7\
MO_KU])^1%_SS3\J/(B_YYI^5 'S9_P *XU[_ )ZK^7_UZ/\ A7&O?\]5_+_Z
M]?2?D1?\\T_*CR(O^>:?E0!\V?\ "N->_P">J_E_]>C_ (5QKW_/5?R_^O7T
MGY$7_/-/RH\B+_GFGY4 ?-G_  KC7O\ GJOY?_7H_P"%<:]_SU7\O_KU])^1
M%_SS3\J/(B_YYI^5 'S9_P *XU[_ )ZK^7_UZ/\ A7&O?\]5_+_Z]?2?D1?\
M\T_*CR(O^>:?E0!\V?\ "N->_P">J_E_]>C_ (5QKW_/5?R_^O7TGY$7_/-/
MRH\B+_GFGY4 ?-G_  KC7O\ GJOY?_7H_P"%<:]_SU7\O_KU])^1%_SS3\J/
M(B_YYI^5 'S9_P *XU[_ )ZC\JDA^'WB&"59(Y@&4Y!Q_P#7KZ/\B+_GFGY4
M>1%_SS7\J /#ET[QTBA1J P/;_Z]+]@\=_\ 00_3_P"O7N'D1?\ /-/RH\B+
M_GFGY4 >'_8/'?\ T$!^7_UZ/L'CO_H(#\O_ *]>X>1%_P \T_*CR(O^>:?E
M0!X?]@\=_P#00'Y?_7H^P>._^@@/R_\ KU[AY$7_ #S3\J/(B_YYI^5 'A_V
M#QW_ -! ?E_]>C[!X[_Z" _+_P"O7N'D1?\ /-/RH\B+_GFGY4 >'_8/'?\
MT$!^7_UZ/L'CO_H(#\O_ *]>X>1%_P \T_*CR(O^>:?E0!X?]@\=_P#00'Y?
M_7H^P>._^@@/R_\ KU[AY$7_ #S3\J/(B_YYI^5 'A_V#QW_ -! ?E_]>C[!
MX[_Z" _+_P"O7N'D1?\ /-/RH\B+_GFGY4 >'_8/'?\ T$!^7_UZ/L'CO_H(
M#\O_ *]>X>1%_P \T_*CR(O^>:?E0!X?]@\=_P#00'Y?_7H^P>._^@@/R_\
MKU[AY$7_ #S3\J/(B_YYI^5 'A_V#QW_ -! ?E_]>F2Z7XYFC,;Z@"IZC'_U
MZ]S\B+_GFGY4>1%_SS3\J /G5_ WB:1MS7 )/M_]>F_\('XD_P"?@?E_]>OH
MSR(O^>:?E1Y$7_/-/RJ_:3[D\L>Q\Y_\('XD_P"?@?E_]>C_ (0/Q)_S\#\O
M_KU]&>1%_P \T_*CR(O^>:?E1[2?<.6/8^<_^$#\2?\ /P/R_P#KT?\ "!^)
M/^?@?E_]>OHSR(O^>:?E1Y$7_/-/RH]I/N'+'L?.?_"!^)/^?@?E_P#7H_X0
M/Q)_S\#\O_KU]&>1%_SS3\J/(B_YYI^5'M)]PY8]CYS_ .$#\2?\_ _+_P"O
M1_P@?B3_ )^!^7_UZ^C/(B_YYI^5'D1?\\T_*CVD^X<L>Q\Y_P#"!^)/^?@?
ME_\ 7H_X0/Q)_P _ _+_ .O7T9Y$7_/-/RH\B+_GFGY4>TGW#ECV/G/_ (0/
MQ)_S\#\O_KT?\('XD_Y^!^7_ ->OHSR(O^>:?E1Y$7_/-/RH]I/N'+'L?.?_
M  @?B3_GX'Y?_7H_X0/Q)_S\#\O_ *]?1GD1?\\T_*CR(O\ GFGY4>TGW#EC
MV/G/_A _$G_/P/R_^O1_P@?B3_GX'Y?_ %Z^C/(B_P">:?E1Y$7_ #S3\J/:
M3[ARQ['SG_P@?B3_ )^!^7_UZ/\ A _$G_/P/R_^O7T9Y$7_ #S3\J/(B_YY
MI^5'M)]PY8]CYS_X0/Q)_P _ _+_ .O1_P ('XD_Y^!^7_UZ^C/(B_YYI^5'
MD1?\\T_*CVD^X<L>Q\Y_\('XD_Y^!^7_ ->C_A _$G_/P/R_^O7T9Y$7_/-/
MRH\B+_GFGY4>TGW#ECV/G/\ X0/Q)_S\#\O_ *]'_"!^)/\ GX'Y?_7KZ,\B
M+_GFGY4>1%_SS3\J/:3[ARQ['SG_ ,('XD_Y^!^7_P!>C_A _$G_ #\#\O\
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M*/#_ +!X[_Z" _+_ .O1]@\=_P#00'Y?_7KW#R(O^>:?E1Y$7_/-/RH \/\
ML'CO_H(#\O\ Z]'V#QW_ -! ?E_]>O</(B_YYI^5'D1?\\T_*@#P_P"P>._^
M@@/R_P#KT?8/'?\ T$!^7_UZ]P\B+_GFGY4>1%_SS3\J /#_ +!X[_Z" _+_
M .O1]@\=_P#00'Y?_7KW#R(O^>:?E1Y$7_/-/RH \/\ L'CO_H(#\O\ Z]'V
M#QW_ -! ?E_]>O</(B_YYI^5'D1?\\T_*@#P_P"P>._^@@/R_P#KT?8/'?\
MT$!^7_UZ]P\B+_GFGY4>1%_SS3\J /#_ +!X[_Z" _+_ .O1]@\=_P#00'Y?
M_7KW#R(O^>:?E1Y$7_/-/RH \/\ L'CO_H(#\O\ Z]'V#QW_ -! ?E_]>O</
M(B_YYI^5'D1?\\T_*@#P_P"P>._^@@/R_P#KTY+#QUO7.H#&>>/_ *]>W>1%
M_P \T_*CR(O^>:_E0!@^$8]1BTYAJ4OF2YX-%="JJHPH ^E% "T444 %%%%
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M^@O85DB=6!]#FO+?$'PLMK73I;BUN9O,4< $UG_#/6KJWUN;3+AF(B7 W'-
MCVSI6!K7BNQT5,RNK'T#<U9U^_;3]#ENEZJ,UXEH^E3>-_$US]IFE6,'< K'
M% '<R?%[35DVBUF/X'_"M?2OB)INIR!%4QD_WSBJD?PNTU8P#*Q..]<CXO\
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MD< &FP:C;7)Q%(&H MT44A( R: %HJC)JUG$^UY0#5B"YBN%W1MD4 34444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME1?F)KJ=:U!=-TR2Y8X"UX[X&U$:%XKO+*5MJ@[5!KJ_B?K2PZ!+:H_[QU#
M?A0!B>%=3U;6_$]X?//V=6RH/I5+X@>*=0T7Q="D<S"(1\J/PKK?AMI'V;2U
MO&7YI4R:X#XG1B7QW"A[I_A0,T[+3?%?B6(3Q7VR)AE0PK(U9_$W@Z[WSWI:
M-1D[17MGA:%(_#MF H'R>E<9\6X$/A^XDVC<!UQ[4".L\*ZVNJ:)!,[9?9EB
M:XOQYXVGMKQM,T]V$[#(*\TWX>3LOA^Y.X_+"<<UP!U58_&RW4V&"DCYN1UH
M ZNR\(^+=5MUNCJ(&\;@&Z_SJH=5U_P9JJQZC<O+;KR=HXKHX?B4D,2QJ(P
M,< 5S/C7Q5'KND21*D?F-T( S0![-H>JQZKIT,Z'[ZYZUIUYM\*II7LF20G"
MKQDUZ30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP,;%Q7B?Q(_Y*!!_N?X5[Z1\N!7C_C?PIJ>I>,8KRWMR\03!;\J /3/#?_(
MM/\ <KC?BU_R+-S]/Z5VVAP/;:/;PR##JN"*YGXBZ/=ZOH4\%K'O=AP/PH Y
MSX<1F30KI!U,)%<;!:6EIX]CBU&+,)R2&X[UZ?\ #S0[O2K5DNXMF5Q@U2\=
M^ O[6E:_M WVD# "<4 ;UKX4\-7-NDJ6L1##/45B>);?PGX=M6EELDD*_P *
MGFN1MI/&VDQ_9H;#>BC +$_X4R#PGX@\4:HLNKP211'KM8XH ]/\'7>G7=MY
MEA:- K+GD5U-9FB:3%I-A%;QC[JXK3H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *0J#U%+10 @&.E+110 4444 -**>
MU'EKZ4ZB@! H'04M%% !1C-%% $1@C8\K3UC5/NC%.HH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!" >M)Y:^E.HH
M ;L7TIU%% !63K^L+HNG27;HSJG85K52U338M5L7M9ON/UH \3\2^-9_$\D%
MI:03("X#?*>E>G>!="&BZ/Y;* SD-3M,\#:;I=P9HQN8_P!Y:ZA5"*% P!0
MM(5!.2*6B@ I" >M+10 @ '2EHHH C:&-CDK3E14&%%.HH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gtinntqqusay000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .D!V8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBDS0 M%1&XC#;2PS4@- "T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'PUX9.D75S*0W[R0MS774F 4444@"BBB@ HHHH **** "BBB@ HHHH ****
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M&?"CFH?$S<HHHKSSJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $9@HR3@
M55;4[)&VM<Q@CJ"U,U=RFG2,.M>*6]W#=Z[>QWLTBJK?+AJ:0'M%S'IVK0&*
M1HYD/;-5[4:/I!*0/#$3U&:XG[5%HOAUM0LY&;:<98UGZ/HMYXD6XNKDN#]Y
M-K&BP'K,5U!.N8I%8>QJ-M2LT;#7,8(]6KR[1=2OM'\1RZ3,?W21DC)Y[UB?
M;$O-5G%U,ZJ)#C#46 ]NBOK:=ML4R.?0&G374-NN9953ZFO&M%U26U\03163
ML\:K_$>W-7]7U:]US7K;3T/[J1</@T6 ]1BU.SF;;'<1L?9JDEO;: XEF1#[
MFO-&\*ZOI5U#)IX9@7&_<QZ51\:WDL>OV\%P[(AB&[![X%%@/55U.R9@JW,1
M)Z#=5H$$9'->/Z4-*:[MR+B4ON'&[_Z]>N6P A7'3%# EHHHI %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 -?[M>17_\ R.4O_70?SKUYAD5X[K+_ &;Q=([< R#^==6%W9A6V1ZQ+_R#
MD_W!_*O+-,./%-T?^FE>BR:K;?V4K[Q@*._M7G6B_P"D>([J1.5+YIT%[L@J
M/5&SKOBN?3=6$*1LXV]!69<:]J\;)=&&81?>([8J'Q$47Q4AD^[M%=EJDUK_
M ,(O@E<F'CI5M1BHZ;DZMO4R;GQ))J7AP211GS#U4=:Y?PU<W2:FWEQNV7^;
M':KOA=9/LS-C]WM./RJ[X)=5U"ZW8_UIZU5E",DD3=R:;-+6_$.H0QB"*UDW
M9QN%83>(=1TV97F,C*><&M'Q-KLW]IM:V; 2!AU^M86O0ZF+</>LARN1CTI4
MX*R36XYR=W9G0>)=1_M+P]:S8P6YJCH?B*/2/#4P&&E#Y"]^]0WW_(K6GTKF
M5TRZ?3Y+U!^Z4X-7"G%QY7M<F4FG='IWA[4;N_22YF#QQJ-PSWK+UOQ7<3WI
ML[-&S_>6M#P_J4=WX=E@0_/'%@UP]FE[_;I%J0)?]JLX4TY2;6Q;DTDEU.@T
M_P 4WMC>Q0W<;D2'&6[5K>(_%IMH]D*\DXR*YJ_T_5;B\MS=M&6!^7!JYJVE
MHVGHC?\ 'R&Y-')3YDV'-*S1%_;6I0E9T>64'G:*[WP_J4VH62/-"T;$<YKS
M*:+6M+M_,#Q^6!FNZ\&ZM)J%HBRGY@,FIKP7+=#IR]ZS.IE_U9KQJ^NI+;Q-
M<^5&79G[5[)+GRS7E$2!_%\^X=)!4X:R4KCK=!\_B+4]-N%DF27RP.AKKKO7
M6_L..Z4$$Q[JQ?'R@6.0!]T?RILV3X5C_P"N-6XQE&,K$W:;1N^%-8DU/3_-
M?.>>M9)\2S#Q!':X;:9,4WP%,B:3M+ '!ZFL!)5D\81X/26A4USR0^9\J.A\
M1^*)M-U)X45FP<#%9%WXBU1"MRT<J1@9P>AIGBT ^(CG_GHO\ZWO%*A?#:X
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M>3O&,U3TCPF-/U&:Y\PGS$*X_.NNHH]I+7S#D1P6H>!3)>>?#<,ASGY:AD\
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MDWC2QAF:-IE!4X-1_P#"<V&?]<M<#96MK<Z_<K<[=N_^(UVL?AW06VX$)/\
MO"NR5.G#1W,(SG+8ZRSO$NX%D0Y##-6:P[N_MM!L5VIE=O 6N7;X@X??]FFV
M>NTUSJE*6L4:N:CN=_<SK;6[2L<!1S67IOB"WU&[:")PS*,X%9BZ_#KF@73Q
MJ5VKSFN$T+6%T?6)IC&SY7&%'UJX4>:+ONB95+-6V/9\T5PFG^/8I;M8)89$
M+'@L,5N:MXFM],LTG8;@_0 UFZ4T[6*4XM7-_-+7G2_$'Y]_V6;8.^TUV.CZ
MQ'JL =$*\9YHE2E!7:",XRV-2BBBLRPHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "DI:* $I:** "BBB@ HHHH **** "BBB@ HHHH 0G'-<=?^
M-DM+IX1M)4XKJ;V40VS.>U>16-HNJ>);C>NY1+S6]&FI)N70RJ2:LD=A#X\A
M+@2LJBNHL-3M]0A\R"0, .<5RWB#PI8+II:"%4<<YK%\'7SVJ7D3-PK8JG3A
M.'- 2G*,K2.DU7QC'IU^UME<J>];.D:JNI6QE&./2O']>W7OB"9Q]:ZWP]J(
ML?#5U(6PR'BJJ4(J"MN3&HW+4VM4\916%VT 92RG!%7K3Q +C29+UL *<5Y#
M?;[N^6[;)$K#%=M<?Z!X+GCZ%L']#53H1226[%&JVV7G\>*LC*NTXJ>T\<V\
MLH29U7-<YX/TW3[LRR7IC.1D;C6?XK@L8+_R[%%SVVG-"I4W+D#GFH\QZ7J.
MOPV5HLX<$,N12:-K8U*T%P<!3W%><>(+B5-+L(W8X9,?SJ&W\1?8=#2RMR5E
MSC<*2P]XZ;C]K:6IWVI>,(+:Y$$#J[$X(K9TN^FO85DD0*"*X?PSX8-VXO+I
MED).ZO0X(4@0(@PHZ"L:JA'W8FD')ZLFHHHK$T"BBB@ HHHH **** "BBB@
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M%% !1110 4444 %-*Y&#3J* /*/&MNBZHK #)E4'CWKK)H;*U\.?OFV(4!)
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M9R7B0V-K8V\5W*5<+A1ZUR%Y/=2:7LMK>-H<\/CG^5=+X\TF>^\B2(%O+Y(
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M%9@03ZUA72YN:/4TI-VLR>BBBL#4**** "BBB@ HHHH **** "BBB@ HHHH
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M?E1L7J5'Y4ZB@!,48I:* &[%SG:/RI:6B@!NQ3U4?E2@8I:* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M-US_ )!DE:59NN?\@R2JA\2$]CPZX_Y#C?\ 72O:/"O_ "!TKQ>X_P"0XW^_
M7M'A7_D#I7=C/A1S4/B9MT445YYU!1110 4444 %%%% !1110 4444 %%%%
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MB^C_ +PJ1;I&[B@"Q13%D5N].S0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MFZY_R#)*TJS=<_Y!DE5'XD)['AUQ_P AMO\ KI7L_A7_ ) Z5XQ<?\AMO^NE
M>S^%?^0.E=V,^%'-0^)FY1117GG4%%%% !1110 4444 %%%% !1110 4444
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M !@8%%%%:D!2TE+2 2BBBF 4M)12 6BDI:8!2444 %%%% !1VI:2D 4M)13
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MG"[7N:/;0#D99HJ%;F,]ZE#!NE6I)[,EIK<=24M%,0E%+24P"EI**0!112T
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M@54M--AM+J2=% =^I%3'S^V*B,LZ<MTK$Z".\TF"[N1.Z R 8R:HR>&X0VZ
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M_P!6* +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5=CK:(W%P2>@Y%;:C"@55LH/*B!QS5NII1LKO=CF[NP4445J0%%%% !1110
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MO^0.E>+W'_(<;_KI7L_A7_D#I7=B_A1S4/B9N4445YYU!1110 4444 %%%%
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M.=HJ4*%Z"@8R*%8Q@"I!12T""HY!E>*DI#2 YV[T5;NX5WSP<ULVT*6L(4<
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M&FK11T2=V%!.!DTM5YY?X%Y)JI245=BBKNPQBT\OEK6O;0B&,8')ZU6L+78
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M+?\ ('2O%[C_ )#C?]=*]G\*_P#('2N[&?"CFH?$S<HHHKSSJ"BBB@ HHHH
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M"CM6"_>2N]C1^XK=1P&!@4M%%=!D%%%% !1110 4444 %%%% !1110 4444
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M4SJNE071!'F+G!K8KE_ HQX<M!_TSKJ* "BBB@ HHHH **** "BBB@ HHHH
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M_NUTNJZ=)>Z!]B3[^P+^0JEX9T.;2-WF@<C'% &/\5?^12G^M:/@/_D V_\
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M!Y-<IX?LY(_"4=RZE=Z'@_2KUG\/;Z\O(YM6 <*><5VUWH*+HZV-JH"*" *
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MH ]3^VVQ/^N6IE=7&5.17EL/AWQBLR%Y$V@\UZ%HT%S;V02[(,GM0!HT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5FZY_R#)*TJS=<_Y!DE5'XD)['AUQ_P AQO\ KI7M'A;_
M ) Z5XO<?\AMO^NE>T>%O^0.E=V,^%'-0^)FW1117GG4%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "DR*20X6J]L[.7R>AH%?6Q:HHHH&%%%% !1110 4444 %%%% !1110
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M+6L(J*LB&VV%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG-:MNJ6=LD*X.T8XJ7)1U8]7HCE+C18])A:_=F\YQM.:Y.+09K=YM4(;Y6W
M9X->F:C:MJ<(BZ '-3Q:5$+3R7 8$8(K%U7+X#50Y?B,SP[<'4=.B=@%8CD+
M70QQ*@XJA8:8-/F9D8"/'"^E6I)BQVH,_2I:A!W>Y>LM$223*@QGFHXK>2Z;
M+#Y?:I[:Q9SOD.?8UJ)&J#"C%1RRJ:RV'=1T1'# L2@ 5-116Z22LC)NX444
M4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME9$-M[A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;2S:G!"(]S@;^E %VBL[^UH VTN,U+;ZA%,V W/:@"Y112T )1110 M)110
M4444@%I***8!1CUHI: &&-3VIODQ^E245/*GT'=D7V>/^[1]GC_NU+VHI>SC
MV'S,B^SQ_P!VC[/'_=J6BCV<>P<S(_(C':G"-!T%.HI\B705V)M Z4M%&:8@
MI:8TJ+U-0M<@_<YJ7.*W92BV6"13&D5>]1!;B4\+Q5B/3=_+DBH]HY?"BN1+
M=E9IRQP@/Y4^.UGF.2>*TXK1(ATS]:G"@=!2]G*7Q,.=+X2G#I\:<LHS5M5"
MC IU%:QBH[$-M[A1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-6X[*).JC-6Z*M4HHES;&K&J]!BG445H2%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %1S-M0U)5:[.(C]* *EL-]WN[5J
M5GZ>N5W5H4 %5KRZCM+=I)" %'>K#' )]*\W\=Z^0?LL3?*PP:TI4W.5D1.7
M*KG'^)KN.\UJ>6,#:QZBL?.***]J*LK'GMW=PS1115 %%%% !1110 Y':-MR
M'!'>NS\)^*Y;2X6&X<NAX&3TKBJ5'*.&'4'(K.I34U9CC)Q=T?1=O.EQ$KHP
M((!XJ6N&\":U]HL_(E;,A; KN:\:I!PE9GH0ES*X5'.NZ%A[5)2,,J14%&99
MML?8:TQTK)^YJ!%:J?=% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-US_D&25I5FZY_R#)*
MJ'Q(3V/#KC_D-M_UTKV?PK_R!TKQBX_Y#;?]=*]G\*_\@=*[L9\*.:A\3-RB
MBBO/.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *8\:L,,,T^B@#,GT[<2R-M^E52DT)Y#-6[32H8<BL725[QT+4^
MYB"X(^\A%2"93W K0>RB?J*KOID?\(-+]Y'S'[K(1LSD$<T[(IIL)5^[49@N
M4I^U:W0<BZ,FS2U6_?KUI/-<=:/;1%R,LT57^T8'.:472>]5[6'<.21/14/V
MI/>C[2E/VD.XN678GI*B^T)[TGVA*/:0[ARLGHJ'[0E'VE*/:0[AR,EHJ'[2
MGO2?:4]Z/:0[AR2)Z*K_ &E>V:/M'IFI]K#N/DD6:2J_FN>E&9STI>VB'(RP
M:3</6H1%=-TIPL[ENM'M>R'R>9)O7^\*:94'\0I1I\A^]4B:8G\0HYYO9!RQ
M[E<W 'O33<MVC)K0&FPCL:E6TB7H*+56%X&3OE?I&PI1;3R=R*V@BCM3L"CV
M3?Q,.==$9*Z9(W)D-6$TU1]X@U?HIJC%"<Y$"VL2C[@J18T'10*?16BBEL3=
MA1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %4[W[E7*IWOW* #3Q_H_XU<JII_P#Q[_C5N@"O
M>RB&UD8G^$_RKP;6;IKK49BQ)PYQ7L/BV\^QZ27SC.17B4YW7$C_ -YB:]#!
M1WD<N(>J1'1117H',%%%% !1110 4444 %%%% '1>#;MH->@7)V^E>UQ/OC#
M>M?/-I//9W*S0JP9>AQ7K'A3Q1'J$0@E8^8@P<UY^,IMOF1TT)I:,[*BD!S2
MUYYU&5/Q?DUI1?<%9MQ_Q_FM*(?(* 'T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;KG_(,DK2
MK-US_D&254?B0GL>'7'_ "&V_P"NE>S^%?\ D#I7C%Q_R&V_ZZ5[/X5_Y Z5
MWXSX4<U#XF;E%%%><=04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4FT'J*6B@!OEH?X133!&?
MX!4E%*R"Y";:,_PBF&SC/\(JS12Y(]A\S*9L4]!2?8$]JNT4O9Q[#YF43IZ>
MM']GKZU>HH]G'L'.RC_9Z^M*+!/:KM%'LX]@YV4_L*>U.^Q1CL*M44<D>PN9
ME<6D8_A%.%O&/X!4U%/ECV"[(Q#&/X!2^6G]T4^BG9"N)M4=J7%%%, HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK=C,9^E6JBG7=&?I
M0!5TYOW6WWJ_67:'9<[*U* .5\<6%S?:2([9"[!LX%>5G0-2\S;]G;=FO?2
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MS?0=>C,3$*\@%>P<"O,O%^)]6M43DB49Q2H5).33'5BDM#T.PG\^U1_85:/
MJCI41ALD4^@JY,VV)C[5RO<V6QF-\VHFM1/NBLRU'F3;ZU!TI#%HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "LW7/\ D&25I5FZY_R#)*J'Q(3V/#KC_D-M_P!=*]G\*_\ ('2O
M&+C_ )#;?]=*]G\*_P#('2N[&?"CFH?$S<HHHKSSJ"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7\*.:A\3-NBBBO/.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!&7<,5ESQF*4..@.:U:BEC#H0: &V\XF0'/-3
MUD?/:2[ADKZ5I0SK*H((S0!+1110 4444 %%%% !1110 4444 %':@U1NKO:
M-B<D\<4 ,O+C<?*4\U+:0;5R1R:AM;<L=[\GWK1 P,4 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6;KG_(,DK2K-US_ )!DE5'XD)['AUQ_R'&_ZZ5[/X6_Y Z5XQ<?
M\AQO^NE>S^%?^0.E=V+^%'-0^)FY1117GG4%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 12PK(O(K.:.2V
M?*=.]:U,>,,,$4 5[>\63Y3]ZK0.:H36A'*''TJ))IH#@@GZT :M%4X[U3]_
M J<7$1Z.* ):*:'4]#2[AZT +13#*@ZL*C:ZB'\8H GIK.J#)-4I+X]$7-0!
M)9VR210!)/>%SMBI;>U).]QR:F@M0G)%6@ .E "*H48IU%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6;KG_(,DK2K-US_ )!DE5'XD)['AUQ_R'&_ZZ5[/X5_Y Z5
MXQ<?\AMO^NE>S^%?^0.E=V,^%'-0^)FY1117GG4%%%% !1110 4444 %%%%
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MZBFP:I9W+[(9U9O04 7**IW&J6=J<33JGUIUOJ-K=_ZB97^E %JBD9@BEB<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M";?S#J5SLQ_?-'@[1-,M-2F^S7KRR*_S GO0!ZK1114@%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO9_"O_('2N[&?"CFH?$S<HHHKSSJ"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ]1M/%>FWDXBC<[CZUM&5!%YF?EQFO'?&&@S>'Q]M@N6^0=!70:MKDMOX3L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXW_72O9_"O\ R!TKQBX_Y#C?]=*]G\*_\@=*[L7\*.:A\3-RBBBO/.H****
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M\)ZI;/X9@;S%&U,D%A7%7DXU;XD6I@R5"D9[=12:-X(N)])AFBO9U60?=#'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3%1S0).A20;@14M%
M'G_B;P2DZ-/:@)CL.]>8WMC<6,S1R1L,'J17T:5!ZC-<_KOABUU:!LKA\9&!
MWKGJ4%+5'HX;'2A[L]CP;=2[JV]>\+WFD2,[1XB'>N>+'/-<CBT[,]B%6,U>
M+)MU*NYSA023V%):V\UW,(XERQKTCPQX%.5N+Q".ZTX4W)Z&=7$1I*[.?\/>
M$[G5)E+ HO7YA7K&D>'[73(5"1J' Y(K0M;2*UC"1J ![59KMITE$\3$8J=5
M^0F*6BBM3E"BF/(%'-57O%!P#S0!<R*,CUJAYLS_ '129N<]* -&BL_[1)']
M^IHKM7[T 6J*0,#TI: "BBB@ HHHH **** "BBB@ K-US_D&25I5FZY_R#)*
MJ/Q(3V/#KC_D-M_UTKV?PK_R!TKQBX_Y#C?]=*]G\*_\@=*[L7\*.:A\3-RB
MBBO/.H**** "BBB@ HHHH **** /(?$?_([R_P"\/YUZ)<:U;:5I<3RNNX1@
MA2>3Q7G7B8[?&<Y]"#^IK)\6:O'+K>GI<R,MN$ ;!]JJUP.Y7XCQ-/L-E($)
MQOQQ76Z?JUMJ%MYT;KCOS7ETFN^%#I9MQ.VY5.#@9S57P9J3N7LK1V99)"1D
M^]%@.[U?QS;Z=,8HX3.P."$YQ2Z-XXM]3N%ADB,#'L_%>;P7<6B^(KQ]48A'
M;C/-;MH?#^LZLDUI._FXX X%%@/1-5UVVTRW$KLIW#*C/6N63XDQF4*UC(J$
M_>(XK$^(-C=#^S)8]WD0\N<]N:IVVN^'+RQ6TN)2K^P%%@/5]-U.'4H!)$P/
M'(!Z5;E_U3_[IKEO!=E:VMO*UH[,CG/S&NIE_P!4_P#NFI \<U6\2P\=VL[]
M%)X_*NJ;XD0K=>4UFX4G <]*Y#6=.74?'MI ^=C$YQ^%=GKWA.RCT8A <QJ2
M#5.PCI8]:MY=/-VA#*.N#3-)UV'59I8XQ@Q]:\\\+2N?"%VC,3B4@9/UK0^'
M)/\ :FH9)//^%*PSLM8UZ'2$W2C/.*+C7H+>QCNF VNN[K7%_$PG[,<$CYA2
M:^"W@^U )R8/6BP&K<_$2WB3=%;-*,_P\U8L_'EE=6DDVT*Z?P$\FL+P+X:M
MIO"Z7,VXR%3UY[5RNGZ'%+XJ$6Y_+,I!&:>@'>P?$6WDNQ#);-&"0 S=*ZY]
M0@CM/M+.H3 .2:\[\=^'[2PT^VDAR&$HY_$5<B1M4\(S1R,0H &0?:E8"W??
M$.&VF9(K1Y@#]Y.:OZ'XTMM7E6(IY,A_A8\UQ]EJ'AC1[?R9YF,N,-N -<]#
MJ%E/XXAETZ1C%CZ>E.P'KFK>*+;2G19<'>>.:PKGXC007&P6CLG]\=*Y?QE
M;V_TB,LP5WP<'ZUUUUX0LH]#\L D@9R>O2BR Z/2=8@U:#S(B.F2 >E:).%)
M]!7F'PQ+1W>I0[B523 R?I7J!Y&*3 \G\?:[)%K$*(K!0.1ZUUOA378[C245
MT,>Q<Y:N5^(-I'_;ML,=14VL-_9?A6T:#AI?E-/H!MZGX_@LI_+AMVGQW3FK
MNC>,K75"591"P_A8\U@^!_#5M+ISSSY9R^>>>N:P_&>D+H&J65S:EAYLHW#/
M%+0#O[OQ7;V>H"UE3:",[STK1N=8MK:Q^TM(N"NX#/6N&\1:2VL^'OML.?M
M  Q]*XB/4]3UF]M=*)^2%O+?!IV ]7_X2"WU>PW&$^6>YZ4_PO)9*ETUNJH
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MM])A$DJ*\S?-N]ZX_P"'5U'8:F=,N0!-&O.1S7KBD%01T-2QE6^O!8P&0J2
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M9&R^X=.M=4C>%3IWGF*U#X^YS78ZGHEIJL'E7"94# KEC\,-&\S[C[<YZT7
MS_!]W;7NHS"WTM841\!P.OZUZ969I&B6FCP^7;)@$<UIU+ \P^)EZL=U%;LP
M"NO-:7ACQ-I>GZ#;P-<Q!E'3-;.O^#M.\03+)=H691@8K&'PKT('_5O^=5I8
M#.\5>,WOK9[#3X3(T@X=*=X<T%M*T6\O[C_6S1$D-U%=1I?@G2M*D62",[AT
MS6S=V$5W:M;N/D88(%*X'E_@"V^V:B;UAD!B,_C6)<7KZ7K6IVR*0UV^U2/P
M_P *]>T3P[9Z' 8K5,*3GFJ%WX)TR[U%+V2,F1&W ^].X'&1:>VC^%%O9_\
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M*** "BBB@ HHI&Z4 4;IRTBJ.YJU!&(XP*I@>9<?0UH]J "BBF3';"[>BDT
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M_O"@#4JC>)M(9>N:O5%<+NC/M0 EN^Y*FJE9-P1[U=H **** "BBB@ HHHH
M*S=<_P"09)6E6;KG_(,DJH_$A/8\.N/^0VW_ %TKV?PK_P @=*\8N/\ D.-_
MUTKV?PM_R!TKNQ?PHYJ'Q,W****\\Z@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIYJ6I/H6G&-W<L7\LG]LP#>W3UHUB:3$ WM][UK*GU)9KV.?!PHHO=26Z\O
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M-?HH%344 %%%!.!S0 5G3/Y\R@?PFI;FXXV)U]11;08^8]30!9C7:N*?110
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M_(,DK2K-US_D&254?B0GL>'3_P#(;;_KI7L_A7_D#I7C%Q_R&V_WZ]G\*_\
M('2N_&?"CFH?$S<HHHKSCJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *BEB#BI:* ,W;);ME.E3QWJ
M]'/-62@8<BH'M5)X&* )1,C=#3MZ^M4C:/V<BD^RR?\ /0T 66NHTZFJSW+R
MG$?2I%M?[QS4Z0JO84 006W.YNM6P,# I:* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J.2,.O-244 9S1O VY*ECO0.'/-6RH(Z5
M]LIZ 4 2+.C=#3MXJD;5NS$4GV63_GH: +37,:]35:2Z9SB.G+:'^)LU.D"K
MV% %>&V+'<_6KH4*,"@#%+0 4444 %%%% !1110 4444 %9NN?\ (,DK2JAK
M$;2Z>ZJ,DU4=T)['A=Q_R&V_WZ]G\*_\@=*\>N;:4:ZR[#_K*]C\,QO%I2*Z
MD'T-=V+?NHYJ'Q,VJ***\\Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D(!&#2T4 8LGAC3I+
MK[2T?[S.<UKQQK&@51@"GT4W)O<226P4444AA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO?4IJV@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gtinntqqusay000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" - !5D# 2(  A$! Q$!_\0
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M]G@_YY+^5 $'_"5?[_Y4?\)5_O\ Y5/]G@_YY+^5'V>#_GDOY4 0?\)5_O\
MY4?\)5_O_E4_V>#_ )Y+^5'V>#_GDOY4 0?\)5_O_E1_PE7^_P#E4_V>#_GD
MOY4?9X/^>2_E0!!_PE7^_P#E1_PE7^_^53_9X/\ GDOY4?9X/^>2_E0!!_PE
M7^_^5!\5X&?G_*I_L\'_ #R7\J9+;P^4W[I>GI0!<TC7TU"<1<[CZUOUP^A
M+KP"C Q7<4 %%%% !45Q*(;=Y#T49J6JFI?\@V?_ ': .<D\6)YI5=U)_P )
M5_O_ )5F:5'&\GS(#]16U]G@_P">2_E0!!_PE7^_^5'_  E7^_\ E4_V>#_G
MDOY4?9X?^>2_E0!!_P )5_O_ )4?\)5_O_E4_P!GA_YY+^5'V>#_ )Y+^5 $
M'_"5?[_Y4?\ "5?[_P"53_9X/^>2_E2&" =8E_*@"'_A*O\ ?_*C_A*O]_\
M*I?)M_\ GFOY4ODVY_Y9+^5 $/\ PE7^_P#E1_PE7^_^53>1!C_5+^5'D0'I
M$OY4 0_\)5_O_E1_PE7^_P#E4_V>#_GDOY4GD0'_ )9+^5 $/_"5?[_Y4?\
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M1110 4444 %%%% !1110 4444 %%%% &3KO_ !YGZ5SNA_\ 'K)_OUT6N_\
M'F?I7.Z'_P >LG^_0!J4444 %%%% !1110 4444 %%%(V=O% 'GOBWQC<0W"
M66F.5G+;2?>L29?'EG;_ &R2\4Q]< '/\ZKZ:%D\:WGVG'$WR[J]5N;FQ6(6
M\S("5^Z: .>\'>+!K"2P3L?/@&)"?6NKBNXIFVHX)]C7BVCNR:QKIMB0N3]W
MMP*W? 5U/+J:B25V&3P30!Z7]LA\S9O7=G'6DN;Z"U7,CK],UY9+>3CQ6Z><
M^WSNF:U?$%E:W>L!CJK1OL_U8- '>6VHV]UGRY%X_P!H4ZZOH+1<R.H]MU>(
M6EW=:5K>U;F22,R<9-;%Q]H\2>-DLS<R11LG\)H WO&/B>[LM2TM+&<".9\.
M <\<UV5MJ$8MU,TBAL<Y.*\>\4Z"^C:]I2M<O,#+QN/3K5[QE-<^8(X9G3('
MW30!Z9>ZFLUA<BTE43*ORG/0UF^$Y]4DM0=1N$D;/4'_ .O6#;>&9-/\(W%Z
M;V1WEAW8)Z5@Z!JUQ8^$OM)D9VWD<F@#U>;5;6&0(TBY)Q]X5:CFCE3>KJ1Z
M@UY-H/AJ?74N[J34)D)^91N/'2MF9+CPSX:/[]Y6!QEC0!VTNJVL4HC:1<DX
M^\*L_:8O+\P.I7U!KQ+3X&U&*^N)-0D63[R+N^E:5CJ-]%X?^RR,YP?]83S0
M!ZF^J6J#)D3C_:%36]U#<Q[XW4CV->0>&-#N=>34'DOYD\OH-Q]JL>&KNZTS
MQ7)I'G/*JH2"Q^M 'J-QJ=M;,%=UR?1JGM[J*Y0-&ZG/8&O#[AM2_M:[%V\L
M432':2>@KM?!2VB7:^7J3328_P!630!Z#1110 4444 %%%% !1110 4444 9
M6L?<_"NC\.?\@6&N<U?[OX5T?AS_ ) T- &M1110 4R;_42?[I_E3Z9-_J)/
M]T_RH \_L_\ C_D_WS6_6!9_\?\ )_OFM^@ HHHH **** "BBD;[C8]* ./\
M8>*_[(;[';L1=2#*$5R:)X\NK?[='>H(B-V"#G^=,\4Y?X@V F^YCH?PKMM<
MU*YTG18I-/M!< \%0.U &9X+\3WMX6M=2+M.'VAL''%=G=:A;V@_>2+GTW5Y
MOX>\:/<ZY%93:9';M(WW@!FI=?L+6XU6X/\ :SK)_P \PQXH ]#M;^WNUS'(
MOTW4ESJ-O:_?=<^FZO&-%NKNQ\66UJL\DB,>A/6EU1M3'B:[-PTL=N3\I)XH
M ]GCU""6$R+(N!_M5R4'C-)]?FL1)C8<<FL7P[:V<_[H:NS2,?N;C7.V&@_:
M?'%W']I=?+8'(/6@#VAM0MXRBO(H9AGEA2P7\$\C(C@E>O->/^,H;EO&=C81
M74J*T0^ZWL*Z&2QE\+:7]H%R\SSJ5^8]* .[FU:U@DV-(F?]X5;BFCF0.CJ0
M?0UY-H7A2XU[39[N34)D;><#<?4U+X8UBXL+_4]/DD:06\9PS'VH ],N=2MK
M4XDD7/\ O"I(;N&>/>CJ1C/6O(-"L[CQ??O/)>2Q!9"N WO74Z?H<VC+J!^V
M22CRSC)Z<4 =B=2MA&7\Q.#C[PIUM?P71(C=21_M5XYX7TZYUO4'22]E53(1
M][WJ72Y+G1/$MY#]IDE16P,F@#V"YO8;52TCJ,=LTEO?07*YCD4_\"KR#5K^
M75_%,$3W3PQ%>0#QVI;-KO1]2807$EPCMCD]* /7GO[='V-(H;W85'#J=K*[
MJ)4RO7YA7DMS'=:GX[M;+[5)&DB9.#]*J:II=UIFM)!'?3$22!2=U 'LL>J6
MTDXA61=Q_P!H5SGB6?5TO;06-RB1F0;P3U'YUPVL:?<:!K<,B7LL@V!L%OI5
MCQ/>3L=#<2L-\@S@]>: /5DNTC1$E==Y49YJ62YCB569@ W3)KS#Q+=3QZ_;
MJLSJIB' /L*T?&-Q-%HFF,DK*6')!Z]: .^%S$8O,WJ%]<U575[5I?+#KG./
MO5YM>2ZE-X%F^S&1I,\,#ST-8NF@N8!?7[P.IYRW6@#W(,&&001[4M9>@F$Z
M<ODW'GK_ 'LUJ4 %%%% !1110 4R7_5-]*?3)?\ 5-]* ,_0_P#D/#Z5V]<1
MH?\ R'A]*[>@ HHHH *J:E_R#9_]VK=5-2_Y!L_^[0!Q6D?ZRMRL/2/]96Y0
M 4444 %%%% !7'^+K?Q+*\;:+<+&H^]G_P#7784R4 QMD=J /#!KGC4ZX^D_
M;E\]!D\''\Z[C3(O%4&C73ZA=HTQ7,;>GZUSD8'_  M6YX_A_J:] \3L8_"M
MRR':1'U% '.RZKK-EX8BN)[E6G)P64_3WK0\*>)'N;>4WTRLPZ<UQ5K-+-X#
MMS([,2>I/L*7PSX8?4=-O9OMDD97H : /7OM*W%HTD#J25.,&N:\.SZO)>7(
MO;E'C$AV 'H/SKDO".H7-MKMSI#RO(L<)(9C['_"I/!MQ))>:F)9F"B8\D].
M: /2KG5+:U;:\BY]-U17FH(VF336\B[E'&#FO.M3TVWGU2XDCU9V;:3Y>X\=
M:R_#-[<QV]]!),\B[R 6/O0!U/ACQ!J.H:_<VL\VZ-8B5'H<&M'09]7>^G%Y
M<H\8D.T ]!^=<QX.X\3WW_7 _P C5/1;B[D_M01R.T@E;:,^] 'JT^JVL$FQ
MG4GV:K4,\<Z;D=2/8YKPQ#??VE(+^:2%<=2:]"\$BUCAD$>HFX)/0GI0!VM<
M3X\\23Z- 8K63;.ZY7%=G*VR)V_NJ37B^N:S;:IXRM3<2A88F*MGI0!T_P /
MO%=WJ\OV6^D+3*N6SQ7?RW$<(R[ #W->(C5+/2?&4MQ93*T4C!1MZ=:['QS>
M2'1%EAE92T0.5/M0!VDFK6L:JQD7!.!\PIFI:I#9Z;)=;P549X->6VOAVXNO
M",&HMJ$V\@MC<>U+H)GU/P=J@FG<F-BH)/N: .T\-^*1J]^Z&3,8&0":Z.YU
M&VM3AY%R?]H5Y+X'T<PRW,PN&^6)FQGT!JA9W$GB"_E,][)"(I"@ ;K@T >W
M0W44\6]'4C&< U"^IVR(S&5/E_VA7EWARYO;'6;^'S))8%B.UB>.AK*TJPO-
M=U=XFO9D1I"#ANG- 'H/B>^U-X;:32[E(PT@W9/49^M=+;3&.RC>XD7=L&3G
MOBO+_'=I+HNG:;;QW+MMG4%L]>12^)=5N9;VPTF.1D$\*DL#["@#TV+5K664
MQK(N1_M"K,MQ'#'O9AM]<UY)K'ABXTC2[:\CU"9GW9(W&IK[6[B^\#W<P=E>
M+Y<@^F: /3?[5MCMQ(IR>,,*N Y /K7EO@KPO/?Z?;7\M_+\WS8+&O4D7;&J
M]=H H 6BBB@ HHHH *HZO_R#9*O52U?_ )!DE &EX:_X]5^E;]8'AK_CU7Z5
MOT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &3KO_'F?I7.Z'_QZR?[]=%KO_'F?I7.Z
M'_QZR?[] &I1110 4444 %%%% !1110 4444 >9^*O"E]'?KJ&G%4;?O?CK7
M,:G/K]]=!HW82@8R5->Y,BN,,H(]ZA^PVH.?L\>?]V@#QSP/&8)-2AO(7,\X
MV[MIQGBK-E::AX?UT8SLZ_*IKU==.M4<ND$:L>X6I6M8';<T*,?4B@#R&TT7
M4[C69+J0_+(^Y>*DU32+BU\4K=W:F2$+@A17K8MX5Z1*,>U(]M!*<R0HQ]Q0
M!XU_8-W+J\$VT^2[Y QT%:FJZ3?Z+XF75+;B)4Q@#)KU'[- ,8A3CIQTI7@B
ME&)(U;ZB@#Q_5K'6-9U73KB9MR(^[E3[UJ^(M&N;B[5D'&!VKTK[- ,?N4XZ
M<=*<88F/S1J?J* ,6[MG?P:UL/O^1MKB- \+W,_AHV<@&[<3R*]3VC;MVC;Z
M4U(HXQA$"CV% 'DEA+K&@M=6NYLO\L>%/%;=MHVL:SH6R]D5R3GD5WK6EN[;
MF@0GU(J545!M50!Z"@#Q:UTJ32I;J">-F=SB,JO2MI],N+?PQYT_WL^E>E-:
M6[MN:!"?4BL_7--%]IIMT7:,]!0!Y-X7OM0L1J"Q,<.>, ^U;_A?P_J$^N-K
M4Q&67'(YKI_"WAU-+^T>;&'WGC<*Z=(DB&(T"CT H \IU.VN4N;A=35IE=OW
M>T=!3_!7AN>V\1?VA$NRV*X"D<UZ@]K!(<R0HQ]Q3DACC&(XU4>PH <.E+11
M0 4444 %%%% !1110 4444 96K_=_"NC\.?\@:&N<U?[OX5T?AS_ ) T- &M
M1110 4R;_42?[I_E3Z9-_J)/]T_RH \_L_\ C_D_WS6_6!9_\A"3_?-;] !1
M110 4444 %%%% '">-?"UQJ5TFH6>U9HEPI-8 UC6K>S%E,[M(!C(4XKUD@,
M,$9%0FRM2VXV\9/KMH \J\-^$M7GUB/4[AU(1LC(YJ"^TBXM?%%W<W2%XY.$
MVCO7L*1I&,(H4>PICVL$AR\*,?4B@#QZST.^7Q9:72C"@<<?2M+58+Q=1N&U
M$-+;MPBJ.E>H"WA!W")01T.*1[:"3[\*-]10!Y-X9\+SGQ!#?VR^7;H?F##F
MG7-C?:3XNN+P [)G &!7K*011#]W&J_04UK:"0[GA1CZD4 >8:OI5U>^.-/O
M0#L6,9X^E=GK6C'4](6+ WHI(SZUN^1#N#>4NX=#BI,<8QQ0!Y%8W&M:!;2V
M1=MS.2I53C%:WACPM=-+?7UYAFNHR!QWQ7H+6ENYRT"$^I%2JBH,*H ]!0!Y
M!;Z?J?A+4&5"?*9B^%'O6YI$>NW_ -NEN)@8)(SL4CGI7?O;02G,D2,?<4Y8
MHT&$C51Z 4 >=>!M(N;&\9IA_P M">GO5670KE_$]U+CY'?TKT]88TY2-5^@
MH\F+=N\M=WKB@#R;7?#4MEKT-[LS;JGS!1SVJQH^FW5]=2/&I6,<@,*]1>"*
M7_61JWU%(EO#%_JXE7Z"@#S6UT:Y7X@VEV1^[1<'CZ5+KVD7$^NP2H/E$H)X
MKT;R8]^_RUW>N*##&QR8U)]<4 >=^,-(N+R_B:,<",#I["J&OZ)=3QZ-L'^J
M<%N/>O4VAC<Y:-3]108(FQF-3CID=* /./&&AW;E+^#^",#ISTK)U./4];L;
M.!"1Y'WLJ:]>>*.1=KH&7T(I@M+=?NPH/H* //TT[58/"4D5NX5\^E<U=Z6F
MH"*$P/\ :APS%>,U[1Y2;=NP;?3%1BSM@VX01Y]=M &%X-TNXTG1A!<$%LYX
MKHZ0  8 Q2T %%%% !1110 4R7_5-]*?3)?]2WTH S]#_P"0\/I7;UQ&A_\
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M*CRD_N#\J .$^SZO_P ]/TH^SZO_ ,]?TKN_*3^X/RH\I/[@_*@#A/L^K_\
M/3]*<EOJN[YI1CZ5W/E)_<'Y57NT00DA0/PH XYK?5L\2_I3?L^K_P#/7]*[
M:"-#&/E'3TJ7RD_N#\J .$^SZO\ \]?TH^SZO_SU_2N[\I/[@_*CRD_N#\J
M.$^SZO\ \]/TH^SZO_ST_2N[\I/[@_*CRD_N#\J .$^SZO\ \]/TH^SZO_ST
M_2N[\I/[@_*CRD_N#\J .$^SZO\ \]/TH^SZO_SU_2N[\I/[@_*CRD_N#\J
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MNK\I/[@_*@#A/L^K_P#/7]*/L^K_ //3]*[ORD_N#\J/*3^X/RH X3[/J_\
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M44 %%%% !1110 A&5(]:X+QQX3L;RQEOYX0TJ#@UWU8WBF%[C0+B.-<L1P*
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MH\^7W_*KVU?04;5]!0!1\^7W_*CSY??\JO;5]!1M7T% %'SY??\ *CSY??\
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M7VKZ"J%V!N''>@ 6:3:.OY4OGR^_Y5<55V+P.E.VKZ"@"CY\OO\ E1Y\OO\
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MB@ HHHH **** ,^U_P"/N7ZUH5GVO_'W+]:T* "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 R7[AJK8]'^M6I?N&JMCT?ZT 7:*** "BBB@ HHHH ****
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MOTK>K!\.?\>Z_2MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS7'_ #UJ]10!1^S7'_/6C[-<?\]:O44 4?LUQ_SUH^S7'_/6KU% %'[-<?\
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M** "BBB@ HHHH **** "BBB@ J@__'Z:OU0?_C]:@"\/NBEI!]T4M !1110
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MB@ HHHH **** "BBB@ HHHH 9+]PU5L>C_6K4OW#56QZ/]: +M%%% !1110
M4444 %%%% !1110 4444 5+[[J?6IX?N"H+[[J?6IX?N4 24444 %%%% !65
MXB_Y TU:M97B+_D#34 5O#G_ ![K]*WJP?#G_'NOTK>H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JO>KNM7&,^U6*@NYUMK9I7^ZO6@#PG5O
M[7TOQ/<W%LTL<;<# K0TK6M>EOXE=YRIZ\4W7]<UG5-<D@M((VMT8$''.,_2
MK4>O:E8:C;'R8Q;@#S#CH?RH ]:TQI'L(S+G?WS5NJ6E7:W^GQW"XPWI5V@
MHHHH **** "BBB@ HHHH **** ,K7/\ CU_"JWA7_D'R?[_^-6=<_P"/7\*K
M>%?^0?)_O_XT ;U%%% !1110 4444 9]K_Q]R_6M"LZU_P"/N7ZUHT %%%%
M!1110 4444 %%%% !1110 56O/\ 4FK-5KS_ %)H DM_]6/I4M16_P#JQ]*E
MH **** "BBB@ HHHH **** "BBB@ J@__'ZU7ZH/_P ?K4 7A]T4M(/NBEH
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M[X8^\M=97)^&/O+764 %%%% !1110 =JH2_\?*?6K_:J$O\ Q\I]: +]%%%
M!1110 4444 %%%% !1110 4444 ,E^X:JV/1_K5J7[AJK8]'^M %VBBB@ HH
MHH **** "BBB@ HHHH **** *E]]U/K4\/W*@OONI]:GA^Y0!)1110 4444
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MVK55=2_Y!L_^[0!SOAC[PKK*Y/PQ]X5UE !1110 4444 ':J$O\ Q\I]:O\
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M ,]C1]BE_P">QJ_10!0^Q2_\]C1]BE_Y[&K]% %#[%-_SV-'V*;_ )[&K]%
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M4 9]K_Q]R_6M"L^U_P"/N7ZUH4 %%%% !1110 4444 %%%% !1110 56O/\
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M*WJP?#G_ ![K]*WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2:LU6O/]2: )+?\ U8^E2U%;_P"K'TJ6@ HHHH **** "BBB@ HHHH ****
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M****U/-"BBB@ HHHH **** "BBB@ JA%_P ?;U?JA%_Q]/0!?[4444 %%%%
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MYJ^M #Z*9YJ^M'FKZT /HIGFKZT>:OK0 ^BF>:OK1YJ^M #Z*9YJ^M'FKZT
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M3^Q'_GH:/L1_YZ&KE% %/[$?^>AH^Q'_ )Z&KE% %/[$?^>AH^Q'_GH:N44
M4_L1_P">AH^Q'_GH:N44 4_L1_YZ&H;BU*1YWDUI56O/]2: (8K0L@/F$4_[
M$?\ GH:GM_\ 5CZ5+0!3^Q'_ )Z&C[$?^>AJY10!3^Q'_GH:/L1_YZ&KE% %
M/[$?^>AH^Q'_ )Z&KE% %/[$?^>AH^Q'_GH:N44 4_L1_P">AH^Q'_GH:N44
M 4_L1_YZ&JK0$7)3>?K6M5!_^/UJ '"R./\ 6&E^Q'_GH:MC[HI: *?V(_\
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MC_ST-'V(_P#/0U<HH I_8C_ST-'V(_\ /0U<HH I_8C_ ,]#1]B/_/0U<HH
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MHHH **** #M5"7_CY3ZU?[50E_X^4^M %^BBB@ HHHH **** "BBB@ HHHH
M**** &2_<-5;'H_UJU+]PU5L>C_6@"[1110 4444 %%%% !1110 4444 %%%
M% %2^^ZGUJ>'[E07WW4^M3P_<H DHHHH **** "LKQ%_R!IJU:RO$7_(&FH
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M7I"+M15'88H =1110 4444 %%%% !1110 4444 96N?\>OX56\*_\@^3_?\
M\:LZY_QZ_A5;PK_R#Y/]_P#QH WJ*** "BBB@ HHHH S[7_C[E^M:%9]K_Q]
MR_6M"@ HHHH **** "BBB@ HHHH **** "JUY_J35FJUY_J30!);_P"K'TJ6
MHK?_ %8^E2T %%%% !1110 4444 %%%% !1110 50?\ X_6J_5!_^/TT 7A]
MT4M(/NBEH **** "BBB@#G_$O^H/TJUX<_Y T-5?$O\ J#]*M>'/^0-#0!K4
M444 %,F_U$G^Z?Y4^F3?ZB3_ '3_ "H X_0O^/\ E_ZZ'^==G7&:%_Q_R_\
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M#5+7&%S"0O''>M#0(S'I,2GM0!IT444 %,F_U$G^Z?Y4^F3?ZB3_ '3_ "H
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M!'X<_P"/=?I6]6)H$9CA"D]!6W0 4444 %%%% !1110 4444 %%%% !1110
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M'2=$(-G;"-@<B@";5TV6 7T%5?#$0>PD)_O_ .-7=<_X]?PJMX5_Y!\G^_\
MXT :_P!F2C[,E3T4 0?9DH^S)4]% $'V9*/LR5/10!EV\0:YD4]JN_9EJM:_
M\?<OUK0H @^S)1]F2IZ* (/LR4?9DJ>B@"#[,M'V9*GHH @^S)1]F6IZ* (/
MLR4?9EJ>B@"#[,M074"K%D5>JM>?ZDT -AMU9!]*D^S+3K?_ %8^E2T 0?9D
MH^S+4]% $'V9:/LR5/10!!]F2C[,E3T4 0?9EH^S+4]% $'V9:/LRU/10!!]
MF6J;1#[65K3J@_\ Q^M0!8%LN!1]F6IA]T4M $'V9*/LR5/10!!]F2C[,E3T
M4 <]KZB&$[?2KOAYB^D1$U3\2_ZD_2K7AS_D#0T :U%%% !3)O\ 42?[I_E3
MZ9-_J)/]T_RH XW1%#7TH/\ ST-==]F6N3T+_C_E_P"NA_G79T 0?9DH^S+4
M]% $'V9:/LR5/10!!]F6J=S$%88]:TZH7?WE^M $ZVZ[1]*7[,E3)]Q?I2T
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MZZ'^==G0 4444 %%%% !5"[^\OUJ_5"[^\OUH O)]Q?I2TB?<7Z4M !1110
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M@ HHHH **** "BBB@ HHHH **** *U[_ ,>YI;7_ %8I+W_CW-+:_P"K'TH
ML4444 %%%% !45Q_Q[O]*EJ*X_X]W^E '*:;_P C*/I785Q^F_\ (RCZ5V%
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M?;1_<- %NBJGVX?W#1]N']QJ +=97B+_ ) TU6OMP_N&J&L3?:=-DBP5SW-
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M'EKZ#\J?10 SRU]!^5'EKZ#\J?10 SRU]!^5'EKZ#\J?10!FVR@W4@([U?\
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M^5474?;",5HU0?\ X_6H MB-=HX%+Y:^@_*G#[HI: &>6OH/RH\M?0?E3Z*
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M "BBB@ HHHH **** "BBB@ HHHH *K7G^I-6:K7G^I- $EO_ *L?2I:BM_\
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M4444 %%%% !1110 4444 5KW_CW-+:_ZL4E[_P >YI;7_5B@"Q1110 4444
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M7ZUH5GVO_'W+]:T* "BBB@ HHHH **** "BBB@ HHHH *K7G^I-6:K7G^I-
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MZU_X^Y?K6C0 4444 %%%% !1110 4444 %%%% !5:\_U)JS5:\_U!H DM_\
M5CZ5+45O_JQ]*EH **** "BBB@ HHHH **** "BBB@ J@_\ Q^FK]4'_ ./T
MT 7A]T4M(/NBEH **** "BBB@#G_ !+_ *@_2K7AS_D#0U5\2_Z@_2K7AS_D
M#0T :U%%% !3)O\ 42?[I_E3Z9-_J)/]T_RH X_0O^/^7_KH?YUV=<9H7_'_
M "_]=#79T %%%% !1110 50N_O#ZU?JA=_>'UH O)]Q?I2TB?<7Z4M !1110
M 4444 %%%% !1110 4444 %4(O\ CZ>K]4(O^/MZ +_:BCM10 4444 %%%%
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M+O-3UR=K>\,>&R,5!H^I:CX8\7VFDWMR]P'&<G\/\: /6M9S]B^;KBH/"O\
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M8;[5"0PV<=ZT="C$6E1*&SCO0!I4444 %,F_U$G^Z?Y4^F3?ZB3_ '3_ "H
MX_0O^/\ E_ZZ&NSKB-'<QWLS 9PYXKJ?MS_\\6H O451^W-_SR-'VY_^>34
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M/_SR:C[<_P#SR:@"]15'[<__ #R:C[<__/)J +U%4?MS_P#/)J/MS_\ /(T
M7J*H_;G_ .>34?;G_P">34 /OONI]:GA^Y6=<732!<QD8-21WK*N/*- &C15
M'[<__/)J/MS_ //)J +U%4?MS_\ /)J/MS_\\FH O5E>(O\ D#35/]N?_GDU
M4M6F-UI\D3*4![F@!GAS_CW7Z5O5BZ%&(XMH;.!UK:H **** "BBB@ HHHH
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MM0!>'W12T@^Z*6@ HHHH **** .?\2_Z@_2K7AS_ ) T-5?$O^H/TJUX<_Y
MT- &M1110 4R;_42?[I_E3Z9-_J)/]T_RH X_0O^/^7_ *Z'^==G7&:%_P ?
M\O\ UT/\Z[.@ HHHH **** "J%W]Y?K5^J%W]Y?K0!>3[B_2EI$^XOTI: "B
MBB@ HHHH **** "BBB@ HHHH *H1?\?;U?JA%_Q]/0!?HHHH **** "BBB@
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M]<4HN+LRPHHHJ0"LKQ%_R!IJU:RO$7_(&FH K>'/^/=?I6]6#X<_X]U^E;U
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M4 %%%% '/^)?]0?I5KPY_P @6&JOB7_4'Z5:\.?\@:&@#6HHHH *9-_J)/\
M=/\ *GTR;_42?[I_E0!Q^A?\?\O_ %T/\Z[.N,T+_C_E_P"NA_G79T %%%%
M!1110 50N_O+]:OU0N_O+]: +R?<7Z4M(GW%^E+0 4444 %%%% !1110 444
M4 %%%% !5"+_ (^WJ_5"+_C[>@"_VHH[44 %%%% !1110 4444 %%%% !111
M0!6O?^/<TMK_ *L4E[_Q[FEM?]6* +%%%% !1110 5%<?\>[_2I:BN/^/=_I
M0!RFF_\ (RCZ5V%<?IO_ ",H^E=A0 4444 %5=2_Y!T_^[5JJNI?\@Z?_=H
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M_P"0--6K65XB_P"0--0!6\.?\>Z_2MZL'PY_Q[K]*WJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#*US_CU_"JWA7_D'R?[_P#C5G7/^/7\*K>%?^0?)_O_ .- &]11
M10 4444 %%%% &?:_P#'W+]:T*S[7_C[E^M:% !1110 4444 %%%% !1110
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MH **** &2_<-5;'H_P!:M2_<-5K#H_UH N4444 %%%% !1110 4444 %%%%
M!1110!3O@"JY Z^E3P*H08 _*H;W[J_6IX?N"@"2BBB@ HHHH *RO$7_ "!I
MJU:RO$7_ "!IJ *WAS_CW7Z5O5@^'/\ CW7Z5O4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &5KG_'K^%5?"O\ QX2?[_\ C5K7/^/7\*S?#F_[#)MS]_\ QH Z>BJ'
M[WT-'[WT- %^BJ'[WT-'[WT- %^BJ'[WT-&9?0T -M?^/N7ZUHUCP[_.?&<U
M9_>^AH OT50_>^AH_>^AH OT50_>^AH_>^AH OT50_>^AH_>^AH OT50_>^A
MH_>^AH OT50_>^AH_>^AH OU6O/]2:A_>^AJ*?S/+Y!H O6_^K'TJ:LV/S=@
MP#3_ -[Z&@"_15#][Z&C][Z&@"_15#][Z&C][Z&@"_15#][Z&C][Z&@"_15#
M][Z&C][Z&@"_2=JH_O?>C][Z&@#S7XK:')="*YC7(C&37C!!'!!'UKZIN[,7
MD+1S1[@1CFN"U/X8V]]>,T<PB!_A KOP^*C&/+(AQ/&[&TDO+N.%%)+''2OI
M+P-IC:9X;@@E&'7K6/H7@&WT8[F"S-U!(Z5UJJZ+M52!Z5GB<0JFD1Q5C1HJ
MA^]]#1^]]#7(47Z*H?O?0T?O?0T 9WB7_4'Z5:\.?\@:&J6KY\H[_3O6CH6/
M[*BV]* -*BBB@ IDW^HD_P!T_P J?3)O]1)_NG^5 ''Z%_Q_R_\ 70_SKLZX
MC1\_;)L==YKI_P![Z&@#0HJA^]]#1^]]#0!?HJA^]]#1^]]#0!?JA=_>7ZT9
ME]#5:??D9SUH UD^XOTIU9X\W:.#2_O?0T 7Z*H?O?0T?O?0T 7Z*H?O?0T?
MO?0T 7Z*H?O?0T?O?0T 7Z*H?O?0T?O?0T 7Z3-4?WOH:/WOH: +V15&+_C[
M?ZT?O?0U63?YS8SF@#7[4M4/WOH:/WOH: +]%4/WOH:/WOH: +]%4/WOH:/W
MOH: +]%4/WOH:/WOH: +]%4/WOH:/WOH: +]%4/WOH:/WOH: )KW_CW-+:_Z
ML53N/,\HYSBB$R;1@&@#4HJA^]]#1^]]#0!?HJA^]]#1^]]#0!?J*X_X]W^E
M5?WOH:9+YGE-D'&* ,'3?^1E'TKL*Y#3L?\ "1CZ5U] !1110 55U+_D&S_[
MM6JJZE_R#9_]V@#G?#'WA765QWA_=@;>M=#F7T- &A15#][Z&C][Z&@"_15#
M][Z&C][Z&@"]GBJ,I_TE/K1^]]#59]_FKG.: -BBJ'[WT-'[WT- %^BJ'[WT
M-'[WT- %^BJ'[WT-'[WT- %^BJ'[WT-'[WT- %^BJ'[WT-'[WT- %^BJ'[WT
M-'[WT- %N7[AJM8]'^M1OYNWD&HK??\ -MSUH UJ*H?O?0T?O?0T 7Z*H?O?
M0T?O?0T 7Z*H?O?0T?O?0T 7Z*H?O?0T?O?0T 7Z*H?O?0T?O?0T 7Z*H?O?
M0T?O?0T 27OW5^M3P_<K-N/,PN<]:DC\W' - &E15#][Z&C][Z&@"_15#][Z
M&C][Z&@"_65XB_Y TU3?O?0U2U7=_9\F_.WWH ;X<_X]U^E;U8NA;?*^7IBM
MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH RM<_X]?PJKX5_P"0?)_O_P"-6M<_X]?P
MJMX5_P"0?)_O_P"- &]1110 4444 %%%% &?:_\ 'W+]:T*S[7_C[E^M:% !
M1110 4444 %%%% !1110 4444 %5KS_4FK-5KS_4F@!]O_JQ]*FJ&W_U8^E3
M4 %%%% !1110 4444 %%%% !1110 50?_C]-7ZH/_P ?K4 7A]T4M(/NBEH
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M@ HHHH *RO$7_(&FK5K*\1?\@::@"MX<_P"/=?I6]6#X<_X]U^E;U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!E:Y_QZ_A5;PK_P >$G^__C5G7/\ CU_"JWA7_D'R
M?[_^- &]1110 4444 %%%% &?:_\?<OUK0K/M?\ C[E^M:% !1110 4444 %
M%%% !1110 4444 %5KS_ %)JS5:\_P!2: )+?_5CZ5+45O\ ZL?2I: "BBB@
M HHHH **** "BBB@ HHHH *H/_Q^FK]4'_X_30!>'W12T@^Z*6@ HHHH ***
M* .?\2_Z@_2K7AS_ ) L-5?$O^H/TJUX<_Y T- &M1110 4R;_42?[I_E3Z9
M-_J)/]T_RH X_0O^/^7_ *Z'^==G7&:%_P ?\O\ UT/\Z[.@ HHHH **** "
MJ%W]Y?K5^J%W]Y?K0!>3[B_2EI$^XOTI: "BBB@ HHHH **** "BBB@ HHHH
M *H1?\?;U?JA%_Q]O0!?HHHH **** "BBB@ HHHH **** "BBB@"M>_\>YI;
M7_5BJVI7UM# 5DF53[T[3[VWG0".56^E.S OT444@"BBB@ J*X_X]W^E2U%<
M?\>[_2@#E--_Y&4?2NPKC]-_Y&4?2NPH **** "JFI?\@V?_ ':MU4U+_D&S
M_P"[0!SWAC[PKK*Y/PQ]X5UE !1110 4444 ':J$O_'RGUJ_VJA+_P ?*?6@
M"_1110 4444 %%%% !1110 4444 %%%% #)?N&JMCT?ZU:E^X:JV/1_K0!=H
MHHH **** "BBB@ HHHH **** "BBB@"I??=7ZU/#]RH+[[J?6IX?N4 24444
M %%%% !65XB_Y TU:M97B+_D#34 5O#G_'NOTK>K!\.?\>Z_2MZ@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH RM<_X]?PJMX5_Y!\G^_P#XU9US_CU_"JWA7_D'R?[_
M /C0!O4444 %%%% !1110!GVO_'W+]:T*S[7_C[E^M:% !1110 4444 %%%%
M !1110 4444 %5KS_4FK-5KS_4F@"2W_ -6/I4M16_\ JQ]*EH **** "BBB
M@ HHHH **** "BBB@ J@_P#Q^FK]4'_X_30!>'W12T@^Z*6@ HHHH **** .
M?\2_Z@_2K7AS_D#0U5\2_P"H/TJUX<_Y T- &M1110 4R;_42?[I_E3Z9-_J
M)/\ =/\ *@#C]"_X_P"7_KH?YUV=<9H7_'_+_P!=#_.NSH **** "BBB@ JA
M=_>7ZU?JA=_>7ZT 7D^XOTI:1/N+]*6@ HHHH **** "BBB@ HHHH **** "
MJ$7_ !]O5^J$7_'V] %_M1110 4444 %%%% !1110 4444 %<QXP\31Z!8Y+
M$2.ORX]:Z>O'?C LWEVV,[<_XUM0@IS28F[(X34_&FK7\S%Y\J34VC^-]5T^
MZC/GXCS\WTKE:*]?V4+6L979]1^%]?BUW35N$).>.:WJ\M^$ZS?V8A.=F:]2
MKQZT5&;2-4[H****R&%17'_'N_TJ6HKC_CW?Z4 <IIO_ ",H^E=A7'Z;_P C
M*/I784 %%%% !574O^0=/_NU:JIJ7_(-G_W: .>\,?>%=97)^&/OBNLH ***
M* "BBB@ [50E_P"/E/K5_M5"7_CY3ZT 7Z*** "BBB@ HHHH **** "BBB@
MHHHH 9+]PU5L>C_6K4OW#56QZ/\ 6@"[1110 4444 %%%% !1110 4444 %%
M%% %2^^ZGUJ>'[E07WW4^M3P_<H DHHHH **** "LKQ%_P @::M6LKQ%_P @
M::@"MX<_X]U^E;U8/AS_ (]U^E;U !16?=:DMK+M? &<9J:>\2&S,Y(QC-*Z
M)YUKY%JBLS3=7CU!1M(S[4E_JZVDR1K@LU%U:XO:1Y>:^AJ45STWB"6#[\0
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M]T4M !1110 4444 <_XE_P!0?I5KPY_R!H:J^)?]0?I5KPY_R!H: -:BBB@
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M_8VM^L__ 'U1[5]@^NS_ )&>I?:8?^>J?]]"C[3#_P ]4_[Z%>6_V-K?K/\
M]]4?V-K?K/\ ]]4>U?8/KL_Y&>I?:8?^>J?]]"C[3#_SU3_OH5Y;_8VM^L__
M 'U1_8VM^L__ 'U1[5]@^NS_ )&>I?:8?^>J?]]"C[3#_P ]4_[Z%>6_V-K?
MK/\ ]]4?V-K?K/\ ]]4>U?8/KL_Y&>I?:8?^>J?]]"J]W<0F'B5/^^A7FO\
M8VM^L_\ WU37TC657+&;'UH]J^P?7)_R,]/@N(1&/WJ=/[PJ7[3#_P ]4_[Z
M%>5KH^M$<&;_ +ZIW]C:WZS_ /?5'M7V#Z[/^1GJ7VF'_GJG_?0H^TP_\]4_
M[Z%>6_V-K?K/_P!]4?V-K?K/_P!]4>U?8/KL_P"1GJ7VF'_GJG_?0H^TP_\
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MJCVK[!]=G_(SU+[1#_SU3_OH51BGB^U.?,3_ +Z%>=_V-K?K/_WU48TG6-Y
M,V?K1[5]@^N3_D9ZM]IA_P">J?\ ?0H^TP_\]4_[Z%>6_P!CZWZS_P#?5']C
M:WZS_P#?5'M7V#Z[/^1GJ7VF'_GJG_?0H^TP_P#/5/\ OH5Y;_8VM^L__?5'
M]C:WZS_]]4>U?8/KL_Y&>I?:8?\ GJG_ 'T*/M,/_/5/^^A7EO\ 8VM^L_\
MWU1_8VM^L_\ WU1[5]@^NS_D9ZE]IA_YZI_WT*/M,/\ SU3_ +Z%>6_V-K?K
M/_WU1_8VM^L__?5'M7V#Z[/^1GJ7VF'_ )ZI_P!]"C[3#_SU3_OH5Y;_ &-K
M?K/_ -]4?V-K?K/_ -]4>U?8/KL_Y&>I?:8?^>J?]]"C[3#_ ,]4_P"^A7EO
M]C:WZS_]]4?V-K?K/^='M7V#ZY/^1GI5Y<0FW.)4_P"^A1:SQ",9E3I_>%>9
MR:1K*KEC-C_>I$TC62/E,W_?5'M7V#Z[/^1GJOVF'_GJG_?0H^TP_P#/5/\
MOH5Y;_8^M^L__?5']C:WZS_]]4>U?8/KL_Y&>I?:8?\ GJG_ 'T*/M,/_/5/
M^^A7EO\ 8VM^L_\ WU1_8VM^L_\ WU1[5]@^NS_D9ZE]IA_YZI_WT*CGN(3
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MLQ[U'X8\ W5EJ$=_JA22XC/RL.PKTBB@#SCQ/X!N;VZ:YTLI%,YRQ/>G>%O
M5QIU_'?ZD4DN(S\K#TKT6B@#*UO_ (]/PJMX5_Y!\G^__C5G7/\ CU_"JWA7
M_D'R?[_^- &]1110 4444 %%%% &?:_\?<OUK0K/M?\ C[E^M:% !1110 44
M44 %%%% !1110 4444 %5KS_ %)JS5:\_P!2: 'V_P#JQ]*FJ*W_ -6/I4M
M!1110 4444 %%%% !1110 4444 %4'_X_35^J#_\?IH O+]T4M(/NBEH ***
M* "BBB@#G_$O^H/TJUX<_P"0+#57Q+_J#]*M>'/^0-#0!K4444 %,F_U$G^Z
M?Y4^F3?ZB3_=/\J ./T+_C_E_P"NAKLZXS0O^/\ E_ZZ&NSH **** "BBB@
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M !1110 4444 %%%% #)?N'Z56L>C_6K,OW#5:QZ/]: +E%%% !1110 4444
M%%%% !1110 4444 5+W[J_6IX?N5!??=3ZU/#]P4 24444 %%%% !65XB_Y
MTU:M97B+_D#34 5O#G_'NOTK>K!\.?\ 'NOTK>H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,K7/^/0\=JQ_#NJPVUG(C@YW_XUT]Q;K<1E&Z$8K$_X16 $D2L,G/%
M%W^W;;_)I/[=MO\ )JG_ ,(M%_SW?\Z/^$6B_P">[_G0!<_MVV_R:/[=MO\
M)JG_ ,(M%_SW?\Z/^$6B_P">[_G0!<_MVV_R:/[=MO\ )JI_PBT7_/=_SI/^
M$6B_Y[O^= $L>H10RM*W1NE3_P!NVW^34#^'(WC5?.;CWJ+_ (1:+_GN_P"=
M %S^W;;_ ":/[=MO\FJ?_"+1?\]W_.C_ (1:+_GN_P"= %S^W;;_ ":/[=MO
M\FJ?_"+1?\]W_.C_ (1:+_GN_P"= %S^W;;_ ":/[=MO\FJ?_"+1?\]W_.C_
M (1:+_GN_P"= %S^W;;_ ":/[=MO\FJ?_"+1?\]W_.C_ (1:+_GN_P"= %S^
MW;;_ ":/[=MO\FJ?_"+1?\]W_.C_ (1:+_GN_P"= %S^W;:HY=6@G78O6J__
M  BT7_/=_P Z?'X9B1MWG-^= $Z:S!&NT]1[T[^W;;_)JJWAB)CGSG_.F_\
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MY_;MM_DT?V[;?Y-4_P#A%HO^>[_G1_PBT7_/=_SH N?V[;?Y-']NVW^35/\
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M3/\ A%HO^>[_ )T 7/[=MO\ )H_MVV_R:I_\(M%_SW?\Z/\ A%HO^>[_ )T
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M;*<=JWJK6=FEG"L:<X%6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUR/Q&L'T2]?6HUVYXSTK&\,>9XMUBSN6RWV9\G_/XT =YXC\=G0H-TB.3G'
MK&N_B/<Q1PW7D3B+&X_*>E4_BI&OVH+CC>/YUN>([:$?#^-A$@;[,.=HH WK
M'QS:W'A2/6"I"/P 3STKCV^),TDDTZ1R^3$<D8/(KE(([B3X36OE9_UG8_2G
M:7/OT:>)T7;MPYQR* /9_"7BF#Q)ID=Q&I4M_">M:>MV,VH:9-;0OL=UP#7
M_#&RABACDMY&:/''->BZA?1Z?927$K;509)H \S?P-IVCZ8T^K"*:?:?F)'7
M%<[X!DN;>#6)(=R0I(=O';-4_$OC#_A)]>?3Q*5LP00Z'!ZUZ!HMMI$/ABX@
MT^7S)'3#9'>@#A_#^GP^(_'-X]^@E0Q$@'UYIVBSGP]XI^R6_P D<DI^44OA
M&]@T?QO>17;[,0G^M06H&K^+!<VWSQQRG)H ZO4?B5]C\37&FK%*Y0?P@GUJ
MC_PM)[&[6"X@F+2GY00:R=*B27XO7ZNH8>7T(S_>I/&<$8\>:,@10I/( ]J
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MK7BGPH/$$2H2ORN&Y^M=310!RFJ>$$U#2$M#MW+&%!-0^$?"-QX=8!Y0T8&
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M* ,S1-(BT>S\B)0.YQ6G110!ROB7PF->E+DKTQS6W8:<MKI$=BP!54VFK]%
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@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gtinntqqusay000027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'T!>,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQZ&O-]7>Y>^F42N%W=,T#1W&DI:16P2T7"5HUSWA5&73EW$DY[UT- @HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI?\ QZ_C4E[_ *D_2H]+_P"/7\:K[(NI>HHHJ1A1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$-S_ *DUD:#_ ,?-U]:U[G_4FLC0?^/FZ^M4OA8C=HHHJ1A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@#UH)1ZR.E5=2_X\9*DM)'EME>088]14>I?\>,E#V".XNG_\>4?TJU573_\
MCRC^E6J:"6Y%<X^S29_NFO)]3MYY;]C"=L>3G->MNH>-D/0C%>=^)V;39S91
M*"D@W%^X_P YI,$=/X:PMHB'E@.36_7)>$)+DIMDCQ&!PWK76TQ%#4/O1?6K
MR_='TJCJ'WHOK5Y?NCZ5*W9<OA0M<'XTB\ZY*!26(KO*YOQ-"+6!M14!Y$&
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M8_\ D+O]*TJS8_\ D+O]*4NA4.II44451 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<_P"I
M-9&@_P#'S=?6M>Y_U)K(T'_CYNOK5+X6(W:***D84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME'<$TR]1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%[36(ND [FNOKE-)B+S!O0UU=<U7<VI[!11161H%%%% !1110 4444 %%%%
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M=112&0W%K#=)LF0,I[&L*Y\%Z-.Q;[&F3UKHZ*+@<O%X'TJ)MRVJ U='AFP
MQY"UMT4^9B<4]S!E\*Z?*NUH%(JM%X*TJ*3>MJ@.:Z>BCF8**1B?\(U8$?ZA
M:I3>"=*F;<UJA-=111S,%%+8P(?"FG0Q"-;= !3!X1TT/N^SIFNBHHYF+E1S
M4_@S2[@Y>V0U&G@;24<,+5 174T478[+8PQX8L ,"!:&\,6#+@P+6Y13YF+D
MCV.7_P"$)TKS?,^RIFK@\,V&W'D+BMRBE=C<4]SEI/ ^DR2EVM4)-6H?"FG0
MKM2W0"M^BB[!I,P)?"NGRKAK=#5/_A ](S_QZ1UU=%%V"26QRR>!M)1MPM4S
M5X>&; #'D+Q6W10FT#BGN8,GA;3Y%VM;J:I?\()I&<_9$KJZ*+L$DMC"C\+:
M?&@18% %-F\*:=/&4>W0@UOT4<S%R1['+1^!])C?<MJ@-7O^$:L ,>0M;=%%
MV-Q3W,3_ (1JQ_YX+4<WA33IHRC6Z$&M^BGS,7)'L<I_P@>D?\^D=36_@S2[
M=MR6R UTM%*[':YS=QX.TR<@O;(<4]?"6FK%Y8MTQ70T4<S#E1RI\"Z27W?9
M4S5N+PKI\*;5MU K?HHNP:3W,-O#%@RD&!<&JJ^"]+2;S!;)N]:Z:BCF8E%(
MQ!X9L /]0M03^$=-G&'MT-=%11S,.6*Z&$GA>P1 H@7 J*3PAILC[FMD)KHJ
M*.9ARHPO^$7T\)M\A<57_P"$*TAY?,>T0FNEHHNQJ*6QG6>AZ?8?\>]NJ'VK
M1HHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MQ?Q_,SWA4YP&XKVBO)?B18M$R2@?>:M*7Q"EL>>4445U&8HI:!130A:***8'
M4^ O^1DB^E=IK.D2W$Y9=0CCYZ%A7#^")D@\01NYPN*D\57K/>L8I7QN[-64
MDW,I;$ZRR:1XC >7[0 .J\UV$L::K'"\=RD+@9 )YKSK0+F%=45[QSLQU/-=
MC)HD$TT5Q:S2%"<GDTIJSU&BAXEM+VWC_>SF6/(Y'2NIO]+34M!L \R1XC_B
M/UK%\2:A:QZ.+%7S*&!YZTSQ+?HVA6"Q2$,(^<''K4V;2&;.B:+%IT9*3QR8
M4_=-97AHE9]8(ZAC_2J/A"]5!^^E8_*>IS5KPS/#]KU17; =CC]*;35[B,.[
MU:]@UG"3,!G^M;OC.-9=-LI6'S&/)-))H-F^H&>5F"]<UG^+]8@N([>WMGW"
M(;35+5JPCCJ6DI:ZB!12TE+0 M%%% %JP<I=QD?WA_.O>=-8MI\!/]P5XCH5
MHUYJ*HHR00:]RLT\NSA7T4"N7$M:(T@3T445R%A1110 4444 %%%% !1110
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MY4W$8/?FH_&%Q=2ND8&$1NQK(T*\'_"26ZKCIS^E )'JM%-0[E!IU,04444
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M5_\ \\J7^P[_ /YY4[Q"S(SJU\PP9VQ55F9V+,<DU?\ ["O_ /GE2_V'?_\
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MRMJBM' >OM6_X<U274K/?<8$F<<4786-7[-!_<%'V>#^X*YKQAK=YI4MG':
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW8"QVL,7W(P*FHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!#@"D5U;[K XIEP<1$BLO19FDGN QZ&G;2X&F
M]K"\GF-&"WK4H  P.@I:*0!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6O?]2?I4
M6E_\>OXU+>_ZD_2HM+_X]?QJOLBZEZBBBI&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 0W/\ J361H/\ Q\W7UK7N?]2:R-!_X^;KZU2^%B-VBBBI&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %:]_U)^E1:7_QZ_C4M[_J3]*BTO_CU_&J^
MR+J7J***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<_P"I-9&@_P#'
MS=?6M>Y_U)K(T'_CYNOK5+X6(W:***D84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444C
M9V\=: *][_J3]*BTO_CU_&LG4]8\@LCY]*31]4\[$29R36G(^4CF5SI:*1<E
M1GK2UF6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444C9V\4 17/\ J361H/\
MQ\W7UJGKNO-II99"=H]*Q-#\3*UVZQDYD;CBM5!N-R;JYZ)14-NSM$#)UJ:L
MB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBF 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110
M8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ1
M10 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8
MHQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ11
M0 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110!73
M_CZ:K%5T_P"/IJL4 %%%% !1110 4444 %%%% !59_\ CZ6K-5G_ ./I: +.
M*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,44
M4 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*
M,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
M &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,
M444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
M(1Q5;_EY6K1Z56_Y>10!9HHHH @'_'R:GJ ?\?)J>D@"BBBF 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!73_ (^FJQ5=/^/IJL4 %%%% !11
M10 4444 %%%% !59_P#CZ6K-5G_X^EH LT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %5C_Q\BK/:JW_+R* +-%%% $ _X^34]0#_ (^3
M4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!73_ (^F
MJQ5=/^/IJL4 %%%% !1110 4444 %%%% !59_P#CZ6K-5G_X^EH LT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4457N[M+2/>X)!]* +%%5K2]BO%+1GI5F@ HHHH **** "B
MBB@ HJ.6411EVZ"LMO$%LDH0AN3BI<XK<:BWL;%9=WJPMWVH Q!Y]JN_:$:/
M<K#D>M<Y!:M=ZC<#J#6=2;32CU-*<$TVS>M-1AN8]RN*5;U&E*9'%87]DW%C
MDP8"9R14MI;3/-N/KS4*K._*T-TXVO<Z/M147G(F%9AT]:?N!7(-=%S$225(
MAEV %$<J2#*,#7/ZG<.^HK;9^0CD53@GOK&9M['RB?E %8.NDV;>Q=D=:74'
M!-*#FN=;4)9#N4FMZV8M A/4BM(5%+8B4''<EHHHK0@3M7+ZAXIEMK@Q00>8
M0<&NH/W3]*X*U0/KT^[_ )Z4#-2S\52-<!+R$0*>YK0O=>2VFMD7#+.< UA^
M.;."+1S.@Q)D<UDWC,W]A[O;^M(#T"_O196GG$5ES^(6B5'$8*'ECZ4[Q*1_
M8@Y]*S[2"&;19_-''ETP-9_$%J+ 72R*5)Q5FQOS=1-*Z[4 R#ZUY58OYFJ_
MV<__ !X@Y [9KNM7U.+3-.@M(<AI4VIBE<"W'XDBDUUM.0J<#.:W@<C->2Z
MGD>+C)<D&8CDBO6(CNB4CN*8F/HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ****  ]*K?\O*U9/2JW_+RM %FBBB@" ?\?)J>H!_
MQ\FIZ2 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF&5 <%ER?
M>@!]%(#2T %%%,:5%."P&?4T /HI 0>E+0 4444 %%%% !1110 4444 5T_X
M^FJQ5=/^/IJL4 %%%% !1110 4444 %%%% !59_^/I:LU6?_ (^EH LT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MR%Q_R,\E=?7(7'_(SR?Y[U,C.IT.LB_U2_2GTR+_ %2_2GU1H%%%% !44T*S
M+M;I4M% $<4"0C"*!]!3G<1J68XIU5;V)Y82$-)NRT&D4CK<7G[01MSR:O\
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M<>AS0!)144EQ'%]]U'U-2 @C([T +1110 444C,%&2<"@!:*:KJ_W2#]#3J
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MV4$=N*JVWAN"WN!*7+X/0UL>;'G'F)GTW"J=UJL%I<+"Y&YAD<T#+RJ%7 &
M*6LB#Q!;3W30#@KW)K561'&593]#0(=1110 'I5;_EY%63TJK_R\K0!:HHHH
M @'_ !\FIZ@'_'R:GI( HHHI@%%%% !1110 4444 )@4N!Z444 &!Z48HHH
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M:\M\+6UV]ZK1$J/7%>GPAEB4-RP'->A1FYQNSP<91C2J6BR2BBBMCD"BBB@
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M4@# HP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** "BBB@
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M#-&>/P-:GP[_ ./>]_ZZG^=066ASVMS.IZ%"!Q[&M+P3I\MC#="7^*0D<>]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH **** "BBB@"NG_'TU6*KI_P ?358H **** "BBB@ HHHH **** "JS_\
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MBB@" ?\ 'R:GJNV5F+8I?./]TT@)Z*@\X_W31YI_NFF!/14'FG^Z:/./]TT
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M[IH\X_W30!/14'G'^Z:/-/\ =- $]%0><?[IH\X_W30!/14'G'^Z:/-/]TT
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M'G'^Z:/./]TT 3T5!YQ_NFCSC_=- $]%0><?[IH\X_W30!/14'FG^Z:/./\
M=- $]%0>:?[IH\T^AH G/2JO_+RM/\T_W334!:4/B@"S1110 4F!Z444 &!Z
M48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444
M &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!
MZ444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@
M>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%
M% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1
M@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110
M8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I
M110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 M%%% !1110 4444 %%%% !11
M10 4444 )@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I11
M0 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48
M'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &
M!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z4
M44 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E
M&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%%
M!@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>
ME%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z4M%% !1110
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gtinntqqusay000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &&!7\# 2(  A$! Q$!_\0
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MJ4&HPK+">#VSS7D5DC:SJLINIF39(5 )[9K5\*7TMIXMU"U+EH(8BRY/'0T
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MGXB7\UI_Q[D?*5Z=Z /7J\]^*>G&]TVT91GRY0WY$5Z"GW%SZ5E>(;(7FES
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M HHHH *1E##!Z4M% '.:AX%T#4Y#)=68=B<YJ*S^'WARPE$MO8A7'0\5U%%
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MLC48 JW10!B>*M1;3=#GG0,67IM&37->!-&9;R;6)%P;D9Y'-=O=V<=Y&4D
M*GJ"*DM[=+:%8XU 5>F!0!+1110 4444 %%%% !1110 4444 %%%% !1110
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M4DP$3+N!]JQ%^(F@LV?MB[/7B@#KJ*R](U_3];#FQF$@3K6I0 4444 %%%%
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M8SV_*@#2^$\0@N=4B'16P/TKU"O+/A$96DU%IAB0GYA[\5ZG0 4444 %%%%
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M\_T'_?=']M:9_P _T'_?=>#_ /"NO%O_ #RE_P"^VH_X5UXM_P">4O\ WVU
M'O']M:9_S_0?]]T?VUIG_/\ 0?\ ?=>#_P#"NO%O_/*7_OMJ/^%=>+?^>4O_
M 'VU 'O']M:9_P _T'_?=']M:9_S_0?]]UX/_P *Z\6_\\I?^^VH_P"%=>+?
M^>4O_?;4 >W37.A7%PMQ)<V[2+T8M5E=8TM5P+V  ?[5>$?\*Z\6_P#/*7_O
MMJ/^%=>+?^>4O_?;4 >\?VUIG_/]!_WW1_;6F?\ /]!_WW7@_P#PKKQ;_P \
MI?\ OMJ/^%=>+?\ GE+_ -]M0![Q_;6F?\_T'_?=']M:9_S_ $'_ 'W7@_\
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MW6O_ #WC_.OG[[%\1O\ GS'_ 'T?\*/L7Q&_Y\Q_WT?\* /H'[=:_P#/>/\
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M^V(=BXYY- 'H]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,,,9.2HI/(C_ +@J
M2B@"/R(O[@H\B+^X*DHH C\B+^X*/(B_N"I** (_(C_N"CR(O[@J2B@"/R(O
M[@H\B+^X*DHH C\B+^X*/(B_N"I** (_(B_N"CR(O[@J2B@"/R(O[@H\B+^X
M*DHH 15"C &!2T44 %%%% #&B1CDJ":3R(O[@J2B@"/R(O[@H\B+^X*DHH C
M\B+^X*/(B_N"I** (_(B_N"CR(O[@J2B@"/R(O[@H\B+^X*DHH C\B+^X*/(
MB_N"I** (_(B_N"CR(O[@J2B@"/R(O[@H\B+^X*DHH C\B+^X*/(B_N"I**
M(_(B_N"CR(O[@J2B@"/R(O[@H\B+^X*DHH C\B+^X*/(B_N"I** &+&B'Y5Q
M3Z** "F-&CG++FGT4 1^1%_<%'D1?W!4E% $?D1?W!1Y$7]P5)10!'Y$7]P4
M>1%_<%244 1^1%_<%'D1?W!4E% $?D1?W!1Y$7]P5)10!'Y$7]P4>1%_<%24
M4 1^1%_<%'D1?W!4E% $?D1?W!1Y$7]P5)10!'Y$7]P4>1%_<%244 1^1%_<
M%'D1?W!4E% $?D1?W!1Y$7]P5)10!'Y$7]P4>1%_<%244 1^1%_<%.6-5^Z,
M4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"A/J*PN5(Z5%_;"_W:S=
M2'[]OK5)>G- &]_;"_W:4:PA_A%<\U P.E '0_VPO]VC^UU_NUSP)SS3FZYH
M WSJZC^&JT_B)(1DI61G-9FI E30!T<7BN.5L>6*F;Q)&O\  *\ZMW*3MSWJ
M]+)N&<T =K_PDT?]P4'Q-$/X!^=<&;@CC-0/>!3\QH ]"_X2>+'W!4,WB^&)
M<E!^=<!)J"A>&KG]8U<) WS_ *T >IQ^/K:278$7KCK6O%XABE3<%%?-NF:T
M6U'!?^+UKU72[G?;*<T =Y+XCCB&2HJA+XUAC./+'YUREY*2IYKGI][OB@#T
MR/QK#)_RS'YT\^,80<>6/SKSNVM'*YYJY':#JV: .W/C%.T.:<OB]"/]3BN+
M*(@^E5Y)@.AH [L^,8A_RR%.3Q<C\"&O.T)E?O6S9V^ ": .V7Q"A&=@%.&O
MI_<%<FP*]*02<]: .P&MH?X:#K2#^&N90DBG,3CF@#H#X@0?P"E&OQG^$5R4
M[A>],A?)SF@#M/[90C[M+_;"_P!RN81R14P8[: .@.M*/X:8=>3^X*Y_)[U#
M(O&10!TI\01@<H*$U]'. HKC+F4J<9J2Q8D@T =K_:ZXSMI/[87^[6$.5HP,
M<4 ;G]M+_=I1K"'^&N<!.[!IV<&@#HO[87/W*7^UU_NUSRGO3B2>E &__:R_
MW::=80?PUA9.*B<DT =%_;*?W:=_:RXSMKEQNW5;3[HH WQJBD?=I#JRC^&L
M7G%1D]J -T:LI_AI1JJ_W:P5IX/- &Y_:B_W:/[47^[6&3S1T% &Y_:J_P!V
MC^U4_NBL(4ASF@#>_M1?[M']J+_=K$4\4X]* -K^TU_NTG]J+_=K%R<TAH W
M!J:_W:/[37^[6$23TIRY'6@#:_M1?[M+_:B_W:Q>M)@B@#;_ +37^[2?VHO]
MVL8$]#2XH V1J:_W:/[37^[6,.*4F@#7_M1?[M']J+_=K$YS0<\4 ;8U13_#
M2_VFO]VL3I2X- &W_::^E)_::Y^[6-T%,4G- &[_ &FO]VD_M-?[M8K4"@#;
M_M)?[M(=34#[M8YZ4A)Q0!L#55_NT'5%'\-8GO1UH W!JBG^&C^TU_NUB#K3
MZ -?^U%_NT'5%'\-8]-/- &T-44C[M.&I+_=K$48XIV"* -@ZFH_AIO]JKG&
MT5D$$U#@[J .@_M)?[M)_::_W:QN:0F@#:_M-?[M!U-1_#6)DTO- &R=54?P
MT#55/\-8A'%(N10!O'4EQ]VD_M-?[M8X.:,$"@#9.IJ/X:3^TU_NUB')-.P<
M4 ;/]IK_ ':7^TU_NUB@<<T4 ;/]I*?X:7^TU_NUB#.:"3F@#9_M1<_=IW]I
MJ?X:P6SFG*U &Y_:2_W:0ZFH_AK('2F$ECS0!M#4U_NT?VFO]VL;MQ2 &@#9
M_M1?[M+_ &FO]VL4YS1NH V3JB_W:7^TU_NUBYYI2: -K^TE_NT?VFO]VL13
MFDR<T ;G]I+C[M-_M11_#6/NJ%VS0!O#5%/\-+_::_W:PD-24 ;7]IK_ ':3
M^TU_NUC4$\4 ;/\ ::_W:3^U%S]VL;)Q30>: -T:DI_AH_M)<=*Q:4T ;/\
M::_W:0:FI_AK&SD4B\4 ;7]IK_=H_M-?[M8P.:7O0!L?VFO]VE_M)<=*Q:,T
M ;']J+G[M._M)3_#6*13E.!0!L?VDO\ =H_M)?2L<DFD.<4 ;)U)1_#2?VFN
M/NUC9]:,^E &S_::_P!VE_M%?[M8JBGYH U_[17^[0=17^[6/GF@L<T ;/\
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ME:CQB@ (QWIJ_>IK,<T]1F@!Y;% YH9>*0?+0 $X-.IO!HP: %-)3@,4N!0
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M7,=I&2Q'2N3U3QE#;,0'7(J/QAJ+P6S%2<D5XO>WLUQ,Q=L\T >B7'Q"8N0
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MU5\E:WK<;5Q4"1+NZ5;1,4 //2J\Z\9JP1Q4,GS<4 5E..U.^E2+&/2I%B%
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MN: , ^%K0#[J\^U-7PQ:@YV+^5="RMMIL:N3S0!F6^@6L)RJ+GZ5N6L*QJ%
MIJ1DFK**5- $^.*,<4W).*7M0 AZT XI.<TI% $UMS<+]:Z =*P+5?WZ_6M\
M=* %HHHH **** "BBB@ HHHH **** "LKQ'9/J&B7%M&6#.N 5/-:M% 'C<'
MA+4]-M92D<A(0Y;/)XK&\ V=_P#VS(0'VB4[N?>O>W4/&R'HP(-96FZ!:Z;(
M[PQA2[%C0!Q'COQT=$MEM+<AIF;8X[@'BL_PG_8%JPO;S4-\S'?A^<9KLM8\
M#Z=J]VUQ/ K,QSDU6'P]TX# @7B@#IXK^VN=.>>U<-'L)!'TKRFT!USQS;W;
M$D0N5_6O5+#2XK&P^RHH";2N*J:=X;L]/G::*(*Q8MF@#: "C &!39/N&GTA
M&1B@#Y]F\,1Z_P"/M75I75D!90IZGFNF\":G+X;O?[%O!L:5R5W=2,__ %Z]
M"M?#=G:ZK-?I$!++]X^M-O?"]C=ZI'?F$>?&,*WI0!Y;XEOK>V\4F65PJ>:.
M?QKT=/'&@PV41:^4809_*F:GX'T_4VWSP*S9SDU5'PZTMAMDME*^E '$0//X
MI\57$D2;K:)M\;#OBD\47IU#Q5::5=RM;1M'@NAP1C KU?2?#VG:.FVT@$9(
MP<5G:UX-L=4NQ=^2OVA1A6/:@#QWQ7H>F:8;,VVJS7+^8,AV)QS]:]A\#,&T
M,8.>E5AX!TV55-S KNO(/O71Z9IT6FVWDQ*%7T% %ZBBB@#B=:EVW3CWK*(,
M@S6CJX#WL@/8U2"X&!0 U!M%)S(<"EYW8JY;Q*!DB@"FT!Q2I V.<UI;%)Z4
M[8O3% %)+<"K A4#-2%:#UH C:,%37/ZKIRW*LN.M=$_W:SYV&[!H \IU;P4
M9)2Z*>363_P@\N/N-7K\K1GKBH280.WYT >3-X)<#D-4#>"Y.P:O5I6B()X_
M.J33Q)Z4 >9GP9*O)5JB?PT8SR#7H=U?Q[2!6.S&8T 2^$]+%O*"!WKU6V)\
MH5P>B(4D'UKOK49B% $=TH,9S7,7*0_:,$#\JZNZCS$V/2N-U%62X)% &Q;V
ML1C'RCIZ4XV,6[.Q?RJM8W#>4,]A4DU^$.* +(M8]OW1^5-^R1=P/RJ"._#\
M<TLMP57(H )(8AT4?E5)U4/T%*;DL>AJ-]S'- &Q8/D  5JXR*R=.7 Z5K@X
MH S[U<*:H0$!JTKP%EK.B3]YTH T4D  J4.K"L^3<!Q4EKO9L&@"T[U'YH7O
M3YT.WBJ8C<F@":5]W2B ?,*9Y; <U8ME^;F@#1C' S2OSP*!T%.QQ0! 1BG"
MGLO>E &*  "G T#IS02.@H :>M+VIP ')I&([4 (2 *<K#%1XYYIX6@!V:8X
MS4H Q33UH 8OI3\4@'-+WH 1ADTX#Y:<P^7BFJ: &\XIIZU-CFF$#- "I3C3
M0*=CB@!N>:3!S0!SS3B: '8R*::>N*0XH 4$8HXI.* : $Q2[>] I=W:@ XI
M"*"#VI#D"@!I&*:"<T_(--(YXH ?D"DZ\T;>*4>E #2>:-U.9:C(.: %%/6F
MXQ3EH >>%J(U)G/%1L.: $SBDW9I'Z4@H ?2[\4T T%30 OF<TH8,:A9232J
M""* +&WBE%,W4\&@!KU!T-2OG&:AY- #PW-+O%0D-2!30!+Y@S1FHBAZTGS4
M 39S0@&:BR:D7K0!8'2FLU.& M,;IF@!F!US1FD!!--(^;B@"4-QS3@1VJ(@
MXI0"!F@!S<TA(QBF\D]:3^*@ V\U97A:A[5(C9%  S<5&N,T]A30 #F@!QXH
MS2%J:&&: ).HH Q29':@MB@ 84SFG9XH!&* $%/ S30.:=T- #9!Q5,Q@G-7
M)6^6JV: %48IX'-,!J7J* $II!IX('6EXH KGDX(I8U -/<9Z4L8YH L1GBF
M3*".:D48%1R\B@"AY:[ZLH@"]*BV@-FI 2: )0 :"@':FJW-2$\4 1X]J78#
MS3ABER* *KP_-FK4.0F*A;.ZIXZ 'CGK5:XC#\59Z5#*>: **VB[LU?C@ 6H
ME/-6%; H 3: <4XQKBCKS2@T 1^4*58P.U2TF0* $  I:8QYXIRYQS0 X4'K
M2@\T'&: $X%'6DZFG=!0!+;$_:$^M= .E<_:_P"O7ZUT Z4 +1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '$:K&3>R$>M450XK?U&!C.Q"$Y/I5);9A_RS/Y4 4(X26Z5<5,+B
MI! X;[C?E3C')G[C?E0 P#%*<5)Y3X^XWY4QHI,_<;\J $[4PBGB.3/W&_*I
M3 ^W.P_E0!5/2L34Y#&Q(K=>&7LC?E6;?V$LJG]VQ_"@#B;[63$2,UCGQ%)O
MQD5T=]X;GF;(B;\JSO\ A$)]_P#J6_*@#+FUN4KD51.K2L>372-X4G QY+?]
M\U'_ ,(I-_SP;_OF@#GEN&D;K6K9Q;V&:OQ^&)XVSY#_ /?-:,6CSQKQ _\
MWS0!9TN)5<5U]N<1C%<[I]E.'&8G_*NDBMY0GW&_*@!DC':16%>68FD)KHGA
M?'^K;\JJR0/VB;\J ,F.U\M,54GL6D;(S70"VD(_U;?E2?9Y,_ZIORH QK;3
M]O7-320 ';6J+:4?\LV_*FM9R$Y,;?E0!D"T&:5K8"M0VLG_ #R;\JC^S2[O
M]6WY4 .M4"+5O@BF0P2*.8V_*IA#)U\MORH @E *D&JL<*[^*ORPR%>(V_*H
MH8)<\QM^5 $;P@BI88E45*T$G_/-ORI1%(/^6;?E0 UT!%1"''.*M>5(!]QO
MRIOER_\ /-ORH JE!FGQJ ]2&&7_ )YM^5/2"3KL;\J )%Y%.X%*L4@_@;\J
M?Y3X^X?RH AS0 <TI1\_ZMORIP23^XWY4 )TI.,U($<_P-^5+Y3?W&_*@!AY
M%, J7RY/[C?E1Y;_ -QORH C*U(G2CRY,_<;\J<(I/[I_*@!*,8YI_EOC[A_
M*D,;G^ _E0 W(HQFG"%_[A_*E"/G[A_*@!!P,&D. :>4?'W#^5,$4F3\I_*@
M SD5&0<U)Y<@_@/Y4OEO_</Y4 ,%/R*#&_9#^5*(7_NG\J &GK2=3Q3S&^?N
M'\J01OG[A_*@!",48S4C1O\ W#^5,V2?W&_*@  P*3O3@DG]T_E2>6Y/W&_*
M@! >:7 I3$_]T_E2B-_[A_*@!,T$BG>6_P#</Y4UHW[*?RH 9P#2Y%((I,\H
MWY4NQ_[C?E0 M)WIPC?^X?RIQC;'W#^5 $9/:FFG".3=]QORIS1OC[A_*@".
MGK3?+?\ N-^52"-\?</Y4 -/M3&S4OEO_=/Y4AC<_P !_*@"$#UIW I6AD'\
M)_*E6)^Z'\J #M2&G^7)_=/Y4TQO_</Y4 -(XIHXI^R3^XWY4HB<C[A_*@!
M,FGD<4+&_P#</Y4XI)_=/Y4 1&F;:EV/_</Y4QED[(WY4 -'-.VB@))_<;\J
M#')G[C?E0 8%)@4NR3'W&_*D\N0?P-^5 $;KS2H,T_RI#_ WY4Y(W!^XWY4
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M;E]11N7U% #?+3^Z/RH\I/[H_*G;U]133(@ZN* #RD_NC\J/+3^Z/RH\Z/\
MOK^=+O3^\* $\M/[H_*CRT_NC\J=N7U%)YB?WA0 GE)_='Y4>6G]T?E2[T_O
M"EWKZB@!OEI_='Y4>6G]T?E3MR^HHW#U% #?*3^Z/RH\M/[H_*G;AZBC<OJ*
M &^6G]T?E1Y:_P!T?E2[U_O"C>O]X4 'EK_='Y4GEI_='Y4[</6C(]: $\M?
M[H_*CRU]!^5+D>M&1ZT ((U!S@?E3J3(]:6@ HHK/U;58M*LI+B0CY!G![T
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M7(7\O[XUHZ2Y8CF@#NUU64Q]?UK*OM;N%Z']: I\G.:PM1DP3S0!IVFNW+R
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M\I KTR[F6&VD=CC"G^5?.]UXAN;KQ:;E;%[D6LQQB@#6\.1R>#O&TD4I*VP
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M\6RCE_TAONBL7X=Z^USX/-I(3]HB@8G/7[M8/@6VBUO69[F]42-'.RC?Z9H
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MT.]T7+GY:EL]%*C.V@#R[6-&\LG:M8\>D2R/@+7K6LZ/N8_)699Z(?-^YWH
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M /,-2\+K)*2$[T[3_"\2$9CYKT.:T1SG J..V16Q@4 8]MH<:(!MJXFD(O\
M#Q6PB "G[/ESB@#'_LV,#!6HY-)1E^[6YL'<4FT4 <7?:$DN1LK.A\-(LH.R
MN]FA5O2H8[<;NE &?;:6B0;-O45GWF@I(Q^2NM2, =*;)&I[4 <E::+&C9V<
MBMJ'3]J@J*OI"H.<"IP/04 55M%QR.:46Z9QBK-*JYH I/:*>"*S[K3D8$;:
MW&7%12*-O- ''OHR%_NUJ66EK$HPM:(A^?I5I5P!Q0!CWFF+(N2M4H='C#9V
MUT[H".E0A &X% %."Q2-?N\U;CMAZ591>.E2 8[4 5OLR^E#0 C JR>33=N#
MF@#/GM5(R16;+IT;MG;70LH88JLT(S0!EV]@B'A:M2V89<8J]&B@8%2;!0!@
M'2DW9V\U;MK,)VK1*#=TI57!Z4 1K"%'2I1&,9Q4@'M3A]* (#$IZBF26Z%>
ME6F7TIA% &/<:<LF<BJL>DHK9"UT!0$T@C!- %*&S4)MQS5>335WYVUMB+C-
M-9!]: *$%JD8R!5Q8@1TJ15 ZU*H H A"<\TOE=ZE([T<T 0,G'-5Y+5&[5>
M(S4;+0!ASZ8DDF-M/BTY5XQ6KL&[-.">U '/WVCK+D[>:JV^BK&V=M=0T>3S
M3!& >E %.WLE4#(XJVML!T%6$49J15':@"KY SD#F@VZ'J*N!12%.* ,BYL5
M92,<5B7&CH[9VUUK+ZU"\:D]!0!S]GI"J!\M6+K2E=!E>@K:6/ P!3BF1R*
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MX"U"H-29./:@ Z]:"G%+G(I>HP: *SKQ38QBIF6FT /0\8I&'-.7.WI0RG%
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M;1F@'"=*09S0 XXZ4 <\TIH% #=H#$U&PXR:E89IAY- $8'>IN,;1WIG%.'
MH 8R4*,"GMDBE % " $4\ L.:*7J<"@ ''TH;KQ2=&Q2,>>: &D9J,C!J:F$
M9- "C!&*'08R:>HP*C;)ZT 1*BY)Q4BCCCK2*<$T]2<].* %&1UIP S[T=Z=
M0 A%1E1GBINU,QSDT 0,H[4Z,8-*>N*<JXH 1QFHR*LD#;47&,4 (@&:FR&X
M%1J,4]1@\4 .4#I1@ YH'4TI':@ QP:;MI1Z4[ITH 84I53C-*1[TX9V]* &
M8.:AEB4]JL$'(IDIXQB@"FB8;%6T3M4:#+<U97@XQ0 @3@TY4RO-/HH 3:,4
MTKQQUI]% #0N*<!2BG "@! M/6FFE% #B#2CI@TA.2*7O0 Z(#?5T52B^\*N
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 1-"&.<4W[.*GHH @^SCTH^SCTJ>B@"'R%]*/(%
M344 0?9U]*/LX]*GHH K_9E]*/LJ^E6** *WV5?2D^R+UQS5JB@"K]C7TH^R
M#'2K5% %/["OH*:VG(>PJ]10!0&FH.PJ06:CC%6Z* *ALE/:F_8$[BKM% %(
M6"+T%'V%?2KM% %/[$OH*/L*=A5RB@"E]A4]10;!".E7:* *']FI_=%*NGHO
M85>HH I&Q7TIITU">@J_10!0&G(!T%._L]",$5=HH I?8$]*/[/3TJ[10!1_
ML],=*;_9J>@K0HH I"P0#I1]@0C!%7:* */]G1]UH_L]/05>HH H_P!GIZ4#
M3T':KU% %(V"'M3?[.3NHJ_10!G_ -FIZ"G#3D'85>HH HFP4]A3?[-3T%:%
M% %'^SUSP!2FP0]15VB@"C]@7.<4OV%?2KM% %(V"D]!33IJ$]!5^B@"@NG(
MIR *=]@0]15VB@"C_9Z^@I?[/3TJ[10!2^P+Z4OV%?2KE% %+[ GH*3^STST
MJ]10!0.G(3T%']FI_=%7Z* *8L5 P *;_9Z=Q5ZB@"B-/3TI18IZ5=HH I_8
M4]*/L*^E7** *7V%1T%'V!/05=HH I?8$]*!8(.PJ[10!1_L]/04O]GIZ5=H
MH H_V>@XP*7[ OI5VB@"G]A7/2D^PKZ5=HH I&P0CD4G]GICH*O44 4AIZ#M
M2'3T]!5ZB@"C_9ZXQ@4OV!.XJ[10!3^PIZ4?85]*N44 4OL"$8P*/L"=Q5VB
M@"E]@3.<"C[ F<XJ[10!2-BI[4?V>GI5VB@"E]@7TH%B@["KM% %/[$OI1]A
M7TJY10!3^PKZ4AL$]*NT4 4?[/7T%+]A7T%7:* *7V%?04OV%?05<HH I_85
M]*/L*CH*N44 4_L*9SB@V*'J*N44 4_L2XQBD^P+GI5VB@"I]B7TIIL$/85=
MHH H_P!G)Z4HL5'85=HH I_85]!2_8E]*MT4 5!9+Z4?8E/45;HH I?8$STI
M18KW%7** *9LE(Z4GV!,=*NT4 4_L*],4OV) .!5NB@"K]C7TH^R+G.*M44
M5/L:>E+]C7' JU10!4^QKZ4[[*/2K-% %8VJGM339J>HJW10!3%BH/04\6BC
MM5FB@"O]F7TH^S+Z58HH @^SCTH^S+Z5/10!7^S+Z4OV=?2IZ* (?LZ]Q1Y
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MC2/&D5YK=Y:RNJQP]#0!VE)N&<9%8D7BW2)I?+2Z!;/2J<6OVGVR8F;Y5Y-
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MW8+.<*/6@#H*0,#T(-8UYXHTNSD:*6X"R 9Q7,>%?&<=_?ZB)Y (HF^4^W%
M'H-%9$/B73)WV1W +5>N+^WM;8W$K[8P,D^U %FBN?B\9:+,,I=@BII_%.DV
M[1K)<@&3[OO0!M45A2>+='B;:UT WI6?J7C>PACS;S*_'- '6T=.M<YI_BNR
MDTA+VYF"*QZU*WB73;JRF>"X#;1S0!N@@]#FEKE[/Q1IMO8+-<7(53W-7K/Q
M3I5[(L<%R&9C@"@#:I"RKU('UI:X[QAK,^GSPP1CY)!\Q]* .P#*PR""/4&@
M$'H0:\[B\5S6EG'&F&!;&37;:7N:V65LY<9H O$@=2!2UD>(+Z.PLTDD?:"V
M,U6;Q=I%M%&)KH*2* .@I"P!P2*R%\3Z4UN)A<C8>AKF-6\;6W]M6UM:2AU?
MK0!WP92< C-+7)6'B&U&IRI--@J,D5H1^+M'EN! MT#(3@"@#=HK"G\6Z1;S
MF&2Z <=16)JGCRV@U."WMI%:-QR: .XHK"7Q1IT5HDLTX7-3P^(],GM7N([@
M&-.IH UJ*Q(?%>DSN$CN023@5JS7,4%OY\C8CQG- $U%8#^,=&CD"-= $G J
M:[\4Z59.B37(5G&5'M0!LT5SH\:Z&6*B[&1UK.U7QU9Q0-)9S*ZCJ: .SHK.
MT34/[2TN&YX^<9XJ[-,D$9DD.%'4T 24C.J_>8#ZFL-_%VCQS>4UT V<8KE_
M$GBU5U^'3H9!Y<J9R.O;_&@#T3<N,[ACZT;AC.1BN>GGFBT..:'+;5R236!)
MXLN)?"=W=0@-<1OM5?SH ] R,9R*;YT0ZR*/QKS_ $'QG+>:?(DX43*AX]ZS
MI+_5)M)GU#804<@8/'>@#U$31DX$B_G3Z\Z\.-J-^Z22!L=3S7>7-W#8VGG7
M#[44<F@"S16$/%VCYQ]J%-D\8Z-$<-= &@#>+ =2!]: P/0BN4USQ'9K!!)#
M/G?T]ZS['Q8([U?M3!(>[4 =Y165)XATZ*%97G 1AD&H[;Q/I=U,(HK@,Y[4
M ;/2D!!Z'-<OJOC'3((9HX[@&9!T]ZG\':I)JNCFXEZ[L4 =#N!. 12URT&O
M6D5[="2; C/S>U3Q^-=$E^Y=@XH Z*BN&M?'<-QJ+P[U\L-@&MV?Q9I%NX26
MY"MZ4 ;E%5[:\@NXA)"^Y2,YK/O?$^EV%S]GN+@+)Z4 ;%%9/_"2:9Y7F?:!
MMQG-16OBK2;NX\B&Y#2=<4 ;=%8$GC+18Y'1KL H<-[4P>-M"*[A>#;0!T5(
M2!U.*Q)_%NCVZQM)= !_N^]9>O>+;4:6);&4.Y;&* .PR#THKFK3Q-:6]G$]
M[,(V=<BM.QUVPU&3R[>8.WI0!I4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %,D;:A.,T^CK0!YE-]@O]1O$MX1;3H>7?C<:Q
M;DWV#8W$AN(R<Y7D5Z%J/@RRU"8RM))&Q.3LXJS8^%[.QMO)4E_]IADT <#+
M)86%K# +?+RC:2.WUKGY=/:SUL2PL"N/X:]4;P58L\C%W._]*;#X'L(3GS'8
M^] ' >%-)@NX=:FN(=TBJ2I([\4FEQR?V44N%)MM_P!TBO4+'P[:6$<Z1$XF
M&&XIC^&;-M.-EDA"<Y YH \V\0PV%JVFRVD X.7"\^M0:U;Q:K!]HB7RV_NG
MK7H<7@BPC8$R.V.F[FEF\$6$T_FF1Q[#I0!Y%-;27.K:5!,I>-7 /'UKM[C3
M+:V\4?9I(L6.S.T],UU2>#K!)XI026C.1Q5[5-!MM5BV2$H?[R]: . TVWM8
MM<'V2(*OF<XK=\?^9_9/(+)N' %:^F^$[/39-\;NQSGYJU-0TZ'4K;R)ON_2
M@#SS48M)M]!A$5J&GDCY*\D&JVF7BVGAI(I.'W?=/6NUMO!UE;.6$COD]&Y
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M* "BBB@ HHHH **** "BBB@ HZT44  &.E%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2  444 +1110 4444 %%%% !1110 4444 %%%% !1110
@4444 )@4M%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gtinntqqusay000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ),!68# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HZ=:*Y+Q
M;X@O--'D6<'FR..!0!T2ZC;O=-;JZEUZ@&K61C).!7A_@>^U*Z\>7;7WF1L5
MYC)X'6O6?$,US!X?FDM$+S!?E4=Z );O7;.S;:[J3G& PJ>SU.VO5S%(OTW"
MO--#\&7NL,U_?W,T+RKS&6.!6?):S>%?&EE9Q7<DR2G)#-0![/145O(985<C
M!-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4AZ4M% 'G'C3PI?ZS;S22,K(@)45S?@CP->V=NMW
M; 1S!NI%>U,JLI5@"#U!IL<4<2[8T51Z 4 <CXFT+4]4T^WA21=H7$P/>O/+
M3X<R6^MC['&$<<Y(KW3&1S3!#&'W!%#>N* .=FTK47T9;,2+GR]IKR>;X=32
M>)V2XC#'KD#BO?:C,$1D\PQKO]<<T <?HVA:Q::1<VLDJX9-L(]*\]U3X=SS
MZ@9+U!).3]X"O=J8T,3G+(I/J10!R/@G0M0T>V9+EU,9'R =A78T@  P!@4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %->-9%PPR*=1
M0!AS^&K*:\%P8OF'>M&VT^"U0K&F,C!JW10!CZIX?L]2LVMY8\JW459L]*MK
M.VCA1,",8%7Z* *%]I-M>C]XF35:R\/6=G(76/!-;%% %=[*!WW%><8K(TOP
MM8:9?75S%%M:<Y8^M;]% #(HDA7:@P*?110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%36O@7P_9W"SP6061>AKI** &HBQH%48 IU%% &/XD_Y UQ_US;^5>._"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*PLO (KT*LCP]:V5EID=O9OOC7H<5KT %%%% !1110 4444 %%%% &/XD_Y
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MBBB@ ZBLT:/;#5?M_ECSL8W5I44 %%%% !1110 4444 %%%% !1110!4U/\
MY!T_^[7$^%_^1@;_ ':[;4_^0=/_ +M<3X7_ .1@;_=H ]!HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CG_
M -1)_NFI*CG_ -1)_NF@#@K+_D:8OJ?YUZ#7GUE_R-,7U/\ .O0: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKC_CW?Z5+45Q_Q[O]
M* //=._Y* OT_K7H]><:=_R4!?I_6O1Z "BBB@ HHHH **** "BBB@ HHHH
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M!KC_ *YM_*O'?A/_ ,A2Y_Z^'_\ 0C0![U1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ->1(QEV"CWKA/'LD<\2XE4Q!?F&>#70>)
M[:_N=.V:>N9<UYS?^'O%%W$UO+"-K\=30!U'@ZR\/RZ#"?+@W_6NA_LS0O\
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MG'A#_D8]5_ZZ_P"%>CCI0 4444 %%%% !1110 4444 5-3_Y!T_^[7$^%_\
MD8&_W:[;4_\ D'3_ .[7$^%_^1@;_=H ]!HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@"IJ?_(.G_W:XGPO_P C W^[7;:G_P @Z?\ W:XGPO\
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M:PB*% B#H!4M%% !1110 4444 %%%% !1110!C^)/^0-<?\ 7-OY5X[\)_\
MD*7/_7P__H1KV+Q)_P @:X_ZYM_*O'?A/_R%+G_KX?\ ]"- 'O5%%% !1110
M 4444 %%%% !1110 4444 %9/B36!H6C2WQ3?L[5K5R'Q+_Y$N[_ ,]C0!P,
MWQU2*5D^P=/?_P"O3/\ A?"?] _]?_KUX5>9^UR?6H* />V^.Z%2/L Y]_\
MZ]<__P +77_A(X]3^R?=&-N?_KUY)10![Y_POA/^@?\ K_\ 7H_X7PG_ $#_
M -?_ *]>!T4 ?0-M\<TGN(XOL&-QQU_^O7JV@:M_;.G+<A-F>U?&6F_\A*W_
M -\5];_#_P#Y%Q/PH ZNBBB@ HHHH *1_N-]*6D?[C?2@#SGPA_R,>J_]=?\
M*]''2O./"'_(QZK_ -=?\*]''2@ HHHH **** "BBB@ HHHH J:G_P @Z?\
MW:XGPO\ \C W^[7;:G_R#I_]VN)\+_\ (P-_NT >@T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q'Q1_Y$N]_W?Z&O
MDQ_O5]9_%'_D2[W_ '?Z&ODQ_O4 -HHHH **** "K>E_\A2U_P"N@_G52K>E
M_P#(4M?^N@_G0!]@^$/^0)'_ +J_RKH*Y_PA_P @6/\ W5_E704 %%%(2!U(
M% "T4WS$_OK^='F)_?7\Z!V8/]VN \'?\C;JW^]_2N]>1-OWU_.N!\',H\6:
ML2P^]Z^U 69Z%13?,3^^OYT>8G]]?SH"S'44W>G]Y?SIU @HHHH **** "HK
MC_CW?Z5+45Q_Q[O]* //=._Y* OT_K7H]><:=_R4!?I_6O1Z "BBB@ HHHH
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M*LX4_NH!7DOPPT>XBU9KJY7ED_QKV <#% 'EGC'_ )#*_P#75?YUZ39MLTV
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M@;Z4 >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Q'Q1_Y$N]_P!W^AKY,?[U?6?Q1_Y$N]_W?Z&ODQ_O4 -HHHH
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MH \]T[_DH"_3^M>CUYQIW_)0%^G]:]'H **** "BBB@ HHHH **** "BBB@
MHQ110 F!1@4M% "8%&!2T4 )@4N*** "BBB@ I&4,N&&0>U+10!6CL+2&8S1
MP(LAZL!S4TD:2H4D4,IZ@T^B@""&SM[;_4PJGT%3T44 026=M*VZ2%6/J14P
M 4  8 Z4M% !4<T$4Z%)4#J>H-244 9W]@Z4#G[##D>U6_LL'E>5Y2^6?X>U
M344 9_\ 86E[MWV*+/KBI4TRRBD$B6T:L.A Z5;HH @6RMEE:585$C?>;')I
M%L;56W+ @;UQ5BB@"".TMXI6ECB59&ZL!R:62TMYI!))$K..A-344 1/;PR1
M['C4KZ&J?]@Z5G/V&'/TK1HH 9%#' @2) JCH!3Z** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "L/Q'K4VD6;R00&9PN0H[UHZA?)86
MQFD!*CTKR;Q-\5-.DN###',"AP<J?\* &#6O$?B>39]BGM$;^(5J6/PP:1A<
M7VH-+GDJ_P#^JJNB_%W1K73DCFAG,@ZD*?\ "I-7^,.FW&G316,5P+AE^0E3
MU_*@#3UKP/;)I8_L_:LBG.4'-7_AZ-02WN8KY)!L;"%^XIWP^OK_ %708+F^
M)+,.<CVKLU0)T% '%?$Z/S-!A!.,2@_J*L^#KRT73UC\]2VT#%:WB+1UUK3_
M +.RYP<BO.;CP3XGL79M*D1.>,__ *Z /70589'(HP*\CM]3\9Z.<:G<JR+U
MQG_&M.W^*^FVS"*]+F3IQ0!Z516;I&M6VLVB7%MG8W3-:5 !1110 5SWC*\A
MM?#UR9%5_E^Z>]=#7&_$&QFN="N)(QG"T >?Z%I&J:C"]W;R2P0.AVHIXZ5=
M\'RMI>NK9W\>9I)#M9^O6M;P?XSL-.\/16-PD@FB4[N/:LA+C_A)_'-G?V:,
M(83AMPH [SQMJ]YI6F)-96[3N3T6O+6^(?B8.0-&GZ^W^->ZRVL<\0249 JK
M_8EE_P \Z /!]0\>^([BTDCETB95*D$G'^-6O@Z[274CL,,TQ)'XUZQXAT>S
M32+AECY$;?RKROX3 +J=P!VN&_\ 0C0![W1110 4444 %%%% !1110 4444
M%%%% !7(?$K_ )$N[_SV-=?7(?$K_D2[O_/8T ?)-Y_Q]R?6H*GO/^/N3ZU!
M0 4444 %%%% %K3?^0E;_P"^*^M_A_\ \BXGX5\D:;_R$K?_ 'Q7UO\ #_\
MY%Q/PH ZNBBB@#F?&/\ R#6_W:\/<G>WUKW#QE_R#6_W:\.?[[?6O/Q7Q'V&
M0?P&)DTN3ZTE%<I[P4N3244 +DU-:D_:%Y[BH*GM?^/A?J*:W)E\+/H+1?\
MD#VO_7,5?JAHO_('M?\ KF*OU[$=D?F]7^)+U84444S,**** *FI_P#(.G_W
M:XKPO_R,#?2NUU/_ )!T_P#NUQ7A?_D8&^E 'H%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <1\4?^1+O?]W^AKY,?
M[U?6?Q1_Y$N]_P!W^AKY,?[U #:*** "BBB@ JWI?_(4M?\ KH/YU4JWI?\
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M;0?#EZAN2UO&N,EMM=7KFB6VMV@M[E-ZALXKF?$&FZ5I6EM%<6[-#LP0H[4
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M4"M*B@ HHHH Q_$G_(&N/^N;?RKQWX3_ /(4N?\ KX?_ -"->Q>)/^0-<?\
M7-OY5X[\)_\ D*7/_7P__H1H ]ZHHHH **** "BBB@ HHHH **** "BBB@ K
MD/B5_P B7=_Y[&NOKD/B5_R)=W_GL: /DF\_X^Y/K4%3WG_'W)]:@H ****
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M:KXJ-RA^Q:-#<D]"%%<D^B:_KDV?[.DLU)X*<5[A8^&=+TX 6T&W'2M95"C
MZ"@#E_!6CW&DZ1##<2N[J.=YKJ:** "BBB@ HHHH **** "BBB@#'\2?\@:X
M_P"N;?RKQWX3_P#(4N?^OA__ $(U[%XD_P"0-<?]<V_E7COPG_Y"ES_U\/\
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M;_=H ]!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#B/BC_ ,B7>_[O]#7R8_WJ^L_BC_R)=[_N_P!#7R8_WJ &T444
M %%%% !5O3/^0I:_]=!_.JE6],_Y"EK_ -=!_.@#[!\(?\@6/_=7^5=!7/\
MA#_D"Q_[J_RKH* "N.\??\@]*[&N.\??\@]*SJ_ SLR__>8GC+_?;ZTE*_WV
M^M)7DGZ$@HHHH **** +NE_\?JU[[HW_ "";?_=KP+2_^/U:]]T;_D$V_P#N
MUVX3J?,<0[1+U%%%=I\P%%%% !45Q_Q[O]*EJ*X_X]W^E 'GNG?\E 7Z?UKT
M>O.-._Y* OT_K7H] !1110 4444 %%%% !1110 4444 -D_U3_[IKY9^*_\
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MJ#>&K,S^8J(N3D@#K6U10!E1Z#:12,\<:*S#!(6K%IIEM:*PCC0;CDX%7:*
M*,.EV\%XURB*KMU(%7J** *M[I]O?1[)HU8=LC-9D/A>TBEWD*P!Z$5NT4 5
M9=/MIK<0M"A0= 1P*S8O#-I'+OPI7/W<<5N44 9UOH]K:S/)%$BEQ@X&*?!I
M=O;L2B*,G/ J]10!1CTNWCFDE5%#2#!.*=8Z=!8*RPHJACDX%7** *4FF023
M>:R*6SG.*DNK"WNX?+EC5N,<BK-% &%'X7LTEW%5(!X4C@5M10QPIMC0*/0"
MGT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (R*XPR@C
MT-<CXML=+M[*2X>"%9%7(&P<UU]<-X_C8QJ[*6A5?G % %/P1.-3B42:7;_9
M\9$GECFD\5:A/H=]"T&CV[6O61S&.!^5;'@B^TT>'X!%)'%_LLX!J3QE>:>_
MAZZ5Y8I&*< .": -'PUJMOJVDQ7$ 15;H%&!6S7G_P ,D8:) RJ5BQPI'M7H
M% !5+5-1BTRRDN)6"A!GFKM<-\0G?[&T?/E,OS4 <_>_$'Q#=3L-(T];B#^%
MQWIEKX_\36DR_P!IZ8L,.?F8]A75^ K2PC\-V[1[ _?YAZ"K?B^TL)="N3-L
M+!>,L* -71M5AU?3X[J)@ROZ5HUY_P##MV6V2%/]0%^4=J] H **** "D) &
M32USGC/4WT[P_<R0MME"_*10!/>^+-'L)C%<7:HX."#5S3]:L=43?:3"0>U>
M;>'="LM:TU=1U:6%Y)5/WG .:OZ)H-WIFM1_8[J/[(6RRHP- 'I5%)G'4T;E
M_O"@#(\2?\@:X_ZYM_*O'?A/_P A2Y_Z^'_]"->P^)&7^Q[CD?ZMOY5X]\)_
M^0I<_P#7P_\ Z$: />J*** "BBB@ HHHH **** "BBB@ HHHH *Y#XE?\B7=
M_P">QKKZY#XE?\B7=_Y[&@#Y)O/^/N3ZU!4]Y_Q]R?6H* "BBB@ HHHH M:;
M_P A*W_WQ7UO\/\ _D7$_"ODC3?^0E;_ .^*^M_A_P#\BXGX4 =71110!S/C
M+_D&M_NUX<_WV^M>X^,O^0:W^[7AS_?;ZUY^*^(^PR#^ Q****Y3W@HHHH *
MGM?^/A?J*@J>U_X^%^HIK<F?PL^@M%_Y ]K_ -<Q5^J&B_\ ('M?^N8J_7L1
MV1^;U?XDO5A1113,PHHHH J:G_R#I_\ =KB?"_\ R,#?[M=MJ?\ R#I_]VN)
M\+_\C W^[0!Z#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '$?%'_D2[W_=_H:^3'^]7UG\4?\ D2[W_=_H:^3'^]0
MVBBB@ HHHH *MZ7_ ,A2U_ZZ#^=5*MZ9_P A2U_ZZ#^= 'V#X0_Y D?^ZO\
M*N@KG_"'_(%C_P!U?Y5T% !7'>/O^0>E=C7'>/O^0>E9U?@9V9?_ +S$\9?[
M[?6DI7^^WUI*\D_0D%%%% !1110!=TO_ (_5KWW1O^03;_[M>!:7_P ?JU[[
MHW_()M_]VNW"=3YCB':)>HHHKM/F HHHH *BN/\ CW?Z5+45Q_Q[O]* //=.
M_P"2@+]/ZUZ/7G&G?\E 7Z?UKT>@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ JEJFFQ:G8RVTO1QC/I5J6:.%-TCJB^K'%<SJ_CBPTM21B8CLAS0
M!Q=[\-9[*=FLKFX*]@'(%9;^%[>UF675]0N(U0\@N2#^M+KWQ(U"_!_L^&XM
MPQP"R'%,\/\ A77_ !.6GO[X20YR5;TH ]4\*2Z<=)B33I!)"/NL!6_61H&A
MPZ)I\=K$H 7TK7H *Q/$FGV^HZ9-!,VW>N,CK5[4WDCM&:+.X GBO%_$GC'5
M1+)&L5P-I(SL- %R"P\2^'CY>CVSW-N.%+$T7,'BK71Y>JVC6\!X9E/:J^C^
M-]5BTV-6@N6([A#4U]XPU>^LY+>.&Y5G& 2AH ](\(Z=:Z9I$-M ^\J.IZUT
M=<9X"M+^/2X9;QR6(Y!'-=G0 4444 %>>_$Z>6'3)6C&<+TKT*N4\>:6VH>'
MKD1C,FWB@#@?#'@V;7_#\5S-<3P@J2 CD#.*GT*[NO#/B:#2)"SK,W#2')_6
MM+P?XH72-$32[F"3S(4.6((SQ69;^;XE\:VFHQPND<+$'<M '=^,]8O]*TQ)
MM/A$LA/(->7M\1?%X<@::G7_ #VKW">SANH@DR;E%4O^$=TP_P#+L* /$-1\
M?>*KBSDCET]%4J03_D5+\'7:2[D=QAFF)(]\UZKXAT'3H])N&6W (C;^5>7?
M"4!=2N .@N&_]"- 'O=%%% !1110 4444 %%%% !1110 4444 %<A\2O^1+N
M_P#/8UU]<A\2O^1+N_\ /8T ?)-Y_P ?<GUJ"I[S_C[D^M04 %%%% !1110!
M:TW_ )"5O_OBOK?X?_\ (N)^%?)&F_\ (2M_]\5];_#_ /Y%Q/PH ZNBBB@#
MF?&7_(-;_=KPY_OM]:]Q\9?\@UO]VO#G^^WUKS\5\1]AD'\!B4445RGO!111
M0 5/:_\ 'POU%05/:_\ 'POU%-;DS^%GT%HO_('M?^N8J_5#1?\ D#VO_7,5
M?KV([(_-ZO\ $EZL****9F%%%% %34_^0=/_ +M<3X7_ .1@;_=KMM3_ .0=
M/_NUQ/A?_D8&_P!V@#T&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** .(^*/_(EWO^[_ $-?)C_>KZS^*/\ R)=[_N_T
M-?)C_>H ;1110 4444 %6],_Y"EK_P!=!_.JE6],_P"0I:_]=!_.@#[!\(?\
M@6/_ '5_E705S_A#_D"Q_P"ZO\JZ"@ KCO'W_(/2NQKCO'W_ "#TK.K\#.S+
M_P#>8GC+_?;ZTE*_WV^M)7DGZ$@HHHH **** +NE_P#'ZM>^Z-_R";?_ ':\
M"TO_ (_5KWW1O^03;_[M=N$ZGS'$.T2]1117:?,!1110 5%<?\>[_2I:BN/^
M/=_I0!Y[IW_)0%^G]:]'KSC3O^2@+]/ZUZ/0 4444 %%%% !1110 4444 %%
M%% !115674+:$X>5%/NU%QJ+EL6J*H?VO9_\]X_^^A1_:]G_ ,]X_P#OH4N9
M%^RGV+]%4/[7L_\ GO'_ -]"C^U[/_GO'_WT*.9![*?8OT50_M>S_P">\?\
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M_P \G_*C[/-_SR?\J\_4^Q]P/M-Q_P ]Y?\ OLT?:;C_ )[R_P#?9H^SS?\
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MI88VD<UV] !1110 4444 %%%% !1110!C^)/^0-<?]<V_E7COPG_ .0I<_\
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MX]W^E2U%<?\ 'N_TH \]T[_DH"_3^M>CUYQIW_)0%^G]:]'H **** "BBB@
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M?S-J^K&N[HH Y'Q'X/AUB-)-\BR(VX;3CFL8^$;S4RMO?"18 -O#'H*]'HH
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MCO'W_(/2NQKCO'W_ "#TK.K\#.S+_P#>8GC+_?;ZTE*_WV^M)7DGZ$@HHHH
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M<GUJ"I[S_C[D^M04 %%%% !1110!:TW_ )"5O_OBOK?X?_\ (N)^%?)&F_\
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MO^[_ $-?)C_>KZS^*/\ R)=[_N_T-?)C_>H ;1110 4444 %6]+_ .0I:_\
M70?SJI5O3/\ D*6O_70?SH ^P?"'_($C_P!U?Y5T%<_X0_Y L?\ NK_*N@H
M*X[Q]_R#TKL:X[Q]_P @]*SJ_ SLR_\ WF)XR_WV^M)2O]]OK25Y)^A(****
M "BBB@"[I?\ Q^K7ONC?\@FW_P!VO M+_P"/U:]]T;_D$V_^[7;A.I\QQ#M$
MO4445VGS 4444 %17'_'N_TJ6HKC_CW?Z4 >>Z=_R4!?I_6O1Z\XT[_DH"_3
M^M>CT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !14-Q=0VJAIY%0$X!8T^.1)5W(P(/<4 /HHHH **JWFH6
MM@@>YF2)2< L<54_X2/2O^?Z'_OJ@#5HJE::K97KE+>XCD8=E-2W%[;6BYGF
M2/\ WC0!8HK('B33"V/MD/UW5HP74%RNZ&57'JIH FHJE=:M969Q/<QQG_:-
M0?\ "0Z7_P _L/\ WU0!J455MM2L[LX@N(Y#Z*:GDE2)-\C!5'<T /HK*D\0
MZ;&VTW<61U^:K5KJ=G>#,%Q')_NF@"W15:[OK:Q0-<3)&#T+&J?_  D>E?\
M/]#_ -]4 :M%9\.MZ?<-MBNXF/H#6@#D9% !144UQ%;IOE<(H[FH;74K.]'^
MCW"28./E- %NBD9@BEF. .IJG%JMC-.(8[F-I#_"#S0!=HJO<7UM:C,\R1^F
MXU7CUO3I7V+=Q%CV#4 :%%,,T:Q^87 3&<U1.NZ8&Q]MA_[ZH T:*C2>*2/S
M$<,F,Y%49=>TV&39)>1*WH6H TJ*S$U_2Y&"B^AR>VZM".5)5W1L&7U% #Z*
M** //OBO9RW/A^/RQG$H)_,5K^"=5M[S28X8V&Z% K?6N@O[&*_MFAE4,"#C
M->1:MX0UG0;U[G3[R9HV8MY<>/\ "@#V;(]17*^/-3@M/#MU$[#>Z?**\V_M
M_P 38\O['=_[V*N:;X0UGQ!>1W%_>3+$IR8GQS^E '2?"N!SH%O<$<,/Z5Z)
M5'2M-BTJQ2UA4*J],5>H *XCQ^,V;#_9KL+N\ALXQ)/(J*3C+5S^N+8ZK:,Q
MNXU0#DYH X>T\%+?>%;>^LE;[5G<<<=,&J4OC&ZT[1[G2M;;9*PVQ =Q7H&C
M:UHNEZ9'9_VC P7OFL+Q5:^&_$$#;;RUCE(X?/(H M_#F19-.B9>A6N^KD/
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MHH **** .(^*/_(EWO\ N_T-?)C_ 'J^L_BC_P B7>_[O]#7R8_WJ &T444
M%%%% !5O3/\ D*6O_70?SJI5O3/^0I:_]=!_.@#[!\(?\@6/_=7^5=!7/^$/
M^0+'_NK_ "KH* "N.\??\@]*[&N.\??\@]*SJ_ SLR__ 'F)XR_WV^M)2O\
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MO2%AB2/8J +C&*K'2;!GWFUC+>N* .#\*^&[JW?4=0G3!NE)%8<<E]HWB 3
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MDGS,<\^U=K7 ?#WSI8$N&5EC9>!VKOZ "BBB@ HHHH **** "BBB@#'\2?\
M(&N/^N;?RKQWX3_\A2Y_Z^'_ /0C7L7B3_D#7'_7-OY5X[\)_P#D*7/_ %\/
M_P"A&@#WJBBB@ HHHH **** "BBB@ HHHH **** "N0^)7_(EW?^>QKKZY#X
ME?\ (EW?^>QH ^2;S_C[D^M05/>?\?<GUJ"@ HHHH **** +6F_\A*W_ -\5
M];_#_P#Y%Q/PKY(TW_D)6_\ OBOK?X?_ /(N)^% '5T444 <SXR_Y!K?[M>'
M/]]OK7N/C+_D&M_NUX<_WV^M>?BOB/L,@_@,2BBBN4]X**** "I[7_CX7ZBH
M*GM?^/A?J*:W)G\+/H+1?^0/:_\ 7,5?JAHO_('M?^N8J_7L1V1^;U?XDO5A
M7#?$S_D76_WJ[FN&^)G_ "+K?[U=&'_BQ.:O_#9X>>M%!ZT5] >*%%%% !11
M10!HZ#_R'+7_ 'Z^C=-_X\UKYRT'_D.6O^_7T;IO_'FM>7F.Z/0P6S+=%%%>
M8=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q'Q1_Y$N]
M_P!W^AKY,?[U?6?Q1_Y$N]_W?Z&ODQ_O4 -HHHH **** "K>E_\ (4M?^N@_
MG52K>F?\A2U_ZZ#^= 'V#X0_Y L?^ZO\JZ"N?\(?\@6/_=7^5=!0 5QWC[_D
M'I78UQWC[_D'I6=7X&=F7_[S$\9?[[?6DI7^^WUI*\D_0D%%%% !1110!=TO
M_C]6O?=&_P"03;_[M>!:7_Q^K7ONC?\ ()M_]VNW"=3YCB':)>HHHKM/F HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG186Z __ *ZV_P"P/'O_ #]1_K_C4?A7X@1:?I<5G)&@"=S71?\ "R;3UCH
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M ,]C0!\DWG_'W)]:@J>\_P"/N3ZU!0 4444 %%%% %K3?^0E;_[XKZW^'_\
MR+B?A7R1IO\ R$K?_?%?6_P__P"1<3\* .KHHHH YGQE_P @UO\ =KPY_OM]
M:]Q\9?\ (-;_ ':\.?[[?6O/Q7Q'V&0?P&)1117*>\%%%% !4]K_ ,?"_45!
M4]K_ ,?"_44UN3/X6?06B_\ ('M?^N8J_5#1?^0/:_\ 7,5?KV([(_-ZO\27
MJPKAOB9_R+K?[U=S7#?$S_D76_WJZ,/_ !8G-7_AL\//6B@]:*^@/%"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ")=W_GL:Z^N0^)7_(EW?^>QH ^2;S_C[D^M05/>?\?<GUJ"@ HHHH ****
M+6F_\A*W_P!\5];_  __ .1<3\*^2--_Y"5O_OBOK?X?_P#(N)^% '5T444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ1BKM% ',_\ " ^'O^?/]1_A5BS\':+87"SV]KMD7H:WJ* #I1110!C^)/\
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M:)>HHHKM/F#@/B7_ ,@6:O%:]J^)?_(%FKQ6O;P/\(\G%_Q HHHKL.8****
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M_P!U?Y5T%<_X0_Y D?\ NK_*N@H *X[Q]_R#TKL:X[Q]_P @]*SJ_ SLR_\
MWF)XR_WV^M)2O]]OK25Y)^A(**** "BBB@"[I?\ Q^K7ONC?\@FW_P!VO M+
M_P"/U:]]T;_D$V_^[7;A.I\QQ#M$O4445VGS!P'Q+_Y LU>*U[5\2_\ D"S5
MXK7MX'^$>3B_X@4445V',%%%% !6CH/_ "'K+_KH*SJT=!_Y#UE_UT%3/X6.
M/Q(^DX/]2OT%2U%!_J5^@J6OFWN>\@HHHI %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKD/B5_R)=W_GL: /DF\_X^Y/K4%3WG_'W)]:@H **** "BBB@"UIO_(2M_\
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M\/[S5;@:AJT@F1CO56["J,]Q8W/Q6NI)&!BVC!(]S7JUOK.G1P(JR@ #' H
MN:?IUMIMLL%M&$C7H!5NH8+F*YC#Q-E34U $%U:07D?ESIO7T-9I\+:.3DVB
MULT4 8W_  BNC_\ /HM'_"*Z/_SZ+6S10!6M;&WLHPD$811T JS110 4444
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M/]2OT%2U%!_J5^@J6OFV>Z@HHHI %%%% !1110 4444 %%%% !1110 4444
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M ,)IXF_YXW?_ 'P:]^^PVO\ S[0_]^Q1]AM?^?:'_O@4 > _\)IXF_YXW?\
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MV,.Q\E_8]9_Y]+C_ +X-+]CUG_GTN/\ O@U]9_8;7_GVA_[X%'V&U_Y]H?\
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M[X-']I:[_P ^US_WP:^FOL-K_P ^T/\ WP*/L-K_ ,^T/_? HN!\R_VEKO\
MS[7/_?!H_M+7?^?:Y_[X-?37V&U_Y]H?^^!1]AM?^?:'_O@47 ^9AJ>O Y^S
M7/\ WP:UH/%WB2"%8U@N\#_8-?0?V&U_Y]H?^^!1]AM?^?:'_O@4 > _\)IX
MF_YXW?\ WP:/^$T\3?\ /&[_ .^#7OWV&U_Y]H?^^!1]AM?^?:'_ +X% 'S?
MK6O^(M8TZ2TEM[HJXY!0UPG_  C&JD_\><__ 'P:^R_L-K_S[0_]\"C[%:_\
M^T/_ '[% 'QI_P (QJG_ #YS_P#?!H_X1C5?^?.?_O@U]E_8;7_GVA_[X%'V
M&U_Y]H?^^!0!\:?\(QJO_/G/_P!\&C_A&-5_Y\Y_^^#7V7]AM?\ GVA_[X%'
MV&U_Y]H?^^!0!\:?\(QJO_/G/_WP:DA\.:K#.D@LY\J<_<-?8_V&U_Y]H?\
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M-K_S[0_]\"J^L5.Y/L8=CY,^QZS_ ,^EQ_WP:/L>L_\ /I<?]\&OK/[#:_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4C*'&&&12T4 8EUX4T>[G,TUFC.3DDUH66FVFGQ[+:%8U
M]!5NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \F^,<,DO]G^6C-@\X'UKI_AJC1^&%#J5.[H:Z#4]%MM5
MV?:!G9TXJQ86$6GV_DPCY: +5%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>/_ !C@EE&G^6C-B49P/>O8*S-3
MT.UU79]H&=AR.* ,CP$C)H*AE(/'6NJJO9V<=E#Y47W:L4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gtinntqqusay000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" **!>D# 2(  A$! Q$!_\0
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M01]:]2L=#M[;5KR61%\DH=N1QT->?:TBI?.%  W'I0!F4M%%,04444 %%%%
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MLHO$%K!K,U[M/SKC^=.C\4PRV5U!*&/F'BN+R?6CGUIC.@T_4K>TED&T[2I
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MG,GUHR>F: .E\/:E8VL\C7$9)(XJ_KGB*VGTR2T4'<W0UQ8)'0XI22>I)HL
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M\(/JW_/LU '+4M=1_P (/JW_ #[-1_P@^K?\^S4 <O25U/\ P@^K?\^S4?\
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MN?\ A6FL?\^K?K1_PK76/^?5OUH]K'N'LI'#45W/_"M=8_Y]6_6C_A6FL?\
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M4 +1FDHH ":<?NBF]J<?NB@!***.] !FBBB@ I*6B@ I*6B@!*6BB@ HHHH
M**** $I:2EH **** "CFBB@ HHI* %I,TM% !1FBB@ HHHH 3-+S124 +2<T
MM% !1S110 449HH *.:** #-%)2T &:3)I:2@!:,\T4E "T444 '-%%% !11
M10 4444 &:*** "CFBB@ HS244 +1110 <T444 '-&:** "BBB@ YHYHHH *
M.:** "BBB@!*6BB@ HYI*6@ YHS244 +1110 4<TE+0 444"@ YHYHHH **2
MEH *.:** #FBBB@ HYHHH .:,TE% "T444 &:,T44 %'-)10 4O-)10 N:**
M* "BDI: #-&:.U% !FBDI: "BDI: "BBB@ YHHHH *,T44 %%)2T &:*,44
M%%%% !FCFDI: "CFBB@!R=:EJ*/K4M $+=:;3FZTV@!:*04M !1244 +1244
M +1110 E+24M "9I:2B@!:*** "BBCM0 4E%% "TE%+0 444E "T44E !12T
ME "TE+10 E+124 +24M% !2]J2E[4 (:2EI* %I*6C% "444M "44M)0 4O>
MBB@ HI*6@!**6B@!*6DI10 E+110 4E%% !VIQ^Z*;3C]T4 )2444 +1110
ME+110 E%+FB@ HHHH *2EHH *2EHH .]%)10 M%%% !1110 4444 )112T )
M12T4 %%)2T %)12T %)12T )12T4 )2T44 %)2TE !112T %%%)0 M)110 M
M)2TE !2T44 )2T4=Z $I:2EH *2EH% "444M !244M !1110 4444 %)2T4
M%%)2YH 2BBEH **2EH 2BEI* "BEI* %HHHH 2BEHH **** "BDI: "BBB@
MHH[4E !1110 44M% "4M)2T %%%% "44M)0 44M% !129HH 6BBB@!*6BC-
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MI:* "BBB@!**6B@ I*6D% "T44F: %HHHH 2EHHH 2BEI* %HHI* #O12T4
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MN[5$HV=BD[A1114C$HI:2@!:\R^(_B:YT6&,PNRY;'%>F]J\4^,?_'O%_O\
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M!*6BDH 6BDHH 6BBDH 6BDI>U !1110 4444 %%%% "444M !1110 4E%+0
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M0 4444 )2TE+0 "DI:* "DI:2@!:2EI* %HHI* %-)2T4 %%)2]Z "D-+10
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M!Z"C ]!3]O,/91/ /^%7W?\ ??\ *C_A6%U_??\ *O?\#T%&!Z"CZQ,/8P/
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M **** "BBB@!**6B@ HHHH *2EH% !1110 4E+10 E%+10 4G2EI* "EHHH
M**#10 E%+24 %+110 444<T )2T44 %%%% "4M%% !1110 E+244 +1244 +
M1110 4444 %%%% !1110 4444 %)2T4 %%)2T %%%% "4M%% !24M&* "BBD
MH *6DHH **6B@ HHHH 2EHHH 0TSRH]V=HS4E% !1110 4E+10 4E+10 44E
M+0 4T@$YQ3J* "BBB@!*6BB@ HI** %I!2TE "T44E "FDI:2@!:*** ')UJ
M6HDZU+0! W6BE/WJ2@ I*** %HI*6@ HI.]+0 4444 %%%% "4M%)0 M%)2T
M )112T %%%)0 44M% "4M%% !1110 4444 %%)FE[4 %%)2T %%%% !1VHI>
MU "444E "T4E+0 44E+WH ***2@!:*** "BBB@!*6BB@!*6BB@ HHI* %HHI
M* "G'[HIM./W10 E%)10 M%%% "4M%)0 M)2TE "T44E "TE+10 4444 %%%
M)0 M)12T %%%% !1110 E%&:6@ HHHH *2BEH **** "BBB@ HHHH ***2@!
M:*** "DI:2@ I:2B@!:.])10 M%)10 M)2T4 )2T44 %%%% "44M% !124M
M"4M)10 M%%% !1244 +1110 444E "T44E "T444 %)2T4 %'>BB@ I*6B@
MHI*6@ H[4E% "TE%% !12T4 %)2T4 %%%% "4M)2T %%%% !1110 E+110 4
M449H ***2@!:**2@ [TM%% "4M'>B@!**6B@ HHHH 2BEI* "EI*6@ HHHH
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MP:3%&32Y- "8HQ1DT9- !BC%&31DT &*,4N32;J #%&*,FC)H ,48I<FDR:
M#%&*,FER: $Q1BC<:-QH ,48HR:,F@ Q2X-)DTN30 F*,49-&30 N*,4FXT9
M- "XHQ2 FEW&@ P:3%&31DT &*-M&31DT &*-M&32Y- "8HQ2Y-)DT +@T8I
M-QHR: %P:3%&3BC<: #%&*-QI<F@!,48-&31N- !MHVT9-&XT &*,49-&30
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M)2T %)2TE "T444 %%%% !1124 +24M% !124M "4M%% !WI*6DH .]+24M
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M (3K0/\ G\'Z5\S_ &F7^\:7[1+_ 'S3^K+N'MSZ7_X3G0#_ ,O@I?\ A.=
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M'XUO/%VI?:!NQ"QY^AIV@7(TV\G9!E!(<@?6IE0CR\JW'&K*]^AZDS!5+$\
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M_2OJ3_A$=$_Y\(ORH_X1'1/^?"+\J?UA=@]DSY<\E_2E\E_2OJ+_ (1'1/\
MGPB_*C_A$=$_Y\(ORI_65V%[$^7O*?TI?*;TKZ@'A+1?^?"+\J7_ (1+1?\
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MCR7]*^EO^$6T?/\ QXQ?E2_\(MH__/C'^5/Z]'L'U)]SYI$+^E'DOZ5]*_\
M"+:/_P ^,7Y4?\(MH_\ SXQ_E1]?CV%]2?<^:Q$_I3O*;TKZ3_X1;1_^?&+\
MJ/\ A%M'_P"?&/\ *G]?CV#ZE+N?-HC;TI?+;TKZ1_X1;1_^?&/\J/\ A%M'
M_P"?*/\ *G_:$>POJ4NY\W>6WI2^6WI7TA_PBVC_ //E%^5'_"+Z/_SXQ_E1
M_:$>POJ,NY\W^6WI2^6WI7T?_P (OH__ #XQ_E1_PB^C_P#/C'^5/^T8]A?4
M)=SPWPWX>N-7OE54RJD$U[SH^E0Z79I%&H!P,\=ZDM-)LK%MUO;K&?45=KCQ
M&)=9^1V4,.J2\Q:**2N4Z!>**** "DI:* "BBB@!*6BB@!*6DI: "BBDH 6B
MBB@!*6BB@ HHI* "EHI* %HHHH **2B@ HI:* "DI:* "BBCK0 4444 %%%%
M "4M%% !1110 4E+24 +1124 %+110 4444 %%%% "44M% "44M% !1110 E
M%&*6@!*6BDH 6BDI: ,W6KA[6Q,D?WJY6S?5[UY"J9 /'-=)XC_Y!C?6N3TK
M3;J9I634O+'IFNFDER-F-1OF1T^G"ZM<-=C:M:8OX#$\N[Y$&6-89MYK:PVO
M=^<P]ZII=(-%U$&4;@GK]*EPYM1\UM#H&UVP6S%T9?W1[U!#XGTRXC=XYLJG
MWJX:,M-X-@^;J_7\JT+ZSCM)--2-0J2@>9CO5^QBM&3[1[G56OB;3+N7RX9L
MMZ4^[\0:?9D>=+MSTKF_$5K:66G++9%%E+8RO6HHHH;F:T-RRG(&0W>DJ47K
MT'SR1UUEK-E?_P"HDW<9JO/XFTV"7RY)L-G%<?>2&R\17"69Q&%X5?QK+L[L
M21W7G0EWW'#'M5+#IZDRK-:'I_\ :EK]E6YW_NV. :LQ3),FY#D5ROAU5FT^
M-)F!C'3-=5$J(F$QCVK"<5%V-8RYE<5I%3J:1WPA85R>LZ#JE_?226]^T2=0
MHJC8:-K$%ZGGW\CQ@\@]*I4HN-^8ES:=K!JE_K\^IS16D2M"@W YINB^*+Q]
M/N3=X62-L 4>)O$,%@/LT&/.)VLP/.#Q3=%TF :)<F2Y1FF^;=GIFNBR]G>2
M,6WSV3,C_A)-<N]2*6R*T>1CFO1]'-V;0&[7:Y%>=W>CI:6Z30:@@?/8UUOA
M'4FFL7^U2X*G +'K2KQ3A>*'2;4K2,[Q7XBO+>3[/88:0-@@U5T3Q/?074=M
MJ(5&DY%4=9=4\02RN1Y988/:J.I?Z5XALVMSN 49*_A6D*<7!*Q$IRYF[FK?
M:]K-WJ]Q#9(K10_-U[5=LO&4K^';FYD*B:%MN/SK/T:>*#5-165PK>4PY^AK
MF[6*1O#NI.H.WS6_F:KV<&K6VL3[22=[]S=_X2/7(_L]ZT:_9YF !S7I=A=+
M=VJ2 Y)49^M>8W5Q"?"FEQAUWAAQW'(KOO#:.FG#?GD#&:PQ$5RWM8UHR?-:
MYLTM%)7&=0M)2T4 %)2T4 %%%% #DZU+42=:EH @;[U0W,7GV[QG^(5.W6DH
M X.X\$A[UIT# MQP:O:3X/MK";[1)N+J<C/-=;01Q@ULZ\VK7,E1A>]CS#QU
M=6VH7*V,!)N%D!8>V:ZS2="C30OLS @2H,XK6?2;"2<SM:H9#U;'-7%4*H4#
M '04Y5KP4(]!1I^^Y,X:7P4"XC5"8@>":T9?"-O_ &<\" Y8<UU-+2=>;ZE>
MRB<6?" DTV"U<';&P8?I70C2HVTPV;CY"N#6G25,JLI;C4(K8X27P0!/B/?Y
M>?6EUS1(M+\,W,,(/S#)KNZBF@BG0I*@=3U!JU7E=7)]C&SL>;:+X1-]HMK(
MP;&<]:Z>7PK;^6JHIZ#-='%#'!$(XD"H.@%/HG7G)W"-&*1S6I>&H[W3[:W8
M'$+!A6+XQO+.TT=],)/VAT&T?A7?U4N=*LKN023VR2..A(I0JV:YMD$J=T['
M+^ ]'-E8I<,N"ZUU.HVHO+)X",AJGBB2&,)&H51T J2IG4<Y\Q4(*,>4X7P^
MNS4KZQ;[NTJ/RJ!? @C=VC#@,Q;@UW*6=O'*TJQ*';JWK4]6Z\D[Q(]C&UF<
MMI/@^UL#)(0Q=QSFA_"D+W/F%3BNJHJ?;3O>Y2IQ2L<=9>#(+6:Z=5/[X8IT
M?A")-"FT\*=LC;L?G774M#K3?4/91[' )X% 41G>$Z=:V;;2[;PUI+&/( .<
MFNFJ.6&.=#'*H93V--UI2TEL"I1CJCC/"&FR1ZK>WCK\LQRIKM^U1QP1PC$:
M!1[5)VJ:D^>5QPARJPE+24M9EB4M%% !124M "4[M24O:@!**** "DHI: (I
MXA- T9Z,*YB3PJOV@R)NY]ZZIF"*68X ZFJ;:K9(^TW$8/IFKA*2^$F23W,B
M'0&C!'S<^]3IX<MCEY 2Y%:D5_;3'$<R,?8U:INI(2BCFT\+P>5*&#9/2H8?
M"L9(27=L'(YKJJ*/:S[AR1,B/18H[B*0 _)TI8M(CBU>2^ .YQ@UK45//(?*
MAI56&" ?K65JVB0:E'&K(/D8-P/>M:H)KRWM\>;*JY.!DT1;3NAM)K4S;_0H
M;N.,\AXU &*IV7AF-9M\VXXY&:Z0,"H8'@]ZB2\MY)FA253(O50>:I5)6LA.
M,295"(%'0#%+245F4%%+10 E./W13:<?NB@!M+110 E+24M !24M% !1110
M4E%+0 E+110 E+110 E+244 +1110 4444 %)12T )2TE+0 E+110 44E+0
ME+124 +1244 +1110 444E "TE%+0 4444 %)2T4 %)2TE "T444 %)2BB@
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MUIPBIR]X4FXKW3J3XA>*,B1OWC\QU"NO7EJ!->$"%C@?6L>^+W%Y92I$=D
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MVHHHH **** "BBB@ I*** %[T4E+0 4444 )112T '6DI:* "DI:* "BBB@
MI*6B@ HHHS0 4E+10 4444 )12T4 %%%% !1110 E+110 4444 )2T4E "TE
M+10 E%+10 E%+10 4E%+0 444E !12T4 &:2BC- "T444 %%%)0 M%%% !24
MM)0 4M)2YH **2EH *2EHH 2BEI* %I*6DH *6BB@ I.]+10 44&B@ HHHH
M,T444 %%%% !1110 4G>EHH **#10 44E+0 E+110 E+24M !1110 4444 %
M)12T &:*2EH *2EHH 2EHH[4 %%%% "4M%)0 M)2T4 %%%% #DZU+42=:EH
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MGTHP?2@ I*7!]*.?2@!**7GTHP?2@ %%'/I1SZ4 )2T8/I1@T )12X-'/I0
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M2@ HHP?2C!H **.?2C!H **,&C!]* #-)2X/I1@T %)2X/I1@^E !11@T8-
M"4M&#Z48- !11@XZ4<^E !24O-&#Z4 )2T<^E&#Z4 %%&#1@^E "4M&/:C!H
M *2EY]*,&@ HHY]*,&@ I*7!]*.?2@ HHP:,&@!*6C!]*,'TH **,'THY]*
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M**6@!.]+124 +1110 E+244 +24M% !1110 "BBB@!*6BDH 6BBB@ HI*!0
MM%(:6@ HHHH 2EHHH 2EHS24 +2444 +2444 %+110 44=Z2@!:**2@!:***
M $HI:* $I:*2@!:2EHH *2BB@!:**2@!:2BEH 2EI** "BEHH 2BEI* "EHI
M* %HHHH **** $I:2EH **** "BBB@ I*6B@ Q124M !1110 4444 )2TE%
M"T444 %%%% !24M% "444M !1110 4E+10 44G>EH *2BB@!:*2EH 2BF32K
M$FYC@4V&=)@=ISBG;J*ZO8EI:K?:X_M)@W?.!TJ&;5+>)MHD&>]-1;)=2*U;
M+]%4[?48+AMBN-_I5NDTUN.,E)704M%%(H**:S!5)-4X]3MY9?+20%@<4TF]
MB7.*=FR]254NM1MK0?O9 M-M=3MKO_52!OI3Y7:]A>TAS<M]2]13'=8UW,<"
MLX:[9&;RQ,N[.*%%O8)5(1^)V-.BJL^H6]O")9) J'H:BM=7M+E]B2@L3P*.
M25KV$ZL$[-ZFA15"ZU:UM6VO* PZBIK6^@O$W0N& ZT<KM>PU4@Y<J>I8I::
MS!5+$X K-;7K%9-OGKQUH47+8)U(P^)V-2BJK7]NL F,@V'H:KPZW9S2^6LP
M+'H*%"3Z"=6"=FS1[TM-R"N0>*HW6KVEJ^R64*U)1;T14IQBKR=C0HJK%?02
MQ>8L@*XSFJHUZQ,NP3BFH2?0EU8+=FI156:_MX(1*\@"MT-06VL6=S)Y:2@N
M>@HY)6O8'5@G9LT**.M+4F@4444 .3K4M1)UJ6@"%NM,90R[2.#3VZU'(X2,
ML>U ,ABL+>&8RHF'/>I98DFC*.,J>HK)77X#=F N-PJ74-9@L-F]P-PR*T<)
MW1SJM146TU8=_8&G[L^2*G&F6HB,0C^1NHIUC=+>VRS(<AJM4G*5[-E0ITFK
MQ2U,R+0=/A?>D.#5DZ?;-*LA3YEZ&K5)2<Y/=E*E32LD4;G1K*Z<O+$&8T^#
M3+6VB,<4>%/45<HHYY6M</90OS6U,QM!T]Y-[0C=5G[!;B$P[/D/45:JI>7B
M6D99SC%/FE+2XG3IP3=DBNF@:>DF]80#4D^D65RZM+%DJ,"K%I.MS;K*IR&J
M:ASE?<4:5)QT2LS._L>S@CD,,6UBI%8NG:!&SO\ :4# L?YUU=(% /  JHU9
M),F>%IR:=MBM;Z=;6R%(DP",&JYT'3V?<8>34%UKL5O<-$6&X4MOKUM+*(VD
M 8]!3M4W1#GAV^5V+J:7:(NT1\4[^S[80-#L^1NHJPK!UW*<@TM9\TNYT*G#
MHC-30-/23>L(#=:LR6%O*P9TR0,"K5-DD6-=SG %'/)]1*E3BM$BO+I]M,$$
MB9"<K[4RYTJTN_\ 71[N,5-#<QSL0C9Q4U'-)!R0DMC/CT6PCQMAQCI4ZV%N
MLPF5,..AJU2=J'.3Z@J4%LBK'IUM$[ND>&?[WO2KI]LC;E3!JU5:]NEL[8RN
M< 4)R;L#C"*NT57T'3WE\QH06)SFIVTVV:'RC'\GI4EK<K<QAU.014]-RELV
M*-.G:Z2U(3:PM#Y)7Y ,8JD- T[IY K3I:2G);,<J4);HHMI5F^S=%_J_N^U
M7%0(N%X%.I*3;>Y2A%;(*=VI*7M2*$I*6DH *6DHH 6BDI: "BL_4+_[&RJ,
M;CTJHNL2C#2( I[U:IR:N92K0B[,VZ*I_;XFM&F1@=HYI]I<"YM!,.]2XM%*
M<6[(LT5GO?XW!<$BBUU*.>1HBP$BC)%/D=KB]K&]KFA16>FH"6X"189<X)I]
M_?QV2*SL!DXHY7>P>TC9ROHB[14%M<"XCWBIZEJQ:::NA***6@84444 )3)9
MXHE&^1%^K 4\UY=\3+Z>VAC\J1E^;L<548\SL9U)\D>8])^W6W_/>+_OL4?;
M[;_GO%_WV*^;/[8O?^>\O_?9I?[8O?\ GXE_[[-;>P\SD>-78^DOMUM_SWB_
M[[%+]NMO^>\7_?8KYL_MF]_Y^)?^^S2C6;W_ )[R?]]FG]7\R?KZ['TE]NMO
M^>\7_?8H^W6W_/>+_OL5\WC6;W_GO)_WV:>-8O#_ ,MY/^^C1]7\Q?V@NQ]&
M_;;;_GO%_P!]BD^VVW_/>/\ [[%?.HU>\_Y[R?\ ?1I_]KWG_/>3_OHT_JWF
M+^T5V/HC[;;_ //>/_OL4?;;?_GO'_WV*^>!J]Y_SWD_[Z-.&KWG_/>3_OHT
M_JOF3_::_E/H7[9;_P#/:/\ [[%'VRW_ .>T?_?8KY]&K79/^OD_[Z-2#5KO
M_GO)_P!]&CZKYB_M-?RGOWVRW_Y[1_\ ?8I?M=O_ ,]H_P#OH5X$-5N_^>TG
M_?1IW]JW?_/:3_OHT_JOF+^U%_*>]_:[?_GM'_WT*/M<'_/:/_OH5X-_:MU_
MSVD_[Z-)_:MW_P ]I/\ OHT?5'W)_M9?RGO7VN#_ )[1_P#?0H^UV_\ SVC_
M .^A7@XU2Z_Y[2?]]&G?VG=?\]I/^^C3^J/N+^UU_*>[?:H/^>T?_?0H^U0?
M\]H_^^A7A8U.Z_Y[2?\ ?1IXU.Z_Y[2?]]&CZGYA_:Z_E/<?M4'_ #VC_P"^
MA2_:H/\ GM'_ -]"O#O[3NO^>TG_ 'T:7^U+K_GM)_WT:?U/S$\X7\I[A]J@
M_P">T?\ WT*/M4'_ #VC_P"^A7B U.Z_Y[/_ -]&GC4KG_GJ_P#WT:/J3[B_
MMI?RGMGVJ#_GJG_?0H^U0_\ /5/^^A7BO]I7/_/5_P#OJG#4;G_GJ_\ WU3^
MI/N+^VE_*>T?:8?^>J?]]"C[3#_SU3_OH5XS_:-S_P ]7_[ZIW]HW/\ SU?_
M +ZH^I/N']M+^4]D^T0_\]4_[Z%2!E894@_0UXN-2N01^]?_ +ZKL?#/B(L1
M!,W).!FHJ8248W6IMA\WA5GR-6.YHIJL&&1TIU<9ZXE%+24 +VHHHH ****
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MYM^5/$,O_/-ORKU__A&++_(H_P"$8L?\BG]<B3_8]3N>1B&7_GFWY4\0R_\
M/-ORKUK_ (1FR_R*7_A&K+_(H^N1["_L>IW/)A#)_P \V_*E\F3^XWY5ZQ_P
MC=G_ )%'_"-V?^11]=B']C5.YY/Y$N?]6WY5TWAK0GNIEFD7"J>0179_\(W9
M@YQ^E:5M:QVR;4  ^E34QEXVB:X;)^2IS5'H.AA2"()&,*.U24M%>>>\E960
ME%+24#%HHHH 2BEI* "BBB@!:2EHH **** "BBB@ HHH[4 %%)2T )WI:**
M"BDHH 6BBDH *6BDH 6BDI: "BBB@!*6DHH 6BBB@ I*6B@!**6B@!*6DI:
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M10 E%&:* %I*6B@ I*6B@!*6DI: $HI:2@ Q3C]T4VG'[HH ;1110 M)2T4
M%%%% !1110 4E%** $I:2EH **2B@!:2BB@!:*** "DI:2@!:*2B@!:*2EH
M*2EHH 2EHI* "BEI* %HHHH 2EHHH **2B@!:**2@!:**2@!:*** "DHI: "
MDI:2@!:*** "BDI: "BDI: "DHHH 6BBDH **6B@!***6@ HHHH 2BBEH 2B
MEHH *2EHH *2BE[4 )12TE "TE+10 4444 %%%% "4M%% !12&EH **** "B
MDI: "DI:* "BDI: "BD-+0 4444 )2T4E "T4=J* "DI:* "BBDH 6DI:2@
MZU7-JOF!\#(-6*6FG83BGN%%%)2&+244O:@ I*** %HHHH *B>&.1@S+DBI:
M*!-)[C54*N!TIU)2T#"BDI: "BDHH *6BB@ I*6DH 6BBB@ I*6B@!T?6I:B
M3K4M $+=:2E;K24 0FVB,OF[!O/>I1P*6BBXDDM@I*6DH&+1110 444E "U"
MUK"THE* N.AJ:BFG832>XE+112&%%)2T %%%% "44M)0 4M%% !1124 +24M
M% "4=J6CM0 4444 %'>BCO0 4444 %+VI*/X: "BBB@ HHHH **** $I:**
M"BDI: "BBB@ I**.U "T444 %%%% "44M)0 IZ4I^Z*:>E./W10 E%%)0 4M
M%% !11WHH *2EI* %HHHH **3FEH 2EHHH ***2@!:**2@!:*** "BDI: "B
MBDH *6DI: $S1110 4M)10 4M%% "44M)0 4M)2T %%'>B@ I*6B@ I*6B@
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M7CW_  LZ_P#[ZTG_  LZ_P#[ZT?4JH?7*1[%S1@UX[_PL^__ +ZTO_"SK_\
MOK1]2JA]<I'L.**\=_X6=?\ ]]:/^%G7_P#?6CZE5#ZY2/8L48KQW_A9]_\
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M@Z:NRE24M)6Q@%%+24 %+124 +1244 +24M% "4444 +2444 +2444 %%%%
M!1110 4444 %+244 %+244 '>BBB@ HHHH **** "BBB@ I:2B@!11244 **
M0]:6DH *6DHH **6B@ HI** "BBEH *2BCK0 44M)0 4444 +1244 %+124
M%+244 +124"@!:2BB@!12'K110 4M)2YXH!!2=Z**8"TE+12 2ES244 +24M
M)0 444N>* "DHHH **6DH 6DHHH 6BBDH *6BDH *6DHH **7-)0 444N<T
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MRH"PVE%+L;^Z?RHVM_=/Y4 )12[&_NG\J7:W]T_E0 RBG;&_NG\J-C?W3^5
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MVU%'UBKW#V-/L<3_ ,*[M/\ GHOY4?\ "NK3_GHOY5VU)1]8J]P]C3['%?\
M"NK3_GHOY4?\*[L_^>B_E7:TM'UBKW#V-/L<3_PKNT_YZ+^5'_"NK3_GHOY5
MVU%'UBKW#V-/L<3_ ,*[M/\ GHOY4?\ "N[3_GHOY5VU%'UBIW#V-/L<3_PK
MJT_YZ+^5'_"N[3_GHOY5VU%'UBKW#V-/L<3_ ,*[M/\ GHOY4?\ "NK3_GHO
MY5VU%'UBKW#V-/L<3_PKJT_YZ+^5'_"N[3_GHOY5VU%'UBIW#V-/L<3_ ,*[
MM/\ GHOY4?\ "NK3_GHOY5VU%'UBKW#V-/L<3_PKNT_YZ+^5'_"N[3_GHOY5
MVU)3^L5>X>QI]CBO^%=VG_/1?RH_X5W9_P#/1?RKMJ*7UBIW#V-/L<3_ ,*Z
MM/\ GHOY4?\ "N[3_GHOY5VU%'UBIW#V-/L<3_PKNT_YZ#\J7_A75G_ST7\J
M[6DI_6*O</8T^QQ?_"N[/_GHOY4G_"N[/_GHOY5VM+2^L5>X>QI]CB?^%=6G
M_/1?RH_X5W:?\]%_*NVHH^L5>X>QI]CB?^%=VG_/1?RH_P"%=6G_ #T7\J[6
MEH^L5.X>QAV.)_X5W9_\]%_*C_A7=I_ST7\J[:DH^L5.X>QAV.*_X5W:?\]%
M_*C_ (5W:?\ /1?RKM:*/K%3N'L:?8XK_A75I_ST7\J/^%=VG_/1?RKM:7O1
M]8J=P]C3['$_\*[M/^>B_E1_PKNT_P">B_E7;44_K%3N'L:?8XG_ (5W9_\
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M *2CO2T %%)10 M%%% "4M&:* "BCO10 4444 %%%% !1110 4444 %%)2T
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MJ7"N0":]6TO1Q80>60,8QQ65?>$B\Y>T"H&.6SWH S_!+W!O6$F[;MZ9K?\
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M $I:** $I:2B@ I:** "BBB@ HHI* %HI*6@ I*** %HI*6@ HHHH 2EI**
M%HHHH **** "BDHH **** %I*6B@ HHI* %I*** %I*6B@!**6B@ Q1110 4
ME+24 %%+24 +1124 +1110 4E+10 4444 %%%% #DZU+44?6I: (6ZTE*W6D
MH .U%4KO4[>T'SNN?3/-)::K;7GW'4'TW4 7J*** "BBD/')H 6BJ:ZC UP\
M(8;E&2,TZUO8KO=Y9!VG!P: +-%%+0 E+124 +1110 4444 )2T4E "T444
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M1110 4=Z** "DHI: "DI31VH **2EH **** "BBB@ HHI* %I*6B@ [444E
M"T4E+0 4E%% "TE+VHH 3M12T4 %%%% !244M !2444 %+110 444E !2T44
M %)2]Z* $I:** "BBDH 6BBDH 7M24M)0 M%%% "4M)2T %%%% !1110 E+1
M10 4444 )2TE+0 4444 )2T48H **** "BBB@!**6DH 6@4E** "BBB@ HHH
MH **** "DI:* "BBB@ HHQ1B@ HHI* %HHHH *2EHH **** "DHHH 6DI:*
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MTM% !1244 +124M !124M !24M)0 M)110 HHH[4E !2T44 )12TE "TE%%
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&4E+0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gtinntqqusay000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 13!,D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT4SSH_[PI1(K' - #J*** "BBFLZKU.* '44SSH_[PH\Z/\ O"@!]%,\Z/\
MO"CSH_[PH ?13/.C_O"CSH_[PH ?13/.3^\*<&##(- "T444 %%%,,J X+4
M/HIGG)_>%'G)_>% #Z*9YT?]X4>='_>% #Z*9YT?]X4>='_>% #Z*8)4)P&I
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M #^?S_QKEJ2@#JO^%A^(O^?S^?\ C1_PL/Q%_P _G\_\:Y:B@#J?^%A^(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KAOBG_P B9>?3^AKN:X;XI_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYHHHH @O?^/*7_=KYI\<_P#(RR?2OI:]_P"/*7_=KYI\<_\ (RRT <Y1110
M4444 %%%% &OX6_Y&6Q_ZZ5]2P?ZH5\M>%O^1EL?^NE?4L'^J% $E%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_D9;'_KI7U+!_JA0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !115>^NELK.2X<X5!DF@ N;VWM$+33(@']Y@*@T[5K;
M4_,\AU;8<':<UX/XJU[5/&'B*32].W&('(*,0>OM7IGP[\*S>';%_.DE9Y>3
MO8G'YT :FN^-++0I62=<D''6L3_A;.D_W/UK@?BVC3:RT6]E#2 <'WK2L/@Q
M87FDQ7(N[CS'C#8W'_&@#T_0?%=EKP'D,H8C.-W-;]?-6D-<>!/'4EL9',(P
MHWL3W(KZ-L9_M-C#-_?0&@"? SFEHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KAOBG_P B9>?3^AKN:X;XI_\ (F7GT_H: .9^#?W6_P!R
MO7Z\@^#?W6_W*]?H *Q/%G_(OSUMUB>+/^1?GH ^9M5_Y",WUJG5S5?^0C-]
M:IT %%%% !1110 5W_PO_P"1BM_K_6N KO\ X7_\C%;_ %_K0!] #I2T@Z4M
M !7D7Q9^Y)]*]=KR+XL_<D^E 'C8Z4M(.E+0 4444 %%%%  O6OH?X5?\BC'
M]:^>1UKZ&^%7_(HQ_6@#N:*** (+W_CRE_W:^:?'/_(RR?2OI:]_X\I?]VOF
MKQS_ ,C)+]* .;HHHH **** "BDI: -?PM_R,MC_ -=*^I8/]4*^6O"W_(S6
M/_72OJ6#_5"@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$_\  J]<\)SF?0K7/:):\;^*&HC4/$/]GQG<R2J<?\"KVCPQ;?9M$M0>\2T
M;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<-\4_^1,O/
MI_0UW-<-\4_^1,O/I_0T <S\&_NM_N5Z_7D'P;^ZW^Y7K] !6)XL_P"1?GK;
MK$\6?\B_/_GUH ^9M5_Y"4WUJG5S5?\ D(S?6J= !1110 4444 %=_\ "_\
MY&*W^O\ 6N KO_A?_P C%;_7^M 'T .E+2#I2T %>1?%G[DGTKUVO(OBS]R3
MZ4 >-CI2T@Z4O>@ HHHH **** %'6OH;X5?\BC']:^>1UKZ&^%7_ "*,?UH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$O5Y+F-#:70!8#[A]:]QTJX:YT^&5P0S("0:JIX?T_AEAC_[X%:L:+&@51@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO/M#^$6E6)2>5I#*.3NY_K7H]O MM D2?=48% $M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<-\4_P#D3+SZ?T-=S7#?%/\ Y$R\^G]#
M0!S/P;^ZW^Y7K]>0?!O[K?[E>OT %8GBS_D7YZVZQ/%G_(OS_P"?6@#YFU7_
M )",WUJG5S5?^0C-]:IT %%%% !1110 5W_PO_Y&*W^O]:X"N_\ A?\ \C%;
M_7^M 'T .E+2#I2T %>1?%G[DGTKUVO(OBS]R3Z4 >-CI2T@Z"EH **2B@ I
M:** %'6OH;X5?\BC']:^>1UKZ&^%7_(HQ_6@#N:*** (+W_CRE_W:^:?'/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA5['X:_Y =I_UR6@#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KAOBG_ ,B9>?3^AKN:X;XI_P#(F7GT_H: .9^#?W6_W*]?KR#X-_=;
M_<KU^@ K$\6?\B_/6W6)XL_Y%^>@#YGU7_D(S?6J57-5_P"0C-]:IT %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLCT>BD0Y13ZBEK<\H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^J?$&RL)C'"%G8?W32_$2]O+71D%E]]VVGZ&N2\#> (+N*6\U'S/-+[ASZT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M';_7^M 'T .E+2#I2T %>1?%G[DGTKUVO(OBS]R3Z4 >-CI2T@Z4M !1110
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MM5F^_P"/Z?\ ZZ-_.JU>.]S]*A\*"BBBD4%%%% !74>"?^0D?J*Y>NH\$_\
M(2/U%:4OC1RX[_=Y'MT?^J3_ '13J;'_ *I/]T4ZO6/SQ[A1110(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHKF_%7BJU\.VC&5]LA7*T =&64=3BD#J
MW0@U\]:E\4?$5PWFV14P$\$UV?A+Q;JFH>%=1O)B#/"/EH ]4HKR7PE\3VN]
M0^QZG( X'3WKU>*19HED7[K#(H ?1110 4444 %%%% ' ?$_7+K2]%'V1'9V
M.T[:\C\*:\VESR7-_I;74I<LK,.1S]:^B-3T.TU5-ERN1G-9?_""Z1_SS_2@
M#C8_B\\:A4T5U4=A_P#KKL/"OBYO$D#2-:&#:<8-._X072/[A_*M73-$M-*0
MK;K@$YH Y'7?'L^EZS]B6P>1=X7</<_6NLO[0:QH?E.,><@)![<4RZ\.6-Y<
M^?*N7SGI6JB!$5!T48% 'A-G>7W@?Q3<'[+)+;GY5XXK:\2_$.;4=)>RM+%S
M)(O!7J*]*U/0;+54VW"#Z@5G67@?2K&<2Q(2P.>10!SGPU\.262?VG<*1-,O
MS!AS7I%,CC6) J@ "GT %126T,IS)&&/O4M% %?[!:_\\5KB/BA:01^#;QDB
M4''4?0UW]<-\4_\ D3+SZ?T- ',_!K[K?[E>OUY!\&_NM_N5Z_0 5B>+/^1?
MGK;K$\6?\B_/_GUH ^9M5_Y",WUJG5S5?^0C-]:IT %%%% !1110 5W_ ,+_
M /D8K?Z_UK@*[_X7_P#(Q6_U_K0!] #I2T@Z4M !7D7Q9^Y)]*]=KR+XL_<D
M^E 'C8Z4M(.E+0 4444 %%)2T *.M?0WPJ_Y%&/ZU\\CJ*^AOA5_R*,?UH [
MFBBB@""]_P"/*7_=KYI\<_\ (RR?2OI:]_X\I?\ =KYI\<_\C+)]* .<HHHH
M **** "BBB@#7\+?\C+8_P#72OJ6#_5"OEKPM_R,MC_UTKZE@_U0H DHHHH
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M#'V5>G\JSK+X6:R&,:ZA-&C'G'?]*L6WQ9UZ[.(VS^!JS+\2O$4";V(P/8T
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MBBB@""]_X\I?]VOFGQS_ ,C+)]*^EKW_ (\I?]VOFGQS_P C+)]* .<HHHH
M**** "BBB@#8\+?\C+8_]=*^I(/]4*^6O"W_ ",MC_UTKZE@_P!4* )****
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MS:='DY^6O$J]L\$_\@Z/_=KIPOQ'AYZDL.CK****] ^."BBB@ HHHH ****
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M=_\ "_\ Y&*W^O\ 6@#Z '2EI!TI: "O(OBQ]R3Z5Z[7D7Q9^Y)]* /&^U%
MZ4M !1110 4444 *.HKZ&^%7_(HQ_6OGD=17T-\*O^11C^M '<T444 07O\
MQY2_[M?-/CG_ )&63Z5]+7O_ !Y2_P"[7S3XY_Y&63Z4 <Y1110 4444 %%%
M% &OX6_Y&6Q_ZZ5]2P?ZL5\M>%O^1FL?^NE?4L'^J% $E%%% !1110 4444
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M "BBB@ HHHH **** $;[C?2O%_B-H&IZG=I]GMI'_P!H=J]?O-0M[&+S)I%
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M+"<7-A#,/XT!KQ#XN6:0:BEXH^=IE&?Q%>M>$IS-H5KGM$M &]1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7#?%/_ )$R\^G]#7<UPWQ3
M_P"1,O/I_0T <S\&_NM_N5Z_7D'P;^ZW^Y7K] !6)XL_Y%^>MNL3Q9_R+\]
M'S-JO_(1F^M4ZN:K_P A&;ZU3H **** "BBB@ KO_A?_ ,C%;_7^M<!7?_"_
M_D8K?Z_UH ^@!TI:0=*6@ KR+XL_<D^E>NUY%\6?N2?2@#QL=*6D'2EH 2EH
MHH **** %'6OH;X5?\BC']:^>1UKZ&^%7_(HQ_6@#N:*** (+W_CRE_W:^:?
M'/\ R,LGTKZ6O?\ CRE_W:^:?'/_ ",LGTH YRBBB@ HHHH **** -?PM_R,
MMC_UTKZE@_U0KY:\+?\ (RV/_72OJ6#_ %0H DHHHH **** "BBB@ HHHH *
M#THH/2@#R;XF?\?\'TK@*[_XF?\ '_!]*X"O+K_Q&??95_ND HHHK$] ****
M "I(/^/B/_?'\ZCJ2#_CXC_WQ_.F*6Q[SX9_Y!J?[HK;K$\,_P#(-3_=%;=>
MO#X4?G.)_BR"H+W_ (\;C_KFW\JGJ"]_X\;C_KFW\J;V,H?$CYWOO^/Z?_KH
MW\ZK59OO^/Z?_KHW\ZK5X[W/TJ'PH****104444 %=1X)_Y"1^HKEZZCP3_R
M$C]16E+XT<N._P!WD>W1_P"J3_=%.IL?^J3_ '13J]8_/'N%>=?$S_CTA^M>
MBUYU\3/^/2'ZUC7_ (;/1RG_ 'N!Y9WHH[T5Y9]X%%%% !1110 5[9X)_P"0
M='_NUXG7MG@G_D'1_P"[75A?B/#S[_=T=91117H'QH4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^-K8W/A>^5>3Y
M? KHJAN;=+JW>&095A@B@#Q+X2ZDEGJ2Z=,P1D7H:]R!# $<@U\_^-?#6I>&
M=?EUC2QLB)P HR<9]JVO#_QBMK>%8-368R*,9P1_2@#V&2U@E.9(D8^I%2?)
M$G95%>?GXOZ!LW;9/S_^M7*>)/C!%=P/#I(F61A@<$T 9/Q-U$:GXD_L^$[M
MDJGC_>KVOPU;?9M$M0>IB6O&OA_X2U#7-:_MO5AO60#J,'/6O>8(A# D:]%&
M!0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#?%/_D3
M+SZ?T-=S7#?%/_D3+SZ?T- ',_!O[K?[E>OUY!\&_NM_N5Z_0 5B>+/^1?G_
M ,^M;=8GBS_D7Y_\^M 'S-JO_(2F^M4ZN:K_ ,A&;ZU3H **** "BBDH 6N_
M^%__ ",5O]?ZUP%=_P#"_P#Y&*W^O]: /H =*6D'2EH *\B^+/W)/I7KM>1?
M%G[DGTH \<[44@Z4M !1110 4444  ^\*^A_A5_R*,?UKYY'6OH;X5?\BC']
M: .YHHHH @O?^/*7_=KYI\<_\C++7TM>_P#'E+_NU\T^.?\ D99/I0!S=+11
M0 44E+0 4444 :_A;_D9;'_KI7U+!_JA7RUX6_Y&6Q_ZZ5]2P?ZH4 24444
M%%%% !1110 4444 %!Z44'I0!Y-\3/\ C_@^E<!7?_$S_C_@^E<!7EU_XC/O
MLJ_W2 4445B>@%%%% !4D'_'Q'_OC^=1U)!_Q\1_[X_G30I;'O/AG_D&I_NB
MMNL3PS_R#4_W16W7KP^%'YSB?XL@J"]_X\;C_KFW\JGJ"]_X\;C_ *YM_*F]
MC*'Q(^=[[_C^G_ZZ-_.JU6;[_C^G_P"NC?SJM7CO<_2H?"@HHHI%!1110 5U
M'@G_ )"1^HKEZZCP3_R$C]16E+XT<N._W>1[='_JD_W13J;'_JD_W13J]8_/
M'N%>=?$S_CTA^M>BUYU\3/\ CTA^M8U_X;/1RG_>X'EG>BCO17EGW@4444 %
M%%% !7MG@G_D'1_[M>)U[9X)_P"0='_NUU87XCP\^_W='64445Z!\:%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 5[JRM[R(I/$C@_WAFN!UCX2Z=J<C2+*(23GY17HU% 'C7_  HVWWX_M"3'
MU-;^B_";3M*E61I!-@YPPKT:B@"O:V<%G$(X8U11T"C%6*** "BBB@ HHHH
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MY2_[M?-/CG_D99/I7TM>_P#'E+_NU\T^.?\ D99/I0!SE%%% !1110 4444
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MS_C_ (/I7 5Y=?\ B,^^RK_=(!1116)Z 4444 %20?\ 'Q'_ +X_G4=20?\
M'Q'_ +X_G30I;'O/AG_D&I_NBMNL3PS_ ,@U/]T5MUZ\/A1^<XG^+(*@O?\
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MG5S5?^0C-]:IT )2T44 %%%% !7?_"__ )&*W^O]:X"N_P#A?_R,5O\ 7^M
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MQAYYMI89_=GUKWC29)9=.@>8DN4!.?6@"]1110 4444 %%%% !1110 4444
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M* )**** "BBB@ HHHH **** "@]**#TH \F^)G_'_!]*X"N_^)G_ !_P?2N
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M445Z!\:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M )"4WUJG0 4444 %%%)WH 6N_P#A?_R,=O\ 7^M<!7?_  O_ .1BM_K_ %H
M^@!TI:0=*6@ KR+XL_<D^E>NUY%\6?N2?2@#QL=*6D'2EH **** "BBB@!1U
MKZ&^%7_(HQ_6OGD=:^AOA5_R*,?UH [FBBB@"O>_\>4O^[7S5XY_Y&63Z5]+
M7O\ QY2_[M?-/CG_ )&63Z4 <Y1110 4444 %%%% &OX6_Y&6Q_ZZ5]2P?ZH
M5\M>%O\ D9K'_KI7U+!_JA0!)1110 4444 %%%% !1110 4'I10>E 'DWQ,_
MX_X/I7 5W_Q,_P"/^#Z5P%>77_B,^^RK_=(!1116)Z 4444 %20?\?$?^^/Y
MU'4D'_'Q'_OC^=,4MCWGPS_R#4_W16W6)X9_Y!J?[HK;KUX?"C\YQ/\ %D%0
M7O\ QXW'_7-OY5/4%[_QXW'_ %S;^5-[&4/B1\[WW_']/_UT;^=5JLWW_']/
M_P!=&_G5:O'>Y^E0^%!1112*"BBB@ KJ/!/_ "$C]17+UU'@G_D)'ZBM*7QH
MY<=_N\CVZ/\ U2?[HIU-C_U2?[HIU>L?GCW"O.OB9_QZ0_6O1:\Z^)G_ !Z0
M_6L:_P##9Z.4_P"]P/+.]%'>BO+/O HHHH **** "O;/!/\ R#H_]VO$Z]L\
M$_\ (.C_ -VNK"_$>'GW^[HZRBBBO0/C0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,U:]T_3K=I[P1@*,Y9
M0:TF.U&/H,UXA\1M7N]8U^UTJSD*)*=C#UH OZM\5M.MYV2RBMI%'3Y!6?!\
M74,@$UK;*N>NQ?\ "NF\-_"O2K:QC_M"V267N:V;OX:>')H2L=@@;'!H =X9
M\5Z+KZ*L7DF;&2H05UZXP-HP*^>=:T:[\!Z^+RU?R[=G5 %^O_UZ]WT6[^V:
M5;2YRS1@F@#0HHHH **** "BBB@ JEJW_(-E^E7:IZFI>PD4=2* /&?!'_)3
M]1_W/\:]Q7[@^E>/>$-(N;?XAWUR\;"-EX)'UKV%?NCZ4 &:Y7XA6S7/A"\5
M1DE:Y?Q+JNNP>(!':O*(?,48"G&,UZ*UL+_28X9QNWQC<#]* /-?A-<*G^AD
M_.B<C\*]'URX6UTF:5C@**\=U32=6\)>(9[^S+^0YP$1<\4:GXGU?Q-;_P!G
MVT5Q"7&TED(&: '?#Z!KSXAZE<X^1ER#^=>X*,*!Z"N,\!^%SHEC'-, ;EEP
M[>M=I0 5YOX\\?W_ (7U6.UMH4=67.6KTBLC4_#6E:Q.)KVV$C@8!- 'D7_"
MYM9_Y]8OR'^%87BKXG:GK>B36<]O&J..2 *]L_X0+P[_ ,^"UR'Q&\(Z+I_A
M2ZGMK14D4<'\#0!3^#!S&3_L5[!7C_P:X1L?W*]@H *Q/%G_ "+\];=8GBS_
M )%^?_/K0!\SZK_R$9OK5*KFJ_\ (2F^M4Z "BBB@ HHHH *[_X7_P#(Q6_U
M_K7 5W_PO_Y&*W^O]: /H =*6D'2EH *\B^+/W)/I7KM>1?%G[DGTH \;[4M
M Z44 %%%% !1110 HZBOH;X5?\BC']:^>1UKZ&^%7_(HQ_6@#N:*** (+W_C
MRE_W:^:?'/\ R,LGTKZ6O?\ CRE_W:^:?'/_ ",LGTH YRBBB@ HHHH ****
M -?PM_R,UC_UTKZE@_U0KY:\+?\ (S6/_72OJ6#_ %0H DHHHH **** "BBB
M@ HHHH *#THH/2@#R;XF?\?\'TK@*[_XF?\ '_!]*X"O+K_Q&??95_ND HHH
MK$] **** "I(/^/B/_?'\ZCJ2#_CXC_WQ_.F*6Q[SX9_Y!J?[HK;K$\,_P#(
M-3_=%;=>O#X4?G.)_BR"H+W_ (\;C_KFW\JGJ"]_X\;C_KFW\J;V,H?$CYWO
MO^/Z?_KHW\ZK59OO^/Z?_KHW\ZK5X[W/TJ'PH****104444 %=1X)_Y"1^HK
MEZZCP3_R$C]16E+XT<N._P!WD>W1_P"J3_=%.IL?^J3_ '13J]8_/'N%>=?$
MS_CTA^M>BUYU\3/^/2'ZUC7_ (;/1RG_ 'N!Y9WHH[T5Y9]X%%%% !1110 5
M[9X)_P"0='_NUXG7MG@G_D'1_P"[75A?B/#S[_=T=91117H'QH4444 %%%%
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M?K6-?^&ST<I_WN!Y9WHH[T5Y9]X%%%% !1110 5[9X)_Y!T?^[7B=>V>"?\
MD'1_[M=6%^(\//O]W1UE%%%>@?&A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %(S!%+-T%+3)$\R,KZT 4)M<L(2RM,
M P%<#J/Q(D@\1VMB@C:WE?#$@=*H>+_!7B"]U::XL;[RH3T6O+[WPMKT6N6\
M#S.TK-A7QTH ^E&U31).76%C[Q@TU;_05.0D'_?M:\=_X5_XN_Z"GZ4?\*_\
M7?\ 04_2@#J?&7Q%&CS)#IJQ,3(%Q@#C->B:)>O?:9!/( &= QQ7C&G_  HU
MFYOUFO[Q90&!YKV_3[065C# !]Q M %JBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "N&^*?_(F7GT_H:[FN&^*?_(F7GT_H: .9^#?W6_W
M*]?KR#X-_=;_ '*]?H *Q/%G_(OS_P"?6MNL3Q9_R+\_^?6@#YGU7_D(S?6J
M57-5_P"0C-]:IT %%%% !1110 5W_P +_P#D8K?Z_P!:X"N_^%__ ",5O]?Z
MT ?0 Z4M(.E+0 5Y%\6?N2?2O7:\B^+/W)/I0!XV.E+2#I2T %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH ^9M5_Y",WUJG5S5?\ D(S?6J= !1110 4444 )7H'PO_Y&*W^O]:X"N_\
MA?\ \C%;_7^M 'T .E+2#I2T %>1?%G[DGTKUVO(OBS]R3Z4 >-CI2TG:EH
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MZ*VZ]>'PH_.<3_%D%07O_'C<?]<V_E4]07O_ !XW'_7-OY4WL90^)'SO??\
M']/_ -=&_G5:K-]_Q_3_ /71OYU6KQWN?I4/A04444B@HHHH *ZCP3_R$C]1
M7+UU'@G_ )"1^HK2E\:.7'?[O(]NC_U2?[HIU-C_ -4G^Z*=7K'YX]PKSKXF
M?\>D/UKT6O.OB9_QZ0_6L:_\-GHY3_O<#RSO11WHKRS[P**** "BBB@ KVSP
M3_R#H_\ =KQ.O;/!/_(.C_W:ZL+\1X>??[NCK****] ^-"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1F"C+' '>
M@!< ]14,EK#*I#Q(<^JBJ5YKVG62DRW<2D=BU<;J_P 5;*Q++!$)R.FTT ;&
ML^ -*U?<90R$_P!P8KS;7? \?AUS/923$KR,L:@U#QWKNO2D6-G<P*W0J*+#
MP1XFUU]]UJDR*?X7Q0!EZ5\4=9TS4DL7*[ P')]37T)I=TUYI\$[=70,:XC0
M_A?9V!5[P1W$@_B->@00I!"L:* JC  H DHHHH **** "BBB@ HHHH ****
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M=5JLWW_']/\ ]=&_G5:O'>Y^E0^%!1112*"BBB@ KJ/!/_(2/U%<O74>"?\
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M8VUNMM D2 !5&!B@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N&^*?_ ")EY]/Z&NYKAOBG_P B9>?3^AH YGX-_=;_ '*]?KR#X-_=
M;_<KU^@ K$\6?\B_/6W6)XL_Y%^>@#YFU7_D(S?6J=7-4_Y",WUJG0 4444
M%%%% !7?_"__ )&*W^O]:X"N_P#A?_R,5O\ 7^M 'T .E+2#I2T %>1?%G[D
MGTKUVO(OBS]R3Z4 >-CI2T@Z4M !1110 4444 *.HKZ&^%7_ "*,?UKYY'45
M]#?"K_D48_K0!W-%%% $%[_QY2_[M?-/CG_D99/I7TM>_P#'E+_NU\T^.?\
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MG4V/_5)_NBG5ZQ^>/<*\Z^)G_'I#]:]%KSKXF?\ 'I#]:QK_ ,-GHY3_ +W
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M#_5"@"2BBB@ HHHH **** "BBB@ H/2B@]* /)OB9_Q_P?2N KO_ (F?\?\
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M^<J_Q&>Y2^!!1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7#?%/\ Y$R\^G]#7<UPWQ3_ .1,O/I_0T <S\&_NM_N5Z_7D'P;^ZW^
MY7K] !6)XL_Y%^>MNL3Q9_R+\] 'S-JO_(1F^M4ZN:K_ ,A&;ZU3H 2EHHH
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M KAOBG_R)EY]/Z&NYKAOBG_R)EY]/Z&@#F?@W]UO]RO7Z\@^#?W6_P!RO7Z
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M%%% !1110 4444 %%%% !1110 5PWQ3_ .1,O/I_0UW-<-\4_P#D3+SZ?T-
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M4 %%%% !0>E%!Z4 >3?$S_C_ (/I7 5W_P 3/^/^#Z5P%>77_B,^^RK_ '2
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M696GK_\ R%Y:S*^CA\*/#E\3"BBBJ)"BBB@ KIO _P#R,=K_ +U<S73>!_\
MD8[7_>K.M_#9=/XT?08Z44#I17SA[@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 57GO8(/OR*/QJAXAU>/1].>9R!E2!GUKQW3;36?'%]
M+,MY/;1)(5X/!&: /;X+^WN#A)%_.K5>#:UH^M>#)H[I;ZXN8VD (SQC->M>
M%-<76M,60$;D #?6@#?HHJM?W:6-H]Q(0%7J30!)+<10C+NH^IJ"+4[:5MJR
M+G_>%>+WU]JGC#Q)/96<\T,*'(=#P:?K?@W6O#]H=0BU2XF\M<E >OZ4 >X
M@C(.:6N&^'WB8ZO8QVLW_'PBY8$\UW- !1110 5PWQ3_ .1,O/I_0UW-<-\4
M_P#D3+SZ?T- ',_!O[K?[E>OUY!\&_NM_N5Z_0 5B>+/^1?GK;K$\6?\B_/_
M )]: /F;5?\ D(S?6J=7-5_Y",WUJG0 4444 %%)2T %=_\ "_\ Y&*W^O\
M6N KO_A?_P C%;_7^M 'T .E+2#I2T %>1?%G[DGTKUVO(OBS]R3Z4 >-CH*
M6D'2EH **** "DI:* %'6OH;X5?\BC']:^>1UKZ&^%7_ "*,?UH [FBBB@""
M]_X\I?\ =KYI\<_\C++7TM>_\>4O^[7S3XY_Y&63Z4 <Y1110 4444 %%%)0
M!L>%O^1FL?\ KI7U+!_JQ7RUX6_Y&6Q_ZZ5]2P?ZH4 24444 %%%% !1110
M4444 %!Z44'I0!Y-\3/^/^#Z5P%=_P#$S_C_ (/I7 5Y=?\ B,^^RK_=(!11
M16)Z 4444 %20?\ 'Q'_ +X_G4=20?\ 'Q'_ +X_G3%+8]Y\,_\ (-3_ '16
MW6)X9_Y!J?[HK;KUX?"C\YQ/\605!>_\>-Q_US;^53U!>_\ 'C<?]<V_E3>Q
ME#XD?.]]_P ?T_\ UT;^=5JLWW_']/\ ]=&_G5:O'>Y^E0^%!1112*"BBB@
MKJ/!/_(2/U%<O74>"?\ D)'ZBM*7QHY<=_N\CVZ/_5)_NBG4V/\ U2?[HIU>
ML?GCW"O.OB9_QZ0_6O1:\Z^)G_'I#]:QK_PV>CE/^]P/+.]%'>BO+/O HHHH
M **** "O;/!/_(.C_P!VO$Z]L\$_\@Z/_=KJPOQ'AY]_NZ.LHHHKT#XT****
M "BBB@ HHHH **** .;\;,5\/R$>M>"W%S+]H?YCU]:]Y\<_\B])]:\ N?\
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MA)*1]&1_ZI/]T4^N 3XG:4(U'VB+@#O3O^%G:5_S\1?G7IGPCW.]KSKXF_\
M'I#]:L?\+.TK_GXB_.N,\<^-[#4[:)8IHV(/8UE63<&D=^63C#$QE+8Y?O16
M3_;EO_?6C^W(/[ZUYWLY=C[7Z[0_F-:BLG^W(/[ZT?VY!_?6CV<NP?7:'\QK
M45D_VY!_?6C^W(/[ZT>SEV#Z[0_F-:O;/!/_ "#H_P#=KY]_MR#^^M>H^%_'
M^FV-DB23Q@A<<FNC#0DI:GCYUB*52@E!W/7:*X+_ (6=I7_/Q%^='_"SM*_Y
M^(OSKN/DSO:*X+_A9VE?\_$7YT?\+.TK_GXB_.@#O:*X+_A9VE?\_$7YT?\
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MO-/&W@ZVT'Q%'911[59<X_*OJFO OBS_ ,CQ#_US_P * -#1?A%IU_I%O<M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 A('4@?6O'?B-X9OM6\61W5N 8PF.GTKT#Q=+>0V2RV<;.RC)"
MUR'ASQTLUR+;6+98)-V,R=<4 =[X<MWM=!M89/O*F#6K4%K<07$*O P9".,5
M/0 4444 %%%% !1110 445%/<16T9DF<(H[F@"KK4+7&BW<2?>>,@5Y-X!\+
M7^F^*UN9P/+!/;WKTM?%>C2W'V<7L1<G&VM>*& 8>-%&>X% $U%%% !1110
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M >[T5R7A/QC!KD&R5E291@K[UUM !1110 4444 %%%% !1110 4444 %%%%
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M8DC;<IZ$4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI%+O,JS>0S<?*>E/\2R_VKX_;2)Y"L&,^W6I/&$.G6UM8Z;;PQ%YALWA>>]
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MX%T2&PT&WD,>)R,,:Q] ^&<&G727,EX\X4Y4.2>*]"CC6) B !1V% #Z***
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MI &;![UV%>.>!O%O]D7,VGZFPB._:F[N*]=M[J&[B$D+AD/0T <_XRTVQO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUVV\37NGV^FE9TBD&_ Z"O4-,T^"RM8UCB13M!X&* +JJ%4 =!2T44 %%%%
M!1110 4444 9VMWXT_2;FXW ,B$CFO(+.P\1>-RVH6]T%MR2 KC_ .O73?$M
M]8-F!96YDCV_/@]JH?"_Q-:V^FIIMTR17&[)7'- &/;ZUK_@Z_6'4Y))H&;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=VWH?3/->CTU45%PJ@ >@IU !1110 4444 %%%4H]5LY;IK9)094ZK0!=I"
M00>AI:* /+/B/X;DAF.O68VR0+@8'/\ GBN5\("\\9:EY.HRAU@(8*W&*]TO
MK..^M6@E *MUR*\5GM;GP3XL>ZB3$-S(%&>E 'MEI:QVEND4:X 4"I!$@8L!
MR:AL+C[5:1R>J@_I5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"AJ^F0:M8M;SH&4CH:\2NK;6O >LO/$SM:2R9
M*1J3Q^%>^56N["WO(V2:)&R,9*@T >?:?\6;&:W!DM9E;_:4C^E86O>-[KQ1
M*NGZ9#/$LAV.2AP:[*[^&^FW4YDWE,]E&*VM(\,V.DKB.-&/J5YH S/ WAC^
MPM*C6<!K@=6%==2  # %+0 4444 %%%% !12,P12S'@56M=1MKQG6"0,4.&]
MJ +5,EB2:,QN,J>HI]% 'B7CO2KKPOJLNM:?E!(=@VC)_P \U-X TJ;Q%<_V
MCJ$BRR0ME<GD5ZEKVD0ZOI[PRJ#@$CCO7DOA>[N_"OB1M.=,1W$IQGTH ]M5
M%5=H'%(D2QYVC&:<IW#-+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!%<3I;P/*Y 51DYKR#7]>NO$OB8:382D1L.O45L_$+Q8\2QZ;IQ$DD_P"[
M<=Q7G>FQ:_X-U%;^6S#1#DN_/OWH ]_T:T>STR"&0Y=5P36A7+>&O&EAKD"J
M)E\X#YE'8UU&01F@!:9)&LJ%7&0:Y[Q1KEYI'D?98E??US5_0-0GU+3Q/<(%
M<GH* #3=!L=+N9Y[:$(\QRQ'>M6BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBJ&JZE#IEE)-*X7"DCZT 8?C7Q/%H6E3$-^^ R #S7._#ZRO[V]DUFXDS
M%<+E5/45P>NOK/C:[DOK2$R)"Q0!3P<<?TKIO!_CJ71]FE:O'';B/Y1P,YH
M]C' HJM97T%]")8'W*1UJ69S' [J,E5)% $E9>J:%9:L8S<PA_+;<,USMEXJ
MU*XU^.RD@40L2"WXUVU $<$"6\82,84#&*DHHH **** "BBB@ HHHH ****
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MY%P:A\(>%D\-QSQI+(ZN>-[$T ;UMIEI9MN@B"FK=%% !1110 4444 %%%%
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M_GV2NCDO(8FVNV#4B2+(N5.0: .8_P"$&TK_ )]DH_X0;2O^?9*ZJB@#E/\
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M^$&TK/\ Q[)6YINEVVEPF.VC"*>H%7J* "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_G5W2?&NIZ5;FTOU1)5.U!["N8OH=9U;Q#%>RPC[.TJE2#[T >^V7_'A;_\
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M>D+!\_ERX;;SC@UK77CCQ+>1&*R@C=FXZ_\ UJM>"/!=XU[)J6L1%9BV].]
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MMMX5C'M5H@,"".#2T4 9<WA[2[B3S);1&;U-3KI%BJJHMU 7H/2KM% "
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gtinntqqusay000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )2!68# 2(  A$! Q$!_\0
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M]PHS(H8]J -&BD5@PR#FEH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS144-S%<+NB<,#Z5+0 456FU"UMSB64*?>F+JEDQPLZDF@"Y14$EY!%&)'D
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M'Y_WD<?6LW3-'L+FP!EU1E&>5S6KJ6G6]CHTGD2^8#'UI@9>D6^H:QHC7#R
MC<>M6O"%]=7']J6DS[A%\J^W2K?@K_D4F_WC6=X*YU;6/]__  I 9%MISS>-
MO(.-V,_K71>+KJ[TM;*WA;"R<-@?6L^VE2V^(@:9MJ[>I^M=CKD&G:E"@GG5
M,CY6H P=$TPRA9A)'N/N*[J%=D*J>PKR2\MO[$O0UG?/-@_=S7JFF2-+IMN[
M?>9,F@#S_P =!C?,$ZYJ"_L+RRT^WN@X&$W"K7C3_D(G_>'\ZT/$'_(N0?\
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MVMY+JTU)E8'[JG% 'H6EVS6]N%+*>.QHK!\'7D\]JR2$L$'#$]:*0'7T444
M%%%% !1110 4444 %%%% !113))%C4ECB@ EE2)"[L  ,\FO-_&'CU+8/;V;
MD2$<$&L[QQXTE$LEE#QM.,@UYC--)/(7D8L2<\FN:I5Z(]W 9=>U2H2WE[-?
M3M-.VYVZFJU%%<Q[J22L@HHHH&%%%% %O3KIK6[C<' W#->CO(NIV0O(ONJ
M#7EM=CX1U/<RZ=*<(YR2:SJTU4@XG+B(VM470TJ*GNX?*G8#[N>#4%>').+L
MQIW5PHHHJ1A1110 Y&V.&]#5G5HO/T8W1^]G&:J5I?\ 'UI!M1UZUU867O-=
MSEQ*]U/L<914DZ>7.Z?W3BHZZ# N:8Q^W1+V9JJ^+$$>MNH]*L::<:C ?1J;
MXO7=J[RCIBO3P#T:/-Q\=4SG****]$\XT_#_ /R'+7_?KTW5?^/YZ\R\/_\
M(<M?]^O3=5_X_GI,91HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[E J8QBEU3PY:ZC=1S21@E*UX;B*X0/$P93W%2T 5[6TCMK40(N$QC%<]?\
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M'W<C!KC?#NN.FK2"XDRNWI3O#EV]SX=O@[E@G )-8N@:,-1UF<&9D^3/!^M
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M:0!3]X=O>NXTW0K?3^1AVSG)%22Z/!+=&<XW$YZ4 >>^*[!1K-C+-&7@$8W
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MNH4*W&_J178:)JTEYHMY;2[MT";>1]*Z>RTF"RM_)505^E10Z'! TQ0X\WJ
M* .,\**PU5B5(^4]JS+.]2T\23EP3^][5Z1;Z1#:,TB8S@]JX2TT2YEUVX:2
M(A&DX- #?$%T-7U;R(4?J#G%1^,#]FN=%W#[@&?UKOK30K>UE$N S8ZD5ROC
MC3+B\U?3C#$616^;';K3 BUO6XIO#T<4<;EBWI3(K22#PQ=LRG]Y'D#%=+8^
M'83$K2@'_9(K8FT^*6U,&T!2,=*0'">&%8>#HP5(.#V]J?X!5@NIY4C]X>H]
MZ[*VTF&VLQ;H!M'M2V&DPV'F>6!^\.3Q0!P.GJP\?WC%3CR^N/K5#4+VVCU(
MF:%W8,<;17I']C0QW<UVH'F,I'2N%6.XM-1E,]H"I<D%A0!/HNHZ-]N,K6SI
M,1RS<?TK?U#Q9;V-Y;V_ER$2#C KD[^UNM4NU2WMMBAP=R#'>NX_X1^&Y6UE
ME WQH!R* -:TN%NK=95! /K4],BB6&,(O04^@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO%?B"/2K)T5L2D?*
M0:UM5U&+3K-I96"\'&:\+\1:U+JM\S,Q"J2!S6%>KR*RW/7RG+WB:G-+X49^
MH7LE_=O/*V6;J:J445YSU/N8Q459!1110,**** "M?2-5^S$03DFV8_,OK61
M133:=T14IQJ1Y9&MKNC (+VV \J3D*.2*YH@@X-=3I&JF$F&8!T<;?FYQ5;7
M-$$)^TVF9(,99O0UMI)71Y,HRHRY)[=&<]1112+"BBB@ I0<'-)10!Z+X=OQ
MJM@T$C?ZA> 30ZE6((KC=%OVLKV/!(5F^:O0+T+<H+F'!CQR17#C:5U[1'$U
M[.I;HS/HHHKRS4**** +=C(1*(^SG!K)\10"WU-D XQ6A;OY=PC>AI/$,/GJ
M;P=#Q7=AG>#B<6(5IJ1S5;7AL;K]@?[IK%K6\/R^5?DGNM=%)VFF855>#1S&
MIC&I7 _VS56M+6H?+OI'_OMFLVO?6QX#W-/P_P#\ARU_WZ]-U7_C^>O,O#__
M "'+7_?KTW5?^/YZ&!1HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %.C<QR!UZ@TVB@#M]"U07$2Q2-EZWJ\S
ML[I[6<.IKO\ 3KQ;NW4@Y8#F@"[1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5&((PVX#FI** "HW
MA21@6&2.E244 (  ,"EHHH **** "JT]A;W)S*F:LT4 5H+&WMCF),59HHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIWEOXCF$2;D]_P : .Q+*#@L 3VS2UR.HZH?[1MI-^ !\PS5D^)3YX7 \LG
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MDY"L<5WOB^_^SZ?M1OFSBO,G8NY8]SFO2P5.RYF>9CJEWR(;1117>>>%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M R6-9HRC#(-<)K6GM:W#.!\I/%=]6;J]BMW;'CE1F@#SRBI)HVBE96&.:CH
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MII16^\H/U%>:>^<I!&]Y]KDV,H(R 144,+G0G@*-N+>E=@(T7HBC/H*/+0#
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MZ^F&*,G)1<_2@#DB)--B6,HS%AG@5<MM,%U!YSK]X=#70F-&^\BGZBG!0HP
M * .)_LMHIC*4)13R,5OZ0LF=W*QD<*>U:VQ/[H_*E"A1P /H* %HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!ROCW4)-.T+S8GVMNQFO&AX
MJU+SB7N&*YZ5Z1\4KK.D&'/1J\9KV<%3C[*[1Y.,J/VED=?;^++;_EYB9ZT(
M_%.CR_+]D()[UP%&2.E=+HQ.;VLCT=&M+[_5,D>?4U/_ &,I7(NXO^^A7F@E
MD7I(X^C&I8[RXC8$32''^T:7LI=&/GB]T=Y-8M%T8/\ 2J_D2_\ /-ORK M?
M%%U;8PJMC^]S6G'X[NONM;PX]=H_PJ>6HN@6IOJ6BC#JI'X4VI8O$%G=_P#'
MRZIGT JVLV@./^/P[CV_R:7.UN@]G?9F?16@UM:R_P#'JY>FC2+P\B+BCGB2
MZ<NQ1HJQ+93P_?3%5^E4FGL2TUN%%%%,04444 ;WABQ^V7N2,[#FO58QMC4>
M@%<;X*LO*#2D?>%=I7D8N?-.Q[.$ART[A1117*=04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=Y7*\XJE?:!)+:375K)+)&IYRQHYY<^KL@Y%R:*YRCKM8BNX^'"_\3J ^_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYD*MZU)7SA[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)#B)C[4^HKDXMI#Z
M*::W%+8\M\5OOU3/M6#6IKLOFWY/IFLNO?I*T$CX+%2YJTGYA1116A@%%%%
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MVR9RRKS725\W45I-'OP=XIA1114%A1110 4444 %%%% !1110 4444 %%%%
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M/FNSTJ+7+9$E%%%8&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#B@#CM,-Q&^XR%0I^Z>]=C:3&> .01GL:K-I$#2*^2"OI5Y$"+M'2@!U%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%9^MVYN](N(!U9<5H4A (P:$!\G>)K%M.UJ6W8?=K'KTWXK:*8=5FOPN%<XS
M^->95Z<)<T4S@FK2L%%%%40%%%%, HHHI %%%% !1110 4444 %%%% !1110
M Z-S'(KJ<%3D5[1\,_&89(].NGRS'[S'I7BM6;&]FL+E9X20R].:BI!35BX2
M<7<^P$=74,I!!Z$4M<!X"\9PZM9I;2R R(N"*[X<C->?*+B[,[HR4E="T445
M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I&8*I8]!2URWB7Q MI$8H6&\\$5=.#G+E1C7KQHP<Y&9XLUX9:VB;(
M(ZBN')+').33YI6FE9V.234=>Y2I*G&R/B<5B98BHYR"BBBM3F"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J[I<!GU"%,<%JI5UG@ZP^T3F7&=AS656
M?)!LZ,+2=6M&*._L+<6MJL0[5:HHKP6[NY]Y&*BK(****0PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** (Y88YAB10P]ZA_LZT_YXK63XIUUM$MD
ME4@;O6N&/Q0E!(WI6<IQ3U.RCA:]2/-#8]/_ +.M/^>*U/'&D2[47 KRM/B=
M*\BKO7DUZ!X>U0ZMI_V@D'GM3C.+>@J^&K4HWJ;&O1156YU"WM#B5L59R%JB
MH+>[BN1F)LBIZ "BBB@ HJ*>XCMUW2' JO'JEK(FY7XH NT54M]2MKEV6-\E
M>M6Z "BBD)P,F@!:*KQWL,HD*M]S[U$5[#,<(V: +%%,219"=IZ4^@ HHHH
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M!&0<BEK@O!_CJVU2%(9Y1YH&,#UKO 0P!'>N*<'!V9V0FI*Z%HHHJ"@HHHH
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M/RXK9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH)7V[=QQZ9IT5Q)"V4=A^-+V>@^?4]+@2V\*Z49%NDF>1"A53SR*AT"^M_\
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M2BD5@V<=J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&"U:U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4A 88(R*6B@#S7XA>"8]2M6N;= LN=Q*CDUX-=VLMI.\4J%2I(YK
M[!=%D1D89!&*\@^(O@3<'OK./Y5&6X[UU4:MO=9SU:=]4>+44^6)X9"CC#"F
M5UG*%:6D:1+J=RJ\K$3@OV%)I.E3ZG<;(ERJ\M]*ZN\NK;0[(V=F?F89.?6C
M5NR'HE=B7]]!H]DMG:A?-7AI%ZFN3DD:5RSDDD]Z)I7FD+N<DTRNB$%%'-.;
MDPHHHJR0HHI\2AI #0 W:?2C!':O4IO#_AK3/#]E>7VY7F7G%<KK7_".FV8:
M<S&7MFL8UE)Z(UE2<5JSEJ*T;G1KNUMHIY$^27[M,;2KE;(W17]V.IK7F1GR
MLHT5L:;X;O\ 5 3;H"!ZU%J6A7NEL1<)C'I2YHWM<.5VO8S**U8/#]]<!"B#
M#]*L7_A/4].M3<3H!&.XHYXWM<.65KV,*EP3VH(P<5VOAK1M*GTU;O4,[<\D
M43DHJ['&+D['%;3Z4E=SJ0\)I;S+;L_G ?+GUJAX2TG3M4O/*N\XQVJ?:+EY
MFA^SULF<K170>*-,M]-N@EL#M)KGZN,E)71,E9V"BBBF(*Z_X>?\AU_^N?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML,2QH,!1@5Y^*Q5O<B?099EC;56J@BB2) J* !Z4^BBO,/I4K!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P
M?Q,_Y!L->+,3N//>O:?B9_R#8?K7BS [CP>M-"'0$^>G/>O>? 7_ " ?QKP:
M 'STX/6O>? 7_(!_$4,9U5<IK,\[:TMNDS(I':NKKF-7TJ\N-6%Q"OR@=:0$
M[7DNF0HS9FW#D^E/;7Q_9YNEBR <8JO/9:C+;K$%&,8-1'1KM-(:U1>2<T 6
M8O$!\EI'A*C&1GO4=MXC:=MQ@(7/6H$TF\GMO*F4?(,+BI;?1[F.P\HJ-V:
M+VK7;BU1D)4N.U9.A74[:H(Y9F;V-:FH6-Q+;0+&.4'S50TS2+J'61<NO[O%
M '3R31Q?ZQPN?6FI<P.<+(I/M45W817FWS,\>E10:3;V\F],YH CU>)Y("R3
M^60.W>L#S[M-- $CL0?OUJZ[:WUPT2V@RG\52V6GR"R$$XX% &'9:Q-&3'(S
M$G@9KI["X66$*7R_I6"^@2^:[A>ARM:&E6,\,_FRCM0!MT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %1S01W$9CE0,IZ@U)10!Y'XY\ ;M]W9CJ<[$'2O([FVEM93'*A4@XYKZV=
M%D0JPR",5YUXR^'\.H1O<6D?[X#CBN_#XJWNS.*OA[^]$\(HJ[J.F7&FW+P3
MJ0RG!XJE7H)WU1P-6"BBBF 4 D'BBB@"_'K>I11A([R55'0 TV?5K^YC,<UU
M(Z'J":I44N5=AW9-)=W$R*DDK,J?=![4IO+@PF$S,8S_  ]J@HHLA79;M]3O
M;48AN70>QIMQJ%W=?Z^=Y/J:K446079.;RX*;#*VT<8I$N[B--B2L%]!4-%.
MR"XI)8DDY)JU;ZG>VJ;(+EXU] :J4463"[1=GU:_N5VS74CCT)J."_N[4?N)
MW3Z56HI6079:GU*\N1B>X=_J:JT44TK!<**** "ND\&-MU=C_LUS=;_A-MNJ
MD^U14^%E0^([&Y'[PGU-059NQRI]:K5K'8^8JJTV%%%%49A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%6+2SENY0D:YR:3=E=CC%R=D111/,
M^V-2Q/85W'AWPOC;-/WYP15[P_X72U59KA/W@KJU4(H4#@5YF)Q=_=@?29?E
M7+:I5^X;'$D2!44 #TI]%%>>?0)6"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S-8TB/5HECDQ@>M<[
M_P *^M<]4_*NUHH XM?A_:JP.4X]JZ;2]/33;7R4QCVJ]10 4444 %%%% "8
M%+110 4@ '2EHH **** "BBB@ HQCI110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BEMX9QB6-6'O6/?^
M%=-O4(^RQ*3WQ6[134FMA.*>YYAJOPF@N=SQ7(3O@#_ZU<7J7PWO+//E;Y<>
M@KZ#I,#T%=$,54B82PT)'RQ<>&]6MV(:QEP.^*HR6-U%_K(67ZU]6W-A!=+M
MD0$?2L6Y\$Z/=Y\V'.:Z(XWNC"6#[,^92"#@TE?0%W\+=$?F* Y-8EU\*8SG
MR(A6JQ=-F3PLT>-45Z9<?"?4L_N46L^7X4Z^IR%3%:*O3?4AT*BZ'!T5V+_#
M?6T."BU"WP_UE>J#\JKVL.Y/LY]CE*D@_P!?'_O#^==)_P ()J_]P?E3XO F
MKB9#L'# ]*/:P[A[.?8['43FPL?^N8K,KJ+KP[>RVEJB@91 #5=?"&I-T I4
MJL%#5GBXS"UI5Y.,6SGZ*Z>/P3J)^\JU=A\$S_\ +115/$TEU,HY=B9?99Q=
M*%+' &:]"@\%P?\ +6.M&'PAID>#Y?-92QM-'3#)L1+>R/,TLKF3[L+&KEMH
M-[,W,#J/7%>HPZ/:0?<3I5Y45%P *PECW]E'=3R)?;D>>V?@EIL&20I]:Z"S
M\)6]MC>5?'J*Z2BN:>)J2ZGI4LMP]/51U*L6GVL(&R!!]!5D*%& ,4M%8-M[
MG:HQCL@HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %-;I110!6=%S]T?E431I_<7\J**M$,9Y4>?\ 5K^5*(H\_<7\J**8BUM7
M X'Y4]0/0444@ZD@Z4M%%0:!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gtinntqqusay000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /< \\# 2(  A$! Q$!_\0
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MT?Y4?V?9?\^T?Y4 5?\ A8NG_P#/.;\C_A1_PL73_P#GG-^1_P *M?V?9?\
M/M'^5']GV7_/M'^5 %7_ (6+I_\ SSF_(_X4?\+%T_\ YYS?D?\ "K7]GV7_
M #[1_E1_9]E_S[1_E0!5_P"%BZ?_ ,\YOR/^%'_"Q=/_ .><WY'_  JU_9]E
M_P ^T?Y4?V?9?\^T?Y4 5?\ A8NG_P#/.;\C_A1_PL73_P#GG-^1_P *M?V?
M9?\ /M'^5']GV7_/M'^5 %7_ (6+I_\ SSF_(_X4?\+%T_\ YYS?D?\ "K7]
MGV7_ #[1_E1_9]E_S[1_E0!5_P"%BZ?_ ,\YOR/^%'_"Q=/_ .><WY'_  JU
M_9]E_P ^T?Y4?V?9?\^T?Y4 5?\ A8NG_P#/.;\C_A1_PL73_P#GG-^1_P *
MM?V?9?\ /M'^5']GV7_/M'^5 %7_ (6+I_\ SSF_(_X4?\+%T_\ YYS?D?\
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MG-^1_P *M?V?9?\ /M'^5']GV7_/M'^5 %7_ (6+I_\ SSF_(_X4?\+%T_\
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M.;\C_A1_PL73_P#GG-^1_P *M?V?9?\ /M'^5']GV7_/M'^5 %7_ (6+I_\
MSSF_(_X4?\+%T_\ YYS?D?\ "K7]GV7_ #[1_E1_9]E_S[1_E0!5_P"%BZ?_
M ,\YOR/^%'_"Q=/_ .><WY'_  JU_9]E_P ^T?Y4?V?9?\^T?Y4 5?\ A8NG
M_P#/.;\C_A1_PL73_P#GG-^1_P *M?V?9?\ /M'^5']GV7_/M'^5 %7_ (6+
MI_\ SSF_(_X4?\+%T_\ YYS?D?\ "K7]GV7_ #[1_E1_9]E_S[1_E0!5_P"%
MBZ?_ ,\YOR/^%'_"Q=/_ .><WY'_  JU_9]E_P ^T?Y4?V?9?\^T?Y4 5?\
MA8NG_P#/.;\C_A1_PL73_P#GG-^1_P *M?V?9?\ /M'^5']GV7_/M'^5 %7_
M (6+I_\ SSF_(_X4?\+%T_\ YYS?D?\ "K7]GV7_ #[1_E1_9]E_S[1_E0!5
M_P"%BZ?_ ,\YOR/^%'_"Q=/_ .><WY'_  JU_9]E_P ^T?Y4?V?9?\^T?Y4
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M[>]@NO\ 4R!_I0!8HK&U_66T6R>YV HO4FJ7AOQ=;Z\S(KJ&4<@4 =-1110
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M10 4444 %%%% !1110!@:5_R-=Q]/\:]"3[B_2O/=*_Y&NX^G^->A)]Q?I0
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% ' ^-/\ D.Z9_O\ ^-;9ZUB>-/\ D.Z9_O\
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M^+7_ !ZR_P"[0!QOPM_Y"DGU%?0Z?<7Z"OGCX6_\A23ZBOH=/N+]!0 M%%%
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M/ZK\/+^YULW"PN5W@Y_&@#TWP5_R!T_W11XV_P"0,W^Z:N>&[!]/T]8G!!
MYH\2V#ZAI[11@DD'I0!\WZ#_ ,C2O_71OYU]*V'_ "+^/^F9_E7D.E_#N_MM
M<%RT+A0Y.?QKV>PMS%IZ0L,<8- 'S7XZ0IK9!&.37HGP_P#%5E9644$OW@,=
M:F\>_#]]3N?M5JK,X'"BN)T[P%KT=[&3;RJBL#P: /H6TNX[R'S(_NUX[\8;
MGS(X4!Z-7JGA^TDL].6.7.[ ZUX7\1+W[=KS6@.=LF* -_X2699X[G'1NM>U
M5PGPQTC[!H&77#%L\UW= !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 8&E?\C7<?3_&O0D^XOTKSW2O^1KN/I_C7H2?<7Z4 +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!P/C3_ )#NF?[_ /C6V>M8GC3_ )#NF?[_ /C6V>M "4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "AB*"2>M)10 4444 %+N-)10
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M\^'_ )ZI_P!]"CSX?^>J?]]"L[_A"O\ IXF_[Z-'_"%?]/$W_?1IC-'SX?\
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M^$*_Z>)O^^C0!H^?#_SU3_OH4>?#_P ]4_[Z%9W_  A7_3Q-_P!]&C_A"O\
MIXF_[Z- &CY\/_/5/^^A1Y\/_/5/^^A6=_PA7_3Q-_WT:/\ A"O^GB;_ +Z-
M &EY\/\ SU3_ +Z%)Y\/_/5/^^A6;_PA>/\ EXF_[Z-+_P (5_T\3?\ ?1H
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M$\><\?,.:N@@C(.:\NU?PD='LX+^*ZG+0+O8%SC^==AX,UAM;T".[;&2<<4
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MQ?A*"/!40;KNK*O[_7-8AM[+[,-C#;+CM^E=OX7TA=$T=+101CGF@#F_&?\
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MZ48'I0!6WO[TUV8CFK>!Z5'*!LH KH6'2I-S^].A YJ; H K;G]Z7<]6,"C
MH K;G]Z7<_O5C ]*,"@"MO?WI=S^]6,#THP* *^Y_>F%FW5;P*B8#?0!'N?%
M&]_>K( QTHP/2@"MN?WI=SU8P/2C H K;W]Z-S^]6<#THP* *VY_>C>_O5G
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M $,W2EAZ4DW2EAZ4 2T444 %%%% !1110 4444 1-UJ4=*C;[U2=J "BBB@
MHHHH **** "HYON5)4<OW#0 R#O4]0P=34U !1110 4444 %%%% !43??J6H
MF^_0!*.E% Z44 %%%% !1110 4444 ,D^X:BA^]4LGW#44/WJ +%%%% !111
M0 4444 %%%% #'IR]*:].'2@!:*** "BBB@ HHHH *:W2G4UONT 01_ZXU9J
MK'_KC5J@ HHHH X>W_Y'"Z_SZUVZ?<7Z5Q%O_P CA=?Y]:[=/N+]* %HHHH
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M%% $;=:D[5$W6I>U !1110 4444 %%%% !4<OW*DJ.7[AH ;!WJ:H8.IJ:@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#@?&7_(PZ5_O_T-=Q$N8A7$>,?^1BTK_?\ Z&NY
MA_U8H 791LI]% #-E&RGT4 ,V5R'CH8L(?\ KH/YBNRKC_'G_(/A_P"N@_F*
MBI\#.;%_P9%_PNN;#\*WME8?A7_D'_A6_3A\)=#^&AFRC93Z*HV&;*-E/HH
M9LHV4^B@!A3BHU3+5,>E,3[QH 791LI]% #-E(T092I[U)10!E'0[<S^;L7=
MZUHK$$0*.@J2N;UWQ)'I14%P": .AV4;*S-"U4:K9+.#G)K6H KS+BEB7(I9
MNE+#TH =LHV4^B@!FRC93Z* &;*-E/HH 9LHV4^B@" I\U2!*:WWJEH 9LHV
M4^B@!FRC93Z* &;*-E/HH 9LJ.5,+4]1R_<- $4*YJ;93(.]34 ,V4;*?10
MS91LI]% #-E&RGT4 ,V5$R?/5BHF^]0 X)Q1LIXZ44 ,V4;*?10 S91LI]%
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M ,CC=?Y]:[A/N+]*XBW_ .1QNO\ /K7;I]Q?I0 M%%% !1110 4444 %%%%
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M110 4444 %%)N'J*6@ HHI-P]1^= "T4FX>H_.ER* "BDW#U'YTM '!>,?\
MD8M*_P!__&NYA_U8KAO&/_(Q:5_O_P"-=S#_ *L4 24444 %%%% !7'^//\
MD'P_]=!_,5V%<?X\_P"0?#_UT'\Q45/@9S8O^#(T?"O_ !X?A6_6!X5_X\/P
MK?IP^$TH?PT%%%%4:A1110 4444 (>E,3[QIYZ4Q/O&@"2BBB@ HHHH ****
M (I@2G%8>H([6LRH"&(X-=">:@:W5CTH \QTG2M2&L>8\TFST->FV8*P*#R0
M*8;=(^5 S4D3@<$T 3T444 %%%% !1110 4444 1M]ZI.U1M]ZI.U !1110
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M:CS30!8KC_'G_(/A_P"N@_F*ZCS37)>.&+6$/_70?S%14^!G-B_X,C6\*_\
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MW3[B_2N&M3GQ=<G_ #WKN4^XOTH 6BBB@ HHHH **** "BBB@ HHHH ****
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M*=10 W8/2C8/2G44 0E!NJ38,=*8WWJD'2@!-@]*-@]*=10 W8/2DV#TI]%
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M^N@_F*BI\#.;%_P9&CX5_P"/#\*WZP/"O_'A^%;].'PFE#^&@HHHJC4****
M"BBB@!#TIJ_>-./2F+]XT 24444 %%%% !1110 4444 0S5"9O+6IINE5)$+
M+D4 027S#L:J3ZU%:D>;*%SZU*]NTG&*Y_7?#LU\R[1TH [#3M0BOH%>-PP/
MI5ZN?\,Z4VFV$:,,$5T% !1110 4444 1M]ZI.U1M]ZI.U !1110 4444 %%
M%% !4<OW#4E1R_<- #8.]35#!WJ:@ HHHH **** "BBB@ J)OO5+43?>H E'
M2B@=** "BBB@ HHHH **** &2?<-11?>J63[AJ*+[U %BBBB@ HHHH ****
M"BBB@!C]*<O2FO3EZ4 +1110 4444 %%%% !2-TI:1NE %:/_7&K558_]<:M
M4 %%%% '#V__ ".-U_GUKMT^XOTKB+?_ )'&Z_SZUVZ?<7Z4 +1110 4444
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M%%]ZI9/N&HH?O4 6**** "BBB@ HHHH **** &/3ATIKTY>E "T444 %%%%
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M** .'M_^1QNO\^M=NGW%^E<1;_\ (XW7^?6NW3[B_2@!:*** "BBB@ HHHH
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M%1X;UHPWK0!)14>&]:,-ZT 245'AO6C#>M  YIZGBH6#4Y0V* ):*CPU&&H
MDHJ/#>M&&]: )**CPWK1AO6@"2FM]VFX;UIK!L4 1Q_ZXU:JF@/F&I\-0!+1
M4>&]:,-0!Q=O_P CA=?Y]:[=/N+]*X>VS_PF%S]/\:[A/N+]* %HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH X+QC_P C%I7^_P#XUW,/^K%<-XQ_Y&+2O]__ !KN8?\
M5B@"2BBB@ HHHH *X_QY_P @^'_KH/YBNPKC_'G_ "#X?^N@_F*BI\#.;%_P
M9&CX5_X\/PK?K \*_P#'A^%;].'PFE#^&@HHHJC4**** "BBB@!#3%^\:>>E
M,3[QH DHHHH **** "BBB@ HHHH AFZ4L/0TDW2EAZ&@"6BBB@ HZT44 5;V
MV$\!3U%<M9>&&M]36XW' ;-=G2$X&: !1@8I:J'4(!*8]PW#WJRK!AD&@!K?
M>J3M41^]4O:@ HHHH **** "BBB@ J.7[AJ2HY?N4 ,@ZFIZ@@[U/0 4444
M%%%% !1110 5$WWZEJ)OOT 2#I2T#I10 4444 %%%% !1110 R3[IJ*+[U2R
M?=-11?>H L4444 %%%% !1110 4444 ,>G#I37IR]* %HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[_Y!\/\ UT'\Q785Q_CO_D'P_P#70?S%14^!G-B_X,C1\*_\>'X5OU@>%?\
MCP_"M^G#X2Z'\-!1115&P4444 %%%% "'I3%^\:>>E,7[QH DHHHH **** "
MBBB@ HHHH AFZ4L/2DFZ4L/2@"6BBB@ HHHH **** "BBB@#G=<ULZ;S@=<5
M8T'6/[4@9^.#CBDU71(]2X=0><U/I&D1Z9$410 3GB@#4HHHH **** "BBB@
M J.;[E25'+]PT ,@[U/4,'>IJ "BBB@ HHHH **** "HF^_4M1-]^@"0=*6D
M'2EH **** "BBB@ HHHH 9)]PU%%UJ63[AJ&+[U %FBBB@ HHHH **** "BB
MB@!C]*<O2FOTIR]* %HHHH **** "BBB@ IK?=IU-;[M %>/_7&K558_]<:M
M4 %%%% '#V__ ".%U_GUKMT^XOTKB+?_ )'&Z_SZUVZ?<7Z4 +1110 4444
M%%%% !1110!XQ\:CML%8]I0?U%4M%\=V%GH2P^5 SB,#!45?^,Z%[)5VD@R@
M' ]Q6QX1\!Z!=Z1#+/9!G* DF@#A/"UE>:]XXGOT@\J&11@IP.];GQ \(Z@M
M]:7]E"TYA7)!KU>PT#3](B86,(C(4XKR_P 4>*]5T3Q%!%<M(]F[?,JJ<8H
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MB,!5]ABK=% &-IOA^'3KJYG$C/YYR58\"LO6/ EIJUT9Q,\#'_GF<?RKK:*
M.:T3P=::,Q82-,QZ%^<5H:SH=OK%J89?ES_$!S6K10!Q5C\.[2SNEG-U+)M.
M0K$D5V4<:Q(%10 .P%/HH X+QC_R,6E?[_\ 0UW,/^K%<-XQ_P"1BTK_ '_\
M:[F'_5B@"2BBB@ HHHH *X_QY_R#X?\ KH/YBNPKC_'?_(/A_P"N@_F*SJ_
MSFQ?\&1H^%?^/#\*WZP/"O\ QX?A6_50^$TH?PT%%%%4:A1110 4444 (:8O
MWC4AJ-?O&@"2BBB@ HHHH **** "BBB@"&;I2P]*2;I2P]* ):*** "BBB@
MHHHH **** (F^]4O:HV^]4G:@!#A03TJI_:5MYGE^8-WI4]P"8' ZE3BO/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK_/K7;I]Q?I7$6__ ".-U_GUKMT^XOTH 6BBB@ HHHH **** "BBB@ HHHH
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M_GUKMT^XOTH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP]1L&W59J)OO4 ( ^.E+AZE'2B@"+#TF']*FHH AP_I2X>I:* (</2X>I:*
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M^?6NW3[B_2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **9YL><;QFGT %%%-9U3[S ?6@!U%-5U;[I!I2P4<G%
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MGW%^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %<?X\_P"0?#_UT'\Q785Q_CS_ )!\/_70?S%14^!G-B_X,C1\*_\
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M **** $/2F)]XT\]*8GWC0!)1110 4444 %%%% !1110!#-TI8>E)-TI8>E
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M]X7)%C^%;VX^E.'PHNA_#0^BF;CZ4;CZ51L/HIFX^E&X^E #Z*9N/I1N/I0
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M%+10!#,.*(0,43=*6'I0!)@4N*** #%)BEHH 3%&!2T4 &*3 I:* (F W5(
M,4QOO5)VH ,4F*6B@ Q28I:* #%&*** #%12CY#4M1S?<H 9 .M38J*#O4U
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#@O&/_ ",6E?[_ /C7<P_ZL5PWC'_D8M*_
MW_\ &NYA_P!6* )**** "BBB@ KC_'G_ "#X?^N@_F*["N/\>?\ (/A_ZZ#^
M8J*GP,YL7_!D:/A7_CP_"M^L#PK_ ,>'X5OTX?":4/X:"BBBJ-0HHHH ****
M $/2F+]XT\]*8GWC0!)1110 4444 %%%% !1110!#-TI8>E)-TI8>E $M%%%
M !1110 4444 %%%% $;=:D[5&W6I.U !1110 4444 %%%% !4<OW#4E1R_<H
M ;!WJ:H(.]3T %%%% !1110 4444 %1-]ZI:B;[] $HZ44#I10 4444 %%%%
M !1110 R3[IJ&( GFII/NFHHL;N: )M@IU%% !1110 4444 %'6BB@"!X(]V
M['-3+P,4UZ<.E '.>)-&;4XF51G-)X:T5M,5P1C-=(0#U%  '04 -E?9&3Z"
MN'/B>Y.KBW#-MWXZ5W++N7!K)_X1^W^T^?A=V<]* -.!R\0)IES=QVWWSC\:
MG50JX%<QXIL+F[0>07''\- '06]Y%<C,9S^-3MTKEO"EC=6D*BX+D@?Q5T\I
MQ&30! G^N-6JQ;>Y9M09".,5LCH* %HHHH X>W_Y'"Y_SZUVZ?<7Z5Q%O_R.
M-U_GUKMT^XOTH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@O&/_(Q:5_O_ .-=S#_J
MQ7#>,?\ D8M*_P!__&NYA_U8H DHHHH **** "N/\>?\@^'_ *Z#^8KL*X_Q
MY_R#X?\ KH/YBHJ? SFQ?\&1H^%?^/#\*WZP/"O_ !X?A6_3A\)I0_AH****
MHU"BBB@ HHHH 0]*8OWC3STIB?>- $E%%% !1110 4444 %%%% $,W2EAZ4D
MW2EAZ4 2T444 %%%% !1110 4444 1MUJ3M4;?>J3M0 4444 %%%% !1110
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M4UONT 4HK:-;@N!\U7NU5H_]<:M4 %%%% '#V_\ R.-U_GUKMT^XOTKB+?\
MY'&Z_P ^M=NGW%^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "L3Q'N^P-CT-;=4]1M_M%LR>QI25T:T9*-1-GAS$^=)G^\:
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M4GF"HO(/J:/(/J: )?,%<AXZ8'3X?^N@_F*ZGR#ZFN3\<1[;"'_KH/YBHJ?
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M:0=*6@ HHHH **** "BBB@!DGW#44/WJED^X:BB^]0!8HHHH **** "BBB@
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MYH X[_A)KC^Y+_WR:/\ A)KC^Y+_ -\FNQ^R6_\ SQC_ .^:/LEO_P \8_\
MOF@#CO\ A)KC^Y+_ -\FC_A)KC^Y+_WR:['[);_\\8_^^:/LEO\ \\8_^^:
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M_P \8_\ OF@#CO\ A)KC^Y+_ -\FC_A)KC^Y+_WR:['[);_\\8_^^:/LEO\
M\\8_^^: .._X2:X_N2_]\FC_ (2:X_N2_P#?)KL?LEO_ ,\8_P#OFC[);_\
M/&/_ +YH X[_ (2:X_N2_P#?)H_X2:X_N2_]\FNQ^R6__/&/_OFC[);_ //&
M/_OF@#CO^$FN/[DO_?)H_P"$FN/[DO\ WR:['[);_P#/&/\ [YH^R6__ #QC
M_P"^: .,/B2X;^"7_ODT#Q+<+_!+_P!\FNS^R6__ #QC_P"^:/LEO_SQC_[Y
MH X[_A)KC^Y+_P!\FC_A)KC^Y+_WR:['[);_ //&/_OFC[);_P#/&/\ [YH
MX[_A)KC^Y+_WR:/^$FN/[DO_ 'R:['[);_\ /&/_ +YH^R6__/&/_OF@#CO^
M$FN/[DO_ 'R:/^$FN/[DO_?)KL?LEO\ \\8_^^:/LEO_ ,\8_P#OF@#CO^$F
MN/[DO_?)H_X2:X_N2_\ ?)KL?LEO_P \8_\ OFC[);_\\8_^^: .-/B6X/\
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M^^:/LEO_ ,\8_P#OF@#CO^$FN/[DO_?)H_X2:X_N2_\ ?)KL?LEO_P \8_\
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MH X[_A)KC^Y+_P!\FC_A)KC^Y+_WR:['[);_ //&/_OFC[);_P#/&/\ [YH
MX[_A)KC^Y+_WR:3_ (2:X_N2_P#?)KLOLEO_ ,\8_P#OFC[);_\ /&/_ +YH
M XL>([@-G9+_ -\FG_\ "37']R7_ +Y-=C]DM_\ GC'_ -\T?9+?_GC'_P!\
MT <=_P )-<?W)?\ ODT?\)-<?W)?^^378_9+?_GC'_WS1]DM_P#GC'_WS0!P
MNA)<7?B&:Y<,%8=Q7?KPH'M3$@BC.4C53["I* "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"NSKB_AQ Z>&K61AC*UVE !1110 4444 %%%% !1110 4444 %%%% !1110
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M^<DBM^B@#@;WP5J,5Y+/I-PL'FME_>M+0/"CZ?<K>7K++=#^,5UE% !1110
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M[,0#U -<?9JO_"8W0P.GI]:PJ04FCS\7AXU)1;-S0DGCLPDS$D# K5I%  X
M%+6R5E8[H1Y8V"BBBF4%%%% !1110 444R:5887E<X51DF@!])D>M>4^)OB?
M<V^HFRT98YY,< XK&'Q%\86;++>6$20GDM[?E0![A17+>$O%]OXBLED\Q3(3
MC KJ P/2@!:*0L!UHR,9H 6BF+(I. :<3B@!:*89% SFG;AC/:@!:*8LJ,<
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MHQM[ZXU@31.-Y0'M7<WGBV6^\"1:I;.4=S^/05P=QI?AV33[=9K^7<Z=,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEMYBQ^<F]NBYZUYSXYU.::[M[>W;E)1G!]ZQYM6NHOB3I5IN_=O""PS_ +M
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M.\=6<MJC/*D> %Z]J]4\,:#<6FMWE[.N#*O6L35O!U[??$.SU Q@VJ+AC^5
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M44 -:-&/S*#3?)C_ +@J2B@! H P!Q31#&IR$ -/HH 1E5OO#-&U<8QQ2T4
M-"*!@#BHI[9)H&CP &J>B@#R[5_AG?W6HRW-MJ\D*O\ PK_^JM/PM\/?[&G6
MXNKG[3*IR&;K7?44 -"*O0 4;%W;L#/K3J* &LBM]X UQGBWP5-K\WG07AMV
M P,?_JKM:* /*++X5WGVJ*2\U5[A(F!"O_\ JKU"TM8[2!8HU   '%3T4 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gtinntqqusay000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +1!= # 2(  A$! Q$!_\0
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MGS-%)<*I*D]A6A\/?%Z7T'V5XTC*#:,=Z[?5[2SO[8PW&W!]12 \"\'>*?\
MA'9F#E@K'D"O5;7XAZ/J</E.K988Y-<MJ_POB:1YK25GW'.!7(WO@_6=/),<
M,NT=P:8'I5MX*T/4;IKI$CW,V[[PKO-+L(]-LEMXEPJ]!7SAHVOZAH^I)YDL
MAVMRI:OH3PWJ_P#;.D1W9 !;L*0&Q1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44FX4;A0 M%)N%&X4
M +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12
M;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N
M% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T
M4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4
M;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0
MM%)N%&X4 +12;A1N% "T4FX49!H 6BBB@ HHHH **** "BBB@ HHHH ****
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M_P +$UW_ )_I:/\ A8FN_P#/]+7'T4 =A_PL37?^?Z6C_A8FN_\ /]+7'T4
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MM'_"Q-=_Y_I:X^B@#L/^%B:[_P _TM'_  L37?\ G^EKCZ* .P_X6)KO_/\
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MN=NO'6N(QQ>2U/)&&&*S;BP#9)%3.A"2LD;4ZK6Y$_Q!UY3S>RTS_A8FN_\
M/]+61?VFPG K(=2IKR:U%TY6.N,N97.N_P"%B:[_ ,_TM'_"Q-=_Y_I:X^BL
M2CL/^%B:[_S_ $M'_"Q-=_Y_I:X^B@#L/^%B:[_S_2T?\+$UW_G^EKCZ* .P
M_P"%B:[_ ,_TM'_"Q-=_Y_I:X^B@#L/^%B:[_P _TM'_  L37?\ G^EKCZ*
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M%%% !7H/PK_Y#!_WQ7GU>@_"O_D,'_?% 'U#'_JU^@IU-C_U:_04Z@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#G/&G_ "+]U_UR-?($O_'Q-_OG^=?8
M/C!=VA7(]8S7R3>6OESRX'\9_G5*#:N@*5%+CG%)4@%%%+VH 2BBB@ HHHH
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M_5K]!3J;'_JU^@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@_"O_D,'_?% 'U#'_JU^@IU-C_U:_04Z@ HHHH **** "BBB@ HHHH ****
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M"H6 KF)!AS7;:G'NC-<G<Q88YKS\;3O[R.VA+2Q2HI3UI*\TZ HHHH ****
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M>QTEF, 5JH>*R+0]*U$/%>LSSY$A-&:*0B@@<&H)J+-)NI#L29I148-.SBF
M_I4;'FES332 <*0BDSBFEJ8 QJ!WIS-43<T%( U,8TA.*:3FF584/5JV7S7
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M'F(<DG8^BT_U:_04ZFI]Q?H*=7.6%%%% !1110 4444 %%%% !1110 4444
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MBBB@ HI0I-2+"QII-@,"$]J>L+G^&KD=NQ[5J6]GE!D5UTL*YF4JBB9"P/\
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M5IV/<%^XOTI:1?N+]*6O".\**** "BBB@ HHHH **** "BBB@ HHHH ****
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MU>5BJ"@[H[:<^9%>BBBN(U"BBB@ HHHH 6DHHH **** "BBB@ HHHH ****
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M.W=OAB:Y,93<HW1U49=#+HI[KM:F5Y!TA1110 4444 %%%% !1110 M%)10
M4M)10 444M "4444 %%%% !1110 5UOPV_Y'G3_]ZN2KK/AM_P CSI_^]0!R
M=%%% "TE%% !12TE !2TE% !1110 4444 +DT9-)10 N31DTE% "Y-&:2EH
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M=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&F/;E14.E-*[0[HKT4I&#BDK,84444 %=9\-O^1YT_\ WJY.NL^&W_(\Z?\
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MV=46DSZ%3_5K]!3J:G^K7Z4ZO(.D**** "BBB@ HHHH **** "BBB@ HHHH
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M!-V""#<>E:]K;D <4^RL^!D5L0VX':O8H45!79RU*G1$4%OP.*O+#@=*ECB
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M  ,RI_$CVA?N+]*6D7[B_2EKPCT0HHHH **** "BBB@ HHHH **** "BBB@
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MK2C!QCJ<N88I5JEX[##0*5A0HS6IP)-["4A'-7(;,R^M3'3&ZX-0ZL4['5#
MUI*Z1F[*4"K#P&,XJ/;5J2>QSSA*#M(05(*0"G8H,A#TJ&3I4QZ57F.%IH$8
M^IR!4-<S/)D5NZL_RFN:D?/%>?C9M/E.V@M+D9ZTE%%>:= 4444 %%%% !2Y
M-%)0 NXT;CZTE% "[C2[CZTVB@!=Q]:-QI** %R:*2B@ HHHH 53@YJW#("Z
MCWJH.3BK,"8=3[UI3;4A/8Z2T&<5JQCI619MTK8CZ"O?3]U'G2W+(KK/ _\
MQ_G_ 'JY(5UO@?\ X_\ _@58UO@8Z?Q(]J7[B_2EI%^XOTI:\(]$**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH P_%+;=&N#_TS-?.$=R#<R#/\9_G7T3XQ
M.-!N3_TR-?*]O=E;N0D_QG^==^#JJ/NOJ8U8<R.TB;(JTE8]G=+(HYK21Z](
MX9*Q;% QFF*_%+NH,K$E,8T$\5&30"0A.*;FBFXH+'4<=Z *;S0 K8J%Q4O-
M!% T5P.:D I^VC;3"Y&5I-@J3%-- QH %.R*80::<T /+5"\N*1FXJE<3[,T
M%)!<3[>]95Q>GIFF7=Z#D9K'EG)/6N6OB5!61T4Z5]6:<=^0W)J_#>[CUKF/
M-.:L0SD$<UA2QCO9FDJ2>QV-O/N[UH1L"*Y2TO@" 36[;7(<#FO0C)25T<LX
M-&G@48J-),U,"*9D-V4NVG44@&'BFY-2XINV@!M(:?MIN*8$>*8QJ8BH'!)H
M&AO6GBFJ*DQ0,2G"@"EZ4"%HXQ4;-BF-+M% 6$F( K"O[@8(!JW>WZJI -<W
M<W!=CS6-:JJ<3HI0;=R&:7)-52<FE9LFFUXTY.3N=B"G(,M3:GBA)-**;>@&
MC9PJQ'%=%:QA5&*QK&!LCBNBMDPHKW*,>6!Q57J6(QQ4PI$%/K0YVQ<TAI":
M;FD IJ!\BI<TQL8IC1""2:=24AH*'[A1FHN<U(M "AL5(&S4;=*C!.:!$KFG
MITJ+K4J]* 8[O2@TPFF[N:!6)N*,U%NI0U K$P<T\-FH13P:0K$F:W?"1_XJ
M.U^M8':MOPCG_A)+7ZU%3X&5#XD>(4E%%>">H%%%% !1110 4444 %%+S4D,
M>YJ:5W8!J)N/2K,=ON.,5;BL@:O06(!KMI823U9C*JD4X;(U;CM-O:M&.U%6
M%MA7HPHPBCFE5DRE%:YJPMF:NQ0"IQ&!6FBV,VVRM%;[14WE5*%Q2XI"N1"*
ME\NI@*-M 7(@E+MJ3%+CB@+D6RD$=2XH H%<C,5*J;:E H*T!<$J2HU&*D'2
MD(",T;:=BB@5QNVEQ2T4 -(II'%/I*!D>VC;3\4NV@"/;2[:?MI,4!<B9:EM
MX=YI",TJ2&,\5,[VT.G#2BJBYMC7M8_+%6B>*I6<V\<U<R*\R::EJ?9X=Q=-
M..Q2GM=V6K*E79)BN@E(\LU@7)_?&NK#2;T9X><4H12:$%+VI@-.SQ76?/C6
M/%5+EL)5AVXK/NI/DIHI&'J;9!KG6^]6YJ#Y!K$8'->5C7>9W45:(VBEVFIH
MX\UQJ+;L;$.*,5=6 &I5M,C.*V6'FR7)&;@^E&#Z5I&S]J/LG'2G]6F+G1FX
MI*O-;@=JJ.A#<5G.G*.Y2=QM)2[31M-9C$HHYHH **** "BBB@ I:2B@!R?>
MJY$.5JG']\5>BZBMZ*NR9;&U9]16[$ORBL*S^\*WH?NBO:C\)P3W)0*ZSP/_
M ,A _P"]7*UU7@?_ )"!_P!ZLZWP,*?Q(]J7[B_2EI%^XOTI:\(]$**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH YSQG_R+]U_UR-?(N\K<R_[Y_G7UUXT_
MY%^Z_P"N1KY E_X^)O\ ?/\ .FG8#7M-0,)&371V.HK,!S7"9.>M:>GW1A(Y
MKT,/BFWRR,*E)-71WJ2U,IK"M+X.HR:TH[@'O7H'%*+1?SQ3#40EI=X-!%AX
M6G;:8CT_>* U$H*C%-SS3MW% QN.:<4XI*<&H$QNRFD8J0M49.30- 1Q417F
MIQTII H&1$5$_%3FH9%S3&BG,^ :Q+ZXZBMF=/E(K!O8#R:FI=1T-J:5]3&G
M=BW6H<YJ292&J.O!E=O4[4% )'2DHJ1DT<I##FM>TO\ R\ FL*I4D*FMZ->5
M-DRBI+4[&WU -CFM..<,.M<+!=%6&#6S;:CT!->K2KQJ(Y9TFMCJ _O3@]8R
MWXQUJQ'=AN];6,'%FEOHW5564'O3MX]:!6+(.:4XJJ)0.]/\[WI"L2-41Q09
M!4+R4QI#SP:=N%4WGQWJ/[4/6BQ5B_Y@%,>8 =:SIKP*,YK-GU,CH:F4HQU9
M48-[&M/=A>]9UQJ8VD UDS:@7ZFJ4DQ/0UR5<8DO=-XT>Y9N+HN<YJBS%C2$
MDTE>;.HYN[.A*P4445 QR?>K6LXPV*R4^]6O9/@UUX.W/J14V-ZTC4 <5J1X
MQ6;:\@5I1CBO89P,F%*>E-%+2(&%J3=0U1MQ0-#\TC=*C#\U)F@8S%+UH- H
M&)MI<5(%XII'- KD;&HPW-3,F:@9<&@9(&IPDJ#- ZTP+6<BF#K0O2E'6D(=
MCB@"G@<4;:!7'*.*7H::#BG=:!$B\UN^$A_Q4=K]:P <5O\ A%O^*CM?K6=3
MX&.'Q(\-HHHKP3U HHHH **** "GHN3TI$&35^"(,PK2G3<WH)NPQ( W:K]O
M9C<#BKEO:*0*T([91BO5IX91U9R3K=$1P6H]*O);J.U/CC%6 HKJN8-D2Q#T
MIXC%3!:=M%(5R-5Q3]M+C%+2$-P*2E-+3$)12GI3:0PH[4F:*!W0M I*3-,0
M\4X<U'FEW4A#\4X4P&ES0!(*6F!J<#0(6DI:* $Q1BEI* &THHHH 6DI:* &
MFHV%2FF8H&F"3-'T-6$NW(^]54K2@<5$J<6=M'&5*:M<F>[D/&XU7)W')H(I
M*<8*.QE6KRJ_$PI"W%(34;MQ5F%ALKX4UE74G!JY,YVFLV3YJ:6A2W,JYRQJ
MM' &;I6KY ;K4D5HH;BN5X?GE=G3[5)6*$=B#VJREBO]VM*.W%6$@ K6-"$>
MAE*JWL9R6*XZ5.MF,=*T5A%2"(8K2R1#DS*^QCTH^QCTK5\H4ODC%&@79B/8
M ]J@;3%S]VNA,*TTP+4N$);H:G)',R:<H'W:IR6FWM76/;*159[%&K.6'@]D
M7&JUN<F\/!^6JQ0@]*ZN;34 JE)8J.@KCJ8*6Z-XUDS P125HW5ML!P*H^6W
MI7'.FX.S-DTQE%.V-Z4A!%9C$HHHH <G#5;C;D53J:%_F%7"5F)G061^85O0
MGY17/V/45T$/W17NT_A."I\19KJ_ _\ R$#_ +U<H*ZSP/\ \?Y_WJBM\#%3
M^)'M*_<7Z4M(OW%^E+7A'HA1110 4444 %%%% !1110 4444 %%%% !1110
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MI1'S57$55@&>E3K"H[5.(Z=LI7&1K&/2I H]*7&*<*0 %IV***!!BEI,T9H
M*2D)I-U "X%)L'I2@TM QC1*1TJ%K9#_  U:I"* ,V6PC?JHJA/IJ <)70;:
M:T2M2<8O=#4FMCC[FTVGA:SYH3Z5V\UFC=JR[FP'.!7+5PJGL;PKVW.4*$=J
M;6I=6K*_ J@\+ ]*\V=*4'8Z5)-$=/B/STP@@\TZ/[U9K<HW;%_G S710-\H
MKDK9R)1716DF0HKW,/+FB<-969K UUO@C_C_ #_O5R*]*Z[P1_Q__P# J*WP
M,BG\2/:5^XOTI:1?N+]*6O"/1"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .=\9*6T&Z _YY&OD>:U<7$N0?OG^=?8'B9=VCW _P"F9KYJN]/5I9"!_$?Y
MUUX?#JJFS*=119QK1E:96W=Z>PZ+6<UJRGD5%7#R@RXS3(!$32F(@9JRJ@4Y
M@"*%0NKA<JQY)Q6K9V[[@<&JMM!F4''>NGM(D"#BNK"4/M,RJSMH,A1@!5^%
M2:<(AVJ:./%>BV<C8Y4XIX%/'%+Q2(N"BI,#%- I3Q2$PP*-M)FG!@!0 TYI
ME/9A3,\T %'0TN.*3!H <#4;\T&DIC(BH)IC1 BIL48H*N8E]9;P<"N>NK)D
M)XKN70$<UFWELC*>*RJT8U%J:TZCB<0R%#S3:T[VV*N<"LYEVGFO'JTW"5F=
MJ=T-HHHK(8445*D1:FDWL!%4D/WJG%FS=!4\6G29^[6L:$V]B7)(="I:K8M\
M]JLV]@RCI5Z.T/<5ZU.E9:G/*HNAG1PD=JMQVY(J\MM[5.EOCM6R26QE*=S,
M>RRO2JAL</\ =KI!",=*8UN,]*&D]R5-HP&M..E0FQSVKH3;Y[4@M1Z4G"+W
M12J,Y:73V["J3V3ANAKN?LJD<BHGL$;M^E<\\+"1I&NT<;]E8+T-0-;/GH:[
M-[!<=*JG3USTJ)8*+V*5<Y-X&49-15T.H6@53@5BM"0W2N*O0=-Z&T)\R(D^
M]70Z;<!0!6$(CFK=NQ5U'O58:;A+452/,CL[=@P!JXO2LJP):,&M-*]<X)(<
M<TF#4E%!)"13&6IFIA% T0!>:'&14M-/-!2$AP.M)*1VH(]*9CFDEK<T=2\>
M4C(.:< <5*H%!Q3,R,4_'%(!S4E $6TU&5.:L$BFG!I@-7.*D4<TT4]3BD!)
MCBFDTI<8IO6@2' TX-2*.*:0<T"+"M70>$C_ ,5%:_6N;2NA\(G_ (J.U^M9
MU?@81^)'A]%%%>">H%%%% !2@<TE.3[U %F)>E=!9+]VL>WC)QQ706:8 KU\
M'#E5SEKOH:D2@(*F IL?W14E=9RCJ*2EH$%&:3-)F@!329I"13&.:"DKDP!/
M04OE/_=-7-/BW#D5J"W3;TKEGB%%V/:P^4.K34[G.%&'8TW-;%S;'D@5B3?*
M^*UIU.<X\7@WA]Q2U 8>M5R])DUJ<25]BUN'K2$U7&ZG9- .+6Y-3330:=B@
M0Y:D%1BG4 /S2@TREH)L2BES48-+FD!(#3@:C!I:!$F:":CSBDWCUH"Q)14>
MX4NX4!85J:32%JC9J!H?FFDU&7'K33(OK3'8D)J!S\U!D'K3"<F@8[-&#2@9
MJ0"@")4.:F"^U. IX% KC,4N*=2-0*XTBDZ4$U&QH*),T5$#3MXH 4FF[J"X
MJ-FH <6IH-1%QGK2>8*=A%G=3PPJL'%.#46&6<T9J#=3U:D!+13,T9H =@&H
MY(E;M4@-+UH$9LUFC?PUB7=F0QPM=85JI/ &!XJ904E9EQFXLX>:!@W2H -K
M<UTEY9-R0M8<UNP8\=*\JOAW!W1VPFI(D@;YQ6_9O]WFN9B.U^:V;.8;E&:Z
M,'.RL9UHW1U2'(%==X'_ ./_ /X%7$P."!7:^!C_ *?_ ,"%=5?X&<U/XD>U
MK]Q?I2TB_<7Z4M>$>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9'B(?\
M2J?_ '#7S^Z RR<?Q&OH#Q#_ ,@J?_<->"LO[V3_ 'C7IX'X6<>)?O(HRVJN
M.E9ESIP.<"NA"YIKPY[5W:/<P4VCCY-/9>U0?9"#76R6@/:J;V0#=*ATHLV5
M9F1#!M/2MBU!P!0MJ!VJW#%M-:))*R(E*Y.B9%3I'Q2(*G6D8MD)7%)CFIV%
M0GK0).XJTKM3:C<T#'9I,TP&G4QBCFE YI 13^*0A10:3-)F@!K4VAFIF[FF
M.Q)MIIXI0U(W- #.M1219%2]*7.1048%]:\$XKGIX?FKLKI-P(Q6#=VAY.*Y
M\11]HKG12G;0Q#%@5$>N*MRY&157:2:\B<;.QU(DBBWUIVUITR*KVB?,*VX5
MQBO1PE!-<S,:L[$D%H..*T([9 /NT0+Q5I:[MCE;8BPJ.U2>6/2E%/H(;&!1
M3P*!2T"%Q2$49I*0!Q2''I2XS2$4P&YIP(IA%)G% [#B :C:,&GYYIPH S[B
MS\P&L>XTT@G KJ#BJ\L88=*3BI;EQFT<B]H4%0HA$HX[UT-S!SP*I?9?FSBL
M98=-Z&\:NFIJ:><1"M-*R;9M@ K2B?-;VL<\BR!1BE'2D8TB!AZTTTZDI@1X
MR:-M/Q29H*N-*X%,(S4IYI M 7& 4FW)J8+3Q'0%R#9BFFK+IQ4.WF@29%MH
MQ4I&*3;F@8P"G8I<8I : $VFGJ**<M #A1C-!IPZT$@!BMWP@?\ BI;7ZUBG
M[M:WA!O^*GM1_M5G4^!E0^)'BM%%%>">F%%%% !3T^]3*<GWJ:W V;0C:*W;
M8C KF[=@,5T-GRHKV\.[Q.*LM35CZ5**B0?+4@K8P'44E(30 O:FFC-!- #"
M:5.:1A2KQ4RV-Z+7-J;FG#"CZ5?S5#3VR@^E72:\BJWSL^ZPEO8JPR=AY;?2
MN5NV_>FMJ[O47<I-<],V]R:[,'%J[9X6=SC*RB(@+-@5?CLW/8U5M$_>K]:Z
MN$#8.!THQ6)=-I(,MR^%2/-(P_L+XZ&H9+1T&2#74 #TJK>(#$>*RIXF39W8
MG+*?(VCG%4@U)BIWC(--"UWJ5SY:I1Y96(\4 5(:;33,I120"BEI":HS%I13
M:4&@30\4ZHP:>#2 :W2HF.!FIV'%5I@=M,:&^<!WI1.OK6=.WECFJ+:@L?5J
M&XQW*46]C?,P]:B>=?6L$ZO'_>J-M31OXJCVM/N5[.78V7NE'>HC= ]ZQ'N@
MYX-30ON4<TE53>A3I66IK"<$U8C;(K,0$D5IVZ'8*VZ&3W+2#BI0*1!Q4H'%
M2)L8!S3Z,44A#33&IYJ-J8(8U1-FK"IO/%2&U8CI6<JBB>CAL$ZT;E MS1OH
MN(BC5",UI%IJYS5J3IR:9+NI":CS1FJ,!&!--VG-2BEH 8H(J4&F \TX T,I
M1;'4]#S4>:532%L3YI"U,S2T@)%-2"H :F7I0 ZFD9I:6@13GA#*>*PKRS;Y
MCBNH(JM<1;HVX[5,HJ2LRHR:9PS1E9*LVQ(D'UJU=VK(2<53C;;(/K7"J?LY
M'9S*2.FMI,X%=YX$YO\ _@0KS>SF!<<UZ+X!;-__ ,"%==9WIMG+%6G8]Q7[
MB_2EI%^XOTI:\(] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R?$'_(+F
M_P!PUX0R_O9/]XU[OX@_Y!<W^X:\(<_O9/\ >->G@?A9Q8KXD*HIV*:IJ45W
M'(R,Q\57DB]JO<4QTR* 4C.V<T]14[1\T@3%!=QR584<5 !BI5:@B0KU7;K4
M[,#434#B1YIAIYJ-J"A,XHWU&Q-1Y.:95B;?S3P_%18XJ,L<T!8M[Z">*K F
MG[J!6%8T@I,YI>U Q<XI0<U$6I5<9H E(I,4C-Q2H<T"(I(\U4FM@R]*TN*:
MR@B@:9S%QIXSFJ;6(SQ71W,1P<"L[RSNQ4.C"6MC:-1E:VM=I%:L4'3BB"("
MM".,5:2BK(B<FQ8H\"I@HHQBDSS09D@44N*:":=2)#%)BC-+0,,<4TU)VJ-J
M8#0>:=UIG>ES0 XBHFZT_=33UH&A *<>!2C%!YH 9G-(1FGA:7% %5XLFJ[0
MCTJ^143+3N5<HA,-5R U'(H J.&3Y\4#W1K*>*7&:CC<$5*#4F8PBDQ4E-Q0
M W%)MI]->F!&W%"\TA!)J2-:!CPM.%3(F12[1FD1<B9>*BV8JVRC%0LM )E9
MA2 5*RTW%,NXS&: M/Q2A>:!7&[>*3%2D<4S% 7 "EZ4=*8S4 .=^*U/!S@^
M*;0?[584SX6K_@J<GQ?9K_M5%1>XS2FO>1Y31117@'HA1110 4Y?O4VE'6@"
M]#U'UKI['[@^E<I#(,@>]='8S_*HKUL')-6.6NC>3[M/J*)\H*EKL.4*::<:
M2@!,48I:2@!#3<4ZDS0-,O6MX(!R*G;5%(Z5E$;J:4K"6'A)W9Z=+-*]./(F
M%U)YLC-ZU4QS5DK41'-;122LCBG6E4ES2)K<[7!]ZZ&"X# "N;0X-:%K-AQS
M7)B**GJ>YEN.4/=9OCUJ"[;]V:038C!JG<7.Y2,URT:;N>KC,3&--E9VYJ(T
M9R:*].,;'R%6NY,2DIQI":HYG)L;11FFTP%HS3<TO:@8N:>&J.E% B7/%12#
M(I]-;I0)&1J"D)7,W60#S76WR92N7ODV@US8I>Y<Z:#U,HL<]:3<?6@]:2O'
M.PNQ9(%:=LGR"LV#H*W+*+<@KT\+&Z.>K*R+5O"3S6K"F$%0PQ86K2C KO;.
M0D6I!TJ,4[-20.-,-!-)3 0TQNE.---!2%B?8>:M"Y7'2J!I-QK*=)2/1PV,
ME15A;MP[9Q52I'.:B-:0CRJQAB*_M97$(I.]!:DJSF'@\4SS06Q2D\5"%_>9
MIC2U+L<18U8,)"YIL!QBK9;*URRD[GMTJ--0U,]DQ2**L.,U&J5M%Z'DUTE+
M03%. IV*<HIF(W93U&*6E% !3A28IPH$Q,4UQE2*DI".*!&/>VVZ,US\EL4<
MFNPFCW(16->6^U6.*BI!35V:TY\NAGV;XD%>F_#ULWW_  (5Y9"^R6O2/AO-
MNU C_:%8N2]DT:N/OIGT"OW%^E+2)]Q?I17C'6+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &3X@_Y!<_^X:\&?_6R?[QKWGQ#_P @J;_<->"L?WLG^\:]
M/ _"SBQ/Q(53S4@:H<TH-=QS$^ZG@U"*<#02T2D TW93EYJ0+F@F]B C%1M4
M\@Q4)ZT#3&8-+M-/! I21B@JY U1-4SD5":"D1,*3BGD5$W!IE$F1BF ?-30
M:>HYH <V *A+<U*_2JYH!$@:I,\56#<U,AS0,'J,9S5@KD5$RXH 4$FI%!J%
M&YJPO- F+@TZG 48H)N02(&%4W@ /2M0Q\5 \>:$QIE*-#FKD8(%(L>*?G%
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M<DFA#10:*HR%IPZTVG"@!U#=*3-(3Q0(JW2Y2N7U(84UU,_*US.JC"FLJ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#I_JU^@IU-3_ %:_04ZO%.P**** "BBB@ HHHH **** "BBB@ HHHH ****
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MK]!3J:G^K7Z"G5XAVA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH *ZSX;?\CSI_^]7)UUGPV_Y'G3_]Z@#DZ*** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ5:2, =*38K#5B %/V"I *=BI"Y%L%=9X'7&H'_>KER*ZKP1_P ?Y_WJRK?
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MK,F\RCS*B%EJ'_/G/_WP:8UEJ.?^/.?_ +X-&G<+,G\RFF857-EJ1_Y=)_\
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M;ROFE+4D-C?D#-I-_P!\FIQIU[_SZR_]\FNJZ.7E96VTX"K0TZ]Q_P >LO\
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MI!115(EDBU*.E%%42**6BB@ I:**!"5;L?\ 6444I;#6YMCI1117.:A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %:]_X]W^E<:?O'ZT44 )1110 4444
M%%%% !4@HHJH[@/7K5E.E%%;(ADHI:**9(M%%% @I*** %I:** $-)110,*0
MT44 ,:H&HHHZ#17?K3***YWN:!1112 *GBHHJX;B>Q:7I3Z**V,Q:*** "BB
MB@ I*** "DHHH 6D-%% ##44G2BBA[#6Y7/6FT45SLT$HHHI %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5<TS_C_C^M%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>geyphazaalhx000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geyphazaalhx000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $' NX# 2(  A$! Q$!_\0
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M#J,EAJ4+JV%W\U]%Z!J(U+34F!SFO Q^&5*7-'9GO8'$NI'EENC5HHHKSCT
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ME<-$XP17T>$Q*K0\SYW%8=T9^15J2&5H95=2000:CHKK.4]O\ ^+$NX%M9G
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MY_Y[2?\ ?1H^W7/_ #VD_P"^C7H__"GM0_Y^8_TH_P"%/:A_S\Q_I1]=P_\
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M@GVKT>UTBRM$58[>,$=PM70 !@#%>=7S&<](Z'HT<OA#66I5LM/@L85CB7
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M$5JT5+JS>[*5*"V16CL+>+&Q,8JS114-M[E));!1112&%%%% !1110 4444
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MKGI-%4K#4[?481) V0?>KM<;33LSK335T%%%%(84444 %%%% !1110 4444
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M\)6ND(K>6ID'>NF  &!TKQ<;B_;/ECL>S@\)[)<TMQ:***\\[PHHHH ****
M"BBB@ HHHH **** "O,/$_\ R';?_KL*]/KS#Q/_ ,AVW_Z["N7%? >IE7\9
M^AZ7!_Q[Q_[@_E4E1P?\>\?^X/Y5)74CS'N!Z5YAX\B$^J6D1) 8XR*]//2O
M-/&G_(<LOK7-B_X9Z64NV(OY,M:;X#M[BR20W=P,]@Y_QJW_ ,*]MO\ G]N?
M^^S_ (UTVB_\@R.M"G'#T^5:$U<PQ*FUS'C?B_PS%I"PND\KY<#YF)[UWG@;
M_D#'ZBL'XD?ZB#_KH/YUO>!O^0,?J*PI04<0TCOQ56=7+HRF[NYU%<]XR_Y
M,E=#7/>,O^0#)]:ZZOP,\C"?QX>IP'A'PS%K,UTSSRQ[3_ Q'I75?\*]MO\
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M %:_2GUV'CO<1ONFO(M?_P"1D'_745ZZWW37D6O_ /(R#_KJ*X\9\*/7R?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gtinntqqusay000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'F!O@# 2(  A$! Q$!_\0
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M24M !FCG%)2T %&:2CO0 N:,TE% !FES244 +FC-)10 N:,TE'>@!<T9I**
M#-+GBDHH 7-&:2B@!<T9I**8"YHS244@%S1FDHH 7-&:2B@!<T9I** %S1FD
MHH 7-%)10 N:#244 +FC-)10 N:W?#6N2:3?*P; 8@5@TH."".U)I-68T[.Y
M]&Z?>QWMLDB'.5&>:MUY/X'\2&"1;29\ACU)Z5ZJDBR(&0Y4]Z\ZI!P=CJC*
MZN/HHHJ"@H/(Q110!PGCCPX+R%[R-,NHP#7DLL;PR%&X8=:^D9HEFC*. 5/8
MUY%XU\-M9SM<Q*2'/0=JZZ%3[+,:D.J.(S1F@CG%)748"YHS244 +DT9I**
M%S1FDHH 7-%)10 N:,TE+0 9I,T44 +FC-)10 N:,TE% "YHS244 +FBDHH
M7-&:3M10 N:,TE%,!<FBDHI +1FDHH 7-&:2BF N:,TE%(!<T9HI* %S1FDH
MH 7-%)10 M&:3-% "YHS244P%HSBDI:0'I/@?Q.5/V6X?*CA17IRD,H8=Q7S
M?:7+VMPDJ$C:<U[/X0\0)J=BJR,!)TQ7'7IV]Y'13G?1G54445S&H4444 17
M$(GMWB89##!KQSQEX=?3[MYXEQ#]*]HK*US2H]3L6B8#)[UI2GR,F<>9'S[2
M5I:UIDNG7LB.I"[N#ZUF5Z*=U<Y&K"T9I** %S1FDHH 7-&:2BF M)FBCM2
M7-&:2B@!<T$TE% "Y-%%% !FC-)10 N:,TE% "TF:*6@ S1FDHH 6DHHH 7)
MHR:*2F N:,TE%(!<T9I**8"YHS24M( S1FDHH 7-&:2B@!<T44E "YHS244
M+FDR:** %S1124 6K&[DL[E98S@@U[9X5UZ+5+)5#?.BX.37A-;_ (:UN33+
MU!D[&;GFLJU/F1=.5F>]452TV_CO[59HV!!]*NUY[T.H**** "L7Q#I":E82
M KF3;\M;5(1D8(IIV=P:N?.VJZ?+IMX\#C!7VJCFO7?&_AP75JUQ F9"<G K
MR66)H9&1A@@XKT*<U-'+./*QF:,TE%:D"YHI*6D 9HI** %HS124 +FC-)10
M N:,TE% "YHS244 +FBDHI@+FC-(** %S29-%%(!<T9I** %S1FDHH 7-)FB
MB@!<T9I*.U "YHS244 +FC-(**8"YHS244@%S1244 +1244 +FC-)10 N:,T
ME% "YHS244 2P3/!*LB'##I7KW@GQ&E[;):R/^\49.37CE:6CZG)IMXLB$\D
M UG5ASHN$N5GT.#D9HK(T'5H]3LE=6!( !Q6O7GM6=CJ3N%%%%( HHHH ***
M* "BBB@ HHHH ;(@>-E/0C%>4>-_#7V>;[1;IA>K<5ZS5+4K"._M'B=1\PQF
MM*<^5W)E&Z/G3&#S16[XFT:33-0D&P^5G@U@UZ"::NCE:L["TE%%,04M)10
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M9EP6'6HY)<NVY7,KG2^/EN7TO,3!H=W '-9?@@'^QK\'K6?9>,"=+%I<QB3
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ME;IQ50UV^OO(?#]N&M@@S]['6N)/6B$G)!)6$HH[451(4444 %%%% "TE%%
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M&9174KX/N=RAT8!N]5-8\-SZ7&9"K&//4T*<6[!RLP:6DHJB0I:2B@ HHHH
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M[_2TMKPQH1U)%8U;VV-*9J65[I/B.,H\#ESQD_\ ZJR-(TZ/3/&]S#" J*G
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M#5TX.3L3*5D<YXFUR35;^3#$PDY K I3DGDTE>C%)*R.5N["EI**8A32444
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M4':5QQ6+12:35AIM&UX@U:/5+A9(\X'K6+FBBB*25D#;;N%%%%,04N2:2B@
MHHHH *=&VR16'8YIM% '=:;XJL/L?D:@C/VXJ6]\86$-H8=-5X\@@Y]*X"BL
MW2BW<M5'8?*YDE9S_$2:9116A 4444 %%%% "Y(I*** %'%)110 N3BBDHH
M6DHHH **** %))I*** "BBB@ HHHH *V-!TB34[V-0N4#?-Q6;:V[W,ZQQJ2
M2:]G\(>'H],M!(PRSC/(Z5G5J<J+A&[-O1],CTRR2!%QMK1HHKSV[ZG4%%%%
M( HHK+UO4X]-L9)&8!P,@>M-*[L!A>,O$0T^S,<+XDS@X->.W,S7$S2,<ECF
MKVMZK)JE\\K$X;MFLNO0I04$<LY<S"BBBM" HHHH **** "BBB@ HHHH ,T4
M44 %%%% !1110 4I.:2B@ I<G%)10 4N3244 %%+24 %&<444 +FC.>*2B@
MI<G&*2B@ HHHH 7-)110 4444 %%%% !1110 4444 %%%% !5W3;"2_NECC&
M>1GBJL<;2N$498]!7J_@;PTMM$MY*N68=".E14FH(N$;LZ'PUHL>E6*J%P6
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MNX<J.5M_ ^F03K(+<9%=+! EO$(XQA1T%2T4G)O<:26P4445(PHHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"< GT%8T^J7*SB.*(,,T
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M+;_\?G_ JV7^XWTKGQ=PV]Y^\<+S0!T51/!'(X=AEATK-G\1:?"/]>N:J?\
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MC<<6IN:3-(33%<7--)I,TE,FXN:3--S29H%<=FJEZY6%B/2K&:@N$WH10U=
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M.=GLT9CDD=:X*T)%E=8/\9_F:[?1.=)ASZ4 :-%%% !1110 R7_5FJE6Y?\
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M^$-C_P"?V;_OHT?(7N]SHO/@QCSH_P#OH56G6VE',D9_X$*QO^$.C_Y_9O\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-9@BDL<
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MO:=_Q[U@@<UO:=_Q[U%38WH?$7****Q.P**** "BBB@ HHHH **** "BBB@
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M?,<=:]3CUJUCN;:R:0>=(@('KP* -BBJ&I:I;Z:(S.X7><#-0W>NV=I%NDE
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'%"0IR3V"C%%&:9 M)110 H/(K>T[_CWK!'WA6]IW_'O45-C>A\1<HHHK$[
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MZU.E&FK1/+G4E-WD%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444
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M;JXQFO4@<BO+UTS5-3UNUN9+-84C;)V#'\J].C7:N* 'T444 %%%% !1110
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M6]I__'O45-C>A\1;HHHK$ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (9[:*X0
MK(N<US&J>'B,O" !UQ76TA (P16-6C"HK,UIUI4WH>:16$TD_E;&'OBNITSP
M\L0#S -Z5NBVB#;@BY^E3=*PHX.,'=ZF]7%RFK+09'&L2;5&!3Z**[3C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP=QS6L\/I>),:O<]PHK"T;Q)::I&H$H,A["MP'(R*Y6FMS5.XM%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%137$=NNZ1L"J<>MV$LFQ)@6]* -&BD5@ZY'2EH **** "BBF2RI"A=
MS@"@!]%5VO8$569\!NE3JP89'2@!:*** "BBB@ HHHH **** "BBHI;B.$9D
M; H EHI%8.H93P>E+0 4444 %%,,J*K,3PO6DBGCG7=&V10!)1110 4444 %
M%0R7,4<BHS89NE34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37<(,DU!+=HF5!^;T
MJ$+-=*5E&T'TH 6XF=ROEY'-2K; R+*PRP'6I8H5C0+UQZU)0 4444 %%%%
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ML%F8?.5R151=7$0WW!"H.] &O164VNVDMM*]O(&9!FH;#7HI-.^TW3!.<<4
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M<<;CFL__ (17[7>B28N@]C0!REXUP^KP;E=H(Y/EXX KHO$$LT]GYMO=*L8
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M F:6BB@8444Z@!,5DZKIDM],C1N% '(K7I*+#3L[G/+H$H()<5-<:+)*GRL
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M(%M8U.0HJ8#'2EQQ2T:+8-7N%%%% PHHHH *7%%% "TE+BBF(,449I* "EH
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M#X2-U>:WJ$DKDQA\IG\*[F?/E$!L<=:R/#-DL&F0S8P\B9:KVJ^:+)O)&6H
MX%K&7[?=/=7B3*6RBY^[6?H][/#XS^S(Y$.W[M,TL6*:I>MJ=S)&^_Y1GZ>]
M%BJ_\)KY\!W0;?O4 2WEA<:CKBB*3:OF?,/6K^O:;=>'H1?1387(&!5:6]>P
MU=92!Y1?+$]A5SQ'J\7B.W%C8,)#D'% &7XCO[J[FT:.*4J9<;O?K5SQ'HMW
MI6CI=1SXEW#YA5?6+&2#4-"0KRI ;\C75^-XV?PZJJ,G<* ,:^UNX33;*U$A
M\R= -WO4UOX6NI=*\QIP9AR6JE?:5/-9V5VB9\A,FM2U\86D>E>5)*!<$8VT
M 9&G:M=-H>L0R2DM "JG\J@\(:->ZKHR7TEQD$9P?I3].TZX71=:GE3 F!9/
M?D5T/P]C:/P=$K#!VG^5 '+0VU[=ZL+<3XC5]I'K1JFGWVGZTT5O<;%SC ^M
M:NDPN->D)''FFIO$$3MK[$#C</YT 4=1TNYL);2X2;!(W-CO5^_6ZU#28W%Z
ML>6YR:N^((V:VM<#H@KD]02;[.@N2T=L&X930 _61]BLO,A<>8J\L/6KEU<R
MW?@'3YIF+.THR3_P&J6KG3FT9DL9VE8I\V?6K(C;_A7VG1X^82\C_OF@">_N
M)8FM%1R 4%4=>L6DM+>=FR6D _45>U*%R]G@=$%.\0(\6B6CD<"4']10 NIK
M-I\MDJ/@-&#Q]*HZOK5Q<PQVD4A5E89/J*NZM=QZA/9&!MVR, _E6=J6DRV^
MR\92$9AD^U "WWF6MF+F!L2*N>.I-2:WJNHR^$K"6/S/,9QOP.<9%2W=WICV
M0CLIC)=%1A#ZU<NKG4+/PY:&2VCY;#@CH./:@#/LU%VB-'*MO+@9+''->CZ0
MKIIT2R2B5@.6'>O,M472+NUW6=TYO,<(#@9_.N]\)1W$>AP+< A@.<F@#?HH
MHH ISZC!!)L9UW>F:;)J5M&H)D7GWKG]?T<_:'O8F<R'J,\5FZ3IBZLDH:1\
MH<'!- '<PW"3P^8A!7VI(+J*<L$8$J<'!JK8V(T_2S""3M4]?I7/>$68W=[E
MB?WAZGWH ZB2^ACE,99=PZC-5FUJV1MI90?3-<[Y?G^,;F-G;;MZ9^M5M5T>
M%=>M$$KX<\\T =:VKVX0,67GWI\6J6\C!2Z@GH":XC6K9;2\:)9&VJ?6J?-Q
MK%IY#L<=>: /4"08R1TQ7&:M_P ?%=;;HR6FU_O8KDM5_P"/B@#/HHHH ***
M* "BBB@ K-US_D&2UI5F:[_R#):<=R9?"SADP)!GIFNA5V;2'\AL?[([US>:
MM6U_):C"8(]#72T<478T2+F#[*[SY!8?+Z5J7MT/[>MMS@Q[!GGZ5R\UY)/)
MO;C!SBFRW+S.&8\@8ZTK%<QLW*W,EY(8Y"(R>*U8;R.PT9UG(E;/:N;75IEA
M\O QC&:JFY=HRA.0?>ERCYDB2[N5N9"RK@$\"ND\,_\ 'K^-<E76^&?^/7\:
M4_A'2^(Z(]*X_7SB_P#PKKSTKC_$'_']^%<.(^ ]C ?Q33U ?:;"Q6*0 @<X
M[56BCDMM2423AN.N:QH;Z6$$ Y^IIC7,C2^82<_6N;G5[GJ*DTK'0R7"?: I
M8$D\'TJ[;(HU("1P>/OUQ[3.S!LG(JQ_:4WE[/USS0JB)E1=M">XF%MJCR*<
M@/GBM(^)P6#!2#7-LQ9B2>M)4J;6QHZ47N=/?Z_%-;; AW,.35#03G40:R,U
MK>'_ /D(#Z54)-S5S.K34*4K'9#I7*^(_P#6-]:ZH=*Y7Q)]]J].&Y\Y5^$;
M8L8[&4P<-M[54:>\6U21Y&!W=#5*SU*6QW",!L^M.NM4ENQAU5><\5M;4YE)
M6.CU&]E,FGH9/D8#<*HZE-=1W[):EA#VV]*QI[Z6<1AOX!@5;AUVX@A\L(C#
MU/6BP^9,W]-N#;6,S.^6(S7-:A>-=2$YXIAU*8JZ]GZU4S0D*4KJR.F\+_=?
MZUU-<KX6/R/]:ZJL9_$=-+X38T/_ %P^M;VK?\>A_&L'0_\ 6CZUO:M_QZ'Z
M&L:GP,WI_$CB;<D/(1UW5:M7=[DB<G;VS69]H:"=RH_BI\NH2RJ 0!CTKQ(U
M$D>S*#9JSR0K>1@J#[TXSK#.S*N<]A6&]T[NKGJO2I8[^2-RV 2?6K]NKD^Q
M=B[>;I8F<G&.QI?#?_'\WTK/GOI)QA@!]*T/#?\ Q^M]*4)*59-!.+C2:9W$
MO_'O^%-M_NBED_U'X4EO]VO</%)Z*** "BBB@"KJ'_'H]<]70ZA_QYO7/5K3
MV.3$?$%(:**T.<2BBB@ [4E+UHIB"BBEZ4AA1124P%I.M***0#&0$54EL(G.
MXH-W8U?HHN-76QS<^CL;@S$Y7'2LV+1VGFD^7 !XR*[0H"*%C5>P_*J4F;1K
MSBK'*QZ)=0S QR[174PAEA16.6 Y-.VBG4-M[D3J2GN%%%+BD9A10:2@8M %
M*!2T7"P 44$T4AA12T4@$/ K$U.=C,(P>#6VW2L'4HF\T.!P*YL7S.B^4Z<(
MX^V7,6;*QCD7YL=*JZE#]D?,9 ^E,@U Q+C-0W$LEXW'(KP:;;:45J>VU9WE
ML4XV\V;<PSFNETU$:+.W&*YM (9MK\8KI=,E0QX!ZU[6&WUW,LQ5Z:<=M#0Q
M2,N13Z0GBNT\(PM1C6++%<YK##E)MR\5NZA,CEE8]*PU0RS[5YKS\3=OW3Z#
M :4GSEJ(>8P9N<U>DMD%N7! (J@,PG#<8I_GO*/+3DFO$<9J=FM36Z:NMC<T
MJ5F783G K4%9^EV[11!F&"16C7TE!25-*1X5=IU'8***=BM3(!UK5L_]366.
MM:MI_JJF6QK2W)Z***S-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J
M:C_QZ-]#5NHY8A,A5NAH \PL[A9KJXMX[-P[N0'QTJW8Z#*FIR^8I+!>6QUK
MNK/2[>S9RB ECDDBKFQ,YVC/TH \UBP9Y+863ABV ^VJ$FF7*ZE)&L3Y49W8
MZUZQY,6<^6F?7:*/*CSGRUSZ[: /)!!<3W:*;:0%3C.VMF?399+>-'B9L-Z5
MZ%Y,6<^4G_?(I?+3^XOY4 <!?V!BL\) Q&WD 56\*Q7*ZHV8G2/' (KT@QH>
MJ*?PI%BC4Y6-1]!0 J?<'TIU%% !45U_QZ3?[A_E4M0W7_'I-_N'^5 'SYXE
M_P"0F_\ O&L6M?Q,?^)F_P#O&L7-=\7H<[W'YHIF:,T[B'T9IF:,T7 ?FBF9
MHS1<!^:,TS=1FBX6'YHS3,T9HN ^C-,S1FBX#Z,TS-&: .\^''_(=BKVJO$_
MAN?^)[%7ME<E;XC:&P4445D6%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %(RAA@]*6B@"M#86\$[31QA9&ZFK-%% $4]O%<)LE4,OI68O
MAG2E?>+1,YSFMBB@"HFF6J)M6( =*:-*LQ;M (1Y;')'K5VB@"*.VBBM_(10
M(\8Q3+:RM[-&6&,("<G%6** *T=A;13/*D8#O]X^M5;K0=.O'WS6ZLWJ:TZ*
M *5II5G9 B"$)GKBGC3[87(N!$/,'1JM44 5[FQM[LH9HPQ0Y7/:H;O2+*]&
M)X5?C'-7J* ,J/P[ID0^6V45.=(LC;F PKY9[5>HH J7#+86#&*,E8UX45Y]
M D_B/Q")Y('CBZ8<5Z60",$ CWIJQ1H<K&BGV6@!MM$(+=(AT48J0J&&".*6
MB@#*E\.Z9+*9'M5+$Y)J2+0]/A?=';J&]:T:* ,^71+"8'S(%.:9:Z!IUG+Y
MD-NJMZBM.B@"I-IMK<2QR21!FC.5/I4EQ:PW47ES(&7T-3T4 0"S@$)BV#81
MC%9Y\,Z47WFT3-:]% %;[#;_ &<P>6/+(P12VMG!9VXA@0)&.PJQ10!433K6
M.4R+$ Q.<TLNGVTTOF/&"WK5JB@"O+9P3!0Z @<"H)]'LKB$120*R#M5^B@#
M)3PYI:*5%JF#5G^R;/[.L'DKY:G(7TJ[10!4;3+5]NZ(';TI)],M+F%898@R
M Y JY10!G)HEA']VW48J>;3K6>$0R1!D'05:HH R(O#>EQ2B1+50P/6KTUA;
MW$(BDC#(.@JS10!D1^&M+BE\Q;5 WK6K'&L2!$&%':G44 %%%% '):K;7RZC
M)()&:%N @[5?\-Z2^G)*[MGS3GZ5NE5/50?J*7I0 UUW(R^HQ7&7&D7>FW;2
MV[G:[;B%KM:0J#U /U% '*Z+I,_]JOJ,S$[QC::N:CILD^L6TZGY4ZUO  =
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M?\\4KIJ*GDCV+]O4[G,_\(=8?\\4H_X0ZP_YXI7344<D>P>WJ=SF?^$.L/\
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M[3_55F#K6I:?ZJHGL:TMR>BBBLS<**** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3O\ GM2?\)+IW_/:CE?8/93[&Q16-_PDNG?\]J0^)M/[34<K#V4^QMT5B?\
M"3:?_P ]J/\ A)K#_GM3Y6/V,^QLO]VN4UCBY%:#>);$KCS:P=1U2">X#(^1
M6&(IR<-$=^71<*]Y::&M8LWECKTJ*]W;34^GF1[=6505(J+4F>.!G88 K"SY
M+'6I+ZQ?3[R3PW_Q]2?2NIK@M&UFWM)V:1\ BMO_ (2JR_YZUO0IR4+-')F$
M7.NW'5'1XI<5SG_"5V7_ #U%'_"5VG_/45MR2./V4^QT=*!7-GQ7:=I12KXL
MM"V#(,4<DA^QGV.DHJ&WF6X@65#E6'%35!F ZUJ6O^JK,'6M.U_U53+8TI[D
M]%%%9FX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB8I:**!B4M%+2N.PE%+24@"BBE H 3%%.HI@)2TM)0,3%%+10 F*4"BEQ0
M4HI:*0PHHI:!A2TH%+0,2EHHH 6DHI:0"4M%+0,*6EHH&%%%+0 #K6E;?ZNL
M\#FM"V_U=1+8TI[DU%%%0;!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<
MQ>= R9QFLS^R?^FE%%7%M(RG%-ZB_P!DG_GI1_97_32BBGS,CV<>PO\ 91_Y
MZ4?V6?\ GI111S,/9Q[!_99_YZ4O]EG_ )Z444<S#V<>PO\ 9G^W1_9G_32B
MBCF8^2(O]F_[=']FG^_112YF')$/[-/]^E_L[_;HHHYF/DB']G?[=+_9_P#M
MT4478<D0_L__ &Z/[/\ ]NBBB[#DB']G_P"W2?V?_MT4478<D0_L\_WZ7^S_
M /;HHHNPY(B?V?\ [=']G_[=%%%V')$7^S_]NC^S_P#;HHHNPY(A_9_^W1_9
M_P#MT4478<D0_L__ &Z/[/\ ]NBBB[#DB'V#_;I?L'^W111=AR(/L/\ MT?8
M?]NBBCF8<B#[#_MTHL?]NBBB['RH/L'^W2_8?]JBBB[#E0GV+_;I?L7^U111
M=ARH7[%_M4?8_P#:HHHNQ\J#['_M4[[)_M44478<J#[)_M4OV3_:HHI78<J#
M[+_M58C38N***39220^BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gtinntqqusay000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /H!X,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HJ&>YAMD+2N%'J:PKWQ"^=EG'YWKBI
M<DMS6G1G4^%'0M(B]64?C52XU2"W&6.?H:YI+/4-5.Z5I(,^AJ['H"6HW3W;
M,/\ :-1SR>R.CV%*'QRU[$DOB^RB.#'(?H*@_P"$ULO^><OY&M&VL].D&%$<
MA^E7!IMF!_Q[Q_E1:H^H<V%CHXO[S#7QI8DX\N7\JO6_B.TN/NJP^M6I=.L4
M7<T,:CUQ6>UC87)*0S*K?[-.U03EA7I9KYFS'<Q2#(=?SJ4$'H0:Y6?PW/&3
M)'>2'V!J*'4M2T]_+:V9TZ%C2]HU\2#ZK&:O3E?\#L**S++6K:YPK2*)/[M:
M0((R.E:)I['-.$H.TD+1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#%]]MTXL3]UMM;E1)6=AIW04444AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#=-<OX5;9<W@]9#64M)H[*6M":[6.KHHHK4XPHHHH **** "BBB@ HHHH
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<Z;X
M'7U%244#3L[G(6#_ &;Q(MKZC-=?7)ZI%]BUT:@>% QFNGMI1-;QR#HPS65/
M2Z.O%>\HS75?B2T445J<84444 (_W&^E>'^)/^0R_P#OU[@_W&^E>'^)/^0R
M_P#OUS8GX3V<E_CF?_R]K]17N>D?\@FV_P!P5X9_R]K]17N>C_\ ()MO]P5.
M%ZF^>?9/*?B-_P AF6N0/WHJZ_XC_P#(9DKD#UBKZC"_P3\_QW^\(]N\"_\
M(M0UTM<UX%_Y%J&NEKQ:GQL]Z'PH****@H**** *FHSBWM68G&016/X6A,9N
MG(^^V:;XMG;[&D41R^\9%:VDP"&RC..64$UEO/T.VW)AK_S?H7Z***U.(***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=2TF&^3)0>8/NG
MT-:5%)I-694)R@[Q.,\Z^T&7]\7FC'917166KP7489F$9(Z,:NR0I*N'53]1
M7/W_ (9C=_.B>0..0 2!6=I1V.SVE*M_$T?<Z(,KK\I!!]*\U\9^%)YIUN+<
M]\D 5N1W&N6)V+ #$.Y/_P!:KB^);:,8OBJMZ8%*4HR5I&E&G6H3YZ6OH>>:
M!X4O;N_5YLA?]H5[!:0_9[6*+^XN*RH?$FCM_JY%'T45:&NV!'$U%-0@M&3B
MZF(KRO.+.3\=^%Y=3A>>$X<FN!TSPCJ%S?QH^X*C8.17L\FOZ8H^>4$>XJFW
MB?1E)$;IN]E%=L,:Z<>5,\Z672JR4G%FAHFG?V9IR6W'R^E7);F&(9>11]37
M-RZYJ%Q_QX1K(#TJ!-*O]4?=?*T7^Z37(ZO,]#MCA.57J.R_$MZEXA(<P6\;
M,?[RC-16&BSW4@N+U_,&<J#VK9L-'M[! J_/CNPS6@ !T&*2@WK()8B,%RT5
M\QD420H$C&%':I***U.-NX4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!D:MH<&HQE@@$V/E8]JY87.H^&Y
M\3&2>'. JCI7H%136\4RE713GU%7&=M&2XWU1G:?KMM>Q@LRQMZ,<&M175QE
M6!'M7*:EX/B>3[1!)()!T4$@50CN?$FFMY:VRF%?XB?_ *U5R1?PL7,UN=Y7
M+>,="EUJTCCB;:5;-1Q>,K>#B_D$;=\5<B\9:)-PMR#^ H@IPES)$S4*D>67
M4I^&/#LNFZ5);RN"6;-8C>#;J37FN/,&P.#BNP7Q+I1'$X_*F/XHTB/EIP/P
M%:*M54F^YF\/2<5%]#8B79"BG^%0*?7-2>.-%7Y5NLMZ8%49O$NI77_(-C64
M'UK+V<F;\R.MENH(1^\E1?J:YG5_%0B/D6T+R,QVAD&<5G+I&K:V_P#Q,D:$
M'KL8UTNE^'K734 7,AQ_&,T[1COJ*[>Q@:=H%WJ$RW-_)YD9_A:NQM[:*UB6
M.)=JCH*E "C  'TI:B4W(I*P4445(PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &LBN,,,BJ,VB
MV$YS);JQK0HI-)[E1G*/PNQC-X<L<_NX%6HCX>3/& *WJ*GDB:K$U5U,-?#T
M!^^JM4R>'=-7DVRYK6HI\D>PGB*K^T5X+*WMQB*,+CTJQ115)6,FV]6%%%%
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MYC0!ZBNL6K*&\U,'WJREW%)$9%8%1WS7"^(="@TC2XF@ED)WXY)]JT-(+?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_GA^M'_  LBW_YX?K7D>3ZFC)]31]9F']AX7L>N?\+(M_\ GA^M'_"R+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '(_$'_ ) 7_ J\6?[[?6O:?B#_ ,@+_@5>+/\ ?;ZUYV*^
M,^SR'_=OF-HHHKF/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NI
M\"_\AH_2N6KJ? O_ "&C]*NG\:.3'?[M/T/;8O\ 4I]*?3(O]2GTI]>N?GCW
M"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5*__P!6:NU2O_N&
M@"Q;_P"H3Z5+45O_ *A/I4M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !129'K1D>HH
M6BDR/6C(]: %HI,CUI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#D?B#_R O\ @5>+/]]OK7M/Q!_Y 7_
MJ\6?[[?6O.Q7QGV>0_[M\QM%%+@^AKF/<$HHHH ***,&@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0MK=]CRJ&]":P;?6!-J4J+)E5/K5""TCUC4Q+<DY4D<&JL5A%9:A>^5G[IH
M[N"YBG3=&X8#KBD6\@=W02*2G4>E<SX1?_09<G_EH>I]S6/'=O%J^HA6/(/>
M@#MSJMH&QYZ8'4YJW%-',H9&# ^E>86EL+FSE+,=Q8]ZZWPN;A=T<G^K4?+0
M!<\1ZH-,TV24?>7M4NFZI%/IL4\CJI9<\FLKQO;))H<SGJ*YZZ)M]+TM(R<2
MD!N: .]35;1FQYR?G5K(DCRAX(X(KBM>T>WTW16O+<MYH4'K[5TF@3/-I%NS
M]2M &1K=A?+NGCO'51_"*S=+M=0NYCF]D 0Y-=9K/_(.>LKPX TLP/<4P,G4
M[Z<:FNG+=%"1]_-0B>\N)5MUNV7:<;O6GZEI\,GC2-&S@K_A6?-!>+J+)8C)
M#=Z -6_@O=*M3=-?/(!_#70V.JE],68H2P3/UKBM0?5A,(-3 %J1SBNZTRSM
MSIT.S[I6D!S%CXCN+[Q6MNT;1H1T-=T.E<(\*0_$"-4&!MKNU^Z* %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D?
MB#_R O\ @5>+/]]OK7M'Q!_Y 7_ J\7?[[?6O.Q7QGV>0_[M\S4T"S6]O_+;
M&,=Z[&?2M.MS''(T2EAU-<MX3_Y"A_W:M>*]_P!JAQFIC90O8WQ"E4Q/LU*R
ML2^(/#2VUK]MMY1)&QP M<W'I]W-GRX';'H*]%M5\SP;:K)T+]_PJ\]B^FVZ
M&R5?G7)S5.DF[G/3S"=*/)+5W:^X\OBLI4NECFC*98 YKIM9T2.SN+%5 /F(
M"16IK%M$UG!<./\ 2FD&['U%6/$"@ZEI(/\ <'\J2@DF5+&2J3@UIO\ @<7J
M>GN)62&(DCL*R?L\PD"&,[CT%=]>SQV6J,3T8A:LW6A(NIV=V%'ED;F-)T[[
M&L,?R12DMUH>=FTN%;:8F#>E2-IEZJ;VMI OKBN^LX(=0\47,( ,:+N7Z\UH
M2?:&<V\RKY'0\=J%25A3S.46ER]+GEL=G<3-MCB9F'85(=,O0<&VDS]*]$T&
MUMTUV["CY$C)'Y&LN+Q 9M?6!\>6'*GBE[-):LOZ_4E)J$=$KG$FWF63RS&P
M<=J26"6 @2H4)Z9KTC^PX[G5Y[H+^[QN'X5R'B>Y2XO%5/X!MJ94^57-:&-]
MM-1BNFH>'O#\FLRR+DJ%4L#ZU1O]-GM;HP^6Q;.!QUKL/A]>/YTZ<86(D?D:
MF@(U+6O.G .QR/UJU!.*.>>,JT\1-2^%(X;^RK[;N^RR8]<559&0X8$&O1VU
MMO[7EL,#R1P.*YKQ?IT5A?1^4,!UW'\:F4$E=&^'QDYU%"<;7U1S\4$LYQ$A
M<CTJ?^R[XKN%M)@>U=!X(16O)RPSA"?TKIM/U$3:JMD0/*8G/%.---)LG$8Z
M=*<HQC>QYR-+OB"1;28'M42VEPQPL3$_2O2DU C6KNR 'EJ,#BF6UE#'=8"_
M>.:?LET9E_:4DO>CYGG"VT[.46-BPZB@6EP9 @B;<>@KM-+@4^(KU2O 'I5J
M,VD&N1"0?/VXJ53-98]IM*-]+G#-IEZBY:VD '?%0QVTTK[8XV9O05ZK=VU_
M<Q3-&J>3M..*R-#TY+;3I[]U_>QN<?K5.EK8RCF=X.32N<.VF7D>#);NH]2*
MZ6VT2-_"4]Z<;T;'\ZGF\1&ZDEAN!\H'RX%:EB _@2\ Z%_\:(0C=V)Q&)K<
ML7)6U1YZEA=3$^5 [_04R:UGMSB6)D/O7J%M8O8:5;SVBC?(/FS67XC@CFTF
M6>8#SQTQ2=*R+IYES5.6VE['GM%%%8GK!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !74^!?\
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MY9^]ZUV])@>E '+/X<<:E!<>:3L7%;5]Y,6G.LSJ/E(&:T*I:CIL6HQJDN<
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M\+7(;^$C[M>ATF!Z"@#SNWTV>XUV.^%JT*J,;<5K>'=.FMM1O9'1@'/&:Z[
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M6FZ#H!M;*XBD/,HQS7544 <!+92:3=M&MB;A?7%6K+29&L;MC&4,@R%]*[3
M/4"C ]* ,;PY;-::,L4H*D=<URGB"#&NVL5H^4E?]YM_K7H,J;XRHK%LM 2.
M[>>5?FW96@#4L+5;.U6%>@K'\1Z0UY+%=H3O@Y"CO7144 <#.U_K4*64EO)$
M%;=O-6KW195U'3F0%A'C<179[1Z#\J7 ]* &'_5M]*\[U2>:WUF.2%6?:WW1
MWKT8C*D>M9']BQF\6<KR#F@#"M;2YU:]DN)XVB#+PK=JH06D^GS2Q/9M<;VX
M<CI7H> .@%&!Z"@#B= L)8=;FGDB,<;)CGIWJAJ]FO\ PD5O%;2;HY&^<+TK
MT&:/?&R@=16-8: D-RT\J_/NRM %/7-(9M-AMX5)"N#Q^%5;_3KBSDMKF!&;
MRU&5'>NTI,#TH X=;:\U^9A/$\*XR-U5EL;C2YO+>U:[R>&(Z5Z#@#H!1@>@
MH \]TG19GUFYNFA:-9$("XZ=:DBBOM'2:UCADE$S$[AVKOL#T%&!Z"@#AM.T
MN[:625MZ$J?QJI-#-<+):G3V#,<"7'2O1,#THVCT'Y4 9^AVKV>E0PN264<D
MUHT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4K_[A
MJ[5*_P#N&@"Q;_ZA/I4M16_^H3Z5+0 4444 %1O!%(<L@)]ZDHH&FUL0_9(/
M^>2T?9(/^>2U-12LA\TNY#]D@_YY+1]E@_YY+4U%%D'-+N,2)(_N*%^E/HHI
MDWN%%%% !1110 4444 %%%% !1110 4444 (2 ,FJ%]JD%M&<.I8=JAUV^:T
MLI/+.'(XKDFLKR[TE+TG,K'DT ==I&JB_CE=EVA#5Y;NW=]BRJ6]*\XBUB33
M;>2 '#-UJ(ZV+:&.>(MY[, WTI@>HM(B+N9@!ZU$MY;M]V537%WVN7%U<6EI
M$W$JC=46JP7VDQQNIPI8"D!W;7$*#+2 "@W4 C#F1=I[UP5[<WUS>VD$;?)(
MHW5<U&*ZL[58I"/+!Z"@#L([J"4XCE5OI3I9XH1F1POUKS6VUK[-KEM!;DA'
M/S9K8EGN=7UF:SSF-!D"@#6N/$"QZQ!9HH82?Q"MJ2Z@B.))57ZUYV]K<VOB
M2U63&[M5O5;ATOIOM1R@&5QZT =I<W\,%J\X=65:H1ZZEQ$&B 8^@KB;;4Y;
MW1;J,GY=V!5W1H7L[-91W% ';65[Y\+/(-@![U.EW;R-M252?05P[:M=23?8
MD;F3I3[RWO=)2&=#AW<!OI0!V[S1QG#N!]:1+J"1MJ2*2.PKA]6U"ZN=:M+:
M!N'09^N!3KD7FBW$<I./,<*: .[J%[J",X>50?>GQ-N@C8]U!K@8S>ZEXEO;
M8G,<?W10!WT<T<HS&X8>U,>[@C.'E53[UP\VK7&@7:VDC8W<U/%;7FI^9<N<
MIC<E ':"1&7<&!'K4?VRVW[?.7=Z5QD6JWMOI$\;-^^#87Z<UEPZD)YT"EOM
M&?GSTH [N^UB&R<(S+DC-7;:=;B!9%/!%<'K-K-<W$;2')V]J['1XO*TV)3V
M% %*YUX6VOQ6#+A7&=Q[=*UQ=0NK>7(&('05PNO02W'C.WCCZE?\*??RWF@/
M&V<>:<&@#IXM59KT1-'M4_Q&M!KRW3&Z51FN%N=4GWJ0>HS3H(+V]AFFD.1&
MNY: .]$B,NX,"/6J%[JL%M$Q5U9E'2N-MM>O(_#LS%OWRO@?K3I]/NYM-2['
M61<M0!MP>(I)[!YU@/!QBMRWO(WMDDD8*2,D'M7 6=S+;Z')L/(:I/M=[<B&
M-&X8X:F!Z!'<PR_ZN16^E$EQ#%CS) N?6N'BFN=*UZ.W)Q$5R11:S7FN7]RA
M.5B/RT@.Y2XBD.$D!/M4E</I<MW;>)H[28_+CI7<4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '(_$'_D!?
M\"KQ9_OM]:]I^(/_ " O^!5XL_WV^M>=BOC/L\A_W;YC:***YCW HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KJ? O_(:/TKEJZGP+_R&C]*NG\:.
M3'?[M/T/;8O]2GTI],B_U*?2GUZY^>/<****!!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5':DV+G.* .!;3+F&87RQ,S1]$]:?>WM_JT<$364D>UP2?QKO-HQC%-$:@Y
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MT 6;?_4)]*EJ*W(\A.>U29'K0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0
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M% &7MG_VJ-L_^U6I10!E[9_]JC;/_M5J44 9>V?_ &J-L_\ M5J44 9>V?\
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M]JC;/_M5J44 9>V?_:HVS_[5:E% &7MG_P!JC;/_ +5:E% &7MG_ -JC;/\
M[5:E% &7MG_VJ-L_^U6I10!E[9_]JC;/_M5J44 9>V?_ &J-L_\ M5J44 9>
MV?\ VJ-L_P#M5J44 9>V?_:HVS_[5:E% &7MG_VJ-L_^U6I10!E[9_\ :HVS
M_P"U6I10!E[9_P#:HVS_ .U6I10!E[9_]JJMVLVPYS6]5*_^X: *L*S^4OWN
ME/VS_P"U5^W_ -0GTJ6@#+VS_P"U1MG_ -JM2B@#+VS_ .U1MG_VJU** ,O;
M/_M4;9_]JM2B@#+VS_[5&V?_ &JU** ,O;/_ +5&V?\ VJU** ,O;/\ [5&V
M?_:K4HH R]L_^U1MG_VJU** ,O;/_M4;9_\ :K4HH R]L_\ M4;9_P#:K4HH
M R]L_P#M4;9_]JM2B@#+VS_[5&V?_:K4HH R]L_^U1MG_P!JM2B@#+VS_P"U
M1MG_ -JM2B@#+VS_ .U1MG_VJU** ,O;/_M4;9_]JM2B@#+VS_[5&V?_ &JU
M** ,O;/_ +5&V?\ VJU** ,O;/\ [5&V?_:K4HH R]L_^U1MG_VJU** ,O;/
M_M4;9_\ :K4HH R]L_\ M4;9_P#:K4HH R]L_P#M4;9_]JM2B@#+VS_[5&V?
M_:K4HH R]L_^U1MG_P!JM2B@#+VS_P"U1MG_ -JM2B@#+VS_ .U1MG_VJU**
M ,O;/_M4;9_]JM2B@#+VS_[5&V?_ &JU** ,O;/_ +5&V?\ VJU** ,O;/\
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M(2 ,D@?6D+H!DL!^- #J*0,K=&!^AI: "BBD) ZD"@!:*.M% !1110 4444
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MX;.<BMKPY<2SVK"0\+P* -NBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[U/,9ZBM;1]/$'AVZEML+.)#M;TZT*G<=3&.+:L>8W6F7ED ;B%D!]:J $G
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MYOFE+8S1R(%C)MIVT;L>844YQAR*;61Z 4444#"BBB@ HHHH$%%%% PHHHH
M****!!1110,*ZWX??\AT_P"Z*Y*NM^'W_(=/T%7#XD<^*_@R/>X?]2GTI],A
M_P!2GTI]>@?'/<****!!16=JVI+IUH\A5C@9XKF])\917=Z8Y"P'8&I<TG9F
M$\13A)0D]6=HS!1DG KC?$GB0QG[+;?,Y.TX]ZM^)]?6RLS'$W[QURI!KGO#
M&C2ZE>?;;L;@W(J)R;?*CFQ%>4I>QI[FQX9T%@/M5UDN3N&ZNP "C &!2(@2
M-5'0#%.JXQ25CKHTHTH\J"BBBJ-0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *YS3-#-EJ5[<@G,QS71T4 9%KIN+T7+_>%4+_19DN&GAE<ECD@&NFHH
M YC3M 8ZFFHS.WF+QM-=%<1>=;/$#C<,9%2T4 <;)H$L:F#YI%)SN-2?\(J%
M\MPYR.<5UU% '$7?AR9[X2[G9 /N]JT(+"X,?DL&"$8KIZ* ./D\//9W&^'+
M#TK3T+138/+,SL3+S@]JW:* *.J:<FI6A@<X%<]_8]RJM:AG\MOESGM77T4
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MR*\ZFM[V#2K:[$@\UW&X^O2NUTBX>>T4N<D 4 :-%%% !1110 4444 %%%%
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M_N&KM4K_ .X: +%O_J$^E2U%;_ZA/I4M !1110 4444 %%%% !1110 4444
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M_N-^5 70VBG>6_\ <;\J/+?^XWY4 -HIWEO_ '&_*CRW_N-^5 70VBG>6_\
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M^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0
MM%)N7U'YT;E_O#\Z %HI-R^H_.C<O]X?G0 M%)N7U'YT;E]1^= "T4FY?4?G
M1N7U'YT +12;E]1^=&Y?[P_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6
MBDW+ZC\Z-R_WA0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12;E_O"C<OJ
M/SH 6BDW+ZC\Z-R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW+Z
MC\Z-R_WA0 M%)N7U'YT;E_O#\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z-R^H_.@
M!:*3<OJ/SHW+ZC\Z %HI-R_WA^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G
M1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +1
M2;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?
M4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +5*_\ N&KFY?4?G5*_8>6>
M10!9M_\ 4)]*EJ&W9?(3D=/6I=R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<
MOJ/SH 6BDW+ZC\Z-R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW
M+ZC\Z-R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z-R^H_
M.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z-R^H_.@!:*3<OJ/
MSHW+ZC\Z %HI-R_WA^=&Y?[P_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<O]X?G
M0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?[PH 6BDW+ZC\Z
M-R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z-R^H_.@!:*
M3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z-R^H_.@!:*3<OJ/SHW+Z
MC\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z-R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^
MH_.C<OJ/SH 6BDW+ZC\Z-R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH
M 6BDW+ZC\Z-R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z
M-R^H_.@!:*3<OJ/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z-R^H_.@!:*
M3<O]X?G0"#T(H 6BBB@#D_'DR0Z)NDQC=WKQ]]4L]YY3KZ5ZG\4/^1;_ .!5
M\_2?ZQOK7;A\-3J1O)&%3&UJ+Y8.R.L_M2S]4_*E_M2S]4_*N0HK?ZC1[&?]
MJ8K^8Z_^U+/U3\J/[4L_5/RKD**/J-'L']J8K^8Z_P#M2S]4_*C^U+/U3\JY
M"BCZC1[!_:F*_F.O_M2S]4_*C^U+/U3\JY"BCZC1[!_:F*_F.O\ [4L_5/RH
M_M2S]4_*N0HH^HT>P?VIBOYCK_[4L_5/RH_M2S]4_*N0HH^HT>P?VIBOYCK_
M .U+/U3\J/[4L_5/RKD**/J-'L']J8K^8Z_^U+/U3\J/[4L_5/RKD**/J-'L
M']J8K^8Z_P#M2S]4_*C^U+/U3\JY"BCZC1[!_:F*_F.O_M2S]4_*C^U+/U3\
MJY"BCZC1[!_:F*_F.O\ [4L_5/RH_M2S]4_*N0HH^HT>P?VIBOYCK_[4L_5/
MRH_M2S]4_*N0HH^HT>P?VIBOYCK_ .U+/U3\J/[4L_5/RKD**/J-'L']J8K^
M8Z_^U+/U3\J/[4L_5/RKD**/J-'L']J8K^8Z_P#M2S]4_*C^U+/U3\JY"BCZ
MC1[!_:F*_F.O_M2S]4_*C^U+/U3\JY"BCZC1[!_:F*_F.O\ [4L_5/RH_M2S
M]4_*N0HH^HT>P?VIBOYCK_[4L_5/RH_M2S]4_*N0HH^HT>P?VIBOYCK_ .U+
M/U3\J/[4L_5/RKD**/J-'L']J8K^8Z_^U+/U3\J/[4L_5/RKD**/J-'L']J8
MK^8Z_P#M2S]4_*C^U+/U3\JY"BCZC1[!_:F*_F.O_M2S]4_*C^U+/U3\JY"B
MCZC1[!_:F*_F.O\ [4L_5/RH_M2S]4_*N0HH^HT>P?VIBOYCK_[4L_5/RH_M
M2S]4_*N0HH^HT>P?VIBOYCK_ .U+/U3\J/[4L_5/RKD**/J-'L']J8K^8Z_^
MU+/U3\J/[4L_5/RKD**/J-'L']J8K^8Z_P#M2S]4_*C^U+/U3\JY"BCZC1[!
M_:F*_F.O_M2S]4_*C^U+/U3\JY"BCZC1[!_:F*_F.O\ [4L_5/RH_M2S]4_*
MN0HH^HT>P?VIBOYCK_[4L_5/RH_M2S]4_*N0HH^HT>P?VIBOYCK_ .U+/U3\
MJ/[4L_5/RKD**/J-'L']J8K^8Z_^U+/U3\JZ'P?>V\^JE8BN['85Y?78_#C_
M )& _P"Z/ZU%3!THQ;2*CF.(F^64M&>YQPSF-2 >E/\ )G]#^=:,'^H3_=J2
MO..DRO)G]#^='DS^A_.M6B@#*\F?T/YT>3/Z'\ZU:* ,KR9_0_G1Y,_H?SK5
MHH RO)G]#^='DS^A_.M6B@#*\F?T/YT>3/Z'\ZU:* ,KR9_0_G1Y,_H?SK5H
MH RO)G]#^='DS^A_.M6B@#*\F?T/YT>3/Z'\ZU:* ,KR9_0_G1Y,_H?SK5HH
M RO)G]#^='DS^A_.M6B@#*\F?T/YT>3/Z'\ZU:* ,KR9_0_G1Y,_H?SK5HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.TG.(6(]#7*>%]0/VC4FG8[(W/4_2NJG_P"/=O\ =KS33Y9$GU-5)VLQS^E
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MB@ KLOAQ_P A\_[H_K7&UV7PX_Y#Y_W1_6LZOP,TI?&CZ&@_U"?[HJ2HX/\
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MPV]M)*MNI993EB>U=?10!RW_  B<,MDJ.SAASC-5Y/#TL]N]N\>$/&178T4
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MBBB@ HHHH **** "BBB@#AOBA_R+?_ J^?I/]8WUKZ!^*'_(M_\  J^?I/\
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MV^&3U-=!%-FT65N,KDUP.H:>]KK>X/\ )_=KN81NTU!ZI2 S(=?636C9[AM
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M-(#<G\2O:V\?G;1*6P16_;7L4\2,&Y89KSNYA:>QAE=LL7'/Y5KW#SV&H:>
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M^L;ZUZF#^ \[%_&-HHHKK.0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M?[PH =13=Z_WA1O7^\* '44W>O\ >%&]?[PH =13=Z_WA1O7^\* '44W>O\
M>%&]?[PH =13=Z_WA1O7^\* '44W>O\ >%&]?[PH =13=Z_WA1O7^\* '44W
M>O\ >%&]?[PH =13=Z_WA1O7^\* '44W>O\ >%&]?[PH =13=Z_WA1O7^\*
M'44W>O\ >%&]?[PH =13=Z_WA1O7^\* '44W>O\ >%&]?[PH =13=Z_WA1O7
M^\* '44W>O\ >%&]?[PH =13=Z_WA1O7^\* '44W>O\ >%&]?[PH =13=Z_W
MA1O7^\* '44W>O\ >%&]?[PH =13=Z_WA1O7^\* '44W>O\ >%&]?[PH =13
M=Z_WA1O7^\* '44W>O\ >%&]?[PH =13=Z_WA1O7^\* '44W>O\ >%&]?[PH
M =13=Z_WA1O7^\* '44W>O\ >%&]?[PH =13=Z_WA1O7^\* '44W>O\ >%&]
M?[PH =13=Z_WA1O7^\* '44W>O\ >%&]?[PH =13=Z_WA1O7^\* '44W>O\
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ML]QZ5IT4 9GV>X]*/L]QZ5IT4 9GV>X]*/L]QZ5IT4 9GV>X]*/L]QZ5IT4
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MO_(PG_=']:BI\++A\2/H^#_CWC_W14E1P?\ 'O'_ +HJ2O-.X**** "BBB@
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M;F/(]ZDBN[><XBE5SZ T 34444 %%%,DFCB +N%SZT /HI 01D=#2T %%%%
M!1110 44UY$C7<[!0.YH1UD4,A!4]Q0 ZBBB@ HHHH **** "BBB@ HHHH *
M*** "BF&6,+N+C'K2I(C_=8'Z4 .HHHH ***;O4G&X9H =1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ' _%7_D6?\ @5?/$G^L;ZU]#_%7_D6?^!5\\2?ZQOK7=A_A.6ON-HI0
MI8X S4GV:;_GFU;F!%13VBD3[RD4H@E9=P0D#O0!'14BP2L,K&349!!P: "B
MBB@ HHHH **** "BBB@ HHHH ***4 DX R: $HIWEN/X30R,APP(H ;1110
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M110 4444 %17,7GVTD1_B7%2T4 <='X8FM]PA7"DYJ];:$S1R+<#J,"NCHH
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M^DF5>&&.:DAT-+6\66$84G)K<HH **** "BBB@ HHHH **** "BBB@ HHHH
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MJW9FC7[YRU=+10!S5SX?*7(GME^8"K6D:%'8323D$22<M6W10 4444 %%%%
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M/S =Z0'=0:A!</M1N:+G4(+4CS#UKDA!)8^(9 )B5V]*BN'<3$QRFXR>0.U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"S(Z*D^SR_W#2_9Y?[AH"S(J*D^SR_W#1]GE_N&@+,CHJ3[/+_<-'V>7^X:
MLR.BI/L\O]PT?9Y?[AH"S(Z*D^SR_P!PT?9Y?[AH"S(Z*D^SR_W#2_9Y?[AH
M"S(J*D^SR_W#1]GE_N&@+,CHJ3[/+_<-'V>7^X: LR.BI/L\O]PTOD2_W#0%
MF145)]GE_N&C[/+_ '#0%F1T5+Y$O]PTGV>7^X: LR.BI/L\O]PTOV>7^X:
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MS^HK1HH SOLL_J*/LL_J*T:* ,[[+/ZBC[+/ZBM&B@#.^RS^HH^RS^HK1HH
MSOLL_J*/LL_J*T:* ,[[+/ZBC[+/ZBM&B@#.^RS^HH^RS^HK1HH SOLL_J*/
MLL_J*T:* ,[[+/ZBC[+/ZBM&B@#.^RS^HH^RS^HK1HH SOLL_J*/LL_J*T:*
M ,[[+/ZBC[+/ZBM&B@#.^RS^HH^RS^HK1HH SOLL_J*/LL_J*T:* ,[[+/ZB
MC[+/ZBM&B@#.^RS^HH^RS^HK1HH SOLL_J*/LL_J*T:* ,[[+/ZBC[+/ZBM&
MB@#.^RS^HJK=V\RH<FMNJ5_]PT 5X;:<PK@CI4GV6?U%7+?_ %"?2I: ,[[+
M/ZBC[+/ZBM&B@#.^RS^HH^RS^HK1HH SOLL_J*/LL_J*T:* ,[[+/ZBC[+/Z
MBM&B@#.^RS^HH^RS^HK1HH SOLL_J*/LL_J*T:* ,[[+/ZBC[+/ZBM&B@#.^
MRS^HH^RS^HK1HH SOLL_J*/LL_J*T:* ,[[+/ZBC[+/ZBM&B@#.^RS^HH^RS
M^HK1HH SOLL_J*/LL_J*T:* ,[[+/ZBC[+/ZBM&B@#.^RS^HH^RS^HK1HH S
MOLL_J*/LL_J*T:* ,[[+/ZBC[+/ZBM&B@#.^RS^HH^RS^HK1HH SOLL_J*/L
ML_J*T:* ,[[+/ZBC[+/ZBM&B@#.^RS^HH^RS^HK1HH SOLL_J*/LL_J*T:*
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M;QU%2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5*_^X:NU2O_ +AH L6_^H3Z5+45O_J$^E2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444UW6-=
MS' H =15 ZSIX)!N5R*FM[^VNFVPRASZ"@"S1110 445%-<10 &1PH)P,T 2
MT4@(8 CH:6@ HHHH **** "BF2RI"A:1@JCO1'(DJ!T.5/0T /HHHH ****
M"BBB@ HHHH **** "BB@G R: "BHS/$%+%Q@=Z6.5)?N,#0 ^BBB@ HHI@E0
MM@-R* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM-2, W8![#WK2F\36UE! LBL6D7C%9_B%8EO6=U7KU(K/5H?[0M?/( S\H-
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M **** "BBB@ HHHH **** "BBB@ JE?_ '#5VJ5_]PT 6+?_ %"?2I:BM_\
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MV*HPIJ,H;,2BBBM3D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *W?"G_(4/TK"K=\*?\A0_2LJW\-G3@_X\?4]4C_U:_2G
M4V/_ %:_2G5X1]RM@HHHH&(2!U.*0.C' 93]#65KTMQ'8R&!"S8[5P>D^);F
MTU-ENLCL0QK.511=F<M;%1I349+<]/FF2"(R.0 />O.M=UJ?5;[[':L=H89[
M\59\5>(O,B6WMFSYB#I5GP?H82-;N8;F<?Q5,I.3Y4<]:K*O4]C3VZFUX>T2
M/3;4$J-[?,:W:0# P.U+6J5E9'?""A'E04444RPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *BN(A/ \9Z,,5+10!R:^%FA)$(4*3FKMKH.V.19P&W#
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MZZ&B@#G;SP]NG$UL K@=35G2=#BT]WEVCS'^\?6MFB@ HHHH **** "BBB@
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M8M)X8GF:9RX? )/UKL/#[-]B122<+U-(#9HHHH **** "BBB@ HHHH ****
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M*QM ]OSKMJ3:/04 <;#X6N(=%6&-E%P#G=2#1]6N9(DFG4QIPP]:[2DP!VH
MY6U\.26NLFX3 CQTJUJ.C376HVDZD;8CDUT&*6@# NM(EFU.2<$;6&*QU\/W
M]G<,T$BKO.:[?BDP#V% '&Z;X>OH=<EO[B16+IC^=2VGAZXA^U;F'[ULBNMP
M/2C ]* ,!](F;18[7(W*<U?TFS>TB*N:T:* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ JE?_<-7:I7_P!PT 6+?_4)]*EJ*W_U"?2I: "BBB@ HHHH **** "BBB@
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MYJ>M #Z*9YJ>M'FIZT /HIGFIZT>:GK0 ^BF>:GK1YJ>M #Z*9YJ>M'FIZT
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M^5&^->7T-']NKZ&L"EH]I/N'L*7\J-[^WE]#6]X2U3[5JAC7(.*X.NI\!_\
M(</T%)SDUN-4::=U%'LL=I.8U.\<BG?8Y_[XJ[#_ *E/I3Z@U,_['/\ WQ1]
MCG_OBM"B@#/^QS_WQ1]CG_OBM"B@#/\ L<_]\4?8Y_[XK0HH S_L<_\ ?%'V
M.?\ OBM"B@#/^QS_ -\4?8Y_[XK0HH S_L<_]\4?8Y_[XK0HH S_ +'/_?%'
MV.?^^*T** ,_['/_ 'Q1]CG_ +XK0HH S_L<_P#?%'V.?^^*T** ,_['/_?%
M'V.?^^*T** ,_P"QS_WQ1]CG_OBM"B@#/^QS_P!\4?8Y_P"^*T** ,_['/\
MWQ1]CG_OBM"B@#/^QS_WQ1]CG_OBM"B@#/\ L<_]\4?8Y_[XK0HH S_L<_\
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M +'/_?%'V.?^^*T** ,_['/_ 'Q1]CG_ +XK0HH S_L<_P#?%'V.?^^*T**
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHIDDJ1*6<X H ?164?$.FAMIG&:T89XYT#QG*GI0!)1110 4444 %%-=UC7
M<QP*56#C(- "T444 %%%% !1110 444A.!DT +14*W4+3>4&^?TJ1W"(68X
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M,\<Z;HSD5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '&_$;_ ) '_ J\2?[Y^M>V_$7_ ) '_ J\
M2?[Y^M,!**<B%SA1S4WV*?&=E BM2TYXVC;##!IM !1124 +12JI8X%*\;1D
M;AC- #*6E ).!3GC>/&X8S0 RDI:* "BBB@ HHHH .])2T4 )2BBGK$[(7 X
M% ##1110 4444 %%%% !1110 44E% "T444 %%)2T %%)10,*6DI:!!1110
M4444 %%%% !12&EH **** "BBB@!*6BB@ HHHH *2EI.: %H[T4AH 6BDI:
M"BBB@ KJ? ?_ "'#]!_6N5[UU7@/_D-GZ#^M SW2'_4I]*?3(?\ 4I]*?2 *
M*** "BBB@ HHIDDBQ(6<X &: ',RJ,L0![UGMJT0G\I1N(/:N=U;Q!)>W(L]
M/PZMP3WS6MHFC?9D$\I;S6'()S4<UWH<RK.<^6GLNIN Y4'U%+115G2%%%%
M!1110 4444 %%%% !1110 4444 %<?XAOIKBZAM[=ROSX;WKL*X?6XVL-2CG
M<?*[YR: -;^P;-;8&38)",[B:ATD3:>]U))<K+"@RJJ>E27KZ=J=L&:Y=1@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJE?_ '#5VJ5_]PT 6+?_ %"?2I:BM_\ 4)]*EH **** "BBB@ HHHH ****
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MBWDVH<$X-+_PF4;HKI;2%2>H!JE'"@\-7QVC/KBI]$@C_P"$<B8JI.T\D>U
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M WX?$UO9VK$1,0#T%/C\7IYT:O;NHD. 2*YFV4/E3TS6YKL2+!INU0.>P^M
M&SJ/B&*R<1A"[D9PO6J4?B^,SQQ/;NI<X&16('$7C"&2<_N0G.>1VJSK]S9S
MZC8_9R,A^<#% '=*=R@^HI:9%_JE^@I]( HHHH **** "BBB@ HHHH ****
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M"1_%-Y&0-NP\?G3K>*/^W8F"C?G@8H YQO"$ZP&3SAN R5[UEVFDSW=SY0!
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MR%L8U*#M5(>&I/.Y<>5G[OM7344 93Z+#Y B1 %!SBGW.EI<"'('[L8%:5%
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MX;J,RJ[9Q7,T4"-S6-;BOXEC@C,:KVK#H%% "444M PHI*6@04444 %%%)0
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M2\W_ (EHE'S#K^M '3:9?SRZR(F<E<=*Z>N-T?\ Y#X_W:[*D 4444 %%%%
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MVG\O(Q@4MCX?G^T":[F\TJ<KGM73T4 <KJ/A=KS5VN]X"GM45_X3>>_LYHY
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MO_J$^E2U%;_ZA/I4M !1110 4444 %%%% !1110 4444 %%%% %;4+<W5C-
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MTH6S-DA2,_A6K10!S%KX;:*RNX6<%IF)!]*I)X;U"*-84NR%4UVE'% '-?\
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M=/*:[.,U8OO#4MR;7]YS%U]ZZJB@#"L=&>VU(7!?(QC%;M%% !1110 4444
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MV*3_ )Z4?8I/^>E7Z* *'V*3_GI1]BD_YZ5?HH H?8I/^>E'V*3_ )Z5?HH
MH?8I/^>E'V*3_GI5^B@"A]BD_P">E'V*3_GI5^B@"A]BD_YZ4?8I/^>E7Z*
M*'V*3_GI1]BD_P">E7Z* *'V*3_GI1]BD_YZ5?HH H?8I/\ GI1]BD_YZ5?H
MH H?8I/^>E'V*3_GI5^B@"A]BD_YZ4?8I/\ GI5^B@"A]BD_YZ4?8I/^>E7Z
M* *'V*3_ )Z4?8I/^>E7Z* *'V*3_GI1]BD_YZ5?HH H?8I/^>E'V*3_ )Z5
M?HH H?8I/^>E'V*3_GI5^B@"A]BD_P">E'V*3_GI5^B@"A]BD_YZ4?8I/^>E
M7Z* *'V*3_GI1]BD_P">E7Z* *'V*3_GI1]BD_YZ5?HH H?8I/\ GI1]BD_Y
MZ5?HH H?8I/^>E'V*3_GI5^B@"A]BD_YZ4?8I/\ GI5^B@"A]BD_YZ4?8I/^
M>E7Z* *'V*3_ )Z4?8I/^>E7Z* *'V*3_GI1]BD_YZ5?HH H?8I/^>E'V*3_
M )Z5?HH H?8I/^>E'V*3_GI5^B@"A]BD_P">E'V*3_GI5^B@"A]BD_YZ4?8I
M/^>E7Z* *'V*3_GI1]BD_P">E7Z* *'V*3_GI4T%N\7WGS5FB@ HHHH YCQM
M_P @?_@5>5-]XUZKXW_Y _\ P*O*F^\: $HHHH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110,****!!1110 4444 %%%% !111B@84444""BBB@
M84444""DQ2T4 %%%% !1110 4444 !HHHH **** "BBB@ HHHH&%%%% @HHH
MH **** "BBB@84444""BBB@85T'A#_D+'Z5S]=!X0_Y"Q^E 'K4?^J7Z4^F1
M_P"J7Z4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE?_<-
M7:I7_P!PT 6+?_4)]*EJ*W_U"?2I: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_LULW[]ONTND:9+<8NKS.]N3BIYM;(Y_;WGR0U.E!R,T4@&  .U+5'0%%%%
M!144DZ1'#'%/5PZ[@>* '457DO8HGVL>:F1UD4,O0T .HHJ(SH&VD\T 2T45
M$DZ/(4!Y'6@"6BBB@ HHHH **** "BBD)"J2>@H 6BHXY4E&5.:>S!5R>@H
M6BF1RK*NY3D4^@ HHJ(SHK;2>30!+1110 4444 %%%% !1110 4444 %%%%
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MHGN$C;#'%,LEHI P*[ATJN]]#&^PMS0!9HI%8.N1WHH 6BHOM$>[;GFI>G-
M!144<Z2DA3G'6I: "BBB@ HHHH **** "BFNP12QZ"DCD61<J>* 'T4UW6-2
MS=!0DBR(&4\&@!U%%% !147GIO"9Y-2T %%%% !1110 4444 %%%% !1110
M445'+,D6-QQF@"2BD5@PR*6@ HHHH **** "BBB@ HHHH ***BFG2!<N<4 2
MT5%;W"7*;XSD5+0 444=* "BD!!Z4M !1137<(,F@!U%,202#*]*?0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S'C;_ ) __ J\J;[Q
MKU7QO_R!_P#@5>5-]XT :>@HDE\5=0PQWJ?Q'$D4L>Q0N1VJ+P]_R$#]*T/$
M5G+++$5':@#G88C-(%%;B^&@T6Y9\L1]VJVDZ?.UX5 Z#FNPL#:+<QH<^9G%
M '%0:1)-J#VG(91DU/+H#1 CS#N[#UKH[?"^-;S':/\ QK-^WO+K\:2$;0^*
M **>'6,"N\NUC_":KW^C2V4B(<DL,BNAU<7?]HCR,>5O&/SJ[K0_XF6G"3'W
M!G\J .:@\.F6W$CR[">QK+O;)[.3:X//0FO0+V2SC"ALXSVKG/%<T,TL)C[+
M0!A65F][-Y: Y]JUIO#@BA+^?E@/NU%X9E>&^9E[CGZ5UK?V?>+L3/G'^= '
M#6NFRW5RT2@\=35^X\.^3 TBS;B!R*Z'1K<6^J72<;Q&?Y&L1VU-GG"8V;SU
MH S;'2FO)2C,4P.M6;SP^UM;M,DGF*O4BMC2;61"TESC!':M24V[^';OR,X!
MYS0!DR6T7_".6[",;SWK)M-!:Z1GD<Q@'O6\V/["LQVW#^E:<YM([+Y^FT9Q
M0!P=_ICV7/+(>C>M5;: W%PL0ZFNLU^XM9-)A6/H#Q7/:)_R&(OK0!=C\.,Q
MP\I7TSWIP\,N)0CR%<],UJZE=R+=PH#QY@_G5O7[N2+5K55(P8@3^0H X^[T
MN2UG\LY()P#6C%X;\Q1^_P .1D+6MJ<3W$=NRXSN&:TK<6L.IVZ2Y\XJ,>G:
M@#BDT>1KIX.?E[U=C\,L_P IEPYZ+WK?7"ZO<,*JK>2'Q1;KGC'^% '-?V7)
M]K> Y^4XS1)I;QWJ6Q)RPS7328.L2'C):FW<#MXHML#C9_A0!F:?H?\ IB>8
M^ &'7O6YXFMX$B$$2*&*CI]*AOG:&^B X^<9INM&:X\0V\$9&6C']* ,F+PX
M)(0_GX8C[M9SZ9,EX+8*Q8]*[6$6L,J1R9\P'!H=8_\ A+[?I]W_  H YO\
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MP?=Q0!Z2DBR)N4Y!%<AJ-S+'JL6)"%W\BNAT976P D^]7*ZVRI?*S?=#9-)
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M=:K6H^&A=B,03>04'5:Z"B@#G+/POY#%YY_.<C&6JK_PATHDD*7K*CG)4?\
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M444""BBB@84444""N@\(?\A8_2N?KH/"'_(6/TH&>M1_ZI?I3Z9'_JE^E/H
M**** "D*@]1FEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J5_P#<-7:I
M7_\ JS0!8M_]0GTJ6HK?_4)]*EH **** "BBB@!-H)R12T44 %%%% !1110
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MF_N-^5;WA.VE35264@8]*!GJD?\ JE^E/IL?^K7Z4Z@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JE?_ .K-7:I7P)0T 6+?_4)]*EJ.#B!?
MI4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R2&.9=
MLBAAZ&J_]FV?_/O'^5%% !_9MG_S[Q_E1_9MG_S[Q_E110 ?V;9_\^\?Y4?V
M;9_\^\?Y444 ']FV?_/O'^5']FV?_/O'^5%% !_9MG_S[Q_E1_9MG_S[Q_E1
M10 ?V;9_\^\?Y4?V;9_\^\?Y444 ']FV?_/O'^5']FV?_/O'^5%% !_9MG_S
M[Q_E1_9MG_S[Q_E110 ?V;9_\^\?Y4?V;9_\^\?Y444 ']FV?_/O'^5']FV?
M_/O'^5%% !_9MG_S[Q_E1_9MG_S[Q_E110 ?V;9_\^\?Y4?V;9_\^\?Y444
M']FV?_/O'^5']FV?_/O'^5%% !_9MG_S[Q_E1_9MG_S[Q_E110 ?V;9_\^\?
MY4?V;9_\^\?Y444 ']FV?_/O'^5']FV?_/O'^5%% !_9MG_S[Q_E1_9MG_S[
MQ_E110 ?V;9_\^\?Y4?V;9_\^\?Y444 ']FV?_/O'^5']FV?_/O'^5%% !_9
MMG_S[Q_E1_9MG_S[Q_E110 ?V;9_\^\?Y4?V;9_\^\?Y444 ']FV?_/O'^5'
M]FV?_/O'^5%% !_9MG_S[Q_E1_9MG_S[Q_E110 ?V;9_\^\?Y4?V;9_\^\?Y
M444 ']FV?_/O'^5']FV?_/O'^5%% !_9MG_S[Q_E1_9MG_S[Q_E110 ?V;9_
M\^\?Y4?V;9_\^\?Y444 ']FV?_/O'^5']FV?_/O'^5%% !_9MG_S[Q_E1_9M
MG_S[Q_E110 ?V;9_\^\?Y4?V;9_\^\?Y444 ']FV?_/O'^5']FV?_/O'^5%%
M !_9MG_S[Q_E1_9MG_S[Q_E110 ?V;9_\^\?Y4^.QMHFW)"BGU HHH L4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-90W49HHH 4# P
M*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gtinntqqusay000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *L!48# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW30/^05!_P!<U_E7A?Q)_P"1HMO^OA?YU[IH'_(*@_ZYK_*@#4HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$C@T 9'CMG_X1"S"'!:8#]175^'_ (?Z=>>'UEU"!9)7C!4^E<OXUY\*V/\
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M_P#S])^E '1>'/#::'$J* ,#M70UA:#XDM==C5[>0.",\5NT %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY?7K724 %%%% !1110 4444 %%%% !1110 45DZUKMIHUN)+B39DX'UKF/\
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MSZ4 <M;:])'X1MT+'>ZD$U;\"Z';7%E-/=1"20R$@GZFN3*.WA^S(^[FO1/
MY!TIL?WJ .2\8V::!?VMS9KY1EF4''?FO2[*X5["&1F &Q<D_2N ^*1!33P.
MOGK_ #KHKA+H^$BMJN9BB[1GVH WSJ%H#@W,8_X%1_:-G_S\Q?\ ?5?/][8^
M-FNW,=L=N>/G/^%5_L'CG_GV/_?9_P * )OB++'+XGMC&ZM_I"]#[U[OH'_(
M*@_ZYK_*OEF]BU2/7;4:E'M;SE[Y[U]3:!_R"H/^N:_RH U**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !132ZCJP_.CS$_O#\Z '44@8'H12T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7F'Q-$TNHV5N"PADX<]J]/K@_B+;RS6H,(S
M*%^6@"3PSX,T7^R8RUK!,?[V.M;7_"':'_T#8/R->0:-XC\6Z7:+;J0$7IG-
M:G_":^+/5?R- 'KEEI5GIZA;:!(@.FVKM<EX1U?4]2@1K_&XCFNMH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#YW^)/\ R-%M_P!?"_SKW30/^05!_P!<U_E7A?Q(_P"1HMO^OA?Y
MU[IH'_(*@_ZYK_*@#4HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1B_ _P"0G)^?_P!:N0\3M<Z<5A^W/,&X(STKUB;=Y3!.I%>::KX2U:_O))"
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MNK=X&+YPU=YH'Q T*RT:.((_F8Q]VN+UJ_N-5\::==%3Y2OE?E[4 ;_B<_\
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M[W?YU](>4GI2>2GI0!\D7AU(Z[:?V@DBMYR_?^M?4^@_\@J#_KFO\J\*^(X
M\3VP'_/PO\Z]UT#_ )!4'_7-?Y4 :E%%%  :J7.FVER#YD",?4BK=%--K835
MSD+_ ,)R;C+;73QXY"K5&#5=5TF01-:R2H/XS7>U'+"DR%'&0:U59VM)7,W2
MZQT,BR\26DX FE2.0]5-;$<J2KNC8,/45S5_X.L97,T$6)NN?>LQH]?T@[C*
M/LZ]@*?)"7PL7/*/Q([NBN5T[QC;3/Y,JR"0<$D<5TD5S%,H977GWK.4)1W1
MI&:EL34445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M90J@DY["O5?#>MP:-9A5@E#,O.%-2GJ<N$Q-2<_?EH>I45Q/_";)_P \IO\
MOD_X5;L/%B7=RD0CE&XXY4UI='JJO!NUSJZ***9L%5-3_P"0=-_NU;JIJ?\
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MX@^S6T<@MT<.-ZG'7_ZU>WZ7;_9=.MXL<J@!H N4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%&: /G?XD_\C1;?]?"_P Z]TT#
M_D%0?]<U_E7A?Q(_Y&BV_P"OA?YU[IH!']E0<_\ +-?Y4 :E%%% !1110 44
M44 %%%)D>M "T4TR(.KJ/QIAN(1UEC_[Z% 7):*J2:C;1C)E3_OH5GS^)[&#
M.Y@<>C4KHESBMV:<UE;S@[X4)]2*YS4_"0N27@N'B]D.*)?'>G1_\LW/T_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5Q7CW2[K4[7R[:#>2N,CJ*[6N=\5^(8]$L)#SYA7*XZT >0Z?H7B/1XP@
MCFVCL6-::1^)Y/NP2G_@1JI&WC+Q0?M5C?-#"_174C'ZTKIXS\-NMS>WYEA3
ME@H[?G0!Z5X0BU*.!/MT;*<<Y-=;7,^#_$B:_I44V"';J&ZUTU %34O^0?/_
M -<V_E7B?P^U2TT_6M2^TRA,W#=?K7N-S$9[>2,?Q*17D%U\*;\7T]Q%<PQB
M1RW)'^- &I\3/$.FWN@PQP7 =A+G'Y58\">(M,M=.99KE5.*YV3X5:G=KL:]
M@<#G 8?XU)%\)M8A7"7,0'U'^- 'IT?BC2)6"I=*2:UT=9$#*<@C(KQZ'P!J
M6G7"237\& PXW#_&O6K!#'9Q(2"0H&10!9HHHH **** "BBB@ HHHH ****
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M@7P=-XBG-QJ#"2*!L!6]* '6EYXC\8ZHLCP.EMN#!D;'>O;]/A:"QAC;.Y4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^05!_US7^5>%_$G_D:+;_KX7^=>Z:!_R"H/^N:_RH U**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O./B1:2"\M=1 _=VXW
M,:]'KFO%>IVUG#Y-S;K(CCDMT% 'E_BOQ=8:OX*M8HWS*)02/RK>3QGIUCX3
M\CS/WQA  K"NO"6D^(SFVU6"U4G(B4]/TK;T/X5+!*DDVHBZC4_=/3'Y4 7/
MAO#+>.NJ,/ED7%>FU4T_3K?3K98+>)41>@6K= !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?._Q)_Y
M&BV_Z^%_G7NF@?\ (*@_ZYK_ "KPOXD_\C1;?]?"_P Z]TT#_D%0?]<U_E0!
MJ4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9
M6LZ#9ZW"8[H$@C'%:M<WXI\2R:##F.V,S$9 % '&7_PPBTYVFTG<''3<U<Y+
MXJ\5>%[CR[QT$ /8]JO2^(O$/B=MD5E<6BM_$,5=T[X6WEY(+C4-2>4$YV/_
M /JH [/P;XL3Q'91R;B789KK*R=$T&VT6V6&!%&WN!6M0 4444 %%%% !111
M0 4444 %%%% &3K/B"ST6#S+EL G Q7,_P#"Q+,/N9F\L=>*?KWARXU;4\O*
MWE!@=IZ=:UKW0M+AT8J]M$I" %B* -#2=<M-7MQ+;MD$9K/UKQ=8Z5*(7<^8
MPXQ7&^$YWM]>U".-B;=(6*8Z=#3?"5N-?U.>XNOW@BF90&^M '2V'CW3YYQ%
M([!CQS781NLD:NO1AD5P?C?0[:"SAFM(EA=9 25'7D5N>$=1:_TX[O\ EG\M
M '15D:QK]IHZ$W#8.,\5JR-MC9O0$UY=JS-J_C.UC9CY/1E['I0!M1?$.P\X
M;W;RV.%XKL+*^AOH!+"V5(K!U?PU8'2G$=O&C1J6! KF/ NK2PZ5>B5BVR9@
M,^F30!UFM>+;'23LD<[\XXK.L/'MA/=+;R.P=^E<]X>MAK7C"\-U^\B R%;H
M*V_&NAVMKHDU[;1)%)&O!4<T =FMS&UOYX/R8S7*ZCX[L+:<PHY+=.*Q;;7Y
M(_"-NK,2[J03FK/@31;>YL9YKR-9G,A(+CW- &YHGC"QU:4P(Y\Q>N:Z4'(S
MZUY5XQM5T#4+:XM!Y8EF (7ZUZ78SB6QA<G^!<G\* +5%1^?%_?%'GQ?WQ0!
M\]_$G_D:+;_KX7^=>Z:!_P @J#_KFO\ *O"?B.RMXHMMIS_I"_SKW;0/^05!
M_P!<U_E0!J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YC\2(BNMZ?<D$
MQQG+5Z3+<10C]XX7ZUAZ]::?K=E)"\ZJS+@-W% ')^(VM]9\%6Y@Y42;L?E5
MC1=4M;OPO=03.N(DVD$BIM$\,VFEVIMGO_.C"D -]*XK4/ CI?2BWU2413L2
MP4\"@#J? =P/[5,$'_'N%^6O2ZY'P3X=@T73XT6;S9 .6/4UUU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?._P 2?^1HMO\ KX7^=>Z:!_R"H/\ KFO\J\+^)/\ R-%M_P!?"_SK
MW30/^05!_P!<U_E0!J4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <9XRTC7]1A(TB=(VSQN__ %UP_P#PA_Q" _X_H?\ /XU[
M77->+O$']C6+B,!IF7Y%]: /-6\+>/%.&U2V!]V_^RI?^$3\??\ 01M^>G/_
M ->N>UW4?$-Q:0ZG,)[=)) ,!N.HKM-3O-6AT:SO;59)1'$"V#0!UO@_2];L
M($&JSI(P')7_ /7775R'@;Q(^M:7%]H4).1DK77T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\[_$
MG_D:+;_KX7^=>Z:!_P @J#_KFO\ *O"_B3_R-%M_U\+_ #KW30/^05!_US7^
M5 &I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5YE\2%9=9T^8@F).6P*]-K%\0:1;ZS8R6\A 9EP&[B@#SKQO?6ESX#LS;NN
MWSA\NX9[5T-K?VD'@EO-D0CR1E=PS7 :S\-]3A3[-;R3S0H<C+'%.L_ VK7(
M1+R6>&!>#\QQB@#JOAWB?4OM,*E8&7C(KU&N:\)Z?8:381V5M*)'0=>]=+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'SO\2?^1HMO^OA?YU[IH'_ ""H/^N:_P J\+^)/_(T6W_7
MPO\ .O=- _Y!4'_7-?Y4 :E%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% ''>/?%/\ PCNE>8A82%MHQ7E@U/QQ>1OJ$-Z1 OS!
M2ISC\ZZ;XJ_O&5#T\T<?B*]"TBRM_P#A&K5?)3YH1GY: .-\'>/&EM1!JDA-
MRJY8MQV]ZYSQ'\0-0UF]:PT;SH\G86VDBL'7M*FO_B3<6-J6C48X0X[FO9/"
M_@ZRT>T1F19)& )++DYH H^ ='U*TLX[C49 \I&":[FD55084 #T%+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13))%
MBC9V. HR:Y6^\;V<,Q2"57QP: .MHK#T;Q+9ZLQCCE4R@<J.U;E !1110!\[
M_$G_ )&BV_Z^%_G7NF@?\@J#_KFO\J\+^)/_ "-%M_U\+_.O=- _Y!4'_7-?
MY4 :E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4455O=1M=/C\RYE"+G&30!:HJ
MM:7]O?)NMY X'I5F@ HHHH **I7NK6>G,JW,P0MTS4]K=0WD F@?>AZ&@":B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_.CSHO\ GHGYU\\_\)=XS_Z!_P"O_P!:C_A+O&?_ $#_ -?_ *U 'T-YT?\
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M /G@*T:* ,[^P]/_ .> H_L/3_\ G@*T:* ,[^P]/_YX"C^P]/\ ^> K1HH
MSO[#T_\ YX"C^P]/_P"> K1HH SO[#T__G@*/["T_P#YX"M&B@#G-?T6Q30K
MQEA (B.*\4^&]I!/XU2.1,KN/'XU[UXB_P"1?O?^N1KPSX8'_BND_P!X_P Z
M /=O[#T__G@*/[#T_P#YX"M&B@#._L/3_P#G@*/[#T__ )X"M&B@#._L/3_^
M> H_L+3_ /G@*T:* ,[^P]/_ .> H_L/3_\ G@*T:* ,[^PM/_YX"C^P]/\
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M/_YX"M&B@#._L/3_ /G@*/[#T_\ YX"M&B@#._L/3_\ G@*/[#T__G@*T:*
M,[^P]/\ ^> H_L/3_P#G@*T:* ,[^P]/_P"> H_L/3_^> K1HH SO[#T_P#Y
MX"C^P]/_ .> K1HH SO[#T__ )X"C^P]/_YX"M&B@#._L/3_ /G@*YGQMI%E
M#H5PR0@$1FNWKE?'?_(OW/\ US- 'EOPCL;>YFQ*@;]X?YU[7_8>G_\ / 5X
MY\&_]>/^NA_G7NE &=_8>G_\\!1_8>G_ // 5HT4 9W]AZ?_ ,\!1_8>G_\
M/ 5HT4 9PT.P!SY J^B+&@11A1TIU% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <7KG@6'5[^.Y95)5PW-=;9
MVXM;=(A_" *<UQ&K8+<U("",B@!:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@""]MQ=V<L!Z2+MKDM!\"PZ-JPO4500<\5V;,%&34:W,3M@-S0!+
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13%D5B0#TI]
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M6Z!&J:# F!C;7":NH@^)ED$X&P]/PH ]1HID1W1@T^@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVD0/)G<1SFN%TWPQJVIZM%?:S$49., G%>C6\"V\*Q)]U>E $M%%% !1110
M4444 %%%% !1110 4444 %-D?9&S'L,TZH;I6DM947[Q7 H \MU%FUCXC0V_
M6$KR.W45ZE:PBWMDB'11BN+T?PW=V_B-+Z:/ !Z_C7=4 9.NZW#HUB\\A!*_
MPYKSJ'[9XOU$N9C%;HV=K="*U_'.A:QJ]RR6D1:$CU-8MGI/B^QA6**S4!1C
M//\ A0!Z7I&GV>FVZPP!!]*TZX'P]#XG74T-_;A8>YR?\*[U<[1GK0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "8%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HQ110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %&*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "C HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFC0>9-*@;IM)KP#1H=0@\>6(U''F>9VKHO$CR>(_'UQH\C$Q1,& !]S_ (4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K@?BM_R+/_ Z[ZL'Q3H8UW3?LQ7/S9H
MQ/AO_P @UO\ =%:OC7_D!/\ C5CPYHHT:V,87&1BK>M:?_:5B8,9S0!Y?\,?
M^/37/]X_S%5O"O\ R4^;_<_QKN_#/A,:+#?($Q]H-1Z5X/6Q\3/J>S!88S0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1U&***
M ./\1>%1?:E!?PG8T/.%[UTFF"06*"7.[OFKE% !1110 4444 %%%% !1110
M 4444 %%%% !7/\ BFSN+ZTCB@9ERV&V^E=!10!A>&]!BT:U95 +.=Q/O6[1
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gtinntqqusay000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /)!#X# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"M>6,%]"T4Z[E;J*Q?^$*T;_GV%='10!SG_  A6C?\ /L*;)X+T<1,1
M;#@&NEIDO^I?_=- 'FUIX<T^35!$T.5W$8KJ?^$*T;_GV%9UA_R&E_WC7:4
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MXG?\C3']#0![O\.?^13L_P#=KKZY#X<_\BG9_P"[77T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4R7_4O_NFGTR7_4O_ +IH XZP_P"0TO\ O&NTKB[#_D-+_O&NTH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *;(XC0N>@IU5K]6>RE5>I'% 'BWC35=1\0^*9M#L)BJJ<^W7_ .M6)XB^
M'YT:R2XGVM(4W$BMG1+F'3/BQ=&^(4;,9;GG)KJ/B;(DNFJ\9RICR* *_AS0
MGU[X96MLA (R1GZ"N2T*ZU/PAXJATZXF)CGEP !VKTKX9NJ>!+9F.  ?Y"N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3)?]2_^Z:?3)?\ 4O\ [IH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (YI1#$7/05R=YX_L;.Z:!XR
M2M=+J7_'A)]*^>O$S-_;L_S'\Z[,)0C5;YCEQ-65-+E/6/\ A9.G_P#/(_G1
M_P +)T__ )YG\Z\0WM_>/YT;V_O'\Z[OJ-(Y/K=0]P_X61I__/,T?\+(T_\
MYYFO#][?WC^=&]O[Q_.CZA2#ZW4/</\ A9.G_P#/,TV3XCV#1L/+/(]:\1WM
M_>/YT;V_O'\Z/J%(/K=0],M?&5I%J(F*' ;-='_PLFP_YY'\Z\/W-ZG\Z7>W
M]X_G1]0I!];J'M__  LFP_YY'\Z/^%DV'_/(_G7B&]O[Q_.C>W]X_G1]1I!]
M;J'M_P#PLFP_YYG\Z/\ A9-A_P \S^=>(;V_O'\Z-[?WC^='U&D'UNH>W_\
M"R;#_GD?SJ]IGC>SU*?RHT(->!;V_O'\ZZ?P0S'5N6/4=ZBI@J<8MHJ&*J.2
M3/?U.Y0?49I:9#_J8_\ =%/KR#TPHHHH **** "BBB@ HHHH **** "BBB@
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M- ';Z9J]KJD"R02HQ(Z!LUH5\^>"]2N?#GC.XTLR,T: *-[$^M>_POYD"/\
MWE!H DHHHH **** ([C_ (]Y/]TU\N_$[_D:8_H:^HKC_CWD_P!TU\N_$[_D
M:8_H: /=_AS_ ,BG9_[M=?7(?#G_ )%.S_W:Z^@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<Q_:H]W&2AKMO 7@.>VF_M#46$DQ;>"1R*]0CL+6/[MO%_WP*L!54850/H*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH J:E_QX2?2OGGQ-_R'9Z^AM2_
MX\)/I7SSXF_Y#L]>EE^[.'&[(QZ***]4\X**** "BBB@ HHHH **** "BBB@
M KJ/!'_(6_$5R]=1X(_Y"WXBLZW\-ET_C1[]#_J(_P#='\J?3(?]1'_NC^5/
MKYP]P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDN/*;(R/2GU
MCZKXETS25_TN;90!X9\1Y[B'Q-,VGV$JS Y\U5//--TWX@Z]:0+'+:W;[1C[
MIKTY?%_A/4;OF9&=O5!726VDZ7=Q"2&*,J1D'8* /'O^%G:M_P! ^Z_[X-:?
MA_X@ZG?ZU;6TEE<JCM@EE.*]4_X1^P_YX1_]\"I(M$LH9%D2% PZ$(* - =*
M6BB@ HHHH **** "BBB@ HHHH **** "N$^)]M+-X9NRF3A.@KNZJ:C81:E9
M26TP^1Q@\4 >4?"#4K:*WCM9&6.54YW'VKUUKB%$WM(H7U)KQ/6? .KZ+JLE
M[H<3OD\ D@5$]]\0+R'[(]B@0C;D,<_RH R/'4R:AXR\NU^=EG4DKS_%7OVC
M(T>E6P;KY2_RKS;P;\.Y(KXZCJB,)W&2#R,UZM&@CC5!T48% #J*** $P*,"
MEHH BN /L\G^Z:^7?B=_R-,?T-?4=Q_Q[R?[IKY=^)W_ "-,?T- 'N_PY_Y%
M.S_W:Z^N0^'/_(IV?^[77T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %%%% $=Q_Q[R?[IKY=^)W_ "-,?T-?45Q_Q[R?[IKY=^)W_(TQ_0T
M>[_#G_D4[/\ W:Z^N0^'/_(IV?\ NUU] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 5-2_X\)/I7SSXF_Y#L]?
M0VI?\>$GTKYY\3?\AV>O2R_=G#C=D8]%%%>J><%%%% !1110 4444 %%%% !
M1110 5U'@C_D+?B*Y>NH\$?\A;\16=;^&RZ?QH]^A_U$?^Z/Y4^F0_ZB/_='
M\J?7SA[@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 1W'_'O)_NFOEWXG?\C3']#7U%<?\>\G^Z:^7?B=_P C3']#0![O\.?^
M13L_]VNOKD/AS_R*=G_NUU] !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0U]17'_'O)_NFOEWXG?\C3']#0![O\.?^13L_P#=KKZY#X<_\BG9_P"[77T
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MC^AH ]W^'/\ R*=G_NUU]<A\.?\ D4[/_=KKZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S]5
MOY+&W:2. RD#.!7)?\)QJ'_0&F_+_P"O7>$ ]0#3?*C_ +B_E0!PW_"<:A_T
M!IOR_P#KTA\<Z@!G^QIOR_\ KUW7E1_W%_*FR1Q^4_R+]T]J //X_B+=RN47
M29"0<=/_ *]6?^$XU#_H#3?E_P#7J?1D3^TYOE7_ %A[5V7E1_W%_*@#AO\
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M-@L>WZUU'V7PU[?I5FPM] 6\C,&/,!^7I0!UX.12T44 %%%% !1110 4444
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MWB"YA61]7N%+#.#C_"K>F^5I/Q9NGN\;"H /XFO;X)89(4=&7:1D<T >%_\
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ML+E(F;#,V,#]:Z^Q^(7AN[<(,Y/J!796#65VBS0;3QD8Q0!HCI2T44 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)WI/]X_G5NP\5Z?J,_DPD[OK2=*:5VAJI!Z7-VBD!R 1WI:S+"BBB@ HHHH
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M0!0U/3VOXMBS-'QC(KG#X)FS_P A2;_OHUV5% '&?\(3-_T%)O\ OHT'P3,
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MHG5_^05<?[M?.VO?\A22O3R_J<&-Z&91117J'GA1110 4444 %%%% !1110
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M 'NL,HFC#J<@U)5:PB,-HJ-U%6: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@".X_P"/>3_=-?+OQ._Y&F/Z&OJ*X_X]Y/\ =-?+
MOQ._Y&F/Z&@#W?X<_P#(IV?^[77UR'PY_P"13L_]VNOH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "D;[I^E+2-]T_2@#B_#7_(;U'_ *Z?X5VO:N*\-?\ (;U'_KI_
MA7:]J "BBB@ HHHH **** "BBB@ HHHH **** *6K_\ (*N/]VOG;7O^0I)7
MT3J__(*N/]VOG;7O^0I)7IY?U.#&]#,HHHKU#SPHHHH **** "BBB@ HHHH
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M%% !1110 4444 %=;\/?^0\?]T?UKDJZWX>_\AX_[H_K65?^&S2C\:/>8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%35/^07<_P"X:^<];_Y"#_4U]&:I_P @NY_W#7SEK7_(0?ZFO3R[J<&-Z&=1
M117J'GA1110 4444 %%%% !1110 4444 %=9\//^1F7Z5R==9\//^1F3Z5E7
M_AR-*7QH]ZB_U2_2GTR+_5+]*?7SI[84444 %%%% %+5_P#D%7'^[7SMKW_(
M4DKZ)U?_ )!5Q_NU\[:]_P A22O3R_J<&-Z&91117J'GA1110 4444 %%%%
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M44 %%%% !1110 4444 %%%% !1110!3U3_D%W/\ N&OG/6O^0@_U-?1NJ?\
M(+N?]PU\YZW_ ,A!_J:]/+NIP8WH9M%%%>H>>%%%% !1110 4444 %%%% !1
M110 5UGP\_Y&9?I7)UUGP\_Y&5/I65?^'(TI?&CWJ+_5+]*?3(O]4OTI]?.G
MMA1110 4444 4M7_ .05<?[M?.VO?\A22OHG5_\ D%7'^[7SMKW_ "%)*]/+
M^IP8WH9E%%%>H>>%%%% !1110 4444 %%%% !1110 5UOP]_Y#Q_W1_6N2KK
M?A[_ ,AX_P"Z/ZUE7_ALTH_&CWF'_4I]*?3(?]2GTI]?.GMA1110 4444 5-
M2_X\)/I7SSXF_P"0[/7T-J7_ !X2?2OGGQ-_R'9Z]++]V<.-V1CT445ZIYP4
M444 %%%% !1110 4444 %%%% !74>"/^0M^(KEZZCP1_R%OQ%9UOX;+I_&CW
MZ'_41_[H_E3Z9#_J(_\ ='\J?7SA[@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '+>/+QK+0&=#@G(KSGX4:-#>WU]=S*&992PR,UW7Q-_Y%K_@
M5<W\'G18K_<RCYNYH ]855484 #V%+4?GQ?\]$_.CSXO^>B?G0!#?VD-S:2K
M)&K?(>HSVKY\T^-M&^(4,,9*K-.>*^AI9HO)D_>)]T]Z^?\ 52#\2].VD']\
M>E 'T/12+]VEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ([C_CWD_W37R[\3O^1IC^AKZBN/\ CWD_W37R[\3O^1IC^AH ]W^'
M/_(IV?\ NUU]<A\.?^13L_\ =KKZ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJG_(+N?]PU\YZW_R$'^I
MKZ+U7_D%W/\ N&OG/6O^0@_U->GEW4X,;T,ZBBBO4//"BBB@ HHHH **** "
MBBB@ HHHH *ZSX>?\C*GTKDZZSX>?\C*OTK*O_#D:4OC1[U%_JE^E/ID7^J7
MZ4^OG3VPHHHH **** *6K_\ (*N/]VOG;7O^0I)7T3J__(*N/]VOG;7O^0I)
M7IY?U.#&]#,HHHKU#SPHHHH **** "BBB@ HHHH **** "NM^'O_ "'C_NC^
MM<E76_#W_D/'_=']:RK_ ,-FE'XT>\P_ZE/I3Z9#_J4^E/KYT]L**** "BBB
M@"IJ7_'A)]*^>?$W_(=GKZ&U+_CPD^E?//B;_D.SUZ67[LX<;LC'HHHKU3S@
MHHHH **** "BBB@ HHHH **** "NH\$?\A;\17+UU'@C_D+?B*SK?PV73^-'
MOT/^HC_W1_*GTR'_ %$?^Z/Y4^OG#W HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .0^(EI->>'3' FYLGBO#]*N/%.@2W"6MEE7;U_^M7TW-#'.
MFV1<KZ52.AZ>3DP"@#P7_A*_&G_/A^O_ -:C_A*_&G_/A^O_ -:O>O["T_\
MYX"C^PM/_P"> H \%/BKQFRD?8.HQU_^M5#0K#7;_P 9V%W>6I55DR37T3_8
M>G_\\!3H]'L8I Z0@,.AH O+TI:** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@".X_X]Y/]TU\N_$[_ )&F/Z&OJ*X_X]Y/]TU\
MN_$[_D:8_H: /=_AS_R*=G_NUU]<A\.?^13L_P#=KKZ "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P 5='\3O^18/U->":%_PD/FW/\ 9=Q+&N[G:* /JWSX_6CSX_6OF[_BN/\
MG]N/^^:/^*W_ .?RX_[YH ^D?/C]:!,A. :^;O\ BM_^?RX_[YK8\,_\)?\
MV_:?:[N9H=_S K0![[12#I2T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% $=Q_Q[R?[IKY=^)W_(TQ_0U]17'_'O)_NFOEWXG?\
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M/QS#'/HFV0@+N[USO@6?3='$Z&[@!D/3<* /1/LT'_/"/_O@4?9H/^>$?_?
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MAY_R,J?2N3KK/AY_R,J?2LJ_\.1I2^-'O47^J7Z4^F1?ZI?I3Z^=/;"BBB@
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M(?\ 41_[H_E3Z^</<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!:*** "BBB@".X_X]Y/]TU\N_$[_ )&F/Z&OJ*X_X]Y/]TU\N_$__D:8_H:
M/=_AS_R*=G_NUU]<A\.?^13L_P#=KKZ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GJO_(+N?\ <-?.>M?\
MA!_J:^C=4_Y!=S_N&OG/6_\ D(/]37IY=U.#&]#-HHHKU#SPHHHH **** "B
MBB@ HHHH **** "NL^'G_(RI]*Y.NL^'G_(RI]*RK_PY&E+XT>]1?ZI?I3Z9
M%_JE^E/KYT]L**** "BBB@"EJ_\ R"KC_=KYVU[_ )"DE?1.K_\ (*N/]VOG
M;7O^0I)7IY?U.#&]#,HHHKU#SPHHHH **** "BBB@ HHHH **** "NM^'O\
MR'C_ +H_K7)5UOP]_P"0\?\ =']:RK_PV:4?C1[S#_J4^E/ID/\ J4^E/KYT
M]L**** "BBB@"IJ7_'A)]*^>?$W_ "'9Z^AM2_X\)/I7SSXF_P"0[/7I9?NS
MAQNR,>BBBO5/."BBB@ HHHH **** "BBB@ HHHH *ZCP1_R%OQ%<O74>"/\
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M:#<6MHI:1UP,&N@HH \T^'W@B?19S<7\'[QEP=PS_.O17MH&3:T28_W14Q(
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M@ HHHH **** "BBB@"IJG_(+N?\ <-?.>M_\A!_J:^C-4_Y!=S_N&OG/6_\
MD(/]37IY=U.#&]#-HHHKU#SPHHHH **** "BBB@ HHHH **** "NL^'G_(RI
M]*Y.NL^'G_(RI]*RK_PY&E+XT>]1?ZI?I3Z9%_JE^E/KYT]L**** "BBB@"E
MJ_\ R"KC_=KYVU[_ )"DE?1.K_\ (*N/]VOG;7O^0I)7IY?U.#&]#,HHHKU#
MSPHHHH **** "BBB@ HHHH **** "NM^'O\ R'C_ +H_K7)5UOP]_P"0\?\
M=']:RK_PV:4?C1[S#_J4^E/ID/\ J4^E/KYT]L**** "BBB@"IJ7_'A)]*^>
M?$W_ "'9Z^AM2_X\)/I7SSXF_P"0[/7I9?NSAQNR,>BBBO5/."BBB@ HHHH
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M9Q2,.^*Z"UT/3;,@V]JB$=,4 : Z4M%% !1110 4444 %%%% !1110 4444
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MC^AH ]X^'/\ R*=G_NUU]<A\.?\ D4[/_=KKZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJG_ ""[G_<-
M?.>M_P#(0?ZFOHO5?^07<_[AKYSUK_D(/]37IY=U.#&]#.HHHKU#SPHHHH *
M*** "BBB@ HHHH **** "NL^'G_(RI]*Y.NL^'G_ ",J?2LJ_P##D:4OC1[U
M%_JE^E/ID7^J7Z4^OG3VPHHHH **** *6K_\@JX_W:^=M=_Y"DE?1.K_ /(*
MN/\ =KYVUW_D*25Z>7=3@QO0S****]0\\**** "BBB@ HHHH **** "BBB@
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MHH *ZCP1_P A;\17+UU'@C_D+?B*SK?PV73^-'OT/^HC_P!T?RI],A_U$?\
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MXG?\C3']#7U%<?\ 'O)_NFOEWXG?\C3']#0![O\ #G_D4[/_ ':Z^N0^'/\
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MW$'M0 >(/ &FZP&D*$2GGY>*XV#1/$_AO4$%HH^R;N<D]*]CICQ1R??4-]:
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MZ*U?_D%7'^[7SKKO_(4DKT\OZG!C>AFT445ZAYX4444 %%%% !1110 4444
M%%%% !76_#W_ )#Q_P!T?UKDJZWX>_\ (>/^Z/ZUE7_ALTH_&CWF'_4I]*?3
M(?\ 4I]*?7SI[84444 %%%% %34O^/"3Z5\\^)O^0[/7T-J7_'A)]*^>?$W_
M "'9Z]++]V<.-V1CT445ZIYP4444 %%%% !1110 4444 %%%% !74>"/^0M^
M(KEZZCP1_P A;\16=;^&RZ?QH]^A_P!1'_NC^5/ID/\ J(_]T?RI]?.'N!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 '6J-UI-K=G,D8/X5>HH
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M\>$GTKYY\3?\AV>OH;4O^/"3Z5\\^)O^0[/7I9?NSAQNR,>BBBO5/."BBB@
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M (]Y/]TU\N_$[_D:8_H: /=_AS_R*=G_ +M=?7(?#G_D4[/_ ':Z^@ HHHH
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MPWKTOAW4X[R.,N4[4 ?9P=2.H_.EW+ZC\Z^<!\:[X#'V-OS_ /KT?\+LOO\
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M^WI?^>1H^O4@^J5#I\T5S']O2_\ /(T?V]+_ ,\C1]>I!]4J'3T5S']O2_\
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M*@#:JCJNFP:M826EPNZ.08(J]10!YTWP@\.,V3:?RI/^%/\ AS_GT_E7HU%
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M_P"?3^5)_P *>\.?\^G\J]'HH \X_P"%/>'/^?3^5+_PI_PY_P ^G\J]&HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2;F8'!1,UX+H"?\ "2_$@27/SH1_6O</$Y(\.7V/^>1KQ;X5C=XM5CUR?YT
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M3@<U\W^(!Y_Q*G5.<3*?UH ^B;(YL+<^L:_RJ>H+$8L+<>D2_P JGH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]!H **** "BBB@ J%;J%W*+*A8=1NJ4C(Q7D.O75[X7\1K< N8KF4 [F. *
M/7Z*IZ;?17]FDT3;AM&:N4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7F:?#ZT;7X=1LY) JMNPI(%:OQ U9] \-J4;E\KR?7B@#/\ $OQ2M=,G-K!
M\TAXS'D_RKG8OBQ=1.))=/N_+)[QFLCX;6FEW<L]_J<Q,BRDJ&Y'7WKU.^N?
M#5U9/"?)'RG!$8H F\+>-;/Q)!N0>6X.-K'FNJKYMM[F+0/'5K'93,8)'+')
MXKZ(T^Y^UV:3?WJ +59>O:@FGZ7-(YQF-L?E6I7G/Q=O6M-"AVG&]MM '(>
M+63Q#XA?5)?F\F9E!/U_^M7M]S*+:UDEQPBEORKS7X,VHBT2Y<CEI"?U->B:
MI_R"[K_KDW\J /.E^+-FDLJM"Y,;E=OK@UCWWQ<F,Y:'3[KRP<Y"'%<'H.D#
M5?'(A<L(VF;.#[U]"?\ ",Z?;:1) ((SMC(R4&>E '+>'_BM8:C:EI8VC93C
M#G!K)UGXL,ER\5K87+*I^\B$@UYU>Z$H\<1:?$[K'*Q)"DCO7ONA>%K&STA(
MFB1VVX)= 30!RGA7XJ0:G?QV,\$D<CG@N"*].-Q&L!FW#:!G.:^??'>FQZ)X
M\M3:_+E<\<>E=_K>NR:?X&MY-WS2H5SF@"/Q+\4[;3;DVEO!)-(>\8)_E6)9
M_%J:*8&XT^ZV,<9*'BJOPJ\,Q:N)M4N\NRS-@-R.IKU/5_#=A>Z;)%Y$:X0X
M*H : ./A^*MG=:];V$<39D7.?3I7HT=P)+/S^@QFOFB'1/[$^)-K!EB&)(W'
MW%?0DURMKX;D=CC$1Q^5 'EOB&5M9^*%E"O,94@^G:N@^)%N+7PU;P@8"BL?
MP%:_VSKIU1N?*E9<_C_]:NA^+'&C1T 5/@N0/#-P2<?OC_,UN>+/'MGX>"+C
MSG8XVH<D5Y5X4\;V_ASP9>1)(/M7FY53WZU=\&^'Y/&.K/J.HEPF=ZC)(H ]
M3\*Z_)K]M]H\J2)<XPX(IOBKQK9^&X 9!YC-P%4\UN1PV^E60"*JJH X&*\!
MNEE\6>.KBV9F,,,P(P: .@;XMW$LIDCTZ[,8/9#6NOQ>M/(026\D;]PP(KO-
M.\.V%I8)"+>)LJ,DQCTKQGXL>$X],GM[NUR/-DR0. * /8O"VO)X@TTW2*5
M..:Q_B'I"W^E&8+\T*E@:K_"?_D5C_O#^M=9KL8ET2\4C_ED: ///A+K[7&G
M/:3L6D\T@9^IKU2OGKX=7#6GCN.R!^5I&./^!5]"T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >#?%[_ (_K7_KNO\Z]4\$_\@2/_=7^5>5?%[_C^M?^NZ_SKU7P3_R!(_\
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MO^1@LO\ KX7^=>TZ!_R"H?\ <7^5>+?$[_D8+'_KX7^=>TZ!_P @J'_<7^5
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MI]3T(!%R8\M^5 %#X0N&T"7'9J[K5/\ D%W7_7)OY5Y=\&-15-/NK61L.)B
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M!Y'X4\ 7/B+2)[M)!M60C!^IKH/ ^O3>%?$$VG7F[RPP1<\"NP^"R@^&;@$
M_OC_ #-9?Q1\(R*8]2L$)D5][XXZ4 >GZFPO-&9H3G< >/I7B'@R5;3Q_J*S
M'!+X&:[;X9>,(M4L/L-W(/M(;:%Z].*Y3QMX7U#1M=.KV$1.^3>W.!B@#W>,
MYB0CNHKRWXR7$4=E9J2"2WK573OBW$EHL5U(BSJ NWCM7G_CO6=6UV>"6>,"
MUWYC8'K0![%\*/\ D6&_W_\ &NOU<XTB[/\ TS-<?\)P1X6.?[P_K72^)KI;
M70KLL<9B.* /#/!/S_%&W9>FYOYBOHNO _A98O>>(AJ.W(65AG\:]\H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(N$ XK9\,07EKH\$-XNV11SS0 6GA;2K*[^TP6J++G.X>M;+*&4J>A&#2T4
M8I\+:4VH+>FU3SUZ-6RJA5V@<4M% &1J'AO3=3NUN;JV6251@,:@UF]3P_I8
M,,),: _*HK>JM?6<=]:R0R#*LI'2@#SS1-?\/^,TD^WVT:NKE,2'!ZXK6FT'
MPEIMM+/%%;*P4D885QFK?"ZXL[YI]*\TY); 8@9-5!X#\0WI6.Z258\\D.:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gtinntqqusay000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" **!>D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#;\2>,=9LM
M:E@@N-L8Z"LK_A/-?_Y^?YU6\7_\C%-6'3$=+_PGFO\ _/S_ #I/^$\U[_GY
M_G7-T4QG2_\ ">:__P _/\Z/^$\U_P#Y^?YUS7>B@1TO_">:_P#\_/\ .C_A
M/-?_ .?G^=<U10!TO_">:_\ \_/\Z/\ A/->_P"?G^=<U10!TO\ PGFO_P#/
MS_.D_P"$\U__ )^?YUS=% '2_P#">:__ ,_/\Z/^$\U__GY_G7,T4#.F_P"$
M\U[_ )^?YT?\)YKW_/S_ #KF:6@#I?\ A/-?_P"?G^='_">:_P#\_/\ .N:H
MH$=)_P )YKW_ #\_SI?^$\U__GY_G7-4E SIO^$\U_\ Y^?YT?\ ">:]_P _
M/\ZYJB@1TO\ PGFO?\_/\Z3_ (3S7_\ GY_G7-T4 =+_ ,)YKW_/S_.C_A/-
M>_Y^?YUS5)0,Z;_A/-?_ .?G^='_  GFO?\ /S_.N9I: .E_X3S7_P#GY_G1
M_P )YK__ #\_SKFJ2@1TW_">:_\ \_/\Z/\ A/-?_P"?G^=<U10!TG_">:]_
MS\_SI?\ A/->_P"?G^=<S2T =+_PGFO_ //S_.M#_A--:_LL2_:/GSUKB:UA
M_P @8?6@#0_X3S7_ /GY_G1_PGFO?\_/\ZYKO24 =-_PGFO_ //S_.D_X3S7
M_P#GY_G7-T4 =)_PGFO?\_/\Z7_A/-?_ .?G^=<U24#.E_X3S7_^?G^=+_PG
MFO\ _/S_ #KFJ* .E_X3S7O^?G^='_">:_\ \_/\ZYJB@1TO_">:]_S\_P Z
M/^$\U_\ Y^?YUS5% SI?^$\U[_GY_G1_PGFO?\_/\ZYFEH Z3_A/-?\ ^?G^
M=+_PGFO?\_/\ZYFEH$=+_P )[KW_ #\_SI/^$\U[_GY_G7-T4 =)_P )YKW_
M #\_SH_X3S7O^?G^=<W10,Z4>/->!_X^?YUWOAWQ//J-LJO+F4#YN:\=K7T+
M5'L+Q>3M8@&JBTGJ1--K0]H^WW']ZC[?<?WJS[2X2Y@5T;/ S4]='+'L<;G)
M=2S]ON/[U)]ON/[U5Z*?*NPN>7<L_;[C^]2?;[C^]5>BCE78.>7<L?;[C^_2
M_;[C^_5:BCE78?/+N6?M]Q_>H^WW']ZJU%'+'L+GEW+/V^X_O4?;[C^]5:BE
MRQ[!SR[EG[?<?WJ/M]Q_>JM24^5=@YY=RS]ON/[]+]ON/[U5J*.6/8.>7<L?
M;[C^]2-?W.TX?FH.]%'+'L'/+N9UUK&HPRE1)Q4']OZC_P ]:MWUL)8R0.:P
MF!5B/2MX1@UL83G-/<TO[?U#_GK1_;^H_P#/6LRBK]G#L1[6?<T_[?U#_GK1
M_;^H_P#/6LRBCV<.P>UGW-/^W]1_YZT?V_J'_/6LRBCV<.P>UGW-+^W]1_YZ
MTO\ ;^H_\]:S**/9P[![6?<T_P"W]1_YZTG]OZC_ ,]:S:*/9P[![6?<TO[?
MU'_GK1_;^H_\]:S:*/9P[![6?<T_[?U'_GK1_;^H_P#/6LRBCV<.P>UGW-/^
MW]1_YZT?V_J/_/6LRBCV<.P>TGW-(Z_J.#B6LJX\3ZS"^//I]5;R 2(6'44X
MPA?83J3[CO\ A+=8_P">]'_"6ZQ_SWK$8%3@TE:^RI]B?:U.YN?\);K'_/>C
M_A+=8_Y[UAT4>RI]@]K/N;G_  ENL?\ />C_ (2W6/\ GO6'11[*GV#VL^YN
M?\);K'_/>C_A+=8_Y[UAT4>RI]@]K4[FW_PENL?\]Z/^$MU?_GO6)11[*GV#
MVL^YN?\ "6ZQ_P ]Z3_A+=8_Y[UB44>RI]@]K/N;G_"6ZQ_SWH_X2W6/^>]8
M=%'LJ?8/:S[FY_PENL?\]Z/^$MUC_GO6'11[*GV#VL^YN?\ "6ZQ_P ]ZCE\
M6:T4.RXYK'HH]E3[![6IW,V\^(/B6WG93=<9XZU7_P"%E>(_^?O^=)KE@)HQ
M(@^Z,G%<DRE3@U#HP[&GMI]SKO\ A97B3_G[_G1_PLKQ)_S]_P ZY"BCV4.P
MO;3[G7_\+*\2?\_?\Z/^%E>)/^?O^=<A12]E#L'MI]SK_P#A97B3_G[_ )T?
M\+*\2?\ /W_.N0HI^RAV#VT^YU__  LKQ'_S]_SH_P"%E>(_^?O^=<A12]E#
ML'MJG<Z__A97B/\ Y^_YT?\ "RO$?_/W_.N0HI^RAV#VT^YU_P#PLKQ'_P _
M?\Z/^%E>)/\ G[_G7(44O90[![:IW.O_ .%E>)/^?O\ G1_PLKQ)_P _?\ZY
M"BCV4.P>VGW.O_X65XC_ .?O^='_  LKQ'_S]_SKD**/90[![:?<ZX_$GQ)C
MB[_G4+?$SQ,#C[9_.N7J.1<BIE1A;1&D*TKZLZO_ (6=XF_Y_/Y_XT?\+.\3
M?\_?\_\ &N.HK+V<>QOSR[G8_P#"SO$W_/Y_/_&C_A9WB;_G\_G_ (UQU%'L
MX]@YY=SL?^%F^)O^?S^?^-'_  L[Q-_S^?S_ ,:XZBCV<>P<\NYV/_"SO$W_
M #^?S_QH_P"%G>)O^?S^?^-<=11[./8.>7<['_A9WB;_ )_/Y_XT?\+.\3?\
M_G\ZXZBCV<>P>TEW.Q_X6=XF_P"?S^?^-'_"SO$W_/Y_/_&N.HH]G'L'M)=S
ML?\ A9WB;_G\_G_C1_PL[Q-_S^?S_P :XZBCV<>P<\NYV/\ PL[Q-_S^?S_Q
MH_X6=XF_Y_/Y_P"-<=11[./8.>7<['_A9WB;_G\_G1_PL[Q-_P _G\ZXZBCV
M<>P<\NYVD7Q.\1[_ )KOC\:V8OB!KTD88774>]>95J:;=8)5C]*QJTE:Z-:5
M1WLSO/\ A/->_P"?G^=+_P )YK__ #\_SKFJ*Y3I.E_X3S7O^?G^='_">:__
M ,_/\ZYJB@#I?^$\U_\ Y^?YT?\ ">:__P _/\ZYJB@#I?\ A/-?_P"?G^=)
M_P )YK__ #\_SKFJ6@9TO_">:_\ \_/\Z/\ A/-?_P"?G^=<S2T".E_X3S7_
M /GY_G1_PGFO_P#/S_.N:HH Z7_A/-?_ .?G^='_  GFO_\ /S_.N:[44 =+
M_P )YK__ #\_SH_X3S7_ /GY_G7,TM '2_\ ">:__P _/\Z/^$\U[_GY_G7-
M44#.D_X3S7\_\?/\Z7_A/-?_ .?G^=<U24".F_X3S7_^?G^='_">:_\ \_/\
MZYFEH Z3_A/->_Y^?YT?\)YKW_/S_.N;HH&=+_PGFO\ _/S_ #H_X3S7_P#G
MY_G7-44 =+_PGFO_ //S_.C_ (3S7_\ GY_G7-44".E_X3S7_P#GY_G2?\)Y
MKW_/S_.N:I:!G2?\)YKW_/S_ #I?^$\U[_GY_G7,TM CI/\ A/->_P"?G^='
M_">:_P#\_/\ .N;I* /4? _B;5-5NY$NYMX'2O2=[>M>/_#;_C^F^M>O5(SP
M3Q=_R,4U8?4X S6YXO\ ^1BFK.TI ^IP*PR"U4(K>5+_ ,\G_P"^32".0](V
M/T%>I!/*+1"RC,8'#[:KZ):PBTO98H$E<-D*1TI7&>:E'7ED8?44>5(>D;GZ
M*:]$U6UBN=*A>:%()"_( ^E1WEU!H36\"6\<HE4$EATH \^VL#@J0?3%.\J4
M<^4^/7::[V+18=1N7O2 HQNV@<<<TU;][Z.2UAL(RJG:6"B@#@Q'(>D;'Z"@
MHZ_>1A]17I-C9_98QBU1Y.ZD53UZV22U;SH%@FQ\B@=:+B."VL1D*V/I0%8]
M%)^@KTC2- ADT%9)%'F%#V]JJ^&-)B,DRSH,>8<$CWHN,X'8Y. C$CJ *,$=
M01]:]2L=#M[;5KR61%\DH=N1QT->?:TBI?.%  W'I0!F4M%%,04444 %%%%
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MLHO$%K!K,U[M/SKC^=.C\4PRV5U!*&/F'BN+R?6CGUIC.@T_4K>TED&T[2I
MK1\.:[;6-I=Q2@DRL2*X[)]:4%AT)I =9J6IVLRQ[5/#@G\ZT)M:TEY;>X:$
MEHE S7!EF/4FC>V,9-,#4U;4DOM5,\>1'N! /UK6O?%$JVZ1VKE,* :Y.E.?
M6BP'5:)X@2SEDN+C+2.I!(J?_A)XI].N+:7<?,8XKCLD#K1D^M '2Z7JMO9"
M92IPR$#\J-,U>"VTNZ@<'=(Y(_,US63ZT9/8T@/0%\16;Z7% 5.Y>M4I==MX
M;=EB!#'I7&[F_O'\Z"S'N:+ =N_BFWFTWR&#%]I&:RK+5H8=!N;5@=[N2/UK
MG,GUHR>F: .E\/:E8VL\C7$9)(XJ_KGB*VGTR2T4'<W0UQ8)'0XI22>I)HL
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M\(/JW_/LU '+4M=1_P (/JW_ #[-1_P@^K?\^S4 <O25U/\ P@^K?\^S4?\
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MN?\ A6FL?\^K?K1_PK76/^?5OUH]K'N'LI'#45W/_"M=8_Y]6_6C_A6FL?\
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M4 +1FDHH ":<?NBF]J<?NB@!***.] !FBBB@ I*6B@ I*6B@!*6BB@ HHHH
M**** $I:2EH **** "CFBB@ HHI* %I,TM% !1FBB@ HHHH 3-+S124 +2<T
MM% !1S110 449HH *.:** #-%)2T &:3)I:2@!:,\T4E "T444 '-%%% !11
M10 4444 &:*** "CFBB@ HS244 +1110 <T444 '-&:** "BBB@ YHYHHH *
M.:** "BBB@!*6BB@ HYI*6@ YHS244 +1110 4<TE+0 444"@ YHYHHH **2
MEH *.:** #FBBB@ HYHHH .:,TE% "T444 &:,T44 %'-)10 4O-)10 N:**
M* "BDI: #-&:.U% !FBDI: "BDI: "BBB@ YHHHH *,T44 %%)2T &:*,44
M%%%% !FCFDI: "CFBB@!R=:EJ*/K4M $+=:;3FZTV@!:*04M !1244 +1244
M +1110 E+24M "9I:2B@!:*** "BBCM0 4E%% "TE%+0 444E "T44E !12T
ME "TE+10 E+124 +24M% !2]J2E[4 (:2EI* %I*6C% "444M "44M)0 4O>
MBB@ HI*6@!**6B@!*6DI10 E+110 4E%% !VIQ^Z*;3C]T4 )2444 +1110
ME+110 E%+FB@ HHHH *2EHH *2EHH .]%)10 M%%% !1110 4444 )112T )
M12T4 %%)2T %)12T %)12T )12T4 )2T44 %)2TE !112T %%%)0 M)110 M
M)2TE !2T44 )2T4=Z $I:2EH *2EH% "444M !244M !1110 4444 %)2T4
M%%)2YH 2BBEH **2EH 2BEI* "BEI* %HHHH 2BEHH **** "BDI: "BBB@
MHH[4E !1110 44M% "4M)2T %%%% "44M)0 44M% !129HH 6BBB@!*6BC-
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MI:* "BBB@!**6B@ I*6D% "T44F: %HHHH 2EHHH 2BEI* %HHI* #O12T4
M)3C]T4T]*<?NB@!*2EHH 2EHHH **** $HI:,4 )2T44 %%%&* "BBB@ HHH
MH ***!0 F**6B@ HHHH **,44 ':BBC% !1110 E+110 4E+10 4444 %%%)
M0 N***2@!:,444 %%)10 M%%% !24M)0 44M% "4M)2T %%)2T %%)2T %)2
MTE "TE%% !12T4 %)2T4 %&*** "@TE% "T44E !112T %%%% !124M !111
M0 E I:2@!:*2B@!:*** $I:** "BBB@ HHI* %HI*6@!*6BB@!*6BB@ HI**
M %HHHH *2J&L7DEC9F6/&[/>H=&U"6^1C)CCTIV=KBN:M%<]_;4__"326''E
M*N:R)]?UF^NY8M)19!$V'SVJE!L3DD=QVI:Y+2-9U/\ M#[+J:JC 9(%=+#=
MQ3$A&R12E%H:=RQ253U/4H-+MO/N&VIG&:KZ?X@L-2XMY=QI<KM<+HU:*CFE
M6&)G8\ $UP#>/'G\0PV-JRM&7VO51@Y;"E)1W/0J6N'\0^++JVO'LM-VM<Q\
MLI]*F\+^*+C4"T5_A9<X %/V<N6XN=7L=C15'5=033;0S.<=<?6N"B\::RUX
M7*I]D5OF;VI1IN6PY22W/2Z*XS6/&(MM&ANK5@7D;:,_A5'2O&.H#4(;;5 J
M&8Y3'<4U2DU<3FD>A4G>N"U?Q;J!U*6STD*\D7+@]A6GX6\3-J\;K<D"96VX
M%#IR2N'.KV.JHHHK,L6BBDH 6BDHH 6BBDH 6BBD- !112T %%)2T .3K4M1
M1]:EH A;K5'5?^09/_NU=;K5>]A,]G)$.K"FMP/!]<MV2[,\0^?.3BB\E.LZ
M?YK#)MUQS7H+^#9Y9G9X_E(XJMI_@6>VT^]A:/YI3\M=JJQMZ',Z;^\P($NK
M7P;97<,C#,@R!Z<5I76K3ZGJVF1V\AVA0'QZXK3N8;;1O"4=A>Y5TSQ[X%9O
MP[TKSYKBY<$A9"4SZ9J;IIR"S5HE64W>H^+KG2VNVBCC&1GIW_PHN?M6DZM!
M8I=F5)NN*Z+6O"=RVJRZC8)F:3@_2FZ5X2NGNDN=13$B'Y:7/&Q7*[G,:-9L
MWC&_'F;62,MG\#5FU^TZ]?LLEX8A&Q7!/6MM_"VH0>(KB]MH_DE&TGVY_P :
M;>^$K^WN$FTY/F/+?6ASBV+E=C%TZ]N]/U^_LS<-+&D1P!T'!JMH]O>ZI:7D
MQNV 60C'XUU>D>$9H[F>[NTQ/*A4_D:GT3PQ/I]G=1.F/,<L/SH=2*V&H2.7
MTBZNDFN;9YV94C./RJ#3]3NAH%_&)6#&0X?TY-=1:^%+F&]N)2G$BD"DM/!T
MB:+=V\B8DD<E?UI.<?R!1E8R['0II].M+HZL(W9@22>M>CV"E+=%,GF84#->
M>Q>%=9(AMY4(MXF!7!->AV5N+:!$YR% -9U7?J7!,\RR@\:76\@#<.M7?'1M
MFM,PE3-L&,=>E/UCPIJ4NKS7=I'G><YHM/".H75['+J*?*HQ6BE&Z=]C/EEJ
MK'/2RWNC:5I]UO?#L,BM-+ZXUKQ+:30S,(0@# =,\5H^,VT^+2XK)L[DX48[
MTWX>:*4TN2293N\S*_3FGS+EYF%FI<IR.I7U]:ZW=(1)*F>/:M7?)>>";DO<
M;CNZ'\:VM1\,ZJ][.]O"I23C)':I]/\ !DD6A36LJD2.V<?G3<XV0U%W.>T2
MSDM-(FE6?DQG&.U+X3L;RXT^74I+EFV2$;3]36S8^&-4A6XA>/\ =,N%K=\,
M:"^F:1):7"XW/NQ^=3*HK,48.Z.%TRVNM6U#4%DOBHBY4$]*+?4+NR#61N&E
M!/WZVKCPEJ5I?7$NGI\LY^;-!\-/I^C23W*D3@U7/$.61AZ79W.H?;Y'OR/+
M4E03TIDEW<-X-FAEE,OS_>/XTFB:9J=S=7:62Y5^'SZ5U*^#I1X:>SV?OF;.
M*<I)/4F*;1S-MI%TNEK<BY("IN ]*G$U[_PB+Z@)G9U?'O77IX?G72!;%/FV
M;:S9K:#1/"LEG?#;\V<5'M+_ 'E\EC!N]:N-5?28;>1@R$"3'X]:]4LHC#;*
MK')P*\N^'VEBXU2\G8$QALIG\*]9QP*BO9/E15*[5V%+11WK U"E[4E+VH 2
MDHHH *6DHH *6DI&X1C[4 ,:XA0X:11]32I-%)PC@_2N$NY;V\U+RX^@;'6B
M[FU30'6:0 0LP4$UK[,ERL=VTJ*P5G )Z T_(QFO.O%6MWEM>Z?+"1Y;J"_Y
M5T]OJ^?#RWC-RP./RI.FTDP4DW8VQ+&<X8<4TW4 .#*N?K7G>CZY?7$-Z\A^
MZYV_3-6+.._U"1G'3&1S3]E;<7-<[Y98V7*N"/6G*ZMT(-><2ZSJ&E2_992!
MO/%:%OXG6SAW7+X+#"_6ATGT#G1VQFC#;2XW'M3ZY'11J-_<_:;D?(&RN/2N
MN[5$HV=BD[A1114C$HI:2@!:\R^(_B:YT6&,PNRY;'%>F]J\4^,?_'O%_O\
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M!*6BDH 6BDHH 6BBDH 6BDI>U !1110 4444 %%%% "444M !1110 4E%+0
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M0 4444 )2TE+0 "DI:* "DI:2@!:2EI* %HHI* %-)2T4 %%)2]Z "D-+10
ME._AI*7M0 VBEHH *2EHH 2EI,4M !24M% !24M% !12=Z6@!*6BDH 6BBB@
M I*6B@ HHHH *\X^(7A*;7HD$;,,-GBO1NU*0-HXIIV=Q-7/G?\ X57>?WW_
M "H_X59>?WW_ "KZ'P/048'H*OVLB?9Q/GC_ (59>?WW_*E_X5;>?WW_ "KZ
M&X]!1@>@I^UD'LXGSU_PJV\_OO\ E1_PJZ\_OO\ E7T+@>@HP/04>VD'LXGS
MW_PJZ\_O/^5'_"KKO^\_Y5]"8'H*,#T%'MI![.)\^?\ "KKS^\_Y4O\ PJ^[
M_OO^5?06!Z"C ]!1[:0O9Q/GW_A5]W_>?\J/^%7W?]]_RKZ"P/048'H*?MY!
M[*)\_#X7W?\ >?\ *C_A5]W_ 'W_ "KZ"P/04F!Z"CV\@]E$^?\ _A5]W_??
M\J/^%7W?]]_RKZ P,=!1@>@H]O(7LHG@'_"K[O\ OO\ E1_PJ^Z_OO\ E7O^
M!Z"C ]!3]O,/91/ /^%7W?\ ??\ *C_A6%U_??\ *O?\#T%&!Z"CZQ,/8P/
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M **** "BBB@!**6B@ HHHH *2EH% !1110 4E+10 E%+10 4G2EI* "EHHH
M**#10 E%+24 %+110 444<T )2T44 %%%% "4M%% !1110 E+244 +1244 +
M1110 4444 %%%% !1110 4444 %)2T4 %%)2T %%%% "4M%% !24M&* "BBD
MH *6DHH **6B@ HHHH 2EHHH 0TSRH]V=HS4E% !1110 4E+10 4E+10 44E
M+0 4T@$YQ3J* "BBB@!*6BB@ HI** %I!2TE "T44E "FDI:2@!:*** ')UJ
M6HDZU+0! W6BE/WJ2@ I*** %HI*6@ HI.]+0 4444 %%%% "4M%)0 M%)2T
M )112T %%%)0 44M% "4M%% !1110 4444 %%)FE[4 %%)2T %%%% !1VHI>
MU "444E "T4E+0 44E+WH ***2@!:*** "BBB@!*6BB@!*6BB@ HHI* %HHI
M* "G'[HIM./W10 E%)10 M%%% "4M%)0 M)2TE "T44E "TE+10 4444 %%%
M)0 M)12T %%%% !1110 E%&:6@ HHHH *2BEH **** "BBB@ HHHH ***2@!
M:*** "DI:2@ I:2B@!:.])10 M%)10 M)2T4 )2T44 %%%% "44M% !124M
M"4M)10 M%%% !1244 +1110 444E "T44E "T444 %)2T4 %'>BB@ I*6B@
MHI*6@ H[4E% "TE%% !12T4 %)2T4 %%%% "4M)2T %%%% !1110 E+110 4
M449H ***2@!:**2@ [TM%% "4M'>B@!**6B@ HHHH 2BEI* "EI*6@ HHHH
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MP:3%&32Y- "8HQ1DT9- !BC%&31DT &*,4N32;J #%&*,FC)H ,48I<FDR:
M#%&*,FER: $Q1BC<:-QH ,48HR:,F@ Q2X-)DTN30 F*,49-&30 N*,4FXT9
M- "XHQ2 FEW&@ P:3%&31DT &*-M&31DT &*-M&32Y- "8HQ2Y-)DT +@T8I
M-QHR: %P:3%&3BC<: #%&*-QI<F@!,48-&31N- !MHVT9-&XT &*,49-&30
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M)2T %)2TE "T444 %%%% !1124 +24M% !124M "4M%% !WI*6DH .]+24M
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M (3K0/\ G\'Z5\S_ &F7^\:7[1+_ 'S3^K+N'MSZ7_X3G0#_ ,O@I?\ A.=
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M'XUO/%VI?:!NQ"QY^AIV@7(TV\G9!E!(<@?6IE0CR\JW'&K*]^AZDS!5+$\
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M_2OJ3_A$=$_Y\(ORH_X1'1/^?"+\J?UA=@]DSY<\E_2E\E_2OJ+_ (1'1/\
MGPB_*C_A$=$_Y\(ORI_65V%[$^7O*?TI?*;TKZ@'A+1?^?"+\J7_ (1+1?\
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MCR7]*^EO^$6T?/\ QXQ?E2_\(MH__/C'^5/Z]'L'U)]SYI$+^E'DOZ5]*_\
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M,295"(%'0#%+245F4%%+10 E./W13:<?NB@!M+110 E+24M !24M% !1110
M4E%+0 E+110 E+110 E+244 +1110 4444 %)12T )2TE+0 E+110 44E+0
ME+124 +1244 +1110 444E "TE%+0 4444 %)2T4 %)2TE "T444 %)2BB@
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MUIPBIR]X4FXKW3J3XA>*,B1OWC\QU"NO7EJ!->$"%C@?6L>^+W%Y92I$=D
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MVHHHH **** "BBB@ I*** %[T4E+0 4444 )112T '6DI:* "DI:* "BBB@
MI*6B@ HHHS0 4E+10 4444 )12T4 %%%% !1110 E+110 4444 )2T4E "TE
M+10 E%+10 E%+10 4E%+0 444E !12T4 &:2BC- "T444 %%%)0 M%%% !24
MM)0 4M)2YH **2EH *2EHH 2BEI* %I*6DH *6BB@ I.]+10 44&B@ HHHH
M,T444 %%%% !1110 4G>EHH **#10 44E+0 E+110 E+24M !1110 4444 %
M)12T &:*2EH *2EHH 2EHH[4 %%%% "4M%)0 M)2T4 %%%% #DZU+42=:EH
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MGTHP?2@ I*7!]*.?2@!**7GTHP?2@ %%'/I1SZ4 )2T8/I1@T )12X-'/I0
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M2@ HHP?2C!H **.?2C!H **,&C!]* #-)2X/I1@T %)2X/I1@^E !11@T8-
M"4M&#Z48- !11@XZ4<^E !24O-&#Z4 )2T<^E&#Z4 %%&#1@^E "4M&/:C!H
M *2EY]*,&@ HHY]*,&@ I*7!]*.?2@ HHP:,&@!*6C!]*,'TH **,'THY]*
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M**6@!.]+124 +1110 E+244 +24M% !1110 "BBB@!*6BDH 6BBB@ HI*!0
MM%(:6@ HHHH 2EHHH 2EHS24 +2444 +2444 %+110 44=Z2@!:**2@!:***
M $HI:* $I:*2@!:2EHH *2BB@!:**2@!:2BEH 2EI** "BEHH 2BEI* "EHI
M* %HHHH **** $I:2EH **** "BBB@ I*6B@ Q124M !1110 4444 )2TE%
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M!,W).!FHJ8248W6IMA\WA5GR-6.YHIJL&&1TIU<9ZXE%+24 +VHHHH ****
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MYM^5/$,O_/-ORKU__A&++_(H_P"$8L?\BG]<B3_8]3N>1B&7_GFWY4\0R_\
M/-ORKUK_ (1FR_R*7_A&K+_(H^N1["_L>IW/)A#)_P \V_*E\F3^XWY5ZQ_P
MC=G_ )%'_"-V?^11]=B']C5.YY/Y$N?]6WY5TWAK0GNIEFD7"J>0179_\(W9
M@YQ^E:5M:QVR;4  ^E34QEXVB:X;)^2IS5'H.AA2"()&,*.U24M%>>>\E960
ME%+24#%HHHH 2BEI* "BBB@!:2EHH **** "BBB@ HHH[4 %%)2T )WI:**
M"BDHH 6BBDH *6BDH 6BDI: "BBB@!*6DHH 6BBB@ I*6B@!**6B@!*6DI:
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M10 E%&:* %I*6B@ I*6B@!*6DI: $HI:2@ Q3C]T4VG'[HH ;1110 M)2T4
M%%%% !1110 4E%** $I:2EH **2B@!:2BB@!:*** "DI:2@!:*2B@!:*2EH
M*2EHH 2EHI* "BEI* %HHHH 2EHHH **2B@!:**2@!:**2@!:*** "DHI: "
MDI:2@!:*** "BDI: "BDI: "DHHH 6BBDH **6B@!***6@ HHHH 2BBEH 2B
MEHH *2EHH *2BE[4 )12TE "TE+10 4444 %%%% "4M%% !12&EH **** "B
MDI: "DI:* "BDI: "BD-+0 4444 )2T4E "T4=J* "DI:* "BBDH 6DI:2@
MZU7-JOF!\#(-6*6FG83BGN%%%)2&+244O:@ I*** %HHHH *B>&.1@S+DBI:
M*!-)[C54*N!TIU)2T#"BDI: "BDHH *6BB@ I*6DH 6BBB@ I*6B@!T?6I:B
M3K4M $+=:2E;K24 0FVB,OF[!O/>I1P*6BBXDDM@I*6DH&+1110 444E "U"
MUK"THE* N.AJ:BFG832>XE+112&%%)2T %%%% "44M)0 4M%% !1124 +24M
M% "4=J6CM0 4444 %'>BCO0 4444 %+VI*/X: "BBB@ HHHH **** $I:**
M"BDI: "BBB@ I**.U "T444 %%%% "44M)0 IZ4I^Z*:>E./W10 E%%)0 4M
M%% !11WHH *2EI* %HHHH **3FEH 2EHHH ***2@!:**2@!:*** "BDI: "B
MBDH *6DI: $S1110 4M)10 4M%% "44M)0 4M)2T %%'>B@ I*6B@ I*6B@
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M7CW_  LZ_P#[ZTG_  LZ_P#[ZT?4JH?7*1[%S1@UX[_PL^__ +ZTO_"SK_\
MOK1]2JA]<I'L.**\=_X6=?\ ]]:/^%G7_P#?6CZE5#ZY2/8L48KQW_A9]_\
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M@Z:NRE24M)6Q@%%+24 %+124 +1244 +24M% "4444 +2444 +2444 %%%%
M!1110 4444 %+244 %+244 '>BBB@ HHHH **** "BBB@ I:2B@!11244 **
M0]:6DH *6DHH **6B@ HI** "BBEH *2BCK0 44M)0 4444 +1244 %+124
M%+244 +124"@!:2BB@!12'K110 4M)2YXH!!2=Z**8"TE+12 2ES244 +24M
M)0 444N>* "DHHH **6DH 6DHHH 6BBDH *6BDH *6DHH **7-)0 444N<T
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MRH"PVE%+L;^Z?RHVM_=/Y4 )12[&_NG\J7:W]T_E0 RBG;&_NG\J-C?W3^5
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MVU%'UBKW#V-/L<3_ ,*[M/\ GHOY4?\ "NK3_GHOY5VU)1]8J]P]C3['%?\
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M]8J=P]C3['$_\*[M/^>B_E1_PKNT_P">B_E7;44_K%3N'L:?8XG_ (5W9_\
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M *2CO2T %%)10 M%%% "4M&:* "BCO10 4444 %%%% !1110 4444 %%)2T
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MJ7"N0":]6TO1Q80>60,8QQ65?>$B\Y>T"H&.6SWH S_!+W!O6$F[;MZ9K?\
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M $I:** $I:2B@ I:** "BBB@ HHI* %HI*6@ I*** %HI*6@ HHHH 2EI**
M%HHHH **** "BDHH **** %I*6B@ HHI* %I*** %I*6B@!**6B@ Q1110 4
ME+24 %%+24 +1124 +1110 4E+10 4444 %%%% #DZU+44?6I: (6ZTE*W6D
MH .U%4KO4[>T'SNN?3/-)::K;7GW'4'TW4 7J*** "BBD/')H 6BJ:ZC UP\
M(8;E&2,TZUO8KO=Y9!VG!P: +-%%+0 E+124 +1110 4444 )2T4E "T444
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M1110 4=Z** "DHI: "DI31VH **2EH **** "BBB@ HHI* %I*6B@ [444E
M"T4E+0 4E%% "TE+VHH 3M12T4 %%%% !244M !2444 %+110 444E !2T44
M %)2]Z* $I:** "BBDH 6BBDH 7M24M)0 M%%% "4M)2T %%%% !1110 E+1
M10 4444 )2TE+0 4444 )2T48H **** "BBB@!**6DH 6@4E** "BBB@ HHH
MH **** "DI:* "BBB@ HHQ1B@ HHI* %HHHH *2EHH **** "DHHH 6DI:*
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MTM% !1244 +124M !124M !24M)0 M)110 HHH[4E !2T44 )12TE "TE%%
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&4E+0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gtinntqqusay000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /!!:H# 2(  A$! Q$!_\0
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MBL[3M<T_5%)M+E)<==M1ZCXBTS2R5NKI(V'9J -6C-<[:^-=#NI1&E_$6)P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MML+S[2/:M_XH^([F?69-)CD_=JXX_&L.9<_$FV'K<&K7Q.TJ:V\62WS!A"S
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ME$T&1G\*Q?A?&9-;*^QH SO$.L3^(O%36EP^Z"*;:0?2C7]/@\.*MYI*;&!
MXJE?V#:=XSF-VQABEG^^?2NIU:71U54@ODN3D?*: -O4-9DU+P,S.3O6WYS2
M?!UV?1D)/8U:U336'@J:2*/ :#/%<Q\+O$ECI%FMO>3I$P!X:@"OXQE8>.]-
M /\ RW_H:U?B7?WT6D[$W&'=T -<KKVI+J7CO3W3!03_ "D=^#7I/BO5XK/3
M!'<6D;QYQO84 >;Z=!X8U&QVK;,MX5^\W'S?E7KGP[L)['38HVEC,8'137F&
MJ:)H%SITE[;ZNL,X7<(TXY]*U?A!<:BVKJCR226VWAB>* /=Z*.U% !1110
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MK_;A;#?OWYXK2OO &EWUR)I;<%AWXKL:* (+2W2TM(K>,86-< 5BZ_X0TOQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHPRGM764 86J>%=-U9RUU!O).:\P\9Z!8Z)K=NMG%Y>5S7ME>4?$O_D.V_\
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M_P!\G_XJC^Q/B+_T$HO^^3_\57L>Q?[HHV+_ '10!XY_8GQ%_P"@E%_WR?\
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M44 %%%% !1110 4444 %%%% !1110 4444 %8GBC_D#S_P#7-OY5MUB>*/\
MD#S_ /7-OY4 <7\&/^05J/\ U\M_Z$:]/KS#X,?\@K4?^OEO_0C7I] !1110
M 4444 %%%% !1110!Y/XN_Y*#;?[G^%>FZ9_R#XOI7F7B[_DH-M_N?X5Z;IG
M_(/B^E %NBBB@ HHHH **** "BBB@!&8*I8]AFN3?QG;OJR6<4<A.[:2 2!7
M3W.?LTF/[I_E7EVBZG9:6^J27K*)?,)3<* -_6O%YBU233;8/YT?)(!(Q5WP
MSXJCU;?$ZNKH=OS#&:Y[PX(;W5YM:E :&1" 2..])I<D=[X@W6.#&DAW[>*
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MR+UM]*VJ "BBB@ )P,U3DU&&)MK']:ML,J1ZUDW.A)<R;S,P^AH L'5K<=6
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M_P!RO-_'G_(TK_N_X5Z1H?\ R!K;_<H T:*** "BBB@ HHHH **** "BBB@
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M5_&$B3>&[LQG.!S0!SVF>'QJ>B#5)@&F*%]Q]0,UK> =1FOK*Y$SEO*D*#Z
MD4[PW>0IX+6-GPWE-Q^%4OALI%I?$CK.Q'YF@#O*\]^*?_(O7/\ N_TKH_$F
MJ:EIUNKZ?;B9B<$&O*_'.OZY>Z3-'>60CC(Y- 'HWPZ_Y$^Q_P!VNMKDOAU_
MR)]C_NUUM !117.>(O%=IH#8N)53C/- '1T5YK_PMO2?^?I/TH_X6WI/_/RG
MZ4 =YJ__ "#+C_KF:YWX>_\ ((N/^NQ_F:YR_P#BKI4]E+&MRF64CM61X2^)
M&FZ9I\L4EP@+2%N?J: /:J*\U_X6WI/_ #\I^E'_  MO2?\ GY3]* /2J*XK
M1/B#I^LW'E0SHQSVKM <J#ZB@!:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *XGXC?\@Z#_>KMJXGXC?\ (.@_WJ )OAY_R!Y/]_\ QKL*X_X>?\@>3_?_
M ,:["@ HHHH **** "BBB@ HHHH \F\>?\C2O^[_ (5Z1H?_ "!K;_<KS?QY
M_P C2O\ N_X5Z1H?_(&MO]R@#1HHHH **** "BBB@ HHHH **** "BBB@ I#
MTI:* /)=>:ZTKQQ/J"AO+*XR!]:R_P"U;Z2_6X19#M;/"FNE\3ZO=7>ORZ1:
MVJ2,HSG S46AW]SI]_':7]E$GFMA=RB@"I837NJ^(#*Z2!3_ 'E(KU2V4K;1
MJ>RT);0(<I#&I]0HJ6@##U^UL9+8M<*K-GU[UQDANWCD7SA]E7@QYY(K;\66
M=](Q>W5F&>F:P;73M2N=5M':$B)#\_I0!)HUKI-Y<+#)9M&J\C>,"O2+:..*
M!$BQM P,5F7^@VU_&JJ?*(.<H,5HVEL+6%8PQ; QDT 6**** ,[5-8M]+A\R
M5E/; /-1:)K46L1R/$" IQS7.^*?#0NY9+IIY #SM!.*F\ IY=K<)G.UL4 =
MBQ"J6/0#-<AJ_CNUTZX\I8)9CW,8)Q^5=1>G%C.1_P \V_E7 ?#JVCO1J37"
MB0B=L;QG'- '6:'XB@UE!Y:LC8R5;@BMNO.-(8V_Q!O8TX0+PHZ=Z]&4Y4'V
MH C>X@C^_-&O^\P%>5?$>>&37;?RY4?Y?X6!KJO$/A:35I69;B9,G/RL17EW
MB?PT^D:Y;[KB63C/SL30![/X4_Y%ZV^E;58OA3_D7K;Z5M4 %-+HOWF4?4TI
MZ5XY\4O'-]X<UB."W4%2F>OL* /8?.B_YZ)^='G1?\]$_.OEW_A;VK?\\Q^=
M'_"WM7_YYC\Z /HCQ#+&;5<2+^=,\+RQBQ?+K][UKYRNOBIJETFUHQ^=)9_%
M/5+.,HD8P3GK0!]5^='_ ,]$_.CSHO\ GHGYU\N_\+>U;_GF/SH_X6]JW_/,
M?G0!]1B1&^ZZGZ&G5XI\-/'M_P"(-2FBN$ "^]>U+RH/M0 M%%% !37177:P
MR*7<!WHW+ZT 9DGA[39'+M "QZFN;\6Z%I]OI4CQP@$5VV]?6N9\9L#H\E $
MFC^'M-DTFW=H 6*<UK6ND6=FX>"+:PIFB,/[&M>?X*T-R^M "T4FX>M (/2@
M!:*** "BBB@"&YN!;0M(5)"C.!6 ?&$ ./LLW_?!_P *Z0J&&" 0?6H3:6__
M #QC_P"^10!S<GCBTC=5:WE!;IE3_A4O_"8P?\^LW_?)_P *RO$\,:Z[IH5%
M +\@#V-=H+2WVC]S'T_NB@"KIFK)J:L4B=-O]X8K1IB1)']Q%7Z"GT %%%%
M!1110 445!=WD-E%YDS[5]: )Z*QCXGTL''VD5&/%ND&0H+I=P[4 ;M%8W_"
M4:7_ ,_(K1M;R&\C$D+[E/0T 6**** "BBB@ HHHH *Q/%'_ "!Y_P#KFW\J
MVZQ/%'_('G_ZYM_*@#B_@Q_R"M1_Z^6_]"->GUYA\&/^05J/_7RW_H1KT^@
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M?^1/L?\ =KK:Y+X=?\B?8_[M=;0 5X=\;?\ 6G_<_I7N->'_ !M_UI_W/Z4
M>!T444 %%%% !1110!Z)\)_^0RW^\*^I8O\ 5)_NBOEKX3_\AEO]X5]2Q?ZI
M/]T4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?B-_R#H/]ZNVKB?B
M-_R#H/\ >H F^'G_ "!Y/]__ !KL*X_X>?\ ('D_W_\ &NPH **** "BBB@
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MVJQ?"G_(O6WTK:H 0]#7SE\=?^1CA_ZY_P!!7T:>AKYR^.G_ ",4/_7/^@H
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M_P#7-OY4 <7\&/\ D%:C_P!?+?\ H1KT^O,/@Q_R"M1_Z^6_]"->GT %%%%
M!1110 4444 %%%% 'D_B[_DH-M_N?X5Z;IG_ "#XOI7F7B[_ )*#;?[G^%>F
MZ9_R#XOI0!;HHHH **** "BBB@ HHHH *R]<U#[!I\L@SN"Y&*U*Q/$L DTV
M5ARP7@>M '&W_BVZ/AR*6%V$[-@^O:K_ (6UR]5UBU"0R-,?D]JPO#^CWU_=
M-]H@Q %ROIFN@T/2+V:_,MY#Y0A?$>.XH [H\ GTKA/$MY>7.KV]K;7 B1SA
M@>]=YVKC?$_AV6ZO(K^UW&6'D*#P: .5\1:+>Z0J7#72,'<* #[U?M9]2TC4
MK&.6Y#1S ,5%2+H6J:[*$U*)HD4[A@GK6R?#+7&H6D\NX?9QA>>M '6Q2>9&
M& ZT^FHH1=HIU !1110 4444 %%%% !7GOQ3_P"1>N?]W^E>A5Y[\4_^1>N?
M]W^E &K\.O\ D3['_=KK:Y+X=?\ (GV/^[76T %>'_&W_6G_ '/Z5[A7A_QM
M_P!:?]S^E '@=%%% !1110 4444 >B?"?_D,M_O"OJ6+_5)_NBOEKX3_ /(9
M;_>%?4L7^J3_ '10 ^BBB@ HHI&7<N* (S<P*<&:,'_>%)]JM_\ GO'_ -]"
ML"X\(Q7$[RFZF&XYP&/^-<_XGT,:-I37,-U,S ]"YH [_P"U6_\ SWC_ .^A
M3UFB<X21&/L:X[3/"L=YIMO</=SAI%R1O/\ C6UIOAZ/3IQ(L\CX[,Q- &U1
M110 4444 %%(S!5+'H*I/J]E&VUI0#0!/=7(M86D*EMHS@5SY\819_X\YO\
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M_P#/5/\ OJGA@PR""/:O&8]:NC(/G;_OJO4?#LK3:1"[')- &M1110 4444
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M221)5W1NK ]P<T^N8\#QSQ^'X%N-WF#KDYKIZ "BBB@ HHHH **** "BBB@
MKRGXE_\ (=M_]RO5J\I^)?\ R';?_<H [SPI_P B];?2MJL7PI_R+UM]*VJ
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M HHHH ?%_K!7L'AC_D"0UX_%_K!7L'AC_D"0T ;-%%% !1110 4444 %%%%
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M3C.0*J:-XPCU&S9Q$^50L3BM77-"AUJ!H9L@,,9%5-'\+V^E020QDE60KDT
M8]AX[BNM4%J(GR6(Z4NN^.H[">.(1."7 /%6=/\  ]K8ZJ+U68L&)P>G6IM4
M\&6FJ78FE+ JVX8H W-)U)=3LUF5"O ZU?JII]FME;B).@JW0 4444 %%%%
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M&O0/#UM+;Z3"LV?, YR: -6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ-XHU-+^.SU:)89)#\H'>@#O*3(I';;&S>@)KSG7/%VN+J2P:3;I,F<,3_\
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M_$"BBBNPY0HHHH *Z#PG_P A1/\ >%<_70>$_P#D*)_O"HJ_ RZ?Q(^A(/\
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M_D,W%?2R?<7Z5\T_!3_D,W%?2R?<7Z4 .HHHH \*\7_\AB?_ 'ZYRNC\7_\
M(8G_ -^N<KQZGQ,_1<)_ CZ!1114'0%%%% !7I_PZ_U2?6O,*]/^'7^J3ZUT
M8;XSR\X_W5GI-%%%>F?#%>^_X\9O]VO&M7_X_FKV6^_X\9O]VO&M7_X_FH H
M4444 %%%% !2K]X?6DI5^\/K0!ZIX-_X\V^E=/7,>#?^/-OI73T %9VL_P#'
MBWT-:-9VL_\ 'BWT- 'C5W_Q^3?[QJ&IKO\ X_)O]XU#0 4444 %%%% #XO]
M8*]@\,?\@2&O'XO]8*]@\,?\@2&@#9HHHH Y;QW_ ,B[<_[M?/XZ5] >._\
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M8O\ 5)_NBOEKX3_\AEO]X5]2Q?ZI/]T4 /HHHH \3\;_ /(0?_>KDZZSQO\
M\A!_]ZN3KR:OQL_0L#_N\0HHHK(ZPHHHH *]-^'7W4KS*O3?AU]U*WP_QGF9
MO_NK/2Z***]0^%*U_P#\>$W^[7C>K_\ '\U>R7__ !X3?[M>-ZO_ ,?[4 4*
M*** "BBB@ I5^^OU%)2K]]?J* /6O"G_ !X_A70USWA3_CQ_"NAH *R?$'_(
M//XUK5D^(/\ D'G\: /'KC_CYD_WC452W'_'S)_O&HJ "BBB@ HHHH L6/\
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ME>F;0>H'Y4;5_NC\J /,]+\+:M_;/VJ[NVD4]C7I,">7 B'L,4_:HZ ?E2T
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M )&:"OH*V_X]T^E?/O@G_D9H*^@K;_CW3Z5Y&8?&CTL%\+):***\\[0HHHH
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M)\)_^0RW^\*^I8O]4G^Z*^6OA/\ \AEO]X5]2Q?ZI/\ =% #Z*** /$_&_\
MR$'_ -ZN3KK/&_\ R$'_ -ZN3KR:OQL_0L#_ +O$****R.L**** "O3?AU]U
M*\RKTWX=?=2M\/\ &>9F_P#NK/2Z***]0^%*U_\ \>$W^[7C>K_\?[5[)?\
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M'%;G_"8Z/_SWH WZR?$'_(//XU6_X3'1_P#GO69K?BS2I;$JD^3S0!YU<?\
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M9&_.D\Z3_GH__?1H^M2#V_D>A_\ "*Z#_?M_SH_X170?[]O^=>>^=+_ST?\
M[Z-'G2_\]'_[Z-'UJ0>W\CT>+PYHT)S'- I]C5A-&TYV"BZA)/09KR_SI?\
MGH__ 'T:M:;-)_:EM^\;[X_BH^L-O5#5=]CU9?!L3+D,M+_PA:?WEKI-/.;1
M,^@JW74CJ,W2M*&FP",$'%:5%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 <AX@\*3W\[7-C<?9YV/+CJ:KZ/X.NX+R.YO[O[0\9^4MVKMZ*
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M7O6B?\@>V_W*UI5',UI5'/<D@TRSMFW0P*C#N*MT45L;!1110 4444 %%%%
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MQM@,L36A]KT/4H#")F\P#@#UK105]310C?4Y&+P\99,"<;0<%NU0WNB/:2(
M^]6.,BMKS8=)F-I=L5B<[L]\5=22VO(RBG,:C]V?4U/*F3RHY#4M/%A(J>8'
MW+FJ-;^IZ-J+!KF5/D7H?:L$C!P:SDK,SDK,=%_K!7L$?_(H1_\ 7(UY!%_K
M!7K\?_(H1_\ 7(UK1ZFU'J>/R_ZZ3_>/\Z6&+S9D0MC<<9]*27_72?[Q_G2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&L_\@N7Z5X3J_\
MR$I?K7NVL#.F2_2O#-6B8ZE+QWKEQ!S8CH9X.#75V,EC>6<,;*D;QG<6/>N7
M\E_2@1R#ID5SQ=CG3L=;J&NP"[C0('C"X([&K%O+8(K7*^6I(R%KBO*?WH\N
M3U:JYV5SNYH:K>#5;]3]T+QFM":]C@M;6.(C<K#<1WKG_*?/0T>5)[TN9DW9
MW.HZC#+IN\3*<* 4SUXKAIF#RLP& >U+Y<N.K4GE/Z42DY!*3D$7WQ7K\?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8@Y%LE6U544*HP!T%+13L.P4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8@DUN273-:6#/\,9Z#\J^@-2LH]0T^6U<?+(,'%>1WGPQU"QU)[C2DP#P,T
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MO$,$1D=_E'L:JVGQ$UN]E:.*3++UZT >UT5Y#_PF/B/^]^AI?^$P\1_WOT-
M'KM%>0_\)CXC_O?H:/\ A,?$?][]#0!Z]17D/_"8^(_[WZ&C_A,?$?\ >_0T
M >O45Y#_ ,)CXC_O?H:/^$Q\1_WOT- 'KU%>0_\ "8>(_P"]^AI'\9^(HT9V
M;A1D\&@#U^BO,?!WC74-:UB.WG?*$X->G4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\A_X3'Q'_>_0T?\ "8^(_P"]^AH ]>HKR+_A,/$?][]#2?\ "8^(_P"]^AH
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M^/\ 6+*>$7;X1V [T >Q45G:+J(U.Q6<'/ K1H **** "BBB@ HHHH ****
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MRB@"G_95A_SZQ_E1_95A_P ^L?Y5<HH I_V58?\ /K'^5']E6'_/K'^57**
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MRB@"G_95A_SZQ_E1_95A_P ^L?Y5<HH I_V58?\ /K'^5']E6'_/K'^57**
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MID;&VMGUH Z.BJM[?16$7F2YQ[5BMXUTQ2<EAB@#I**I6&IP:C&'@.01FKM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 8_B?_ ) 4_P!*X;X<_P#(>NO]VNY\3_\ ("G^E<-\.?\ D/W7^[0!ZC11
M10 4444 %%%% !1110 53U;_ )!-U_US-7*IZM_R";K_ *YF@#S?P)_R%O\
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MLK2Y[J5F^T'(QQ6K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8
M7C#_ )%JZ^E<K\.?]<W^[75>,/\ D6KKZ5ROPY_US?[M 'H]%%% !1110 44
M44 %%%% !7G?Q2_U-C_OC^=>B5YW\4O]38_[X_G0!O\ @K_D"CZBNEKFO!7_
M "!1]172T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<Q\0/^1.O/I_C73US'Q _Y$Z\^G^- &#\,O\ CR3_ ':]
M%KSKX9?\>2?[M>BT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR_X\D_W:]%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **9)(L8RQJ'[=#_>'YT 6:*J_;X/[X_.E^W0_P!X?G0!
M9HIB2+(,K3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$__
M " I_I7"_#G_ )#]U_NUW7B?_D!3_2N%^'/_ "'[K_=H ]2HHHH **** "BB
MB@ HHHH *IZM_P @FZ_ZYFKE4]6_Y!-U_P!<S0!YOX$_Y"W_  ,_SKU2O*_
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MZ "BBB@ HHHH XCQ[UT__KL/YUV5M_QZP_[B_P JXWQ[UT__ *[#^==E;?\
M'K#_ +B_RH EHHHH **** "BBB@ HHIK.J#+$#ZF@!U%0_:8O[Z_G1]IAS_K
M%_[Z% $U%1?:(O[Z_G4BL&&0<T +1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 87C#_D6KKZ5ROPY_US
M?[M=5XP_Y%JZ^E<K\.?]<W^[0!Z/1110 4444 %%%% !1110 5YW\4O]38_[
MX_G7HE>=_%+_ %-C_OC^= &_X*_Y H^HKI:YKP5_R!1]172T %%%% !1110
M4444 %%%%  >!FN*\2>)+BWU*WLK:/?YIP2.U=HPRI'J*\S\3EM(UVVNW1FC
M5MQVB@";7];N[;3DLH0QN V" >:JV%YJ&B:E9Q3&21;KDEC]VDTB8^(/&,]_
MY;BT*94,.>YI^KZDNJ^)[&&UC<+"VULB@#TU'#KN'>N*\9VT@U&WOMI,<(RW
MI79P1^7$%]*CO;*&_MGMYUW1N,$4 8NC^)M+GL$)N(T;NH[5D>*]=L+RV:TM
MI$EED&!CK3I? -I%(3:1!15G3O VG6]PMS+ #,IR#0!H^#X)+;PY;Q2J58=0
M?PK=IJ(L:A5' IU !114<LR0QEW8 #U- $E%4K74X+N8QQ$$CT-7: "BLS4-
M<M=._P!9ECG&%-2Z?JEOJ,9>(XQV)H O5S'Q _Y$Z\^G^-=/7,?$#_D3KSZ?
MXT 8/PR_X\D_W:]%KSOX9?\ 'DG^[7HE !1110 4444 5M1_Y!UQ_P!<S7-^
M!/\ D&S_ /74_P S72:C_P @ZX_ZYFN;\!_\@V?_ *ZG^9H ZVBBB@ HHHH
M**** "BBD8X&: %HKG+CQ$L,[Q['^4XZ&J5YXS@L83+*DFT>QH ["BN4A\5Q
MSQ+*B2;6&1P:U--U<7L@4*PSZB@#7HHHH **** "BBB@ I&^XWTI:1ON-]*
M.-'_ "&5_P!^NSKC!_R&5_WZ[.@ HHHH **** "BBB@ HHIID1?O.H^IH =1
M4?GP_P#/5/\ OH4>?#_SUC_[Z% $E%,$T1.!(A_X$*?0 4444 %%%% !1110
M R2-94*. 5/8U#;V-O;.7BB56/4@59HH **** "BBB@ HHHH **** "J>K?\
M@FZ_ZYFKE4]6_P"03=?]<S0!YOX$_P"0M_P,_P Z]4KROP)_R%O^!G^=>J4
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M03=?]<S5RJ>J_P#(*NO^N9H \W\"?\A7_@9_G7JE>6>!58:KRI'SGM[UZG0
M4444 %%%% !1110 4444 %%%% !1110 4444 <MXJUY-.@*1VZ7$H/\ JR*Y
M5?&US;)Y3:4D,DOW% 'S5-XAG2'Q=(9P3'_]>LOQ'J5E-KNCR(AQ&>?R- &E
MIOB2]AU$/?:2L"GCS"!7I5O*)K>.0=&&:\Y\8ZQ;7FGQQP [O,'\Q7?:1_R"
M+7_KF* +A(%1SS)! TKG"J,DUFZ[%J$EI_H$JQR Y)/I7+W&O31V,UA?,9)I
M!M!7I0!I3^+G6XVPQ!X<\/716%_%?P[XV!('(':O+;?2=2E18X)D"9^Z3_\
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MU)O8KFNYH **** "BBB@!LG^K;Z5Q\7_ ".,?TKL)/\ 5M]*X^+_ )'&/Z4
M=E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/\: ,'X9?\>2?[M>BUYU\,O^/)/]VO1: "O+OC#_ ,B_<?[O]*]1KR[XP_\
M(OW'^[_2@#YDHHHH **** "BBB@#N?AG_P AM?\ ?%?6$/\ J(_]T?RKY/\
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MW( >: %7P[-;O]OAE=V;_EGG@5U.DSW$L)$\10KP/>N7M/B3I4C+$EK<("<
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MF/B!_P B=>?3_&@#!^&7_'DG^[7HM>=?#+_CR3_=KT6@ KR[XP_\B_<?[O\
M2O4:\N^,/_(OW'^[_2@#YDHHHH **** "BBB@#N?AG_R&U_WQ7UA#_J(_P#=
M'\J^3_AG_P AM?\ ?%?6$/\ J(_]T?RH ?1110!XMXY_X_C_ +U<A77^.?\
MC^/^]7(5Y-;XV?H.7_[O$****R.P**** "O5?AU_QYI7E5>J_#K_ (\TKHPW
MQGE9S_NK/0Z***],^'*6K?\ (,N/]RO&+S_CX:O9]6_Y!EQ_N5XQ>?\ 'PU
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M?NGZ5X[XR_Y*;I?^[_A7L1^Z?I7COC+_ )*;I?\ N_X4 >N6?_'JE3U!9_\
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M"MK72:;_ ,>25Y9?^(9;VXCE9B2E78/&$\,00.<"@#U&BO,O^$TN/^>C4?\
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M+]Q_N_TH ^9**** "BBB@ HHHH [GX9_\AM?]\5]80_ZB/\ W1_*OD_X9_\
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M_C1]3PB]_P"/R3ZU7JQ>_P#'Y)]:KUX[W/T6'PH****104444 6],_Y"5O\
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M&\31&))#;@G<0>*TO$TFI1Z7!):AV<MR :[_ /LZUR3L'-.>QMY(Q&R94=J
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MO,#@!^#_ "H ]"KF/B!_R)UY]/\ &NFR!U-<QX_9?^$/O/F'3U^M &%\,O\
MCR3_ ':]%KSKX9?\>2?[M>BT %>7?&'_ )%^X_W?Z5ZC7EWQA_Y%^X_W?Z4
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M6%QY]BLI[BO+_'U[;MXGLS<6LLT('S!5)S^E 'H-GXITJ^E\N"Z5F]!6R"&
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M10 4444 ;OA;_D+P_6O7EZ5Y#X6_Y"\/UKUY>E "TV3_ %;?0TZFR?ZMOH:
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M"@#C[CP/#/J2WI9@R]J["R@%O:I$/X1BD%];GI-&?HPIPNX2<"1/^^J )Z*
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M_P"% 'KEG_QZI4]06?\ QZI4] $-U_QZ3?[A_E7R?\3/^1@_.OK"Z_X])O\
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M $%%%% !1110 4Z/_6I_O"FTZ/\ UJ?[PH ]JT?_ )!T/^X*T*S]'_Y!T/\
MN"M"@ KC_'O_ ""E_P!ZNPKC_'O_ ""E_P!Z@#S.BBB@ HHHH **** -WPM_
MR%X?K7KR]*\A\+?\A>'ZUZ\O2@!:;)_JV^AIU-D_U;?0T >%_$;_ )#2?2N-
MKLOB-_R&D^E<;7T5#^$CQ:WQL****U,@HHHH *]C^&O^J/\ NUXY7L?PU_U1
M_P!VN3&_PCIPO\0]%HHHKPSUC(\2?\@6:OGK5/\ D(S?6OH7Q)_R!9J^>M4_
MY",WUKU<OV9Y^-W13HHHKTC@"BBB@ JUIW_(2M_]\55JUIW_ "$K?_?%*6PU
MN?1/A_\ Y!B?05JUE>'_ /D&)]!6K7S<_B9[D/A04445)04444 %%%% !111
M0 4444 9VHZKI]@A-XZJ!ZBN0U7Q#:WB-'I<<4C'CA13_&GA/4=<=V@NXXHR
M?XB!7&P>"=4T^0>3J]LK9Y^<?XT :&DZ#K4VK_:9UEC0]@QQ7K5JACM8T;J%
MP:\YTK1/$YF5CK4,B?W58'^M>C6ZNEO&LAW.!@GUH D;[I^E>9^)8E_M6**X
M/,A^4&O3:X?QEJVEV-Q$UQ:M-,/N,HSB@#DKJYTVWN_L%R438<@[1G->A^%)
M'DLVRH" ?*?45P,]YHMS!'J%SISR2.P'3G^5>FZ));26$9MDVKM''I0!IT44
M4 %%%% !1110 4444 (?NGZ5X[XR_P"2FZ7_ +O^%>Q'[I^E>.^,O^2FZ7_N
M_P"% 'KEG_QZI4]06?\ QZI4] $-U_QZ3?[A_E7R?\3/^1@_.OK"Z_X])O\
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M!CGK6A<^.-&UN$&ZTZ1L]B#3=-O]"BN5>WT:56SD,%/^% 'HGA*&6#P[;QS
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M_P"0[-7K+?=->3>,?^0[-0!SM%%% !1110 4#K10.M 'I/@'_CRE^M=G7&>
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M% 'IFDW#W6G1RNBHQ[*.*O51TF=+C3XY(XS&IZ*1TJ]0 444QI8T^^ZK]30
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M+7T1X7_Y%^V^E?.]E_Q]+7T1X7_Y%^V_W:\W,/A1W8+=FQ1117E'HG"?$?\
MY!$WT_I7B0Z5[;\1_P#D$3?3^E>)#I7MX'^$>5B_X@4445V'*%%%% !74>"O
M^0HO^\*Y>NH\%?\ (47_ 'A65;X&:4OC1[]'_JD_W13J;'_JD_W13J^=/;"B
MBB@ HHHH **** "BBB@ K"UZ6\B*FWMDE3'.X9K=IK(KJ589!H XV#Q'HUO&
M%U%8(IA]Y0@J3_A*_"Y_U<L);M\@K8N?#&D7<A>:T5F/4U O@W0E.19)F@"A
M::YJ%W=;;.!&M?X6 KK(RQC4L,-CFH+6QM[) D$811T JS0 R5_+A=_[JDUY
M_)J%]X@O'6W!,<;%25.*[R\S]BGQ_P \V_E7#_#W@W^_KYS8S]: )O#.MW8U
M^?2;A0(X5X)Z]Z[*[N%MK9IF. HK@;7:?'5YY?WL<X_&NM\09/A^8*?FVT <
MC]MO]<U2YC (AB4NA4XSBM'PMKUP\C6EZ DF\JH]1FJ_@XKF4,1N\LY_*J,/
MS>,(#%]T,<XH ]+KF/B!_P B=>?3_&M+7-7_ +'M1-Y+RY[*,UYEXI^(3:KH
MES8QZ5=!GX!\LT ;OPR_X\D_W:]%KPKPAXUDT.W5)=+NF(&.(S75?\+6'_0(
MN_\ OVU 'I=>7?&'_D7[G_=_I4W_  M8?] B[_[]M7'>._%TWB33);>'2[E&
M<8R8S0!X?16G_8&I_P#/E/\ ]^S1_8&I_P#/E/\ ]^S0!F45HOH>HQJ6>TF
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MN ZG^S+G@Y_U9H ^@]'_ .0=#_N"K]>5V/Q.^S6L<9TBZ)5<?ZLU9_X6L/\
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M?Q&&HW:0?V9<Q[FQED-24=[12 Y4'U%+0 4444 %%%% !1110 4444 %%%%
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MQK"MG/!-" C-,H.T8[BN_L2386Y/4QC^5>;W][)XIU);>*"2,1N'W,O'7/\
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M'S?[C?RKA/\ A:P_Z!%W_P!^S5:^^)WVFU>,:1= LI'^K-..C%+8\SOO^/\
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M  M8?] B[_[]M70^&?%__"0R2*+*:#9_?4C- '54444 %%%% !1110 4444
M%%%% !1110 V1=\3H>C*17GE]IVM:'>DZ-;>:DA+,3ZUZ+10!POAG1+Y-5N-
M6OHBEQ*ARO;.#6Q$NI79>"ZA"Q$XS[5T5% 'FUSINN:/JEQ)IEMYD<@V\GM6
MOX3T*XBW7-_&4GW9 KLL9HH :\:2##HK#W&:@.GVAZVT/_?L59HH K#3[,?\
MNL/_ '[%'V"T_P"?:'_OV*LT4 5OL%I_S[0_]^Q1_9]G_P ^L/\ W[%6:* *
MW]G6?_/K!_W[%']G6?\ SZP?]^Q5FB@#!\0:/#<:5<1P6D.]HR!B,5R_PR\,
MRZ7I-Q'J%G&':8D;D!XR?6O12,C!H50HP!B@"O\ V=9_\^L'_?L4?V?9_P#/
MK!_W[%6:* *W]GV?_/K!_P!^Q1]@M/\ GVA_[]BK-% %;[!:?\^T/_?L4?8+
M3_GVA_[]BK-% %;^S[/_ )]8?^_8H_L^S_Y]8/\ OV*LT4 5O[/L_P#GU@_[
M]BO/O'_AF?4(V%E9QG/]U0*]*IK(K=10!CZ%I,$&A6<4UK#YB1X;,8ZUH_V?
M9_\ /K!_W[%60,# HH K?V?9_P#/K!_W[%']GVG_ #ZP_P#?L59HH K?8+3_
M )]H?^_8H^P6G_/M#_W[%6:* *WV"T_Y]H?^_8H_L^S_ .?6'_OV*LT4 5O[
M/L_^?6'_ +]BFOIUH8V M8<X/_+,5;HH \K7PK=?\)*D_P!C3R1+G[O&*]+_
M +/L_P#GUA_[]BI]BYSBG4 5O[/L_P#GU@_[]BC^S[/_ )]8?^_8JS10!6^P
M6G_/M#_W[%'V"T_Y]H?^_8JS10!6^P6G_/M#_P!^Q1]@M/\ GUA_[]BK-% %
M;^S[/_GUA_[]BC^S[/\ Y]8?^_8JS10!SOBK1XKOPY=P6UI$967Y<(!6%X!\
M./I]A&E[:1A@.=R UWQ (P: H7H* *_]GV?_ #ZP_P#?L4?V?9_\^L/_ '[%
M6:* *W]GV?\ SZP_]^Q1]@M/^?:'_OV*LT4 9FH1V5E9O.UM  O_ $S%<F_B
M[2E;'E6__?M:Z7Q3_P @"X^E>%3C]Z:YZU1Q>ASUJCB]#T[_ (2_2O\ GE;_
M /?M:/\ A+])_P">-M_W[6O+:4*3T&:Q]O(R]O(]1_X2_2?^>5M_W[6L37+K
M0M<,/FF./RG##8@&:XC'/2E*$#)!Q3]O(/;2/38/%.D00I&([<A0!S&M2?\
M"7Z3_P \K;_OVM>7!">@)I-I!P1S1[>0>WD>I?\ "7Z3_P \K;_OVM'_  E^
ME?\ /*W_ ._:UY:5*]1BBE[>0>VD>K0^+-+ED"B*WY_Z9K6]=75A;V$=R8(-
MKC/^K%>*6 _TM:]-UK_D5K7_ '*UA4DTV:0J2:=QA\7Z4&(\JWX/_/-:3_A+
M])_YY6W_ '[6O+W_ -8WU--Q6?MY&?MY'J7_  E^D_\ /*V_[]K37\6:2Z,O
ME6_(Q_JUKS'8<9VG%(!GM2]O(/;R.UANM"AU==0!C+K_  E!BMS_ (2_2?\
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M10!6_L^S_P"?6'_OV*/L%I_S[0_]^Q5FB@"M]@M/^?:'_OV*/L%I_P ^L/\
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MI-V'&M)NQ[4+&T*@_9H>1_SS%21V\,/^KB1,_P!U0*?'_JU^@IU=AV!1110
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MP9@WF#-8VOZ*+"-&&.:B4=-"91TT.=KH/"G_ "$D_P!X5S_>M_PI_P A)/\
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M]!3Z;&,1J/04ZN\] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#B/'W_'JW^[7D8Z5[3XPTZ6^MV6,'[O:O-_\
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M 'IU%>;+XON],N(ENH96$C!02*F\1>+I;?5X+.W5B98PWR_A_C0!Z'17F?\
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MRK+\/ZLFK6 E4], _6M>@!GE1_\ /-?RH\J/_GFOY4^B@!GEQ_W%_*G;5QC
MQ]*6B@!GE1_\\U_*CRH_^>:_E3Z* &>5'_SS7\J/*C_YYK^5/H/2@!GE1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'0?E5KQ(+G3OB%#JB6LDT:)T4?2K&I^);G6XUM5TV:/=\NXJ: .O\(R6TFD
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M **** "BBD) ZT +7*>)_#3:RS%2XR/X2:ZNDR,XS0!Y5_PK:3^_-_WT:/\
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M;2?WYO\ OHUZM10!S?A;0&T6T$3%SSGYC72444 %%%% !1110 4444 %%%%
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MS#*>]5[;QMIT]TUN9OG SBN.NX%N=0T43+N''7\:T_%EA;65P9+>)8V+8R*
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MC\W4+4VJ_9")!NQ_%0!Z^#D9]:6HX,_9X\G)V#G\*DH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$)P,UR.K^,[;3-:6RDDQD9KH=6NEM-,N)2<%4)%>02FVUW2I[]YT2X5RHR>>
M] 'L<-[')8"[S^[*[LURU[XLDFNC%IS!OK3O#>HQZEH<E@DH+1Q[2P-<F9[C
MPO?%5L'O1DG>HH Z_2_%J/<?9[U\2$X 'K6EK7B2TTF(^8^'QD5REAJMEJMQ
M&\MFMG(IR-W5C5.Z']H?$J&UF.Z I]P].U &S_PE&H ?:6Q]F/S9]JZ/1-?M
M-:MQ);ON[58DTNT-D8?)3;MQ7GVELVG?$9-.@.V KG:.G6@#U"BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '&^.[MXXK:V7I.=AJAI?PYL%L\2!QO^8CZUW-Q96]TR-/$K
ME#E<]JG    & * /(=)M;GPSJ6H1Q@@2_+%FM33O%B:2AMM?"K*3GIGBO09-
M.M97#O I8'.35>ZT+3;QM\UI&[>I% 'FM]+:>)-6M)-')(CD!D[5HZUI=UI?
MB*/6U7]W&@!-=Y::-I]D<V]K'&3W45:GMH;F/RYHPZGL: .,;XAZ6UGY(E/V
MDKC'O53PSI5Q?Z\NN3KSTS76_P#"-Z3YF_[#%G.<XK2A@BMTV1($7T% $E%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gtinntqqusay000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .1!:H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBD) ZF@!:*3<OJ/SHW+_>'YT +129&
M,Y%&1C.>* %HI 0>A!I: "B@D#J:,@]#0 4444 %%(2!U(%&1C.: %HI 0>A
M!I: "BBB@ HHHH **3(/0BEH **** "BBB@ HHHH **** "BBDW#U% "T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-
MDDCB4M(ZHHZEC@4R*YM[C/DSQR8Z['!_E0!+1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$@=3BEZT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML#CGOC(-<%\.O^2VQ_\ 7U<_R>FEO83>USZ<9E12S$*HZDGBH/M]G_S]P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$84 1N IP<^E=5=Z=%>:3+ITA80RPF%B#S@C'YTG)60TMSPW]GO_ )"NK?\
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M^)SZD^M<ZGPOT5/&;>*!/=_;3<&X*[QLW9STQT_&CG5V'+H=O1116984444
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M,]\0./)_QK#L;J[^(OQ$6TU[5V@@>1PN#A5 Z(O/&:^C]!\-Z5X;LA:Z7:)
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M6'\6=<LM:^(%O]@N([B& (GF1ME2>,C/L:]!O?@-HLNHK/9WUU;P%BSQ[AD
M]E..!^=:,OP2\+2):!#=QM;Y.]9!ND.<Y;CFJYHWN39VL2^--:\,6/A.PL/$
M]M<36]S$&C,46[:P'7/8\UYU_P *P\-:]I7]M:#XC6ULQ'N>.Y =HSZ,<C'Y
M5[?K/A;2]?T(:1J$/FVZ@;&_B4@8!!]:\XN/@+8?:0+/5[J*T/WHW;)/XC _
M2E&22&TSD/@AJM_'XY.EB[=K.2&1FCW?*2HX-?2%<MX0\ Z+X,CD_LZ-WGE^
M_/,07(],@#BNIJ9--Z#BK(****DH**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"\N5L[.:Y9'=8E+%
M44DGZ 5/10!Y#HOB[Q/K7Q1TU;ZTETW2+BWE:WM9,;VQCEQU!_*O7J\]UG_D
MLN@?]>DW\A7>3W=M;-&MQ<11-*VV,2.%+GT&>IH \Q\:ZKJC_$K3]'MO$_\
M8NFFQ,MQ()(UP^YL<N#SP*ZGPA8SQ2SW)\7RZ] 5V!2\3+&W7.4 YQ68^C^!
MM=^(5X+A4N=<MXP)()MP !'4 \-P>V:PO"=A8:%\8]6T[0)";%[027-NKDI"
M^1T]SQ^= 'K=%>;>,-)U[0M)OM;M_%NH-Y4JNMLT46P!I -N=N< -7H=J[/:
M0NQRS("3^% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_X"S?\ Q-=+10!S7_"?>&O^@@__ ("S?_$T?\)]X:_Z"#_^ LW_ ,372T4
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MG'PJ_P"/GQ9_V%YO_0WH ]'HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#U(^M)V!7-FBBBD,**** "BBB@ HHHH Y/XE_P#)/]2^L7_HU*Z6R_X\8/\
MKFO\JYKXE_\ )/\ 4OK%_P"C4KI;+_CQ@_ZYK_*@">BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *YO6?^1V\,?2[_\ 18KI*YO6?^1V\,?2[_\
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M#'IS7I]*0T%%%%2,**** "BBB@ HHHH Y/XE_P#)/]2^L7_HU*Z6R_X\8/\
MKFO\JYKXE_\ )/\ 4OK%_P"C4KI;+_CQ@_ZYK_*@">BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *YO6?^1V\,?2[_\ 18KI*YO6?^1V\,?2[_\
M18H Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+VZ6RL+B[<$K!$
MTC =2%!/]*\-MU^(OQ)5]8TW4ET[3UD9+93*T6]<G^Z.<=.:]G\0_P#(M:I_
MUYR_^@&N1^#DT2?#+35:1%.Z7@L/^>C52T5R7J[%7X>>*->DUV^\*>)DSJ-E
M&'24 8:,8 .>^<@YKTJO*K.9!^T)J;"10ITZ,9W<'A*]1$\+' E0D]@PHEN-
M$E<)\49KB72=/T6VG>W?5;Q+<RH<%5) /\Z[NN*^(7A[6]<BTJ;06MEO+&Y\
M]3<-A<C!'8YZ4H[@]BYI?P[\+Z98):KI%K-M'S23QB1B>_)YKD[_ ,/V?@+Q
MYHNH:09(+/4I6@N+57.QFVG!Q^7'M4GD_&3_ )^= _+_ .M5;_A'?B)KFM:5
M/KUQH\EI8W'G?Z.V&!Z'MS5+S9/R/6J***@L**** "BBB@ HHHH *\X^%7_'
MSXL_["\W_H;UZ/7G'PJ_X^?%G_87F_\ 0WH ]'HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N?\=_\ (@^(/^P?-_Z :Z"N?\=_\B#X@_[!\W_H
M!H T](_Y MA_U[Q_^@BKM4M(_P"0+8?]>\?_ *"*NT %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U6R_M+2+RQW^
M7]I@>+?C.W<I&?UJW10!X<O[/TZKM7Q,0!V%L?\ XJC_ (9]G#EQXF^8]3]F
M.?\ T*O<:*OGD3RH\C\.?!>?0?$5EJC>(#.MM)O,7D$;N",9W>]>N445+;>X
MTDCA?B+KVH6;Z1H.E3&UO=9G\E+H?\L@,9(]^16/XUGUK3](\-^$X-7EDU#4
M)1!<WP'S[01EB,]#D]^U=#X\\,7NLC3=4TC8=7TJ?SK9)3^[;ID-^0[UC>'?
M#7BJ_P#'H\2^*8[2#[/;^3!#;MN!SGGJ<$52M83O<JBTD^&?B?188M2N9])U
M20P203-N(F(X8>F21^5>J5YK86.N>,?&MOJ^L:<UEH^FLPM[6?[SR=G[>QS[
M5Z52D-!1114C"BBH+V![FRF@CF:%Y%*B1>J^XH R7\7:0GBF'PX+C?J,D;2>
M6G.P#U]*W:\?L/".F>$_BUHD%@)7:6VG:2:9]SN<#J:]@H Y[7_&>E>'K^UT
M^X%Q<7]T"T5K:Q>9(5&>=H[<'FG>&?&&E>*X[AM.:426S^7-#,FQT;W%</X1
M=KOXZ^,O//F?9H8DAW<[ 0"<?F:T=*LX[#XW:N\.!]LTY9)%'0$,H_I0!M?$
MO_DG^I?6+_T:E=+9?\>,'_7-?Y5YI\0/'.F7OAO4M(CMM26X,J1;WLW6/*RK
MGYB,8XZUZ79?\>,'_7-?Y4 3T444 %%%% !1110 4444 %%<?J_Q,\-:'J<N
MGWL\ZW$1PP6$L/SJC_PN/P?_ ,_5S_X#M0!WU%<#_P +C\'_ //U<_\ @.U'
M_"X_!_\ S]7/_@.U '?45P/_  N/P?\ \_5S_P" [4?\+C\'_P#/U<_^ [4
M=]17 _\ "X_!_P#S]7/_ (#M1_PN/P?_ ,_5S_X#M0!WU<WK/_([>&/I=_\
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MD9KQ31SQ++#(DD;#*NC9!^AI]8OA*SGL/"FFVERACGBA"NI/0Y-;5 !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!P./:NVKG_">K:WJ^G2S:[HO]E7"R%4BW[MRX'/\_P JZ"DQH****0PHHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^_\ U-<A77_$W_D?=2_W_P"IKD* "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %?0WP8_P"1-;_KL:^>:^AO@Q_R)K?]=C0!Z/1110 4444
M%%%% !11534]1MM(TZ:_O'*6\(R[!22!G'0?6FDV[(3:2NRW17&_\+1\*_\
M/Y-_X#O_ (4?\+1\*_\ /Y-_X#O_ (5K]7K?RO[C+ZQ2_F1V5%<;_P +1\*_
M\_DW_@._^%'_  M'PK_S^3?^ [_X4?5ZW\K^X/K%+^9'945QO_"T?"O_ #^3
M?^ [_P"%'_"T?"O_ #^3?^ [_P"%'U>M_*_N#ZQ2_F1V5%<;_P +1\*_\_DW
M_@._^%'_  M'PK_S^3?^ [_X4?5ZW\K^X/K%+^9'945QO_"T?"O_ #^3?^ [
M_P"%'_"T?"O_ #^3?^ [_P"%'U>M_*_N#ZQ2_F1V5%<;_P +1\*_\_DW_@._
M^%=9:745[:QW,#;HI%W*<8R*B=*</B5BXU(3^%W)J***@L**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ J"]M([^QN+2;/E3QM&^/1A@_P ZGK-\
M0W$EKX;U2XA;;+%:2NC>A"$@T >47?PDT2P::'3?&<UE<EN(7ND0 GH"!S6-
M_P *G\;^&[Z+6-$U.&ZO0<YA;:2,=]W!JWX3^%%GXP\+0:_?ZK>?VC>EI#)U
MV$,0/Y5TOPOU#5].U[5O!NKRR7#V"^=#+(V3Y9(P,]3G<#6MVNIG9#M'\8>/
M(-?TW2M>\.0QPW#;'N8\N1QU)4D"O4***S;N6@KSG4=!OK'5=<MKC5K2+0]>
MCE+"9U1K>4KC*YQG/'KTKT:O%/$FD67B4>,]1U:[DGNM,\R.SM#(5$ 5<AL
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M@ HHHH **** "OH;X,?\B:W_ %V-?/-?0WP8_P"1-;_KL: /1Z*** "BBB@
MHHHH *Y_QN ?!]^",@A/_0UKH*Y_QM_R*%__ -L__1BUI1_B1]415^"7H7K'
M3+ V%N38VQ)C7GRE]/I4_P#9>G_\^%K_ -^5_P *?8_\@^W_ .N:_P JXOQ-
MX@\3:%]HNC%:"S$NR'<3N?/0?6JA&527*F3*481NT=C_ &7I_P#SX6O_ 'Y7
M_"C^R]/_ .?"U_[\K_A7&ZAXMU:VCTG3MEM#JUZN9O-;Y;<'&"?U_*EN_%6N
M6/A6YN;FU@6ZCF6&.X5PT3ACC<,'J/<5?L*FFN_F1[:GKIMY'8_V7I__ #X6
MO_?E?\*/[+T__GPM?^_*_P"%<7;>,+]/#5ZTYCN-1CG%K \.,2.P7! /'!;]
M*[734N4TZW6\E,MSL!D8J!SWX''M43A.&[+A.$]D)_9>G_\ /A:_]^5_PH_L
MO3_^?"U_[\K_ (5SVN^))]*\9Z1IQD1+*YC=YF;M@'_"J>E^)M5\4^()%TE%
M@T:V;;)<.H)D/M]?Y52HU''FOI:Y+JT^;EMKL=;_ &7I_P#SX6O_ 'Y7_"C^
MR]/_ .?"U_[\K_A7$6^M^*M6U36H]-DM/*TZX,8CD7YG&3C''M6[X0\2S:_#
M=0WMN+>_M)-D\0.0/3^1HG1J15[[!"K"3M8=XKTZQC\):LZ65NK+:R$,L2@C
MCZ5;\*_\BOIW_7$4WQ=_R)^K_P#7I)_Z":=X5_Y%?3O^N(I-MT=>_P"@TDJO
MR_4V****P-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LGQ3SX
M2UC'_/E-_P"@&M:JNI7%O:Z7=W%VF^WBA=Y5 SE0"2,=^*$!Y=\-/B'X8TSP
M18:=J&J1VMS;AE9)0><L3Q@>]2>&]3L;OXXZ_=P743V\NG1>7)NP&_U?2J"Z
MI\(/$UI(DMO;:;@\EXEA<_0C-*WPA\(:M%#=^'=>DM0#D2J_FY^F2,5IH1J>
MR@Y&117EVC^"_&VB^*;*9?$\NH:/&W[U;B9@2N.R\CT[UZC4-6*1A>(_%^C>
M%1;_ -K7(@^T9\OCKC&?YBO,/%,O@3Q-<RWUOJMYIUW<)LFFMHVQ,OHR\ ]3
MS7J7B/PIH_BJT6VU:T68)G8XX=,]<'M7'7?@?5/#L<UQX>U]=NT".SU,>9&H
M&>C$\?E51L)W*'@*+PG9:Y"\.J7VJ:N4,<=Q=*V53'09X'>O6J\O\)_$6'4?
M$O\ 8EYIELMT!M6YL7\R-F YR2!BO4*4KWU''8****D8445S?CSQ _AGP;J&
MI0,JW*)M@W#(\P],T =)17C6J:+XR\.^#4\4CQ+>SZI;*;JZM)9&,!3&2H&>
MV/3G->L:1?QZII%I?1,'2>(.&'0^OZT 7:*\<^)-]?7'Q LM-C\63:!I<=CY
MMU<12$;6W,!D C.< 5TOP[T>2V:;4D\<W7B2TGCV(LI^5"#]X?,>>,4 :7Q+
M_P"2?ZE]8O\ T:E=+9?\>,'_ %S7^5<U\2_^2?ZE]8O_ $:E=+9?\>,'_7-?
MY4 3T444 %%%% !1110 4444 ?,/Q-_Y'W4O]_\ J:Y"NO\ B;_R/NI?[_\
M4UR% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7]#_ .0_IO\
MU]1?^A"OKU?N+]*^0M#_ .0_IO\ U]1?^A"OKU?N+]* %HHHH **** "BBB@
M KC_  7_ ,A7Q)_U^#_T&NPKC_!?_(5\2?\ 7X/_ $&MJ?\ #G\OS,I_''Y_
MD=%K-^FF:-=WLF[;%&6.T<UR/A;21_P@%U/J4#W,NHJTTWE??D4\@<XYYKN9
MH8[B)HID5XV&&5AD&B**.&)8HD5(U&%51@ 4HU.6'*NXY4^:5WV/#;JWM]3M
MM'TC3=6N[IO.*K;30[3!G'WB"?P_&N_\3Z7I>D1#6TL]^KE5AMPF,-*>%)4\
M$@]ZZN#2["VNI+J"SACN)?OR*@#-]33[FPM+R2&2YMXI7@;?$SJ"4;U'H:WG
MBN:2MLOQN80PW*GW9Y9=ZMJGA""6ULI$B-O'%*Z-"N;EW?#<]L#CCTKT>\E:
MX\*W$SKAY+)F(]"4)J>ZTC3KVYBN;JR@FFBQY<CH"RX.1@_6KC*KH490588(
M/0BLZE:,[.VO4TITI1NKZ'A^D^#[J;P7%XAM;B9KVW<R0P@]%5L$>W<UM>*_
M$$7B#P/I-\ RNE]&)U*\JP!R?IUKU*&U@M[?[/#"B0\C8HP.>O%5O[&TSR3%
M]@M_++;BOEC!/K6SQBE/FDMGIZ=C)85QCRQ>ZU_S. \=:]9>);&RTC1F>]N)
M+I),Q(=J@9X)/UKTJ%/+A1,D[0!S4-MI]G99^S6T4.>NQ0,U9KGJ5(N*A%:(
MWA!J3E)ZLY/1O^2@Z]_U[P_^A/765R>C?\E!U[_KWA_]">NLI5OB7HOR"C\/
MS?YA11161J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!G>(/^1;U3_KTE_] ->6_"OX@>&M'\$6NF:G
MJ4=I<P,^Y90><L2,8^M>MWTT-MI]S/<+N@CB9Y%QG*@$D8^E>11ZQ\(?$MM-
M'+:VVG<Y+R0K"[?0C-7':Q+W)M)U:QO?CS?WEK=Q26TNG1A9 V W">M>O @C
M(.1ZUXV?A)X,UFVCN?#NN/;8;(E63S<_F16AIW@?QMHWB*QEMO%,U_I4;#S4
MN)F7*^@7D?K0[,%<]5K'\0>)]+\,6T=QJMP(8Y&VJ<=36QVK*U_PYI?B;3S9
M:I;":+JIZ,I]0>U2O,H\K\4W?@3Q1</?PZI=Z?>RQ^7)<6L;?O%[A@, YR1S
M4W@R'P?8:Y:3MJ^H:IJ:?NK>6Y5\(I&-H'(QR:VKGP'?^'DDG\.:]L0)MCL]
M1'F1C'HQ/'Y51\/?$F&3Q''HFJ:9:FXR$%SI[^:A?WR!BKZ:$==3U>BBBLRP
MHHH/ S0 45Y=IEAJ_C;Q?KU[<ZU?6VBVDYM+..QN6C#LO5CCOR/K6E\.=<O'
MO-:\+ZG>R7M]H\^P7#CEXR!MR<\G.: ._HKB?BQK%[H7P\O[W3I6BNMT<:.C
M8(W.%X/XUR?AE-)U*YTZ./XD:E/J#*DCVANW^9@ 67!/L10![%7G'PJ_X^?%
MG_87F_\ 0WKT>O./A5_Q\^+/^PO-_P"AO0!Z/1110 4444 %%%% !1110!YE
M\;?^12A_Z^%KY_KZ ^-O_(I0_P#7PM?/] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?0WP8_Y$UO^NQKYYKZ&^#'_(FM_P!=C0!Z/1110 44
M44 %%%% !7/^-O\ D4+_ /[9_P#HQ:Z"N?\ &W_(H7__ &S_ /1BUI1_B1]4
M15^!^AL6/_(/M_\ KFO\JXWQ CZU\0-)TO:WV:T4W,ZN/W<G3 ]">M=E8_\
M(/M_^N:_RJ?:N[=@;O6G"?))OU%*'/%(\N\=:5'#XYTO5;U"^G2A8Y@%)"A3
MSGVYJSX$TV*\EUN'[*[:!)(!:QSC(SWX/X5Z.Z+(I5U#*>H(I54*H50 !T K
M5XENGR&2PZ]ISGF=S!']LOKC1[-19:+&WE((U*O.1RWN0"I_"K_@/6M0OM8U
M"RFNFN[2*-)(YF7'S, 6'X$FNVM;"TLHWCM;:*%)&+.J* &)ZDTMK96UDC):
MP1PJS;B$7&3ZT2KQE%QL$:+4E*YYWX\T?^W/'>@V+F1(98F#R(.@!)_7&*;I
M'F^ O%[:0YF?1[WYH7*Y"-]?0<CWKTPJI8,0,CH:1D1R"R@XZ9%"Q+Y%3:TM
M_3!X=<[FGK?^D>7:'XCM?#>O^*/MD-P6GO2T82,G=@M_C6U\/K>ZGNM:UR:$
MPQ:E.'CC;[P SU_.NV\J/.=BY]<4^E.NI)V6KM^ X4'%J[T5_P 3%\7?\B?J
M_P#UZ2?^@FG>%?\ D5]._P"N(IOB[_D3]7_Z])/_ $$T[PK_ ,BOIW_7$5'_
M "Y^?Z%?\OOE^IL4445B;!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %17-O%=VLMM.@>*5"CJ>X(P14M,EEC@A>65U2-%+,S' 4#J30!XCXG^"
M;V5PVH>&EAN%&XM970W#&#T/<^@Q7,Z?X>\*:@QTN^FO?#6O(5R+N3=&2?0<
M8)SP*]SN?'_A2UB:1M>L7Q_#',K'\@:X#Q-\0?AGXDM7AU"*XGE7B-TMRK@_
M[+5JG(AI&II'@WQMHNO::X\53:CI43 312,4&S'0#)SVKT^O!/A[JGBRR\2V
MMG8V>HR>&IY2 ;J)F$:')SNX&>G->]U$MQQV.#^)&K^,=,CL5\*:>UUYN\7!
M6 R%,8V]#QWKS2.Q\2ZCY;^*?#7B/6)(I"\:ERD:YQQMVGTKV?Q-;^(F\B[\
M/74 E@5]]K.N5GSC'.1@C!Y]ZP8_B3+9O*FO>&M4T]8N#,D32HQ]B .*:>F@
M-:E;P?JES:WL>G6WP_N=&M96+/-MPH..I^7VKT>O/Y/B1<W\J1:!X9U*^648
M6XD0Q1JWOD=*Z3PQ#KZ64TWB&>![J:3>L4"X6%<8VYR<],Y]Z30T;E%%%2,*
MX#XS64M[\.+PQ=+=UG?_ '5SG^==_45Q;Q75O);SQK)%(NUT8<$4 <-XXU_3
M9/@]J%\ERK6]Y8&*!P?OLRX4?G6[X+LFT;P7H]A<.!)' %Y/4GG^M8EC\(?"
MMCK(U%(KF0*^^.UDES#&?9<=OK71ZSX9T_7+C39KOS0VGS": 1OM&[CKZC@4
M <=_9'@/Q%\1]7MKVSEO-8A1?.CO%S"!@8\NJ7AC3M/T/XR:II_A]4CL_L2O
M=6Z<)"V1C ]^/SKK/%?P]T'Q@\<VH1S17*#:+BV?9)MSG&<'BKWACPAI'A*S
M:WTN!@SG,DTC;I)#_M'O0!YMXZ\&>);32M1U2X\:WMS8"X60Z>R'85,JX7[W
M09';M7K]E_QXP?\ 7-?Y5S7Q+_Y)_J7UB_\ 1J5TME_QXP?]<U_E0!/1110
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M?_8T?;_$_P#T [3_ ,#O_L:Z"BCG7\J_'_,.1_S/\/\ (Y_[?XG_ .@':?\
M@=_]C1]O\3_] .T_\#O_ +&N@HHYU_*OQ_S#D?\ ,_P_R.?^W^)_^@':?^!W
M_P!C1]O\3_\ 0#M/_ [_ .QKH**.=?RK\?\ ,.1_S/\ #_(Y_P"W^)_^@':?
M^!W_ -C1]O\ $_\ T [3_P #O_L:Z"BCG7\J_'_,.1_S/\/\CF- TW58_$6I
MZIJ-O# +J*-$2.7?]TL3V'K73T45,YN;NRH1459!1114E!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 ?,/Q-_Y'W4O]_^IKD*Z_XF_P#(^ZE_O_U-<A0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %_0_\ D/Z;_P!?47_H0KZ]7[B_2OD+0_\
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M>FXJ,<9Y_.LGPK\/_P#A%=?EN+:>!].>!5$3QYD$H !?=CC// ]: .YHHHH
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MKY^3Q==^,_B3X3N;G2I;*6UD=) 5.WGD8)^E?0-$N@1"BBBH*"BBB@ HHHH
M**** "BBB@ HHHH Y/XE_P#)/]2^L7_HU*Z6R_X\8/\ KFO\JYKXE_\ )/\
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MK;_OZO\ C1_:=A_S_6W_ ']7_&@"U157^T[#_G^MO^_J_P"-']IV'_/];?\
M?U?\: +5%5?[3L/^?ZV_[^K_ (T?VG8?\_UM_P!_5_QH M44=1D44 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 QX8I61G
MC5BARI(Z&GT44 %%%% !1110 4444 %%%% !1110 4444 <G\2_^2?ZE]8O_
M $:E=+9?\>,'_7-?Y5S7Q+_Y)_J7UB_]&I72V7_'C!_US7^5 $]%%% !1110
M 4444 %%%% 'S#\3?^1]U+_?_J:Y"NO^)O\ R/NI?[_]37(4 %%%% !1110
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M0 4444 %,DACE*F1%;:<C(Z&GT4 %%%% !1110 4444 %%%% !1110 4444
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M= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G'PJ_X^?%G
M_87F_P#0WKT>O./A5_Q\^+/^PO-_Z&] 'H]%%% !1110 4444 %%%% 'F7QM
M_P"12A_Z^%KY_KZ ^-O_ "*4/_7PM?/] !1110 4444 %%%% !1110 4444
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M0 5Y]\:+N6T^'%V(C@3R)"_NK9S7H-<_XV\/GQ/X2O\ 2TVB>6,F%F/"OV-
M&-XYTBQ7X0ZG:+;((+;3V>% .$95R"/I6QX%OI]2\#Z/>7 Q-+;@M^&1_2O.
MKRX^(7B/PRGA.XT![2:8>1=:D[?NVCZ$CCN"?RKOK^YU3PW!H.G:-HAOK>21
M8+ET?:+9.,OTYZG\J .1\(RO=?'7QEY[>9]FAB2'=SY8(!('IU-:.F6L=G\<
M-6DB.6N].5Y1Z$,H_D*J:SI>N>$?B#<>)M"T9]5MM5B6.\BC;]XCKT('I@#O
M5[P-HNM7/BC5O%^N6OV"6^0006);<T2+CDGL3CI[T <]X\^)-MJ&BZIH<.A:
MQYXE$8D, V'9("2#G.#M.*T;?XS:?%;11GPYKQ*J <6Z_P#Q5>I44 >9?\+I
MT[_H6]?_ / =?_BJ/^%TZ=_T+>O_ /@.O_Q5>FT4 >9?\+IT[_H6]?\ _ =?
M_BJ/^%TZ=_T+>O\ _@.O_P 57IM% 'F7_"Z=._Z%O7__  '7_P"*H_X73IW_
M $+>O_\ @.O_ ,57IM% 'F7_  NG3O\ H6]?_P# =?\ XJC_ (73IW_0MZ__
M . Z_P#Q5>FT4 ?)_C#4KGQ!XFN]2M=%U)(9FRJR0X(_(UA>1J/_ $"+[_OU
M7V;10!\9>1J/_0(OO^_5'D:C_P! B^_[]5]FT4 ?&7D:C_T"+[_OU1Y&H_\
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M\DC%,*!U/6OK-+B&4XCFC<^BL#4%V=/NH);2\:WDB<%9(I2""#U!!H ^5X?
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MM'C_ -"KV2B@#@_^$U\3?]")JOYQ_P#Q='_":^)O^A$U7\X__BZ[RB@#@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZE>ZKIL5S<_VE.GF.,G:,8'ZU!=Z/'\+OB'H3Z--,-+UR;[++9,_RJ_'S?\
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M]:N444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%127,$3;9)HT/HS 4 2T4@((R#D'N*CDN8(6VR31H>N&8"@"6BD!!&0
M<@]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!H \I^*VN7FK07?A31"XD2 W&I3@X6.'GY<]RV&X]JZCX6#;\,= 7.<6V/\
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M * *I?$K_DG.M_\ 7#_V85=\$?\ (B:#_P!@^#_T 4 ;U%%% !1110 4444
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MO[MU_P" [?X4R7Q?I4$+RS-<1QH"S.T# *!W)Q6WY4?_ #S3_OD5S_CJ*,>
MM?(10?L$W;_8- $Z^+-,=0RBY*L,@BW;D?E2_P#"5:=_=NO_  ';_"KFD11_
MV+8_NU_X]X^W^R*N>5'_ ,\T_P"^10!C_P#"5:=_=NO_  ';_"C_ (2K3O[M
MU_X#M_A6QY4?_/-/^^11Y4?_ #S3_OD4 4+'6[34+CR(!.'VEOGB91CZFM*F
MA$4Y5%!]A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .4^)7_).
M=;_ZX?\ LPJ[X(_Y$30?^P?!_P"@"J7Q*_Y)SK?_ %P_]F%7?!'_ "(F@_\
M8/@_] % &]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(F@_]@^#_P! %4OB5_R3G6_^N'_LPJ[X(_Y$30?^P?!_Z * -ZBBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JO?7::?I]S>R@F.WB:5@.I"@D_RJQ61XI_Y%+6
M/^O*;_T T(#R:S\6_$[Q;)=:CX?ABM],R?(5X4;<!Q@$C.:ZWX:^.[_Q+->Z
M3K=N(-6LN7 &-P!P21T')[5=^$?_ "3'1_\ =D_]&-61H0"_'OQ*  /^)?%T
M_P"V=:.VJ(5]&>FT445F6<)\2]7O(;/3] TNY-KJ.LSBWCFZ!5Z-R.0>1R*J
M6_P7\+O C:HMW?WI'[VYDN7#.?7K47Q/L-<DU[PQJNBZ3+J+:=.\KQH<#^'
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MWIOA3P3=:-K-YK>LZLVJ:I<*(UDV;$C3C@*2><CUH X[XD)\2/[%UHM-I/\
M8.WE=O[W9N&/QZ5Z-X(_Y$30?^P?#_Z *I?$K_DG.M_]</\ V85=\$?\B)H/
M_8/@_P#0!0!O4444 %%%% !1110 4444 ><>-?BD_A'Q =+&E+<@1+)YAFV]
M<\8P?2N=_P"%\R?] !?_  )_^QKG?C/_ ,C^W_7K'_6O/: /9/\ A?,G_0 7
M_P "?_L:/^%\R?\ 0 7_ ,"?_L:\;HH ]D_X7S)_T %_\"?_ +&C_A?,G_0
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M_P"QKV&PN?MNG6MV5V>?$DFW.<;@#C]:^.J^O=!_Y%[3/^O2+_T 4 :%%%%
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MTC_D"V'_ %[Q_P#H(J[5+2/^0+8?]>\?_H(J[0 4444 %%%% !1110 4444
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M"_XUG?\ "OO"O_0&A_[[?_&C_A7WA7_H#0_]]O\ XT6H=W^'^87K=E^)H_\
M"2Z%_P!!BQ_\"%_QH_X270O^@Q8_^!"_XUG?\*^\*_\ 0&A_[[?_ !H_X5]X
M5_Z T/\ WV_^-%J'=_A_F%ZW9?B:/_"2Z%_T&+'_ ,"%_P :/^$ET+_H,6/_
M ($+_C6=_P *^\*_] :'_OM_\:/^%?>%?^@-#_WV_P#C1:AW?X?YA>MV7XFC
M_P )+H9Z:O8_^!"_XUI@AE# @@C((KR_XB>$M"T?PG)=Z?IT<%P)D4.K,3@G
MGJ:]*LO^/"W_ .N2_P J*E."@IP;UON%.<W-QET)Z***P-@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#SOXOZ=<W/A^QU&WC:4:9>)<R1
M(,LZY P!7$:CK+?%/QQH-II]M=0Z?9D/<EU^57'/Z=*]6\:R^(H=&67PW"D]
MTL@\R%E4^8G<<UQ&C?%"TT:[:S\0>&#HEPTF));>$"(<9RQ'7\,UI&]B'N0^
M(=:'C+XG:3H^EP2/!IEP?M5SMP%89! /L>*]BK%T/4?#FHQM>:++8M]H8EGA
M4(TASR2, G\:VJAOH4C%\0^&+'Q'"BW33QRQJPBF@F9&3=C)X(ST'6N:'AWQ
M+H$EG%IOBZ.6 -@6^IJO[SV!4;C^==\[;4+8)P,X%>%^.O' U'Q#X7E71M3M
MQ8WYD*RJH,W*\+@\GCOZTXW>@G9'?6GBGQ1:7:0:WX7<)),L27%G(K( 2!N(
M+;L<^E=O6+X;\0CQ'927*Z?=V6R39LNE 8\ Y&">.:VJ3&@HHHI#"BBB@ HH
MHH **** .4^)7_).=;_ZX?\ LPJ[X(_Y$30?^P?!_P"@"J7Q*_Y)SK?_ %P_
M]F%7?!'_ "(F@_\ 8/@_] % &]1110 4444 %%%% !1110!\Z?&?_D?V_P"O
M6/\ K7GM>A?&?_D?V_Z]8_ZUY[0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7U[H/_(O:9_UZ1?\ H KY"KZ]T'_D7M,_Z](O_0!0!H4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<O\ $73KK5O &L65G$9;B2(;$'4X8$_H#745D>)Y-6B\.WDFAH'U
M)5!@4@'<=PR.>.F::W$]CPS5?$[^-O#_ (=\'Z;IEW]KMWB6X5AC&Q=ISZ ]
M>:Z?XEW4,\.D_#_1;6:>]CEBD 4?+&B@@9)]<]?:I-.^)2Z%J4D?B?PD=+O6
M(#W-M"I&#R2[#^F:]!TC6O#.N3?VCIES8SW##R_.50)"/3) ;%6W;H2E<W(U
MVQJOH,53U72K76;$V=X)#$6#?NY&0Y'3E2#5ZBLRSSUO!VO:#;HNB^,)44R@
M^5J(5D(S]W=@M[=:NP:_XPLM2-OJGAR.XM=RHMW8RC'.!N(9LX&?2N,\=>/1
M??V="NB:K!]GU")RTB*!)M<' PW4XX^M>A^&/%Z^))YH5TC4+'R4#;KI% ;G
M&!@FK:=KLE6OH=*.11114%!1110!Y+\7?">K:QI.K:G<ZTT>DV-F9H+*$8+2
M*"3O..0>.]>@^$_^13TS_K@M4/B.K/\ #GQ J*68V,H  R3\IJQH=TFF^!;6
M[G5]EO:>8X YP!D\4 <E\9=1DBT_0='P?L^K:E%;W&&*G9N4D9'KTJ+XF^&M
M,TCPYI^KZ=;I92Z3=0LK6Z!&==RJ5)')X-)\0D'BOP?H?BG38;B5-.O$O5MU
M3YW0. W!] ":I^,O&5EXUT_2]!\/*]]/>W,1NHPC*8$4AVSD 9&,=: /29?$
M>E6EM:RWU[!:M<Q+*BRN 2"*XOX231W#^*9HG#QR:M*RLIR""[8-=M<^'=(O
MHX$O=.M;KR(Q'&9HE<JH[#(KB?A)#';OXIAA18XX]6E5$48"@.V !0!Z5111
M0 4444 %%%% !1110 45YS\8[RZLO"T,EI<S6[F=06BD*''U%>%?\)#K?_08
MU#_P*?\ QH ^NZ*^1/\ A(=;_P"@QJ'_ (%/_C1_PD.M_P#08U#_ ,"G_P :
M /KNBOD3_A(=;_Z#&H?^!3_XT?\ "0ZW_P!!C4/_  *?_&@#Z[HKY$_X2'6_
M^@QJ'_@4_P#C1_PD.M_]!C4/_ I_\: /KNN>\=?\B#X@_P"P?-_Z :^9?^$A
MUO\ Z#&H?^!3_P"-,EUS5YXGBFU6^DC<%61[AR&![$9YH ^L=(_Y MA_U[Q_
M^@BKM?(:Z_K**%75[]5 P +EP /SI?\ A(=;_P"@QJ'_ (%/_C0!]=T5\B?\
M)#K?_08U#_P*?_&C_A(=;_Z#&H?^!3_XT ?7=%?(G_"0ZW_T&-0_\"G_ ,:/
M^$AUO_H,:A_X%/\ XT ?7=%?(G_"0ZW_ -!C4/\ P*?_ !H_X2'6_P#H,:A_
MX%/_ (T ?7=%?(G_  D.M_\ 08U#_P "G_QKWOX0W=S>>$FDNKB:>3S2-TKE
MC^9H ] HHHH **** "BBB@ K@OBE_P >&B_]A&/^1KO:X+XI?\>&B_\ 81C_
M )&NC"_QHF&)_A,[WH,UQ%Y\18;6ZO%72;N6VLYO(EG0KC=DX(YZ<&NTE;9"
M[XSM4G'K7AMQ -2T[7=774?LF+G>=.WD;^3P15X6E";?/Y$8FI*%N4],U3QK
M!9ZC#I]G93WUU)#Y^V(@83UYQ5:3X@6TFE6-S8V<L]Q>3&!("0"KC&03T[BN
M/GV^(_%NGJ9&T65]-$C2Q/M/^[SC K4\):!;>)?!L$;E[6:RO'\JXB)W%OER
MWU/'Y5LZ-*$4Y+U_'^M#)5JLY-1^7X'2R^,HO["L[Z&W9KF[E$,=N>3NW8.<
M>G6NGC+&-2XPQ R/0UY9"[6-RU[8QQS6FFRI96AE8A9))&PTC?3?^E=EX2\0
MW&OVUX;F&*.6UG,+>4Q*MP#D?G6%:CRQYHK0VI5>:5I;CSXI@7Q1-HCPLK11
M^8TI(VXQFH--\8IJ]_=QV5G*]I:ABUR<;6(["N'\2:7>ZS\2KRQLKC[.985#
MOG'&T?UK6\":D+33-3\-W:QQ7EF)-N!@RKSS6LJ$%3YEJ[+_ (<SC6FZG*]%
M=_\ #%NV^),ES9&]BT"]DM5)!>/:>GMFNKT'6[7Q#I,6H6FX1OP5;JK#J#7%
M_#[4K*P^'\SW5U%$%>4G<W/Y=:M?">&9/"KR.3Y<D[%%(Z>_XTJ]*"C)I6L[
M>HZ-6;<;N]U<F^*W_(CR_P#7>/\ G7867_'A;_\ 7)?Y5Q_Q6_Y$>7_KO'_.
MNPLO^/"W_P"N2_RK&7\"/J_T-8_QI>B_4GHHHKG-PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#.UG7=,\/V?VO5+N.VA)P&?N?2O,=:^)
ML'B8KIN@>%9-;8DY%U& G&?F7J#7IFLZ!IOB"&*'4[=;B&)]XC;E2?<=ZM6&
MGV>F6JVMC;16\"_=CB7:H_"J32$[GCG@7X6ZY9^*HO$6I20Z>@8RBUM^N3_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "JNHZC::3I\U]?SK!:PC,DC]%&<?S-6JIZKI=IK6FS:??1^;;3
M8WI_> (/\Q0!YEKGQ4T_6A_96@^'Y==FDDV;)HQY3CGD'G/XBN?T'X4^(=3\
M1)KM_P"1H<1/F+!:C#QG/"[0 ,>^:]LTW2-/T:V^S:;9PVD&<^7"@49^E7:O
MFML3RWW$ P /2EHHJ"C$\1^'8_$26*R7#0_9;E+@;5SN*L#C]*V^U<AXD^)/
MA[PO?"ROI)Y+C&62WCWE?KSQ67:?&;PO>WD%K%%J7F3R+&FZVP,L<#//O56;
M0KH]#HHHJ1A1110 UT21&1U#*PP01D&CRT,?E[%V$8VXXQ3J* &1QI%&(XT5
M$'15& *@MM-L;*626UM((9)#EVC0*6^N*M44 %><?"K_ (^?%G_87F_]#>O1
MZ\X^%7_'SXL_["\W_H;T >CT444 %%%% !1110 4444 >9?&W_D4H?\ KX6O
MG^OH#XV_\BE#_P!?"U\_T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5]#?!C_ )$UO^NQKYYKZ&^#'_(FM_UV- 'H]%%% !1110 4444 %<%\
M4O\ CPT7_L(Q_P C7>UQ7Q)TZ_U#2]/.GVDEU)!>+*T<8YP :WPS2JJYCB$W
M2=CM:P+KP7H5YJXU.:Q1K@'<?[K'U(Z$UA?\)EXJ_P"A)NO^_A_^)H_X3+Q5
M_P!"3=?]_#_\351HU8_"[?-?YDRK4I?$OP?^1T6M>%-'U\+]OM%9UQB1?E;
M[9ZXJ[!I=I:Z<UA:Q_9X"I7$/RD9[@CO[UR'_"9>*O\ H2;K_OX?_B:/^$R\
M5?\ 0DW7_?P__$T_8UK6OIZK_,7M:5[VU]'_ )'2_P#"-:8=#&CF%C: YP6.
M[.<YSUSGO4^CZ+8Z%9"UL(O+CR68DY9CZD]S7)_\)EXJ_P"A)NO^_A_^)H_X
M3+Q5_P!"3=?]_#_\30Z-9JS?XK_,%5I)W2_!_P"1UHT:Q75FU,0C[6R[2_M4
M5QX=TRYU4:E+;@W8&WS!U(QC^5<O_P )EXJ_Z$FZ_P"_A_\ B:/^$R\5?]"3
M=?\ ?P__ !-'L:W?\5_F'M:7;\'_ )&O%X"\.12B0:=&Q!SAN1^5=#!!%;0)
M#!&D<2#"H@P /85P_P#PF7BK_H2;K_OX?_B:/^$R\5?]"3=?]_#_ /$T2I5I
M?$[_ #7^81JTH_"K?)_Y$OQ6_P"1'E_Z[Q_SKL++_CPM_P#KDO\ *O+_ !5J
M7BGQ-HC::WA*ZMPSJ^\,6Z>V*]1M%9+.!6&&6-00>QQ15BX4HQ>]W^@4I*56
M4EM9?J34445RG2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U
MK[2-"U V6[[4+:0P[/O;]IVX]\XJ]2,P52S$!0,DGM0!POPU\=#Q3IC6=\0F
ML6?R7$9X)P<;L?S]Z[F21(HVDD8*B@LS$\ "O,/B%X.N;>Z3QCX6/V?5+;YY
MECZ3KWR/I^E<=H[>*OC%=2)>ZI#8:?:D>9!!D%C_ +N<],\]*OE3U)NUH>CO
M\5-#F\5V.@:8?M\MS($::)OD3@G@]^E=W7/>&O!6B>%+;RM-M%#G[TS\NQ]S
M70U+MT&K]0KQBS\>^'?"/CGQ3:ZO;.))+S<MPD>]G&!\I^G]:]GKR'Q;XWU^
M&_U=]$\/6<EGI4FRYN;F+?O/JN,=._I3B*1T>A?%+PGKVKPZ=IWG_:9<[-UO
MM''O7=UY1X>\0>,AXPTS3=:T;2K:"]B:5)K>+J N<!LXS[5ZO1)6&F%%%%2,
M**** "BBB@ HHHH Y3XE?\DYUO\ ZX?^S"KO@C_D1-!_[!\'_H JE\2O^2<Z
MW_UP_P#9A5WP1_R(F@_]@^#_ - % &]1110 4444 %%%% !1110!\Z?&?_D?
MV_Z]8_ZUY[7H7QG_ .1_;_KUC_K7GM !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %?7N@_\B]IG_7I%_Z *^0J^O=!_P"1>TS_ *](O_0!0!H4
M444 %%%% !1110 5P7Q2_P"0=H__ &$8_P"1KO:X+XI?\@[1_P#L(Q_R-=&%
M_C1,,3_"9WO09-4FUC3E8JU[ ".H+BKC ,I4]",&O+_%_AW2SJUAH^G6^R^O
MI-SSAB?*4=21[YJ:-.,Y6D[%5IR@KI'I$VHV=O;+<S7420-]V1FP#^-.GO;6
MVM3<SSQQP 9,C-A?SKSB;2;:X^(EGX>N=TVFVVG9CA9N-WK530;34-6\$J(@
MUTMEJ1)MV?&^-2IVY_/\ZV^K1LG?M^)E]8E=JW?\#U%;^T:R^VK<1FUVEO-#
M?+CUS4R.LD:R(P9& *D="#7D,%I/8V4>@:G,EO!+<&]N@YRL4(Y5"<\$E2,>
M]>GZ-JFGZI8K)ILJR01_)@?PX['\*SK4?9JZU+I5N=V>A:DO;:*ZCMI)XUGD
M&4C+?,WT%,EU*R@N5MI;J))F&1&S $_A7G/Q!U.71_'&B7L,+321P/MC7^(G
M('\Z=X&@CU>+5=:U&1I=64NCHX(\G@\ ?A5_5DJ:J-Z?J1]8;J.FEJ=XOB#1
MV<(NI6I8G  D%:76O)O WAG2]<\+WDMY;[K@.P68,0R]>E;_ ,,+^>XT2>SG
MD:4VLI578]1V'Z4JV'C%2Y7\.XZ5>4FN9;DGQ5_Y$>;_ *[Q_P ZZ^Q_X\+;
M_KDO\A7(?%7_ )$>;_KO'_.NOL?^/"V_ZY+_ "%3+^!'U?Z%1_C2]%^I/111
M7.;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 5M1CFFTRZBMSB=X76,YQAB#C]:\_\ A]XXFGNI/"WB
M/-OKEJ2B>8<>>HZ8SWQS[CFO2&8*I9B H&23VKSSXD>!_P#A)K&+6-'8)JUI
M^\A>,_ZP#G&:I6V8G?<]$)P,GH*X'Q-\6="T*[6PM2=1OS($,4+<+V.6YP1Z
M5YSI^K^-?B;.=!;4(=.AME$5X,[9'QC)92<GD=L5ZKX3^'.A>%466*#[1?$$
M/=3?,QSU_"G9+<5V]CKE.5!]12T45!1XFWBW0O!GQ8\1RZFTLJ783++#DQL/
MX?<=.?>NFM/C#X*O+VWM8/M/G32+&F;7'S$X'ZFJ?BOQCJC:QJEEX:T>QN'T
MF,RW\UXHQC&<+TR<"L6U\7^,XM3T07VE>'X;34I%\N=4&",\@-NP&P#@>M:6
MN1>Q[91116984444 %%%% !1110 5YQ\*O\ CY\6?]A>;_T-Z]'KSCX5?\?/
MBS_L+S?^AO0!Z/1110 4444 %%%% !1110!YE\;?^12A_P"OA:^?Z^@/C;_R
M*4/_ %\+7S_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7T-\
M&/\ D36_Z[&OGFOH;X,?\B:W_78T >CT444 %%%% !1110 4444 %%%% !11
M5+5;R73],GNH+5[J2-25A3JQ]* +M%>,67Q3U >*[V-=*U"Y>:,+'IV?FA<$
MY/W>F,&ND\=>-;[1=*"IIMY$)[<-]LCZ0.>QX_"@#T.BN(\!>,[GQ/!'&^F7
M4<,=N,WDG*S., XX]<UV] !1110 4444 %%%% !1110 4444 %%%% !1110
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M]>CUYQ\*O^/GQ9_V%YO_ $-Z /1Z*** "BBB@ HHHH **** /,OC;_R*4/\
MU\+7S_7T!\;?^12A_P"OA:^?Z "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^AO@Q_R)K?]=C7SS7T-\&/^1-;_KL: /1Z*** "BBB@ HHHH *
M*** "BBB@ IKJ61E#%21C(ZBG44 <6OPTTF/[$\5Q=1W%M=&Z,ZL-\K9'#''
M3C&!6SKWAFT\0RV1O9)3%:R^:(0?ED/;=ZUMT4 8?ASPO:^&A>K:3S/'=3&8
MI(1MC)[+CH*W*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *R/%/_(I:Q_UY3?\ H!K7JM?R6T.G7,MX%-LD3-*&&04
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M;@^V6_G>3CR_-7=G<.V:UO!'_(B:#_V#X?\ T 5P?Q(^&?AA?#NM:^+23^T
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M]I^J6UEK_@NST^^EN%2WDMH8Y$)R,-NX(Y]JUZ:$>IZ]1116184444 %%%%
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MU/3K:[@C.4CFC#*OT!HTC0-(T"&2'2-.MK*.1MSK!&$#'IDXK1HH Y3XE?\
M).=;_P"N'_LPJ[X(_P"1$T'_ +!\'_H JE\2O^2<ZW_UP_\ 9A5WP1_R(F@_
M]@^#_P! % &]1110 4444 %%%% !1110!\Z?&?\ Y']O^O6/^M>>UZ%\9_\
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M8U\\U]#?!C_D36_Z[&@#T>BBB@ HHHH **** "BBB@ HHHH **** "N?T/\
MY#^O_P#7RO\ Z+6N@KG]#_Y#^O\ _7RO_HM: .@HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** .4^)7_).=;_ZX?^S"KO@C_D1-!_[!\'_H JE\2O\
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MCT444 %%%% !1110 4444 >9?&W_ )%*'_KX6OG^OH#XV_\ (I0_]?"U\_T
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M0 4444 ?.GQG_P"1_;_KUC_K7GM>A?&?_D?V_P"O6/\ K7GM !1110 4444
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M_P#KJO\ *O4*^=QJM7D>[A/X,0HHHKE.D**** "BBB@ HHHH **** "BBB@
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M %\+7S_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7T-\&/\
MD36_Z[&OGFOH;X,?\B:W_78T >CT444 %%%% !1110 4444 %%%% !1110 5
MS^A_\A_7_P#KY7_T6M=!7/Z'_P A_7_^OE?_ $6M '04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!Y&#110
M!G?V!I'VY;[^S+/[6IR)_)7>#]<9K1HHH **** "BBB@ HHHH **** "BBB@
M HHHH Y3XE?\DYUO_KA_[,*N^"/^1$T'_L'P?^@"J7Q*_P"2<ZW_ -</_9A5
MWP1_R(F@_P#8/@_] % &]1110 4444 %%%% !1110!\Z?&?_ )']O^O6/^M>
M>UZ%\9_^1_;_ *]8_P"M>>T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5]>Z#_P B]IG_ %Z1?^@"OD*OKW0?^1>TS_KTB_\ 0!0!H4444 %<
M9\4O^1(G_P"NJ?SKLZXSXI?\B1/_ -=4_G6^&_C1]3'$?PI>AX%1117TQ\\%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110![!\&?^0?J?_75?Y5ZA
M7E_P9_Y!^I_]=5_E7J%?.8W^/(]["?P8A1117*=(4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9MWX?T;4)Q
M/>:79W$HZ/+"K$?B16E10 =!BBBB@ HHHH **** "BBB@ HHHH **** "O./
MA5_Q\^+/^PO-_P"AO7H]><?"K_CY\6?]A>;_ -#>@#T>BBB@ HHHH **** "
MBBB@#S+XV_\ (I0_]?"U\_U] ?&W_D4H?^OA:^?Z "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *^AO@Q_R)K?]=C7SS7T-\&/^1-;_ *[&@#T>
MBBB@ HHHH **** "BBB@ HHHH **** "N?T/_D/Z_P#]?*_^BUKH*Y_0_P#D
M/Z__ -?*_P#HM: .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#E/B5_R3G6_^N'_LPJ[X(_Y$30?^P?!_Z *I?$K_ ))SK?\ UP_]
MF%7?!'_(B:#_ -@^#_T 4 ;U%%% !1110 4444 %%%% 'SI\9_\ D?V_Z]8_
MZUY[7H7QG_Y']O\ KUC_ *UY[0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7U[H/_ "+VF?\ 7I%_Z *^0J^O=!_Y%[3/^O2+_P! % &A1110
M 5QGQ2_Y$B?_ *ZI_.NSKC/BE_R)$_\ UU3^=;X;^-'U,<1_"EZ'@5%%%?3'
MSP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'L'P9_Y!^I_]=5_E
M7J%>7_!G_D'ZG_UU7^5>H5\YC?X\CWL)_!B%%%%<ITA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %><?"K_ (^?%G_87F_]#>O1Z\X^%7_'
MSXL_["\W_H;T >CT444 %%%% !1110 4444 >9?&W_D4H?\ KX6OG^OH#XV_
M\BE#_P!?"U\_T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]#
M?!C_ )$UO^NQKYYKZ&^#'_(FM_UV- 'H]%%% !1110 45\[7/CGQ.EW,JZS<
MA5=@!D<<_2HO^$[\4?\ 0:N?S'^%>E_9E3NCS_[0I]F?1U%?./\ PG?BC_H-
M7/YC_"C_ (3OQ1_T&KG\Q_A1_9E3N@_M&GV9]'45\X_\)WXH_P"@U<_F/\*/
M^$[\4?\ 0:N?S'^%']F5.Z#^T:?9GT=17SC_ ,)WXH_Z#5S^8_PH_P"$[\4?
M]!JY_,?X4?V94[H/[1I]F?1U<_H?_(?U_P#Z^5_]%K7B/_"=^*/^@U<_F/\
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M!,'_ ,71_P )=KW_ $(VI_\ @3!_\70!V%%<?_PEVO?]"-J?_@3!_P#%T?\
M"7:]_P!"-J?_ ($P?_%T >2?&?\ Y']O^O6/^M>>UZ;X\\.^+O%OB0ZG;>%K
MJ",PI'LDN(B<C/HWO7,_\*W\;?\ 0NR_]_X__BJ .8HKI_\ A6_C;_H79?\
MO_'_ /%4?\*W\;?]"[+_ -_X_P#XJ@#F**Z?_A6_C;_H79?^_P#'_P#%4?\
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M6_C;_H79?^_\?_Q5>VZ=XE\066F6EJ_@C4F:"%(R1<P8)"@?WO:@#N:*X_\
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MS@D'JWJ#1]<H?S!]4K?RE&BMK_A"/&?_ $+4_P#W_B_^*H_X0CQG_P!"U/\
M]_XO_BJ/KE#^8/JE;^4Q:*VO^$(\9_\ 0M3_ /?^+_XJC_A"/&?_ $+4_P#W
M_B_^*H^N4/Y@^J5OY3%HK:_X0CQG_P!"U/\ ]_XO_BJ/^$(\9_\ 0M3_ /?^
M+_XJCZY0_F#ZI6_E,6BMK_A"/&?_ $+4_P#W_B_^*H_X0CQG_P!"U/\ ]_XO
M_BJ/KE#^8/JE;^4]&^#/_(/U/_KJO\J]0KR#P)_PE'A.VNXKGP??3F=PP,=Q
M",8'NU=?_P )=KW_ $(VI_\ @3!_\77AXJ<9UG*.Q[&&BX4E&6YV%%<?_P )
M=KW_ $(VI_\ @3!_\71_PEVO?]"-J?\ X$P?_%USFYV%%<?_ ,)=KW_0C:G_
M .!,'_Q='_"7:]_T(VI_^!,'_P 70!V%%<?_ ,)=KW_0C:G_ .!,'_Q='_"7
M:]_T(VI_^!,'_P 70!V%%<?_ ,)=KW_0C:G_ .!,'_Q=*OBW7BP!\#ZF 3U-
MS!Q_X]0!U]%(.0"1CVI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHI')",1U H X6]^(-S+XFOM!\/Z'
M+J=Q8!3<R><L:H3G*_-WXK<\)>*K;Q;I+7D$$MO+%(89[>48:)QC(]^HYK!^
M%Z^?::[J,\(6^GU683-C#$ +@'\S61\/Y)!\6_'MN"1 LL;*@Z GKQ0!WOB;
MQ%9^%M"GU:^#M%%@!(U)9V)PJ@#U) KDU^)=U8:AID6O^'Y]-M=3<+;7!E5P
M"1P& Y!-9GQHED6X\&PAB(Y=9C$BYX8!E//K6S\7(D_X09YEC4S6]Q \)QRK
M>8HXH [VO./A5_Q\^+/^PO-_Z&]=%=Z]JMA9:>;?P_=ZFTUNKRO#+&@1L#(.
MXC]*XOP=-XF\-2ZT\_@Z_F%_?/<IY=Q#\H9B<'+=>: /6:*X_P#X2[7O^A&U
M/_P)@_\ BZ/^$NU[_H1M3_\  F#_ .+H ["BN/\ ^$NU[_H1M3_\"8/_ (NC
M_A+M>_Z$;4__  )@_P#BZ .PHKC_ /A+M>_Z$;4__ F#_P"+H_X2[7O^A&U/
M_P "8/\ XN@#L**X_P#X2[7O^A&U/_P)@_\ BZ/^$NU[_H1M3_\  F#_ .+H
M POC;_R*4/\ U\+7S_7N/C]O$_B_18[&V\'WT#K('W2W$)''T:O-?^%;^-O^
MA=E_[_Q__%4 <Q173_\ "M_&W_0NR_\ ?^/_ .*H_P"%;^-O^A=E_P"_\?\
M\50!S%%=/_PK?QM_T+LO_?\ C_\ BJ/^%;^-O^A=E_[_ ,?_ ,50!S%%=/\
M\*W\;?\ 0NR_]_X__BJ/^%;^-O\ H79?^_\ '_\ %4 <Q173_P#"M_&W_0NR
M_P#?^/\ ^*JIJ7@KQ7I&GS7]]H4L5M"I9W\Z,X'X&@##HKI(OAYXSGACFC\/
MRLDBAE/GQ\@\C^*G_P#"M_&W_0NR_P#?^/\ ^*H YBBNG_X5OXV_Z%V7_O\
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M]"-J?_@3!_\ %T?\)=KW_0C:G_X$P?\ Q= '845Q_P#PEVO?]"-J?_@3!_\
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M%B6SNK6:^\-ZA;Z/>2+';WC!?G9NG&>!6SXH\?Q:'JD.C:?I]QJFKSQ^8EO
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M^D>?&IDW9/7CK7MUY:6]_9S6EW"DUO,A22-QD,IZ@USH^&W@P'(\-:=_WZ%
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MRZ_=6&I7FI"YNE,EY<1;1,PW?,IW'<#GKQ7IU06=G;:?:16MI"D-O$H1(T&
MH'0"IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\
M#\/?#[0?&_Q!\=/K,<[&UU(B/RI2GWB^<_D*]\JC8Z-INFW=Y=65E#!/>OYE
MS(BX,K<\GU/)H Q/"_P\\-^$',NDV 6<@CSY#NDP>HW=<5YKHB>"V\=>+/\
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M%WI5A?V2V5W:Q36R[<1.N5&W&/RP*KZMX<T;7;>.#5-.M[J*(YC65<[3TXH
M\N\(Z9:VWQ:D23Q9>ZSJMO:,LA>V'EA<KD;]YYZ<8KV6LO1O#>C>'DE72-.M
M[,2D&3REQN(Z9K4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gtinntqqusay000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" E<!?,# 2(  A$! Q$!_\0
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MC28-6^(%W'<)N52#_.NS\-O=7]C/-+I2P?-P0M8_A6PN8_B!>2-$0AQ@_G0
MWXJ:!962Q&"/:1$/Y5T'@KPIITG@O[7)#F5H&)/X5'\6+.>X6/RHRW[H=/I7
M3^#()(O *QNI#>0PQ^% 'DWP^06_CA8DX7SF_P#0JF^(?_(WP_\ 7RO\ZF\%
M:?=1>.ED>)@OG,<_\"J3Q]I]U-XLB>.(E?M"G/XT =9\1O\ D2?^V"?^@U)\
M*_\ D!K_ -<C_*KWC?29K_P04B0M)Y*#:/\ =KSSPAXFU/08GL39$L$VC- #
MO%9!^)5IC^Z?Z5?\=Z!>7.D6=Q$1A3NK DBU34?&UM=7%HT?!Z_A7<^)KK4[
M+3+4PV)G4'D'TH X"S\36L%F;/5()F3H<*?\*]7^'EYH5P&_LN(QOM^;)KS[
M5M974M+>(:5%'.>.%&:W/A-H5_:7]Q<W"/'&X^4'I0![112#H*6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Z52GU.W@DV,XS]:
ML7*&2VD1202I (K@[[0#!837%S?2(0QZF@#OHI4E0,C @^AHDE6)"SD #U-<
MCX->X,DBN6:$#Y')ZTOBZ[DD)L(W*%QG<#0!TL&HP3R,BN,CWJW7F=Y93:0F
MG2K<NQE8;N:]&MGWVZ'_ &10!-17.:KXF_LYRNT'!I=%\3PZK*L8*[CV% '1
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 53U*>""U8W'W&!!JY6)XGTQ]4TMXHW9& )&V@#S;5O &E^))I)]+C0/D
MYR1UKD-6\)^(/!ZK<QRHL8;M_P#KJ:PU/7_!>HRHUM++&TA(+'MFK'B+QSJW
MB:V6T&F8RW44 =1X5\:W5_X4NY)Y"TT1V@UR/A73H?$_C>Z-^H< ;N?QKL/A
M_P"#IH]!N4NE:-I6W8-<G>6>J>#/%-Q>VUJ\D3' /:@#LOB#X+TJV\+SWD,(
M62)!@Y'I6#\/]4GGT&XM'8F..W; _P" U4\0^--8\36)TV.Q.)%"G;74^%?"
MTFD^%7ED4B9X&!4_2@#@/ MPUM?W4JG!6X?_ -"-9USJ,$OC.[EOHWD7=D!1
M70> -'N)-5GCFB*JT[<G_>-1:QI5WX;\5W%X+#[1"[#&X<4 4/%%_I^H0AK.
MUF694 4E3Z?2NTBN9I/ ,$4N<K$>HK+N?%$M]/%#;:%"V5 .U1UKO+O39;WP
M<O\ HWE2^6<H!TXH Y/X,_\ 'O<?]=V_F:ROB<1_;UK_ -=U_G69X0UK4_"E
MW+;FR)S*S#/UJ#Q)+JVM:U;W,EFR1F8$'\: .O\ %6AW6H^&/-A*X$:C'X5Q
M>F^(%TRW%EJ,,KQJ-IPIQ7H^L2ZC9Z &M[1I@(UR/PKEYO$ N]-,$VD0I-M(
MSM&<T =5\.[_ ,.SR*+"!HYBW<]_RKU2O!/AGH5__;L=Z\3QPASQVZU[T!@8
MH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q/$EU=6MHCV
MQ(.[YL#M7&:AJ-MK$BQ0V\HN\8#E3C/Y5Z8\:2##J&'H:A6PM%;<MO&&]0M
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M-EN@/]T5!#I=M"Y81)[<=*NT 8VJZ'8W=O*\T66VDUQ/AJUBM?%4<<2X7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(V=O'6
MEI",C% '+ZAIDUY?.+BZA\CLA< _SJ,>$?#Q&YEA+^N\51US0;2ZU:2234IH
MG;^!6.*I7'A&UM4#3:K<*",CYS_C0!NQ:!-;3!M-FC6//0$'BNHB#+$H<Y8#
MDUC^';**VL8S#</,F.&8YS6W0 4444 %%%% !1110 4444 %%%% '-^+_P#C
MQ3ZU'X(_Y!DO^_\ XU)XO_X\4^M1^"/^09+_ +_^- '44444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M*ZTJTO#F>/=FKM% &3_PC>E_\^XH_P"$;TO_ )]Q6M10!Q6N:%I\5U&%A !%
M:FG^'=,>S1C ,FF>(?\ C\B^E;&F?\>*4 5?^$;TO_GW%'_"-Z8"#]G'%:U%
M $4-O';IMC7 J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)+M67(Z$UUM !1110 4444 -9U099@H]S40N[=FVB:,GTW"LOQ);W-S:1I;
MDEOFP>U<?J&E)H]Q&\=U,UT1D1EC@F@#TH$$9!J-[F&,X>5%/H6 JAI<\S:(
MLTZ[9 A)'X5QA@?Q+J19II$5&*_(Q% 'HB2I(,HZM]#3ZX;PM=RP^(KK3&8M
M'"."QR:[6:9((C)(<*.IH Y_Q?\ \>*?6H_!'_(,E_W_ /&LWQ7XDTN6!84N
M 7!QBM'P.0VER$="^?YT =31110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S?B'_C\B^E;&
MF?\ 'BE8_B'_ (_(OI6QIG_'BE %RBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *1MNT[NE+5'5W,>FRLO4"@#D-6?01
MJCF:S\R53DL*IWFOZ5<7\$9LW9 ,;L<"LLWVF_:I3=7&V3:<BDL]3T=?#]\G
MGJ92QVDCF@#U+2V@>PC-N-L?85<KG?!L@DT"W(8D8ZU?U:>]@A9[2(.P' H
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M $K7U3_D'R5D>'_^/E_I0!T=%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/ZG^=>A7G_'G-_NFO/="_P"1NC^I_G0!Z31110 4444 %%%% !1110 4444
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M]* .U\(VL@A6Y"E(F'"$=*ZNL#PYJS7MJD=PBQW 'S(HX%;] !1110 4444
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]4_P"0?)61X?\
M^/E_I6OJG_(/DK(\/_\ 'R_TH Z.BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** &R#=$Z^JD5YF_AN5=5D*WT8CD<EDR.:]-891@>A%>>ZW:Z397#3B\E^T
MY"YXS^= %_2?#4MKJS2B0&#'"BNR5<(%]!7!>%=<UF\U(PR0+]C ^5^_\J[X
M9P,T <1JGAO41K<VH6ESL608 %00>$]2D@E:>ZW2GE6/:N^(!ZBLVYU>VM;Z
M*U=P'DZ"@"KX?T6338E:=P\V,%O6MVBB@ HHHH **** "BBB@ HHHH ****
M.;\7_P#'BGUJ/P1_R#)?]_\ QJ3Q?_QXI]:C\$?\@R7_ '_\: .HHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH YOQ#_Q^1?2MC3/^/%*Q_$/_ !^1?2MC3/\ CQ2@"Y11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*@M/^/:/_='\JGKU%L?&2W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH @O/^/.;_=->>Z%_P C=']3_.O0KS_CSF_W37GNA?\
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MJ3F@#OE97&5.12UR'AG69YM6GTR?&Z$=*Z^@#F_%_P#QXI]:C\$?\@R7_?\
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M HHHH *]$^$W_(PG_<_QKSNO1/A-_P C"?\ <_QH ]\7[HI:1?NBEH ****
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MC(K%M?#=K:S>8CR$^YK95=JA1VH 6BBB@ HHHH **** "BBB@ HHHH ****
M*&IW%C!;DWC1A/\ :->>:QK>FJS+96J;C_&E=;XL\.IKMEY3EP <_*:XJ+0;
M&Q;R@S%AQS0!I^#C?3W_ )TMVQC(XC/:O1E^Z*Y+P]I/D3"= =I'%=:.!0!@
M^+))X]-3R"P8M@D5YSK%A<1W$*B[P)!ECZ5ZIK,MO#9EKDX7M]:\SOVM9I'$
MKG:3P?:@#K?![M$BVI;S-H_UG8UV%<SX1%E'I\<=NQ9@.]=-0 4444 %%%%
M#)8TD3#J"*X;48UC\9V01<#_ /57>5F3:-!-J,=XV?,3I0!:NYHA;2H9%#%"
M,9]JX;P_+'IU](MPP3=(2"WUKL;C28IYO,8MG/K6=JGA.SU&59'+!E&!MH P
M/#0,GCG49E&8V'##H>M=S>PR3VC1Q/L8]&JEI.AV^E#,6=V,$FM6@#RKQ-X:
MU>(K,^ILT>[.VNK\"@KI+@G)#8)J;Q?_ ,>*?6H_!'_(,E_W_P#&@#J****
M"BBB@ KGO&.IOI6@3W29W+Z5T-<=\2/^12NO\]C0!Y<WQ,O Q&9*3_A9EYZR
M5P<GWS3: .]_X69>>LE'_"S+SUDK@J* .^_X6;>>LE)_PLR\]9*X*B@#L/\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IKE54EB
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M2O(=VGH&DW9YK/@G\910)&(4PHQ0 [15N]+\2R6DMPTD:C@'IWKO5.Y0?6N
MTC3M?EU][O4(E",.HKO5!6,#N!0!D>);)[W3PB$Y4YX[UYCJ-S=F^BB72I2J
M<$A>M;WB;Q/K^FZO+' B_9A]W-5K/Q!XCU#_ %,$)/N/_K4 =7X5L9$B6Z93
M&&&/+/:NHK(T-M1:U7[>BJ_<+6O0 4444 %%%% !1110 4444 %%%% '-^+_
M /CQ3ZU'X(_Y!DO^_P#XU)XO_P"/%/K4?@C_ )!DO^__ (T =11110 4444
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M444 %%%% !1110 4444 9FO?\@J2JGA[[I^E6]>_Y!4E5/#WW3]* -ZBBB@
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M&/3TKNDY12?2O,Y[27PVUD;<<2L V:](MI#);HQZE10!'?2HMG*"P'RFO/\
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MXA?\BI<?Y[5X2>M>[?$+_D5)_P#/:O"3UKV,!_#9Y>-^,2EI**[CC%I*6DH
M***6@!*6DI:!A24M% "4^/\ UB_6FTZ/_6+]: /<_ /_ "+T-=97)^ ?^1>A
MKK*^>K_Q&>W1^!!11161H%%%% !1110 4444 %%%% !1UHHH P-8\/'4,O;S
M>1*>KKUK!_X0S5\D?VU+^G^%=[10!R^D^%I;20->W1NL?WJZ=5"J% P!TI:*
M "BBB@ HHHH **** "BBB@ HHHH YOQ?_P >*?6H_!'_ "#)?]__ !J3Q?\
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M6'ZU\[1_ZQ?K7T3\,?\ D58?K0!VU%%% !1110 5!=?\>[_[IJ>H+K_CW?\
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M% !37_U;?0TZFO\ ZMOH: /EKQ7_ ,C%>_\ 74UBUM>*_P#D8KW_ *ZFL6@
MHHHH **** "BBB@ HHHH **** "O1/A-_P C"?\ <_QKSNO1/A-_R,)_W/\
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MJ*,CU% "UQWQ(_Y%&Z_SV-=AD>HKC_B01_PB-US_ )P: /G%_OFFTZ3[YIM
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M5X0>M>[?$(C_ (12?D?Y%>$GJ:]C ?PWZGF8WXPHI*7-=QQB4M%% !111F@
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M )])?RKZ+VCT'Y4;1Z#\JUA6G!6BS.5*,G=H^=/^$4U;_GUE_*C_ (135O\
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MCY1_=X[4 >L(ZNN5.13JY#P;JMQ>6NV=LG=77T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 5-48IIEP1P1&:X/PK8)JNB74UQAY!,0&;J.37?WT1GL9H
MAU9"!7GEG-/X;LI[!PWFR.7&!QU/^- &GX/NI#K%Y:$DI%P*D\5S/+>?8\D(
MPH\/64EA)+J$@_UPS1K4,E]:O?1 [TX'% &=K5JEA;Z6T ",SC<5[\UWUHY>
MV0G^Z*\_GEDUL6-O"K>9;L-^17H5NGEP(OHHH EHHHH **** "BBB@ HHHH
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MQ)[]: /4(KB&;_5N&^E2UYMH>LSC7A!&2+?'0UZ/&VZ-6]10 ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQ5I;:GITD*@G-=%10!EZ3
MI=O:Z=!&8%WHN,XK(\8Z;+>:<X@0LW8"NKHH \WA.I7%C'8/8.J[=A>KX\*S
MV>@-!!.X<G/%=S10!YP_]I74(L)K%RH&SS#_ #KK?#6D?V/I@M]Q;G/-;5%
M!1110 4444 %%%% !1110!2U: W.EW$*]77%8FA:&(=%6UG3. ?O#VKJ** /
M,4\%3V]_*ZRN0[Y'M4S:;>6US)";5IAC&\UZ110!YII'A6:WTS4(V5O]().#
M3K7PG+INE0O;AA*6PP7KBO2:* //=2T"6&:WN4A,K*,E<5-INBR7EW+<2V_D
M[T/RXKO** /,Y=,U"SM+NQBB=UG)^;TKJ_"6GR:?HT,,N=RCG-=#10!R6OZ3
M-J&O6KX8PK]X=JMZIX8M+FS$:0HI7D8%=%10!YU'X>OQ&]P)95,1PJ9ZU'*F
MHZBL=K-8L K [S7I-% '(7/A8?V?O1SYP48(ZBLU+G6(;<6/V:5EQM\SZUZ#
M10!SGAC0CID#M(Q9W;=SVS71T44 %%%% !1110 4444 %<SXOTV6_@A,0):,
MYP*Z:B@#SF.XUAK8V@M)$!_B%;FEZ)'I]E<3S/AYD.[-=54%W;)=0-$XRK#!
MH \OT;2]WB^-K=S):Y.['3.:["71V^VJZ@[0V:TM)T.UTI"($VY;-:M ''7.
M@R3>,8+T@[%3!_2LF71I].U"Z>.T,PG/7'2O1Z* .<\,:<UK:[I$V-G.*Z.B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"2RMIGW20HS>I%3T4 ,$
M,80($&T=J3R(MA3RUVGJ,5)10!!'96T3%HX44GN!4]%% !1110 4444 %%%%
M !1110 4444 %,E7=$R^HI]% ''>%_#RV6HZC+/$&\U\C</I74O;QK"RQH%X
M/2K%% 'FEK!J.C7]X8K)Y5F?.:N:+X?GN->?5IE:)G7&P]J[^B@#SZ;3]1T2
MZE>$272RMG'I4NC:3/=ZR;^: P%A]VN\HH :B[4"^@IU%% !1110 4444 %%
M%% !7)IHT@\33W9!VN/\:ZRB@#A/%GA)M2N(YK=C'M7E5[UGS>'KRTTN ('E
M(;[GI7I=% 'F,.A7-WK]G>M;-$(A@C'6M+_A$EN==NKJ5/O*2I([\UWE% '
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M1]8B'MXGLF]?6C>OK7C?_"::M_SWH_X335O^>]'UB(>WB>R;U]:-Z^M>-_\
M"::M_P ]Z/\ A--6_P">_P#.CZQ$/;Q/9-Z^M&]?6O&_^$TU;_GO1_PFFK?\
M]Z/K$0]O$]DWKZT;U]:\;_X335O^>]'_  FFK?\ />CZQ$/;Q/9-Z^M&]?6O
M&_\ A--6_P">]'_"::M_SWH^L1#V\3V3>OK1O7UKQO\ X335O^>]'_"::M_S
MWH^L1#V\3V3>OK2A@>]>-?\ "::M_P ]ZV?#WBC4;V]6.6;*EL4U7BW8:K1;
ML>FT4@Z"EK8U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM(OW1]*6O1.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+2+]T?2EKT3N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS/B^TFNM-E2%"S$=!7F \.ZGC_CV:O=&4,,$5']GC_NUC.DI.YE.DI.YX?\
M\([J?_/LU'_".ZG_ ,^S5[AY$?\ =H\B/^[4?5T3[!'A_P#PCNI_\^K4?\([
MJ?\ S[-7N'D1_P!VCR(_[M'U==P]@CP__A'=3_Y]6H_X1W4_^?9J]P\B/TH\
MB/\ NT?5T'L$>'_\([J?_/LU'_".ZG_S[-7N'V>/TH\B/^[1]70>P1X?_P (
M[J?_ #[-1_PCNI_\^S5[A]GC]*/(C_NT?5UW#V"/#_\ A'-3_P"?9J/^$=U/
M_GV:O</(C]*/(C_NT?5UW#V"/#_^$=U/_GU:C_A'=3_Y]6KW#R(_[M'V>/\
MNT?5UW#V"/#_ /A'=3_Y]FH_X1W4_P#GV:O</(C_ +M'D1_W:/JZ#V"/#_\
MA'=3_P"?9J/^$=U/_GV:O</(C_NT>1'_ ':/JZ#V"/#_ /A'=3_Y]FK=\,Z+
M?6]^C2P,H#5ZGY$?]VE$**>!35!)W&J*3N/7[H^E+1170;!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI/I7SOXGG6#XD(SN0H7U]Q7T1<_\>TGTKYJ\=6LMYX]$,+;7*\'\: /<M/\
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M\1:I]F-O,G&<LI% 'I%?/GQ3)'BHX)_UJ_\ H5?08Z5\]_%3_D:F_P"NJ_\
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MNO2:=$RLR$ BN!\&^*#IWA+4HYI,21L57)YX-)X!TYM6\07NJSJ65HBRDCN
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MPVPT ?1&F:G;ZK:B>V?>A[U=KS#X075TVA>7<(ZG?QN&*]/H **** "BBB@
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MJG9?$U+V\,<;(8P>N!7F_CVV%[XSLX6&0T?]!7K'ASP?I%OH44S6R"39EFH
MAUKXD6MA,D-O*C2,N<'%9MG\5%-TD5VR(&8 <"L;Q!<:#8:PK-9"Y=1_!S7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSHZ%)J_P_N(8T)E.  /H:Y+PYK6O>%II;1;9< ;5W?\ ZJ]@\2V4EEX>G73
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0@,,$9!JO]@M\Y\I/^^15FB@");>-!@(H_"E
M\F/85V+M/;%244 01VD,;%EC3)_V14]%% !7D'C3_D>8_P#<_P *]?KR#QI_
MR/,?^Y_A0!ZCI'_(*M_]VKU4=(_Y!5O_ +M7J "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 445%/<1V\99V QZF@"6BN4O?&:VLI6
M.S>4#NHS4=KXW\^4(]C)&#W8&@#KZ*KVMY%=1AD<$GL#5B@ HHHH **** "B
MBB@ HHHH **** "O(/&G_(\Q_P"Y_A7K]>0^-/\ D>8_]S_"@#U#2/\ D%6_
M^[5ZJ.D?\@JW_P!VKU !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %(2 ,FEI&^[0!R^L:SJ2W#0:9&LD@[&LL7
MOC,\_8T_/_ZU.U?Q:-*U>2%-(EE9?^6BJ>:K'XD7 X_L:X_[Y- &G8:WK4,X
M&JQ+&AX!'K^5=?&XDC5QW&:P](OH]>M4FGLFC)YPXZ5NJH50H& .E "T444
M%%%% !1110 4444 %%%% %#6/^07<_\ 7-OY5QOPM_Y!EY_U\-_Z$:[+6/\
MD%W/_7-OY5QOPM_Y!EY_U\-_Z$: /0:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHI,CUH 6L;7A8_9F:]E:- .2*V:R];-LMA(]PJNH'W30!S=IKW
MA>TC"K<[L=V /]:M+K'AW5I!:Q3#>_3"BH[#2M,OH#*MBH4*2..M0:6VF+JJ
MQ_8EAE#$+GK0!TVFZ-;Z>YDA=VR.YK3I!@#BEH **** "BBB@ HHHH ****
M"BBB@ KR'QI_R/,?^Y_A7KU>0^-/^1YC_P!S_"@#U#2/^05;_P"[5ZJ.D?\
M(*M_]VKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 A( R:8\R(A9CP*Y;Q?>SK (8)#$P<?,*P]5NKMIK"SCN6S.H!
M84 >APW,5P,QG(J4D 9/2O/]'2\TGQ"]M-=&95'2N^_UD(]Q0!QUSJUU<^(Y
M+&VAB<+@\J,XJ_KHO+:R$UK;1%E7+94=?RKGY[J71/%]Q<M;L\9&,XX[UH:G
MXN26P>..V+LPZ"@#6\,ZK]NL8UG55N,?,JBM^N3\(VDK1+?.ICWC&P]JZR@
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M^;YFQ6^OAZ_*@_;CR* .D^TQ^M N(SWKG/\ A';_ /Y_C4D.@7T<@9KPD>E
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MTFX4M>9Z!9W\[Q7$FMY#'.PD5Z5&,1J"<\=: '5Y!XT_Y'F/_<_PKU:;4+.
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MY=VTMU.*A^%*;-(ND'\,Q'ZFNTUC_D%W/_7-OY5QOPN_Y!MY_P!?#?\ H1H
M]!HHHH **** "BBB@ HHHH **** "BBB@#CM;_Y"EK_OUUZ?<7Z5R&M_\A2U
M_P!^NO3[B_2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M <+J6GV.EMISZ=*Y5W'4UZ9:%FMHRW7:*PK/PN(9@UPXE53E >U=&JA5  X
MH YC6/"%MJLN^1Y <Y^4UY?K.@0Z-XTB2)G.%S\Q^E>\5Y#XT_Y'F/\ W/\
M"@#U#2/^05;_ .[5ZJ.D?\@JW_W:O4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_KI77I]Q?I0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 %>0^-/^1YC_W/\*]>KR#QI_R/,?\ N?X4 >HZ1_R"K?\
MW:O51TC_ )!5O_NU>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .3\6Z1?W\&;! TF[/-<M<:'XNN)K>5HEW0?=ZUZK
MT&:IOJ=I&&+3I\O7GI0!SNA+XE%W_P 3%%$6.U=9SLYZU2M-7L[R39#.CGT!
MJ_VH \TNM?>V\9WENQ^4)Q^M1V6FPZI;W=[*S;XV)7!K:\206'VF1T6,W7\6
M.M8>GWJ)!-;;@BN<%O2@#I_"M[*X%L3E%'%=56/X?M[:'3X_*=9&_OCO6Q0
M4444 %%%% !1110 4444 %%%% %#6/\ D%W/_7-OY5QOPM_Y!EY_U\-_Z$:[
M+6/^07<_]<V_E7&_"W_D&7G_ %\-_P"A&@#T&BBB@ HHHH **** "BBB@ HH
MHH **** ..UO_D*6O_72NO3[B_2N0UO_ )"EK_UTKKT^XOTH =1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !01D8-%% $1MX2<
ME%_(4GV> ?P)^0KG/&VK2:5I\,J$C+@''U%<9?ZQ>WK1W5O=.L:+\P4\4 >M
MJ HPH&/:L?Q!IC:A8R(@RY'%'AJ[>ZTB%W)8D=35?Q5=RPZ=+'&QCR/]8.U
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M4 %%%% !1110 4444 %%%% !1110!0UC_D%W/_7-OY5QOPM_Y!EY_P!?#?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %%%% &1XD_Y TM1^'O^/9?I4GB3_D#2U'X>_X]E^E
M&W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 54U*%KBPDB7JPJW4-TC26[(IP3WH \PDT_P 36=Y,+6:)8F4J
M 34.BV?BS2_-"SQ 2,6/-1:_HNMC4Y'AFG,9/8\4RRT2<L/MFLR0-Z,?_K4
M>J:0UTUA&;Q@TW<BK]9NB0+;Z;%&MQYX ^_ZUI4 >;:AB_\ $5Q;7AS"I^45
MJ:7HFF07T<L0^<=.:S?%-O;"]D=+L)*3R!UK.T*7&N0)]M+DG[N>M 'JZC"X
M%+38_N#-.H **** "BBB@ HHHH **** "BBB@ KR#QI_R/,?^Y_A7K]>0>-/
M^1YC_P!S_"@#U'2/^05;_P"[5ZJ.D?\ (*M_]VKU !1110 4AZ&EI#T- '@_
MQ9_X^X/][_&O-Z](^+/_ !]P?[W^->;T %%%% !1110 4444 %%%% !1110
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M"$G^[6V'_B(X<S_W69Z;1117KGQ(4444 %%%% !124N: "BC-)F@!:*,T9H
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ML.]4=+N$@\06R?9%YZMCI0!ZC#N\H;NM24V-@Z CO3J "BBB@ HHHH ****
M"BBB@ HHHH *\@\:?\CS'_N?X5Z_7D'C3_D>8_\ <_PH ]1TC_D%6_\ NU>J
MCI'_ ""K?_=J]0 4444 %(>AI:0]#0!X/\6?^/R#_>_QKS>O2/BS_P ?D'^]
M_C7F] !1110 4444 %%%% !1110 4444 %=)X(_Y#H_"N;KI/!'_ "'1^% '
MTM9_\>4/^X*GJ"S_ ./*'_<%3T %%%% !1110!Q?CG_4'_=KRNO5/'/^H/\
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M/>-?^1:N*Z&N>\:_\BU<4 ?-%_\ \?LGUJM5F_\ ^/V3ZU6H **** "BBB@
MHHHH **** "BBB@!1UKW_P"%G_(MP_6O !UKW_X6?\BW#]: /0:*** "BBB@
M IDW^I?_ '33Z9-_J7_W30-;GANN?\A*;_?-9E:>N?\ (2F_WS697B3^)GW]
M'^&@HHHJ30**** "BBB@ HHHH **** "N[^'7_(0D_W:X2N[^'7_ "$)/]VM
ML/\ Q$<.9_[K,]-HHHKUSXD**** "D/ )I:1ONGZ4 >=>,O%E]I&I+#!+M4K
MFN:_X6)JO_/<_K3OB7_R&T_W/\*X>O:H4*;IIM'DUJTU-I,[7_A8FJ_\]S^M
M+_PL35?^>Y_6N)I*V^KT^QG[>IW.W_X6)JO_ #W/ZTG_  L35?\ GN?UKBJ*
M/J]+L'MZG<ZZ\\=ZE=V[0O-E33;3QSJ5HFU)L"N3I*/J]+L'MZG<[?\ X6)J
MO_/<_K1_PL35?^>Y_6N)I*/J]/L'MJG<[?\ X6)JO_/<_K1_PL75?^>YKB:2
MCZO3[![>IW.W_P"%B:K_ ,]_YUIZ'XXU&]OXXI)B59L&O-JW?"G_ "%X?]\5
M%2A34&TBZ=:;DM3Z#0Y13ZBEIJ?ZM?H*=7A'KA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !534IF@L))%."!5NH+RW%U:O"3C<.M '"Z/
MIUGJ>L2W%WM)8=R*N^(M TNWTN6Z@"":,?*=PJI)X%G%X\T5_*@;L#39O UU
M/$8WU*8J>H)H Z/PE*\F@VY<Y;%;K,JCYF 'N:S=#TO^R=-BM=Y?8.IJKXFL
MKB\TZ1;>1U<CC:: .;\1:#J$MW)=:5/$DCGDEAT_.J?A_P .:RFIQSZA/$ZJ
M>0#_ /7KG5TC7HYRDLURL8_B+5TF@Z=#%J<+-K3O(/\ ED6/- 'I**$4*.@I
MU-084<YIU !1110 4444 %%(2 "3T%9L^O:;;2^7+=(K>AH TZ*B@N(KF,20
MN&4]"*2ZNX+.$S7$@2,=6- $U%9<7B+2IW"1WD;,3@ 5I@@C(Z&@!:\@\:?\
MCS'_ +G^%>OUY!XT_P"1YC_W/\* /4=(_P"05;_[M7JHZ1_R"K?_ ':O4 %%
M%% !2'H:6D/0T >$?%G_ (^X/][_ !KS:O2/BS_Q]P?[W^->;T %%%% !111
M0 4444 %%%% !1110 5TG@C_ )#H_"N;KI/!'_(='X4 ?2UG_P >4/\ N"IZ
M@L_^/*'_ '!4] !1110 4444 <7XY_U!_P!VO*Z]4\<_Z@_[M>5UY>+^,^OR
M?_=PHHHKF/5"BBB@ HHHH **** "BBB@ J:T_P"/R'_>%0U-:?\ 'Y#_ +PH
M6XI?"SV_0O\ D'K]!6G69H7_ "#U^@K3KVX?"CX&M_$844451D%%%% !1110
M 4A&1BEHH R+S0;6\F\R1,M5;_A%;'_GE7044 <__P (K8_\\JY?6]*AM=3L
MXHUPLCX/ZUZ17$>)?^0UI_\ UT_QH UE\+6)4'RNU+_PBMC_ ,\JWU^XOTI:
M ,.+PU91/N6/FMJ-!'&J#H!BG44 %%%% !1110 4444 %%%% !1110 4444
M9FK:#8:U#Y5[%O7.<5B_\*X\.?\ /I_*NMHH P-,\':/I%QY]I!L?&,UO;1M
MV]J6D8X6@#@_$OP]TW5;V2^$:"Y?JQ(KCKGPS;:&V^_42Q#G"<\5K>+-7\1/
MKDUG:V,IMQ]V13UK/M+?68W$EQ:23YY*OS0!Z#X.FTZ;3(GL(7C0C@,*Z>L+
MP[*[6:![-;?CH!6[0 4444 %%%% '+^--4GTRQ@,#;3)($/XD"L2>*]TR%+\
M. FT,WXUH_$&"6:PM3&A;;,"?89%4M7U2VO=&6Q@D5YFC"[1USB@#K=(OC?:
M/'=$Y++FN \2:U*->B0AS#T8 &NO\/S16/A^&WF<+(JX*FLXSZ8+S-]Y:-GC
M<.U %_PR\,@WQ\9'3O71.XC4L>U<!X6\P^+KUXF)M2/DQTKOV7<N#0!RNM^*
MK)+:YMBC[]A%9/PK8-I5VPZ&=C^IK9UOP] ]K<SDC.PGI6-\*QMTJ[7TG8?J
M: /0J*** "BBB@ KGO&O_(M7%=#7/>-?^1:N* /FB_\ ^/V3ZU6JS?\ _'[)
M]:K4 %%%% !1110 4444 %%%% !1110 HZU[_P#"S_D6X?K7@ ZU[_\ "S_D
M6X?K0!Z#1110 4444 %,F_U+_P"Z:?3)O]2_^Z:!K<\,US_D)3?[YK-K2US_
M )"<W^^:S:\2?Q,^_H_PT%%%%2:!1110 4444 %%%% !1110 5W?PZ_Y"$G^
M[7"5W?PZ_P"0A)_NUMA_XB.',_\ =9GIM%%%>N?$A1110 4C?=/TI:1ONGZ4
M >+_ !+_ .0VG^[_ (5P]=Q\2_\ D-)_N_X5P]?08?\ A1/%K_Q&%)2TE;&0
M4M)10(6DI>]% PHI*6@!**6B@ K=\*?\A>'_ 'Q6%6[X4_Y"\/\ OBLZOP,N
MG\:/H*/_ %:_04ZFQ_ZM?H*=7SI[@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !65K>MP:+9O<3*Q51D[:U:Q/$$?FVS(T0
M=".<B@#@;SQG<Z[E+!G1#V8'I4GAK2HUU>*>Y7,V<@UIV]CH<2#S+F.&3NN.
ME7;=M'MIEEBOU=UZ+0!VBXV\4M96FZC+>3,IBQ$!\K>M:M !1110 4444 5-
M3D,>FW#+PPC)%>=Z#HMMXBTNYO+]/,G24JK>V37HVH1F73YXUZLA KSW2)[S
M0=-N+0P$N\A89^IH U?!UY)_:5U89_=0<*/2IO'LN[1IH"I92.@%0>&K2>SN
MKB_>,@S#.#5W5-0G:V>7[$)0.,$4 <?H,>@V9MS-;.)F(P2._P"5>KQ%3$I7
M[N!BO.=4WZFUA]FLPC(X+A1TKT*U0I;H#UVB@#-O_$EII[[95<G..*\I\1ZO
M!J?C:-X0P&WO^%>L7VA0WK[G(KRGQ+ID=AXVC5#_  _X4 >OZ1_R"K?_ ':O
M51TC_D%6_P#NU>H **** "D/0TM(>AH \'^+/_'Y!_O?XUYO7I'Q9_X_(/\
M>_QKS>@ HHHH **** "BBB@ HHHH **** "ND\$?\AT?A7-UTG@C_D.C\* /
MI:S_ ./*'_<%3U!9_P#'E#_N"IZ "BBB@ HHHH XOQS_ *@_[M>5UZIXY_U!
M_P!VO*Z\O%_&?7Y/_NX4445S'JA1110 4444 %%%% !1110 5-:?\?D/^\*A
MJ:T_X_(?]X4+<4OA9[?H7_(/7Z"M.LS0O^0>OT%:=>W#X4? UOXC"BBBJ,@H
MHHH KWEVEE;F:3[HKFY/'NF1R%#NR/>M#Q82-"E(->!WLLGVR3YSUKNPN&C5
M3;.3$5Y4W9'M?_"P-+_VOSH_X6!I?^U^=>&^;)_?-'FR?WS75]0IG-]<F>Y?
M\+ TK_:_.C_A8&E?[7YUX;YLG]\T>;)_?-'U"F'UR9[C_P + TO_ &OSKF-:
M\4V-WJ5I-'G;&^37FOFR?WS2%WSRQH^H4P^N3/<5\?Z6% ^;IZT[_A8&E?[7
MYUX;YLG]\T>;)_?-'U"F'UR9[E_PL#2O]K\Z/^%@:5_M?G7AOFR?WS1YLG]\
MT?4*8?7)GN7_  L#2_\ :_.C_A8&E?[7YUX;YLG]\THED_OG\Z/J%,/KDSZ/
MTS58-4MUF@SM/K5^N*^'9)T*$DYKM:\NK%0FXH]&G)RBFPHHHK,L**** "BB
MB@ HHHH **** "D;)7BEHH Y/43J=IJ$D[OFU[*!S53_ (3*S0^6UO-N'&=I
M_P *[1XTD&'4,/>H/[-LB<_9HL_[M ',17>J:FZO8N8XR<X8=JZZ$.(4$AR^
M.?K21P11#$<:K]!4E !1110 4444 0W-K%=Q&.5<J:Q;?PAI5M=BYC@Q(#D&
MN@HH SY-(M97W-'DU4O_  MINH2+)/#N91@5MT4 4-.TBTTU<6\>WC%7Z**
M*&L?\@NY_P"N;?RKC?A;_P @R\_Z^&_]"-=EK'_(+N?^N;?RKC?A;_R#+S_K
MX;_T(T >@T444 %%%% !7/>-?^1:N*Z&N>\:_P#(M7% 'S1?_P#'[)]:K59O
M_P#C]D^M5J "BBB@ HHHH **** "BBB@ HHHH 4=:]_^%G_(MP_6O !UKW_X
M6?\ (MP_6@#T&BBB@ HHHH *9-_J7_W33Z9-_J7_ -TT#6YX9KG_ "$YO]\U
MFUI:Y_R$YO\ ?-9M>)/XF??T?X:"BBBI- HHHH **** "BBB@ HHHH *[OX=
M?\A"3_=KA*[OX=?\A"3_ ':VP_\ $1PYG_NLSTVBBBO7/B0HHHH *1ONGZ4M
M(WW3]* /%_B7_P AM/\ =_PKAZ[CXE?\AM/]W_"N'KZ##_PHGBU_XC"BBDK8
MR"BBB@044M% P[4E%+0 E%+24"%K=\*?\A>'_?%8-;WA3_D+P_[XK.K\#-*?
MQH^@H_\ 5K]!3J;'_JU^@IU?.GN!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %,EB6:,HXRIZT^B@#G+KP9I%U*9'M\L>IX
MID'@C1X9 XM^1]*Z:B@"&WMH[:)8XAA1T%3444 %%%% !1110 54GTZVN)1)
M(F6'>K=% $?D1B,1X^44W[+%Y1BV_*>HJ:B@"I!IMM;.7B3#'K5NBB@ KR'Q
MI_R/,?\ N?X5Z]7D/C7_ )'J/_<_PH ]0TC_ )!5O_NU>JCI'_(*M_\ =J]0
M 4444 %(>AI:0]#0!X/\6?\ C\@_WO\ &O-Z](^+/_'Y!_O?XUYO0 4444 %
M%%% !1110 4444 %%%% !72>"/\ D.C\*YNND\$?\AT?A0!]+6?_ !Y0_P"X
M*GJ"S_X\H?\ <%3T %%%% !1110!Q?CG_4'_ ':\KKU3QS_J#_NUY77EXOXS
MZ_)_]W"BBBN8]4**** "BBB@ HHHH **** "IK3_ (_(?]X5#4UI_P ?D/\
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M]-HHHKUSXD**** "D;[I^E+2-]T_2@#QCXE?\AM/]W_"N&KN/B5_R&T_W?\
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M\<_Z@_[M>5UZIXY_U!_W:\KKR\7\9]?D_P#NX4445S'JA1110 4444 %%%%
M!1110 5-:?\ 'Y#_ +PJ&IK3_C\A_P!X4+<4OA9[?H7_ "#U^@K3K,T+_D'K
M]!6G7MP^%'P-;^(PHHHJC(**** ,+Q;_ ,@*6O ;W_C\E^M>_>+?^0%+7@-[
M_P ?DOUKULO^%GFXWXD0BBDI17H'$%'2BB@!*6DI: "DI:* $HI:* "@=:*!
MUH ]K^'7_("AKMJXGX=?\@*&NVKY_$?Q&>U0_AH****Q-0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AK'_(+N?\
MKFW\JXWX6_\ (,O/^OAO_0C79:Q_R"[G_KFW\JXWX6_\@R\_Z^&_]"- 'H-%
M%% !1110 5SWC7_D6KBNAKGO&O\ R+5Q0!\T7_\ Q^R?6JU6;_\ X_9/K5:@
M HHHH **** "BBB@ HHHH **** %'6O?_A9_R+</UKP =:]_^%G_ "+</UH
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M*=38_P#5K]!3J^=/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZT;U]: '44@8'O2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2%E!P2!^-1W4WV>VDE_N*37 OXBU/45DN
MK.#>D;%>/\^U 'H=%8'A[6SJ2F*0 3(/F7TH\2:T^G6SK  TV.%H W@P/0@_
MC2UP$&OZC9/;R3PX%PP'-=Y$_F1*WJ : 'UY!XT_Y'F/_<_PKUXL!U->0^,R
M/^$YC_W?\* /4=(_Y!5O_NU>JAI#K_95OS_#5W>OK0 ZBF[U]:-Z^M #J0]#
M2;U]:"ZX/- 'A/Q9_P"/N#_>_P :\VKTCXL$&[@_WO\ &O-Z "BBB@ HHHH
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M)I_G\:]"HH \]_X1WQC_ -!-/\_C1_PCOC'_ *":?Y_&O0J* //?^$=\8_\
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MZ]Z6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M":?Y_&O0Z* //?\ A'?&/_033_/XT?\ ".^,?^@FG^?QKT*B@#SW_A'?&/\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JM_="TM6E/:K59>O\
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MIHFMQ:E8I<%@@;^\<5YOI-W-'H^HQ,[.O0%CFJND:E/-%%8S$Q6ZL"KJ<$T
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M,S6D1<88KS0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?-%'M9![21W'_"?/_MT?\)\_^W7#9HR*/:R#VDNYW/\ PGS_ .W1_P )\_\
MMUP]%'M9![21W'_"?/\ [='_  GS_P"W7#T4>UD'M)'<?\)\_P#MUJZ+XO:_
MNEC.[DXKS*NB\)?\A%/]ZJA4DV5&<FSV<<@&EI%^Z/I2UVG6%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 -8X7->?:MXS:SOI(1N^4XKT"3[AKQ'Q+_P ABX_WJQK2
M<5H959-+0W_^$^?_ &Z/^$^?_;KAZ*YO:R.?VDCN/^$^?_;H_P"$^?\ VZX>
MBCVL@]I([C_A/G_VZ/\ A/G_ -NN'HH]K(/:2.X_X3Y_]NC_ (3Y_P#;KALB
MEH]K(/:2.X_X3Y_]JC_A/G_VZX>BCVL@]I([C_A/G_VZ/^$^?_;KAZ*/:R#V
MDCN/^$^?_;H_X3Y_]JN'I.*/:R#VDCN?^$^?_;H_X3U_]JN&R*6CVL@]I([C
M_A/G_P!NC_A/G_VZX>BCVL@]I([C_A/G_P!NE7QZY./GKAJ<GWA1[60>TD>Y
MZ!J!U'3([@Y^;UK5KF_!?_( AKI*[8.\4=<7=!1115%!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 <GXW_Y!<OTKR$=*]>\;_\ (+F^
ME>0CI7%7^(Y*WQ!1116!D%=)H-G:-EK@*^1P":YNM&QMKI7290=@.>M5'<<=
MS?UC2+=M/DNX(Q$%XVGJ:-+T6*"U2XN(O-60<#%:5UMU+PY+<YQLPI JZUV+
M30K/8%)(YR*WY5>YMRJ]SG+W3;::\411B)<=#5R+2;2XM)4$ 5XU^\>],U4>
M;9/J XD3@ =*J:?KUW.JQ+&NT?>/M4Z)BT3*L>G11:3+/*!N5L 'K6"Y!<E1
M@5W%S:07ARS$6Q'S$>M<[K6DIIRI)'DQO]TFIE$F423PM917^LQ02J&4]0:O
MCPZTVL3J$V0Q-W'&*B\#?\C'!FNUN=6LC<7%HK*)'^7@<U<(IQU*A%..IQFK
MQV$=R+:&)=V.HK9N++2].T^UEGME8R+UKGM1TR6PU;#9*GG)-;'BT,=&T_;_
M '?\:%U;0N[([_1[6\TMKRS14'H*XV1#'(R'J#7<Z KQ>'R\OW,]ZXR^(:^F
M(Z%JB:5DR9K1,KT445D0%=%X2_Y"*?[U<[71>$O^0BG^]5P^)%0^(]G7[H^E
M+2+]T?2EKT3N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5<C-\6]!CNO*\\]<4 >B45@VGBK3[[3'O8),QH.36=8?$'2+V_:T2;]XO44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME:TB!STQ6W/X:L+B[2Y=/WB'(-:L<:QIM7H* *]CIMKIT0CMH4C&.=M6Z**
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M>%M*T]M\5E"K>H%;=% &7J6A6>IC$\*. ,?,*LV.GP6-HMO$BK&!C:.E6Z*
M.?U/PAI6HL7:TBW>I%)IGA#2].?>EI%N]0*Z&B@"C?:39ZA#Y=Q;HXQCYA7/
MKX TE9_,^RPXSD#%==10!CWMA;V6D216T*QCT6O$O#NE?:?'.H"YMMR%N-PK
MZ"EC66,HW0UE6_AJPM;Q[J-,2/U- &9;^!M)2:.;[)#P.F*Z:"WBMHECB0(J
M] *D P /2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH XKXA?\>UI_UT'\ZV_#7_ "#1]!6)\0O^/:T_ZZ#^
M=;?AK_D&CZ"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2O+=7_ .2J6_\ N?U%
M>I'I7ENK_P#)4[?_ '/ZB@#T^#_4)]*DJ.#_ %"?2I* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHY
M9XXERS#\ZS6\0V:R["3F@#6HJ"&ZBG4,K#GWJ>@ HHHH **** "BBB@ HHHH
M **** .*^(7_ !ZVG_70?SK;\-?\@T?05B?$+_CUM/\ KH/YUM^&O^0:/H*
M-JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUG^%O^0/']:T-5_Y!=Q_NU0\+?\ ('2@#;HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 4]5_Y!=Q_NU0\+?\@=*OZK_R"[C_ ':H>%O^0.E &W1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!D:_;V<]GB[E6)<_>-<W:P:+9VTP34(W9NC?W:E\<$
MSVP@8C;O[URUQH=C;ZEI\2!?+FQYG(YH Z[PY!IYOS+'>+/.1R.]=CVKSS3M
M.L]+\62K9 !0.,'ZUZ I)B!'7% #STYJC<:C8638GF2,GUK'U#77TR[<3DF/
MH /6N3U:2+5+A99QN7L* /2[>[@ND#P2!U/0BIZY3PK:30@,AQ:X^5:ZN@ H
MHHH **** $/0UQVHV5R_BVTF6)C&O5J[*DP,YH R[R_N8W:..W+#IFN9N;^^
MM+Q0-,\U3R6(Z5W6T9I&C5^HH X7PKI]S_PD5U?2P&)91P*[IXTD3:ZAE/8T
MJJ%&!2T <%X_L;6*"T9($4^8.0/>NC\-?\@U?H*Q/B%_QZVG_70?SK;\-?\
M(-'T% &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UV54)?[O>G51UAF73)
MBO7% '-:AJNFK?NI@A=EYR16;<>(A<7D;)9J]LG#OC@5B&ZL%NI?M,3F3:<G
M%.LM6L8O#E];K$X+L<<4 >I:9/#<V,<D(4(>@%6RP'4USO@QLZ!;X! QT-:.
MK1W;0,;614?'!- %JZNXK2+?*X4=LUE6_B**:Y$3%1D\5R^KZA.+9;>^<22
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M444 %%%% !1110 4444 %%%% !6)J.B/>S,XN73/8&MNB@#EO^$5E_Y_I?\
MOHT?\(K+_P _TO\ WT:ZFB@#SS5-)GM-2@@%Y*0_^U6O%X7E= WVZ7_OHTOB
M'_D.VE=-;_ZD4 <W_P (K+_S_2_]]&E7PM(K@_;I>#GJ:ZBB@"*WB,,00L6P
M.IJ6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M <4 ;'444@&!BEH **** "BBB@ HHHH **** "BBB@ HHHH **** .4\0_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6^F6UN@ B0D=]M<[9>(G@U26TO"WR#[Q& :K:MXL>><66GAQ*_ < D"@#M@
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MSGBYIGU,<FH.*9Z]_P )G9_\]5H_X3.S_P">JUY#12^MS*_L6@>O?\)G9_\
M/5:/^$SL_P#GJM>0T4?6YA_8M ] U?Q';7.J6\RR*53K6W#XQLTC \U:\DHH
M^MS#^Q:!Z]_PF=G_ ,]5H_X3.S_YZK7D-%'UN8?V+0/7O^$SL_\ GJM+_P )
MG9?\]5KR"BCZW,/[%H'KW_"9V7_/5:U=+UJ'4VQ&P/&>*\,KT7X??Z]O]VM:
M.(E.5F<>-RRE1HN<=ST.BBBNX^>"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ IDS%(BP&2*?4%Y,L%J\C= * //O%?VC4-T4</ELISN3@FJ'A6XU
M&QCD6XLE9@WRLPR:?>0ZMJNK2R6=P$A7YL'T%=7X6:._M)/-7<\9VD^] &]I
M\[W%JCN@5CV%6)$\Q"N<9I418UVJ, 4Z@#S7QAX*FO)HIH)I7+2#(W'CFNL\
M/Z#_ &3:(OGNYP"=QK8EF@3_ %DJ+]6 IJ7EL[!4GC)/8.* +%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!P_C:18D#R8V!QUKG]1URQ?4-,DB9 (@-Q KIO'.H65A8;[NSD
MN%W8PBDUQ$&L^'9E!.F2*?0@_P"% 'INF>)++4)O*AF#-CI6V#D9KS[PK=:7
M-J'^BV3QMC[Q'_UJ]!7[HH RO$&I2:98B6)0S,<8-<Q'-K-UF3R" >1@UTWB
M'3WU&P\I)%1@<@L:X8:;XC@9E77+<*#P-XX_6@#O-'%R+=?M"E6[UJ5A^'DO
M4M4^UW23MCEE.<UN4 %%%% !1110 4444 %%%% !1110!Q7Q"_X];3_KH/YU
MM^&O^0:/H*Q/B%_QZVG_ %T'\ZV_#7_(-'T% &U1110 4444 %<!\4/^1=N/
MI_2N_K@/BA_R+MQ]/Z4 ?/M%%% !1110 4444 %%%% !1110 4444 2V_P#Q
M\)]:^D/AW_R*\7UKYOM_^/A/K7TA\//^17B^M '64444 %%%% !5+5/^/-_H
M:NU2U3_CS?Z&E+8NG\:/#M1_X_YO]\U5JUJ/_'_/_OFJM>)+<^_A\*"BBBD4
M%%%% !1110 4444 %%%% !7HOP]_U[?[M>=5Z+\/O]>W^[6^&_B(\[-?]VD>
MAT445ZQ\8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+58WFTZ5
M$&6(XJ[4%WO^S/L.&[4 >8)<^(--NYXX=/#H5*@FH_#NI^)M,$ZG3AB1RW/U
MJMK=_P"((]8DBBED"9P,*<5:L[/Q'/M9M3C3/9CC^M 'IFEW-Q=6227,>R0]
M5J[6=HT4\6GQK<2K+(!RP/6M&@#S35(8]7\07%I=W<EO$ARI5B,U>TCPMI]I
MJ,4\6J3R,O12YP?UIOB-+2WOGFVAI"><'FJFC:I"VK0Q!2">E 'I*C"XI::A
MR@IU !1110 4444 %%%% !1110 4444 (>E>6ZO_ ,E3M_\ <_J*]2/2O+=7
M_P"2IV_^Y_44 >GP?ZA/I4E1P?ZA/I4E !1110 4A^Z?I2TA^Z?I0!\__%'_
M (_T_P!ZO/Z] ^*/_'^G^]7G] !1110 4444 %%%% !1110 4444 %=!X._Y
M#:_A7/UT'@[_ )#:_A0!],V/_'A!_N"K%5['_CP@_P!P58H **** "BBB@#E
M/&%U);VS%&(^7L:\U_MN[_YZ/_WU7HGCC_CU;_=KRBO-Q4FIZ'UF44X2H7:-
M/^V[O_GH_P#WU1_;=W_ST?\ [ZK,HKFYY=SU/8T^QI_VW=_\]'_[ZH_MN[_Y
MZ/\ ]]5F44<\NX>QI]C3_MN[_P">C_\ ?50IJ=PDK2!V#'J<U2HHYY=P]C3[
M&E_;=W_SU?\ [ZI?[;N_^>C_ /?59E%'/+N'L:?8T_[;N_\ GH__ 'U1_;=W
M_P ]'_[ZK,HHYY=P]C3[&G_;=W_ST?\ [ZI\.M71G0>8_7^]634EO_Q\1_[U
M-3E?<3HT[;'M?AR9IM.W,23QUK9K#\+?\@O\JW*]B'PH^'Q*M5D@HHHJC **
M** "BBB@ HHHH **8TL:'#2*I]S3?M$'_/9/^^A0!+147VB#_GLG_?0H^TP?
M\]H_^^A0!+147VB#_GLG_?0H^T0?\]D_[Z% $M%1?:(?^>J?]]"I 01D'- "
MT444 %%%% !1110 4444 %%%% !1110!1U);,P'[6J%/]I<UY[JFG^'Y96>V
MN1YP/" <9KI_&&C:CJ]CY5C<K"V<Y/I7%P>!;V%@SZA!Y@[[AU_.@#:\)/JL
M>H^4]BBVH'RRXY->A#.T9KDO#VE:I9S#S[U)8<<!376CIS0!@>+I)4TM?*)!
M9L$@UY9K&B017$>-1N!YG+?.>/UKV'6GMX[(M<+N4=!7F&H:G83O)FS?<IPN
M0: .M\$$06Z6J2M*BCAF.2:[2N6\&FU?38GCCV2$<@]:ZF@ HHHH **** "B
MBB@ HHHH **** .*^(7_ !ZVG_70?SK;\-?\@T?05B?$+_CUM/\ KH/YUM^&
MO^0:/H* -JBBB@ HHHH *X#XH?\ (NW'T_I7?UP'Q0_Y%VX^G]* /GVBBB@
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M]T_2EI#]T_2@#Y_^*/\ Q_I_O5Y_7H'Q1_X_T_WJ\_H **** "BBB@ HHHH
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M@4444 %%%% !1110 4444 %%%% &)XJ_Y 4U2:!_R#HO]VH_%7_("FJ30/\
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MW*P_"W_(+_*MRO:A\*/@\5_&D%%%%68!1110 4444 %%%% !1110 5R_B?\
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MO"I6&*#CHQQ5_P"PZ3ICBYB\IW3H%;)H Z],!!BG5DZ5JXU!RHA9 !U(K6H
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M/TI:0_=/TH ^?_BC_P ?Z?[U>?UZ!\4?^/\ 3_>KS^@ HHHH **** "BBB@
MHHHH **** "N@\'?\AM?PKGZZ#P=_P AM?PH ^F;'_CP@_W!5BJ]C_QX0?[@
MJQ0 4444 %%%% ''>./^/5O]VO**]7\<?\>K?[M>45Y>+^,^OR?_ '<****Y
MCU0HHHH **** "BBB@ HHHH *DM_^/B/_>J.I+?_ (^(_P#>H6XGL>T>%O\
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M+=7_ .2IV_\ N?U%>I'I7EFK_P#)5+?_ '/ZB@#U"#_4)]*DJ.#_ %"?2I*
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MPW\-!1117,= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Q7Q"_P"/6T_ZZ#^=;?AK_D&CZ"L3XA?\>MI_UT'\ZV_#
M7_(-'T% &U1110 4444 %<!\4/\ D7;CZ?TKOZX#XH?\B[<?3^E 'S[1110
M4444 %%%% !1110 4444 %%%% $MO_Q\)]:^D/AY_P BO%]:^;[?_CX3ZU](
M?#S_ )%>+ZT =91110 4444 %4M4_P"/-_H:NU2U3_CS?Z&E+8NG\:/#M1_X
M_P"?_?-5:M:C_P ?\_\ OFJM>)+<^_A\*"BBBD4%%%% !1110 4444 %%%%
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M1XM;XV)12TE:F0M)2T4 )2T44 )2T44 )12T4 %=#X1_Y"T7^^*YZNA\(_\
M(6B_WQ6=7X&73^)'OR?ZM?H*=34_U:_04ZOG3W HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 0]*\MU?_ )*I;_[G]17J1Z5Y;J__ "52W_W/ZB@#
MT^#_ %"?2I*C@_U"?2I* "BBB@ I#]T_2EI#]T_2@#Y_^*/_ !_I_O5Y_7H'
MQ1_X_P!/]ZO/Z "BBB@ HHHH **** "BBB@ HHHH *Z#P=_R&U_"N?KH/!W_
M "&U_"@#Z9L?^/"#_<%6*KV/_'A!_N"K% !1110 4444 <=XX_X]6_W:\HKU
M?QQ_QZM_NUY17EXOXSZ_)_\ =PHHHKF/5"BBB@ HHHH **** "BBB@ J2W_X
M^(_]ZHZDM_\ CXC_ -ZA;B>Q[1X6_P"07^5;E8?A;_D%_E6Y7M0^%'P>*_C2
M"BBBK, HHHH R]?_ .05)7SYJG_(3G_WJ^@]?_Y!4E?/FJ?\A.?_ 'J]3+]F
M>?C>A4I:.]%>D< E+24M !24M)0(6DI:*!B44O:DH$+2444 >J?#7[L?TKTZ
MO,?AK]V/Z5Z=7A8O^*SV,-_#04445S'0%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 5-0U"#3H/,G;:#TK!MO&%I->"!I1ECQ5/XB.R6%F
M%.,S*#^8J#6M/MK;01=PQJLPC!##KTH [E)5DC\Q3\M8.J^*;33[@0&3$A'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&2R+%$TC'"J,FN.O/%DYF+V15K=>&)]:ZC5<_P!EW./^>9KB?!=O#/H%V9P&
M/G'D_4T =AI.JQZC I#9DQ\PINM:LFF6;R%L,*Y?P<[_ /"07\>3Y:_=':I?
M%)+ZHL3<Q%>1VH GL?%$XF0WNU8I3B,CO77JP9 PZ$9KS[Q%%'%:Z3Y8 ^<=
M/K7=69)MH\_W10!.>E>6ZO\ \E3M_P#<_J*[#Q-X@FT6.-HK.2?=_='2O+;S
M6M0N?%L>KC2YPJ#&W;0![C!_J$^E25YG'\0[U$"_V-<<?[)IW_"Q;W_H#7'_
M 'R: /2J*\U_X6+>_P#0&N/^^31_PL6]_P"@-<?]\F@#TJD/W3]*\V_X6+>_
M] :X_P"^30?B+>D8_L:X_P"^30!Q'Q1_X_T_WJ\_KM?%1U'Q!<+(NG3I@Y^[
M7/?\([JG_/G-_P!\T 9=%:G_  CNJ?\ /G-_WS1_PCNJ?\^<W_?- &716I_P
MCNJ?\^<W_?-'_".ZI_SYS?\ ?- &716A-H6I0PM(]I,%49)*U%9Z5?WD(DBM
M964]PM %2BM3_A'=4_Y\YO\ OFC_ (1W5/\ GSF_[YH RZ*U/^$=U3_GSF_[
MYH_X1W5/^?.;_OF@#+KH/!W_ "&U_"J?_".ZI_SYS?\ ?-:&C:=J>EWHN#8S
M-C'&V@#Z5L?^/&#_ '!5BO,8/B#>PP1Q_P!C7!VC'W34G_"Q;W_H#7'_ 'R:
M /2J*\U_X6+>_P#0&N/^^31_PL6]_P"@-<?]\F@#TJBO-?\ A8M[_P! :X_[
MY-'_  L6]_Z UQ_WR: -GQQ_QZM_NUY172ZYXKO]6A*#29UR,?=-<GLU+_H'
MS_\ ?-<&(HSG*Z1]'EN.H4:/+.5F3T5!Y>I?] ^?_OFC9J/_ $#Y_P#OFL/J
MU3L>C_:F%_F)Z*@V:C_T#Y_^^:39J7_0/G_[YH^K5.P?VIA?YBQ15?9J7_0/
MG_[YJG%?7<MV]NME*73J,4?5JG8/[4PO\QJ457V:E_T#Y_\ OFC9J7_0/G_[
MYH^K5.P?VIA?YBQ15?9J7_0/G_[YI=FI?] ^?_OFCZM4[!_:F%_F)ZDM_P#C
MXC_WA5/9J7_0/G_[YI\8U%)%;^SY^#G[M"PU3L)YIA;?$>X^%O\ D%_E6Y7D
M^E>-K[3[7R3I%PWOM-7O^%BWO_0&N/\ ODUZD%:*1\C7DI5')'I5%>:_\+%O
M?^@-<?\ ?)H_X6+>_P#0&N/^^35&1Z517FO_  L6]_Z UQ_WR:/^%BWO_0&N
M/^^30!VVO_\ (*DKY]U3_D)S_P"]7H6H>.[Z\M6A&CW S_LFO/;JUU*XNI)?
M[/F&XYQMKOP=:%._,SCQ5*4[<I3I:F_L_4O^?";_ +YI/[/U+_GPF_[YKM^N
M4NYR?5:G8BI*F_L_4O\ GPF_[YH_L_4O^?";_OFG]<I=P^JU.Q%14W]GZE_S
MX3?]\U3N_MEG+''+9RJ9#@ K1]<I=P^JU.Q-14BV.HL,BPF_[YI?[/U+_GPF
M_P"^:/KE+N'U6IV(:*F_L_4O^?";_OFC^S]2_P"?";_OFCZY2[A]5J]B*DJ;
M^S]2_P"?";_OFC^S]2_Y\)O^^:/KE+N+ZK5['IWPU^[']*].KP[PUKE_H04-
MI<[X']VNG_X6+>_] :X_[Y->3B)J=1M'I4(N,+,]*HKS7_A8M[_T!KC_ +Y-
M'_"Q;W_H#7'_ 'R:P-CTJBO-?^%BWO\ T!KC_ODT?\+%O?\ H#7'_?)H ]*H
MKS7_ (6+>_\ 0&N/^^374^&M?FUJ%WEM)(-IZ,* .AHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH YWQ;I$FK642Q+N:-MP_"N:-OKE^Z6<\(^SXVG'H*]
M'ZTP0QJ<A1F@#GK>WO;&R6RA0>6!MK"NM/U;2KY9+"(&-OF8GUKT JI/2D:-
M'^\H- ''^&-'NH=8GU*Z3:\PYKL2H88(!'O0JA1@# I: (OLT!_Y91_]\BD^
MRP?\\8_^^14U% $/V6#_ )XQ_P#?(I?LL'_/&/\ [Y%2T4 1?98/^>,?_?(I
M/LL'_/&/_OD5-10!#]E@_P">,?\ WR*7[+!_SQC_ .^14M% $/V6#_GC'_WR
M*/LL'_/&/_OD5-10!#]E@_YXQ_\ ?(H^RP?\\8_^^11=3BVM99R,[%W8KBD^
M(<DI;RM,D=0<9 H [7[+!_SQC_[Y%!M8,?ZF/_OD5SNG>,([ZVN9&A\MH5R5
M-9,7Q&DN S0Z9(Z@XR!0!)I/A>:VUR[N9(%\N1\K\M=H+6# _<Q_]\BLK2_$
M$6HV\DNT(T8RRGM63>>-S#<&."Q>=1_$M '5_98/^>,?_?(H^RP?\\8_^^16
M5H?B :QO'E&)DZ@UMT 0_98/^>,?_?(H^RP?\\8_^^14U% $/V6#_GC'_P!\
MBC[+!_SQC_[Y%344 0_98/\ GC'_ -\BC[+!_P \8_\ OD5-10!#]E@_YXQ_
M]\BC[+!_SQC_ .^14U(3@$T 1?98/^>,?_?(H^RP?\\8_P#OD5@7WB^WL=3A
MLY$&96V@DUH:QK<6E62W.!(K-MXH O\ V6#_ )XQ_P#?(H^RP?\ /&/_ +Y%
M,MKQ+BU2<X4,N>:>+F%E8I(K8&>#0 ?98/\ GC'_ -\BC[+!_P \8_\ OD5E
MZ=X@CU":6,)M\MMI-; D0C(8&@"/[+!_SQC_ .^11]E@_P">,?\ WR*5;B%F
MVK(I/IFG/(D8R[ #WH X[Q)X:DU#7+2Y@@4QQ_>PM=/9V,45LJ-"F1_LBJ=Q
MK\,.HPV@4,9.XK9H A^RP?\ /&/_ +Y%'V6#_GC'_P!\BL/6/%4.DZE#:,@;
MS/XO2MB*^CELOM*D;<$T 2?98/\ GC'_ -\BC[+!_P \8_\ OD5R,_CMDE=8
M+!Y@IP2HK<TG7$U*#>R>4X&2IZB@#2^RP?\ /&/_ +Y%'V6#_GC'_P!\BN9U
M+QF+2X\NVM6N0.I3G%2:3XO74+DPSVYMO0OQ0!T7V6#_ )XQ_P#?(H^RP?\
M/&/_ +Y%2@AE!'0TM $/V6#_ )XQ_P#?(I?LL'_/&/\ [Y%2T4 0_98/^>,?
M_?(I?LL'_/&/_OD5+10!#]E@_P">,?\ WR*/LL'_ #QC_P"^14U% $/V6#_G
MC'_WR*/LL'_/&/\ [Y%2DX%<7>^/#;:A+:16+RM&<$K0!U_V6#_GC'_WR*/L
ML'_/&/\ [Y%<WI?C$7]TL$UJ;=F_O5TZ2QR?<<'Z4 87BK1AJ6A36UO AD;I
MA:7P[HWV"PCBFA0,%P<K6XTB X+ 4TW$((!D49]Z $^RP?\ /&/_ +Y%'V6#
M_GC'_P!\BI"ZJNXL /6FI-'(2$<-CTH ;]E@_P">,?\ WR*/LL'_ #QC_P"^
M14U% $/V6#_GC'_WR*/LL'_/&/\ [Y%344 0_98/^>,?_?(H^RP?\\8_^^14
MU% $/V6#_GC'_P!\BC[+!_SQC_[Y%344 0_98/\ GC'_ -\BC[+!_P \8_\
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M[+!_SQC_ .^11]E@_P">,?\ WR*XL_$";S'":7(RJ>H%:$7C.%[ 7#P[)/\
MGF>M &MK&FQW6DW,$<*;W3 ^45E>$-!;2]*C@N($#CKE:S5^(4CNP&F2%%/+
M8XKHK#7X;O31=D!,_P )H T_LL'_ #QC_P"^11]E@_YXQ_\ ?(KD)/'DBS.B
M:=(ZH<;@.*Z+1]775;59=FQC_#0!=^RP?\\8_P#OD4?98/\ GC'_ -\BIJ*
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M/_OD5-10!#]E@_YXQ_\ ?(H^RP?\\8_^^14U% $/V6#_ )XQ_P#?(H^RP?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:]C894BN-T_1Y$\7W=TX/ER)CD?6@#FO[:.HR+&[?-#\GY5I7&ISV]@BS'$
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MO%2:SXSEB@TY-X E'[S]:U[[1II?"/V0 []^>E9>K^%W$%A,(C)Y(RRXZ]:
M)-"\2LVNBTA?-OCO7H\;;XU;U%>?Z#I_VG61<_8C;KC&"*] 1=J!?2@!U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKM9Y=V5;<*;_ ,)99_WT_.C_ (2RS_OI^='/'N',C>2-4C" < 8IV!Z"N?\
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MP,TM% "$ ]0*0HIZJ#^%.HH 38O]T?E1@>@I:* $VKC&T?E2!$!R%4?A3J*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% ')^-_^07+]*\A'2O7O&_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 44C,%7<QP!5?[?;$X$HS0!9HI P*[@>*@>]M
MXVVO* ?2@"Q13(Y4E&4;(I] !1110 4444 %%%% !1110 444A('6@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJTU_;0'$LH7ZT
M 6:*K17]M.<1RJWTJS0 4444 %%%% !1110 445";N /L,@W>E $U%'49HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M4C<*3[4 <?XY\7)X=L756(F9<J17DME>^,/%LIEMKG$;#(W*?\:O?%Z9[C7K
M2$L0I&#7IWP\TZWM_"=J1&N[NV/84 >1WUSXQ\*2K+<7.8QR=JG_ !KU3P%X
MR3Q#81I(Y:X"Y8DU=\=Z=;W'A>\9HTW!>#CI7C7PMN9+;Q#>P*QVK V.?8T
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M#R-/*7'0'/-;/@/0M4T75Y;.2V<6X3 <]^M '(:=(MK\0H/,^4>:>3QWKO\
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M !ZVG_70?SK;\-?\@T?04 ;5%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!!>"1K241'$A4[3[UY:?#^O-J9O
M)YE:52=K8Z#/UKUFF>6G]P?E0!SNG+JHMMLDH+ <<56U#1[V^TR1RX^UY^5O
M:NL"*.BBEP,8Q0!Y[!HFK7LEO'=2JRP,#TKT")/+B5?0 4H15.0H%.H 0C(K
MRO5!CXK6_P#N?U%>J'I7EFJ_\E7M_P#<_J* /4(?]2OTJ2HX?]2OTJ2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F[1N
MSCFG44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A>*M#.O:-+
M9#'S^M9_@_PHWAP/D+\PQQ76T4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '%?$+_CVM/\ KH/YUM^&O^0:/H*Q/B%_QZV?
M_70?SK;\-?\ (-'T% &U1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>E>6:I_R5:W_W
M/ZBO4STKRS5/^2K6_P#N?U% 'J$/^I7Z5)4</^I7Z5)0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45F
MWVN6.GY$\P5AV-9!\86WF?*ZE/6@#J:*R+'Q'I]ZWEI.#)W%:P((!'>@!:**
M* "BBB@ HHHH **** "BBB@#BOB%_P >MI_UT'\ZV_#7_(-'T%8GQ"_X];3_
M *Z#^=;?AK_D&CZ"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JCJ6H+86[2,C-@=%&:O5EZS/-!;,\,*RL!P"* .7GO]8U1BUC(T*GH&4T
MD4^NZ:?-O)S*@ZA12+XBUA!\NFQCZ 5;L-<U.\O4AN+!!&W4X% &]I&KKJ*
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M7#@_.IP#VK)BOI=+\116-UEVE)*D#@"K.B^*].L]-C@O)EBF4<KCI6;<7_\
M;7BFUELU62 ##.!TZ4 >AJ0RY%+3(4V1A?2GT %%%% !1110 4451O=6M+ ?
MOY0IH O45%;SI<P++&<JPR#4=]?0:?;-<7#[(UZF@"S16';^*M,N9 D5P&).
M!6V"& ([T !Z5Y9JG_)5K?\ W/ZBO4ST->6:I_R5:W_W/ZB@#U"'_4K]*DJ.
M'_4K]*DH **** "BBB@ HHHH *JWULUS 44X-6J* .>_L&7^\*/[!E_O"NAH
MH Y34='G@T^:57 95R*I^'M-N;[2DFDD!8GK74ZS_P @BY_W*SO"'_(!C^M
M#?[!F_O"C^P9O[PKH:* *6GV;6BD,0<U=HHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'UW7
M(M&MQ(ZE\MC"UD:EXL6WAB14?S)URO'2F^,;><0^=&F_YNAZ5S\7G:G>VES)
M&!%:_>P.!0!T6@>)'N+W[%<*XD49)88KK'),1*^E<+:L;_Q9*]N@\@CAE&/6
MN[C&(U!["@#@+58)/'-R+K  7.6./6NEUQ-/FTJ02/&P"X W"L_7O"4=]<-=
MQ2.LK'G:2*QT\(W5TPCGDF6/IG>: -+P>75Q%'D6X'RCM795GZ1I46DV*6T9
M+!?XCUK0H **** "BBB@ HHHH **** "JU]=K96K3LI8+V%6:CFA6>,HW0T
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MH-2UJ.WLA/ P8-TKF;'QA>S:FD$D:A&/6@#OJ*CAD\V(/ZU)0 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M749>OK_]>NDTS^QM4U>VNHKMWEC&%7/!_6@#O(GWQAL8S3Z0# P*6@ HHHH
M**** "BBB@ HHHH **** $/2O+-4_P"2K6_^Y_45ZF>E>6:I_P E6M_]S^HH
M ]0A_P!2OTJ2HX?]2OTJ2@ HHHH **** "BBB@ HHHH **** *.L_P#((N?]
MRL[PA_R 8_K6CK/_ ""+G_<K.\(?\@&/ZT ;]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %2[TZUODV7,0=?0U1_X1?1AUM$K7D;;&S>@)KS^?Q9?2K>)$JEHB0M
M'86>C:;9R[[:%%?U%:..,5YYX6\0:G<WNV]157'8UZ$K9C#>HH \U\0>';I/
M$$^I)=K&D@Q@GZU)HY-MI-W";I&D?I@T_57EUOQ)<Z6Y(BC7<"IY[_X5SO\
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MBBB@ HHHH **** "D/0TM(>AH Y#2/\ D-W?^_77CH*Y#2/^0W=_[]=>.@H
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M?X0.-"C^M &_12;A1N% "T4FX4;A0 M%)N%&10 M%%% !1110 4444 %%%%
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MZY1@?H:EK/T[38+)1Y+,P]S6A0 4444 %%%% #7174AAFN'U*/'C*RVKQ_\
MJKNJH2Z3!-?)=MGS$Z4 2W<\8MY4+C<5(QFN'T.5=+OG6<A=TA8%OK79SZ3#
M/+YC,V<YZU1U/PM9:HZM*S*5&/EXH YOPTK2^-]0G53Y;#ANQZUW%];-=6K1
M*VTGO5?3-'M]+C"PY.!C)ZUHT >4>,O#\]H+61YMP,@X_&N]\,C&F*/0"L3X
MA?\ 'K9_]=!_.MOPU_R#1]!0!M4444 %%%% !7%_$+4KG3M#GEMI6C<#@BNT
MK@/BA_R+MQ]/Z4 >0?\ ";:Y_P _\E)_PFVN_P#/_+^=<[10!T7_  FVN_\
M/_)2_P#";:[_ ,_\E<Y10!T?_";:[_S_ ,E)_P )MKG_ #_R5SM% &W'XIU6
M*1I$NW#,<DU/_P )MKG_ #_R5SM% '1_\)MKG_/_ "4?\)MKG_/_ "5SE% '
M1_\ ";:Y_P _\E'_  FVN?\ /_)7.44 =/!XUUQIT!OI,$U[MX(O)K[P]'-.
MY=R>IKYGM_\ CX3ZU]'_  [_ .17B^M '6T444 %%%% !1110 4444 %%%%
M!1110!RGB'_D.VE=-;_ZD5S/B'_D.VE=-;_ZD4 2T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRVMGXFN9;QR$8\5M:9JNB37L:02YD/08% '9 Y&:6D4@KQ2T %%%% !1110
M4444 %%%% !1110 AZ5Y9JG_ "5:W_W/ZBO4STKRS5/^2K6_^Y_44 >H0_ZE
M?I4E1P_ZE?I4E !1110 4C?=/TI:1ONGZ4 ?//Q*_P"0G_P.N%KNOB5_R$_^
M!UPM !1110 4444 %%%% !1110 4444 %=7\/_\ D8/P%<I75_#_ /Y&#\!0
M!](6O_'K%_NBIJAM?^/6+_=%34 %%%% !1110 4444 %%%% !1110 R3[AKE
MM#_Y&6\^E=3)]PURVA_\C+>?2@#K**** "BBB@ HHHH **** "BBB@ HHHH
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M\?\ /_OFJM6M1_X_Y_\ ?-5:\26Y]_#X4%%%%(H**** "BBB@ HHHH ****
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M73^-'AVH_P#'_/\ [YJK5K4?^/\ G_WS56O$EN??P^%!1112*"BBB@ HHHH
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MMKP$F-1(?XL<US[>#+@R[EU!@N?N_P"178T4 9&GZ#;VB+YBK*X_B(K6 "C
M& *6B@ HHHH **** "BBB@ HHHH **** .*^(7_'K:?]=!_.MOPU_P @T?05
MB?$+_CUM/^N@_G6WX:_Y!H^@H VJ*** "BBB@ KS_P"*'_(NW'T_I7H%>?\
MQ0_Y%VX^G]* /GZBBB@ HHHH **** "BBB@ HHHH **** );?_CX3ZU](?#O
M_D5XOK7S?;_\?"?6OI#X>?\ (KQ?6@#K**** "BBB@ JEJG_ !YO]#5VJ6J?
M\>;_ $-*6Q=/XT>':C_Q_P _^^:JU:U'_C_G_P!\U5KQ);GW\/A04444B@HH
MHH **** "BBB@ HHHH *]%^'W_'PW^[7G5>B_#[_ (^&_P!VM\-_$1YV:_[M
M(]#HHHKUCXP**** "FR?ZIOI3J;)_JF^E 'A_P 0O^0VO^[7'UV'Q"_Y#:_[
MM<A7T-#^&CQ*WQL2EHHK4S"DI:2@ I:** "DHI>*!"4M%% Q*Z+PC_R%HO\
M?%<]70^$?^0M%_OBLZOP,NG\2/?D_P!6OT%.IJ?ZM?H*=7SI[@4444 %%%%
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MKF^M>OE_P,\S&_&AE)12UWG$%%)10,***6@04444# TE%+0 4J??%-IR??%
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MC!^ KE*ZOX?_ /(P?@* /I"U_P"/6+_=%35#:_\ 'K%_NBIJ "BBB@ HHHH
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MUN*?PL]STO\ X\D_W15VJ6E_\>2?[HJ[7MQV/S^K\;"BBBF0%%%% '->.?\
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M?I0!\J_\([KO_0,F_*C_ (1W7?\ H&3?E7U5Y$?I1Y$?I0!\J_\ ".Z[_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH\Z3UH^L/L'MV>Y_\)!I?_/TE'_"0:7_ ,_25X9YS^M'GOZT?6'V#V[/<_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH Q/%_P#R*U]_USKQ3X3_ /(VS?\
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M?P?TKM?#T2K\.8L#_EDW_H- &'\-?&5WJ+/:7> ZN5Z^AKUJOGSX:<>))O\
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MU#2-9DN)X"JF4MG\:]:HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&CZ"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L+Q/K9T73Q.I&XMCFMVO-O'<SS77V9B=@<']: .RL-6WVL<MR0OF+E
M<5935K1[@P+)^\':O-_%\US#'H\%M,8]Z <?C6+JL>I:/:I>&\9G+ $B@#VB
MXO8+5-\K8&,TEK?07D0DA;<IKPSQ-XFU S::JR/M91N'K6GX.UJ_;Q#-&[.L
M C.$/;K0!ZS<:S96L@CEDPQZ5,=0MUMQ.7_=GH:\,\0ZS<@W124R,"<,/X:L
M+J]_)X$LV^T-YC/@M^5 'M$>J6LKA%DRQZ5<)"@D]!7G_@O1KTQI<W%SYG<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@""\_X\YO]TUY[H7_(W1_4_P Z]"O/^/.;_=->>Z%_R-T?U/\
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MXSD&I:XZ'1+V&19(M0+QY^Z#771 B% QR0.30 ^BBB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% &#XAZ)5O0?^08E5/$/1*MZ#_R#$H
MTZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!POCAT\L"7.P..GUK%U&_L4U+27C) 0#->@:MHT6J1;'P.<Y-8Q\%1,
M5+2 E>GM0!MV>LVMX^R-LM6CP16)IN@?8)O,\W=Q6V1\N* .)OM-T/4->G67
M=]I4;F_6H+7Q5I&E.\-N6VJ<-Q6/K!U&R\7W5Q#9RR1LN 0..]7='C1]*O)I
M]+'FYR PY- '=:7J5OJ=HEQ ?E;I5^N2\)P3\3LC11L.(^PKK: "BBB@ HHH
MH R=>T*VUVU6"Y!*J<C%9%MX'L+5PT:L,5UM% &2-#@"J.>*IZEX2LM0G29U
M;<HP,5T5% &5I6AVVEG=""&(P<UJT44 <5\0O^/6T_ZZ#^=;?AK_ )!H^@K$
M^(7_ !ZVG_70?SK;\-?\@T?04 ;5%%% !1110 4444 %%%% !1110 4AZ&EI
M#T- '(:1_P AN[_WZZ\=!7(:1_R&[O\ WZZ\=!0 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC$RL,G/6M(6LNG>(K-4U R*5!* ]>E 'I$:"- HZ"G4R)B\8)&":?0 4444
M%%%% ",H=2IZ&L]M&M&;)3]*T:* *T=C#$N%'%/%M&(S'CY34U% %2#3H+>1
MG11ENO%6Z** (+S_ (\YO]TUY[H7_(W1_4_SKT*\_P"/.;_=->>Z%_R-T?U/
M\Z /2:*** "BBB@ HHHH **** "BBB@ HHHH P?$/1*MZ#_R#$JIXAZ)5O0?
M^08E &G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH **** "D/0TM(>AH Y#2/^0W=_P"_77CH*Y#2/^0W=_[]=>.@H 6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!CF-!
MEMH^M5I;ZVAD5&*Y/3I7,?$*:YBTN%K9V1A(,E?J*XR8WVIVPNUNI$,0P1GK
M0![)&RN@9<8/I6;KL-G)ILIO?]5CYL55\*22OHL'FDLV.IJ'Q:DW]G2/&K.
M/N#O0!Y_+/X6T^XWQB4<\5T>D7&B:IJMO.F_ST&$S6/<3V\VEVL?]FH9]PW<
M<BK<5M+#X@LU@M2B%020.G2@#TT<#BEJ.$$1 -UJ2@ HHHH **** "BBB@ H
MHHH **** (+S_CSF_P!TUY[H7_(W1_4_SKT*\_X\YO\ =->>Z%_R-T?U/\Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5BPEUF&Z1+E@4/7%<UXT\4:A;S111VSJJR#YAWYKK?#NJ3:G:H\]KY;  9-
M'0J<J#2T44 %%%% !1110 4444 %%%% !1110!!>?\><W^Z:\]T+_D;H_J?Y
MUZ%>?\><W^Z:\]T+_D;H_J?YT >DT444 %%%% !1110 4444 %%%% !1110!
M@^(>B5;T'_D&)53Q#T2K>@_\@Q* -.BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_D&CZ"L3XA?\>MI_UT'\ZV_#7_(-'T% &U1110 4444 %%%% !1110 4444
M%(>AI:0]#0!R&D?\AN[_ -^NO'05Q^D?\AN\_P!^NP'04 +1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45QO,+>6<-VJ6J>J2
MF'3Y9%Z@4 >9>))]:DOWM_-4QYP!4FC:#XFM8R;66,(YR:LV=FE_?7%Q-<8.
MPD _0UM^";Y6M[E9)<[9"!GZT ='I4=W'8QK>$&8?>(JZ1FA65QE3D4M &!K
MOAZ/5!%\@)5PWZUK6EHEK"J*,8 %9&I^)4LYFAB DD4\KZ5!8^)KBZNTA:VV
MAN] '3T4BG(S2T %%%% !1110 4444 %%%% !1110!!>?\><W^Z:\]T+_D;H
M_J?YUZ%>_P#'G-_NFO/="_Y&Z/ZG^= 'I-%%% !1110 4444 %%%% !1110
M4444 8/B'HE6]!_Y!B54\0]$JWH/_(,2@#3HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=?I.HIJEDMPF,'TH OT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5'Q-KCKJ,MO%IB3LAY.*R]"UR6;7X(GTE(5)Y<#I0!ZXI!7(Z4M,C(* BGT
M%%%% !1110 5BZOXCM-*RLN=V,\5LNNY"N<9%<!XQT;9;271F+$=C0!V]C=+
M>V<=PGW7&14&K:M!I-F]Q-G:O8=:B\.?\@&U_P!VN=\5,TFI"!O]65Y]* +M
MCXTL[J8*5<!SA<BNI5@RAAT(S7GNOVT5M;Z284527&2HZ\UWEF2;:,G^Z* "
M\_X\YO\ =->>Z%_R-T?U/\ZT?$WB+5K)9([;3FE0\9%<[X*O+B]\0QRW,)B?
M/W3]: /6J*** "BBB@ HHI"< GTH 6BN(OOB#:V=W) S)E&P:K?\+,L_[\=
M'H%%>?\ _"S+/^]'1_PLRS_OQT >@45Y_P#\+,L_[\='_"S+/^_'0!T7B'HE
M6]"_Y!B5Y_JOC^TN@N'3BI],^(EI;6:QEDXH ],HKS__ (699_WTH_X699_W
MXZ /0**\_P#^%F6?]^.C_A9EG_?CH ] HKS_ /X699_WXZU]"\8V^M7?D1LI
M.,\4 =311VHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM]#0!\M>*_\ D8[W_KJ:Q<5M>*_^1BO?^NIK%H 3%+BBB@ Q1BBB@ HQ110
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M ^@I] !1110 4444 %%%% !1110 4444 %%%-D!,; =Q0 &1!U=1^-)YL?\
M?7\ZYZ[TJXEF+++(![&J_P#8MU_SVD_.@#J?-C_OK^='FQ_WU_.N6.C76/\
M72?G60JW;79A\R3AL=: /0/-C_OK^='FQ_WU_.N6&C76/]=)^=']C77_ #VD
M_.@#JA(AZ.I_&G5SEEI=Q#<!FE<CW-="@P@% #J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "FO\ =-.H/(H \L\1>$;[5M?FGCGB5#R Q'^-2VOA;Q#9
MJ!!?0*/K_P#7KJ=5\+F]NFN$NI$)_A4FL_\ L>^3]T))2O3.: -72GNK"V0:
MA<1RR=#M-;ZL&4,.]<G9>$V6X^T27<I)_A+'%=7&FR-4]!B@!U%%% !1110
M4444 %%%% !1110!Q7Q"_P"/6T_ZZ#^=;?AK_D&CZ"L3XA?\>MI_UT'\ZV_#
M7_(-'T% &U1110 4444 %<!\4/\ D7;CZ?TKOZX#XH?\B[<?3^E 'S[1110
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M%_R%V_WZZX_=/TKD8O\ D+M_OT =<.@I:0=!2T %%%% !1110 4444 %%%%
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M*+:1<,14<DKGOZG*@^HI::G^K7Z"G5XIZH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 07G_'G-_NFO/="_Y&Z/ZG^=>A7G_'G-_NFO/="_Y&Z/ZG
M^= 'I-%%% !1110 4U_]6WT-.IK_ .K;Z&@#Y;\5_P#(Q7O_ %U-8E;7BO\
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M_O4 245'YT?]ZE\Z/^]0 ^BH_.C_ +U'G1_WJ )**C\Z/^]1YT?]Z@"S;_\
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MFE>B44<J#VD^YX;XD\%K8:Y:6\47R2=<"NGL_AM:RVRN8DR:[ZZTV&ZN$FD
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M)I(%W'UKU"[@M[H@28./:I[6%((0D?W10!YW_P *IT__ )X)^E'_  JG3_\
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MI6I7FCZY%I=[*9&E.5(["O0:\U9O[<\:6=_:?/#%PS#\*]*H **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &R?<->.>(=4O(M5G5)B &X%>Q2?<->(^)?\ D+W'^]7/B'9&%?8J?VQ?
M_P#/<T?VQ?\ _/<U1HKENSFNR]_;%_\ \]S1_;%__P ]S5&E R<"B["[+O\
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MN[M)Q?)Y\8#3)\H7'%97BNW2*"%P )&^\ *F<=+DRCI<B\$J'\0P@C(KJ?\
MA'XXKV\NY0K;3N45R_@<X\1P&MJZ\22KK<EJ^T1L^W\*J#2CJ5"W+J8.H:F]
MYJ.S:40<;371:[?OIVD6+1$KN7G'XU0U[252[%W ,Q8Y-:.NZ3=:GH]B+=-V
MU>?UII/4+/4@MFBUG0F:1,RD_>-<-=1^5=2)_=.*[BWB&AZ$R7/R3 ]*X>ZD
M$MS)(.C'-9U-E<F>RN14445D9A71>$O^0BG^]7.UT7A/_D(I_O5</B*A\1[.
MOW1]*6D7[H^E+7HG<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,D^X:\1\2_\A>X_
MWJ]ND^X:\1\2_P#(7N/]ZN?$;(PK[(QJ***XSF"KFEPB?48%/0N,U3J]I,P@
MU&!FZ;QFFMQK<]"O+/[)<JD,@1-N=@KCI;N.UU"0O"=V[@UUEY#<W^K1W=L-
MT 0 G-8>H6]M?7 BS^^4XP/6NB:[&TO(U()1=Z9YT@WK_<JGH+0?:;H;EBYX
M!-7=*L;C3"/M:;;;'4UQ5ZY?5YA QP[\8.*4G:S$W:S.IN+2.;5<L0ZX^]VK
MG-6:>68IY;[(S@''%;43K9Z8(IF(N,]ZV)(#)I#.\:X*9SBAKF06N><C[P^M
M>CV.FB^TV%<8!3FO/)@JSX7IFO0[?49+#1%:, DQ]ZFE:[N33M=W*NK*FB:8
M88H_G'_+052\(R%X+Z9N6'(/Y5H6UTGB'1OL\F#/UP*K>%[.2$:A;[>2<#]*
MO[2:V*^TK$$>NN-2,<N60\8JKXMLH[?[/-&H'FC)Q5Q/#5XNHF::,K&.<U2\
M67L=Q]GAC;/E#!J97Y7<3ORNYS-%%%8&04Y/O"FTY/O"F![)X+_Y $-=)7-^
M"_\ D7X:Z2O0A\*.Z'PH****LH**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#D_&_P#R"I?I7D/:O;O$>F2:E9/%&N217!_\()??\\37
M)6A)RT.:K!N6AQM%=E_P@E]_SQ-'_""7W_/$UE[*78S]G(XVIK>ZFM2QAD*[
MN#BNL_X02^_YXFC_ (02^_YXFCV<P]G(X^21Y6W.<FK-OJ5W:C$,S+]*Z?\
MX02^_P">)H_X02^_YXFG[.8^21RES>3W;[YY"[>IIUO>RVRL(V*[A@XKJ?\
MA!+[_GB?UH_X02^_YXFCV<Q<DCE[;4+BU;,<A49SQ275[/=G][(6 Z9KJ?\
MA!+[_GB:/^$$OO\ GB:/9S'R2.2M[F:UE$L#E''0BD>>62;S7<F3.<UUW_""
M7W_/$T?\()??\\32]G,7LY',/JE[)%Y;SL5]*F37=21 BW3A1T%=#_P@E]_S
MQ-'_  @E]_SQ-/DF/DF<O<:C=W8Q/,7^M5:[+_A!+[_GB:/^$$OO^>)I>SF+
MV<CC:*[+_A!+[_GB:/\ A!+[_GB:/92[![.1QM=%X2_Y"*?[U:'_  @E]_SQ
M-:NA>$KJQNUDDC( ;-5"G),J,))GH2_='TI:0< 4M=QUA1110 4444 %%%%
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MV<CL_!?_ " (:Z2LCP]82:=I<<$BX9>U:]=T%:*.N.B"BBBJ*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HI.]+0 444E "T444 %%%% !1
M110 44=Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gtinntqqusay000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /O!UX# 2(  A$! Q$!_\0
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M0UB>4F<>;S59[FU21HS<@,O44 =)_:4-']I0US]LT-TA>&;< <$BIOL_^V:
M-K^TH:/[2AK&^S_[9H^S_P"V: -G^TH:/[2AK%^S_P"V:1X/W$GSG[M '007
M4=P,H?UJ>N2\-EQ(07)&X]:ZV@ HHHH **** "BBB@ HHHH **** (+K_4-]
M#7.V/27_ 'C7177^H;Z&N;LG4"7)_B- %NBF[U]:-Z^M(!U.C_U@J/>OK2B1
M5;.: . U)L>)&R0!O'6MWQ-J\EG9+%:R@2F,$$'CI5?6O"T>J7!G6Y:-B<\5
M&OA)9+1H9;QV)Z,3TI@<5=R7\D7FW<JONZ8J33+C5+6PDN[6=4C1NG>NI3P)
M"N0UXS ]B:$\"Q(=HO'V'JN>* *$NS5M-$LY!F"Y))K6\"SB/2Y%.<B3C]:?
M<^#XI;=(DNV3;UP>M:VAZ/!I%L8!)NR<Y- &#IT1U+6[]).0OW:RXH38^.+=
M&Z8[?A6U9Q2Z?KMS($)25L9K0DT"&37(M2,OS*OW: //=2#SZY<NA "-GFJS
MSW.I7ZVZ-M0C!W5W5WX+@N+YKD7)7<V2!3[KP9:R1_NY]CXZK0!'X1ND\NZ@
M4'?"O)[5CZGJ6M2ZMY5K.%C]#78:3HT&E0.JR;F<8)JJWAR$WGVCSCGTH XG
M5+R_O+JR@FD!*N :W$#Z?KT3 C[HZ5H7/A*"243^>0R'<*J6]E-+X@0.#Y0&
M-QH [6)B\"/_ 'A3ZC0JD:H#P*=O7UI .HIN]?6CS%]: (;[_CSE_P!VH-'_
M .0&/K4MZZ_8Y>?X:AT?_D!CZTP+-M_%4]5K=U!;FI]Z^M #J*;O7UHWKZT@
M'CJ*XGQ9(\EX;=_]3NZ5V?F+ZUEZQI$&K0;&DV-G.X=:8'.7^D:9:6<,D"J)
M&7)P1UK%_M.>PP]NQ61N,UT</@Y0<R7TC = 34\GA*VE3:9L>] &*UUKEGIT
MEP]TAW#<,'_Z]4$U77ETV&^-P/+D8#^5=)%X058)8GO796Z GI5@^&(#I,-C
MYQVQMNS^5 &!KT4DXM9V.3L!-=AH3?\ %.*W^R?Y56N]"AN8HXS+C8N*T;*W
M2STW[*&R I /X4 <KH]M!J)O);U=ZQR$?K69%HUM?Z[<QVR8C5"5S^-;&G6L
MT#W-J5(2=R=WI6SI^C0V#.5DRS*5)H \TDA:QFDW$&56.S%=\EY<1^$+>8-B
M4YY_*JA\%P-J'VEKEF&[.TUT-S813:<MF&VJO0B@#SVSU/7GN&F>X!B5CQ_D
MTFF_:;_7+N21P?D)Y^AKKH/#,,4;IYQ.XYJI)X:6Q,D\,Q+,I&!0 GA*Y>(R
MP,<Y<_SKL2,5RGA2P>*.:2<%6#G&>_-=3YB^M #J*;YB^M&]?6D ZJ&K?ZA:
MN[U]:H:JZ^0O-,"D/^0)-]?\:U=/_P"0=%]*R1_R YOK_C6II[K_ &=%SVH
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M(G/X5RDNKZVZ3W,5P!'&Y'ZUWVFZ;#INGFV1]V5*DUE?\(M +2:#SSB1BQ-
M''W=S>WT-JTD@+,PS71V.^Q\06EL"-CH"0/PJ:Y\(PM:QJMP08?F&.]-TVTE
MEUF&YE! B&W)H [(_>I*0NN>M)YB^M #J*;YB^M&]?6D ZLC5ONFM7>OK63J
MS*00#3 TY?\ D'VGTJ11P*BF(&G6GTIZNNWK0 ^BF[U]:-Z^M(!U%-WKZT;U
M]: .!^(2R-<V)C/S*W'ZU@2:O+%,(;C<9@.N*]$U?18=5N+>5Y-ODG./6J-[
MX1M+R_\ M7F!3C&!3 X^'Q+J4DJHLN(T.,5"UQ?WGB4R6\H23;U:NM7P5;1W
M"R+.>#DBFWO@B&>^^TQW;1G&,+0!8\):Q<W2WB7;EV@X!'X56MF.H>,G#\H5
MZ5N:+HL&D12(LF\RCDFLF.UDLO%[7"(3$5QF@#!U"V:RUQ"O&9.*9J4:76KL
M]QRV.]=C=:%#=WL5TTN"K;L54U3PC#J%\;D7)CSV% '&W%I>:@,B11'#T!]*
MZSP=-&%^S8/FJI.>U2W?A&*>*-$NF3:,''>M'1=%ATF+"R;VQC<: .0U'5-9
MDN[@6TX58V(YK-OK_4+O38DGE!<N,G\J[<^&X=\[><?WIR:K3>$()+=4\\C:
M<T 9DZR:??Z5L(Q( 6Q7?AMZ[_6N(EL)I]6LL@F. XS7;ED7Y0>* "BDWKZT
M;U]: '4E)O7UHWKZT@,?5/\ D,VU:MU_JE^M9.IL#K%M@UJW; 0KGUI@2C[J
M_2EIH==J\]J/,7UH =13=Z^M&]?6D!A>+[B6#0;@Q$YQ6!I6BZ9<Z';WEPJF
MX89))'6NTO;>&^M'MY",-WKECX+ FRE_(L8.0H)Q3 P[_4M236(;&QG$<;#H
M:2;Q5J.GRO;2REF'&5Z5+K.@33>([6.)F$>W!D';I6_'X.M?+/F3;W(ZGK0!
MR+:]J,MNT4LNZ-CDBGV]UJMH$DAN%$3GIGG%=/#X,MT1E,Y.340\$1>;N^V/
MM!R%S0!DZH;6Y@\VY&ZY X.:ZCPY#+;Z1+,[ IY9*@=JR[WP3'<W"RB[<!1C
M:#71:;8+86$EOYI<,A49H Y2RB.L)+/,02KE03]:R[F. W>-. 2:!LR$GK6P
MNE3),VGJ62.5BQD';_.:FM/!<=M<^;]J9LGG/>@#F-3U9+RZ6>5'+(NW)%=^
M+QE\,1R0':PC)%0WOA>SNQP53CL*T3I\7]F+9A\*%VYH X'3M5UUK>2]>X!C
M1B*99"YO+B>21P=WK76V_A>&'3I+03DAVSFJT_AI+2!GBF)8#.!WH ?X;N&@
MNUL<_*W.*ZXC!Q7+>&K1LB[G&R13@ UTQD4G.: '4E)O7UHWKZT .K'N?^0C
M!_OUK;U]:R+A@=1@P?XZ -6[_P"0B/I4E17C :B,GM3MZ^M #Z2DWKZT;U]:
M '4R?_CW?Z4N]?6FNRO&RYZT >4:A(UGXKENNQ&*HF:235(IR>0V17?7_A*W
MO;DRM.034,W@Z!(Q*DQ+1C@>M '/2ZMK4^J-'#<JL8&<'_\ 73I?%6HW4R6<
M,I5_NDGIFEM_#4]_KS&21X8\=0:Z2X\&VLJ+LFV.H^\.IH Y73Q?1>(9EEF0
MRA.6SQWK1T"YU>^U9L7"^2CX8>OZU=7P.BN9/MS[R,$YYJSI'A9=+NO-6Z=L
MMDC- "^)YFFF-H#P#Q7*ZU9/:PJ\I!.W*XKK_$UJY"W$ +.S#(%07/AI-6C@
M>6=DVKR* .+MTN9M.5YF'D?PBN@\"SR_:'C4_)OP:V)_",$FG):K<%0IZBM#
M0-#@T-&"R;RQSDT <[J]]JTOB6ZM+.8*D:[@#^-84FJ:E=VTZW$NYD.,UWK:
M'$=7GO\ S3NE7:1^?^-9_P#PA\'DS)YY_>G.?2@#!$4FGZ%97BD>9)( 2/J*
M]%M7WVD+'J4%</-IDVR'2QN:*!PP?UY_^M7<P;([>),_=4"@"6BF>8OK2^8O
MK2 =2K]ZF;U]:577=UH R+;_ )#4U:5Q_P ?D?TK,M2#K4V*TKE@+R/)[4P)
MSUHIN]<]:-Z^M #J2DWKZT;U]:0&7XAOUT[3V+''F*17F>@ZD+;Q CE6"[B<
MD>]>D:]I":TD*-,4$;9X[U2N?"5G+%M1PC8QN YI@<BDE]/JUY<6<RICYCDU
M-;>)]3NH6M!-B8G 8]*V%\#QH<K>N,]<'K5O_A#K9;)H4GPY_C'6@#*74M8L
M(2+BX5S(,+M[4R Z]/&=UU&4)Z9_^O6U:^$HHHG62[:3(P-QZ4VP\)+:3[S?
M.PST)H X6Z$EKJL1SF0OR17?ZM>S1>$'FR1(,8/X55'@JW.H_:FN2V&W &MG
M7K-+O0WM8^OM0!SLFGVUQI$<TP'F.F02>]<T8IEB-E"P$A.0>U=7#H[ZK:K;
M2RM (!@$=ZLV_A""*WV&Y)?^\>M ''Z>[6VHVT<7WRX$A'>NP\5ZA>VMK_HL
MFU\"G:9X3M[&[:=IBYSD9K2U;28M37#2;: .'&J:Q!82"ZG#"9>,4RSM97T'
MS'8;MU=9/X8@FA2,S'Y1BLO4M'DT^Q\JV9I.>E '1^'[EKFS6-C_ *M<5KUF
MZ-;K:6,9)P[K\P]*T/,7UH =13=Z^M&]?6D I^Z:S--_Y&.3_=K1+KM/-9VF
M$'Q$Y']VF!;B_P"/B7_>JS52-@+F7)_BJSO7UH 6EIN]?6C>OK2 =2/_ *F3
M_</\J3>OK2,RLC+G[P(H \C!N8M2N+J(_NHI"6%5[FZDU"\-Q$<;SWKT2V\-
M6\(N 9-PF;)S5)O!=MYV]9\#T%,9R<*26VKVD8(!>KM[KFK1ZXUE%. BL/YU
MT<OA*&2YAG\\AH^E1W'@N&XNOM/VI@^<F@1JW\LMMX<DD9@9"@.161I^G?;=
M#%V0#(R$D_A6W=V8;1)+7>6.W JCH(DCMSI\BE452-WX4 8?AFW\W3+^-R-O
MF$'/UK-:SBFO3;:>0DR'+L3P176P^&HX+*YMTN&'G,3D=JS[3P6EK*7%VY8C
M!.: ,/5M/BMI(YXMOR+\X!ZFNRMKME\*Q2PY5BIQFLY_!D;W"NUZ[+W!-= ;
M"(::MDK851C- ' 6&I:])YUT]P#'&Y&/Q^M)IWVK4-2N)9'!W+WKK+;PS#!:
M2P"<D2-FJS>&4LXW>*<EL=!0 SPU,]K/]ESP[$FNQ(P<5RGAFT?YI[A2C(Y
M![\UU)D4G.: '44W>OK1YB^M(!U))_J)/]TTF]?6DD=?(DY_AH J^'/]<?\
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M\:[0KQ2*O% '&?V-K?\ SV7_ #^-+_8VM_\ /9/\_C7:;?:D*T <9_8VM_\
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M ,]E_+_Z]=HJTNWVH XK^Q=;_P">R?Y_&E_L;6_^>R?Y_&NSV\TNWVH XO\
ML;6_^>R?Y_&D_L;6_P#GNO\ G\:[0KQTI%6@#C?[&UO_ )[I_G\:/[&UO_GN
MO^?QKM-OM2;?:@#C/[&UO_GLO^?QI/[&UK_GLO\ G\:[3;[4NWVH XC^P]9+
M9\Y<C_/K3_[&UO\ Y[+^7_UZ[$#FG[?:@#B_[&UO_GLO^?QH_L;6_P#GLG^?
MQKLROM0%XZ4 <9_8VM_\]E_S^--.BZTW!F3_ #^-=MM]J81S0!QHT365&!,O
M^?QI?[&UK_GLO^?QKM-O'2C;0!Q7]BZW_P ]D_S^-']BZW_SV3_/XUV@7VI=
MOM0!Q7]C:W_SV7_/XU3U'2]6BC1I95*YYKOFQG%96OC_ $1: ,6UM&N= F1<
M;\XS^=00:+K'DJ$F4*.G^<UI:1_R")O][_&M^S'^C)QVH Y+^QM;_P">R?Y_
M&C^QM;_Y[K_G\:[1EXH"\=* .,_L76_^>R_Y_&C^Q=;_ .>R_P"?QKM-OM2;
M>>E '&?V-K?_ #V3_/XT?V-K?_/9?\_C7:;?:D*\=* .+&C:W_SV3_/XTO\
M8VM_\]D_S^-=DJ\4[;[4 <7_ &-K?_/9/\_C1_8VM_\ /9/\_C79[?:EV^U
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M^?QKLPM+M]J .(.A:QNWF5=PZ?YS3_[&UH_\ME_S^-=DPI0O'2@#C/[%UO\
MY[+_ )_&C^QM;_Y[)_G\:[3;[4@7F@#C/[&UO_GNG^?QI/[&UO\ Y[+_ )_&
MNTV^U(RT <7_ &'K!;<9EW#_ #ZT[^QM;_Y[I_G\:[-5XI=OM0!Q7]BZW_SV
M7_/XT?V+K?\ SV3_ #^-=IMYI=OM0!Q?]C:W_P ]E_S^-(=$UIN#,O\ G\:[
M">5((R\A 4=ZHV^L6D\IC6520:3:1<:<I*Z1SHT364&%F7'^?>E_L;6_^>R_
MY_&NSQD9 H*^U,@XS^Q=:_Y[+_G\:/[%UK_GLO\ G\:[3;[4;: .*_L;6_\
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MM)JZL3*/,K'FVGZ5//J.)AE=W/%=[;65I:?)'$0P[U/#9*CEM@!!]*NIL')
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M.U1C[U/R,4P$;J )*1NE&:0D8H 4=*6D!&*,B@!IZT^HR?FI^10 'I2+1D4
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M_CV]#09A+:R8!^Z:JA8?,"!\YJ[(JK:2 ?W30!S^A_\ 'V?]X_SKJ:Y;1/\
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MJ9.E ')M_P AN;ZUKQ?\?<?TK(;_ )#DWUK8B_X^X_I0!JXIH4;JD[4P?>H
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M&5CEO2@#;M=1-UH<+VH*Y]JT]!9S!(7/.:;I6E+INE)">2H/6K&D?=DX_BH
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M+4$M4E(: &9:C+5)1VH A&<T[+4J]:?0!'DXHRU//2@=* &9:FY.ZIJ8?O4
M)DU7N+C8NWN>*LR.L:%FX JC&&N)B2/D[&@ M+5QEYCN;.0:N\TY1@8IU $3
M9S61KY/V1:V6ZUD>(?\ CT6@#.TC_D$3?[W^-=!9Y^S)]*Y_2/\ D$S?[W^-
M=%9?\>R?2@"1B<4H)Q2MTIR]* &9-)DYJ6D[T ,RU(2<5+2'I0!$I.*=DTJ=
M*?0!'DT9-/[TM $>335)R:E-,3[QH ,M02:DI#0 S+49-/'2@CB@"HT0:?=Q
MFK R!BHA%B?=DU.[!$)]* (WDV+DFLXRR7TN(\JJGYL]Z?(YN7VK^E7H(5C0
M8 SWH K@);+POS5,KEL&GF$,^ZE(P10!A>*,_P!GK_OT0_\ 'M#_ +M+XI_X
M\%_WZ(?^/:'_ ': -:VS]G7%2,326G_'NM2-UH :"V*7+4\=*6@"($YI?FI1
M]ZGT 0L3BE7=3WZ4@X&: &LY49)K/DDENIAY9P@X(I]W<&1O*AY8'D59MH!$
MO/4]: "& 1<@8-2'.*EI#TH S=1MI+JT=$.#M->>Z;X6O8M<65F&-Q/3WKU)
M:7RT!R%&?I4RC=F%7#QJ24GT(($:*!4)Y%2Y:GFEJC<CR<4T$YJ;M3!UH 3)
MHRV*DI#0 SYJ,FGCI2T 0DG-<_XBSL;/I71'[U<]XD^XWTH F3_CSM*V4)VC
MZ5C1_P#'G:5N)]P?2@!C;LBAEWKM;I3VZBJU_?Q:?;--*P51WII-[ 9K>&-.
M:Y^T& >9G.:UXT$2A5X KG=/\965[=M#YJYS@5TRD, 1T-5-37Q )EJ1LXJ6
MHGD4<$\U #))O*C+'L*H1*]W-YQXB]#3W?[1* G(4\U>1$"[%XH 2/ &%[4_
M+4D<00GG.:EH B).*12<5(W2D3[M "9:D)-2TA% #/FHR<5)VI#0!"I.33\M
M0G4U)0!$<TOS4\T#I0 S)IF3N-34P?>- '*Z]_R&+:M%.B_6L_7O^0Q;UHQ_
MP_6@#77.U?I2'.:D3[B_2D/6@!,F@DU)10!$"U+DT]:6@"%B:<"<4K4Y>E #
M,FDR<U)TJC<W)SLBY)X- #KB[\I>.?I5:*VDF8RRG*-T%6;:T"_,W.?6K3
M8 H AAC6)<(,"EF+@#::F3I2X% $2EL<T[YJ?WI: (B6Q0":D;I2+0 W+4AS
M4M(>M #,M1DU)2'I0!$"<US&J9_M*W_WZZD?>KE]5_Y"4'^_0!I_\Q)?I6H"
M<"LO_F)+]*V%^Z* (LG?3LFC^.I* (_FH^:GGI0* &9--.<BIJ8WWA0 G-&6
MJ2DH CRV:7+4X=:=0!"Y.*4$XIS]*<.E #,M29.:EIO>@!N6K+UO3S?VCH"
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M*7'%- H ?FF.>*=BFN.* *>J?\@Z7_=K!TG_ )! ^M;VJ?\ (.E_W:P=)_Y
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M*9CYC0!RVO?\ABWK1C_A^M9VO?\ (8MZT$_A^M &VGW%^E(>M*@^1?I32.:
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M: ):0]:;O--+'- $M!Z4S<:3>: %'WJY;5O^0E!_OUTP8YKF=5_Y"5O_ +]
M&G_S$5^E;"_=%8__ #$A]*U0QP* #_EI4E0[COI^\T ./2@4S<:-QH DIC?>
M%&\TQF.10!-143.P7(%1QS,0Q<8 H L#K2U$LFX9%*7(&: %?I56\N4MH][N
M  .A-2^;O.*Y/Q;!/>QXMRQ(&, TI-I$5).,;HV(]234@(H) &[\U<C@2W'
M^8UY[X:232+CS;UF7(QR:[^TNH;T!XWSBIC*XZ7/*GSRC8T(B2@S2MTINXCM
M0S'%64.7[M.J)6.*=O- "GK3JC+&C<: 'GI34I-YI$8T <JW_(;F^M:\7_'W
M']*R&_Y#<WUK6B_X^X_I0!L]J8/O4A<TS<=U $](W2F[S2%CB@!XZ4M1AS2[
MS0 A^]4E0ECFG;S0 \]*1:3>:0,: )*8])O-(S&@"0=*"<4P.0*HWFJVMN2D
MLFTTFTMRHQE)VBBTV[=D,,4R4Y&[<,53$_F1[HCE6'6F1@NWE@DTQ--:,A:8
MW;LI.Q4_O<9K1T\1K& CJ?H:YWQ2;B"WC\A<<?,1Q5'PG=7;7"JP)3U)K)U;
M3Y3LA@W*@ZUSOZ;WIH<U$9G$VW'%:G$6:1NE-WG%(6.* &M_JG^E<M:?\C-)
M_NUU#,?+;Z5R]I_R,TG^[0!L:?\ Z^7ZUK'I61IY_?R_[U:NXT "]33ZA5CD
MT_>: '&@=*86-&XT 24S^.C>:9N.^@"1GV+FD1]ZY%,9PPVD]:8[M&@"#- %
M@=*JW-QA=J]:9/=[ $/WVZ"F01N_S.* &VUN7?S)N6SQ7)^+M6N[9C% 67!Z
M@5W.<8P*SM0T>#40/-&,'/2IDFUH95H2E&T6>965I>ZI*';=G/4BO3]#M9;6
MRC20Y(%2V>GPV4>Q$4^^*M@D'@5$*?*[G9]9J2H1I3Z$M,?M1O--9C6I@2#I
M2U'N-&\T /\ XJ6HMQS3MYH 5_NU%/\ \>LG^Z:<S';4<S'[+)_NF@#GM#_X
M^_\ @1_G755RNA_\?7_ C_.NJH **** "BBB@!",J1ZBN \3Z/<I?1W%L3QR
M<"O0*:R*WWE!^HH \_TG2KN&4ZB2?,D&#QS4]^FI2 S!VPO;%=R$0# 5<>F*
M/+0C!1?RH \STW0KJ_O)IY<@,AQN%5AH]_9"6P!8K,QY XKU58T7[J*/H*0Q
M1DY*+GUQ0!S^D:2++1HXI0"RBKVCJ D@ XW5>N1^Y./2J.D?=D_WJ -,@8I$
M Q3CTIJ=* ';132!FGTT]: %P*,#%+2=J (LA31M67G%!7=FH&9X5.!S0!#>
M;R52-L8/-6[:!8X^G-5H(FEE+OQ6@.E !@5'CYZEJ/\ C% #\"@@8I:0]* $
M %+@4"EH 8P&13L"FMU%/H 3 Q2 "G4T4 +@4UP,4^F/TH IZH/^)=+_ +M8
M.D?\@<?6M[5/^0=+_NU@Z1_R"!]: -[3ON&KC@;:IZ;]UJNO]V@ 4#%+M%"]
M*6@!F!FG8%%+0 T@8I% IQZ4U* '8%(0*=2&@ P*-HI:* (P!FGX%-'6GT )
M@4G&W/I2]JK7$^U"J_>(Q0!2N93/,%5L+T(K!O\ Q,EA<_9@IRK8XK;M+,?-
M)*2#G(K#U+PU%=7GVC+?,PK.ISV]T[,'['G_ 'VQT^F7RW]N) ,<5>(%4=+L
M$L;8(A)R.]7JN-[:G/5Y>=\FP@ I=HH%+3,QC ;JR/$ _P!%6M=OO5D>(?\
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M0_>IU #6SBFKFGMTI%H 7FFD'-/I#0 <T'.*6@]* (@#FN8U7_D)6_\ OUU
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MJA-=%G*("?<48GN!AAA3W%3V]LL("]<=S0!#:V;$[YCN/;VJ]MP,"GB@T -
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M#- #Z8WWA2\TQLY% &)XI_X\%_WQ1!_Q[0_[M)XI_P"/!?\ ?I8?^/:'_=H
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M6YQ0 B=Z?42YR:?S0 IH'2FG- S0 ^F?QTO-,YWT 2T&F\TG- #A2TP9I>:
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MU&X(,)(]*I:3]V3_ 'JSM)UD7>C1RSM\S"KNDRJ89'4\;J -25PB$^U9<FH
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MDCM(E</DY%3K&BG/K0!1%O+-.'9SL_NU=CMT3L*DR*7(H *8GWC3\BF*1N-
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M&*12* 'TAHW"FDB@!](>E&106&* &CK7+:M_R$H/]^NH!YKE]5_Y"5O_ +]
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M_.C^R=/_ .>C_G0!T7VVU_Y[I^='VZU_Y[I^=<[_ &3I_P#ST?\ .C^R-/\
M^>C_ )T ="+VUS_Q\)^=+]NM?^>Z?G7._P!D:?\ \]'_ #H_LG3_ /GH_P"=
M '1?;;7_ )[I^='VVU_Y[I^=<[_9-A_ST?\ .C^R=/\ ^>C_ )T =%]MM?\
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M/^=']DZ?_P ]'_.@#HOMMK_SW3\Z07EJ/^6Z?G7/?V3I_P#ST?\ .C^R=/\
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M^>Z?G7._V3I__/1_SH_LG3_^>C_G0!T7VVU_Y[I^=(+VU_Y[I^=<]_9.G_\
M/1_SH_LG3_\ GH_YT =%]NM?^>Z?G0;VU_Y[I^=<[_9.G_\ /1_SH_LG3_\
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M=']DZ?\ \]'_ #H Z'[;:_\ /PGYTOVVU_Y[I^=<[_9.G_\ /1_SH_LG3_\
MGH_YT =%]MM?^>Z?G2?;+7.?/3\ZY[^R;#_GH_YT?V3I_P#ST?\ .@!FLS12
MZO;^6X;Z5I;UC"F1@HSWJI;:1IPND<.Q<'C)K1U2QM9H%64D 'M0!<6]M=@_
M?IT]:#>6O_/=/SKG_P"R=/Q_K'_.D_LG3_\ GH_YT =%]MM?^>Z?G1]MM?\
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MUSO]DZ?_ ,]'_.C^R=/_ .>C_G0!T7VZU_Y[I^=-:\M<C]^GYUS_ /9.G_\
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MC_G1_9-A_P ]'_.@#HOMUK_SW3\Z3[;:Y_UZ?G7/?V3I_P#ST?\ .C^R=/\
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M?V3I_P#ST?\ .C^R=/\ ^>C_ )T =%]MM1_RW3\Z/MUK_P ]T_.N=_LG3_\
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MI^:JFE22KKSQER5"]*T3]TUF:;_R,;_[M %C:\MS)ESPU2^0?[U-B_X^)?\
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MU1KK,3_N4.&H [&[_P!0WT-<W8LH$N6'WC6Q#?1ZAIOG1'(93BN22PUAY9#
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M2_:0=IS27?A"=]2:ZAO2F[C _P#U5T/]FZ]_=6C^S=>_NK0!C1>#UBNX9_M
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MV;KW]U:/[-U[^ZM &SO7^\*RM6*D'!J+^S=>S]T50N[/589MUR!L YH Z6;
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MULMI>NL,%5IJ:1K<9)5%&>M &]O7CYAP*3<O]X5B_P!F:]_=%']FZ_\ W5H
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M0 4444 %%%% !7)^,K*.33Y)6 RJ\5UE9NL:?_:%F\.,[AB@#&\%ND>A0DD
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M:W[,$VR?2L#2/^03-_O?XUT5C_Q[)]* )&4XH"G%/?I2K]V@!FTTFTU+2=Z
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M4]*:G2@#DS_R&YOK6M'_ ,?4?TK);_D-S?6M>+_C[C^E &IBF8.ZI^U1C[U
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MU%,#]ED_W35A_NU%-_QZ2?[IH YS0_\ C[_X$?YUU5<MHG_'W_P(_P ZZF@
MHHHH **** "BBB@ HHHH **** (;G_5-]*H:1]V3_>J_<_ZIOI5#20-LG^]0
M!ID\4B'BE(&*10,4 .S2$\TN!2$#- "YHSQ1M%&T4 ,4_,:?FF*/F-/VB@ )
MHS2%12[10 9IG\=/P*9CYZ 'YH)XHP*0@8H 4&C-( *7 H :QY%.S3&'(I^!
MB@ R*0&EP,4@ H 7--<\4[:*:X&* *>J'_B72_[M8.D_\@<?6M[5!_Q+I?\
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M!FEVB@ S3$^\:?M%,0?,: 'YH)%&!2%10 H/%&: .*,"@!F?GI^:9CYZ?@4
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MK 8-(@&V@!V:3/-+M%(0* %S03Q0 ,4$#% #$ZFGYIB 9-/P* $)I0:0@4H
MH ,TS/S&GX%, ^8T <MKW_(8MZT(_P"'ZUGZ]_R&+>M!/X?K0!M(?D7Z4$\T
MJ ;%^E(0,T .S1FC HVB@!%-+FD %+M% #7I0?EI&%* ,4 +FD!YI=HI .:
M%S36/%.VBFL.* %4\4N::H&*=M% "9YI<TT@;J=@4 (Q&VD4TI Q2*!0 [-(
M3S2[132!F@!V:,T8%&T4 ,'6N7U7_D)6_P#OUU '-<OJO_(2M_\ ?H T_P#F
M)+]*UU/RUD?\Q)?I6N!\HH 9_P M*DS3,#?3\"@ SQ0#2$"@ 4 +FF,>13\"
MF,!N% #\T9HP,4;10 @/-+FD"BEVB@!K]*4'BD<<4H Q0 N:3/-+M%)@9H 7
M-(QXI<"D8#:: !3Q2YIJ 8IV!0 TFG9I"HI<"@ )XIJ]#2D#%-4#!H Y-O\
MD-S?6MB+_C[C^E9#?\AN;ZUKQ?\ 'W']* -?-,!^:GX%, &Z@!^:0GBEP*0@
M8H  >*7-(%&*7:* &$\T_-1D<U)@4 &:0&EP,4@% "YIKFG8%,<4 /!XHS2
M#%+@4 (",TN:0*,TNT4 -8TJGBD8#%*H&* %S29YI<"FX&Z@!V:1CQ2[12,!
MB@"-_P#5-]*Y:T_Y&>3_ ':ZEA^Z?Z5RUI_R,\G^[0!L:?\ Z^7_ 'JUB>*R
M=/'[^7ZUK8&* &(>33\TQ0,FGX% "$TN>*0J*4*,4 &:B9$9L, :EP*9CYZ
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M"U $M-?I3<M2,3B@"KJG_(.E_P!VL'2?^00/K6YJ9/\ 9\W^[6'I/_(''UH
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M<VFBK;[B&"D9_"N6FT"^\Z2U+2-'*Q);TKTFDQ0!AZ9I*Z;I20'YMH/6K&D
M!),#^*K]S_JC]*HZ1]V3_>H TR.*:G2G'I34Z4 .Q2'K2TAZT +BC'%%!Z4
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MZFGYH 0BE XH- - !BF?Q&GYIG\9H Y;7O\ D,6]:$?\/UK/U[_D,6]:,?\
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MTKEK3_D9I/\ =KJ7_P!4_P!*Y:T_Y&:3_=H V-._U\O^]6M63I_^OE_WJUJ
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M=BD?J*<.E !BFXYI]-'6@ V^](PXI]-?I0  <4NWWH7I2T ,QSUIVWWH[TM
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M@!BCDT_%-7J:?0 TBC'%*:!TH ,4S'SU)3/XZ '8I-OO3J* &A?>EV^] I:
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MI7+VG_(S2?[M=0W^J?Z5R]I_R,\G^[0!KZ?_ *^7_>K5W&LO3_\ 7R_[U:Q
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M ?LZU(V<T /'2EIH'%+S0 G\5.IG\5.Q0 C]*$Z4C]*%Z4 /IO\ %2XIO.:
M'TC=**1LXH %IU,6G<T !I:8V:7!H =VIB]:=@TP YH DI#1@U'(_EC)H <Q
M4+\QQ38E3&5(JE=3%P@7/)JU;1&./![T 2'[U<]XD^ZWTKH.=U<_XD^ZWTH
MFC_X\[2MR/[@^E8:?\>=I6X@.P?2@ ?J*<.E,;.13QF@!:0=:,&D'6@!U-?I
M2\TU^E #EZ4M- .*7% "=Z=3<'-+@T (W2D3I2MG:::@.V@"2FFEIISF@!PZ
M4'I1@TA!H :G4U)429R:DP:  T"D-'- #JC'WS2YSW%)SN- '+:]_P ABWK0
MC_A^M9^O?\ABWK03^'ZT ;:?<7Z4AZT)G8OTI"#F@"2BDP:,&@ %+30#2XH
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M0 C4+TI'!H4'% #Z;WI<&DQS0 ZD;I1@TASB@"-O]4_TKEK3_D9Y/]VNH?\
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MNW J*SMDM+=8P,8&*LJ5'2G&*2.J52<TN=W'U&?O4_<*C+?-5$DM(:3=06%
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MNM]* )H_^/.TK<3.P?2L./\ X\[2M6>8PVVX9X':@"9LY'%4-7U./3+%IY&
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M>M=M%+<JNTQ]*GLX)(QESDU;P*F$%!61IB,1*O+FD4$NIB[!DP *:-1.T[@
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M_6M>@"-<Y-/YIJ]33Z &\T<TIH'2@!.:;SOJ2F?QT +S1S3J#0 T9I>:!2T
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M%--S#D?O4_[ZH R_%)_XEZ_[XHA_X]H?]VHO$TT3V"A74G?V-/B(%K$3P-M
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M^^J8B8D;JY[Q'RC?2MG[3#G_ %J?]]"L+7YHW5@KJ3CL: +4?_'G:5J3$F+
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MJ'[5!_SU3_OH4W[3#N_UJ?\ ?5 %O(I"1BJ_VJ#_ )ZI_P!]"D^TP8_UJ?\
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MCO\ V9"G/E@<5W= &9!HMO!;+"H&!WQ1)HMO) T1 ^;OBM.B@#*L-"MK#.P
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M_P!J0;]IE4$^]7XU:1-RN,4 0?V%;_\ /U+_ -]&C^P[?_GZE_[Z-6?+8?\
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MM60M[&I_[,C]!0!4^PV'_/[+_P!]'_&C[#8?\_LO_?1_QJU_9B>@I?[,3T%
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MH K?V';_ //U+_WT:/[#M_\ GZE_[Z-6?*8?\M!39,1+N>55QZF@"#^PK?\
MY^I?^^C1_85O_P _4O\ WT:FCS,F]'!4]P::[".14:1=S=!F@"/^P[?_ )^I
M?^^C_C1_85O_ ,_4O_?1I9;B.%]CS(&]":;+=Q1,JM,GS?[5 "_V';_\_4O_
M 'T:/["M_P#GZE_[Z-3Q@R('20%3W!IWEM_ST% %;^PK?_GZE_[Z-+_85O\
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M_P"]0 O]AV__ #]2_P#?1H_L*W_Y^I?^^C31>1&7R_.3=G'WJMF-@N2XQZT
M5O["M_\ GZE_[Z-']AV__/U+_P!]&AKF-,[ID&/>B.YCDCWB= /]Z@ _L*W_
M .?J7_OHT?V';_\ /U+_ -]&DANXYG9%E3(]ZM>4_=Q0!6_L*W_Y^I?^^C1_
M85O_ ,_4O_?1JR4(4GS!@=>:KFXC'/G)CUW4 )_8=O\ \_4O_?1H_L*W_P"?
MJ7_OHU9$;LH8,,'I1Y,G]Z@"M_85O_S]R_\ ?1H_L*W_ .?J7_OHU9\F3^]1
MY,G]Z@"J="M\?\?4O_?1K2TC2;:TDWI*SMCO5<Q2;3\U5=+GG&N/"SY0+TH
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MJEHA:39%UV-0!9N_%]]<+&;9%; ^:HV\8WD%L-ZJ'/&*JZ_8M8,D=K&5XPQ
MZU-I'AR75K93*=K=<M0 UO$^H36$T;( )!P14VE:?/<Z8)#))G:3]X^E:]KX
M.>*WDCEE1B?NGTK9T_239V7D%U)P10!B^!2^VZ5W9L.1R<]Z77)GO;^6S5B/
M+Y&#6OH6CG27F+.K>8Q;BLK7('L]0:[0%O-.WC_/O0!QURMU"'DD9PR'Y?F-
M5UO[[48!""WR?,2&KM)O"=S>R13&X41L,E2:DN?!S>0%M)4BD_B.>HH 3P/=
M![.5&<E@V.35*^\0:D==N+2"(,L0S71:!H*Z/ RNRL['.15=/#KKJ]S>^8N)
ME( _.@#DI];O-3EW-\I3Y<*:T-/EEL)(YV9B9" 036C'X0DBBE E7>[$@YJG
M;6,TMZ+.3)\D@[NQH [I3F)#ZJ#2TBX$:#(^50*7(]10 50U7_4+5[(]15'5
M2/(7D4 4%_Y DWU_QK5T_P#Y!T7TK*'_ " YOK_C6KIQ']G1<CI0!9HI,CU%
M&1ZBD M%)D>HHR/44 0WA(M6->0$/)JU_F5^#_>->Q3J)82@(YKG+3PI%#/=
MR2E6,P^7VI@<OH>I7.G::UP"6C5NK'-7D\57MRDC1(IVC-3ZKHQTOP_-%]_+
M9PM/T#0"]DS'"^8O>@ L;C4M;TII)T*+G&5-/\"%QJ6H1.[-M..3GTKHM,TX
MV&FM:EP23G(J#0]&.E7UU<,ZD3'(Q0!F>))VFU#^SU8@$9R#S65XDL9+4Z41
M)(.>?F/O6MXEMVBOO[00%L<8%7K_ $TZU9:?(&"F,9(/XT <KK<-[=Q[+?<>
M.QK1\%7(_?PR.?,3@@FM&]T"[FCQ;7*QMZU-H7A_^RC(\KJ\DG)(H Q=9U[4
M8]>-C;1AE S61=Z]>ZA,L3C:T1P=IKL)?#[2:V=0$BX(QBL__A#W6:>7S4RY
MR.>E &1:2364JWC.V3Q@GBO0[=_,M(9/[RYK@UL)_M_]FR9;'._M7>0*([6*
M/(^5<4 244F1ZBC(]12 6BC(]129'J* ,O7O^/)/]\4V]_U=K_NBG:^1]A3G
M^,4V^_U5K_NBF!I6O_'JM2U#:D?95Y%2Y'J* %HI,CU%&1ZBD M8GBLE="N2
MI(.WL:VLCU%4=6L?[2T^6V5@"XQDTP/+='M[N>WC?+D=CN-=)/K]WI"+#*H#
M$<9IUOX-U*T"+'>J%4YP#5;Q+9O<:K:0;2QVX+8XH ENO$UXE@LX4<U'I_C"
M:?39Q<85\\5I7/A.6\TF*".5493SFC3/!2VBE;ATDR?6@#!\,7T<GB&:5IF)
M8=">*Z3Q'>.-1@M%)"R*#P:=9>$8K/5'ND*!#T%'B*S/]H0WBC(B7&!0!Q%T
M]W)J4ELC.5B.?O&GO+<7;J$=S&HPQ#'BNH?PQ+?HMY;2K$TA^8'KBII/!\HM
M6C@F1&/4Y[T 9/@>[F.LW4!8LB+QDU=\0Z]?VVM165K&&#C-;/A_P\-'9I)&
M5I'&"13;SP\USK,5\)% 0=* ./U37;Z\,5K(-C(W.TU=MFFM;J*Y9V^4=">*
MUY?"+27LEP9%^;D50>QG75([)R65A][M0!VUI-Y]I'+_ 'A4U0VL8@M4AR/E
M%2Y'J* %HI,CU%&1ZBD M9&K=#6MD>HK)U;&#S3 TI?^0?:?2I%^Z*CE_P"0
M?:?2I%(V]10 M%)D>HHR/44 (_W#7EGB;4;RS\39MLL<=,UZH<%2,CFN<F\,
M)<:W]NE963&-M &%I4</V&YN5G=IW7<ZD]#6+YEQ=)M#OMSV8UUR^%)XI9S%
M.JQRGIFG6_A1X5QYJ]<T <_J]K-:7.CGS)/F(S\Q]ZTO$=BDZ^:DTGG8^Z&.
M*V]4T)M0>Q99%'V;K[]:@U;P]=7K;[>X6/\ &@#F-'UF33X+B)'+N1C#'.*T
M?#'B:[O=9^PS* N,U./!4@C^69 Y^\<]:DT;PC-IFK?;9)D;C'!H 7Q%=22Z
MO90*2%+X.#]:SO%%B]G-O663&1_$:TO$-J\>K6,Z E5;)Q^-:>IZ:=<M@ZL%
MYSS0!SVLV<4NG6KS7$B.$^4!CS7-S-=QVBH7<0YX;<:['5_"U[J"6ZQW2J(A
MCDTT>$+A[(0/<*2/>@#+T,FRU"U2*5W$Q^;<:VO%.M7=A?20VJ!B*GT7PT^G
M3>9<R+(5.5]JL:KHC:A?/<B11N]: .0?Q!J$^E7*S)L8CC!J&T^T1>'+6Z+O
MN9P#EC[5TC^$W>!X_-7+5E7^FW%E80V&2^QQT_"@#N-/G,]C"3U"BK55;"(0
M6,(R,E!FK.1ZB@!:*3(]11D>HH QM5_Y#-K6K=?ZE?K63JA!UFUYK6NO]2OU
MH D'W5^E+2 C:O(Z49'J* %ILG^HE_W#_*ER/44C8:-UR/F!% 'C^I[IM49?
M-<'<< ,:N6]_J>A[7VDQR':I8UV$'A:-+_[1.5<;B<5G^.;8&TM8[9"/W@Q@
M=.: ,^7Q5J%C<QQ2QJ!(-W-(WB?4VEW+&/+)ZU--X7N38K?7,HD**,#OTJKI
M>@7FH7!Q+Y<8YVM0 FK,-5L7O$F<3(,!58XHM-?GLK&&* [YCPP8UMWGA"=U
M"6LZ1KCD9ZFE;P:?LL:I(@F7JV>M %3_ (2+4[&R9IXE#'D9J?2=8U269)9(
M0(I3P:LIX6N9+-HKJX61B>#GM3]-\/7MG./-NE:%3\JYZ4 .\473!ULU)'F+
MG@UA:E80)IT9GN9$<CY!N/)K=\46YR+U1N\M<8'6LF?PW?:U9V\HN @'(5NU
M %/3]+<:!+<WLDB!6X.X].:T?"&D&*[FG,DC1MRN6-:*^'[LZ$^GR7"L6/6M
MG3+(6%G'"2"RC!(H YC7]<OX-=2PM8PP9:QKG7K^\+02KL:/T-=?=:$T^OQZ
MB)%"J,8JB?"3FXGF,J_O.GM0!@VK36EF=39V+(<8)XKT*QF^T:=!,>KKDUQ$
MUA/&3H[$L7.=PZ5W%C$+?3X(21E%Q0!/129'J*,CU%(!:Q[G_D(P?[];&1ZB
ML>X_Y",'/\=,#4N_^0B/I3Q4=V1_:0^E29'J* %HHR/44F1ZBD M<1XNN9)-
M2L[4L4CD;:2IQZUVV1ZBL;6]#&JE'C95D3[K'L:8'/'0[/2Y6DBNYF;'0L?\
M:R])U>:R^VA&+%CQDUT-IX6OTF+W5VLBD8QFH3X*F#2E9D&\Y'- &7IOC"_:
M\:V,:D@9IL/BV^2[=9E ^;BM"R\#7%M>-<-<(21CK4<_@JX3S+EIU8+SB@"M
M+XGU*2\*Q1@H.<U8U"\FUC2I9MS*T*\[3BLVQT*^OM3*Q2^4OO7:+H"QZ7+:
MHRAY%PQ]30!#X,=F\.1,S$D G)/M63>7CRZD+HN0(&Z \5TVBZ:=+TQ;5G!(
M!&17.7-K]FUB.!T+QS-S@<4 <SK&J1W.IM<^>PW'H&XJOJ=S)<1I);RNRJOS
M'<:[?4O!5O=29@"(,U4N? TKA4MYD1,?,,]: -;PI/N\-HVXLZH3R?:N97Q/
MJKO<S)$ICA<C-=MI.EKINE_92REMI&1]*QX/"KQ6EW#YJ_OV)% '(SZI=Z@Z
MSDD%S@@&NBTB633[Z"W+,1+R<FG/X/EBL45)5#Q_,3ZXI-(MY+W4(YG!'D';
MSWQ0!VS=>*2@D9ZBC(]10 4J_>%-R,]13E(W#D4@,:W_ .0U-6E<?\?D?TK-
MM\?VU-S6E<8^V1_2F!,>M%!(SU%)D>HH 6BDR/44N1ZBD!D>(K-KNS5E+#RO
MFX-</%J,FHDZ<';<QQP>:],D"R0R1DCYQBN;T_PHMEJRWA9< DXI@<]!K6HP
MF2TC3<+<<DFG_P#"7ZA-ISLL:[@<5$NEWE[XAO5@<Q(6YSWK8'@R1;%HDF0,
MQSG- %.PU=]9@>&Y<HRKQM-88CEL=;6))9#GG!8UU-CX/GM%D)G0LPX.:6S\
M(7$=Z+FYN%D8=#F@#BIWN;?5HG+O\TG3<:]"U34)8O"C7'208_E6?_PADSZB
M+B6=&C#9"YK9\0V"S^'WMHL T <Y/IT=SI:7,D\BR.N0 QY-9.F*C-]CN;B1
M"3V8UO0:=<:M9I:Q/Y30+@EN]20>#I4BS),C3]GS0!@V"-9:PJM*^QGPN6/-
M=5XFU>XTZWW6ZAFQWJM8^$KB*\$US.L@5LJ,]*U=8T8ZDN%=1]: .1'B/4?L
M$PGC"^8O!S52T2XET/S2[[MW]XUU-QX6>>&./S5^48ZUEZGID^E:?Y2MO&>B
MT =5H5V;FQ1#UC7%:=9FAVWV:PC<D R+DBM+(]10 M%)D>HHR,=12 #]TUF:
M;_R,;_[M:9(VGD5F:;_R,;_[M,"W%_Q\2_[U6:K1$?:)>?XJL9'J* %KD/&U
MY+'9K$I*J7 R#BNNR/45F:UI$>K6OE94,#G)H Y=-"LK-;:\^V3>85#8+''\
MZIZGXJN[6YVP@,@/4UKQ^%-0\Q?.O%:->BY[57O? T]S=&1;A F>F: (+OQ9
M?3F"*V169UYHO_$>J6-C&K0@2%L$5=E\&7'R-!.B.@ZYJ6;PK=7-M&D]PK2*
MV2V: ,R/Q/J-HT:W$:KY@R*AF\67L-XQ"C8_RYK=U'PK)?&$B51Y:XK/E\#W
M,C<W"8!R.: ,[4[>*1!)]HD%RXW*@8\TZVUW48M.^PHFZ5%.[)YJ]+X*U"2>
M.4WB?)TYJU+X1N6BS%<*LY^\V>M &#HC7-Y!.)6<,6/1C6QX.#Q^([B)W9@%
M[G/K5_1O#,VFHXFF5V8YSFK^EZ,=/U>:]9U(D&,"@"AXHO'74XK%"0LHYP:Y
M/4+*^,NR/>4C.2=QZ5UOBFT9[^._3D1#H*I_V'?ZE;)<P7(B#]5/I0!0MX[6
M\T">Z>X</%\N :N^#]*,4SWAD=D=>,DXK03PQY6ER6:NH,G)/O6QIMF+#3X[
M;()48R* .6\0Z[?6VL16=J@8.*QM2UR^NS':R#8R-S@UUUYX?:YUB*^$B@(.
ME4YO";RWDEQYB_-R* ,F$RVUQ'=L[?*.A/%=Y9S&XLHYCU85Q,MG/'J4=@^6
M#C[P' KMK2(6]G'#D?** )Z23_42?[IHR/44DA'D2<C[IH I^'/]<?\ >/\
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MM5./;_ZU2Q66K0QA$ME 'I_^JNVYI.: .-^SZS_SP_6C[/K/_/O^M=GS2<T
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MX?K75K>0.VT3(2/>IQD]#0!QOV?6?^>'ZT?9]9_YX?K79\TTYQ0!QWV?6?\
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M <9Y&LY_U _.C[/K/_/#]:['G?3N: .,^SZS_P ^X_.C[/K/_/#]:[(YHYH
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MC[/K/_/O^M=ES00: .,:#6-A_<#\ZCT)9UUU_/7:^WI7:-GRVKF+3_D9I/\
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M*Y,<.\PR'+<FN_HH RK33H].TU8$'"@]11I'W9/]ZK]S_JC]*H:1]V3_ 'J
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M>KE]6_Y"5O\ [] &G_S$E^E;"_=%8_\ S$E^E:AE"[1ZT +_ !U)4>?GI^:
M ]*!02* : %IC?>%.S36^\* 'T4E&:  4M-%+F@!KTX=*:].!XH 6D[T9I,\
MT .IK=*7-(QXH $Z4ZF*>*=F@!#UIU--+F@ /2FI3CTIJF@#DV_Y#<WUK7B_
MX^X_I60W_(;F^M:\7_'W']* -CM3!C=3LTP?>H DI#THS2'I0 HZ4M(#Q1F@
M!AZU)49/-/S0 M-%+VI!0 ZF/3LTUS0 X=!2T@/%&:  =:6F]Z7- "-0O2D:
ME4\4 .I.]+3?XJ '4AZ49I">* (W_P!4_P!*Y:T_Y&>3_=KJ6_U3_2N6M/\
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M -8<&D0?+3FZ4U.E #L4A%.I#UH ,4$<4M(>E #$[T_%,3J:DH :12@4&B@
MQ3,?.:DJ/^,T <MKW_(8MZT$Z+]:S]>_Y#%O6C'_  _6@#90?(OTI".::[[(
M0?:DC;>H- $V*,5#<W*6L#2.0 !WKC)O'ENNHFW49^8#(-)NQ$ZD8?$=P!2X
MJ"TG%Q L@[@&K%,L8_6E XI'ZTY>E !BD YIU-'6@!=M-8<4^FM0 *.*7%(O
M2G4 -(YI<4A^]3J &L.*113FZ4BT +BD(YIU-/6@!<4$<4HH/2@",#FN7U7_
M )"4'^_74CK7+:K_ ,A*W_WZ -/_ )B0^E7G1BR$"J(_Y"*_2M*298@N[O0
M['SU)BHDD5SN!XJ0.#P#0!$5?SL_PU*!Q2F@4 &*8P^85)3&^\* '8HQ2T4
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MQ0.E+0 S'-.Q1WI: &N/EJ&;_CTD_P!TU,_W:BG_ ./63_=- '.:'_Q]_P#
MC_.NJKE=#_X^_P#@1_G754 %%%% !1110 U_]6WT->9:LHN==B$A. U>G$9!
M'K7%>*/#<]W<I/:R%"OI0!G^'&,7C"XB4_(%X'YUU^MM#'I\D[@94=Q7.Z9X
M;NK>(7)E/GL,%N]79M(O+C3IH))F8OT)H PM&TPWMS-?!?ED0XQ]#6?%::EI
M0N+AX5\I6)R:[O2=(>ST5;;?\X4C/X5RD_AS5&N'@DNG>.5B?:@#=L]7DN=$
MBDA +-U%:>A.[PR%QSFF:=I*:=I20, 2HZU/I  20#^]0!HECBD1CBI".*:@
MXH -S4A)J3 IIZT )N-&XT[ H(XH C4G<:=N-"_>-/Q0!&6:E#-3B*,4 -W&
MF9.^I<4S^.@!=QH).*=B@]* & FEW&G"EQ0!$S'(IV6H;&13L4 ,RU )I^*0
M4 )N--8G%28I'Z4 4=4)_LZ;_=K"TC_D#CZUO:H/^)=+_NU@Z3_R"!]: -S3
MR=C5<8MBJNG?<:KC_=H 12V*7<:5>E.Q0!'ELTN32]Z=0!&6.*12:D(XIJT
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MEA_X]H?]VCQ3_P >"_[XH@_X]H?]V@#7M2?LXJO>(-P)%6K3_4+3Y$5CR,T
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M #MS4TELT]2&%!H 3<U!)Q3L4'I0!$A.33\FHHI-S$8Z&K&* (RS9I=QIQ%
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M[44__'K)_NF@#G-#_P"/H_[Q_G755RNA_P#'V?\ >/\ .NJH **** "BBB@
MI" >H!I:* $P,=!1@>E+10 4FT9S@?E2T4 0W/\ JC]*HZ1]V3_>J]<_ZIOI
M5#2>$D_WJ -0]*1.E5/M>Z=HP.G>K2#CK0 ^FGK2X]Z:1S0 ^D/2DQ[T$>]
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MK0 ZHV^\*?CWIC#YA0!A^*O^/!?]^B'_ (]H?]VCQ3_R#U_WZ(?^/:'_ ':
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M[&8YSDU9Q[T !H%(1[T >] #JC_C-/Q[U'CYS0!R^O?\ABWK1C_A^M9VO?\
M(8MZT$_A^M &N90BJ#Z52O+*.X&\DYSVJ\$#(N?2@KQB@##E$]LO[KENV:L6
M.J9PDQQ)W%.N+=S<+R<4W^SP6+=#ZT :R,&7(IU9%N\EH_ELQD![^E:<<BR#
MAAF@!STY>E,8<TJD=,T /IHZTN*;@YZT /IK=*7!IK#B@!4Z4ZF*..M.Q[T
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MIBM&P_T*0QXPO0"NFM6C**C%"2-JD/2F[_:@MQTKF&"=*?4'F[1TJ0/D9Q0
M['-+3-_M1O\ :@!QZ4Q/O&EW^U,5N30!-2&F[_:@M[4 .'2EIF_VHW>U "?Q
MU)4.[Y^E/W^U #CTH%-+<=*-WM0 ^F-]X4;_ &IK-\PH Q/%7_'@O^^*(?\
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M!TI:8&XZ4N[VH !UIU1AN>E+O]J %?I0GW::S>U*K<=* 'TW^*C=[4F[GI0
M^D;I3=_M07XZ4 ,;_5-]*Y:T_P"1GD_W:ZAF_=-QVKE[3_D9I/\ =H V-/\
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M&Z4 1,/W3?2N6M/^1GD_W:ZIO]4U<K:?\C/)_NT ;&GC]_+_ +U:V.*R=/\
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MK7B_X^X_I0!K<TT9S4E,_BH 7FD.<4^D/2@!HSBEYI1TI: (CG-/YII^]4E
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MK"C_ ./.TK<0G8/I0 /U%/%1L3D4[)]* '4T=:,GTI >: 'TQ^E+D^E(QXH
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M$EDAB* =:A-O*BX7MTJ_D^E12RLI "YS0!2\^XC7YCS4QO0BKOSS4%X&5_,
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M"#^-&]0<;A^=><Z3XDN;:XEBN%;Y4)RQJJ/$=[>-+>JCK' Q! /!H ]+N?\
M4GZ51TC[LG^]532]72_TB.>0A2PZ59T=E9)"#D;J -4]*:G2E)&*1",4 *R*
M_44@4+P!3LBD.,T .'2D[49%!(Q0 U?O&GU&I&XT_(]:  TM(2*,B@ 90W6H
M7B5OEQUJ;(IF?GH \J\2:%="^>;'R;LBIM$UG[%!]F<GKTKTB[LXKJ%D91DC
M&:X]_!P%[O$G%83C).\3; 8?#1E*=5FTCN\,4J'KS5EKR9%SFI;?3PELD>_[
MHQ4JV2CJV:W1E*UW8S;W6_LQARWWCS5V/4UD4,#D5P_B.UNQ>#8KE=W%=+X8
MAD^P@7"'.>]91J7ERV.RIA%"BJO-N;#:A&NW.>:7^T81)LYS4S6\;#H.*JS:
M>K_,&P:U.(7^U8/,V<YSBK/GHQV@\UCQZ:P=F).1TH\N?S]V&Q0!H:I_R#I?
M]VL'2/\ D#CZUM7^?[+ESUV5BZ3_ ,@<?6@#>TW[IJZ_W:I::?D-7'(Q0 Y>
ME+35QCK2Y% "=Z=321FER*  ]*:E.)&*:AH ?2&C(I": '4=J3(HR* &+UJ2
MHP1FGY%  >E& 102,4 C% $,D 89 YKS7Q##=?VJP(.S<,<>]>H9%4YK*WFD
MW/&I.>XK.I!S5D=>$Q*H3YFKF;H%JS6@:<?, ,5J/8Q$DXY-6(U2-<* ![4/
MRN,U<596.>I/GFY%(6B1MN'05"B/Y[E",'I4\ENS1, YYJHMC+'\WF,?:F07
M($G7[Y%4O$'_ !YKFI%EN VTHV/6H=<)-BF>M %'2/\ D$3?[W^-=%8_\>R?
M2N=TC_D$3?[W^-=#8G_1D^E %A^E*OW::Q&*52,4 .IO>ER*3(SUH =2'I1D
M4A(Q0 B=*?3$(Q3LB@ /6EIN1FER*  ]*8G4T_(Q3$(W&@!&A5FW5%\YROY5
M9R*0[: *P01)O8<U79/M4<BL."*T" RX-(J*F<8YH X:?PDEQ?;MGRUU,&E)
M#;(BC!48J^ OF9P*DR*E02=T;5*]2HE&3V,Z6VF6'"8W9J*XEN853:>@YK3E
M7>F <57D@'EG)SQ5&)1CU"9CC-7XY78KN[U2%N4&]1D^E.CGF\P Q$#/6@"K
MXJ_X\%_WZ(/^/:'_ ':3Q.<Z<A/]^EA_X]H?]V@#9M/^/=:D?J*CM#_HZU(V
M,B@!PZ4M(",49% #1]ZGTP8W4[(]: $?I0G2D<\4*>* 'TW^*ER*0XS0 ZD/
M2C(]:0D8ZT "TZF*:=D>M  :6FDBER* %[4P=:=D8I@(S0!)2&C(I"10 [M2
M8&<T C%&1ZT ,_BKGO$GW6^E=#D;JY[Q']UOI0!-'_QYVE;J?<'TK"C_ ./.
MTK<0C8/I0 /U%/%,8\BG B@!::.M+D4@(S0 ZFOTI<BFN1B@!R]*6FJ1BER*
M $[TZFY&:7(H &Z4U.E*Q&.M(A&* 'TAHR*0D>M #J0]*,B@D8H 8G4U)4:'
MDT_(]:  T#I2$BE!&* %J/\ B-/R/6F9&\T <MKW_(8MZT8_X?K6=KW_ "&+
M>M%/X?K0!M)]Q?I2'K2H1L7Z4A(S0 ^BDR*,B@!%IU-!%+D>M #7ZTY?NTQ^
MM.4C% #J0=:,BD!&: '4UJ7(]::Q% "ITIU-4C%+D>M  >M+3<C-+D>M  W2
MD6AB,4BD4 /IK $\TN12$B@"*XC+IM%5&M"F-@Z]:T<B@XH I01/$^!TK!U7
M_D)6_P#OUU QFN7U7_D)6_\ OT :?_,27Z5L+]T5C_\ ,27Z5KJ1M% "?QT^
MH\_/3\B@ - H)%("* '4QOO"G9%,8_,* )**3(HR*  4M-!&:7(H :_2G#I3
M7/%.!&.M "TG>C(I,C/6@!U,E7<A%.R*1B-M $%O$8SGM5FF(1MIV10!#+YF
M?EJL;TQR!)#UJ\Q%4+JT%PX(.V@"PDJ2DU,F .*SFMGA0!6)([U+:&3HP/7O
M0!S[?\AN;ZUKQ?\ 'W']*R&_Y#<WUK7B_P"/N/Z4 ;':F#[U.R,4P$;J )*1
MNE&102,4  Z4M(",49% ##]ZI*C)&ZGY% "TU:7(I 10 ZF/3LBFN10 X=*6
MD!&*,B@!!UIU-!&:7(H 1J%Z4C$4JD8H =4#PJ7W]ZFR*3(S0!C3I+%-N'0&
MKT%R7B#,:LLB,.0*IS6QW?*<#T% %C>'B?'I7,6G_(SR?[M=#&"L+@^E<]:?
M\C/)_NT ;&G_ .OE^M:]9&G_ .OE_P!ZM;(]: &KU-/IBD9-.R/6@ - Z4$C
MUH!% "TS^.G9%,R-] $E%)D>M&10 "EI 11D>M #3]X4\=*C)&ZG@B@!3TIH
MZTI(QUIH(SUH ?3&[4[(IK'I0 X=*6D!&*,B@!.].IN1FER* $?[M13?\>LG
M^Z:E<C;44W_'K)_NF@#G=$_X^_\ @1_G74URVA_\??\ P(_SKJ: "BBB@ HH
MHH :_,;#V->9:S(+'7(FE4X+9X%>GUD:KH$&J$,V%8=\4 <5H=PH\4W%X0?*
M9>/UIWB*\CFUNUN%5MD?7BNPMO#T%O;+$"-P_BQ22^'8)8'C;&6_BQTH \\F
ME&HZC/Y*G 4GI3-,O8X= U"U96\QF..*]$TWPS;V#%N')&#D5!-X2MI+H3*P
M5<Y*@=: ,G0+%Y= AR,8'>MS1F2"*168#GUK4BLXX+7R4 50".*YR;1E\UBM
MZRY.< T =$;B+^\/SH%Q$/XA^=<S_8P_Z"#?G1_8W_40;\Z .G^TQ?WA^='V
MF+^\/SKF/[&_ZB#?G1_8O_40;\Z .G^TQ?WA^='VF+^\/SKF/[&'_00;\Z/[
M&'_00;\Z .E%Q'G[P_.G?:(O[P_.N8_L8?\ 00;\Z/[&_P"H@WYT =/]IB_O
M#\Z!<1?WA^=<Q_8W_40;\Z/[&_ZB#?G0!T_VF+^\/SIOVB/=]X?G7-?V-_U$
M&_.C^Q>?^0@WYT =/]IB_O#\Z0W$7]X?G7,_V-_U$&_.C^QO^H@WYT =/]HB
MQ]X?G2_:8O[P_.N7_L;_ *B#?G1_8W_40;\Z -^=;6<J7(./>IHY8(UPK#'U
MKFO[&'_00;\Z/[&_ZB#?G0.[M8Z?[3%_>'YT@N8O[P_.N9_L8?\ 00;\Z/[&
M'_00;\Z!'3_:8O[P_.D:YCQ]X?G7,_V-_P!1!OSH_L8?]!!OSH V]2N(VL)0
M&'W?6L?23_Q)Q]:C.B*W#7[$'WK:LM-B@T[R%DW#^]0 ZQGC56!8?G5LW$6/
MO#\ZYI]%7SG(OV&3TS2?V,/^@@WYT =,+B+'WA^=+]IB_O#\ZYC^QA_T$&_.
MC^QO^H@WYT =-]HB_O#\Z7[3%_>'YUS']C#_ *"#?G1_8W_40;\Z .F-S%C[
MP_.D%Q%_>'YUS7]C?]1!OSH_L;_J(-^= '3_ &B+^\/SH-Q%_>'YUS']C?\
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M;0HOMD<KWA<J> :T]5TY)[=5$_EX/44 :"W,6P?,.GK2?:(\_>'YUS0T8?\
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M2@#T?R01Q@TOD#TK-\,WC7FBI(Y^8FMB@"'R!Z4GD"IZ*0&5JQ>UM4DB.&+
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M: .L$:,<*0<>AI?('J/SKA_#FH7$":K)([.8N0"?I5G2];O];MR1 R)S\PH
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M%SCD"K%-D_U$G^Z:8%?P[<S.Y1FXW5U5<EX<_P!<?]X_SKK: "BBB@ HHHH
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MN]/OX;_>OE1+\P'6K_AR RZM<7;<+(.,U>EM+^:,HT#$'UI(;*^@7:ENP^E
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M9J6FGK0 WYJ/FIXH/2@"(;MU.PU*OWC3Z (_FHPU/-% #/FIGS;NM3U'_'0
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MNQ4M(>E $:[L4OS4J=*?0!%\V:7YJ?WI: (SNIJ;B34U1I]XT 'S4$-4E(:
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M: (CNH7<13VZ4)TH ;AJ3YLU+3>] #?FI#NQ4E#=* (&W>6WTKF+3_D9I/\
M=KJ7_P!4WTKEK3_D9Y/]V@#6L<^=+]:+J2[65MC?+VXIVG_Z^7ZUJE%/.T4
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M6S1C,/&*O;>:7;FD!EPW9N"4Y!7@YK1BPJXR*KW%H"=R<'VJHLCI)M;(7UH
MU\T&F1D,@YIQ% "YHS1MHQQ0 P'FGYI@'-/Q0 $\4#I2%: .* %S3#]ZGXJ,
MCYJ ),T$T8I"* !32YI *7% #6^]61XA_P"/1:UF'S5D>(!_HBT 9^D?\@F;
M_>_QK?M6VVB'VK TC_D$3?[W^-=#9#_1D^E #TD\Q":F4\4UE&.*#A(RQ/09
MH =FD[UP^N^.5TR_$";2,=373:/J::I:)*",L,G%:2IRBN9@:>:">*,4A'%9
M@(AXIV::@XIV* #/-&:0CFEQ0 9IB'YC3R*8@^8T /S2&EQ2$4 **,T 48H
M8/OU)48'ST_%  3Q0#2$<4 4 +FF-]X4_%,8?,* ,/Q3_P >"_[XHA_X]H?]
MVD\4C_B7K_OT0_\ 'M#_ +M &U:'_1UJ1CR*AMB%MP2:?N5S\K9Q0!*#Q2YI
MH''6EQ0 G\5+FFX^:G8H 1SQ0O2D<<4(.* 'TWO2XIN/FH =FD)XI<4A'% "
M+3\TQ13L4 !HS2$4N* #--!YIV.*8!S0 _-!HQ2$<4 +FC-(!Q2XH 8?O5SW
MB3[C?2N@/WJY_P 2?=;Z4 31_P#'G:5I73;;7(ZXK-C_ ./.TK6D@\V+&>U
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M_P"/1:UV^]61XA_X]%H SM(_Y!$W^]_C70V7_'JOTKGM(_Y!$W^]_C716/\
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MTZF]Z '8I&'%+2-TH :M/Q3$I] "$48%!I: $QQ30.:=31UH ?BD-+2'I0
M<4N*0=*6@"/^*N>\2?<;Z5T7\5<[XD^ZWTH FC_X\[2MQ!\@^E8<?_'G:5NI
M]P?2@!KCD4\4UNHIPZ4 5KI'*_*:;9Y";6/-6SR*@6+$NX4 3,BNI5AP:RI[
M1K:7S8^(_2M:FR ,N#0!!:W*2KCH1ZU9P*QIK5XI1*A. <UI6L_G1 GK0!-W
MIV*3O2T -8<4B?=I6Z4B?=H ?BD(I:0T %!'%':@]* &)C)J3%,3J:?0 A%
MZ4&B@ Q3/XS4E1_QF@#EM>_Y#%O6A'_#]:S]>_Y#%O6C'_#]: -I/N+]*0]:
M5/N+]*0]: '8HQ2T4 -44[%-6G4 1OUIZCBFOUIPZ4 &*H3VVR3S(QACUK0I
MF <YH KV\^?D;K5AL8JE<P-'F2/EAVI;:]2;]V3^\7J* +J=*=BFJ<"G9H :
M1\U+B@]:6@!K#BD44X]*:M #\4TXS3J:>M "XH(XI:0]* &#K7+ZK_R$K?\
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MZ]_R&+>M!.B_6J&O?\ABWK0C_A^M &R@.Q?I2$'=3D^XOTI#UH 7!HP:=10
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M,HPP5]>]6RHJC<V^U@Z\8Y.* +I<4U&Y-5H6$XW9JS&!0 _?2%_:G8!II H
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M_D,6]:"#[OUH VE;Y%^E-+#-.1?D7Z4A S0 [?1OI=M&T4 -#>U+OH %+M%
M#&;FE#<4,*4#B@ W4F[FG8%-P,T +OIK-[4_:*:RB@!A.8R*P]1O(-/_ 'A
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MQA\PH H2H(9=ZC!]:M02%ER3FBY@\U<537?:G:.0?6@#2#4NZHX274$U+M%
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M-SME.5S2TQ%*J!2\UJ<(W_EI4E1<[Z?S0 IZ4HIISB@9H =3&ZBG<U&V=PH
MQ/%/_(/7_?HA_P"/:'_=H\4_\@]?]^DA_P"/:'_=H VK3_CW6I&ZBHK3/D+4
MC9S0 \=*6FC.*7F@!H^]3Z9SNI>: !^E,*!T(8<4YLXH7.* ,QU:UF+#E3P
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M8SF@!3TH%(6&* PH =3&^\*=N%,8C<* ,/Q3_P >"_[]$/\ Q[0_[M'BDC[
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MK_R$H/\ ?KHXXU1N":YS5?\ D)0?[] &G_S$E^E;"_=%8_\ S$5^E:P8;10
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MU:QZ5DZ>?W\OUK5W#% "+U-/J-&&33]P]:  T#I2%A0&% #J9_'3BPIFX;Z
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M4^D/2@!B+Q3MM"=*=0 PKS1LIW>EH ;MIB#YC4M,3[QH 7;44T2E<D9J>D-
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M>U5@<=36>+&6!L*/E/)-4DDM#IG.4W>3-./"H.13P!FLD7#JY5^%6IXK]99
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MTR"N+UE?!0U,LP<CC%/V1RKFD\E588H Q?%)_P")>O\ OT0_\>T/^[2^*?\
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MR=/_ -?+_O5K&@!BGDT_--3J:?0 TF@'BE- Z4 &:9_&:DJ,??H ?FDS3J*
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M[*ZV_O8[*W:1SC R*XZ'QNOVO=*P\@'!- &A_P ([?\ _/\ -2?\([J'_/\
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MH_X1W4/^?YJZVB@#DO\ A';_ /Y_FIDWA[41"Q6^;-=A6+KFM)IL+*&'FD9
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MQ(NGX6)AOS@YH I6OA_4FB):^?.>]3?\([J'_/\ -4FA^*H;UQ!.P$S'@5U
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M3QJ$O-^X?9NF:Z[3M2@U&!7B;/&30!S_ /PCNH?\_P U'_".W_\ S_-76T4
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M-P ;U]M=?>W<=G TCG''%<<GC0"\_>,/)!()H N_\([?_P#/\U'_  CNH?\
M/\U='8WL-];K+"<JPR*M4 <E_P ([J'_ #_-2_\ ".W_ /S_ #5UE5[NZCL[
M=II#A5ZT <?+H.IB4 7SXS5L>'=0P/\ 3FJG'XKDEU%UR/)4\?2NNL=0@OH@
M\39H YW_ (1W4/\ G^:C_A';_P#Y_FKK:* .2_X1W4/^?YJJW6@:FI^2]?\
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MUK;\HQVO0!;\/&YA\2-''(SVX'!'2O24SL&:R-%T.#3(5V#YAZUL,P523T%
M QVJ3Z#-<5JOBHIJ4<,:G9G#,.U=@)HYE*@@Y%<!KWAV:&\$D*_Z.YS(: *.
ML/&UVUY$XG9C@H*KQR.VJVCVL1B /S!>]%E;0+JICL]S-WW>E=_8>'K2'RY]
MI\S&3]: -2S9GME+@AO>IV8*,DX HX JO++%*IB+=>.M '(^)_%$D#?9K6,N
MZMR5]*QI+*37(?M2L1(@_&NO/AJU2::Z4$R,A'-<YH,[:?J4EE.,>;(=HH Q
M;FVFM(H3'.3/O&X#KUKTW1FD:QC\S.=HZU2_X1>R;4&NR#N:MQ$6- HZ 8H
M=6-KFM+I<#';N;&0*UPP)QGFN;\5:3)>0-/ ,RJ.* .+U;67UJ-1+"80IW M
MWJLTZW-HSI;^5.G"GN:6[GA:VBM+H$7"-R .]=;X>T..]A%Q=KAEX7'I0!K>
M%9)VTN$3[MV.2:T=5U!=.LGG89V]JE4PVB+&" !P*H>(+ ZEI<L<?+,.* ./
MN_%4FH*Z/;LD;#"L>AK&A>.*"2U>#?YC;O-_NU)+(+5#97XP(Q\F!WK>\+:2
MFI:=)]I7Y=W'TH E\&/<BZDB8-Y*CY3VKNJJ66GPV,02(< 58DE6)<L<4 0W
MMTMI;M(V.!FN!O/%S7LC0FV/DYP7[5VU_;)J5L4!SD=JX?6--31]%G61< G.
M?SH STTAF:2Y\[RT<9%:WA<W,6I)&KL\.>2.E5M%9];MH[=>8T'Z5W6E:/;Z
M9#LB'7GF@#1'2DD<1KN-#.J#+'%1%HKJ,J#D&@#B=1\3F>\DM5!15."U<].\
M-OJJRA1<1XY K3U;P[-!>R3;?W+'+'VK-TVUAFUV.WL\M;D<Y]: +.@O/'JI
MD@5@DC\J.U>IK]Q<^E96F:);6&9$7YFZYK5X% ".XC0LQP!7#>)/%<D,C06T
M9<?WEKL9GBN8Y(2W48/-84_A>V2W8QJ2_7F@#EKS2Y-1BM[A&(8C+X[53DAG
ML[@>1.7D'9>M=!X<N_\ 2[RSN/NYVK^E;]OX8LH;S[4 2WO0!I:87;38#)G<
M4YS5ND "( .@I RG@&@#$U_7ETE%&S>[C@5P.IZM)J8W20F-B>AKK_%NCR78
MCNH1EH?FKB+R[2:W"R#_ $W/( XH E,HF: PP^4\?<?Q5Z3X?DFETM&F#!_>
MLC1- @FMX9YE^8#(KI1+%"?+R!B@"EK.K+IELSD9;&0/6O.M5UU]>M_+EA,"
M YWMT-=SXETQM0LVDB&9%7Y:\[GD6.Q6QOQMF4Y.!0 X7"SVK+]GV21C"-ZU
MW7@V2Y;2XA.&SZFLSPWHJ:A%YETO"?<QZ5VUO;QVT0CC& * ):HZGJ":?;&5
M\>U6I)DC^\<5EZQIR:O:*@YPV>* .-O/$\FI.UD]LRK(<!C6>FBM;2-OGVP@
M?+GIFM'7[=-)DA,@P%'I3M+CD\1;8G&;0<J1UH L^#'NEDE1V9TW\&N^JCIN
MF0:=#LB'7K5QY%C&6.* &7$XMX&D;H*XB?Q/]JU">V;]W'M.&/2NQN$BOK9X
MLY!X.*\[U+0'MKZ4SJ1:@?*1UH SU:&TNFB*"X21LENPK6\*O<+KTVP,+?'R
MJ.E4-&LH[J]$$ )@+8<FO1].TBWT\9B'.* -!?NCZ4V618HV=C@ 9IS,%&3T
MJK,8;Q&AW=1@\T <3K7BV7[9LMXV:(<,R]!6?<:3+>1)?1N09#EL5TEYX7@M
MM(N4MU)=SGFJOAJY#E],FZHN"* ,&&*6UUNW%O.77'(7UKTZS+-:H7SN[YK)
ML?#-G9W'GH#NSGFMS@"@!:YGQ%XE&E*%2/S&)Q@5TJL&Z&N(\7:-.62YM5R0
MVYL^E '+ZEJ;W]R+V2$K(HP(CU-#RF1K5[:$Q2%AOV]:9=7,-U.K(#]L4;5&
M.*[O0_#\#6D5S,O[YADT ;6E.[V2F0'.!UJ]2*H10HZ"EH **** "BBB@ HH
MHH **** "LW79Y+?2II(P2P'&*TJBGA6XA:-Q\IZT >3I-?3R?:$O'#CDQ ]
M*ZC3_$C7.DS>9 7>/Y=IZM5'5O#%]9WDESIB#,G!SZ5H>&/#]S C/>KARV:
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MMS:;>_S5AZ#X=OFN/-OU *G(Q7=QPI']T8H (HEAC"*  !@4]CA3]*6@\C%
M'G7B'4]1MM4BEA24Q(?F Z5T^D:_%J%D"<"7!)3O6G-I\$T;HRY#=>*YJV\,
MRV.M27%NN(B,"@"6".'5+E_/L0-K8!85T=M:0VD02) H'I3H8%C4<<]ZFH X
M+QA?W2WT5O&[1(XY<=!638:M=Z+.))9GN(6^4$]*[K7M#BU6W8%<R8P*X63P
MSK4CI9%!]EC8%?6@#HOM<6JW,*/9!U<?>/:NEL].M[-1Y42H?:H=+TU;.W12
MOS "M*@ KC_&U]<6UK&(2R[GP2*["L[5M+BU.V,<@S@<?6@#SNVO+S2KB.?[
M4]Q#C<W/ KIAKSZA H2W++)QD5ST_AK68F>SB0?9Y"<YKM=!T<6&G11R+\ZC
MF@!FE>'+6R/G>6I=CNSCIFMT  8%+VHH Y[Q9=S6NERM"&! ZBN(M[B]MHXK
MQ;MY2YRT8_AKT^^LH[ZV:"495NM>?7OAO5K.Z<6*#R7..?2@#<7Q ;S36=("
MY'! J_I.DV[*+MX%#OS@CI4/AK0FT^R99U^9FR:Z15"+@=!0   # JIJ4KQ6
M4KH"6"DC%7*;(@DC9&Z$8- 'DHN+Z\9[@7;I*K$"+N:Z32?$TQB,#Q,TD8YS
MWJ+6_"]U#>_;-,3YQTS4WAK0+R*YDGOE 9^>* -RPC35H3//;A7!Q\U;$<8C
M0(HP!1'&L2[5&!3Z &N<+FO-=1U?4K/6&98Y6A#\^F*]+(R,&J5SID%Q#(C*
M/G&#Q0!1T_78;^Q#K@OTV#K6?8P0:K?3":P5/+;AB.M,TWPS+INK!X1_H_4Y
MKJHH4C)(&">M #8;>.VBVQ(% ["O.==O+NYU!HO/>WPV%]Z]-KE_$?AM=0VS
MPK^^CY7ZT 8NAZW<:?=BQN6:08SYC5I0/%J]VZS6 VJW#$=:QM/\/:O/J :^
M0;/:O0+6S2WA50.0* "TLH+.,+%&JCVJS110!Q7C&^N(PT2,T:Y^^*P;*_O-
M)FA=IWN$E.3_ +-=[KFCQ:M9F)UR>M<,WAW6DN1 $'V<G'X4 =$-6;6+C[/]
MG)B(^_VK5TO0;:P9I!&NYSFG:)I2Z=9+&5^85K4 %<MXNO+BWA"1;E5ARP[5
MU-4M3T^/4+22%QG<,4 >8VM]>Z;&EZ+E[A6.-N:ZR37#>P11I!YF]?FQVKGK
MKPSJ]I+]GLT'V8'C-=AX>T3[!;DRK\[#)H FTK2;>,"X,*AS6T!@8%( %&!2
MT 9NM3R06+-&"3@]*\UCGO9'FNEO')C8_N\]:]8FB6:-D8<$8K@-7\+WUI<-
M)I:#:QRV: +=GXIE;38E\EGG)PR]Q6_96<-TR7+VX20<\]:Q?#/A^>&?[7>J
M/,8<UV*H$&!0 ZHKABD+,.HJ6D90RX- 'FL^M:CI^OR2/'*\#$ >@KL5UF&Z
MTMIHL2,!RH]:M7NDV]W T;KV..*PM%\.SZ9,ZJ/W3,2<T 26%E;:E-YDMBJ-
MUR171>6MO!B) ,#H*DCB6/[HQ3^M 'EFIW-W>:S/";IX%3E>>M:.@^()[246
M5T&=F/!;TK3\1^%S=M]HM%_?9R:Q]+\/ZK<:K%<WZ#$?RC'I0!MVZ0:KJ4B2
MV*@+SO(ZUTMK:Q6L>R) H]!1!;)"/E'-3T (>E<%XLO+DZFMJLK0QLO+]A7?
M5A^(-!CU:U<;<R$<4 <58:O=Z).#+*]Q&YPI/2M^>X.O2K:-;_NY!RYZ"N?/
MAS6I9XK:1!]GB8;?I7H6FZ>EG HQ\P H 33-(M]-B58T4$#DBM&BB@#C?&5]
M<P+#'$60.<%AVKGK;4;O1IUG:X>X@')/:O0-8TJ+4[8HXRP'RUP%SX:UD(UA
M&@^S,<GUH Z.YUAKV"W"6Q=9N#CM6UINC6UH%D6)=_7-,T;25L[&%)%^=1S6
MQVH *QO$MU-::2\D*L6'I6S45Q;I<PF-QD&@#RJ*:]67[4EX[X.YHP>E=/:>
M*))]/WK 6?.-M9>H^&-2L[F5M.0;9C\V:V_#&@2VD :[7]YF@#7L;&!T6Y\A
M4=_F-:M(JA1@4M %:_=DLI2F=P7C%><P:]J%CJ_FSQR&#I\W2O370.I4]#69
MJ.AVU]9F!EXZ\"@!AU:*ZTQI8@)3LR4%4-)L;744%Q+8K&Q/0BD\/Z%/IDDZ
MN/W;'Y?I72QQK&N%&!0!!<C[-82>4GW5X KS&[N+V_U5E%V\+#G97J[*&4J>
MAKB_$'AB5KEK[3E_T@\4 0:)XDD$,T%PA9T^5=W\5:%G;P:K=9GL%4]=S"LC
M0O#>H/=B:_0 HV1BN_2%(SE10 D%O';H$C0*!Z5(W"GZ4M% 'G7B>\NI-1B@
M69X QQFF:7K-QI-XUO/(TT2CB0]#73>(O#R:FGG(N9D'RUR=OX<UF>=8+I!Y
M*D'B@#<7/B"3]];[5' )KI=/TV#3X%CB11CN*?96BVUO&@&"J@5:H *X3QA?
M7*/Y2.T2[L!Z[NL;7M$BU>UV.N2#D?6@#B+#4KO2+N%7F>XC?DL>@KH[C4?[
M2PJVVY"?O5SH\.ZU]I\AD'D$X_"N\TG3%LK".%ARM "Z=I5O:1ADB4,W/%:5
M'044 <]XKNYK;393%N''WAVK@[>ZOK:.*\2[>8N1NC'85ZGJ%E'?VCP2#*L.
M:\^O/#>JV%RPL$'DM\O/I0!NV_B5KP(D<!<8 8CUK<L+& '[2(521^OK69X8
MT Z;:MYR_.YW&ND  &!0 M4M3E>*SD* [MIQBKM,DC608:@#S32/$-_8W[)>
M1R>47)WOT S75ZGK*M:0O##YZR'!"]JL:QH%OJ-D\6SYF]*KZ%HLUC^ZF7]T
MH^6@"6PTFSG(N&M$1O3%;B(L:A5& .U*JA1@4M !1110 4444 %%%% !1110
M 4444 %%%% ", 1R*JF^@2=8=ZACVI]Y<+;V[LQQ\IKS)M89]>2;=\B,0:B<
MU$YJ]=4K+N>JT55L+E;JT253G-6JLZ$[JX4$9ZT44#$"J#D"EHHH **** "D
MV*.@I:* "BBB@ HHHH 0JI.2*6BB@ HHHH **** "BBB@ I"H;J,TM% "  =
M*6BB@ HHHH 0@$8- 4+T&*6B@ HHHH **** $"J.@Q2T44 %%%% !2!5!R!S
M2T4 %%%% !1110 4444 %%%% "%0>HI0,=*** "BBB@ I"H;J,TM% "  =!2
MT44 %%%%  1GK2!0.@Q2T4 %%%% !1110 @50>!2T44 %%%% !1110 4444
M%(44G)&:6B@ HHHH **** $*ANHS2XQTHHH **** "D(!&#2T4 (% Z#%+11
M0 4444 %(%5>@Q2T4 %%%,FD$49=N@H CGO+>V7,TJH/>H8-5LKEML5RC'T!
MKSZ\N+SQ)K,]E$V8XCT]JBO]%O?#:_;+;A$&3GUH ]3!R,BBN-TOQC UM MP
M_P"\;@UHW7B>UM]2CM&;YG7(H Z&BN*N/'=K%=^4'/!P:LW'C>PAMC/O.T=<
M4 =644G)%!( R:Y$^-;5;<2DMAQE:AL_&=O?2_9MY\QNE '6?;[8,5,RY':I
MTD61=R,"/:O'VU&Y;6+@!OE#\5Z/X<F9M*WR'G- &W32JGJ*Y#4?&]K;71A1
MSE#AJD;QO8IIYNV9M@XH ZS@#V%5WOK:-MK3*#Z&N/B\>6LQV%F_><+6%?:F
M6UW]ZQ\DCL: /4XY4E&48'Z422I$NYV"CU-<=_PD]CI5JOS'+CBH/^$PLM1M
MO(D+;S0!VT<T5QG8P;'I4@ 48 Q7!P>*+#2<C<V7Z5<T_P ;VMU?>06/3/-
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M4 '2BBB@ HHHH 0@$8(H"@=!2T4 %%%% !1110 4444 %%%% "!5!R!2T44
M%%%% !2;%)SBEHH **** "BBB@!"JGJ*6BB@ HHHH *0@'J,TM% "  # &*6
MBB@ HHHH **** "BBB@ I JCH,4M% !1110 4444 )L7.<<TM%% !1110 4F
MU2<XYI:* "BBB@ HHHH 0J#U&:  .E+10 4444 %%%% !1110 4F >M+10 @
M4#H,4M%% !1110 4FU<YQS2T4 %%%% !1110 FQ<YQS2T44 %%%% !2%5;J,
MTM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A>
M(K:>ZM=D18>XKSY]"E6[$.\[G/6O7'^XWTKD)_\ D8H/K6-6">IPXJC&34F:
M?ARTGLX%AE+$*.IK>I .*6M4K([(148V04444R@HHHH **** "BBB@ HHHH
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MT2'^9KT_P=Y7_".6NS'3M4,OA"R:SF@$?$AR:T]&TM=+M4@0851@4 :=%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "-]QOI7'SX_X2.#ZUV!&01ZUEOI$
M;7Z7.WYEJ))LQJP<K6-0=*6CI15FP4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'AC
MD^^@/UI]% " !1@# %+110 4444 %%%% %>2QM96W/ C'U(J6.-(EVHH4>@I
M]% !1110 4444 %%%% !2$!A@C(I:* *W]GVF_?Y";O7%6  HP!@4M% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS0,\8."XS0L\3-M#@GTKE;BYE^W, WR[JOV;)]N7GG%)2N0JMW8WZ1F"C+'
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M#=1 XW#/UJ5'5QE3Q0 ZBBB@ HHICR(GWF _&@!]%,61'^ZP/T-)+,D*[G8
M>YH DHJK'?V\K;5D7/\ O"K6<T %%%% !1110 45&\R1G#,!GU-(UQ&B;V8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(;3[;K$^9"%#=*L:K9C3YQ-$V,#H*H^;/;:K,83@!N:O%+K5KM<_ZK&""*E
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M_9CM.>:7Q!G[+QZ5H6MC!9)LA7:*;J%M]IMG7OCBJMI8OE?L^4RO"F/[.?\
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M8J>B@"N+&V4Y$*#\*4V<#')B4D>U3T4 1&VA*@&-<#VH^SP[@WEKD=#BI:*
M*[6-LS[C"A;UQ3_L\.X-Y:Y'0XJ6B@"(6\0)(C7)Z\41VT41RD:K]!4M% !U
MJ![.!VRT2D^XJ>B@:;6PQ(DC&%4 >U1265O*V7A1C[BK%% B+[-#LV>6NWTQ
M3%L;9#E84!^E6** (OLT/_/-?RH%O"&W"-0?7%2T4 1"VA!)$:\]>*8+*W63
M>(4#>N*L44 (  ,"HI;:&;[\:M]14U% $,5K##]R-5^@I\D,<JX=0P]#3Z*
M*RV-LG*PH#Z@5@ZAX2CU#4_M4DQV_P!P]*Z>B@"M!90PP)%L4A!@<5)]GA_Y
MYK^52T4 5WLK>0@M"AQTR*F1%C7:B@#T%.HH 8\:.?F4''K37MXG3:T:E?0B
MI:* (5M854A8U /;%'V6';M\M<>F*FHH K3V44T138HR.N.E<E>> 8KJ\\YK
M@]<XKMJ* *&GZ5!8P+&B+P,9Q5K[/$6+>6N3WQ4M% '/ZUX8AU3D/Y?':JNA
M>#;?2+DW ?>Q&.:ZJB@"-X8Y$VN@8>XJNFF6B/N6",'V%7**=V @ 48 Q00"
M,&EHI 5C8VS-DPH3]*JZGI*7UJ(4;RA_LUIT4 8.A^&8-&5PI#EFSDBMK[/%
MDG8N3UXJ2B@"+[-#L*^6NT]1BFQVD$392)5/L*GHH CD@BE'SHK?45&EE;1G
MY84'T%6** (/LEOO#^4FX=\4[[/%DGRUYZ\5+10!%]FA"E1&N#VQ6!KGA2+5
MU4>9Y84]JZ2B@#F=%\(V^ED,6$C ]2*Z$V\+  QJ<=.*EHH IWFG0W<10J 3
M_%BN4/@"!KWSVG)^;.#7;T4 5[.T2S@$48  ]*L444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gtinntqqusay000028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *=!>4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "D)P"?2EIDW^ID_W30!FOK]G'=K;LX#L
M<#FM%YD2,R9&T<U\W>-M4O+'Q+'/%+)A')V@UZCX:\3#6/"8WOBX\MB5SSTH
M [.SUFUOI&2)LE3@\UHUXI\-+J9]6U#S9F91.W4^]=[K/CFRTVX:W21'E7JM
M '75F7.MVEK/Y4C -G'6L/1?'5EJ<PA>1$D8X"^M>=^.;J9?%'R3,%\U>A]Z
M /<4<2(K#H1D4ZN0D\76FFVUI;F96F>)<*>IXK8778(],6\N76)6'&: ->BN
M%_X6-9_:=H=/*!P7]*ZJSUBTO;(7,4RLF,Y% &A6;-K=I#<>2[#=G'6N<OOB
M!8P7H@BE1QT)]*\TU+6VO_%*O#<'!E7Y0?>@#W]2&4,.A&:HZEJ]MI:*]PV
M>G-6;3_CR@)_YYK_ "KRGXT2RI962QRM'ND )!]Z .Z_X3/3/[__ (]5VRU^
MSOPYA;.P9/->-Z!X+M]1L!--K<B,<<9-=OHOA:/0].OIHM0:XW0G&3TXH Z=
M?%.GM<>2'&[_ 'JU&NHUM_/)&S&>M?*=W?WUKJDMX)Y"B.PQGCK7LUYK^/ E
MJPD_>31$=>: .RM_%&GW-S]GC<%R?[U; =?+WYXQ7S!X-EO8_&\*37$A#,3@
MGWKV#Q9XHOM+TN.*TMC*TB[21VH [$:U:&^%H'!D/H:O/*D<9=B  ,\FOGOP
M9?:A/X_MQ=O(I;G:Q]Q7H_Q&UJ73--ABB)#3#;D&@#I_^$FT_P"T>3YB[O\
M>%:T<BRQAT((/3!KYX'AF]/A6363J$WF!N%W5Z;\-]=DU*S-M(26@7!)/6@#
MO:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_$?EFZDFC>0(-Q]Z]YLY?.M(9/[R*?TH GHHHH **** "BBB@ HHHH ****
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M>%GFT(FYC,<K1D%2/:@#DOAIX;TW7K6[NM0C#R"=@"2/4UC:EI5MIOC0I;*
M@F4 ?C5^SL?$'A.^D@LK*6:*20MG\:9'X>UJ\UU-0GM9%+R E3VYH ]WL_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(TI+2!^A/UH [JBL[3M4COV901N7J*T: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ;L&<T[K110 @4#I36B1CDBGT4 -**>W2C8N>E.HH 0J"
M,&@* ,"EHH C,*;LXYI_04M% #&C5FR1S2[%]*=10 4A4-UI:* $ QTI:**
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45C:WJ\FG1*T2AB>N:DT'4I-3LVED4*0<
M<4 :M-?[AKD=8\5S6MRT-N@=E."*U-#U6?4K RW$81@<8H H>'O^0]??6NKK
ME/#ISKM]CUKJZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHKFO$GB&;2540('8N 0: .EHJK9W)FLHYG&"R@FN2U7Q?<6VK/:11JR
MJ>#0!T^M_P#()G^E4_#/_(-C^E137TEWH,SS+M.WBI/#/_(-C^E &[1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!L?TH W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\U%(F5805+G)KNH69HE+C#'K53FIR;0Y4)4DE(?1114D!1110 4444 %%%%
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M3@D8%>=^(&?2MWFMYAS]U>M>DUYOXP@N4U9Y[=/,;^Z>E ":-?!KNWR"N\\
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M[B]>TCES,GWE]*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH 0]#7/0?\A&3_>KH3T-<]!_R$9/]ZID;T=I'1#I10.E%48!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@V?_ ':<=R7L4O#/_((3ZULUC>&?^00GUK9JI_$Q1^%!1114%!1110 4444
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M1RON'M:?\GXG*FXC/_,,/Y57F>0_ZJS9/H*[+:O]T?E1M7^Z/RHY7W#VM/\
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ML6?_ !Z1_2L8_$SJJ?PHD]%%%6<P4444 %%%% !1110 4444 %%%% !1110
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M'&5JEX<U2/[#$F>:FZN;QI2<+V.J0%44$Y('6G4BG<H/J*6J, HHHH ****
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M/)':N2\+Z3Y5\INM0 RV?)8]:Z[Q3J]Q#:*++!8G!SZ5S.D6%O=ZE'=7VX3
M\8Z4 >G0*B0JL>-HZ8J2HK=46!0GW>U2T %%%% !15"_U>UTX SMC)Q4ECJ$
M-_%YD!RN: +=-D^Y5"^UJTT_'G-C)QQ5.361<PF2U.5H J:!_P AN]^M=17
M:)?7"ZU<$?Q'FN\B8L@)ZTD74W'T444R HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "L_6)G@L7:,$G:>GTK0J.:)9HV1AP1BD]BX-1DFSYYO\
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M'H=4I!0$=,4M(H"J .U+6904444 %%%% !1110 4444 %%%% !1110 4444
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M129'J*1 M%&11D4 %%&1ZT4 %%)D>M+F@ HHS29'K0 M%%&1ZT %%)D>M+0
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MPNR[21TIDFE)I^B7'R_.XRWUJ?PS_P @V/Z4 ;M%)2T %%%% !1110 4444
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MYK@;7_6II?#FI+9B>(?Z5UZT =WO79NR-OK4)O;8'!F7/UKDH-0U*'0[T7A
MDC3Y*YG1[VXU"%'E;YR>>: /6/-CV;]PV^M,CNH)6PDJL?05Q.MZQ/8/9V$;
M#=<C'6J.H2ZCX:C2[<X5F"T >E455TZX^U6$,Q.2Z FK5 !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %,E<QQE@,X[4^D(!&#0!Y]XGU2XO&^S
MBT90ASN]:P+&.XGU:'8&2(?>4=#77>,2]M;!K8 .3S7+Z+/>K-Y[%=JGF@#U
M*P3R[-%QC':K-5=.E,]E'(>XJU0 4444 %%)D#J:7K0 5C:_:3SVCM!*RMV
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M[3]37N?$>H(WR:=(W/;_ /76K9ZE<S:<\[VS(XZ(>]6M.U&UU&(20<J1Q5[
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M*HX(E@@2)/NH,"I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3\,_\@V/Z5=UO_D$S_2J7AG_ )!L?TH W:*** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY&'V=>@'I6E8:W!>8495NAW<5LX=4>2I=S5HIGF)_?7\Z<&!Z$'Z5!0M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <UK>@-=MOAD9&
M8\[:2P\/-:6#Q^:Q<G.[O7344 <%?^$;BZD#-<R'!R!FM[1M*-G8F*;+C/\
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MIP2!7I-C.;BU20G.Y<U$97-:V'E1MS=2S1115'.%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<IJOAUY=1>\BE92_! KJZ* .<M=!:TVF.5@6Y;%8E_X0GN=7>[:XD*GHN>!7
M?44 <W+I_P!GT*=91O(7C=4_A@ :9$ ,#%7=;_Y!,_TJEX9_Y!L?TH W:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 3:/2EHHH **** .>UB:\:1HHH&91T-5]'>]@FV/;L%8\
MFNIHK15/=M8APUO<*8\:2##J&'O3Z*S+,F^T2*ZCVQD1?[M<5>Z1-IFKQ!"T
MQ//->E$@#DXKG;]U_M^W.Y?SJ)['1AE[S]&)8:I/"-MQ;^4H[FM5-8L)"%\]
M"Q[5-<6D%XFV0!A[&LQO#%@A+PQ8?L:LYR]+:V]VA*!<D=17 >*;"6Q9I&C,
MJ 9+'M75-8ZO"<6\JJHKD/%]_J<4+6=Q)N#CM42IJ1TT,5*B[[D_AS4+/]W^
MZC5O7%>CPR))$I0Y&*\5\,21P3L;M&9<?+@=Z[%=>GMR/)#B+TP:23AH:5)P
MQ#YMF=VR*XPR@CWKG?$=C%;Z=)<QOY.WNO%)I_BRWN#Y;I)O'4D5#XQO8IO#
M%P%89/;/L:WHN\TCCK4Y0BVT><-XLEAN#%]H8J#C.:]#\(:U!=6@5KD.Y/0F
MO KE6\]CM/7TKT_X>:>LNCF>,JMP&X+'ZUZN*H0C3N>3AL1.=3E9ZX"",BEK
ME!J%[IK?Z7,KIV"FMBQUNUO5&U@O^\:\IP:U/34D:=%-$B'HZG\:=G/2H*"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"<4M<CJVI7T]Q)!82;&B
MY;-6?#>J7,\9BO'W2[L T =(3CK2/]RN.U'5-0NKNXAL9=GD<MFKGAO5Y;NQ
M;[7(#(&QD\4 1^'O^0[??6NKKD?#\T0UV^)D3!/]X5U/VB'_ )ZI_P!]"@"6
MBHOM$/\ SU3_ +Z%'VB'_GJG_?0H EHJ+[1#_P ]4_[Z%'VB'_GJG_?0H EH
MJ+[1#_SU3_OH4?:(?^>J?]]"@"6BHOM$/_/5/^^A1]HA_P">J?\ ?0H EHJ+
M[1#_ ,]8_P#OH5'-?6\,>\RH1[,* +-%5++4(K[?Y7\/6HSJUNM^;1B X[DT
M 7Z*B^T0_P#/5/\ OH4?:(?^>J?]]"@"6BHOM,'_ #VC_P"^A1]IA_YZQ_\
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MSD9%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDD #FK<DJ1HS%AP,]:Y4>)OM&NQ6L18(3@@T =;1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C#<I%</</-8>
M)+B4Q_NV7:&_.NYJM<6%O=']ZF><T <MH,<UH;@.A G;(JC-+/9ZY,WE91EV
M@_G7<_9(?E^7[O2HY]/M9CF1 3G- '%Q^&9[O3[EC(\9DY !ZT:9X&F%JH>^
MF0^FXUNZ_KB:/!Y:*^<<$#@53D\02_\ ".P72L?,D.,_E0 W_A"&_P"@E/\
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M?,: ,)O [D?\A*?_ +Z-5[?P)(DKEM3GP?\ :-=S10!Q%WX%D>$JNI3Y]F-
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MZ4 )_P (0W_02F_[Z-59? <K72L-3GVC_:-=U10!QQ\#OM(_M*;_ +Z-5X?
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MG;M*YR!Z&@!]FK+:1*^=P7G-3UR_AG7WU>[O$).V-L#/X5U% !1110 4444
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M<1K4('A33"HY,@_F* .QM?$<\\RJ8P%;O4UGXGMKG4Y+,R*'3M6-I5M*'@+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$]%0?;;7_GXC_P"^A1]MM?\ GXC_ .^A19A=$]%0?;;7_GXC_P"^A1]MM?\
MGXC_ .^A19A=$]%0?;;7_GXC_P"^A1]MM?\ GXC_ .^A19A=$]%0?;;7_GXC
M_P"^A1]MM?\ GXC_ .^A19A=$]%0?;;7_GXC_P"^A1]MM?\ GXC_ .^A19A=
M$]%0?;;7_GXC_P"^A1]MM?\ GXC_ .^A19A=$]%0?;;7_GXC_P"^A1]MM?\
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MN;W_  E6H?\ /1O^^C2?\)7J'_/1O^^C6'11R1[![2?<W/\ A*]0_P">C?\
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M:RL<U[RN?3/A?_D#Q?[J_P J*/"__('B_P!U?Y45XLOB9[4=CP3QQ_R,\_\
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M[?\ "KH/5*/^%70>J4?6Z8?4YGA-%>[?\*N@]4H_X5=!ZI1];IA]3F>(6/\
MQ_0_[U7-=_Y"+?2O9!\-(+<^;E/EYH;X>0:@WG_(,U/UJ%[E+"SY;'A%%>[?
M\*N@]4H_X5=!ZI5?6Z9/U.9X325[O_PJZ#U2C_A5T'JE'UNF'U.9X117N_\
MPJZ#U2C_ (5=!ZI1];IA]3F>$U9AOIH$VJQQZ9KVW_A5T'JE'_"KH/5*7UJF
MQK"U%L>'I=RI+O#MG.>M)/<R7#EG8G/;->X_\*N@]4H_X5=!ZI1]:IA]5J6M
M<\(XIXD?;MW-CTS7NG_"KH/5*/\ A5T'JE/ZU3%]4F>$TE>[_P#"KH/5*/\
MA5T'JE'UNF'U.9X325[O_P *N@]4H_X5=!ZI1];IA]3F>$THD=1@,1]#7NO_
M  JZ#U2C_A5T'JE'UJF'U2H>$T5[M_PJZ#U2C_A5T'JE'UNF'U.9X117N_\
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M444 %%%% !1110 4444 %%%% !1110 4A( R:6O.O$FK7&HWQL;2Y-N8VPS
MT >A)(K_ '309%7J:\TTZVU"PUR%CJAN8\9* _2M/5O#6KZ@3<0ZH\"GG;Z4
M =QYJ>M/!R*\3CLM<3Q-%8)JLDJ,.7'3M7L>GQ20V,4<KEW4<L>] %FBBB@
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M&  Y[T 7Z*H7NJ0V+()F"[C@9-%QJUK;Q;C*A.,XS0!?HJ*WF%Q"LB]&%2T
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M3.>E165G,UN")B* -FBL[[#/_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\
M/P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/
M_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\
M/P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/
M_P _!H^PS_\ /P: -&D(4]0#]:S_ +#/_P _!I?L,_\ SW- %X*@Z*H^@I2
M>H!JA]AG_P">YI/L,_\ S\&@#0&*6L[[#/\ \_!H^PS_ //P: -&BL[[#/\
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M_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\
M/P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/
M_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\ /P: -&BL[[#/_P _!H^PS_\
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M\XY]:M_89_\ GX- &C16=]AG_P"?@T?89_\ GX- &C16=]AG_P"?@T?89_\
MGX- &C16=]AG_P"?@T?89_\ GX- &C16=]AG_P"?@T?89_\ GX- &C16=]AG
M_P"?@T?89_\ GX- &C16=]AG_P"?@T?89_\ GX- &C16=]AG_P"?@T?89_\
MGX- &C16=]AG_P"?@T?89_\ GX- &C16=]AG_P"?@T?89_\ GX- &C16=]AG
M_P"?@T?89_\ GX- &C16=]AG_P"?@T?89_\ GX- &C16=]AG_P"?@T?89_\
MGX- &@0#U -($0=%4?A5#[#/_P _!H^PS_\ /P: - A3U /UHP,8XK/^PS_\
M_!H^PS_\_!H O[$!R%7\J=6=]AG_ .?@T?89_P#GX- &@0IZ@&@@$8(!K/\
ML,__ #\&C[#/_P _!H T!@=,4M9WV&?_ )^#1]AG_P"?@T :-%9WV&?_ )^#
M1]AG_P"?@T :-%9WV&?_ )^#1]AG_P"?@T :-%9WV&?_ )^#1]AG_P"?@T :
M-%9WV&?_ )^#1]AG_P"?@T :-%9WV&?_ )^#1]AG_P"?@T :-%9WV&?_ )^#
M1]AG_P"?@T :-%9WV&?_ )^#1]AG_P"?@T :-%9WV&?_ )^#1]AG_P"?@T :
M-%9WV&?_ )^#1]AG_P"?@T :-%9WV&?_ )^#1]AG_P"?@T :-%9WV&?_ )^#
M1]AG_P"?@T :-17'^K/TJG]AG_Y^#3);*94R9R: 'Z=_JW_WJ*33N(6'HU%
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M?6@"2:[B@(#L 2<5,#D CO7BVKZS?W.O12+)(D#2C;Z'FO9;4DVD)/4HO\J
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M24ECTZ%)22X')-7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_GI0!/YR>M'G)ZU!]C/_ #TH^QG_ )Z4 3^<GK1YR>M0?8C_ ,]*3[$?^>E
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M_P">AH L><GK1YR>M0?8S_STH^QG_GI0!/YR>M'G)ZU7^Q'_ )Z&C[$?^>E
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MA5"Q8@8R:EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM_:47]UJ/[2B_NM5GR8_[@H\F/\ N"@"M_:47]UJ/[2B_NM5GR8_[@H\F/\
MN"@"M_:47]UJ/[2B_NM5GR8_[@H\F/\ N"@"M_:47]UJ/[2B_NM5GR8_[@H\
MF/\ N"@"M_:47]UJ#J46/NM5GR8_[@H\F/\ N"@#*^W1_;5;:V/I5S^THO[K
M59\B+.=B_E1Y,?\ <% %;^THO[K4?VE%_=:K/DQ_W!1Y,?\ <% %;^THO[K4
M?VE%_=:K/DQ_W!1Y,?\ <% %;^THO[K4?VE%_=:K/DQ_W!1Y,?\ <% %;^TH
MO[K4?VE%_=:K/DQ_W!1Y,?\ <% %;^THO[K4?VE%_=:K/DQ_W!1Y,?\ <% %
M;^THO[K4?VE%_=:K/DQ_W!1Y,?\ <% %;^THO[K4?VE%_=:K/DQ_W!1Y,?\
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JB_NM4<VH1LF K<^U7?)C_N"CR(_[@H I:=_JG..K45H*BJ,* ** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gtinntqqusay000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (#!98# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH 0G )/:N)\7?$&Q\/'R"6,Q&1M
MYKKK^3RK"X<=1&Q_2OG;2XV\2>.D^TL61)67:W(ZT ='_P +3U D3#SO*//W
M379^$_B-8Z\P@RPF)Q\W%=%_PC6EI8M!]CA/RD9VUX;KED?"?Q LUMV(1R6*
MC@=J /HO<HZL/SHR,9S7DGBGQO<Z;IUC+&A)EE53S[BNU75Y#X7:]Q\P0''X
M4 =,&!. 0?QH+*O5@/J:\Q\#^+[G6/$%]:R(<1(6'/L:J>*/$VOMJHM[6PD,
M9XW+0!ZP'0]&4_0T[.*\%T_XAZIIFL);7<# .X3YCZUZ!XS\:?V%I*M&H:9X
ME<+]1F@#LKJY6&UED#C**3UKA= \='5-;%GO8Y<K^1KBHO$_B2YT^6[_ +/E
M,,J'G/ %9OPUN'N?%4;R+M;S#D?C0!]$;E_O#\ZS]7OQ8Z;).K#*^AKR/Q+\
M1;[3/$5S90PE\-M7FIK37-=>Q:>^L)%B//S=,4 =EX4\5R:UJEQ;.6Q&.XKM
M"RCJP'U->3^ ?$*7>L:@/LR1>4I)8#KQ5/Q%\0;^ZUM=-TRW,NX$90]Z /9
MZGHP/T-+TZUXII?BWQ%I^HQQ76GR;'<+ECTKK_&/C8Z)I1,:AK@H&"=^E '=
M>8F<;U_.ES[UX.GB[Q$$COS92^2WS'GC%=]H_C0:QX8DO0 LB';M'X_X4 =U
MO7^\/SH#J>C _0UX7%\0]7NM4NK2TLVE*G'!Z4ZT\>:OHVM1PZE:M'&>27-
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M/4X].N8MK,V,D^]'C7X@W5M?BPL(?-D#[3M/- 'K.],9W+^=+N'J/SKPN_\
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M,'PZU-9$MEO+D0H<##'I7:GP_P#V!X1FM_.:4DYRQ^M 'G'PYN+:+QAJ/G$
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M/I6SX6T?^QM*AMLD[$QS0!O4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZSIBZI:- P!!!%:5%
M'+^$_"D?AR"2.- N]RW'UKJ*** "BBB@ HHHH **** "N'\3_#VRUN43)"OG
M9SDXZUW%% 'E4/PK\V4"\5'B].*]&TG2[?2K*.W@3:J#&*OT4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !115:6_MX9TA=\._04 6:*AN+F*UCWRMM6HK7
M4K:]SY$F['6@"W15*YU:SM'V32;6SBK44J3(&0Y!H ?1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !15:]O8;"V>>=MJ(,DU1TOQ!9:J-UO*'7&<T :
M]%<Q?^.-'L;D127(!!P:TTU^P?35OUFS W1J -2BN8LO'&D7EY]F2Y!D+8 K
MIE8,,CI0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=5
MN'M[-FC4EB"!BO&I+S5X_'=BES<N8WDX4^E>XN RD$ \=Z\I\50'_A/M(95
M ?G% $_C_5;N:Y.GVLIC97'/XUAG4;[PUJ5C$\Y83@$XK5\>VDMEJ+:@R_NV
M<<_C6)>H?%.IZ?)9_.L( <CM0 ]VU'7?%%X4N2L*1EU4]L9-=/\ #/7I[RSU
M$74A?[/(4&?8URL-ZN@>)[V*Z.Q6B*#ZG(KH?A?HSBSU3SP52XE+*1W!- '7
MS>+[*&0HQ7(]Z+?QA8W%TD = ['@;JSKGX;:9<SM*UQ."?0G_&N U[P[!X?\
M>Z5%:SRLKG)W,?\ &@#W)6#+D4M06G_'NM3T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '#_$'2=1OK)I;6Z\N%%^=/6N>\#![2RD7.2(FY_"O1]>@>XT:XBC&7
M9< 5R'A70[NW61;B/;NC('Y4 <+I%I%JFEZ[<72AY8I&V,>W--O=1N+;P5I\
M".0IE ./PJW/H?B'1UU"SL[4-'=N3R?_ *U:Y\&7MSX)LX9(2+N-]Q7Z8_PH
M RM3L8-/OM,N+9 CN@9B.YQ7=R^+VT;08;E[26X9CC"@GTKAXM*\0ZIK%HES
M:A;>#Y"0>P_"O7+32X8K%+=T5@O]X9H X-_BXL:%GT>Y"CN4-=9X:\4Q>(K=
M98X6CW#.#3/$^FVJ>'[IE@C!"]=@K!^'H"@ =-M 'H5%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% ",VU2Q[#->?:_X^6RU:&SCB<[C@D5Z ZAT*GH1BO*O&.B6]AK
M$$D9+%SN.: .JU/Q7'I/AR*_E!/F-M'UX_QKF[#QS/#JUO!<)(5N#E21P!63
M\0!(? NG8SC[0O\ -:-=>%KC0UCQYGE+T'M0!T?B#QQLO9+*U5C)'R2O/'^1
M5WP;XQ76EDCD1E=&V_-7GVDYB\<W_P!IZ>4>O/\ >K1\([I-8E-N/E$ISCZT
M >QF>)3@R*#]:!<0DX$B_G7GNL6OB9]3D:UM]T/8[C_A7.W6J>(])U>WANH0
MBOU^8_X4 >S@@]*6L_1KA[G3(Y7^\:T* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BJM_<-;6S2)U KA!XG\0SRS?9X4:.-L9_R* /1:*\XMO&VI1W8
MCOE1%SCBO0+2Y6ZMTD4YW#- $]4IM*L[BYCN)(5:5/NL>U7:* *E]IMIJ,7E
MW40D7K@U7L= T[3R3;VR)D]JTZ* ,B[\-:5?3F:>T1Y">6-7[2RM[*/9;QA%
M]!5BB@ KR7Q[_P E#T?_ #VKUJO)?'O_ "431Z /4[3_ (]UJ>H+3_CW6IZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 444A.!DT +159[V!&VLW-"WT#G ;F@"S7/:_X>;6+F*4
M.%V>M= #D9%+0!S>H>%X]0T*/3Y=K;#D$^M<WIOP\O(=4BN;N[$J1-\BGL*]
M(HH X7Q'X%?49VN+&58)7/+#N*M^$?!Y\/QR>>XED8YW5U]% !7FGQ _Y#UG
M]*]+KS3X@_\ (>L_I0!VWAW_ ) L-:M97AW_ ) L-:M !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %5=1D:*PE=<Y XQ5JHYPA@82?=QS0!Y;%87VJ:M),=4\
MA6'^K)Z5D:M:ZKI5THCU5I58\E3TK;UR?1;35)#%,XGZ$ \5-I-KHFIQO#YK
ML\GK0!TW@Z\FGTF))G,K=W/>NFK-T;28=(L4MHL[5]:TJ "BBB@ HHHH *\T
M^(/_ "'K/Z5Z77FGQ!_Y#UG]* .V\._\@6&M6LKP[_R!8:U: "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWBE5_P"$=NOE'W?2N8^'W;_=H ]!HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** (IU+PLH."1UKS6:\FT_Q7.'TPW"A?\ 6$=>OO7>:D+_ ,Z,VI'EC[V:
MY74K;Q!/J+FU:/R^V: .?O\ 5[J76;:>#1VC6,\[1U_6O2M)U*74(%DD@,1/
M8UR5A'K,6H117IC*L><5WL<2QC"B@!]%%% !1110 4444 8WBG_D7;K_ ':Y
M?X?=O]VNH\4_\B[=?[M<O\/NW^[0!Z#1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5=1#&PE"$A
ML<$5:K'U<WWFHEN1Y9^]F@#CK%[0:H\>H0I(0/O/WJK>7T4&O6K6*B&$-\X3
MH:FU30-0N+]Y(]NTT[3/#<K7"K=X()[&@#T*SNTO(1(A!!]*LU5LK"&P@6*$
M84=*M4 5KVPMM0A\JYA61?1A69:^%].M9Q,+:+<#E3CI6Y10!EZAH-CJ',MO
M&S9Y)%2Z=I%GIB%;:!(\]=HJ_10 5YI\0?\ D/6?TKTNO-/B#_R'K/Z4 =MX
M=_Y L-:M97AW_D"PUJT %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <EXA
MU2]M9WCBM'D3H"*\^U"WU!K^.X-L\<><LG9J[;5-3U"Y\1S:;;. L8W8-95Y
M>ZEJUY';V[C$9VO0!T/A.X:5% L_)3'! KK*XKP[?W4&N-I,S B-<X%=K0 4
M444 %%%% !1110 5Y+X]_P"2B:/7K5>2^/?^2B:/_GM0!ZG:?\>ZU/4%I_Q[
MK4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !112;E_O#\Z (;F\M[0 W$JQ@],U4/B#2AUO8OSI=3TFRU9%6Z 8
M+TYKE];\&Z/;Z<\D<>&'O0!TP\0:2>E]%^=6+?4[*Z8+!<(['L*XS1?!^CW$
M69$R<>M=)IWAS3=+F$MLH5ATYH VJ*3<O]X?G2]: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@"G?7T%HF)I%3([UYGXAUUM.OGO
M;2Z,P<[?+4]/>NS\5'31#B]4EB/EQ7'7MEX>M]#CO3"^7.,=Z -'PLB3SK<2
MZAYDCG<$)Z>U>BUY?X9_LF"]BW1L)'.8\UZA0 4444 %%%% !1110!C>*?\
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M** "BBB@ HHHH **** "O/O&DCIXBTTNQ6 -\_IBO0:S-6T.SU=<7,>X@<4
M<1YEMJWB:6TC*O:*-PQT[TR[$2^)+"/3<>6C8D\OI^-=;IOA33]+R]O%M<C!
MI^F^&K.QN))UCP[-NS0!NT444 %%5;Z^AL(#+,P"_6L&R\<Z;?7HM8TD#EMH
M)Z4 =116%K'BNPT;_7Y8YQA:GT;Q!9ZW$TEL2 .H)H UJ\T^(/\ R'K/Z5Z7
M7FGQ!_Y#UG]* .V\._\ (%AK5K*\._\ (%AK5H **** "BBB@ HHHH ****
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MYQ7E'CM%3XAZ/@?YQ0!ZK:?\>ZU/4%I_Q[K4] !1110 4444 %%%% !1110
M4444 %%%% !1110!#+:P3?ZR)6^HK"\3V-M'HDS)"@/J!71UB>*O^0%/0 F@
MV%J^C6[- A)7J16O%;Q0C$:*H]A5'P__ ,@2W_W:TZ "BBB@ HHHH **** *
MFI_\@RX_W#7SEK7_ "$'^IKZ-U/_ )!EQ_N&OG/6O^0@_P!3_.O3R[J<&-Z&
M;1117J'GA1110!+;?\?,?UKW_P #_P#("7ZUX!;?\?,?UKW[P/\ \@%?K7GY
MA\".S!_&=-1117D'IA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #)'\N,L>U</?>*=1;69+*ULS(BC(8=Z[B9!)$RGN*\PU:UUO3O$4UQ9
M74<<)& I//\ .@#IM,U+59KE%GM&12>2:ZRN$T*[UV>Y3[3>1O'GD __ %Z[
MN@ JCJT)FTZ95Z[&_E5ZD(#*0>A&* /GC388M/M=9CNY/*G>1C&#U/-:-]:7
MMWX'T\ .ZI*&)_*O5+[P-H6HW'G7-KN<'.>*T8]"L(M/6Q2+$"]%H \@U"_C
MU+4--M[<AV1 K8['%=[-X2DU70H;9KIX&4YR#]*T;/P/H5C=_:8+7;+NW9XZ
MUT0  P* /)M<^&SVFD3S'59FVCH2:T_AI!]F@2+<6PO4UUWBK_D7;K_=KE_A
M]V_W: /0:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "LC7-&?5XT5+EX-O=3UK7HH \WUOP?<V.G/.NJSDCMN
M-/TSP;<7=JDC:K.,C/WC75>*O^0)+4F@?\>$?^[0!!HWAZ32F!:\DFQ_>-;U
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'-
M*(86D8X"BI*K7Z"2RE0C((H Y*]\8:@MZT-C8^>@Z,*N:3K^KWDX2YTXQ*3U
MKFHM2;1-9<9*Q 8 KI]*\2C4)@B[CDT =11110!Y=\8M0GMM$@6%F4^<.AZ\
MBL'3-2G6^TW[19B#*CYL?>]Z[CXC^&I=?T>-+8#S(Y-YS[$'^E<;%INJ:KJE
MA&Q/EVP"-E?2@!KR?VIX]U"W>0O"L1*@]/XJG\&7$MAJ<T*,64RGC/O3M6\-
M:AHVM7&HV^ )5V# ^O\ C6GX"\.WBRS7-[@L7W#B@#1U;QOJ=AJ,EO%I^]%Z
M-7#Z_P")KW5]?M!<6GE=J]GET>RFD,CQY8]37G/CC3K:UUZS\I,<4 >@>'?^
M0-#6K65X=_Y L-:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?K$#SV
M15"01SQ7$6.J+9-<1W-E'NS\NY>M=]?+*ULWE,%;!Y->5WNLVEG=RP:A&TTS
MMB-TY"_6@#I/#<<UQX@>]\KRX67A1TKN:X[P@EVX6<S*;8CA,\UV- !1110
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MO^/F/ZU[]X'_ .0$OUKS\P^!'9@OB.FHHHKR#TPHHHH **** "BBB@ HHHH
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M,,T2G#2(#[L*;]H@_P">T?\ WT* ):*C^T0_\]H_^^A3U96&58'Z&@!:***
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M4_\ D&7'^X:^<M:_Y"#_ .\:]/+NIP8WH9U%%%>H>>%%%% $MM_Q\Q_6O?O
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M"Y_YZ4?VA<_\]*/[/CW#ZZ^Q]&0^(--G?;'< FM($$ CH:^??"][.^IJ&?\
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MU:0G&*W001D5X=?Z=#I>HZ;<VRA&D0.V.YQ7>W'C)=&T*&YGMY9BQQ\BD^E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOAI);6UU):M*[2$MC<:E3P=>R^ [&$HYFB?<4R>V/\*]C>-9%PPR*%A18_+
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M?\'^^*3V&MSZ&\+_ /()3\*VZQ/"_P#R"4_"MNOG*GQL]N'PH****@L****
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M#X$=F#^,Z6BBBO(/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPUJUE>'?^0+#6K0 4444 %%<QJ?B&6RNWB6VE<+W -9,_CIX)1&UG-D_[)H
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M!_J:S:^DA\*/#E\3"BBBJ)"K%C_Q_P '^^*KU8L?^/\ @_WQ2>PUN?0WA?\
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M60? FE'J'-=110!@V7A.PL9EDBW;E.1FMZBB@ HHHH **** "BBB@#&\4_\
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M HHHH **** "BBD)"C).* %HJ)+B&0X20$^U2T 8WBG_ )%VZ_W:Y?X?=O\
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M?I7C8_\ B'J8/X!:***X3K"BBB@ HHHH **** "BBB@ HHJO>S_9[227^Z*
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M/X#_ !KTE/B/JBQJO]BOP .W^->9C*D9RO$[\+"4(ZGI]%>9?\+)U3_H"O\
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M-=_12N,X'_A5VB_\\#1_PJ[1?^>!KOJ* .!_X5=HO_/ TG_"KM%_YX&N_HH
M\_;X6:(PP8#4/_"H?#__ #[?RKT:BG=@><?\*A\/_P#/M_*N<\9_#;1](T&>
MZMX-LB#@U[57+>.[";4/#MQ! A=V' %%V*R.(\,?##1-2T*VN9K?+NN2:V?^
M%0^'_P#GV_E75>$K62S\/6L,JE75<$&MVB["R/.1\(O#X.1;?RJ<?"W10,"
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MO]AV7_/.C^P[+_GG6E10!F_V'9?\\Z/[#LO^>=:5% &;_8=E_P \Z/[#LO\
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M+33;W$8+DY.*[*B@#S-_A[=MJGFG9]G#Y ]J]"L+**PMEAB7  JU10 4444
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MVM(BO<#Y_2@#5HJ"[G^S6KR_W1FN N/']_\ VB]M:VRR;: /1J*\\3QIKC.
M=/ !KL++4RVDK=W@$3$$D4 :=%<#>^/+B2=H])B6YVG!QV-1VWCR^@E U:V6
MWC)P"?6@#T*BL^/58)]/-U X< 9-<3/X_OVU66SL[992G- 'HU%>=GQOK,(W
MW%B$C'4UU&@>([;6H@$D4RXR5':@#<HK U[Q/:Z/^Z,B_:&&50]ZY<^-M>)W
MIIP,/][VH ]'HKFO#_BRVU==CNJS9QM'K67X@\;3Z7>M;P1*[*<8H [FBO.1
MXWUP@$:>,&MWPUX@U'5;IX[RU$2@9!H ZFBBL+Q/K_\ 8%DL^!SZT ;M%<KX
M1\71^)+>23*AE?;@5T=Y<K:VLDS'&Q2: )Z*X30_'Z:QJWV-=GWRO'L<5J:[
MXLATUO*MV62?."M '3T5P5OXWO8IU&HVZP1'G<?2NHFUVTBTU;PRC8XRI]:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M("N 0?K0!M_VSK\ENU^DKB '[FTYKI="\8P:A8SY#>;;)E\]:W[2&U_L^/\
M=ILV#/R^U>2>$U63Q5XBB+D0DD''88% &T_BC4-<N6.F7/DH"1M:M/POXJN)
M[N>TO$E9HC@N5.#7*C09[&=KC0]URH)/7O5[2?%=Z/M-KJ%C%;R ;58*,DT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<-J_A>YO/$CWR,
M A[?C7<TF!Z"@##U70EU'2! 0/.5,*Q[&N'AT/Q-ID7V.&]Q&., 5ZK32B$Y
M*@_A0!Q7A;PC-9-)<:@RRRN=P/I65KWA/5/^$FEU2PG$?F<?AFO2\"@JIZ@&
M@#RK5O!NK?:K2]MIPKH-S^YI]]X:\0:];JEQ=AHP<[37J153U4'\* JCHH'X
M4 <!'X5NQH%Q9,XW,NT&N@\&Z3+HOAV"RF8%TZD5OX'H*4 #I0!5U&!KFQEA
M7JPQ7+>'/#EQIFM/=2,"I7'\Z[.DP/2@!:I:GIL.IVIAF0,,'&?6KM% 'E<W
MA;Q!H]PYTZ[$<+'.T4P>'/$NLR*EY>AH00=IKU8JK=5!^HH"*O10/H* ,.S\
M/PZ=I#VUN@5G7YB.YK#\->&+G3/$UQ?2,"CK@#\Z[FDP!V% %74K&/4;&2VD
M4%7&"#7"Z!X4U#1/$MQ*LH%DRX6,=NM>BTFT9S@4 <1XH\'2:A,E]8E8[F,?
M*Q[&N>_L[Q@$\@ZAD]"<?_7KUFF^6F<[%_*@#AO"_@N6RF%YJ3+-<AMRL.U9
M7BGPAJUYJLEW8SB,LV:]0I"JGJ ?PH \I72?&:HJC4^ ,=/_ *];OAFQ\1P7
MK-J-[YL>.!7<;%_NC\J4*HZ*!^%  ,[1GTKF?&6B3:U;6Z0L 4<,<_6NGHP#
MU% '*7?AU[GPQ+8,07< 9K)\&>"Y=!NIY)"I#I@8KT' ]*3 ':@#AG\,W/\
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MHU#2YEAVK@52CT'Q'JES#]IO-R1M\P(ZUZ@0#U -($5>B@?04 5M/LQ96JQ
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M8#[S<FHK+P]OU&2YN 20^4SS0!L:-9#3]/2 =JT*.E% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gtinntqqusay000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0:!+T# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+\4YV
MC\'7B ]1_0UW5<'\58F;PA>,!T']#0!G_":V":5%-CEDKN/$,8ET>9#T-<7\
M*)@VBPQ]PE=MKSA-)E8]J /'OAK*8?'FJ19X' KVF]O8K"S:YF^XHYKQ3X<1
MF7X@:HXZ5ZUXIT^34O#TUK$2'8<$=>E &6_Q$T=&*ECD?[5-_P"%CZ-_>/\
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MYT?\(A?_ //>;\Z+ >^_\+'T;^\?^^J#\1]&'\1_[ZKP+_A$=0_Y^)OSI/\
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M >O?\+'T;^\?^^J/^%CZ-_>/_?5>0_\ "K-5_P">UQ^9H_X59JO_ #VN/S-
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M0>O?\+'T;^\?^^J/^%CZ-_>/_?5>0_\ "K-5_P">UQ^9H_X59JO_ #VN/S-
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M\_Y^)?\ OJCZM4[![>GW/IG_ (6/HWJ?^^J/^%C:-_>/_?5?,WV"\_Y^)?\
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M\+'T;^\?^^J\A_X59JO_ #VN/S-'_"K-5_Y[7'YF@#U[_A8^C?WC_P!]4?\
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M *Y-_*OF?P#_ ,E(B_ZZ-_Z%7TOK_P#R [S_ *Y-_*OFCP%_R4B+_KHW_H5
M'U-!_J5J2HX/]2M24 %%%% !1110 4C=*6D;I0!YEK'_ "$)O]ZJ%7]8_P"0
MC-_O50J@"BBB@ HHHH **** "BBB@ HI*7O0 4444 %'>BB@ K4\/_\ (3%9
M=:GA_P#Y"0H ]&B_U2_2GTR+_5+]*?4@%%%% !1110 4444 >%_'7_76O^[7
M@]>\?';_ %UK_NUX/0 4444 %%%% !1110 4444 %%%% !1110 4444 %3V7
M_'];_P#71?YU!4]E_P ?UO\ ]=%_G0!]@>"O^0)#_N+_ "KI:YKP5_R!(?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH S-?_P"0'>?]<F_E7S1X!_Y*
M/%_UT;_T*OIC7_\ D!WG_7)OY5\S^ ?^2CQ?]=&_]"H ^IH/]2M25'!_J5J2
M@ HHHH **** "D;I2TC=* /,]8_Y",W^]6?6AK'_ "$9O]ZL^J **** "BBB
M@ HHHH **** "BBB@ HHHH **** "M3P_P#\A(5EUJ>'_P#D)"@#T:+_ %2_
M2GTR+_5+]*?4@%%%% !1110 4444 >%_';_76O\ NUX/7O'QV_UUK_NUX/0
M4444 %%%% !1110 4444 %%%% !1110 4444 %3V7_'];_\ 71?YU!4]E_Q_
M6_\ UT7^= 'V!X*_Y D/^XO\JZ6N:\%?\@2'_<7^5=+0 4444 %%%% !1110
M!A^+O^1<N?I7@TW^L->\^+O^1<N?I7@TW^L-<&+^)'UO#W\&7J,HHHKD/H0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ].^'/^J3ZUZ57FOPY_U2?6O2
MJ]2A\"/A,V_WJ04445L>8%%%% !1110 U_\ 5M]*^=?%7_(;NO\ KI7T4_\
MJV^E?.OBK_D-W7_72O1R_P")G%C?A1A4445ZQYH4444 %%%% !1110 4444
M%%%% !1110 4444 =)X)_P"0X/H*^@+;_CUC_P!VOG_P3_R'!]!7T!;?\>L?
M^[7D9A\:/2P?PLEHHHKSSM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,W7_\ D!WG_7)OY5\S^ ?^2CQ?]=&_]"KZ8U__ ) =Y_UR
M;^5?,_@'_DH\7_71O_0J /J:#_4K4E1P?ZE:DH **** "BBB@ I&Z4M(W2@#
MS/6/^0C-_O5GUH:Q_P A&;_>K/J@"BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 -?_ %;?2OG7Q5_R&[K_ *Z5]%/_ *MOI7SKXJ_Y#=U_UTKT<O\
MB9Q8WX485%%%>L>:%%%% !1110 4444 %%%% !1110 4444 %%%% '2>"?\
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M?_KHO\Z@J>R_X_K?_KHO\Z /L#P5_P @2'_<7^5=+7->"O\ D"0_[B_RKI:
M"BBB@ HHHH **** ,/Q=_P BY<_2O!IO]8:]Y\7?\BY<_2O!IO\ 6&N#%_$C
MZWA[^#+U&4445R'T(4444 %%%% !1110 4444 %%%% !1110 4444 >G?#G_
M %2?6O2J\U^'/^J3ZUZ57J4/@1\)FW^]2"BBBMCS HHHH **** &O_JV^E?.
MOBK_ )#=U_UTKZ*?_5M]*^=?%7_(;NO^NE>CE_Q,XL;\*,*BBBO6/-"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#I/!/_(<'T%?0%M_QZQ_[M?/_ ()_
MY#@^@KZ MO\ CUC_ -VO(S#XT>E@_A9+1117GG:%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 9NO\ _(#O/^N3?RKYG\ _\E'B_P"N
MC?\ H5?3&O\ _(#O/^N3?RKYG\ _\E'B_P"NC?\ H5 'U-!_J5J2HX/]2M24
M %%%% !1110 4C=*6D;I0!YGK'_(1F_WJSZT-8_Y",W^]6?5 %%%% !1110
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M^NC?^A5],:__ ,@.\_ZY-_*OF?P#_P E'B_ZZ-_Z%0!]30?ZE:DJ.#_4K4E
M!1110 4444 %(W2EI&Z4 >9:Q_R$9O\ >JA6AK'_ "$9O]ZL^J **** "BBB
M@ HHHH *2EHH **2EH **** "BBB@ K4\/\ _(2'TK+K4\/_ /(2% 'HT7^J
M7Z4^F1?ZI?I3ZD HHHH **** "BBB@#POX[?ZZU_W:\'KWCX[?ZZU_W:\'H
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M9[+P!)<,Q#K&N#^%<'X<T*^\7^('U.]0_9F8.A!KT/XAPBW^']U&@QM0#]*
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M_P#Y"0^E95:GA_\ Y"0^E 'HT?\ JU^E/ID7^J7Z4^I **** "BBB@ HHHH
M\+^.W^NM?]VO!Z]X^.W^NM?]VO!Z "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ J>R_X_K?_ *Z+_.H*GLO^/ZW_ .NB_P Z /L#P5_R!(?]Q?Y5TM<U
MX*_Y D/^XO\ *NEH **** "BBB@ HHHH P_%W_(N7/TKP:;_ %AKWGQ=_P B
MY<_2O!IO]8:X,7\2/K>'OX,O491117(?0A1110 4444 %%%% !1110 4444
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M .K;Z5\Z^*O^0W=?]=*]'+_B9Q8WX485%%%>L>:%%%% !1110 4444 %%%%
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MK;Z5\Z^*O^0W<_\ 72O1R_XF<6-^%&%1117K'FA1110 4444 %%%% !1110
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MHH **** "BBB@ HHHH XKX@?\>D?TJQ\/?\ D7%_WJK_ ! _X](_I5CX>_\
M(N+_ +U '6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?QV_UU
MK_NUX/7O'QV_UUK_ +M>#T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]VOG_P $_P#(<'T%?0%M_P >L?\ NUY&8?&CTL'\+):***\\[0HHHH ****
M"BBB@ HHHH *XGXD2/%X=NF1BI$?45VU</\ $O\ Y%RZ_P"N= &/\'YY9O#M
MLTCECCJ?I7J%?,G@KX@?\(_I<5N&8;1V%=9_PN1O[S_E0![8T,;'+(#0L:)]
MU0*\3_X7(W]Y_P J/^%R-_>?\J /;Z*\P\(_$<Z_JIM2S' SR*]-0[D!]10
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MHHH **** /"_CM_KK7_=KP>O>/CM_KK7_=KP>@ HHHH **** "BBB@ HHHH
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MMYI(%>E6UPEU DL?W6&10!-1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!8GZUZ#X6MM3M=+5-3(,X/.* -ZBBB@ HHHH **** "BBB@ HHHH ****
M/"_CM_KK7_=KP>O>/CM_KK7_ ':\'H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "I[+_C^M_P#KHO\ .H*GLO\ C^M_^NB_SH ^P/!7_($A_P!Q?Y5T
MM<UX*_Y D/\ N+_*NEH **** "BBB@ HHHH P_%W_(N7/TKP:;_6&O>?%W_(
MN7/TKP:;_6&N#%_$CZWA[^#+U&4445R'T(4444 %%%% !1110 4444 %%%%
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MB_ZZ-_Z%0!]30?ZE:DJ.#_4K4E !1110 4444 %%%% !1110 4444 %&***
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M HHHH **** "BBB@!DC[(G?^ZI->%>+_ !QJ6I:M]ATV-R58H3&:]RNP39S
M=?+;^5>$>#K>.W\871NAAFN"5SQ0!GIH_BZ5=Q:\4GMFG?V%XM_YZ7G_ 'U7
MT2&7'# _C2[AZB@#QWP-I?B"VUHO?/<&+;_&>*]ACR(USUQ2Y'J*6@ HHHH
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MHHH **** "BBB@ HHHH **** "I[+_C^M_\ KHO\Z@J>R_X_K?\ ZZ+_ #H
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M* "BBB@ HHHH **** /"_CM_KK7_ ':\'KWCX[?ZZU_W:\'H **** "BBB@
MHHHH **** "BBB@ HHHH **** "I[+_C^M_^NB_SJ"I[+_C^M_\ KHO\Z /L
M#P5_R!(?]Q?Y5TM<UX*_Y D/^XO\JZ6@ HHHH **** "BBB@##\7?\BY<_2O
M!IO]8:]Y\7?\BY<_2O!IO]8:X,7\2/K>'OX,O491117(?0A1110 4444 %%%
M% !1110 4444 %%%% !1110!Z=\.?]4GUKTJO-?AS_JD^M>E5ZE#X$?"9M_O
M4@HHHK8\P**** "BBB@!K_ZMOI7SKXJ_Y#=U_P!=*^BG_P!6WTKYU\5?\ANZ
M_P"NE>CE_P 3.+&_"C"HHHKUCS0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Z3P3_P AP?05] 6W_'K'_NU\_P#@G_D.#Z"OH"V_X]8_]VO(S#XT>E@_
MA9+1117GG:%%%% !1110 4444 %%%% !6)XDTE]7TZ6W25HRZXRIK;HH X?P
MCX0ET*$H]U)+\A7YC[5RVK_"ZYO[^6==1N%#L3@,:]AHH \._P"%0W?_ $%+
MG_OHT?\ "H;O_H*7/_?1KW&B@#R[PC\/+C0M5-R]]-*,8PS'%>GH-J >@IU%
M !1145Q,((6D;HM $M>.?%^*UCN8KAY LR+\H]:[33_'EA?^(I=(C5_.C&23
MT[_X5HZUX2T?Q&Z2ZA;>:RCCF@#QWPK\6I--T^.RDB7:@^\:Z@?&&#'(CKH?
M^%4>$_\ H'_J/\*/^%4>$_\ H'_J/\* ,*+XO023(F(_F8#\Z]+L;H7EK',/
MXE!KDT^%?A6.176PPRD$<C_"NOMK:*UA6*)<(HP!0!-1110 4444 %%%% !1
M110 55U"S6_LWMV. U6J* .:T'PC;Z'J$MW%)N:08(KI,9&"*6B@#DO$/@:T
MUOYU80R$Y+*.:P;+X5I%.'FU"650?NN217I=% %+3M,@TVV6&%%&T8R!5VBB
M@ HHHH S=?\ ^0'>?]<F_E7S/X!_Y*/%_P!=&_\ 0J^F-?\ ^0'>?]<F_E7S
M/X!_Y*/%_P!=&_\ 0J /J:#_ %*U)4<'^I6I* "BBB@ HHHH **** "BBB@
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M110 4444 >G?#G_5)]:]*KS7X<_ZI/K7I5>I0^!'PF;?[U(****V/,"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!5_LRQ_Y](?^^!1_9EC_ ,^D/_? JW10!4&F6(.1:0_]\"K2J%&%  '84M%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;K_ /R [S_K
MDW\J^9_ /_)1XO\ KHW_ *%7TQK_ /R [S_KDW\J^9_ /_)1XO\ KHW_ *%0
M!]30?ZE:DJ.#_4K4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7\=O]=:_P"[7@]>
M\?';_76O^[7@] !1110 4444 %%%% !1110 4444 %%%% !1110 5/9?\?UO
M_P!=%_G4%3V7_'];_P#71?YT ?8'@K_D"0_[B_RKI:YKP5_R!(?]Q?Y5TM !
M1110 4444 %%%% &'XN_Y%RY^E>#3?ZPU[SXN_Y%RY^E>#3?ZPUP8OXD?6\/
M?P9>HRBBBN0^A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T[X<_ZI/K
M7I5>:_#G_5)]:]*KU*'P(^$S;_>I!1116QY@4444 %%%% !1110 4444 %%%
M% !1110 5QOCW_CP/^[795QOCW_CP/\ NT 2?#G_ )%6+ZUUU<C\.?\ D58O
MK774 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$
MA5)/0#)KF]0\2^'6+07<\18<$,H-=%-_J)/]T_RKYL\4Z=<ZEXE^S6+8:20@
MD<XH ]"O[/P7?2F0WD:9[!14NFP^#-.D#+=Q.0?XE%<[IWPCU?R%,UQ&3^'^
M-4-?^%>M6=J]Q%<)M09(% 'K=OXO\.1*(X;J-1V"@"MFSU2TOUW6TH<>U?-O
MAOPKJ6L7!M$N$2X49.[@UMP-X@\#ZY;07ET9(9&R0HXQ0!]!T50T?4$U/3H[
MI/NO5^@ HHIKNJ*69@ .Y- #J*YS4_&6FZ8Q5Y48@]G%2Z9XJL]3LI;J+A(^
MO- &]16?8ZQ:7QQ%*A;TW#-:% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &;K_\ R [S_KDW\J^9_ /_ "4>+_KHW_H5?3&O_P#(#O/^
MN3?RKYG\ _\ )1XO^NC?^A4 ?4T'^I6I*C@_U*U)0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >%_';_76O^[7@]>\?';_76O\ NUX/0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %3V7_ !_6_P#UT7^=05/9?\?UO_UT7^= 'V!X*_Y D/\
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M^/\ 7M,00W45U*XZD1FH;GQ/XC\2?Z-;_:(E?@[D- &GX:F$WQ;O6M#F$H,
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M10!X7\=O]=:_[M>#U[Q\=O\ 76O^[7@] !1110 4444 %%%% !1110 4444
M%%%% !1110 5/9?\?UO_ -=%_G4%3V7_ !_6_P#UT7^= 'V!X*_Y D/^XO\
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MXW_Z#='_  AOC?\ Z#= 'L 8,,BEKG_"VGZEI^F1Q:E<^?,.K>M=!0 4444
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M!?\ )1XO^NC?^A4 ?4T'^I6I*C@_U*U)0 4444 %%%% !1110 4444 %%%%
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M** "BBB@#T[X<_ZI/K7I5>:_#G_5)]:]*KU*'P(^$S;_ 'J04445L>8%%%%
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MTQK_ /R [S_KDW\J^9_ /_)1XO\ KHW_ *%0!]30?ZE:DJ.#_4K4E !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X7\=O]=:_P"[7@]>\?';_76O^[7@] !1110 4444
M %%%% !1110 4444 %%%% !1110 5/9?\?UO_P!=%_G4%3V7_'];_P#71?YT
M ?8'@K_D"0_[B_RKI:YKP5_R!(?]Q?Y5TM !1110 4444 %%%% &'XN_Y%RY
M^E>#3?ZPU[SXN_Y%RY^E>#3?ZPUP8OXD?6\/?P9>HRBBBN0^A"BBB@ HHHH
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MEKJRBE8#+*#Q7AVN>%K7P?K:WTD"R0R2*JKC@<__ %Z]PTB6*;38&B "F,'
M[<4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=?_P"0
M'>?]<F_E7S/X!_Y*/%_UT;_T*OIC7_\ D!WG_7)OY5\S^ ?^2CQ?]=&_]"H
M^IH/]2M25'!_J5J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH , ]11@#H*** "D(!["EHH *0HIZJ#^%+10 @51T4#Z"EHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\4SW\&F3-8*#*%^7/K6]
M4<PB,9,H&WOF@#P0ZYX^(_U"?K_A7/:IIGB_5;R.YE@421G(VYKU?Q/XWTC0
MI_(BM(IWW8PIKI_#\MIK%DLYLU3<,X- 'C%EJ'CNRA$20J0/4G_"K7]N^/\
M_GBGYG_"O;KJQM(K>1Q;*2%)Q^%>1P_$."PUF6TN]+PAD(#MTQ^= &EX+U7Q
M;<ZP4U.)5AV]LUZRF?+7/7'-9&AW>FZE:I=6JQ@M_=K8H 6BBB@ /2O&/BA
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10!FZ_\ \@.\_P"N3?RKYG\ _P#)1XO^NC?^A5],:_\ \@.\_P"N3?RKYG\
M_P#)1XO^NC?^A4 ?4T'^I6I*C@_U*U)0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >)
M?&ZTEN9K7RUSA:\/_L>[_P">9_*OM*[TNROR#=6Z2XZ;JI_\(OHO_0.A_(T
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M\:^)?LL+%HUD*'!KU#Q)KUKIO@]&MY4 <%0%/L*Y7X0Z6+B2\OY1R)BP)^M
M&%Y&N?#W4(Y7.V%W5!DGN<?UKWS2;T7VG039R60$UY9\8[VVEL[2&-E:47"Y
M Z_>%=_X.1TT6'?GF-<9^E '14444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!FZ__P @.\_ZY-_*OF?P#_R4>+_KHW_H5?3&O_\ (#O/^N3?
MRKYG\ _\E'B_ZZ-_Z%0!]30?ZE:DJ.#_ %*U)0 4444 %%%% !1110 4444
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MJ/\ A!]=_P"@U<_G_P#6H ]9\V/_ )Z+^=*'1ONLI^AKR7_A!]=_Z#5Q^?\
M]:NB\)>'-2TO4&EN]0EG0KC:YH [JB@=** "BBB@ HHHH **** "BBB@ HHH
MH P_%W_(N7/TKP:;_6&O>?%W_(N7/TKP:;_6&N#%_$CZWA[^#+U&4445R'T(
M4444 %%%% !1110 4444 %%%% !1110 4444 >G?#G_5)]:]*KS7X<_ZI/K7
MI5>I0^!'PF;?[U(****V/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS'G+GUQ6'K7P>:W@>XLKU@ZC(5/_ -5 'HEEH.BW<:S0H",Y'2NBBB6) BC
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MJM?N8[*1AV%6:IZI_P @Z7Z4 >$:9;KJ?Q7O1*-P"@_J:]^MD$=M&@' 4"O
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M[@2#GZB@#ZO@_P!2M25'!_J5J2@ HHHH **** "BBB@ HHHH **** "BBB@
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MLFE^)K"[TZ.59% 5 ""P]*=K_ABTUV#RY%56_O8YKAI/A%*)#Y6LSHA/0,:
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M44 %%%% 'IWPY_U2?6O2J\U^'/\ JD^M>E5ZE#X$?"9M_O4@HHHK8\P****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W7_
M /D!WG_7)OY5\S^ ?^2CQ?\ 71O_ $*OIC7_ /D!WG_7)OY5\S^ ?^2CQ?\
M71O_ $*@#ZF@_P!2M25'!_J5J2@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=?\ ^0'>?]<F
M_E7S/X!_Y*/%_P!=&_\ 0J^F-?\ ^0'>?]<F_E7S/X!_Y*/%_P!=&_\ 0J /
MJ:#_ %*U)4<'^I6I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#FO&.I7.GZ/-):A_-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT=S'E#E2*@CTVVC?>(D+9SDJ* /FC3=,N]/\5XO)/,F\Q=Q_&OIRS_X\8/\
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MN58']TO3Z5POQ)\*2ZO9Q36<9::-]_'L<USFB>-M8TJS:UOHT21#M49[#\*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M-?[M?*?BT'_A8;?]? KZM(R,5YMJ?PNL=0UPZB^_?Y@?B@#L_#G_ ""8?]Q?
MY5KU5L+1;.U6%>B@"K5 !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>)?'GI8_3_&O;:Y#QIX,M_%?D^?N_=],4 <I\%_^
M1>@KUJN9\)>%8/#5BEO#NPOK734 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !132ZJ<$BE!!'!H 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D 9-<=XA^(>D:
M&QBEGQ(#C% '945Y=9_&'1Y)PDUQ@&O0-*UJTU>!9;5]RL,B@#1HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL;7?$5EH
M5LTEU)MXR* -FBO'[CXO1&4FWE!C]:Z'P[\3M)U:00//^])P![T =_134=77
M<IR*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 444C$*,F@!:*\W\1^/Y([MK/2G#3JVU@?6N>?X@>)=)D$FJ[$@[D4 >TT
M5A>&_$=MK]FLD+Y;;EJW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y+QKXH&@Z>#&OF2,VW:.HKK,CUKQWXBS?9M4\R
MYR(!(,?G0!GOIGB35H'U :G<6T8^8*<=/RI_A#QAJ-GKS:;.9;O8!EC6EJ_C
M(75E:Z5I)#/-&%QCOBKVB>$WT6P?5I4 OV0[\].E 'I5M.MQ K@\D9(]*FKS
MKX;>(+S5S?K=$?NI2JX^M>BT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %(S*BEF. !DFEJM?1-/931I]YD(% 'G_CKQMY"OIVF_O9W'
M#1GD5F>%? 4NI'^T-68R^:,^7(.E<?JMA>^%/&$=_=J?(4EB3SW!KV_PSKMK
MK&FQ20,"2N: ,75?AQI5W:LEO;10R$<,!7F7F:OX$UP+))+):O(%'H!7T)7(
M>/=$@U/1I'=1NB0L"!0!MZ%J\6L:>MQ$P(P <>M:E>2?!V_D&G36S'($Q'/U
M->MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)D>H
MH P/$_B>U\/V#RNZF0<;,\UY3IUAJGCK6&N)I)8K6-\A6Z,*ZOXF^$9M9LGN
M+4,TV<XSQ6+\/?&*:?,VE:B0DB'RT&* /0+7P1HD-L(VL(6..N*X?QG\//L\
M9O\ 2B(&B&_;&.M>M1R+(@93D&B:)9HFC<95A@T >4_#;QA/*Z:3J!;SUZL_
M6O6 0P!'0UX1XEM5T3X@O<VOR]!^M>V:5(9M*MI&ZL@)H N4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "LS6=9@T>T:>9E 7UHUG6;?1K?S9\XQGBN9$VC^/M*>(
MDLK'&,T =;8:A%?VJ3Q,"&&>*X?X@^,%TRUDLT;9(?X@>:=JNM67@I+*TC+*
MCG8:S_%7AFQ\:Z2U_8#=<D<<T 2>#/"ECJ%M)>7BQW+3KN&\=*QO&'@VZT*X
M;5=(9U"=(HJ;X(\4R^'[UM*U1BH4^7'7L'[C4+;LR,* /./#FNZ=XHL?L&IP
M1+<1+MS)US5L_#"$S^9'<A8SSL X_E56_P#AY);Z]%?::F TNZ2O2H%9(55N
MH H SM)\/V6DQ!8H$#XY8#K6M110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !2,<(Q S@4M% 'G&M^/IM+UJ&TN+%EA=L%VZ8_.MY#IEQ:MJM
ME;Q23.I^9.IXH\7>$[7Q#:,63,ZK\F*\RT?6M0\$:K_9NH$BR7Y1]>E &YHW
MC@MJ4^G:M:[$DD*KYOI6?XP\'-:7)U[19.&;[D/H.:V/$OABT\1V2ZIIPS<(
MFY3[UE>$O%LUC<?V%K;?=7!'UXH Z7P/XXCU*$6EX!#-'\@#'EJ[#5-(M-8M
MC'-&C@]":\VU?P-*-7M]2T-<*3O;\:]+T5;I=,C%Y_KOXJ ,[PUX97P\LRI(
M&61L@#M70T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R21
M8HV=B %&233ZY'Q[J\FF:6HC./-^4_C0!FZ]\2DTR<Q65J+PC^X?_KU0TSXH
MKJTC6=]9"T\P;?G]_P :C^'WA6RO;26]N5W2^82#]2:J?$?PC:VJ6MW9H5D$
M@8G\: .WT+PS:V,@NH&0[COX]^:3Q'X3_M]X2\^$C<,5/>F> K^2_P!$S(<E
M"%_*M#Q'K']CV@FY_"@"-O!^C-9^1]AAS@ MBO)=)CDT/QS=0V\A\HR!0B]!
M71'XM6KVTD2&3[3G"\5'X-T"[U+6Y]6OES'*=R&@#TN72[*_BC>YMDD8J.6'
MM5N"WBMHECB0(HZ 5(HVHJCL,4M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%17,GEVTCC^$9H R-?\2VNB6[.SJT@_@SS7!/\ %^Z2XVG1
MG$.?]9VQZ]:RKO/B7XC?8;HDVY'(S[UZ#?\ @S3&T62$1](\"@"/3KC2_&-J
MMPR1&1C]WO72RV"/IC62X52FT>U>-^"&?1?'BZ0I(A SC\:]LE<K SCJ!0!@
MZ7X0TZQCQ+;QRR9^^1S7'?$CP[8QB"YMHXX)(_F&T<D\TFN>/;_2=<:%R?LX
M'85BW%YK/C74;;RN;9&^?(/2@#O?AW(]YX4B-R"QS_%740:?:6SLT$"(S')(
M'6JVAZ7'I&G);1C"BM*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***9)(L2;G( 'K0!5U33HM2LY()%!W+@$]J\5U/3M2\!ZW]LMS+-:K
MR57[M=UK7Q0TC2[@PDN64X;;S4EEX@T3QS8&U.2'.,-0!3WZ=XZT49,:W*)G
M'=37%Z=J&H^!=:%K<B26T!R7;[M+J6F:IX#UC[59?+:2OEL?W:['_B5?$#1"
M,;I6X.?6@"#7_#]EXJTR/4=.D2.=%WD1]2:7X>ZAJT,BZ=>V\Q7/^M>J7A'1
MO$.C:K/;Y468;"CVKU.*VCC(8* V* )Z*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $) &3P*X?Q;X[&C,]O:0_:9P<;%ZUTWB"Y>S
MT.ZGCX9$R*\P\'6=OKNL-JEZI:1ER2?SH K6'Q.U.VOT2_TR2&*5OO/C 'YU
MV6JZ3IOC71A- T0E.6#KUKB?'7E^(=3M[#2QG:=C<5DZ-KVI> M:_LW4'Q:Q
MX  _*@"_H^L7_@S5387RR2V\KX#OT KJ]=\*V?BJTCO].F2*1G!WQ]36A=Z=
MI/CO3/.5"TH3@UN^%M"&A:1%:8P4H ?X=TJ73;%89YC,0H +5M@8Z444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4A.!FEI" RD'O0!PWBGX
MA0>'=32U95;<,Y)J:[^R>-]$C,4R!\9P.U<5\6/"B3W@U'8?*C3YC^%<OX9U
MS4O"CPW!8BSE(50/2@#V7P1H$V@V$L$LS2;I"1GZFJWQ%=5TZ$'N<5T&AZ[:
MZU9+-;N#P,\]ZY#XJN4T^T(Z;^?SH O?#A1#H<I8X'F9_G5C4_$^F27GV%UB
MG;=M*GM7G47C;[#H<FG:>Q^V/RM;G@KP3)=3_P!K:LF9)/FS[T =S#X5T8E9
MA80989^[ZULP6T-L@2&-44= *>BA$51T48%.H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH QO$NM?V%I+WA3?M[5Q/A?XEV^O7=U:7*K!
MSM7<>O2NV\3:2FLZ1):NN0>:^<8] GM-;O7MAM>WDRN?PH ]>3P8Y\<+JT%P
M1'MZ#I7?SCR].=2<X7K7FO@3QV7V:;J;G[5[]*]'OI!)I4SH<@ID4 >0:0GF
M?%[<.FW^M>L:MK-II-H6N)44[>%;O7BMKKEOHOQ :[N21A2*LG^U?B!K0VG=
M9PR<@Y^[_DT >G:3_97B6S%V]E"Q8]2*W+;3+*S_ ./>VCC_ -T54T'0[;0]
M/6UMUVJ*UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ
M.:=+>,O(P"CU- $E<!\1]<DM-,FM(6*R$9# \U=NOB1H]K>?9F#E]VWBJ^M:
M)'XLB-W;+R1@9H Q='\(646@/J5_(DKS1[OW@Z5YQ++?Z3JYU/3(W>UC)&(_
MN]:[OQEJEQ8VNF:/ ^W<?+D'KUK=70K+1?!KQ3!=K?,<$=Q0 W0_$.F^+M*-
MG>^4LX3;\W4&LS1O!MYHGBQ&M[B1K3K@?=ZUS/ACPCJ,OB&2[L,+#YFXY]*]
MWM8VC@57^\ ,T +#"BH#M&[N:FHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH "<#)KE_$/C&UT4,B,DDZ]8^]:OB"[>QT*[N8SAHTR*
M\C\-VUGXEU$ZKJI#;UR<G!H [/2?%DGBB&:TEM/+1OES3=;TY/"NC&6VP2<K
MQ7/WOBW0/#\C6^FQR"8G (&>:I1^.DUQS8:GO*D< C'- %[X<K8"2^O+NY1W
MWEAO_AJCK-A#XL\;3V\6TQ\,)!WY-5X/A_X@BE9[!D6UN#N(]J]&\)>$8M%B
M2>9!]JQAB* +WACPZ-!M#&)=^X?E6_110 4444 %%%% !1110 4444 %%%%
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M]EHTD=\CJV_C=Z<UWE'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAJ]W+9:=)/$F]UZ"I
MI;ZWA8*\T8).,%A4CK%=1;20RGT- 'D=F8/&6NO#>3>6UN^[97JMKIMK;6BP
M1PH(\#@#K7B_B+3KCPCXG74(!MCN9AG [5['HVI1:GI\<T3 _* >>^* /-?'
M?@5XY/[2TW<LBG>RQ\5+X#\<M\NG:H?*FW8 8\X%>IR1K+&R.,JPP:\G\>>
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M_7(H @\*^%X=,@2;:%=L,1CUKKJ10%4*.@&!2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 445ROBSQ?;:%:[<[I7&%V')!H Z9YXXSAFQ5'7
M$^T:%=JG.Z(@5XN]UXUUP->6=X8X<X"LIS_.M/P?XWODU"72]:D:1L[!P0*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M L<,:# QD+UJ\N=HSUQS2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gtinntqqusay000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Y!8<# 2(  A$! Q$!_\0
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M6N_\_/\ .C_A.M<_Y^?YUS=(>* .E_X3K7/^?G^='_"=:YG_ (^?YUS5 ZT
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M!7%)FIR,TTQBBPK$:C-2JN*%7%.S0-(,TE%)0,#2TE+B@0F>:>2-M1XRU.-
MPSCI1DXI*6@!<Y'-1D="*=2XS0(=GBBE(.*;3&':HSE34O I&.:!"@Y(I>M,
MVXYI?,Q0,4^E-Y%+24@'!RIRO!J]%,DT3"3D@5G=J56*9QWJE*Q496 ]3CUI
MA!!I13A4D"9XI11BDH 4GTI,T44 -'WN:?4;9)I0Q'% #Z2@$FB@!:2@T4#%
MK0T+_D.V?_72L^M'0O\ D.V?_72@1];>&_\ D$1UKUD>&_\ D$1UKTB0HHHH
M XGXH?\ (KGZFOE:Y&;V0?[5?5/Q0_Y%<_4U\M2(7OI HR2W%"&E=D#_ "MB
MHQ4MQ&\<Q5QAA48Z&F]P>XG6E'%-IPZ4A"'K244N!0 "C&:#TI* %(Q0!2KS
MUI#0 \D;:9D4=J2@!<TE%** "@T9P:7.: &T4N*2@!>U)3NU)0,*2E^E)0(6
MI;<.91L.#ZU$!D@#O5]56VMR6XD["JBBX*[N6%GB@'[T;FIAGCNOW2#;GUK,
M=R[$D]:0$J<@T^=[%NJ]NA+/"T;$'\ZAK1BF2X3RY< CI[U5N(#"^,<4FNJ(
ME'JB"EI**D@49!S5O[]H>,M53-3P7+0=%!^M4GW+BTMQ@@<]B/PI3 P.*FDO
MWD_@4?04R.Y8-T!H]T=H#XK;9\[$<<XJ9+R/S=K#,?I56=R0#GK5>G>VB!RY
M=$:%S:!AYD>,'G JCL;=C!_*IK>Z>$^H]ZL&Y5GWX&?3%&C'[LM22V_<W, '
M\1YKZD^''_(J0_6OE2VD,FH0_P"]7U7\./\ D5(?K4MW9$G=G7T444B0J*Y_
MX]I?]P_RJ6HKG_CVE_W#_*@#Y%\8)_Q/KHGM*:YIB<UTOC23_B?7(_Z:FN8)
MYILIA24M)2)%I*6DH >#GBIC(J1@ ?-ZU$@YS22<FF4G9"%BQYI***1(4E+U
MIR(6; % [#XQD9JR(2R [@/:FH@CYJ"60ER03BKV6I?PK4F:(DX!%5V&&(/4
M4^%RLRMUJ6Y7)\SUI=+@TFKD87,+-Z5!FITQY97UJ%A@XI,E[""I8(][U'FK
M=DO+'VIQ5V."NR25Q;8 ^]CK5*1R[;B<FG3N7?)[5&,T2=V$I7=BQ#+A=K<J
M>U128W';P*(_OX%#@[C1T%=M#.<T=Z.M*!4B#ZT4=Z6@! .*,>E+13 3O124
MX#BD +GO4\>=K<U#VQ3XFPV.QJEN..XS%)4TZ;6^7I4:@L<"DT#6MB2!"SX%
M/8,YV^E3QQK%!YC'#>E0"<B3.!C-7:RU-+)+4B:)D."I_*IH. P(QFK37B/'
M@@?E5<D/\W0#TIV2>@^5)W3/=?A",::GTHI/A"V[34Q_=_I16;W,7N>$7W_'
M\<>M:K%TBC=F^51R/6L^6,RZB0.U2ZG,P2-!V&*N&D6S:G[L7(CN=3=V(A)1
M.PJ@9Y"V2W-1T5#;9E*;>Y;CU&ZB'RRD5I:?J4ES<)'.VXDX!-8520R&*57'
M44XR:94*DD]R_K:M'?.F<H.E9E;-^ADTU+EOO,:QJ)[A57O!1114F8Z/B13[
MBMS479[=?3:*Q8(VDE4*,\BNCF,$<:1W#;016D%=,Z**O%G,45NM9Z9+_JI6
M+51GTV6,%U7Y!WJ7!HSE2DBA5O3Y!%>(QZ"JI&#BE3[PI+1D1=G<OZI%F0S@
M\,:I02>5*']*TI5$MHBGM51M/FQE5XJI)WNC6<7S719O5,EJDH4G=2Z9:@,+
MB9?D4\@T];J188X7484U->W!6T,8  ([5=EN:6C?F*6I7QFD,:'$8/ K.HHK
M)N[.>4G)W85/:R>5.K^E05)"K/( HR:%N);FQK#;[*%L=:PZZ#55W:; H^\H
MYK JJFYK6^(2BBBH,34TW4/*/ER\JW JS>::)7\V(C9[5A#@YKH]$N?/06K<
MYK2+OHSHI-3]R1'JLPBL8(T."!@XK [U?U0L+ED/13Q5&IF[LBK*\A****DR
M%!(8$5KM&9='\PC+9JG9:?-=O\BY4=:W=JVD'V8]/>M81ON=%*#:;>QRY!'4
M4^*)I7"J":Z);+3)48M*0_84ME9P6TV\'/'>CV;N"P[ON-N?*TVP55QNE7G%
M8-NQ:[C)_O#^=2ZA<--<N">%/%0VO_'S'_O#^=1)W9%65W9;(^Q_"G_(M6'_
M %Q%;58OA3_D6K#_ *XBMJI,@HHHH *\5^,__'H_^]7M5>*_&?\ X]'_ -Z@
M:/"Z<!Q2"G$\8JBA*2C%% #C3#3C3: #M1VI:-N:0 /6D)YIQ&.E-QFF +UI
M6I,$"G=N: &T9I=N:-N#S2 ;3L@4$8J)B<T"+':D8C'%)N)7%)BF4PH%!HH$
M&:B_BJ?'%,P,T !%)3\8XH&#Q0 WM24XK24@"D-+@YI0.: $P:3-*S8;%'%,
M!*6D-%( QDTPJ<]:?2]10(0=*6D'!Q3LB@8AZT#K2YXIO- #JT-"'_$]L^?^
M6E9PZUHZ$,:]9_\ 72F(^MO#?_((CK7K(\-_\@B.M>I)"BBB@#B?B?\ \BP?
MJ:^98MK:J3T ?FOIKXH?\BN?J:^6)W:.^D(_O4T[,J+LR?6B/[2DVGBJ .!3
MYG,DI9NIJ,T-W=PF[R;%P*-PZ4VEP:1($44HQT-'>@ /2FXS3J7H* $Z4VCK
M10 X4VG"DS@T )2XXH/-*.E #:6DI3[4 *3Q2#I24HZT +FDJ:. L<D?+4TB
M6RD ,::BRE%M7*=&#G%6U%O_ 'J=$L!D #<T^4:@.@B2!/,D&<CBJL\QE?-7
MK^*185.,+VK,[TY::%3]WW1*7%)2YJ#( 2IR.HJ^K?:+4AN9.QJA4]K(4F!%
M5%EP=G8A92K$'M3:MWD8&''5NM5*35F3)6=A:7M3:<*0A*=&/FH">M+D*<4Q
MH)&W<>E1U840D<MS08D(^7DT[,=F]2N*D)P,4FW;G--)S4B+5AC[;%_O5]7?
M#C_D5(?K7R?8?\?T/^]7U?\ #C_D5(?K0(Z^BBB@ J*Y_P"/67_</\JEJ*Y_
MX]9?]P_RH ^0?&?_ "'[K_KJ:YNND\:?\A^Z_P"NIKF^U "T444 % HYJQ';
ML5W$<4TKC2;(1PPH?[W%3!8QG)YIC(1\P'%%M!VT&B-R,[3^5)L8?PFKB7Q1
M-NU?RIAN2Q)P*=EW*Y8]R".(NV.E3%?*^4'YO6D\S;R*B>0LV31HA:)%H*?L
M[$G-4ZT(@'L9&/45G<TY=!SV0O(YJQ*Y:V45 .3BK$I'DJHZBDMA1V974E>:
MG=HY(@ ,-W-0=Z"I!I)B3MH&RK"MY:<'J*K_ #$[0*G6)RN&%->14?(KGDT@
MXIYC8'&*;@@X-(AW);< S#-.N4VMGL:CC1CRHJS.DAA7<.*I;%I>Z4QUHZ&E
MQBBI($I>E)SFG<T@$HQ4B;"/F-(^!TIV';2XS'K2]*7&1DTAH$'O2J<'-)S1
MB@"=)5SAAFK2&%1NVU5MT4O\_2FRN=Q4=!TJT[*YJI-*Y)<3B0_+POI58FCF
MEQQ4MW,VVW<.M3$[4^HJ$5+)AE'M0AH]V^#O_(+3Z?THH^#O_(+3_=_I14D'
MDK6?V6\:=CNSQBLW5P2ZD+@4Z^U&87AZ8J\/(U&R8YS(HXK96:LCJ7+./+$Y
MKM13Y8FB<HPP13*Q.4***GMK9KF9449S0-*[T-F-/M.D1Q9Z&LR?3IHSPI;Z
M"M.XDCL+98,XF4\BJW]NW & JX^E:RY>ITSY-I;F8;>91EHV'X4S!SBMR'58
M[CY+K 7V%3"QT]YE:)B0>M+DOLR%24OA96LH5LX/M$@SN& /2LRYN'GD)8D@
M'BKNJW!#FV3_ %:GBLNE)]$34=O=0Y9&3E3@U=MM0=6 E)=>XJA14IM$*36Q
MLRV*7@\V$@9YVCM5=M-,4;2%NG:HK&\>VF&T_>XYK4U1QY'R]QFM$HM7-TH2
MBY=2C/(!:)M89JM'>2HW+$KZ57R3WI*AR,7-MW1N+LNHU95Y7DU8,:7NGNRX
M#KP!6/8W3P2;5_BXJ^TG]GWB#/RL-QK12NC>,TU=F-(AC<H>HIM;6IV8>,7,
M8^_R:Q]I)P.M925F83BXNP*A=@ ,YK>T[3UMT^T3, 1_":6RL(K2W^TW/&1E
M?K69?:A)=2<G ' Q5I<NK-%%4US2W-@7L$\CQ,HP> :R]0TXV[%T.Y.N1TK/
M#$'.:W=-F%Y:FS;EF-._-HQJ2JZ/<P**GNX/(N'C]#4%9&#5G8*V='MW5Q/G
M:!WK,MHC+.B^IK<U&86-F;1>"1FKAIJ:TDE[[Z$CS6DCLKHI;^]56728I1O2
M=![9K%WGKDTY)WC;(8_G3<T]T-U5+XD33V4L38"EAZXJ>PT]II1Y@VKZFM#3
MK_[2C1R@9 PO%)J-T]O;FW( ;KQ3Y8_$4J<+<_0==:C%9Q^5 H#8P6%8CW<T
MC99R:A9BQR325$I-F4ZCD2":0'(8UL:1?J7\N7GCJ:PZ?$Y20%:(R:80FXRN
M6-0A,=RS8^5CQ45K_P ?,?\ O#^=;>J6_P!HL[=HQDA?FK&MT9+J,$?Q#^=$
MU9A5ARR/L7PI_P BU8?]<16U6+X4_P"1:L/^N(K:J3,**** "O%?C/\ \>C_
M .]7M5>*_&?_ (]'_P!ZA#1X8.:<1WI,@4I;BJ*&T8I<BEXH BW?/BI,9-18
M^>I:$"#&*,TE+0 $\TN1Z4G6@=: $8T#DTC=:4#B@!^1MS3-V:0TG:AL+BYY
MI&6BG=J0 .E+2C'04$4P&]:7I1323F@!X.1BC&!FHP34AY% #>] /-+Q2T -
M=L4@Y%.; I ,T  (]::7 H(%-*>E(0A.XYJ0=*8J]JD(P!0 VE%)3E% "=**
M=@&E Q3&19P]/QWH*@G-/7&.* 1'THI6&#2XXXH !QS6AH7_ "';/_KI6=S6
MCH7_ "';/_KI0!]:^&_^01'6O61X<_Y!,=:]20%%%% '$_$__D5S]37RM=G_
M $R3_>KZI^)__(KGZFOE:\Q]KE_WJ (B<F@$4G0<4V@8_:#WI",4W)HS0(<!
M2'K3NU,H 7FE-)VI1S0 E%*:2@!4&:0TY>*;U- Q*<: /6D[T )1110(*<JE
MFP*05=M8U6,S'^&FE=E15V).^RW55X;O5/.>M23/OD+=C4=#=V$G=B4JDJ<@
MXHI0,G%(1N6,GGPE9ER .":C.E1S9*S*.>F:D.;>P1CQN%9*3O'+N4GKZUM)
MI63.F3224E<GNM,DMQD9;Z51((ZC%:T6L2D;)0NVI);6UNH2\!)D]*EQ3^$A
MPC+6!B#G@5J:98F2=6D.Q?>I+?3DM_WEU\N.5J*\U$L#'%C9ZT)*.K",%#WI
MD]\(HB5W!_3%4HS$>H%5"Q)R2:;FDY7(E4N[V-,6L4G\:BH9[3R3D,&7VJH"
M?4U?B(:R(8T*S&FI:6*!8YZTW-.;AC3:@R"GHQ]:;U.*>1L'O3&AK$YIM%%(
M18L?^/Z'_>KZP^''_(J0_6OD^Q_X_H?]ZOK#X<?\BI#]: .OHHHH *BN?^/:
M7_</\JEJ*Y_X]I?]P_RH ^0?&G_(?NO^NIKG.]=5XR@<Z[<G'_+0US9MG W8
MIV97*R+I2JI8\#-/$+,<8YJ^D0M+<2M]X\4U&XXP;*T4:Q_,_;L:;-<[SA!M
M7TJ.64R,346*&^B!RMHA3ZU<M9$9=C#M5+O3D^^,>M).S%%V8^2/:QI(\5:O
MXRGE^XJFO7BFU9CDK2L.<'.!2>6_]TU*#L.34ANLC'%%D%EU'VX/V5QN_"JP
MAD9L!34FXJP9>G>K OB@X S5:/<OW7N,^RB(;RP..U5W.6)[4_SVF?![U$XP
M^*3MT)DU;02@]N:,>E2>2VT-BI)2;)0%2$\?-ZTV&X\MOFY!I6R8B1T%5>:I
MNQ;;3T--+B%V&4 I'2-R2J@UG &K^G#]XV:I2OHRHSYG9CE0/"<+LH*;TVF4
M<4Z^FVJ8UZ&LY6(.<FAM)V'*2B[#I$,;[3S[T!<]ZF8F6(L?O"JW?FH9E)),
M=MP>M(U&<]*?& V<]J0MQJ8 Y&:G6:+&TI4#<-BDIW:&I-$CK@Y'2HJ?N.-E
M-[XH8,2I$3=S32.>:FC(53N_"A($M=0(VQ[@>:@/K3V8GCM3#0V#8=J,TO:D
M/'2D2 Y/2K$<1DX]:9 NZ3%7YMMH(V[FJBNIK".EV>V_".W:'34!_N_THJ3X
M37/GZ8AXZ?THJ7:^AG)*^A\_ZA_Q]M2Z=<&&Z09^4GD4W4?^/MJKQYWC%"=F
M$6T[FQK%NLDIN(NC'H*S5M)V'$3?E6W:)^X#3?=[55FUF2-BD6,#BM91CNSH
MG"'Q/J5H-+>4X8E?K6I;VPLK.5\;F'0UEMJ]RW4BK-IJ33 PRGAJ47%"@Z:>
MAEW$S3REW))/K4=7;ZT\F0LH_=]JHUFTT]3"2:>HM;NBJ94.3WK"K:TEO*MG
M?T-53^(TH?&4=47;?R#.:I5HW\+R,9P.&K/(P:4MR*B]YB4445) ^/\ UB_4
M5J:F3L3G^$5E)]]?K6Q=INM=S=0*N.S-8?"S%HI<'TI*@R'1G;(I]#6I>+]I
MA$X/W1BLFM2T=9-/>#^-CQ5Q[&E/6\2>PN!/"87/ '&:EL]-CA<W,CAE!Z&L
MNV0QW/EGKG%:&K2/:J( >&&:I-6NS:+7+S2Z%74K]IG,:'"*>!6;116;=SGE
M)R=V%7M,F\B^1_2J-6+*-I;E5'4T1W"#]Y6-R\L$O=KJX#-UIL/AZ/</-NE3
MZT^4BQA#.<,>E8USJ,URV6/Y5K)Q3U.F;IQ=Y+4W5LX+611&RRG/45F:ZLGV
MP%@>E4[:]EMY RGOWK:GE35;$N>9^@HNI*R%S1J1:6AS=%.D4QR%3U%-K$Y2
M]IQ*R[AV-+JLOFW6[VJQI%NTD4SX^Z,UG7+;I2:M_":NZIHAI>V:2CO4&0^-
M#(X4#DUOV>D1Q1">>0#_ &6J/3;)+>(W$XP0,K5/4-3DNG(!^6M$E%79T148
M+FEN7I-:B63RA$"JG'UJY;?9-0EC 5(VW"N4S5FQD:.[C93_ !#^="J/J)5W
MM+8^Q_#2"/0+-0<@1#FM:L;PJQ;PY8D]XA6S69B]PHHHH$%>*_&?_CT?_>KV
MJO%?C/\ \>C_ .]0-'AG2BBBJ*$I11]*7':@!"!O%./6D(&<TN,B@!**.:#0
M E.7K3?I3AZT A"O.:0FE!R#3: $I124O:D(2G"@"D<]A0,16.ZG9YI -HI*
M ' TK+QD&F4H..E "J.:<>*9N.*<"",4P"EZ"FGBC)(H 2CZ449I %)2TE "
MC[].)%-QSFB@ H!H-*!0 Y1QFD-*">E(:8"4HI*7M0 -2"CK10 5H:%_R';/
M_KI6?FM+01_Q/+/_ *Z4 ?6GAO\ Y!$=:]9'AS_D$QUKU) 4444 <3\3_P#D
M5S]37RO=C_2Y/]ZOJCXG_P#(KGZFOE>Z_P"/N7_>H @/%-IQQFDH *,44O6@
M Q\M-IQ]!2<T )3NE-IQH 7((I,&D%/)H&&,"C %(3Q3>: '9I,<T4H/- "?
MA28IQ/I2 T *@RX^M6[EO*01CH155,>8/K5B]!W*3Z52V+C\+*E+24G>I,Q:
MMV=HTSACPG<U7A3?*H[$UJWTWV.'[/'PK#)JHKJS2$5;F>Q/*HN(3$'_ -6/
MSK#=2K$$=ZL6=R8Y>3PW!JY=67GR!X?N8YJW[RNC27[Q76YE=JMV)D\]0"=M
M6ELH(AF>F2W-M"O^CGFDHVU8E!Q=Y,FU-9#"FUBWJ!VK$YSS6C#?DMB0\'K3
MIK6*;FW[^M$O>=T*:YW=&915TZ9/C.!436LBG!%1RLS<)+H05HQ#&GEO>JHM
M9&(&*MNOD69B?[U5%6+@FKMF:W+&@ GI0?O5*F$&>]2C-:L79Y8R>IJ)FW'-
M*\A<\TRAL;?86BBD-(DLV/\ Q_0_[U?5_P ./^14A^M?*%C_ ,?T/^]7U?\
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MBIXILKYX]:E-)$)I+022=Y.K&HJ*6I;(;;W%3E@*LR[X1A7(JO%_K5^M6;S
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M&F\=Z3-%(0X 4C=:!0W6@!!0:2B@05(IP,TRE)P,4 3V1S?P_P"]7U?\./\
MD5(?K7RA8?\ ']#_ +U?5_PX_P"14A^M '7T444 %17/_'M+_N'^52U%<_\
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MJ$D"[16A RW4BR1J"!UXKEZZ70QY=FSOT![UI"3;LS>C.4Y<K*6J:E(S&#
M7TK(+%NI)K4U&S=YWFC!8'GBLLJ0<'BLYWOJ95>;FU$HHHJ3(Z!9S-IZQ_W5
MK!;[Q^M;&DD2PS*>RUCO_K&^IJY:I,VJ.\4QM%%%08FMH]ZUN[1YXDXYJ'5X
M1%=X'<9JO9Y^U1GT:NFN[:&YF5WVIQWK6*YHV.F$7.G;L<C6AHV?[07%:IM;
M-01N0_C46V*(9AP7[8H4+.XHTG%WN4]7;,N/>LNNGDCAEB4R *P'.>]11:;;
MWGRI(B&B4&V.=)REH<[16C?Z7+9MW9?451BB:5]J@DUFTT[&#BT[,FL[1[F4
M #*YYK=FGBTJW\J/'F#U%,*I86BL,!F6L*>=YY"S')K3X%YF^E)>8];ES<^8
M3SG.*VG<S6T<QX.\=*YT<$5TUL VC1<<[Q2AJF32;:DCZF\*?\BU8?\ 7$5M
M5C>%>/#=C_UR%;-9F 4444 %>*_&?_CT?_>KVJO%OC-_QZ/_ +U"&CPQ0,@&
MGMM!X-1T515Q<T9I*.U ",H;GO4)X.*G%1RCC-)B8Y#Q3LU"G6I>] (6BDI1
M3&% Y-)2B@ R11FCO0!0 XL#]:;2\4 T )2@>M(?O@"E- "&CM112 *!12TP
M$' Q24M)2 *,TE+0 [.12;3F@<BEP?6F QSMZ4P98\U(_2D48YI"%  I<BD[
MT4#%SD>U,9BIIU(1D=*!"+,2<&GDU"%*MTI^: N.-%%% Q<5I:"!_;EG_P!=
M*S"#ZUHZ!QKMGS_RTI@?6WAS_D$QUKUD>&_^01'6O4D!1110!Q/Q/_Y%<_4U
M\N2QF6_<=MU?4?Q/_P"17/U-?,8($MQ_>W<545=E05V1SS_9U\A0.*I-(S'K
M22EC(2^<^]-H;;'*3;%$C#N?SJ>&[>/L#]:KT4KLE2:+^R.[&Y3^\[BH%LY7
M8A5S3('*2C:<9.*U]2<6R1[."RYR*M)25V:I*4>9]#-;3KE1RE*FGSN"=M1&
MZG/60T"ZF7I(:7NDW@6?L#!>!\W>JLL;(<,*!<R[L[S5KBY@+9^8=J-'L.T9
M;%"E'6@_*<$4E09#J.*".,TV@8_B@[<=:92T +C XIIZTHI.] @I,T44 .!I
M,8HI>HH 3%** .:7@"@!?K3B"(SCI4>:D0EAL ZTT4B(T5*8']#2>2Z_>!%%
MF+E8L:@ DU&[%FR:<S8XJ.@&^@4M)2TA"K2[32=!1D^M Q,8I0O&:7ZTF:!"
MC -#@=13:!0!/8_\?T/^]7UA\./^13A^M?*5CC[;#_O5]6_#C_D5(?K0!U]%
M%% !45S_ ,>TO^X?Y5+45S_Q[2_[A_E0!\B^,#_Q/KK_ *ZFN?ZUT/C ?\3Z
MZ_ZZFLFULFG((.!UJDKEQ3>B+%C$JP.93@4\/$Z[8#N8>M-OY%B58T(Z8.*H
M6\ODRY'?BM+VT-W)1?*-GD9G()QBE$I>(1GH*MW\ VJZ+U&36?SUJ'=,RE>,
MATB;2,U'WJ499?FJ(YSTI,ABBCKBC/%.09-($:-JLB)YR\A:J7,S2REB3S5U
M7*63H.]9GUK23TL:U'9)!UI*4 D9I.]9F0H!/2M1E"6,9Z&J=F@:Y4'I5N1P
MD\B-RH'%:11M36ES/E()S3 :5N2?K3:A[F3W'48HS2@YXQ2 M6J^6/-'45-
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MNGI4&*O79_T:+/I5'-$E9A-),7:: ,<TF31GBI( TE%+VH 4=*2G=J;0 E.
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M_D$1UKTB0HHHH XGXH?\BN?J:^5+O_C[E_WJ^J_B?_R*Y^IKY4N_^/N7_>H
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M:*#U% AYZTE*W%-H&+FDS2 \TM(1)&=HW5((BY+ BHD(QBE)([FJT+35AS
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M0,4_=%(, 4IZ4V@0O%%)10 [--HHH **** %!H/6DI<\4 %)2DYI!0 4444
M%%+24 %%%% %BQ_X_H?]ZOK#X<?\BI#]:^4+$?Z=#_O5]7_#C_D5(?K0!U]%
M%% !45S_ ,>TO^X?Y5+45S_Q[2_[A_E0!\C>,?\ D/77_74UA1#<^*W/&/\
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M1\0^*Y)+N2**./:&(. *N&FK-J5H^\SD9H'A<JP/'?%15U.B0_\ "0W!MY%
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MQ;2TANC'(B_,V/NBJOB.QLX[94C"@[QT%1)6,FNJ/<?"G_(M6'_7$5M5C^&
M%\/60':(5L4B0HHHH *\4^-'_'F_^]7M=>*?&C_CS?\ WJ 1X52"ES6_HOAY
MM34.P.S&<BF,P:7/&*[E/!UC<V\DUK([I#_K3Z52OO#=DNFI-9R,\K'&#0.Y
MR53+;3&+S IVGOBNFM?#-M!%G5&:)FY3'>MS5M.M]/\ "UM+  T3OM#$=>E
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M07&F7-N,M$Y4=3MXKT#5=;DTSPS:&*"(G.,E13-#UH^(+)["XAB5I#C(49H
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M>:K)9322F,1MN!YXKT;1=0O]7U2$VEI$\(&"=H_PI\44$6L7!VKYRM\RXX%
M'!'0KI1RC?3%4)[::V?$D;*.Q(Q7<^(?%=Q8ZBJ1V\) 7^Z/\*DUG9KVC0S"
M-%=%W-L % C@?O)47>G@[6(/8XIIZY]:8V)2#K1WIP!I ./*TOV:?;N\I\>N
M*% ##=7IMC';ZCIMO#9(DA"XE.T<4P9YDL$I7=Y3E?7%1D$$Y[5ZU9Z5 +_^
MRF1?*QNW8YKDK7PW#J%_JBDMBW8[<?A2$<AFBNWTCP=:WK@2LP'M6O=^!=#@
M55%Q)YK=![_G0%SL?@W_ ,@J/Z?THK3^'&FC2HQ;+G 4]:* /%;S6/)U?,.5
M)(&1]:]!N[BV@\.&5]K,\>3S7D%^2M\3W!S5N;Q#=SVH@8_(!CK5.3;+=23=
MST/PO/:>([-=/8*HC&_YC_GTK'\56RZE<K&DRX@^4#-<?I&LW.C3M-;GYF7:
M<FEMM0FDU#S'8_.V3S3BU?4J$DY>\CT+P^(K32C"<"0(<G\*X^SU+3[+4+@W
MMJ)\R$BDO-7N;:1O+QM(Q7/2.9)&<]6.32GN*K\5CN]-U2SN]3D;3X!;<9/N
M/2NEL]6M;A&M_L#1$\-(1P?>O)K.\DL9O-BZUN2^-;^6V\DQQ@8QD#FI3(3:
MV/0GTNW@5IRR3H1_JU.:T-&GLQX4U(1VWV<@]#QFO)[#Q;J%@Y9,-D8PQS5]
MO&=]=V[PL$4/U"\52=RTTWYG8ZM,C^&+'##_ %@X_$4_4)U6"%E<9"#O[5YO
M=:_=M;I:MC9&<CFFR>([R50K8P!CK2>Y,G=G8>$+D_\ "2:B[/UA;G\#6[H5
M[9Q>&]361!(QE/R=SR:\UTVYU"&>2>!03(N#]*T=/NY=.D,LAPQ.2I/%-1;&
MJ<F==HVH6H\X)9FVRAY88SQ7GGB H;]MF,$GI6WJ?BEKN-8AL4Y_A&*YW48F
MWA^H(R:=K(OEM%HSZ***@Q'*[(<J<5,MY,."Y(]*KT4TVAIM;&KYT<L&".<5
MFM&VXX!-/B1V&1T%3PW"JXW8JF^;<T;YK7*95AU!H"LQP 36OMBG!*^E5T>&
M!MP/(]:.4'32ZD4-FS'+';]:NB)0FUY ?QJG<7SS<< #IBJFYO4_G3YDMA\\
M8Z(TOL"R-E6 %.CMHH)@),,*I0731G&>#UJ_+&K6;3QDD#O35GL5'E>J0MQJ
M$:@+$FTCH:SY;R:5LLY-0,<G-)4.39G*I*1-%=2QMD.:N&\$RY==QK-JY"$6
M#>3S3BV$)/8L?:XXE^5>M/M[B.XDV$;<]S64YRQ/:D!*G(-'.Q^U=R[(9[&?
MS(F*\Y!%=EX?N[G4K=3+=;9/[[&N5BE6[@*2=5'RXJNM[<6D?D+P/8TI+JA3
MBMT=I?:/->3#S]5C<*> 6'%:$4<]MIWV2WU6./'HPKS)KB9F),K\_P"T:3SI
M?^>C_P#?1J3,]/M+&5+2YGFU%)7097FN8.KS7ETMO+(3\PY/UKG[?4[FVC=%
M=B'ZY-,@E9[R-CUW#^=-.Q496/L?PR,>'[+G/[H5KUB^%/\ D6K#_KB*VJ1(
M4444 %>*?&G_ (\W_P!ZO:Z\3^-/_'F_^]0!X4.M=]'(;#P1;W$3[9&;:<=>
MU<"#BM!]7N)-.2R./*0Y%,9VME?&P\.7J;_FG7-0Q.L/A"RG+#S&D /Z5Q\V
MJ3S1*C?=48XILFL7#V26?'EH<B@#N/%$$]]<::D!)5D&2.W%)KGFC0+72P^]
MXY 3C\/\*YRW\8W\$2H$0A1@$U7;Q+>-=-.0I9AC!I >FHT5IX7D1YE>Z,8\
ML@\K7#6^MZ?;.RZE9>?/C!8UB#6[KSA+N)(.<9XJG=W3W<[32 !FZXI@=QH^
MH6[PRRP0[;<'YH1_%6MBSU:%4@M?L9Z[FXKSG3M5GTUMT(![X-:-YXMOKV,(
MRH@!S\O%(#K[J"#28C'<0_;=PSN7G%:NO36\O@_2_)C$7[Y?D[CD5YU;>+[^
MUB,85'![MS3+SQ5>WL21R!0J'( H$>@ZO(AUG3L,.(QW]A576+C9YNQP,@UP
M4WB*\FN(Y7QNC&!S23ZY=7 .['/O0,Z[PY,%\(ZBK,.9#Q^)K?O+^Q7PA8H;
M<7# _=7DBO+K?5KBWLY+5,;)#DU:T_Q'=Z=]P*X]&Y% 6.PO=1MV\*744<'V
M<G^ \9ZUYH#FM?5-?NM4/[U548QA:QONFF&P_K24 Y%% "YHW4VB@!PI:;2Y
MH ,XHS248-  ::!S3O:DYI .'6EIHS1FF I.!30V32YR.:;MYH DI,XH'%%
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MB@ KS+XE^%[C7;9EASDMG@5Z;5>XZ4 ?,W_"K-1]7_*C_A5FH^K_ )5](44
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G_E1_PJG4?[S_ )5])T4 </\ #CPS<:'8)',3D#N**]"@Z44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gtinntqqusay000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6O NP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'@M6-:-XLZJ,K2/;Z*0'(S2UY9Z(4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1XE_Y
ML_TKQB7_ (^&KV;Q+_R!9_I7C,O_ !\-7/6/5R_9D\7%6H^M58ZM1]:Y6>Q$
MM)UJRE5DJRE ,FIK]*=36Z4R$5WJM)5ENM5I*DT14DZ52FJZ_>J4U4B)G:>
MO^/A/K7I=>:> O\ CX3ZUZ77;3^$^>Q?\5A1116ARA1110 4444 %07G_'I)
M]*GJ"\_X])/I36X,\.\2_P#(;DJE'TJ]XE_Y#<E48J]:G\*/*J[LL+5B.JZU
M8CZ5J<TBPG2IEJ%*F6@S8X]*B:I3TJ)J0BM)WJK)5J2JK]:9K$JRUJ>%/^0_
M;_6LN6M/PG_R'[?_ 'JRJ?"SJI;H]RC^X*=38_N"G5Y!Z@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<8_N"G4V/[@IU>2>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>)?^0+-
M]*\8E_X^6^M>S^)?^0+-]*\8E_X^6^M<]8]7+]F6(NE68^M5HJLQ]:Y6>S$M
M)5E*K)5E*!,FIK=*<.E-;I3(1 U59.]6FJM)WI&B*;U3FZ5<>J<W2FB)G9^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEX6_Y#UO_O5E4^%G52W1[E%_JQ3Z9%_JQ3Z\@]0**** "BBB@ HHHH ****
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MOK7L_B/_ ) TU>,3_P#'TWUKGKGJY?LR>*K,=5HJLQURL]F.Q:2K"572K"4
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M2-8MM7MQ-;ON4]Z -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX]DN9U@O' S2L!Z?14<,JS1+(IR&&14E !1110 4444 %%%% !1110 4444
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M,^7O6;/WK2E[UFS]ZN!G4V/1?A=_Q]1_6O9*\;^%W_'U']:]DKT:/PGR>/\
MXS"BBBM3B"BBB@ HHHH *K:A_P >$W^[5FJVH?\ 'A-_NTUN#/FWQC_R,4U9
M$745K^,?^1BFK)BZBO<H_"CQL1\1<3I5J.JJ=*M1UT'%(MQU96JT=65H,'N.
MJ&3I4U0R4A%.7I5*:KTM49J#>!0EZUM^"/\ D9[7_>K$EZUN>"/^1GM?]ZN>
MO\+._#?$?2<'^J%25'!_JA4E>&>P%%%% !1110 4444 %%%% !1110 4444
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MJOR]*H34S>!1EZUM^"/^1GM?]ZL.7J:W?!'_ ",]K_O5S5_A9Z&&^(^DX/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDUO@48I:\]MMW9U)6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MMEKW@SZ#HKGM \4V>M0J8F^8^IKH0<]*W33V/*E%Q=F%%%%,D**** "BBB@
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M>()-)U)8]Y"R, :Z*52S/+QN%52-UN?1=%06EPES;K(AR"!4]=A\\] HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!A^+?^1>N/I7SK=?\ '\_UKZ*\6_\
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MY&>U_P!ZL27K6YX(_P"1GM?]ZN>O\+._#?$?2<'^J%25'!_JA4E>&>N%%%%
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MY&>U_P!ZL27K6WX(_P"1GM?]ZN:O\+._#?$?2D'^J%25'!_JA4E>&>P%%%%
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M_(SVO^]6)+UK;\$?\C/:_P"]7-7^%G=AOB/I2#_5"I*C@_U0J2O#/8"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"1GM?]ZL27K6WX(_Y&>U_WJYJ_PL[\-\1]*0?ZH5)4<'^J%25X9[ 4444
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M8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_C]B^M>RUXU\+_\ C]B^M>RUZ-'X3Y/'_P 9A1116IQ!1110 4444 %5K_\
MX\9?]VK-5K__ (\9?]VFMP/FSQI_R,DU8L=;7C3_ )&2:L6.O;H?"CR<3N7H
M^@J[%VJE'TJ[%70<$RZG2IUZ57CZ586@YWN*:A>ICTJ%Z *DO2J,O6KTO2J$
MM!M I2]:V_!'_(SVO^]6)+UK;\$?\C/:_P"]7/7^%G?AOB/I2#_5"I*C@_U0
MJ2O#/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8?BW_D7KCZ5\ZW7_'])]:^BO%O_ "+UQ]*^=;K_
M (_I/K7+B#V\IV98AZ5>BJC#TJ]%7!(^ACL78ZLI56*K24T$B<=*1J4=*1JH
MS(&JG-WJX]4YN]0S6.QGRUFS]ZTI:S9^]7 SJ;&AH4>^5:Z<6P]*P/#8S,M=
M<$%>C2^$^3Q_\9E'[,/2E^S#TJ_L%&T5J<11^S#TH^S#TJ_L%&P>E %#[,/2
MC[,/2M#8*-@H S_LP]*;+;#RFX[5I;!3)D'DM]*:W \RU9=NH.*@CJWK8QJ;
MU4BKVZ'PH\G$[EZ/H*NQ=JI1]*N15T'!,NQU86JZ=*L)TIG.]QQZ5#)4W:H)
M*0D5)>E49:ORU0EZTS>!1EZUN>"/^1GM?]ZL.7K6YX(_Y&>U_P!ZN:O\+._#
M?$?2<'^J%25'!_JA4E>&>P%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A^+
M?^1>N/I7SK=?\?TGUKZ*\6_\B]<?2OG6Z_X_I/K7+B#V\IV98AZ5>BJC#TJ]
M%7!(^ACL78ZLIUJM%5E.M"'(G7I2-2CI2-TJS(@?K5.;O5QZIS5#-8[&?+6=
M/WK1FK-N*N!%38U_#9Q,M=>'KB=#DV2KS72BZ'K7HTOA/DL?_&9I"04N\5F_
M:1ZT?:AZUJ<1I;Q2[Q6;]J'K1]J'K0!I;Q1O%9WVH>M'VH>M &CO%,F<>2WT
MJC]J'K4<MT/*;GM36X'$ZV<ZF]58NM3:JVZ_<U#%UKVJ'PH\G$[EV/I5R*J<
M?2KL5=)P3+D=6%Z57CJPM!SO<<>E0R5,>E024(14EZ51EZU>EZ51EH-X%&7K
M6YX(_P"1GM?]ZL.7K6YX(_Y&>U_WJYZ_PL]##?$?2<'^J%25'!_JA4E>&>N%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!A^+?\ D7KCZ5\ZW7_'])]:^BO%
MO_(O7'TKYUNO^/Y_K7+B#V\IV98AZ"KT548>E7HJX)'T,=B['5E*K1592FAR
M)QTI&Z4HZ4C51D0-5.:KCU3E[U+-8[&?-6=/6C-6;/50,ZFQ=T:TN+B4"$9K
MH/[&U'^Y6G\,X(I;R,2(&Y[U[!_9]I_SP2O1H_"?)X_^,SPS^QM1_N4?V-J/
M]RO<_P"S[3_G@E']GVG_ #P2M3B/#/[&U'^Y1_8^I?W*]S_L^T_YX)1_9]I_
MSP2@#PW^Q]2_N4?V/J7]RO<O[/M/^>"4?V?:?\\$H \-_L?4O[E,ETC41&Q*
M<5[K_9]I_P \$JO?6%H+*4B!/NTUN!\OZE&\5ZRR##5%'6SXR14\13*HP/2L
M:.O;H?"CR<3N78^E7HJHQ]!5V*N@X)%V/I5A:KQ]*L+0<[W''I4#U.:@>A"*
MDO2J,M7I>E49:#>!1EZUN>"/^1GM?]ZL*7J:W?!'_(SVO^]7/7^%GH8;XCZ3
M@_U0J2HX/]4*DKPSUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A^+?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-=4X-L]'\&Z0-*T=(BN#P:Z6F1H$0*!C Q3Z[DK*Q\M.3E)R84444R0HHHH
M**** "BBB@#S/XHZ,UQIK7,:Y8M7B!4QN5/4'!KZPU&SCOK1XI%##!ZU\Y^+
M?#\^E:E(WEML=B17?A:FG*SEKPOJ<^IJW$]4 U3+)7I19YDX&HDF*D$WO66)
M33Q,:HP<#1\[WIK3<=:H&8XIAF- *!8E>J4C<TK2&H6;-3)F].#  LZJ.YQ7
MMGPMT,V]BTTJX;=D5YQX0\-S:SJ*Y1A&I#;O6OHG2[&.QLXXD4#"@'%>;BJN
MG*CTZ%.VI=HHHK@.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=OX>^%[3!)KF0H>I5A7J&D:#:Z5"$CC3([@5RU<2EI$ZJ=#N5?#'AR#1+&-
MF)0,&NAHHKSVVW=G4E8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***ADN88CAW"GWH FHJ*.>.7A'#?2I: "BB@\4 %%5GO[:-MKRJ".U2Q31
MS#,;!A[4 24444 %%%% !103@9-5GO[:-L-*H- %FBF1S)*,HP(]J?0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO$$H/>2O;?!40BT- !WH SO!_A*70WF:<#YCQBNUHHI %%%% !1110 4444
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M** "BBB@ HHHH **** $;[I^E>-?$W_D)Q?2O93]T_2O+O'N@WNHW\;P0LX
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M84445H0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@5C@L(Y/VDS3%8GE7)$6UM([2()&N!BK%%%>TE;1'E-W"BBBF 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG?RXF;TKR76
MY#/KDQSQ7J.JOLTZ5O05Y1<'??2/ZUY>9SM!(]# 1O)L=90FYU&*(=#7JVFV
M_P!FLDB]*\_\+P"6_20C[K5Z6!CI59;3Y:?,3CIWGRBT445Z1PA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]3MEVP*/05+2*,+BEKZ1'AL**** "BBB@ HHHH **** "BBB@ HHHH ****
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MRM%11U -<6746Y<[.K&U;1Y$7Z***]L\D**** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M45#+<Q0C+MBLB]\2V=NIV2J6':HE.,=V5&$I;(VV=5'S,!]365JFM06,3-N#
M$>AKC-0\5W5T[(B@+V(K$DE>0[I)&/L37G5\QC'2&IVTL#)ZR+FJ:K-JDQRQ
M\O.0#6<<_<C4DGT%+''+<R".!=QSSBNX\.>&1$@FN%^<'.#7#3HU,3/FD=DZ
ML*$;(3PIH?E#[3,OWAQ78@8&!34C6-<*  /2GU[U*FJ<>5'CU*CG+F84445H
M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5E:Q>BW@P#R1BM0]*Y_6=.EN/F0$X]ZN"7-J8UW)0?*<R6,CEF
MYYJ510]M) V'7%*M=AXUG?44U"YJ5JKN:82()#5&=JMRFL^8U2,),ISM73>"
M]1=9WC))!.!7*SM6YX+0O>.1V:G47N.XL-)JO&QZL.@I:1?NBEKS#Z<****
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M^VR\[$?YXKB9CDUZAX+L_L]H7(^^N:FN[0-,!#FKI]CJQTI:**\X^D"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*=<,!^55)_#BD%H@2:UY8HY'5FUN4!KNHO\ >N6-(;VXF^_(33)=-N+<_.F
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M ):*** "BBB@ HHHH **** "BBB@ HIK.%&348N8V. >: )J*0'-+0 4444
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MRZKJ2DY.YQ_.O<O"FF_V=IBIC[P!KR7P/IAO]4Y7(7!KW:% D**.R@4P.?\
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MBF1RZ8X->)&0RW>X]VKLM-\&:E>AFNE) Z<FJ][X(U"._'D1_NP: /6?#?\
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MY6*%#\WJ*]G\)^$(-'A#M'B5A\QKFJ5%$]'#T'4?D:_AS2ETO3DB YP#6S2
M8&*6N-N[N>Q&*BK(****104444 %%%% !2$@#)I:Q?$.I_V=82,K8?;\M-)M
MV1,I**NR;4=<L]/0F2= P[&N#UGXCXW101@YX# UY_K>L7NHW+-.Q(-9:]:Z
MZ=!+<\BOCI/2!O76O7MZY+3. >V:J!BQR3DFJT=6$KKBDMCR:LG)W8YZ@DZ5
M.U024V1 IOUJ!ZL2=:KO6;.JF0$D-Q7HWP\M)+NZ28J<(U<'8V$M_=+%&I)R
M.U>^^"_#_P#8VG ,N&< UA4J<JL=]"A[22;Z'4@8&*6BBN(]D**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH :T:L.5!JK-I\4O\ "!^%7**:
M;0G%/<P+G0E.2K5DW.D3)G:I-=K2%0:T562.>>%A(\TN;6:+.Y"*R9R1G->K
MSZ=;W (D3.:Y[5/"\<B$VZ &MH5UU."M@9I7CJ><3-5'K,H]ZV-5TV>PD*R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *JS6:33K(P&5JU11<32>XBC:,"EHHH&%%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>gtinntqqusay000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" / !2H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;ZQ9Z)X-LK^^D*6\=O$&8 MC( ' INB>-M"\0WSV>G79DN$3>4*,IVYQGD4
M=#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )M7^Z/RH  Z#%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$%Y96NH6YM[RWBGA)R4E0,#^!I+FQM;VU-K<V\4UN1@QR(&4_@:L44 9MYX?
MT?41&+S3+.X$8VH)85;:/09'%00>$_#UK.D\&BZ?%*ARKI;("#['%;-% &1X
MJ_Y%/5O^O23_ -!-5O __(D:-_UZ1_\ H(JSXJ_Y%/5O^O23_P!!-5O _P#R
M)&C?]>D?_H(H Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/&
M_P#R).K_ /7NU;%E_P >,'^X/Y5C^-_^1)U?_KW:MBR_X\8/]P?RH GHHHH
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MZP_[_K1_PG?A7_H/6'_?]: .BKG;+_D>M5_Z]X/_ &:C_A._"O\ T'K#_O\
MK6':>,?#B>,-2N6UFR$,D$*HYF&"1NS0!WU%<[_PG?A7_H/6'_?]:/\ A._"
MO_0>L/\ O^M '145SO\ PG?A7_H/6'_?]:/^$[\*_P#0>L/^_P"M '145SO_
M  G?A7_H/6'_ '_6C_A._"O_ $'K#_O^M '145SO_"=^%?\ H/6'_?\ 6C_A
M._"O_0>L/^_ZT =%16?IFN:9K*NVFWT%T$^\8G#8_*M"@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ'HVIR&.QU.VG<=51P36ID'H:\[L_!OPY\1PR)I$=DY3[SV,HW+^(S70>'-
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M;/\ Y^8O^^J/[1L_^?F+_OJOC[SI?^>K_P#?1H\Z7_GJ_P#WT: /L'^T;/\
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M8O\ OJOC[SI?^>K_ /?1H\Z7_GJ__?1H ^P?[1L_^?F+_OJ@:A9DX%S$2?\
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M"N(\':_?O?ZSI>KW*3MITFP3A=NX#.2>?84_P?JNH^(M8U'4VG<:4CF.UBZ
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M6OT%<)\2O];X>_Z_U_FM=VG^K7Z"NBI_"A\S"'\6?R'4445SFX4444 %%%%
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M_CRU+_>6O7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"MI_UU7^=5*MZ7_R%;3_ *ZK_.@#Z]M?^/2'_KFO\JEJ*U_X](?^N:_RJ6@
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MLN(A$YVMC:,8XV>U=]X:A\10V<B^([FTN+@M\C6RX 'OP*)=P1F?$W5;G2/
MFH7%H669E\M77JF<_-^%<;XITY?#O@32_#FF7DWVS6[I$:X9R6<MMW?F"*]2
MUG2+77='NM,O%W6]PA1\=0#Z>]<;H/PNCTO6K74+[6;O4Q9C%K%<<K'Z'KU]
M_:A-6$T<WKWAZQ^'VM>%+O04:WN;FZ6UN5$C,)5; 8D$^YKV6N,B\%75WXQ7
M7];U+[8MME;.V" )&/4C^]SU^E=G0W<:"BBBI&%%%% !1110 5Q4O_)88?\
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MM6[K[G_F87_"RO"?_05'_?E_\*/^%E>$_P#H*C_OR_\ A6[_ &'I'_0*L?\
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M14F<L,@Y[FNZ P !VHJRAR1C%WM<*2ES2E)6N+1116!L%%%% !1110 4444
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M_P#R$M(_ZXO_ #%>0UZ]\=_^0EI'_7%_YBO(: "BBB@ HHHH **** "BBB@
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MT;_KTC_]!% '04444 %%%% !1110 56U#_D&W7_7%_Y&K-5M0_Y!MU_UQ?\
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MT ?'A^\:2E/WC24 %%%% !1110 4444 %%%% !1110 4444 %%%% !5O2_\
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M_M52_P"$;T?_ )\8_P S_C3E\.Z2CJRV,893D')_QH TZ*** "BBB@ HHHH
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MD:-_UZ1_^@BK/BK_ )%/5O\ KTD_]!-5O __ ")&C?\ 7I'_ .@B@#H****
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MZ=ZXFU\(>-?#$>H:=X:O-/DTVY=I(3=NPDA9NN,*<C\: +_ACQA<ZAX!DO\
M2=#CEU.UF\B>RM@J*9-WS$=!T.:H>'=5U;5OBIYNKZ-)I<JZ9M2-W5BP\SKP
M377^#/"\?A/P_'8AQ+<.QEN)<8\R0G)/]/PK,E_Y+##_ -@@_P#HV@#M:***
M "BBB@ HHHH **** /$/CO\ \A+2/^N+_P Q7D->O?'?_D):1_UQ?^8KR&@
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MR_-;_OGK]WVZ5=T31+/P_8"QL%=;<,656<MM]AGH/:K/]H67_/Y;_P#?U?\
M&C^T++_G\M_^_J_XT 6:*K?VA9?\_EO_ -_5_P :/[0LO^?RW_[^K_C0!9HJ
M.*>&<$PRI(!P2C XJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X3XEVOAXV%O>:U=75O,A*6QM9&61F/. %/MWKNZ\S\?S00
M_$3P<UVZ+;B9R^_[O0]:J.XGL<5H7A&'7M06_P##GBR]76[7YA%J2D2*ON<$
MD?G7JOAA/&5M>/;^(YK*ZAV96>V!'/IC KFO$4MG;_%KPK>:<\/F7B20SO$1
M\ZY7 .*]1IR8D@KA_&.N:VNNZ?X>\.FWBOKI'E:>X7*JJ@GT/7!KN*XKQQ9P
M6UUIWB'^UH=,N+*3:9)5R)$;AE_(G\ZE;C9P2>*/'XTJ'5Y=3L6L1>K;7(BA
M7?#\^TDY7I]/6O;K=M]M$V\/E =P_BXZUX>=&_M"]-EI/B:P_P"$=UF[6X>-
MP1(SK@D(<=/E]17M]O"MM;10)]R- B_0#%5*PD2U%<DK:3%?O!&(_*I:0C(P
M>AJ"CS;X-LT_A34+FX'^E37\QF)').>]2?"A1#'X@MX?^/6/4I/+ Z=LU')X
M4\8Z%J^KOX7NM.-AJ,AF$=T2IA<YSM 4@CFM+1_">L>%_ DFFZ)>0'69':9I
M[@90R-U['C@=J .;^*<^H?\ ":^%X+""*6<R,(?.^Y&YP Y_W>#^%2OJOB+P
MIXOTB#Q;<6.J6=^YB@N$MU#P2$< ?*.O'YUT/B_PAJ/B+3]+N[>[C@US37$T
M4G\#-QD'VX]*HVWA/Q+KOB?3]3\6RV'V73AO@M[0EMTF,;B2HQV/X4 1^.O$
M/BJV@U>QM/"SW&G"!E%X)5 *E.3C=GCGMVKJ/ __ ")&C?\ 7I'_ .@BK'BK
M_D4]6_Z])/\ T$U7\#_\B1HW_7I'_P"@B@#H**** "BBB@ HHHH *K:A_P @
MVZ_ZXO\ R-6:K:A_R#;K_KB_\C0!\>'[QI*4_>-)0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %6]+_ .0K:?\ 75?YU4JWI?\ R%;3_KJO\Z /KVU_
MX](?^N:_RJ6HK7_CTA_ZYK_*I: "BBB@#S[XB^,-3\,WEC%8% LR.S;E!Z$?
MXUQ7_"U_$7]Z'_O@?X5J_&?_ )".D_\ 7*3^:UYA7NX3#TI48RE'4\;%5ZD:
MK2D=U_PM?Q%_>A_[X'^%'_"U_$7]Z'_O@?X5PM%=/U6C_*CG^LU?YF=U_P +
M7\1?WH?^^!_A1_PM?Q%_>A_[X'^%<+11]5H_RH/K-7^9G=?\+7\1?WH?^^!_
MA1_PM?Q%_>A_[X'^%<+11]5H_P J#ZS5_F9W7_"U_$7]Z'_O@?X52B^(>LPZ
MQ<ZHAB^T7$21.=HQM3./_0C7)44?5:/\J#ZS5_F9W7_"U_$7]Z'_ +X'^%'_
M  M?Q%_>A_[X'^%<+11]5H_RH/K-7^9G=?\ "U_$7]Z'_O@?X4?\+7\1?WH?
M^^!_A7"T4?5:/\J#ZS5_F9W7_"U_$7]Z'_O@?X4?\+7\1?WH?^^!_A7"T4?5
M:/\ *@^LU?YF=U_PM?Q%_>A_[X'^%'_"U_$7]Z'_ +X'^%<+11]5H_RH/K-7
M^9GOOP]\2WWB73KF>^*[XY=J[1CC _QKLZ\T^#G_ "!;W_KO_05Z77@XJ*C6
MDH['M8:3E2384445SFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7E?Q+UCPA9ZQ#:>)]$>X\R+*74,0:11GH#_P#7KU2L[6-$TW7;)K34[2*X
MA8='&<>X]Z:=F)GB&G6'P]/^EZ#XIU#P_=,-FZ60A\>G7IQ7JW@>WN[:PF6X
M\1?VW$2IBG(^8#G.>3GM7":]X./A9=]NUGJ^D(06T_42"Z#'\#?TQ75?#.\\
M,W]C>S^';%K%BR"ZMBN!&^#@#]:N6J$MSNZ\+\;FPM?$WBUO$*QFXGTS;I4D
MBY X?Y0>QS7JGC'6[_P_X?DU#3M-DU"9'4&%.H4YRWT%>8)X[N?'$:V<OAO2
MKUP?^/6>Z&]3_N[:44]P;)=,O=+U;Q#X0'A]HI-5MXV^VSQCI'MY5CZ]>/>O
M:J\Z\(6^LZ9J*P)X.L=+LY"3++!+G'X;:]%I2&@HHHJ1A1110 4444 %<5+_
M ,EAA_[!!_\ 1M=K7%2_\EAA_P"P0?\ T;0!VM%%% !1110 4444 %%%% 'B
M'QW_ .0EI'_7%_YBO(:]>^.__(2TC_KB_P#,5Y#0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'MWP+_P"/+4O]Y:]?KR#X%_\ 'EJ7^\M>OT %
M%%% !1129'K0 M%)D>M&1ZT +69J?AS1M:E234]+M;QT&U6GB#$#T&:TLCUH
MR/6@#GO^$"\)?]"YIG_@.O\ A1_P@7A+_H7-,_\  =?\*Z'(]:,CUH Y[_A
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MBBB@ JMJ'_(-NO\ KB_\C5FJVH?\@VZ_ZXO_ "- 'QX?O&DI3]XTE !1110
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MBBB@ HHHH **** "BBB@ HHHH TO#_\ R,>F_P#7RG\Q7TXG^K7Z"OF/P_\
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M\)_!B%%%%<IT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ]T5]4:A_P @VZ_ZY-_(U\KC[HKV,KVE\CRLQWC\Q:***]4\T**** "BBB@
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MQ#@GS.M 'I%%%% !1110 4444 %%%% 'B'QW_P"0EI'_ %Q?^8KR&O7OCO\
M\A+2/^N+_P Q7D- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
MW? O_CRU+_>6O7Z\@^!?_'EJ7^\M>OT %%%% %;4/^0;=?\ 7)OY&OE<?=%?
M5&H?\@VZ_P"N3?R-?*X^Z*]C*]I?(\K,=X_,6BBBO5/-"BBB@ HHHH ****
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "K>E_P#(5M/^NJ_SJI5O2_\
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MHOYT /HIGFQ_\]%_.CS8_P#GHOYT /HIGFQ_\]%_.CS8_P#GHOYT >)_'?\
MY"6D?]<7_F*\AKUWX[.K:CI&&!_<OT/N*\BR/6@ HHR/6C(]: "BC(]:,CUH
M **,CUHR/6@ HHR/6C(]: "BC(]:,CUH **,CUHR/6@ HHR/6C(]: "BC(]:
M,CUH ]N^!?\ QY:E_O+7K]>/? QU6SU++ ?,O4UZ]YL?_/1?SH ?13/-C_YZ
M+^='FQ_\]%_.@"'4/^0;=?\ 7)OY&OE<?=%?4VH2Q_V==?.O^J;O[&OE@,-H
MY%>QE>TOD>5F.\?F.HI-P]11N'J*]4\T6BDW#U%&X>HH 6BDW#U%&X>HH 6B
MDW#U%&X>HH 6BDW#U%&X>HH 6BDW#U%&X>HH 6BDW#U%&X>HH 6BDW#U%&X>
MHH T_#__ ",>F_\ 7RG\Q7TXG^K7Z"OF+P^R_P#"1Z;R/^/E._N*^FTEC\M?
MG7H.]>-FGQ1/5R[X9$E%,\V/_GHOYT>;'_ST7\Z\L](?13/-C_YZ+^='FQ_\
M]%_.@!]%,\V/_GHOYT>;'_ST7\Z 'T4SS8_^>B_G1YL?]]?SH ?1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%-D<1Q,YZ*"30 -(B8WNJYZ9.
M*=7D.AZ+_P +(FUO7+_4[](?M+P6"6]P\0A5<\X4@$\CK72?"S5;^]\.SV.I
MS&:\TZY>V:1CDLHQ@D]SR: .Y) &2<"D61'&4=6'L<UY[\2[K4+S4-"\-Z?<
MR6XU&X/VF2)BKB-<$X(Y'>LV>R7X<^.-#^R:A>/I>I[K::"XG:7,F#M8%B<<
MXZ4 =_XJ_P"13U;_ *])/_035;P/_P B1HW_ %Z1_P#H(J3Q9<P+X7U:-IHP
M_P!ED^4N,_=-5?!%W;+X)T=6N(@1:1Y!<?W10!TU%0?;;7_GYA_[^"C[;:_\
M_,/_ '\% $]%0?;;7_GYA_[^"C[;:_\ /S#_ -_!0!/14'VVU_Y^8?\ OX*/
MMMK_ ,_,/_?P4 3U6U#_ )!MU_UQ?^1IWVVU_P"?F'_OX*KW]Y:G3KH"YA_U
M3_\ +0>AH ^0C]XTE!==Q^8?G2;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O\
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MB32[18KJ2[%J\$W(1N0?U%-OO$GQ)\/:=+K&K:7I=QI]NOF3+!.0VWO_  T
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M8\W_ .%(^$O^HC_X&/1_PI'PE_U$?_ QZ](HHYY=PY(]CS?_ (4CX2_ZB/\
MX&/1_P *1\)?]1'_ ,#'KTBBCGEW#DCV/.4^"GA2.19$;4E=3E6%X^0:T/\
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ML5D>;?\ "C?!?_/"^_\  MJ/^%&^"_\ GA??^!;5Z311S/N'*CS;_A1O@O\
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MOPLU,6PT@>*KT: I^6T&-P7.=N['3->C6-G%I]C#:0 B*% BY.3@4 6****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 R6&.>)HYHTDC;JKJ"#^!HBAB@C$<,:1QCHJ* !^ I]% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110! ;.V-S]H^SP^?C'F[!N_/K4]%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%17$Z6UO)
M/)G9&NXX%8OAKQAI?BM;AM,:4B @/O0KUS_A3L[7%=7L;]%<WJOC?2-&\0VN
MB7;2B\N=GEA8R1\QP.?J*Z3M0TUN":84444AA1110 45G:EKFG:2\*7EU'')
M,VV.,GYG/L.]: .0".]%@%HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHJ&ZN8[.SFNI<^7#&TCX&3@#)H FHKSP_&?PF#CS+
MK_OP:WO#OCO0/$\K1:=='SE_Y9RKL8_0'K5N$DKM$J<7LSI:*Y[4_&>DZ1KU
MMHUTTHN[C[@5"1^==#4M-#NF%%%%(8445SB>-=)?Q:WAH-+_ &@IP1Y9V_=W
M=?I32;V$VD='1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&^:QTE%%%8FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(S!5+
M,< #)->=S?%6RN/'FF^'-)C6[BG<I/<Y(53D<+ZGU_"@#T6BBL7Q3XDM/"N@
M7&IW;#]VN(T[R/V4?4T ;5%<_P""O$,OBKPI9:S-;K ]P&)C4YVX8C^E=!0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF65U9K:3VL4EN@ 6-E!48Z<5/!;Q6L"0P1K'&@PJJ, "I**5QA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 (ZJZ,C#*L,$5Y1XET?3]#^(?
M@.STVTBMH%EF.R-0 3E.?K7K%<SKWA0ZSXJT'61=>4-+9V,>S/F;MO?/'W:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>;_"7IXG_P"PM-_Z&U>D5YO\)>GB?_L+3?\ H;4
M>D4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<__ ![R?[I_E7/^
M /\ D0]&_P"O<?S-=!/_ ,>\G^Z?Y5S_ ( _Y$/1O^O<?S- '24444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5@:AXOTK3O$=AH4DP>^O"0D:')7IU]
M.M;LB>9$Z;BNY2,CJ*\4OO!UGX4^)?@TQ7%Q=W5S-*9[FX<L\F"F/88R>E '
MMM<GX@^(.C>']1&G2"XN[[;O:"UA:5E7U.T''2NLKEKRT\-^#[O4_%%SM@N+
MH9FD=R2Y'90>GT% %[PWXKTKQ5:27&F3,_E/LEC="C(WH0>:Y#XN??\ "O\
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M="-XQ-J4D@1QAERS'!]Z /4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@".?_CWD_P!T_P JY_P!_P B'HW_ %[C^9KH)_\ CWD_W3_*N?\  '_(
MAZ-_U[C^9H Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N&\6Z'J
M.H^/O"6H6MNTEK9/(;B0$83)3'\C7<T4 8NM:AK%GJ6E0Z;IBW=M<3%;R4OC
MR$X^;'?J?RKRKQ=IWC/5/'TE[+X9?5=)M& L[=Y@L;8YW$9YY]?2O;Z* .3\
M'ZQXEU*2>+7?#J:3%$@\DI)N#>WM6#\7/O\ A7_L++_Z":]*KS7XN??\*_\
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M:@#TBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG_X]Y/\ =/\
M*N?\ ?\ (AZ-_P!>X_F:Z"?_ (]Y/]T_RKG_  !_R(>C?]>X_F: .DHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BHKBZ@M8P]Q*D2$X!<X&:D5U=0R,"I&01WH 6BBB@ HHHH
M**** "BBJ%WK6G66HVMA<74<=U=$B&(MR^,=!^(H OT45C:WXKT/PZ475M2M
M[5I.561P": -FO-?BY]_PK_V%E_]!-=_INIV.KV27FGW45S;O]V2-@P/XUP'
MQ<^_X5_["R_^@F@#TJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 45Y?K'QEM='UF\TYM(ED:VE:(N)@-V#C/2J/_"][/\
MZ DO_?\ '_Q- 'KU%>0_\+WL_P#H"2_]_P ?_$T?\+WL_P#H"2_]_P ?_$T
M>O45Y#_PO>S_ .@)+_W_ !_\31_PO>S_ .@)+_W_ !_\30!Z]17D/_"][/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(?\ /]+_ -^6KYJHH ^KO#WC'1O%$L\>E7#RM  TFZ,K@'..OTK?KQ#X#_\
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M444 %%%% 'RCXV_Y';6?^ON3_P!"-8%;_C;_ )';6?\ K[D_]"-8% !1110
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M 1D3:WR\Y/3%>EV\*V]M% GW(T"+] ,5!8ZG8ZF)397"3"%_+DV_PMZ5;H;
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M5U\2IX/'4[1:.MN/[/#OB(MSN)_VNGZ4 >S(ZR*&1@RGH0<@UYM\7/O^%?\
ML++_ .@FD^$,ERVGZH(Y9Y=#6Y/]G23G)\O SC_9SNIOQ9EC>3PJ$=6(U5>
M<]C0!Z;1110 4444 %%%% !1110!YI\;O^1-MO\ K\7_ -!:OGVOH+XW?\B;
M;?\ 7XO_ *"U?/M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
MO? ?_D):U_UQB_FU>WUXA\!_^0EK7_7&+^;5[?0 4444 %%5;_4K/2[8W-]<
M1V\(."[G K(_X3OPM_T';/\ [^5<:<Y*Z5R7.*T;.AHKGO\ A._"W_0=L_\
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M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 444R4,8G"'#%3@^]
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MO% 'T57F_P )>GB?_L+3?^AM7H:RA(D\YT5RHR"<<]Z\[^$A!'B8CD'5IO\
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MI_JU^@KHJ?PH?,PA_%G\AU%%%<YN%%%% !1110 4444 %%%% !1110 4444
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M_D3;;_K\7_T%J^?:^@OC=_R)MM_U^+_Z"U?/M !1110 4444 %%%% !1110
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M#.*XG^T?B+_T"]._[[_^O1_:/Q%_Z!>G?]]__7J50DOM+[Q^V3^R_N.\555
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MR&Q@.8XA@$@ GGVH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ)X?TC4_C+XL_MV-)1&XDMH+@_NVW#!;:>#T_2@#M_ 4_B -J%GJ]PE]:02
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M=_8OC#_H/1?]^11_8OC#_H/1?]^11[*/\Z_$/:R_E?X'8@!1@  >@IDL$4X
MFB20 Y =0<&N1_L7QA_T'HO^_(H_L7QA_P!!Z+_OR*/91_G7XA[1_P K_ ['
M QC'%,BMX8<^5%''GD[% S7(_P!B^,/^@]%_WY%']B^,/^@]%_WY%'LH_P Z
M_$/:/^5_@=E28&<X&:X[^Q?&'_0>B_[\BC^Q?&'_ $'HO^_(H]E'^9?B'M9?
MRO\  [$@'J*-J_W1^5<=_8OC#_H/1?\ ?D4?V+XP_P"@]%_WY%'LH_S+\0]K
M+^5_@=CM'8#\J6N-_L7QA_T'HO\ OR*/[%\8?]!Z+_OR*/91_F7XA[67\K_
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ML"M_QM_R.VL_]?<G_H1K H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_\ (2UK_KC%_-J]OKQ#X#_\A+6O^N,7\VKV^@ HHHH **** "BBB@ HHHH
M**** .+UWQ_#HOB:TT=["Y<S=6"C+?[@SS^E,U+XAPZ?XJ@T9M,O6WJ^\B,;
MBV1MVC/(//.1TKH+[PQHVHWWVV[T^&:YX_>,O(QTIT_AS2KJ_-]-9QO<ET?>
M1SE,[?YF@#GM3^(<.G>*K?1CIMZY</O(C&XGC9M&>0>?3I1J?Q#AT[Q5;:,=
M-O&WAMYV#<>/E*C/()X[=*Z"X\-Z3=:B;^:SC:ZW(WF$<Y0DK^63277AG2+R
M_P#MT]E&]SE#YA'/R'*_K0!JHV^-6P5W#.#U%.H' Q10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'>/?A_9^-[2+S;B
M2WNK<'R9%Y SZBNQKC/'WC2_\'V\$UKHLM_'(#OD5]JQ_7@TU>^@G:VIY6-%
MU[PA.EGJNM:KI-KN"I?6LC2P.>VX97;^M>I^#3XD>7S;W6K+5-):/,,T2X=C
MZFO.+7XG:QXEWQSZMH.F6C\-'>)N8C\Q7;_#OPE_8EU<:C;Z[;WEK=#/D6D6
MR)3ZCYC5RVU$O([Z[NH;&TFNKAQ'#"A=W/10.IKS+Q5XC\"^*H(<^(?LMY;,
M6@N8#\T9KTZZMH;RUEMKB-9(95*.C#A@>H->>7_PGTZT>2ZT"_ETJ9FWLI^>
M$X[;>/YU,;#=SC=$TKP?!>VR7WC:YU*W2<2QVK*47S,Y!ZGO7O$95HE*?<(!
M7'I7BEKXX71M9@TO4;/1]8DDF$:S:>P#)_O)SS^->U1$-$C!2H(!P>U.5Q(?
M1114%&#XF\':-XMAACU2W+/"VZ*:-MLB>N&ZBG>&_".C^%+:2'2[<H93F25S
MN=_JW>MRB@#"T;PCH^A:3=:7:6Y:SNI'DFCE.\,6&#^%8NG_  G\*:=J<5]'
M9RR-"^^**:3?%&WJJG@8-=O10 5YO\)>GB?_ +"TW_H;5Z17F_PEZ>)_^PM-
M_P"AM0!Z11110 4444 %%%% !1110!\H^-O^1VUG_K[D_P#0C6!6_P"-O^1V
MUG_K[D_]"-8% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ4M(>E
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M-MO^OQ?_ $%J^?:^@OC=_P B;;?]?B_^@M7S[0 4444 %%%% !1110 4444
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M..S.:IBZ5.7++<]OHKQ#_A<'B#_GTT[_ +X?_P"*H_X7!X@_Y]-._P"^'_\
MBJO^SJ_D1]>HGM]%>(?\+@\0?\^FG?\ ?#__ !5'_"X/$'_/IIW_ 'P__P 5
M1_9U?R#Z]1/;Z*\0_P"%P>(/^?33O^^'_P#BJ/\ A<'B#_GTT[_OA_\ XJC^
MSJ_D'UZB>WURNG?\E,UW_KPM/_0I*\Z_X7!X@_Y]-._[X?\ ^*K/A^)6LP:Y
M=:LMM9&XNHHX74JVT!"Q&.>OS&C^SJ_D'UZB>_T5XA_PN#Q!_P ^FG?]\/\
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M:7#,TR1%B'< $Y8MV^M<9\7/O^%?^PLO_H)H ]*HHHH **** "BBB@ HHHH
M\T^-W_(FVW_7XO\ Z"U?/M?07QN_Y$VV_P"OQ?\ T%J^?: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ]>^ __ "$M:_ZXQ?S:O;Z\0^ __(2U
MK_KC%_-J]OH **** (+QVCLIW0X98V(/H<5\\#Q[XHQ_R%Y?^^$_PKZ&O_\
MD'7/_7)OY&OE8=*]7+81DI<ROL>;F$Y1<>5VW.D_X3SQ1_T%Y?\ OA/\*/\
MA//%'_07E_[X3_"N<HKU/8T_Y5]QYWM:G\S^\Z/_ (3SQ1_T%Y?^^$_PH_X3
MSQ1_T%Y?^^$_PKG**/8T_P"5?<'M:G\S^\Z/_A//%'_07E_[X3_"C_A//%'_
M $%Y?^^$_P *YRBCV-/^5?<'M:G\S^\Z/_A//%'_ $%Y?^^$_P *KWGC#Q!J
M%G+:76IR2V\J[70JH##\!6)11[&G_*ON#VM3^9_>=$/'?B=0 -7E ' ^1?\
M"E_X3SQ1_P!!>7_OA/\ "N<HH]C2_E7W![6I_,_O.C_X3SQ1_P!!>7_OA/\
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M HHHH **** "D/2EI#TH ^Q--_Y!=I_UQ3_T$5:JKIO_ ""[3_KBG_H(JU0
M4444 >0_&C_C\TC_ *YR?S6O+:]2^-'_ !^:1_USD_FM>6U]'@?X$?ZZG@XS
M^-(****ZCF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#VSX/?\BQ=?\
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MJFGG6/$VK(IU;53YOV=3@(H VJ??@<UROC[5]=O[_P -Q:GH/]GPKJBE)?M
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MB@ HHHH *0]*6D/2@#[$TW_D%VG_ %Q3_P!!%6JJZ;_R"[3_ *XI_P"@BK5
M!1110!Y#\:/^/S2/^N<G\UKRVO4OC1_Q^:1_USD_FM>6U]'@?X$?ZZG@XS^-
M(****ZCF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#VSX/?\BQ=?]?1_
M]!6O1*\[^#W_ "+%U_U]'_T%:]$KYO%_QY'T&%_@Q"BBBN8W"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI
MLDB11M)(P5%&68] *X>/XM>%Y-26U6XE\EFV+=F(^43]: .ZHI%8,H93D$9!
MKF/$OCW1O#%REK=-+-=,N[R($+L%]3^M '45YK\7/O\ A7_L++_Z":[7P_XC
MTSQ-IXO=,N!+'G:PQ@HWH1ZUQ7Q<^_X5_P"PLO\ Z": /2J*** "BBB@ HHH
MH **** /-/C=_P B;;?]?B_^@M7S[7T%\;O^1-MO^OQ?_06KY]H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#U[X#_ /(2UK_KC%_-J]OKQ#X#
M_P#(2UK_ *XQ?S:O;Z "BBB@"O?_ /(.N?\ KDW\C7RL.E?5-_\ \@ZY_P"N
M3?R-?*PZ5[&5[2^1Y>9;Q^8M%%%>J>8%%%% !1110 4444 %%%% !1110 44
M44 %%%% &MX7_P"1KTG_ *^X_P#T(5]-#I7S+X7_ .1KTG_K[C_]"%?30Z5X
MV:?''T/6R[X9!1117EGHA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !16!XE\8Z3X5CB_M"5C--GRH(E+.^.N!^5+X
M:\7:3XJMY)-.E;S(CB6&12KQ_44 ;U%07=W;V%G+=W4JQ01*7=VZ*!UKD--^
M*?AO4M42Q66:$RMMAEFC*I*?130!VU>;_"7IXG_["TW_ *&U>D5YO\)>GB?_
M +"TW_H;4 >D4444 %%%% !1110 4444 ?*/C;_D=M9_Z^Y/_0C6!6_XV_Y'
M;6?^ON3_ -"-8% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ4M(>
ME 'V)IO_ ""[3_KBG_H(JU573?\ D%VG_7%/_015J@ HHHH \A^-'_'YI'_7
M.3^:UY;7J7QH_P"/S2/^N<G\UKRVOH\#_ C_ %U/!QG\:04445U',%%%% !1
M110 4444 %%%% !1110 4444 %%%% 'MGP>_Y%BZ_P"OH_\ H*UZ)7G?P>_Y
M%BZ_Z^C_ .@K7HE?-XO^/(^@PO\ !B%%%%<QN%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')_$RXDMOASK<L
M+%7%N0&'4<BN8NM*M%_9Z%N8T(CTL2JVT??"_>^OO7?>)=&3Q!X<O])=MJW4
M13=Z5Y.MOX]F\'Q^ W\.B-5B%H^I>:3&8QQD?+0!Z/\ #V\GU#X?:'=W+F2:
M6U5G8G))KF/!4(G^*_C2ZE8R212I#&6.=BX!P/3J:Z,)?^%[?P[HVCZ8US8@
MB"XDW?ZA!CYNG/4_E7+ZC8>(_!OCK4]=T31GUBSU95,L22$-'(/P/&,4 1>"
MIUTSXG^/+2*/990%;@11CC.Q<X'J:POB#X[L]>ET06>EZJ/L.H":7?;@94 C
MCFNW^'OA[5;6^UCQ'KL"0:EJTH8PH<[$   /OQ7>8'H* //?^%PZ+_T"=;_\
M!1_\51_PN'1?^@3K?_@*/_BJ]"P/048'H* //?\ A<.B_P#0)UO_ ,!1_P#%
M4?\ "X=%_P"@3K?_ ("C_P"*KT+ ]!1@>@H \]_X7#HO_0)UO_P%'_Q5'_"X
M=%_Z!.M_^ H_^*KT+ ]!1@>@H \]_P"%PZ+_ - G6_\ P%'_ ,51_P +AT7_
M *!.M_\ @*/_ (JO0L#T%&!Z"@#POXD^.K3Q5X>AL=/TK51*EP)#YMN , $>
MI]:\I^S7_P#T#+S_ +]5]E8'H*,#T% 'QK]FO_\ H&7G_?JC[-?_ /0,O/\
MOU7V5@>@HP/04 ?&OV:__P"@9>?]^J/LU_\ ] R\_P"_5?96!Z"C ]!0!\:_
M9K__ *!EY_WZH^S7_P#T#+S_ +]5]E< 9.*9YL/_ #T3\Q0!\<?9K_\ Z!EY
M_P!^JC87*SI"UA=B5P2J&/D@=:^S<IMW97;Z]JS9M+TVXUFUU63:;NVC>.-M
MPP V,_R% 'R1]FO_ /H&7G_?JC[-?_\ 0,O/^_5?97&,\5&)X"^P21EO3(H
M^.?LU_\ ] R\_P"_5'V:_P#^@9>?]^J^RL#T%&!Z"@#XU^S7_P#T#+S_ +]4
M?9K_ /Z!EY_WZK[*P/048'H* /C7[-?_ /0,O/\ OU1]FO\ _H&7G_?JOLK
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M4C49+-%@#]:^NL#T%4M6TFTUK3)M/O8]]O,NUP#C(H_M&MY!]0I>9\JB>X8
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M%PZ+_P! G6__  %'_P 54MM\6='NKN&W32]95I9%C!:V  )..?FZ5WN!Z"C
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MLK ]!1@>@H ^-?LU_P#] R\_[]4?9K__ *!EY_WZK[*P/048'H* /C7[-?\
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M2*QD87.T#!^E>O\ BG_D5=5_Z]9/_037F7PU^'/AS6/ ^GW][:O+-(&W_O"
M>?2@#"TN_N#\-?B#IT=[)<Z9I[^593,^3LW'H>_05%;:!\-3X.@O)_$31:E]
MF#LJ7H+"3'3;UZ]J]'\=:'IGA_X1Z]9:79QVML+<ML3IDL,FN.TT?"B/P5:2
MZG%ILETMJK2J'S)OQZ YS0!H:AJ?BJ/X"K>*9SJ6P;I,'S/)[L??%8]AX<\
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M4+07_AO4+'2[MQ'#?S A23@#(QP,GUK5\2>/X]'U*+2],TNYUC4G3S3;V_\
M"GJ3@^E8_P 3U4?#6QP ,75ICV^85Q;V<NE_%;49=1U^YT.+4K>-[6Y1E57
M494LP('0T >K>$_&UKXGDN;-[2:PU2T_X^;*<?/'GH>V1R.U=17DWP]CL;CX
M@ZQ=6FI7VJR1PK'+?RNIC<\' *J 3^->LT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M=%D1D=0RL,$$<$4R"WAM85AMXDBC7HB# %2T4 1SP17,#PSQK)$XPR,,@BJ
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>gtinntqqusay000026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,:!3@# 2(  A$! Q$!_\0
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MH **** "BBB@ HHJO<7UM:G$TH3ZT 6**9%*DT8DC;<IZ&GT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #7_P!6WT->>W4;_P#"9VC;&QGKBO1*B-M"9!(8EWCH
M<<T <!X[\4W%BJV]HLN=V'PI.15;PKK>D0S)&+.=9Y#DL5.,_E7HDVGVDYS+
M;QN?]I<TU-,LHV#);1*PZ$+0!R,_B7^S-5FEN8Y7@;A0JFL2>1?$WBNUN[:)
MUC08.\'VKTN6PM9OOP1M]5HAL;: YCA13Z@4 >=6NHCP_K]\9XI&0J0NU35G
MP^KZYJZ:D$94C8CYA@]:[N;3[69MSP1ECU)6I(;6"W7;#$J#_9&* ,*]\$:'
M?W+W%Q:[I'.2>*X/QQX3TC2H6DM+?8P'!KU^O._B3_QZR?[M '3^#O\ D5[/
M_=K=K"\'?\BO9_[M;M !3/-CW;?,7=Z;N:2<[;>0CLM>-7&O7:_%&SLQ(_E,
MIR,\=10![336D1/O.J_4XIL!)A4FN(\=RA(WS<M#QV.* .Z!##(((]12UA:/
M?06GA^WEGGRNS.]N]1)XVT*238M_&6SC% '0D@#)( ]Z19(W^ZZM]#FN=U'7
MK.]T>]:RN [QQ$_+VKS_ ,!^+HH8W?4;LJ!(1\Y]Z /9*3< <$C\ZQ[/Q/I>
MH12O:W22>6,MCM7GVH?$J./QFEB746I'+YH ]:HJII]W%>6<<L3AE89!JW0
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MM8633!$Q_*@#V+1[*.QTZ&&-<*JX%:%96@W-U<Z9"]U%Y<A7)7TK5H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N(N- O'\837P8>2PX'XFNWJ@VJV
M"WK6K2KYXZK0!<B4K$JGJ!3Z0$, 1T-+0 4444 %%%% !1110 4444 %%%%
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M  M;PW41C<=0?I0!Z#1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>=_$G_CUD_W:]"=UC4LQP!7F7Q#U*UN()$CD!;&,4 =EX._Y%>S_P!V
MMVL+P=_R*]G_ +M;M !3&B1CDBB5_+B9_09KRGQ'\3-2TW75TZSMTD=@2 :
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M3LR+@MUJ:B@"*6WCF&'7(IZ(J*%48 IU% $%Q:0W*[95W"B"TAMAB)=M3T4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2G\*S2^)Y-3$H"/\
MPUUM93^(+"/4FL&E_?KU6@#2B79$J^@Q3Z16#*&'0TM !1110 4444 %%%%
M!1110 4444 %%%% !6?JGW8_]X5/>WD=E;M-(V%7J:X+5?&3R3!8"K(K9!H
M]$3_ %:_04ZN6T+Q5%?E897 E/  KJ <CB@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:\1^'I=8;
M,<@7C%=+6=J.M6>F'%S)MXS0!)I-FUAIL-LS99!@FKM0VMS'>6Z3PG*,,@U-
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ':W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNVVE'$[[>,T 6M+LCI^GQ6Q;=L&,U<JO9727MHEQ&<JXR#5B@ HHHH ****
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M'; YV#&:M55T^[6]LH[A?NN,BK5 !1110 4444 %%%% !1110 4444 %%%%
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M \CKNO =M*MTTK A"O!K-\.:!%J<DK2+E$<C]:](T_3X+"!8H1@"@"Y1110
M4444 %%%% !2,<*3C-+2$XH X+QQISZA8RS" [P, XKCO"7AYY;UO.@+!><$
M5[-=B*:W9'P0:S]+MH+:XD:, 9KJA7E&FXG/.E%S4@L]%T\Q M8Q*1QTJZNE
M6"_=M8Q^%6@P/2G5SN4NYNHH@6SMT^[$H_"I#$A0KM&#3Z*5V%D>?:EX8BN?
M&D,F (]O*XX[5U;^'[![98S;QY X.*9-_P A^/Z5LUM.I*RU,H0C=G"ZCX.N
M8W,UI>O&!T1:IV^N:OHTGE26<LR X+FO1JAGMH[B,I(N0135>ZM-7!TM;Q=C
MA=<\61R:0[B01S?W,\UY_)XRN22N&_.O3]5\ Z;=AI(XCYIKR3Q)H,NC7)#+
MA2>*[L-[&6B.3$>UCJRW#XONQ\B*Y)/8U[%X7:>73XYIMWSKG!KQ;P=8QWNN
MQ1S#]V>N:^@+*-(;2.*/&U1@8K+'<L;1BB\)S/WFRQ52]LH;N%ED5<XX)[5;
MIDJEHF5>I'%><=QY9K=S/I%ZUK#<,5Z\&L>/5KR.;S//?KDC-:7BNTGBU5FD
M';KBN?H ]4\*ZV;ZW6-_O^]=17G7@BTG\])P,)7HHZ4 %%%% !1110 4444
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MHD-MN::(*2.N<5F)XS\/:=JO^B02HS$+NQQ_*NCO=7T(:O8M<PN9Y%#(W84
M;?@:SDL/"MK!*I5U'(/X5TE0VTD<L"O$<H>E34 %%%% !1110 4444 %%%%
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M "BBB@ HHI-Z_P!X?G0 M%'7I10 4444 %%%% !1110 4444 %%%% !1110
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MVUF)%>[5YW\2?^/23_=H Z?P=_R*]G_NUNU@^#O^17L_]VMZ@ HHHH ****
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M?_UT <1\3O&5WHDL8M\G+8ZUYQ_PM+5/0_\ ?5-^(5EK5I)&-5N1,2>,5PE
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M*** "BFLZK]Y@/J:;]HA'65/^^J )**8)HCTD4_C3^M !1110 4444 %%%%
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M\M '4>#O^17L_P#=K=K"\'?\BO9_[M;M !1110 4444 %%%% !1110 4444
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MVMTM8%AC "KTP*FK'\,:G_:^A07G/S^M;% !1110 4444 %%%% !1110!5U
MSK:2&W7=)M.T>]>%^*+CQ0\\@U&S6.#)Y![?E7OU>=_$G_CTD_W: .G\'?\
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M:R[1Z1=NIPPB8@_A0!%<ZS9"-AYO(JA8:Q9+<2$RU\N:EXKUI;^X07K[1(P
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MBG#,!0 ZBH_/B_OK^=*)48X# F@!]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5&TZ!KHW!4;SWQ5NN'N-3OE\836
MRK)Y '![=30!VX&!@=J6F0DF%">I%/H **** "BBB@ KR3QE.9M=,&>!(/YU
MZRYVJ37C.M,;CQO,G4!A_.MZ.TGY&-7=(]1\/0>3IT8QU45P?Q(D&HR06:\F
M.921^(KTFP01V,/^X*\I=SJGQ$O;0\K'AOYU@;(]!T.,1V=NN.B#^5;]8^G+
ML"+Z#%;%*.QK5^(****9D>:_$[PSJ&O1D646_P"7'Z5XC=?#+Q#:!3+:8W'
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M>Z?::C%Y5W LJ>C5RVH^"]& +0QPVQ]10!IV0TB_4- J$'_9%7QI%GU$:?\
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MM7MS,3QNS_\ 7H ]CCC6) B# %/K/T74O[6TR*\V;-_\/I6A0 4444 %%%%
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MPHHHH **** "BBB@ HHHH **** "H)H(I?\ 68_&IZXWQA+?1O\ Z*)#\O\
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M1I)1@H6)'^>:Z+QEX>75K%Y?.>-XUXVG% %WPQI%GI6EQ16VS"]U(-;M>>>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU#GC^$D4 =;&ZN@92"IZ$4ZL[0X);?2((IL^8HYS6C0 4444 %%%% !1110
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M8->86.GO=Z_YCCY-P(/XURN[.N$E%,]PT*!8-(M0!@F)<_E6E5>R798PJ.R
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M?#GB :O WF$>8K;2!0!T!&1S7G'Q(C5;63 _AKT>O._B3_QZR?[M '3>#O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%_US_P *]Z\'_P#(K6?^Y7E?Q;\%ZGK&LK?VT&Z%$P3^5 TFW9'@M=S\*/\
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M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%=!I7_'A'5]3EWIM^9:CB2)=J* *?115&(4444 %%%% !1110 4444 %%%%
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MNGDP_/(QV_+VS4.A:,PS<71\QR=RD]J@T+27NG%]= [G'X5UBJ%4 #@5(P
M&!1@4-G:=O7'%93OJFX[4&,\4TKB;L-LQ_Q-YJU)88YHRCJ"IZ@US5L=2&HR
MD(-W>M:W?43,OFH G>GR];A*6MK'GWBW0)--N3>VZDJS?=4=*UO!WB0.HM9F
MRQ.,D]*[+4;>&XM'68#&TUXSJ.W0]9#6A.S))S6LIQG'WGJB:=&IS>XKH]IN
M;Z"W@:1Y5&!D9->/>,->:^U']R^$ QQ4SZAJ>MP>6O*@<8-8LGAO4MQ+1]Z\
MRO.3?*D?497AJ-->UG)7/1_ VMK=6JVSMRB]Z[8$$9!S7AVA?;-*U%5(QN8
MU[79@_9D)ZE0:VH2YHZ[GG9KAU2K<T=F3T445L>6%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)'HMM&H"[N*KWKW.:]+DY;LT0P89!S2TR.,1KM%/JSG84444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP  8 Q2U6LKV&_MUGA.4;I46HZE#I]NTDK8P*3=AQBY.RW'WM]#90L\CJ..
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 5[RW-S;O$'*E@1FO&/&/A"72VDG:_>4<MM)
MKV^O._B3_P >LG^[0!TW@[_D5[/_ ':WJPO!W_(KV?\ NUNT %%%% !1110
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M6C5+2KAKG3XY&SN/K5VNU.Z/E91<9-,1@&0J>A&*X_5?!>EZA<>;,8MWN*[
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M_(]=HIJ.)$#+T-.KJ/ "BBB@ HHHH **** "BBDW#U% "T4FX>HI<T %%%%
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MVZ;;);C9ENI-=?"Z_:@<U\V>(M8U'2?%=[)9S!"9>:D_X6/XE2/<+T;A]?\
M&@#Z?# ]#2UXIX!^(.HW;SG5;CS%7H!76W_Q1TNU)00SEO55/^% '?5X]\8[
MVYM=/E,$[QG_ &35N3QWJ&IMMT[S8R>FY37GWQ 7Q'<6CR:A,'B/4 &@#@[?
M6=2>-RU[,<#CYJM:)KU^NI)YM_+MR.K5EVL,@BD^4]/2IM(L6N-05'0D$^E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39$$B%
M3T-.HH X(9TKQ;-,>(F  ].]=#>.)-0M''\0S67XVM/]$CFBP'\P9_,4ZTO4
MN9K,;AE% /-90]V3B>CB5[2C"MUV?R.NIKNJ*68X ILDT<:%F=< 9ZUQVKZ_
M+?3_ &.P+ M\I..*N4U%'+0P\JTK+8L:YXA;<;:R7S9"<';VJ#3="DCB:[N
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M=%>-R_%V'<NV1L=^:LVGQ8@FE1#(V20.M 'K=%064XN;*&<='4-4] !1110
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M0 ^BF>;'_P ]$_[Z%'FQ_P#/1/\ OH4 /HIGG1?\]$_[Z%'G1?\ /1/^^A0
M^BF>='_ST3_OH4>;'_ST3_OH4 /HIGFQ_P#/1/\ OH4>;'_ST3_OH4 /HIGF
MQ_\ /1/^^A1YL?\ ST3_ +Z% #Z*9YL?_/1/^^A1YL?_ #T3_OH4 /HIGFQ_
M\]$_[Z%'G1?\]$_[Z% #Z*9YL?\ ST3_ +Z%'G1?\]$_[Z% #Z*9YL?_ #T3
M_OH4>;'_ ,]$_P"^A0 ^BF>;'_ST3_OH4>;'_P ]$_[Z% #Z*9YL?_/1/^^A
M1YL?_/1/^^A0 ^BF>;'_ ,]$_P"^A1YL?_/1/^^A0 ^BF>;'_P ]$_[Z%'FQ
M_P#/1/\ OH4 /HIGG1?\]$_[Z%'FQ_\ /1/^^A0 ^BF>;'_ST3_OH4>;'_ST
M3_OH4 /HIGFQ_P#/1/\ OH4>;'_ST3_OH4 /HIGFQ_\ /1/^^A1YL?\ ST3_
M +Z% #Z*9YT?_/1/^^A1YT7_ #T3_OH4 /HIGG1?\]$_[Z%'FQ_\]$_[Z% #
MZ*9YL?\ ST3_ +Z%'G1?\]$_[Z% &/KFG->P.,G !(KRVUOI=/UCRIG95#D9
M)KUK6-3AL;%Y"ZG((X->$ZG>-=:A(['*[SBN7$5.1IK<][*,)]8A)37NG=RW
M=]JUU]GMBYASPZGK79:+H45C$&<!Y#SDCD5C>!);/^S(MN%EQR2:[+S8_P#G
MHG_?0K2FN9<S.+&5'2DZ$%9+\1](0",&F^=%_P ]$_[Z%13W<4,9<NIQZ&MC
MSTKLK:E&HA7 '6G6$:F(\"LV\UB&:,*IZ'UIUKK$,28)_6HYE<Z?92]G:QO
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MWC^=04?3/AYU?0++!S^Z&:TZQ_#JQV^AVBETSY0SS6L)$8X#J?H:& ZBBB@
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MKXE )^S2\>]8%CXBUZ\OYK58'+1MM(S7O+_ZMOI7DGA:.0>+=2)1@#-U(^E
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M_$2QJ([:78!Q@UN>&EUL:E_I<,BQXZDUWMNACMXT;JJX-2TR&(OW1GK2T44
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M,-O%7/%"32Z0Z6\@22N9T>RTO4HIH7B5;M!C>QZF@"MI6H6^G:EY$RH]H?\
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M'.%49)KG[OQ5I@+(UP N.M:.N-C2;D!@&*<#UKBO#5CIM_8^1>0C[22>6X-
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M1O45U$^D?:M1,TF3&5Z'I6#XDT5;;['<PI@6WS-COUKH] U1=5TQ9AP3Q@T
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M>HI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***S]1U>WTU0TSJH/J: -"BN:;QIIB#+7$0'^]0OC/3&&1<
M1$'_ &J .EHK(3Q!9O8M=^:GEJ>3GBM"UNH[N%98V#*PR"* )Z*** "BBB@
MHHHH **** "BBB@ HIDDB1(6=@H'<U@'Q=8F\^S)(CMNVG!H Z*BF1N)$##O
M5'5-9M=*V_:)$3=TW&@#1HKFQXSTT_\ +>+_ +ZJY:>)=,NF"K=Q;CT&Z@#8
MHI%97&5.12T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %8NN>&;/7HU2Z+84Y&TUM44
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M(<@XZ=* /3HD5(P%Z8KROXN1^=J&E0EF"NV#@_6O5QP,5Y5\5O\ D+Z/_O\
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M- 'K(.11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >=?%W_D4+OZ?T-;'PZ_Y%"P_P"N=:OB'0H]
M>T^2TD8 /ZU8T?3%TG3XK1""(Q@8H Y7XI_\B==_Y[&N> /_  @MGQ_RRKT;
M7=&36].DM'8!7]:J?\(Q%_9<=EN&U%VYH P_A5QX<E_ZZG^9KFK\?\5=T_Y;
M"O3-!T9-$LVMT8$%L\52E\*Q2ZA]K+C.[=B@"C\0?^1)E_W1_*N(L=,>_P##
MDQ49V1$FO5M7TI-5TQK-R I&,U7TO0(M.MFAX967!% 'DO@+1="O;-H;W>+@
MR'C..]:6M:?X8TN_M8H_,,CO@=ZZK4_ "W-P9;*Y^R9_N4[2O *6EP);RX%T
MP.5W]J .CT2&.#3U6(84@&H/%%NUQH-VJC)\HXK71%C0*H  ]*)$62-D894C
M!!H \G^&6K1:;!_9EP2LI<G'XUJ^/_$-MY$5FC9><;1BM35O L=[<&:TF%JY
M[I4.G> %M[A9;RZ^U%3E=_:@#"LM.DT[X=-#(,,7S6I\.,YN_P#/I787^E17
MEA]E "+4&C:(FD>9L8'?Z4 :]>4_%E@FJ:0YZ!\G]:]6KG/$_A:/Q%Y1>0(8
M^A- %+P_XCL(=*17?D5A^,_'=G+82:=:,QEN%V >]65^&LJ#"ZDP'I_D5I:=
MX"M;659+@I.RG(+"@#G_  1IEQH_A);F1<7&#_*N8\.:?:^+-:U#^UV;]S*=
MF#CTKW'[)"(/)6-0F.G:N*O/AWYEV\]G>?9M[98)W_2@#A/B#INAZ1I26UD7
M,RR#KS7H/A> 7WA+R,9#P@4W_A7T<MN([NX$[ YW-6[8VUIX=M2LUPBICC/:
M@#Q+6=0F\.:^^EH2L8.,?CBO5O .D_8+*2X*X-P-]</JL-KXE\>2);*DB<$2
M+WYKV'3[<6UA#$!C:@% %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&U[0H=:MS',"1C'%;-%
M'*^&_!.GZ!()X8R)<8R:ZJBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>gtinntqqusay000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gtinntqqusay000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -K!0(# 2(  A$! Q$!_\0
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M?@CQ3;J)I&AN)NA/ '^17N^G7:7MHDJ$$$#I0!;HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=CDYKD?C(X\S3E[D_P"-=3\.$*^$T!ZT ;5]XBLM/<+,X!/^U5/_ (332_\
MGHO_ 'T*\N^)'AW7M0OD:Q2<J&_@-<)_PA?BW_GG=?\ ?5 'T9_PFFE_\]%_
M[Z%'_"9Z7_ST7_OH5\Y_\(7XM_YYW7_?59>K:5K^C1^9=M<1J#C):@#ZUT[5
M;?4U9H&!"]><U>KR/X(W$T^GW9ED9\?WC]*]<H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5[2\L4F2:,+M'5QZ5D>+_"-OXCM1D[)(Q\I YS7FJ^"]<L ;:"6Y://WMQH
M;\1=437_ !'IMI:Y;RY=K8Y'>O7?#6G'3-(C@(QC!KBO"/PZ6PN6O+N5Y)6.
M[#\X->F* J@#M0 8!HVBEHH 3:*\;^-@_P")0W^_7LM>-?&W_D$-_OT 2? O
M_D'7?^?2O8:\>^!?_(/N_P#/I7L- !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7CWP+_Y!]W_GTKV&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_GHWY4?\*AT7_GHWY4 >:_\+>O_ $F_[Y-'_"WK_P!)O^^37I7_  J'1?\
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MPMZ_])O^^37I7_"H=%_YZ-^5'_"H=%_YZ-^5 'FO_"WK_P!)O^^31_PMZ_\
M2;_ODUZ5_P *AT7_ )Z-^5'_  J'1?\ GHWY4 >:_P#"WK_TF_[Y-'_"WK_T
MF_[Y->E?\*AT7_GHWY4?\*AT7_GHWY4 >:'XOWRC+&8#W!KNOAUXZF\22S+(
MS'8>]8/Q$^'FF:'X=>ZMW8N#W%97P3&+R['HW^% 'T1VHH'2B@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH \\^+_P#R)\G^]7G?P4_X_;S_ 'O\*]$^+_\
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MBB@ HHHH *\:^-O_ ""&_P!^O9:\:^-O_((;_?H D^!?_(/N_P#/I7L->/?
MO_D'W?\ GTKV&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Z!:TF ZF
M-A^E?.%WX>OV\:QSBWDV"0G.WWKZ4J+[/!NW>3'GUVB@"EH4;1:3"C @@=#6
ME2  # &![4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7]JDR'(90: +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7C7QM_Y!#?[]>RUXU\;?\ D$-_OT 2? O_ )!]W_GTKV&O'O@7_P @
M^[_SZ5[#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>XOK6T7
M=<3I&/5C57^W])_Y_P"'_OJN4^(/A_5=:L3'IRDMNSU->9?\*V\7_P#/,_\
M?1H ]5\56OA_7[%D:[MA(,G<37S]?VC6?B&.UDOQ+;LY'7@"NL_X5MXO_P">
M9_[Z-5;CX2^)[EP[P<COS0!ZMX0A\-:?I4+B6U$O=L\UV-OJNGW!"0743GH
MIKY_B^&/BV&,(L9P/]HUUW@OP;X@TK4(Y+U2$#9/)H ]?HHHH **** "BBB@
M HHHH **** "BBB@#R7XN:HZ-I]K&Y E?:V*W?!EMI7A_1E^T2PQRG#98X->
M>_&"YDCU&S9/O)+E:ET30M:\8VZ3W*G[/@*2I- 'I>LQ:+XF@\A;N OC .:M
M>%?#9\.Z>;<3>8N=W%>0:SX7UGPA-'=V@;RP=S$D]*]0\ ^*&\0:'YDK R@[
M: /+M9F?7/'4<$C%D@N,8->]6=E!;VB11QJJ[1P/I7@6C_-\1+[=VN>/R%?0
MT?\ JU^@H \2^*.G1Z5KNEW=NH0M)N;;WZUZCX2OSJ.B1SL>>E<'\9 -^G'N
M#_C74?#9C_PB<9/K0!V5%>4>-OB/=>'KM8HW !.*Y/\ X77?_P#/1: /H.O&
MOC;_ ,@AO]^L'_A==_\ \]%KD_&'CVX\36ODRL""V: /3O@7_P @^[_SZ5[#
M7CWP+_Y!]W_GTKV&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &NZHI9R !W-<S?\ C;3+.]2V6>)W8XQGI69\2_$CZ)H>Z!L2,VW\Z\T\
M'^![_7M1_M.\#%=^\')H ]]M+I+NU$ZXVFN2\5?$*R\.G8NR9\= :U=1FC\.
M^'F . %8#\J\$T+1YO&OB>62YR]NDQ!Y[4 =_I_QHAN;A4EL1$I(&XG_ .O7
MI^F:I;:I;+-;R*X(R=IZ5YQKWPFTI-+9K.-O,0%ORK ^%^N3V&HS:7,_64J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"IJ.GPZE:M!.BLI!ZUY#K7P=>2[>6TOS$KG.U?_ -5>TT4 >5^$OA3%
MI5V+N[G%PV.CBO0]3A=='DBM\A@N%VUHT4 ?/USX%UK7M>875Q.L&01NZ=:]
M?\+>%[?P]8B*,*6(&2!70X'H*6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O&OC;_P @AO\ ?KV6O&OC;_R"&_WZ )/@
M7_R#[O\ SZ5[#7CWP+_Y!]W_ )]*]AH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,+Q7_R!GKDOA=_Q]:I_O?X5UOBO_D#/7)?"[_CZ
MU3_>_P * /2J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KQKXV_\@AO]^O9:\:^-O\ R"&_WZ )/@7_ ,@^[_SZ
M5[#7CWP+_P"0?=_Y]*]AH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,+Q7_ ,@9ZY+X7?\ 'UJG^]_A76^*_P#D#/7)?"[_ (^M4_WO
M\* /2J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3Q
M=XLD\-6IF6#S #BN#_X7><X^R+FO3]?\/V>O6+P74>\8) ]Z^=M=\'Q>'?$L
M*W<7^B22$D =J .\_P"%UO\ \^:T?\+K?_GS6MK1/A[X1UC38[N*TRK].G^%
M:7_"J/"__/G_ "H Y/\ X76__/FM=!X9^)3:]>) ;<)N.,U<_P"%4>%_^?/^
M5:6E> ]#T:=9;2VV,IR#Q0!T]%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5XU\;?^00W^_7LM>-?&W_ )!#?[] $GP+_P"0
M?=_Y]*]AKQ[X%_\ (/N_\^E>PT %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBESSP:]ANF5;67<0!L/4^U>$6#1O\08#;#Y?..['- 'OM%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XU\;?^00W^_7LM>-
M?&W_ )!#?[] $GP+_P"0?=_Y]*]AKQ[X%_\ (/N_\^E>PT %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 5XM\2/^/V3_>_K7M->+?$C_C]D_P![^M=F!_BG+B_X9Y_1117MGE!1110
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M&Q_[H_E7SE8?\A"W_P!\5]&Z#_R#8_\ ='\J\W,-D=V"W9J4445Y1Z(4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O%OB1_P ?TG^]
M_6O::\6^)'_'[)_O?UKLP/\ %.7%_P ,\_HHHKVSR@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"Q8?\A"W_WQ7T;H/_(-C_W1_*OG*P_Y"%O_ +XKZ-T'
M_D&Q_P"Z/Y5YN8;([L%NS4HHHKRCT0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \<^,Y/V!/^NP_F*[;P#_R H?^N8KB?C1_QX)_
MUV'\Q7;> ?\ D!0_]<Q0!F_%EV3PPA5BI\SL?I5'X/R.^G76]F;YNYJ[\7/^
M17C_ .NG^%4/@[_R#;K_ 'J /1K_ /X\+C_KFW\J\ \&_P#([2?]?#?SKW^_
M_P"/"X_ZYM_*O ?!O_([2?\ 7PW\Z /H>BBB@ HHHH **** "BBB@ HHHH *
M*** "N4\;>)DT'2)7C8>>.BFNAU"\CL;*6>1@-BD\FO&U:?QSXM4X8V/*LI'
M'6@#A-(O+V\\8Q74[.%EG! W<5]2P_\ 'O&?]@?RKYVN;-+#Q?;6\8 5)P!B
MOHB+_CU3_<'\J /'OB-XCGO=2M=+M'/SOY;[3@CK6EI/PHMGTT&YN9_,89Y8
M_P"-<7"/M_Q#G#<^5<\?E7T+$,1(/]D4 ?/ZI>^!/%$,/F2-!<38!=B>/\BO
M>K&Z2\M5EC.017D_QCMPMYI<P'*MG^==M\/KAKCPS&[')S0!U=%5Y;^T@.);
MB)#_ +3@5'_:VG_\_L'_ '\% %RO&OC;_P @AO\ ?KUG^UM/_P"?V#_OX*\?
M^,][;7&DL(9XW._HK T 6_@7_P @^[_SZ5[#7CWP+_Y!]W_GTKV&@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ;XD?\?LG
M^]_6O::\6^)'_'[)_O?UKLP/\4Y<7_#//Z***]L\H**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH L6'_(0M_P#?%?1N@_\ (-C_ -T?RKYRL/\ D(6_^^*^
MC=!_Y!L?^Z/Y5YN8;([L%NS4HHHKRCT0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \:^-)VZ<K'H)03^8K0\'>/M L-(BBGO KA
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M@)-F?XG)K[ _LBR_YXBO(/C-906^E,8D"G?0!<^!?_(/N_\ /I7L->/? O\
MY!]W_GTKV&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVFO%OB1_Q_2?[W]:[,#_ !3EQ?\ #//Z***]L\H**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 %%%% !1110 5XU\;?^00W^_7LM>-?&W_D$-_OT 2? O\
MY!]W_GTKV&O'O@7_ ,@^[_SZ5[#0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5XM\2/^/Z3_ 'OZU[37BWQ(_P"/Z3_>_K79
M@?XIRXO^&>?T445[9Y04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8L/\
MD(6_^^*^C=!_Y!L?^Z/Y5\Y6'_(0M_\ ?%?1N@_\@V/_ '1_*O-S#9'=@MV:
ME%%%>4>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M $4]O'<1E)%# ^HS7)7OPWT:]F,C[@2<\"NRHH YS1_!>F:+)O@7<0/XA71
M!1@#@4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7C7QM_Y!#?[]>RUXU\;?\ D$-_OT 2? O_ )!]W_GTKV&O
M'O@7_P @^[_SZ5[#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5XM\2/^/V3_>_K7M->+?$C_C^D_P![^M=F!_BG+B_X9Y_1
M117MGE!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %BP_Y"%O\ [XKZ-T'_
M )!L?^Z/Y5\Y6'_(0M_]\5]&Z#_R#8_]T?RKS<PV1W8+=FI1117E'HA1110
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M5[3O%NGZE*(X)XV8G'!H Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L6'_(0M_\
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M"?\ "Q[?_GDOYU&?B;9APA5-QZ#- '?T5PG_  L>W_YY+^='_"Q[?_GDOYT
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M?_05N/\ /X5U/@[P1J6D7\<MQ?2RJ&SAO_U4 >L4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7C7QM_Y!#?[]>RUXU\;?\
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MXC7^NWR0S:<T09L9/_ZZ /4J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KQKXV_\@AO]^O9:\:^-O\ R"&_WZ )/@7_ ,@^
M[_SZ5[#7CWP+_P"0?=_Y]*]AH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KG?%W_(-;_=-=%7.^+O^0:W^Z:B?PLZ<)_&B>%R?ZU_J:;3I/\
M6O\ [QIM>0?HJV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O3_AU]R/Z
M5YA7I_PZ^XGTKHP_QGEYQ_NK/2:***](^%"BBB@ HHHH **** "O%OB1_P ?
MLG^]_6O::\6^)'_'[)_O?UKLP/\ %.7%_P ,\_HHHKVSR@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"Q8?\A"W_WQ7T;H/_(-C_W1_*OG*P_Y"%O_ +XK
MZ-T'_D&Q_P"Z/Y5YN8;([L%NS4HHHKRCT0HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-_'I6GEB=^Q\<BNZ^'WAPZ#H CE4"0_-Q6+X%\ K:*+^^)DFD&XB09(->F;
MD>U1@ 4 ?/6D_OOB)>[OX;GC\A7T-'_JE^@KYZM?]"^(=P6X\RYX_*OH2/\
MU2'_ &10!Y/\9$!DTYO0_P"-=5\-WW>%(V/K7(_&.<&ZTR('EFQ_.NR^'T#0
M^%XT88- &/XJ^)5IX=N5BE+Y)QQ7._\ "[]._O25M>,/A=%XENEE:Y9,'/%<
MS_PH:#_G]>@"Y_PN_3O[TE<-X\\?VOB>S,,););/-=9_PH:#_G]>N,\;_#J/
MPK:>>DYDPV,&@#T;X%_\@^[_ ,^E>PUX]\"_^0==_P"?2O8: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YWQ=_R#6_W3715SOB[_ )!K?[IJ
M)_"SIPG\:)X7)_K7_P!XTVG2?ZU_]XTVO(/T5;!1110 4444 %%%% !1110
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MWQ=_R#6_W343^%G3A/XT3PN3_6O_ +QIM.D_UK_[QIM>0?HJV"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O3_AU]Q/I7F%>G_#K[B?2NC#_&>7G'^ZL]
M)HHHKTCX4**** "BBB@ HHHH *\6^)'_ !_2?[W]:]IKQ;XD?\?TG^]_6NS
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M1%/X@\3'42AV13'!'IF@#WNBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG2?ZU_\ >--KR#]%6P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<)_&B>%R?ZU_]XTVG2?ZU_\ >--KR#]%6P4444 %%%% !1110 4444 %%%%
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MU[37BWQ(_P"/Z3_>_K79@?XIRXO^&>?T445[9Y04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!8L/\ D(6_^^*^C=!_Y!L?^Z/Y5\Y6'_(0M_\ ?%?1N@_\
M@V/_ '1_*O-S#9'=@MV:E%%%>4>B%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5:_MDN[*2"3&UQ@YJS5#6FF32;AK<9E"_** /$
M?$GA+6=&U>:\T>X*1O\ *%C&>*E\$^ ]2NM6CU+47+-&^[YA@U(?B'JVC7Q@
MU*VA$2]V /\ ,5W&A_$G0+U50W$:2'LJ@<T 9WQ&.KQV8ATQY$#/M^49X-1?
M#OP/-IH-Y>D/,[;P3U&:](AFM+^,2($D4]"5!JRJA1A5 'L* %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O&OC;_R"&_W
MZ]EKQKXV_P#((;_?H D^!?\ R#[O_/I7L->/? O_ )!]W_GTKV&@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N=\7?\@UO]TUT5<[XN_Y!K?[
MIJ)_"SIPG\:)X7)_K7_WC3:=)_K7_P!XTVO(/T5;!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7I_PZ^XGTKS"O3_ (=?<3Z5T8?XSR\X_P!U9Z31117I
M'PH4444 %%%% !1110 5XM\2/^/V3_>_K7M->+?$C_C]D_WOZUV8'^*<N+_A
MGG]%%%>V>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6+#_D(6_\ OBOH
MW0?^0;'_ +H_E7SE8?\ (0M_]\5]&Z#_ ,@V/_='\J\W,-D=V"W9J4445Y1Z
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(RAU*
ML,@TM-DD6-"['"CK0!A:IX0TC5 QGM$9SW->>ZU\)'4M/ITJ6^.1BNTUKX@Z
M'I&Y);K;(O; KSG5OBY?W;M!I(CE#<#/_P"J@#"EU'Q!X1FV3ZDTD:'H*ZOP
M[\9;:5E@N(6+="QKF(_#GBCQ7)YU[9!8W[J3_A75:?\ !/3C:,T[S)*><#/^
M- 'I>E^(K#5(E>*XBW'^'=S6N#D9%?-VM:3J'P^U1)[9I6MVD5 7<^M>[^&M
M4_M32H9203L&: -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KQKXV_\@AO]^O9:\:^-O_((;_?H D^!?_(/N_\ /I7L->/? O\
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MI/\ >_K79@?XIRXO^&>?T445[9Y04444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC/+SC_=6>DT445Z1\*%%%% !1110 4444 %>+?$C_C^D_P![^M>TUXM\2/\
MC^D_WOZUV8'^*<N+_AGG]%%%>V>4%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 6+#_ )"%O_OBOHW0?^0;'_NC^5?.5A_R$+?_ 'Q7T;H/_(-C_P!T?RKS
M<PV1W8+=FI1117E'HA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!XW\:#C3T)Z"8?S%=-X&U[2X-$A66^A1A&."U5_B7X2U#Q)IYB
MLH][;LUY:GPD\5(,+$X^C&@#Z#_X271O^@C;_P#?5'_"2Z-_T$;?_OJOG[_A
M4_BS_GG)_P!]-1_PJ?Q9_P \Y/\ OIJ />;[Q'H[6,X&HP$F-L?-[5XEX)D2
M3QH[(P93<,01]:I?\*G\6$8,<G_?1KJ_ GP[UG0]3CGNX-JALD\T >V4444
M%%%% !1110 4444 %%%% !1110 4444 %0W4OE0,WM4U4]2&;-\>E '@OAY/
M[2\?W[2?,([C*Y[<"OH- !$H_P!FO _ N!XYU;/_ #W_ *"O?E^X/I0!X=\4
M+5=/\2Z1/$ I:7)(_&O6_#=V;S28Y2<\"O+?C%SJVD#OO_QKT3P4"OAU,]<?
MTH WI+RWA.))D7ZFF?VE9?\ /S'^=>)_$G6=8M+]%M/N[O6N$_X27Q+_ ))H
M ^I_[2LO^?F/\Z\>^-%U!-I+".56._L:\Y_X27Q+_DFLS5;S6=4CV7*Y&<]3
M0!Z[\$+J"#3[L2RJF?4_2O7?[2LO^?F/\Z^1M)OM:TE&6U7 ;KUK2_X27Q+_
M ))H ^I_[2LO^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+_ ))H ^I_[2LO
M^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+_ ))H ^I_[2LO^?F/\Z/[2LO^
M?F/\Z^6/^$E\2_Y)H_X27Q+_ ))H ^I_[2LO^?F/\Z/[2LO^?F/\Z^6/^$E\
M2_Y)H_X27Q+_ ))H ^I_[2LO^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+_
M ))H ^I_[2LO^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+_ ))H ^I_[2LO
M^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+_ ))H ^I_[2LO^?F/\Z/[2LO^
M?F/\Z^6/^$E\2_Y)H_X27Q+_ ))H ^I_[2LO^?F/\ZY[Q9?VCZ<P6X0_*>]?
M//\ PDOB3_)-0W&N>(;E-D@X^II25U8UHU/9U%)]#>DGB\QOG'4]Z9YT7]\5
MQY352<[*39JO]RN'ZK(^G7$%/^4['SHO[XH\Z+^^*X[9JO\ <HV:K_<H^JR'
M_K!3_E.Q\Z+^^*/.B_OBN.V:K_<HV:K_ '*/JL@_U@I_RG8^=%_?%'G1?WQ7
M';-5_N4;-5_N4?59!_K!3_E.Q\Z+^^*/.B_OBN.V:K_<HV:K_<H^JR#_ %@I
M_P IV/G1?WQ1YT7]\5QVS5?[E&S5?[E'U60?ZP4_Y3L?.B_OBCSHO[XKCMFJ
M_P!RC9JO]RCZK(/]8*?\IV/G1?WQ1YT7]\5QVS5?[E&S5?[E'U60?ZP4_P"4
M['SHO[XH\Z+^^*X[9JO]RC9JO]RCZK(/]8*?\IV/G1?WQ1YT7]\5QVS5?[E&
MS5?[E'U60?ZP4_Y3L?.B_OBCSHO[XKCMFJ_W*-FJ_P!RCZK(/]8*?\IV/G1?
MWQ1YT7]\5QVS5?[E&S5?[E'U60?ZP4_Y3L?.B_OBCSHO[XKCMFJ_W*-FJ_W*
M/JL@_P!8*?\ *=CYT7]\4>=%_?%<=LU7^Y1LU7^Y1]5D'^L%/^4['SHO[XH\
MZ+^^*X[9JO\ <HV:K_<H^JR#_6"G_*=CYT7]\4>=%_?%<=LU7^Y1LU7^Y1]5
MD'^L%/\ E.Q\Z+^^*/.B_OBN.V:K_<HV:K_<H^JR#_6"G_*=CYT7]\4>=%_?
M%<=LU7^Y1LU7^Y1]5D'^L%/^4['SHO[XH\Z+^^*X[9JO]RC9JO\ <H^JR#_6
M"G_*=CYT7]\5Z9\/;RVC1-\R#CN:\"V:K_<J_9ZEKMB!Y0QCW-:4L.X2N<>.
MSB&(HNFD?6G]I67_ #\Q_G1_:5E_S\Q_G7RQ_P )+XD_R31_PDOB7_)-=9\\
M?4_]I67_ #\Q_G1_:5E_S\Q_G7RQ_P )+XE_R31_PDOB7_)- 'U/_:5E_P _
M,?YT?VE9?\_,?YU\L?\ "2^)?\DT?\)+XE_R30!]3_VE9?\ /S'^=']I67_/
MS'^=?+'_  DOB7_)-'_"2^)?\DT ?4_]I67_ #\Q_G7C?Q%N8)+V0I*K?-V/
MO7GG_"2^)/\ )-9MY=ZU?,6E7)/UK?#U52GS,QK4_:1L;'F)_>%'F)_>%<YY
M.J?W*/)U3^Y7?_:$>QQ_4I=SH_,3^\*/,3^\*YSR=4_N4>3JG]RC^T(]@^I2
M[G1^8G]X4>8G]X5SGDZI_<H\G5/[E']H1[#^I2[G1^8G]X4>8G]X5SGDZI_<
MH\G5/[E']H1[!]2EW.C\Q/[PH\Q/[PKG/)U3^Y1Y.J?W*/[0CV#ZE+N='YB?
MWA1YB?WA7.>3JG]RCR=4_N4?VA'L'U*7<Z/S$_O"CS$_O"N<\G5/[E'DZI_<
MH_M"/8/J4NYT?F)_>%'F)_>%<YY.J?W*/)U3^Y1_:$>P?4GW.C\Q/[PH\Q/[
MPKG/)U3^Y1Y.J?W*/[0CV#ZE+N='YB?WA1YB?WA7.>3JG]RCR=4_N4?VA'L'
MU*7<Z/S$_O"CS$_O"N<\G5/[E'DZI_<H_M"/8/J3[G1^8G]X4>8G]X5SGDZI
M_<H\G5/[E']H1[!]2?<Z/S$_O"CS$_O"N<\G5/[E'DZI_<H_M"/8/J4NYT?F
M)_>%'F)_>%<YY.J?W*/)U3^Y1_:$>P?4I=SH_,3^\*/,3^\*YSR=4_N4>3JG
M]RC^T(]@^I2[G1^8G]X4>8G]X5SGDZI_<H\G5/[E']H1[!]2?<Z/S$_O"CS$
M_O"N<\G5/[E'DZI_<H_M"/8/J4NYT?F)_>%'F)_>%<YY.J?W*/)U3^Y1_:$>
MP?4GW.C\Q/[PH\Q/[PKG/)U3^Y1Y.J?W*/[0CV#ZD^YU=C+&+^ EQ]\5]#:'
MJ%HNG(#<1@[1W]J^3TCU5'#!.0<BMF+Q!XCB0*HX'N:Y<3B562L=%"@Z;=SZ
MJ_M*R_Y^8_SH_M*R_P"?F/\ .OEC_A)?$O\ DFC_ (27Q+_DFN,Z3ZG_ +2L
MO^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+_DF@#ZG_ +2LO^?F/\Z/[2LO
M^?F/\Z^6/^$E\2_Y)H_X27Q+_DF@#ZG_ +2LO^?F/\Z/[2LO^?F/\Z^6/^$E
M\2_Y)H_X27Q+_DF@#ZG_ +2LO^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+
M_DF@#ZG_ +2LO^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+_DF@#ZG_ +2L
MO^?F/\Z/[2LO^?F/\Z^6/^$E\2_Y)H_X27Q+_DF@#ZG_ +2LO^?F/\Z/[2LO
M^?F/\Z^6/^$E\2_Y)H_X27Q+_DF@#ZG_ +2LO^?F/\Z/[2LO^?F/\Z^6/^$E
M\2_Y)H_X27Q+_DF@#ZG_ +2LO^?F/\ZL1R)*@9&#*>XKY17Q+XD+?_7-?0_P
M_N+BZ\)VLMU_K3U_(4 =31110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %1S()(F4^E244 ?/6G,=%\?W1E^59[C@GZ"OH".9&
MMU<,"NWK7FOC[P/->S17^FQYGC.\_6N8BU[QS;VWV/8F[IWH ;\0KT:SXKTN
MWA^;RIL-CMUKV;1+/[%IL<7L*\R\%>![^349-2UF/$C-O3ZUZ\HVJ!Z4 4;G
M1=.O&W7%I'(?4BJ__"+Z+_T#X?RK7HH R/\ A%]%_P"@?#^5'_"+Z(>NG0_E
M6O10!D#PMH@Z:=#^5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P!
M^'\JUZ* ,C_A%]%_Z!\/Y4?\(OHO_0/A_*M>B@#(_P"$7T7_ *!\/Y4?\(OH
MO_0/A_*M>B@#(_X1?1?^@?#^5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\
M"+Z+_P! ^'\JUZ* ,C_A%]%_Z!\/Y4?\(OHO_0/A_*M>B@#(_P"$7T7_ *!\
M/Y4?\(OHO_0/A_*M>B@#(_X1?1?^@?#^5'_",:+_ - ^'\JUZ* ,C_A%]%_Z
M!\/Y4?\ ",:+_P! ^'\JUZ* ,C_A&-%_Z!\/Y4?\(OHO_0/A_*M>B@#(_P"$
M7T7_ *!\/Y4?\(OHO_0/A_*M>B@#(_X1?1?^@?#^5'_"+Z+_ - ^'\JUZ* ,
MC_A%]%_Z!\/Y4?\ "+Z+_P! ^'\JUZ* ,C_A%]%_Z!\/Y4?\(OHO_0/A_*M>
MB@#(_P"$7T7_ *!\/Y4?\(OHO_0/A_*M>B@#(_X1?1?^@?#^5'_"+Z+_ - ^
M'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P! ^'\JUZ* ,C_A%]%_Z!\/Y4?\(OHO
M_0/A_*M>B@#(_P"$7T7_ *!\/Y4?\(OHO_0/A_*M>B@#(_X1?1?^@?#^5'_"
M+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P! ^'\JUZ* ,C_A%]%_Z!\/
MY4?\(OHO_0/A_*M>B@#(_P"$7T7_ *!\/Y4?\(OHO_0/A_*M>B@#(_X1?1?^
M@?#^5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P! ^'\JUZ* ,C_A
M%]%_Z!\/Y4?\(OHO_0/A_*M>B@#(_P"$7T7_ *!\/Y4?\(OHO_0/A_*M>B@#
M(_X1?1?^@?#^5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P! ^'\J
MUZ* ,C_A&-%_Z!\/Y4?\(OHO_0/A_*M>B@#(_P"$7T7_ *!\/Y4?\(OHO_0/
MA_*M>B@#(_X1?1?^@?#^5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+
M_P! ^'\JUZ* ,C_A%]%_Z!\/Y4?\(OHO_0/A_*M>B@#(_P"$7T7_ *!\/Y4?
M\(OHO_0/A_*M>B@#(_X1?1?^@?#^5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y
M4?\ "+Z+_P! ^'\JUZ* ,C_A%]%_Z!\/Y4?\(OHO_0/A_*M>B@#(_P"$7T7_
M *!\/Y4?\(OHO_0/A_*M>B@#(_X1?1?^@?#^5'_"+Z+_ - ^'\JUZ* ,C_A%
M]%_Z!\/Y4?\ "+Z+_P! ^'\JUZ* ,C_A%]%_Z!\/Y4?\(OHO_0/A_*M>B@#(
M_P"$7T7_ *!\/Y4?\(OHO_0/A_*M>B@#(_X1?1?^@?#^5'_"+Z+_ - ^'\JU
MZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P! ^'\JUZ* ,C_A%]%_Z!\/Y4?\(OHO_0/A
M_*M>B@#(_P"$7T7_ *!\/Y4?\(OHO_0/A_*M>B@#(_X1?1?^@?#^5'_"+Z+_
M - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P! ^'\JUZ* ,C_A%]%_Z!\/Y4?\
M(OHO_0/A_*M>B@#(_P"$8T7_ *!\/Y4?\(OHO_0/A_*M>B@#(_X1?1?^@?#^
M5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ ",:+_P! ^'\JUZ* ,C_A%]%_
MZ!\/Y4?\(OHO_0/A_*M>B@#(_P"$7T7_ *!\/Y4?\(OHO_0/A_*M>B@#(_X1
M?1?^@?#^5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P! ^'\JUZ*
M,C_A%]%_Z!\/Y4?\(OHO_0/A_*M>B@#(_P"$7T7_ *!\/Y4?\(OHO_0/A_*M
M>B@#(_X1?1?^@?#^5'_"+Z+_ - ^'\JUZ* ,C_A%]%_Z!\/Y4?\ "+Z+_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\HEV@?@*]S'(!KPGX9VYO/%^LS ?+YV0?P%>[#A1]* %HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ(G%<)XK\8WGBF:*QL(2T;'8S)Z5V"_"#PZ#S9C]*W]'\":)HS![6VV-Z\4
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MW>VT=U/;&+<*] JO9V4-A;+! NV->@JQ0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 'I7FWC/P9>:S<Q^3=S(A/S!6->DT4 <GX-\)1>'K%%+>9*
M/XVZUUE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>39
<FILENAME>dyn-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-02T07:22:25.4920071+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : ae64fadccf2840c0b084487bdd0b9296 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:dyn="http://www.dyne-tx.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="dyn-20201231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_dynSegment">
    <xbrli:measure>dyn:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_dynInstallment">
    <xbrli:measure>dyn:Installment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217EUR">
    <xbrli:measure>iso4217:EUR</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001818794_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20210226">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-02-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_dynSeriesARedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dyn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200921_20200921">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-21</xbrli:startDate>
      <xbrli:endDate>2020-09-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200921">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_dynFollowOnPublicOfferingMember_20210125_20210125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dyn:FollowOnPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-25</xbrli:startDate>
      <xbrli:endDate>2021-01-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_dynFollowOnPublicOfferingMember_20210125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dyn:FollowOnPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynLaboratoryEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dyn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCreditFacilityAxis_dynPacificWesternBankMember_us-gaapDebtInstrumentAxis_dynLoanAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dyn:LoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dyn:PacificWesternBankMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20200901_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCertificatesOfDepositMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dyn:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dyn:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dyn:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dyn:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dyn:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dyn:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20200921_20200921">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-21</xbrli:startDate>
      <xbrli:endDate>2020-09-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20200921">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20200921">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynPreferredStockTrancheObligationsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dyn:PreferredStockTrancheObligationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynPreferredStockTrancheObligationsMember_us-gaapVestingAxis_dynTrancheRightOneMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyn:TrancheRightOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dyn:PreferredStockTrancheObligationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynPreferredStockTrancheObligationsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dyn:PreferredStockTrancheObligationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynSuccessFeeObligationMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dyn:SuccessFeeObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynSuccessFeeObligationMember_us-gaapFinancialInstrumentAxis_us-gaapDerivativeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dyn:SuccessFeeObligationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynLaboratoryEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dyn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynLaboratoryEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dyn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynOfficeAndComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dyn:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynOfficeAndComputerEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dyn:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dyn:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dyn:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200220_20200220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dyn:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-20</xbrli:startDate>
      <xbrli:endDate>2020-02-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200901_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dyn:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20181129_20181129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-29</xbrli:startDate>
      <xbrli:endDate>2018-11-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20190401_20190430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200318_20200318">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-18</xbrli:startDate>
      <xbrli:endDate>2020-03-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200701_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20181129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-11-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20190430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200318">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_20200801_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-01</xbrli:startDate>
      <xbrli:endDate>2020-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRightMember_20181129_20181129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyn:TrancheRightMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-29</xbrli:startDate>
      <xbrli:endDate>2018-11-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRightOneMember_20181129_20181129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyn:TrancheRightOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-29</xbrli:startDate>
      <xbrli:endDate>2018-11-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRighttwoMember_20181129_20181129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyn:TrancheRighttwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-29</xbrli:startDate>
      <xbrli:endDate>2018-11-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRightMember_20181129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyn:TrancheRightMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-11-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRightOneMember_20190401_20190430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dyn:TrancheRightOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandEighteenStockIncentivePlanMember_20200915">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyn:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyn:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200916_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyn:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-16</xbrli:startDate>
      <xbrli:endDate>2020-09-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyn:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200916_20200916">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-16</xbrli:startDate>
      <xbrli:endDate>2020-09-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyn:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dyn:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001818794_20201201_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001818794</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001818794_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001818794_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001818794_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001818794_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001818794_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:CurrentFiscalYearEndDate id="F_000005" contextRef="C_0001818794_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001818794_20200101_20201231">Dyne Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001818794_20200101_20201231">0001818794</dei:EntityCentralIndexKey>
  <dei:EntityFileNumber id="F_000008" contextRef="C_0001818794_20200101_20201231">001-39509</dei:EntityFileNumber>
  <dei:EntityIncorporationStateCountryCode id="F_000009" contextRef="C_0001818794_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityTaxIdentificationNumber id="F_000010" contextRef="C_0001818794_20200101_20201231">36-4883909</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000011" contextRef="C_0001818794_20200101_20201231">830 Winter Street</dei:EntityAddressAddressLine1>
  <dei:EntityAddressCityOrTown id="F_000012" contextRef="C_0001818794_20200101_20201231">Waltham</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000013" contextRef="C_0001818794_20200101_20201231">MA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000014" contextRef="C_0001818794_20200101_20201231">02451</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000015" contextRef="C_0001818794_20200101_20201231">781</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000016" contextRef="C_0001818794_20200101_20201231">786-8230</dei:LocalPhoneNumber>
  <dei:EntityCurrentReportingStatus id="F_000017" contextRef="C_0001818794_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent id="F_000018" contextRef="C_0001818794_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityFilerCategory id="F_000019" contextRef="C_0001818794_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000020" contextRef="C_0001818794_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000021" contextRef="C_0001818794_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000022" contextRef="C_0001818794_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:EntityCommonStockSharesOutstanding id="F_000023" contextRef="C_0001818794_20210226" decimals="INF" unitRef="U_xbrlishares">51457555</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityShellCompany id="F_000024" contextRef="C_0001818794_20200101_20201231">false</dei:EntityShellCompany>
  <dei:DocumentAnnualReport id="F_000025" contextRef="C_0001818794_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000026" contextRef="C_0001818794_20200101_20201231">false</dei:DocumentTransitionReport>
  <dei:Security12bTitle id="F_000027" contextRef="C_0001818794_20200101_20201231">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000028" contextRef="C_0001818794_20200101_20201231">DYN</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000029" contextRef="C_0001818794_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityWellKnownSeasonedIssuer id="F_000030" contextRef="C_0001818794_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="F_000031" contextRef="C_0001818794_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:IcfrAuditorAttestationFlag id="F_000032" contextRef="C_0001818794_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <dei:EntityPublicFloat id="F_000033" contextRef="C_0001818794_20200630" decimals="0" unitRef="U_iso4217USD">0</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000034" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">300852000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">14632000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000036" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">44462000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000037" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">3773000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000038" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">127000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000039" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">349087000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000040" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">14759000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000041" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">1946000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000042" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">1486000</us-gaap:PropertyPlantAndEquipmentNet>
  <dyn:RestrictedCashAndOtherAssetsNoncurrent id="F_000043" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">2301000</dyn:RestrictedCashAndOtherAssetsNoncurrent>
  <dyn:RestrictedCashAndOtherAssetsNoncurrent id="F_000044" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">191000</dyn:RestrictedCashAndOtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000045" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">353334000</us-gaap:Assets>
  <us-gaap:Assets id="F_000046" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">16436000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000047" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">3440000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000048" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">1256000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000049" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">7527000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000050" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">1102000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:LiabilitiesCurrent id="F_000051" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">10967000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000052" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">2358000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000053" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:Liabilities id="F_000054" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">10967000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000055" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">2400000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000056" xsi:nil="true" contextRef="C_0001818794_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000057" xsi:nil="true" contextRef="C_0001818794_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000058" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">27429000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="F_000059" xsi:nil="true" contextRef="C_0001818794_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000060" xsi:nil="true" contextRef="C_0001818794_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000061" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000062" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="F_000063" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">421572000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000064" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">6352000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000065" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000066" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">-79183000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000067" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">-19746000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000068" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">342367000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000069" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">14036000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000070" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">353334000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000071" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">16436000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000072" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000073" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000074" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000075" contextRef="C_0001818794_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000076" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000077" contextRef="C_0001818794_20191231" decimals="INF" unitRef="U_xbrlishares">68000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000078" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_xbrlishares">45446903</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000079" contextRef="C_0001818794_20191231" decimals="INF" unitRef="U_xbrlishares">3239017</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000080" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_xbrlishares">45076574</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000081" contextRef="C_0001818794_20191231" decimals="INF" unitRef="U_xbrlishares">2586535</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000082" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">45200000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000083" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">11040000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000084" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13447000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000085" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2786000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000086" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">58647000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000087" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">13826000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000088" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-58647000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000089" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-13826000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeOther id="F_000090" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">56000</us-gaap:InterestIncomeOther>
  <us-gaap:InterestIncomeOther id="F_000091" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">290000</us-gaap:InterestIncomeOther>
  <us-gaap:InterestExpenseOther id="F_000092" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">396000</us-gaap:InterestExpenseOther>
  <dyn:ChangesInFairValueOfPreferredStockTrancheObligations id="F_000093" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1323000</dyn:ChangesInFairValueOfPreferredStockTrancheObligations>
  <dyn:ChangesInSuccessFeeObligation id="F_000094" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">450000</dyn:ChangesInSuccessFeeObligation>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000095" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-790000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000096" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1033000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000097" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-59437000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000098" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-14859000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000099" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-4.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000100" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-6.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000101" contextRef="C_0001818794_20200101_20201231" decimals="0" unitRef="U_xbrlishares">14395955</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000102" contextRef="C_0001818794_20190101_20191231" decimals="0" unitRef="U_xbrlishares">2442872</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000103" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000104" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-59464000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000105" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-14859000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:SharesOutstanding id="F_000106" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">2110404</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000107" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000108" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000109" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-4887000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000110" contextRef="C_0001818794_20181231" decimals="-3" unitRef="U_iso4217USD">-4879000</us-gaap:StockholdersEquity>
  <dyn:ReclassificationsOfTemporaryToPermanentEquityShares id="F_000111" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">32500000</dyn:ReclassificationsOfTemporaryToPermanentEquityShares>
  <us-gaap:ReclassificationsOfTemporaryToPermanentEquity id="F_000112" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">27429000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
  <us-gaap:ReclassificationsOfTemporaryToPermanentEquity id="F_000113" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6319000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
  <us-gaap:ReclassificationsOfTemporaryToPermanentEquity id="F_000114" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">33748000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000115" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000116" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <dyn:StockIssuedDuringPeriodSharesRestrictedStockVested id="F_000117" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">476131</dyn:StockIssuedDuringPeriodSharesRestrictedStockVested>
  <us-gaap:NetIncomeLoss id="F_000118" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-14859000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000119" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">32500000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000120" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">27429000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000121" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">2586535</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000122" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000123" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">6352000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000124" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-19746000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000125" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">-93159724</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000126" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-162215000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000127" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">28086375</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000128" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000129" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">162212000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000130" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">32197</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000131" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000132" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000133" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6591000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000134" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6591000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <dyn:StockIssuedDuringPeriodSharesRestrictedStockVested id="F_000135" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">282153</dyn:StockIssuedDuringPeriodSharesRestrictedStockVested>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000136" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000137" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-59437000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000138" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">45076574</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000139" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000140" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">421572000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000141" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000142" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-79183000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000143" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">12500000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000144" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">9061000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <dyn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000145" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">20000000</dyn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000146" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">19989000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <dyn:SettlementOfTrancheRightOne id="F_000147" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1621000</dyn:SettlementOfTrancheRightOne>
  <dyn:ReclassificationsOfTemporaryToPermanentEquityShares id="F_000148" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-32500000</dyn:ReclassificationsOfTemporaryToPermanentEquityShares>
  <us-gaap:ReclassificationsOfTemporaryToPermanentEquity id="F_000149" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-27429000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000150" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">19500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000151" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">19467000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000152" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">19467000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000153" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">41159724</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000154" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115319000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000155" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115319000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000156" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">14089314</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000157" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000158" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">246387000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000159" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">246388000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <dyn:StockIssuanceCosts id="F_000160" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_dynSeriesARedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</dyn:StockIssuanceCosts>
  <dyn:StockIssuanceCosts id="F_000161" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">100000</dyn:StockIssuanceCosts>
  <dyn:StockIssuanceCosts id="F_000162" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">400000</dyn:StockIssuanceCosts>
  <dyn:StockIssuanceCosts id="F_000163" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">2600000</dyn:StockIssuanceCosts>
  <us-gaap:ProfitLoss id="F_000164" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-59437000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000165" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-14859000</us-gaap:ProfitLoss>
  <us-gaap:ShareBasedCompensation id="F_000166" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6591000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000167" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000168" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">700000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000169" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">271000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfDebtDiscountPremium id="F_000170" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">64000</us-gaap:AmortizationOfDebtDiscountPremium>
  <dyn:AmortizationAccretionOfPremiumDiscountOnMarketableSecurities id="F_000171" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">12000</dyn:AmortizationAccretionOfPremiumDiscountOnMarketableSecurities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000172" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3455000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000173" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">284000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities id="F_000174" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8567000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities id="F_000175" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1689000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000176" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-46508000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000177" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-11834000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000178" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1161000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000179" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1647000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000180" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">44500000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000181" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45661000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000182" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1647000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000183" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">246388000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <dyn:PaymentsForSettlementOfSuccessFeeObligation id="F_000184" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">450000</dyn:PaymentsForSettlementOfSuccessFeeObligation>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000185" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">134786000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000186" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">19989000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="F_000187" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9936000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:RepaymentsOfDebt id="F_000188" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">10000000</us-gaap:RepaymentsOfDebt>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000189" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000190" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">380690000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000191" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">19989000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000192" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">288521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000193" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6508000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000194" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">14632000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000195" contextRef="C_0001818794_20181231" decimals="-3" unitRef="U_iso4217USD">8124000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000196" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">303153000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <dyn:CashPaidForInterestAndIncomeTaxes id="F_000197" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">328000</dyn:CashPaidForInterestAndIncomeTaxes>
  <dyn:ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity id="F_000198" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6319000</dyn:ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity>
  <us-gaap:ConversionOfStockAmountConverted1 id="F_000199" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">162215000</us-gaap:ConversionOfStockAmountConverted1>
  <dyn:SettlementsOfTrancheRightOne id="F_000200" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1621000</dyn:SettlementsOfTrancheRightOne>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000201" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2021 Annual Meeting of Stockholders within 120 days of the end of the Registrant&amp;#8217;s fiscal year ended December&amp;#160;31, 2020. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="F_000202" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Nature of business and basis of presentation &lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dyne Therapeutics, Inc. (the &amp;#8220;Company&amp;#8221;) is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases that was incorporated in Delaware on December 1, 2017 and has a principal place of business in Waltham, Massachusetts.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, fluctuations in operating results, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes, the impact of the COVID-19 pandemic and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of a product. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&amp;#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 21, 2020, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) pursuant to which it issued and sold 14,089,314 shares of its common stock, including 1,837,736 shares pursuant to the full exercise of the underwriters&amp;#8217; option to purchase additional shares, at a public offering price of $19.00 per share, resulting in net proceeds of $246.4 million, after deducting underwriting discounts and commissions and offering expenses. Upon the closing of the IPO, all of the Company&amp;#8217;s then outstanding convertible preferred stock automatically converted into shares of common stock.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 25, 2021, the Company completed a follow-on public offering of common stock pursuant to which it issued and sold 6,000,000 shares of its common stock at a public offering price of $28.00 per share, resulting in net proceeds of $157.3 million, after deducting underwriting discounts and commissions and offering expenses. &lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations with proceeds from the sales of preferred stock and common stock, including the IPO completed in September 2020 and the follow-on offering completed in January 2021. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance of these consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To continue its development efforts, the Company will need to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements in order to fund its research and development and ongoing operating expenses. The Company may not be able to obtain financing on acceptable terms, when needed or at all, and the Company may not be able to enter into collaborations, strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&amp;#8217;s stockholders. Any collaborations, strategic alliances or licensing arrangements may require the Company to relinquish rights to certain of its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to obtain funding, the Company could be forced to delay, limit, reduce or eliminate some or all of its research and development programs, pipeline expansion or future commercialization efforts or grant rights to develop and market product candidates, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date, the Company has not experienced material business disruptions, including with its vendors, as a result of the COVID-19 pandemic. In March 2020, the Company implemented a remote working policy for many of its employees and began restricting non-essential travel, and on May 18, 2020, when Massachusetts began its staged reopening plan, the Company began implementing a return-to-work plan, in accordance with the guidance and requirements of federal and state authorities. The Company expects to continue to take actions as may be required or recommended by government authorities or as it determines are in the best interests of its employees and other business partners. The Company is continuing to monitor the potential impact of the pandemic, but cannot be certain what the overall impact will be on its business, financial condition, results of operations and prospects.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000203" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of significant accounting policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements reflect the operations of the Company and the Company&amp;#8217;s wholly owned subsidiary, Dyne Therapeutics Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) in the United States of America. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) and Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Concentrations of credit risk and of significant suppliers&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company believes the depository institutions in which the cash and cash equivalents are held are of high-credit quality. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&amp;#8217;s marketable securities as of December&amp;#160;31, 2020 consisted of commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of any single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the development of its programs and future production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash includes cash in readily available checking accounts and cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Restricted cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&amp;#8217;s leased facilities. Restricted cash totaled $2.3 million and $0.0 million at December 31, 2020 and 2019, respectively. These amounts are classified as restricted cash on the Company&amp;#8217;s consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s marketable securities as of December 31, 2020 consisted of commercial paper, certificates of deposit and corporate debt securities and are classified as available-for-sale and are reported at fair value. Unrealized losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&amp;#8217; equity. Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&amp;#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &amp;#8220;other than temporary,&amp;#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furnitures and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of life of lease or 10&amp;nbsp;&amp;nbsp;years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. &lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company has not recorded any impairment charges in the periods presented in these financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Segment information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&amp;#8217;s chief operating decision maker is the chief executive officer (&amp;#8220;CEO&amp;#8221;). The CEO views the Company&amp;#8217;s operations and manages the business as one operating segment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Research and development costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are consumed or the services are performed. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Research and manufacturing contract costs and accruals&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#8217;s estimates. The Company&amp;#8217;s historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Patent costs&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;font style="color:#000000;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&amp;#8217;s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;1&amp;#8212;Unadjusted quoted prices in active markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;2&amp;#8212;Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level&amp;#160;2 inputs include the following: &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.69%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;quoted prices for similar assets and liabilities in active markets; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.69%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;quoted prices for identical or similar assets or liabilities in markets that are not active; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.69%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;observable inputs other than quoted prices that are used in the valuation of the asset or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals); and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.69%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;inputs that are derived principally from or corroborated by observable market data by correlation or other means. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;3&amp;#8212;Unobservable inputs for the assets or liability (i.e., supported by little or no market activity). Level&amp;#160;3 inputs include management&amp;#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, the Company does not allocate loss to participating securities because they have no contractual obligation to share in the losses of the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net income loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Redeemable convertible preferred stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&amp;#8217;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for stock-based awards at fair value, and measures fair value using the Black-Scholes option-pricing model. Stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period, on a straight-line basis for all time-vested awards. Forfeitures are recognized as they occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Success fee obligation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s loan and security agreement (the &amp;#8220;Loan Agreement&amp;#8221;) entered into in 2020 required the Company to pay a success fee of $0.5&amp;#160;million upon the occurrence of a specified liquidity event, as described in the Loan Agreement, which included the Company&amp;#8217;s IPO. The liability was initially deemed immaterial upon entering into the Loan Agreement and was subsequently remeasured to fair value at each reporting date. Following the completion of the IPO, the success fee of $0.5 million was paid in September 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Comprehensive loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended December&amp;#160;31, 2020, the Company&amp;#8217;s only element of other comprehensive loss was unrealized gains (losses) on marketable securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Accounting pronouncements issued and not adopted &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The Company plans to adopt ASU 2016-02 on January 1, 2021 using the modified retrospective approach transition method as of the date of adoption such that prior periods will not be restated. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. The adoption of the new standard is expected to result in the recognition of material liabilities and right-of-use assets, however, the Company has not completed the assessment. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <dyn:MarketableSecuritiesAndFairValueMeasurementsTextBlock id="F_000204" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Marketable securities and fair value measurements &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities by security type at December&amp;#160;31, 2020 consisted of the following:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,572&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,462&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not have marketable securities as of December&amp;#160;31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables set forth by level, within the fair value hierarchy (see Note 2), the assets carried at fair value on a recurring basis for the periods presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;207,787&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of U.S. government money market funds and commercial paper were determined by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. Certificates of deposit and corporate debt securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the years ended December&amp;#160;31, 2020 and 2019, there were no transfers between Level 1, Level 2 and Level 3. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the scheduled maturity for the Company&amp;#8217;s marketable securities at December 31, 2020:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing in one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing after one year through two years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing after two years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,770&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no sales of marketable securities during the year ending December&amp;#160;31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the preferred stock tranche obligations in connection with the unfunded tranches associated with the Series A Preferred Stock Purchase Agreement (see Note 7) was determined based on significant inputs not observable in the market, which represents a Level&amp;#160;3 measurement within the fair value hierarchy. The fair value of the preferred stock tranche obligations was determined by considering as inputs the future value of the Series A Preferred Stock, the difference between the future value of the Series A Preferred Stock and the contract price, the number of shares underlying the contract, the probability of achieving the funding of the tranches, expected timing of the tranche closing and the discount rate. The future value of Series A Preferred Stock was estimated by calibrating, or backsolving, to the price of the Series A Preferred Stock as set forth in the Series A Preferred Stock Purchase Agreement. The contractual price of the shares to be issued in addition to the number of shares underlying the contract are both provided for by the Series A Preferred Stock Purchase Agreement. The probability of achieving the funding of the tranches and the expected timing of those closings were estimates made by the Company. The discount rate was equal to the risk-free rate for the estimated timing of each tranche closing. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the liability recognized in connection with the contingent success fee associated with the Loan Agreement (see Note 6) was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the liability was determined using the probability-weighted expected return method (&amp;#8220;PWERM&amp;#8221;), which considered as inputs the probability of occurrence of a specified liquidity event, the expected timing of a liquidity event, the amount of the success fee and a risk-adjusted discount rate. The initial fair value of the liability was de minimis due to the low probability of the events probable of triggering payment. As of September 21, 2020, the closing date of the IPO, the event occurred and the probability increased to 100% and the discount rate was assessed to be 0%. Based on these inputs, the Company determined that the fair value of the derivative liability was $0.5 million as of September 21, 2020. Following the completion of the IPO, the success fee of $0.5 million was paid in September 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents a roll-forward of the aggregate fair values of the Company&amp;#8217;s liabilities for which fair value is determined by Level&amp;#160;3 inputs: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred Stock Tranche Obligations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Success Fee Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,375&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Settlement of Tranche Right I&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,323&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification of Tranche Right II to equity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,319&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Initial fair value of success fee obligation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;450&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Settlement of derivative instrument&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(450&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Financial instruments not recorded at fair value &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of cash, cash equivalents, accounts payable and accrued expenses that are reported on the balance sheets approximate their fair value due to the short-term nature of these assets and liabilities.&lt;/p&gt;</dyn:MarketableSecuritiesAndFairValueMeasurementsTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000205" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,744&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,705&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in process&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&amp;#8212;at cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&amp;#8212;net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense totaled $0.7 million and $0.3&amp;#160;million for the years ended December&amp;#160;31, 2020 and 2019, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock id="F_000206" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Accrued expenses and other current liabilities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;540&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consulting services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;263&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,782&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Facility costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="F_000207" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Debt financing &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 20, 2020, the Company entered into a Loan Agreement pursuant to which the lender made term loans to the Company in an aggregate principal amount of $10.0 million. Borrowings under the Loan Agreement were collateralized by substantially all of the Company&amp;#8217;s assets, excluding intellectual property. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on the outstanding loan balance accrued at a variable annual rate equal to the greater of (i) the lender&amp;#8217;s prime rate plus 0.25% and (ii) 5.00%, and the Company was required to make interest-only payments on the loans on a monthly basis through August 2021. The outstanding borrowings were repaid in October 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the Loan Agreement, a success fee of $0.5 million was required in the event of a liquidation event, including an IPO. The success fee represented an embedded derivative which the Company bifurcated from the debt arrangement and carried at fair value. In September 2020, the Company completed its IPO and paid the success fee of $0.5 million. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:PreferredStockTextBlock id="F_000208" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Convertible preferred stock &lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception, the Company issued Series A convertible preferred stock (the &amp;#8220;Series A Preferred Stock&amp;#8221;) and Series B convertible preferred stock (the &amp;#8220;Series B Preferred Stock&amp;#8221;). Collectively the Series A Preferred Stock and the Series B Preferred Stock are referred to as the Preferred Stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the closing of the IPO in September 2020, the Company&amp;#8217;s Preferred Stock automatically converted into 28,086,375 shares of common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Series A Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November&amp;#160;29, 2018, the Company entered into the Series A Preferred Stock Purchase Agreement with its initial investors committing to purchase an aggregate of $50.0&amp;#160;million in shares of Series A Preferred Stock. At the initial closing, 12,500,000 shares of Series A Preferred Stock were issued by the Company at a purchase price of $1.00 per share, for gross cash proceeds of $7.5&amp;#160;million. Of the 12,500,000 shares issued, 5,000,000 shares were issued upon conversion of the then outstanding SAFEs, which had a fair value of $5.0&amp;#160;million. In April 2019, the Company issued an additional 20,000,000 shares of Series A Preferred Stock under the terms of the Series A Preferred Stock Purchase Agreement at a purchase price of $1.00 per share for total gross proceeds of $20.0&amp;#160;million. Issuance costs associated with each closing of the Series A Preferred Stock financing were $0.1&amp;#160;million. On March&amp;#160;18, 2020, the Company entered into a separate Series A Preferred Stock Purchase Agreement with an additional investor and issued 2,000,000 shares of Series A Preferred Stock at a purchase price $1.00 per share for gross cash proceeds of $2.0&amp;#160;million. In July 2020, the Company issued and sold 17,500,000 shares of Series A Preferred Stock at a price of $1.00 per share, for gross proceeds of $17.5 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Series B Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company issued and sold 41,159,724 shares of Series B Preferred Stock at a price of $2.81 per share for gross proceeds of $115.7 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Tranche Rights&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Included in the terms of the November 2018 Series A Preferred Stock Purchase Agreement were certain rights (&amp;#8220;Tranche Rights&amp;#8221;) granted to the investors who purchased the Series A Preferred Stock purchased in November 2018. The Tranche Rights contingently obligated the investors to purchase, and the Company to sell, up to an aggregate of 37,500,000 shares of Series A Preferred Stock at $1.00 per share upon the satisfaction of specified research and development milestones by the Company. The Tranche Rights are also exercisable at the option of the holders of the Series A Preferred Stock. The Tranche Rights were divided into separate rights and obligations to purchase 20,000,000 shares (&amp;#8220;Tranche Right I&amp;#8221;) and 17,500,000 shares (&amp;#8220;Tranche Right II&amp;#8221;) based on the achievement of specified milestones for each tranche. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company concluded that the Tranche Rights met the definition of a freestanding financial instrument, as the Tranche Rights were legally detachable and separately exercisable from the Series A Preferred Stock. Therefore, the Company allocated the proceeds from the November 2018 issuance between the Tranche Rights and the Series A Preferred Stock. As the Series A Preferred Stock was redeemable upon a deemed liquidation event at the election of the holder-controlled Board, and therefore outside of the control of the Company, the Tranche Rights were initially classified as a liability and were initially recorded at their fair value of $3.4&amp;#160;million. The Tranche Rights were then remeasured at fair value at each reporting period, with changes in fair value recorded in the statement of operations. The estimated fair value of the Tranche Rights was determined at each reporting date using a probability-weighted present value model that considers the probability of closing a tranche, the estimated future value of the Series A Preferred Stock to be issued at each closing, and the investment required at each closing. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2019, Tranche Right I was settled when the Company closed on the issuance of 20,000,000 shares Series A Preferred Stock. The fair value of the Tranche Right I as of the closing date was reclassified from a liability to Series A Preferred Stock within equity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2019, the size of the Board was increased from five to six members, including three independent members, which allowed the Company to conclude that the redemption rights of the holders of the Series A Preferred Stock was within the control of the Company. As a result, the Company concluded that Tranche Right II qualified for equity classification as of that date. The preferred stock tranche obligation liability, with a fair value of $6.3&amp;#160;million, was reclassified into permanent equity and was no longer remeasured at fair value. In July 2020, Tranche Right II was settled when the Company closed on the issuance of 17,500,000 shares Series A Preferred Stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Preferred Stock had the followings rights and privileges: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Dividends &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holders of the Preferred Stock were entitled to receive non-cumulative dividends when, as and if declared by the Board. The Company did not declare dividends on any class of preferred or common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Liquidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the event of any liquidation, dissolution, or winding-up of the Company, which would include the sale of the Company, the Preferred Stock was senior to common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Voting &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of the Preferred Stock were entitled to the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by each holder were then convertible. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Conversion &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of the Preferred Stock were able to convert, at any time, each share of Preferred Stock into shares of common stock at the stated conversion price. &lt;/p&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000209" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Equity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the Company&amp;#8217;s restated certificate of incorporation authorized the Company to issue 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, the Company had authorized 68,000,000 shares of common stock. The voting,&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; dividend and liquidation rights of the holders of the Company&amp;#8217;s common stock was subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock as set forth above.&lt;/font&gt; &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000210" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;2018 Stock incentive plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s 2018 Stock Incentive Plan (the &amp;#8220;2018 Plan&amp;#8221;) provided for the Company to sell or issue incentive stock options or nonqualified stock options, restricted stock, and other equity awards to employees, directors and consultants of the Company. The 2018 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of the board of directors.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total number of shares of common stock authorized under the 2018 Plan was 8,267,252 shares. Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under the 2018 Plan, and the 1,928,487 shares of common stock remaining under the 2018 Plan became available for future issuance under the 2020 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;2020 Stock incentive plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020 the Company&amp;#8217;s board of directors adopted and the Company&amp;#8217;s stockholders approved the 2020 Plan (together with the 2018 Plan the &amp;#8220;Plans&amp;#8221;), which became effective on September 16, 2020. The 2020 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards to employees, directors, consultants and advisors of the Company. The 2020 Plan is administered by the Company&amp;#8217;s board of directors or by a committee appointed by the board of directors. Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under the 2018 Plan. The number of shares initially reserved for issuance under the 2020 Plan was 4,884,233. The number of shares of common stock reserved for issuance under the 2020 Plan automatically increases on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030, in an amount equal to the lower of (1) 5% of the shares of common stock outstanding on such date and (2) an amount determined by the Company&amp;#8217;s board of directors. On January 1, 2021, 2,272,345 shares were added to the shares reserved for issuance under the 2020 Plan in the first of these annual increases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, 3,237,244 shares remained available for future issuance under the 2020 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;2020 Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020 the Company&amp;#8217;s board of directors adopted and the Company&amp;#8217;s stockholders approved the 2020 Employee Stock Purchase Plan (the &amp;#8220;2020 ESPP&amp;#8221;), which became effective September 16, 2020. The 2020 ESPP is administered by the Company&amp;#8217;s board of directors or by a committee appointed by the board of directors. The 2020 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of 488,414 shares of common stock. The number of shares of common stock reserved for issuance under the 2020 ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030, in an amount equal to the lowest of (1) 1,953,656 shares of common stock, (2) 1% of the shares of common stock outstanding on such date, and (3) an amount determined by the board of directors. As of December&amp;#160;31, 2020, no offering periods have commenced under the 2020 ESPP and 488,414 shares remained available for issuance.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Stock option valuation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company typically grants stock options at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time of grant. In the periods prior to the IPO, the fair value of the common stock was determined by the Board at each measurement date based on a variety of different factors, including the results obtained from independent third-party appraisals, the Company&amp;#8217;s financial position and historical financial performance, the status of development of the Company&amp;#8217;s programs, the current climate in the marketplace, the illiquid nature of the common stock, the effect of the rights and preferences of the preferred stockholders, and the prospects of a liquidity event, among others.&amp;#160;&amp;#160;In the periods following the IPO, the fair value is determined based upon the quoted price of the Company&amp;#8217;s common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company&amp;#8217;s stock options has been determined utilizing the &amp;#8220;simplified&amp;#8221; method for awards that qualify as &amp;#8220;plain-vanilla&amp;#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions that the Company used to determine the grant-date fair value of options granted were as follows:&lt;font style="color:#000000;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.31% &amp;#8212; 1.67%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.46% &amp;#8212; 2.50%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock option activity&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the option activity: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except share and per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;311,303&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,252,967&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(110,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,421,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable&amp;#8212; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,282&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested or expected to vest&amp;#8212; December 31,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,421,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value of the options granted during the years ended December&amp;#160;31, 2020 and 2019 was $4.50&amp;#160;per share and $0.62 per share, respectively. As of December&amp;#160;31, 2020 there was $20.3 million&amp;#160;of unrecognized compensation expense, which the Company expects to recognize over&amp;#160;a&amp;#160;weighted-average&amp;#160;period&amp;#160;of&amp;#160;2.71&amp;#160;years. Additionally, as of December&amp;#160;31, 2020, the Company has unrecognized compensation cost related to unvested stock-based awards with performance-based vesting conditions for which performance has not been deemed probable of $2.6 million.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A restricted stock unit (&amp;#8220;RSU&amp;#8221;) represents the right to receive one share of common stock upon vesting of the RSU. The Company grants RSUs with service conditions that vest in four equal annual installments provided that the employee remains employed with the Company. The Company also grants RSUs with performance conditions that vest upon the achievement of specified milestones. The fair value of each RSU is based on the closing price of the Company&amp;#8217;s common stock on the date of grant. A summary of the Company&amp;#8217;s RSU activity and related information for the 2020 Plan for the year ended December&amp;#160;31, 2020 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Shares Underlying RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;403,355&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;403,355&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, there was $7.7 million of unrecognized compensation costs &amp;#8203;&amp;#8203;&amp;#8203;&amp;#8203;&amp;#8203;&amp;#8203;&amp;#8203;related to unvested RSUs, which are expected to be recognized over a weighted-average period of 2.75 years. Additionally, as of December&amp;#160;31, 2020, the Company has unrecognized compensation cost of $0.6 million related to unvested stock-based awards with performance-based vesting conditions for which performance has not been deemed probable.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Restricted common stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2018, the Company granted restricted common stock with service-based vesting conditions. Shares of unvested restricted common stock may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting conditions of each award. The grant date fair value of these shares was immaterial. The following table summarizes the Company&amp;#8217;s restricted common stock award activity for the year ended December&amp;#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&amp;#160;of Restricted&amp;#160;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;652,482&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(282,153&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370,329&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its statements of operations: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,699&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,591&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000211" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Income taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There is no provision for income taxes because the Company has historically incurred net operating losses and maintains a full valuation allowance against its deferred tax assets. The reported amount of income tax expense/benefit for the years ended December&amp;#160;31, 2020 and 2019 differs from the amount that would result from applying domestic federal statutory rates to pretax losses primarily because of changes in the valuation allowance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&amp;#8212;net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of preferred stock tranche obligations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal &amp;amp; state R&amp;amp;D credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&amp;#8217;s net deferred tax assets at December&amp;#160;31, 2020 and 2019 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,349&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,858&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;580&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,607&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had federal and state net operating loss carryforwards of $69.1 million and $68.9 million, respectively.&amp;nbsp;&amp;nbsp;The federal net operating loss carryforwards are indefinite lived and the state net operating loss carryforwards begin to expire in 2038. As of December 31, 2020, the Company also had federal and state research and development tax credit carryforwards $0.8 million and $0.4 million, respectively, which begin to expire in 2039 and 2033, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&amp;#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and concluded that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2020 and 2019. The increase in the valuation allowance for deferred tax assets during the years ended December 31, 2020 and 2019 totaled $16.3 million and $4.2 million, respectively, and related primarily to the increase in net operating loss carryforwards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s policy is to record estimated interest and penalties related to uncertain tax positions in income tax expense. The Company has no amounts recorded for any unrecognized tax positions, accrued interest or penalties as of December&amp;#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates, including the United States and the Commonwealth of Massachusetts. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&amp;#8217;s tax returns are open under statute from 2018 to the present. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000212" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share was calculated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except share and per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(59,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,859&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average common shares outstanding&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,395,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,442,872&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.08&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,421,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;311,303&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370,329&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;652,482&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;403,355&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,798,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,195,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,762,083&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock id="F_000213" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Commitments and contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Operating leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2019, the Company entered into a sublease agreement for laboratory and office space in Waltham, Massachusetts. The term of the sublease commenced on July&amp;#160;1, 2019 and expires on December&amp;#160;31, 2021.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company entered into a lease agreement (the &amp;#8220;Lease&amp;#8221;), pursuant to which the Company will lease approximately 68,187 square feet of additional office and laboratory space located in Waltham, Massachusetts (the &amp;#8220;Premises&amp;#8221;). The Lease will have a term of eight years and six months that will commence when the Premises are ready for occupancy. The Company&amp;#8217;s obligation for the payment of base rent for the Premises begins six months after the commencement date and will be $0.4 million per month, increasing up to $0.5 million during the term of the Lease. The Company has two options to extend the term of the Lease, each for a period of an additional five years. The Company expects the Premises to be ready for occupancy in the second half of 2021.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense for the years ended December&amp;#160;31, 2020 and 2019 totaled $0.8&amp;#160;million and $0.7&amp;#160;million, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments under the non-cancelable operating leases consisted of the following as of December&amp;#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,603&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,883&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,728&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Legal proceedings &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any such legal proceedings. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Other contractual obligations &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into contracts in the normal course of business with third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancelable by the Company upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancelable obligations of the service providers, up to the date of cancellation and in the case of certain arrangements may include non-cancelable fees. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has also entered into a license agreement (the &amp;#8220;UMONS Agreement&amp;#8221;) with the University of Mons (&amp;#8220;UMONS&amp;#8221;) in April 2020, pursuant to which UMONS granted to the Company an exclusive, worldwide license to certain patents and patent applications and a non-exclusive, worldwide license to existing, related know-how. Each of the issued patents licensed to the Company under the UMONS Agreement is scheduled to expire in 2031. The licenses under the UMONS Agreement confer on the Company the right to research, develop and commercialize products (&amp;#8220;licensed products&amp;#8221;), and to practice processes, in each case, covered by the licensed patents and existing, related know-how. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the UMONS Agreement, the Company is obligated to use commercially reasonable efforts to develop at least one licensed product and, to the extent regulatory approval is obtained in such jurisdictions, to commercialize at least one licensed product in the United States and the United Kingdom or a member country of the European Union. Unless terminated earlier, the UMONS Agreement will remain in effect until the last to expire of the licensed patent rights on a licensed product-by-licensed product and country-by-country basis. UMONS may terminate the UMONS Agreement in the event of a material breach by the Company and the Company&amp;#8217;s failure to cure such breach within a specified time period. The Company may voluntarily terminate the UMONS Agreement with prior notice to UMONS. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&amp;#8217;s entry into the UMONS Agreement, the Company paid UMONS an upfront payment of &amp;#8364;0.1 million. The Company also agreed to make milestone payments to UMONS upon the achievement of specified development and regulatory milestones up to a maximum aggregate total of &amp;#8364;0.4 million for the first licensed product to achieve such milestones and up to a maximum aggregate total of &amp;#8364;0.2 million for each subsequent licensed product to achieve each such milestones, as well as a low single-digit percentage royalty on net sales of licensed products by the Company, its affiliates and sublicensees. These royalty obligations continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the last licensed patent rights covering such licensed product in such country. In addition, if the Company sublicenses rights under the UMONS Agreement, the Company is required to pay a low double-digit percentage of the sublicense revenue to UMONS. Additionally, if the Company chooses to file, prosecute or maintain any patents included in the licensed patent rights under the UMONS Agreement, it will be required to bear the full cost and expenses of preparing, filing, prosecuting and maintaining any such patents. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No amounts have been accrued under this arrangement with respect to potential milestone payment obligations or royalty obligations given the uncertainty of achieving the specified milestones and commercial sales of any licensed products. &lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000214" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Subsequent events &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December&amp;#160;31, 2020, subsequent events were evaluated through March 4, 2021, the date on which the audited consolidated financial statements were issued. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:UseOfEstimates id="F_000215" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. &lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000216" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Concentrations of credit risk and of significant suppliers&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company believes the depository institutions in which the cash and cash equivalents are held are of high-credit quality. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&amp;#8217;s marketable securities as of December&amp;#160;31, 2020 consisted of commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of any single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the development of its programs and future production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000217" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash includes cash in readily available checking accounts and cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000218" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Restricted cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&amp;#8217;s leased facilities. Restricted cash totaled $2.3 million and $0.0 million at December 31, 2020 and 2019, respectively. These amounts are classified as restricted cash on the Company&amp;#8217;s consolidated balance sheets.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:MarketableSecuritiesPolicy id="F_000219" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s marketable securities as of December 31, 2020 consisted of commercial paper, certificates of deposit and corporate debt securities and are classified as available-for-sale and are reported at fair value. Unrealized losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&amp;#8217; equity. Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&amp;#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &amp;#8220;other than temporary,&amp;#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:DeferredChargesPolicyTextBlock id="F_000220" contextRef="C_0001818794_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000221" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furnitures and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of life of lease or 10&amp;nbsp;&amp;nbsp;years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000222" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company has not recorded any impairment charges in the periods presented in these financial statements. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000223" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Segment information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&amp;#8217;s chief operating decision maker is the chief executive officer (&amp;#8220;CEO&amp;#8221;). The CEO views the Company&amp;#8217;s operations and manages the business as one operating segment. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000224" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Research and development costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are consumed or the services are performed. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <dyn:ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock id="F_000225" contextRef="C_0001818794_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Research and manufacturing contract costs and accruals&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#8217;s estimates. The Company&amp;#8217;s historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;</dyn:ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock>
  <dyn:PatentCostsPolicyTextBlock id="F_000226" contextRef="C_0001818794_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Patent costs&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;font style="color:#000000;"&gt; &lt;/font&gt;&lt;/p&gt;</dyn:PatentCostsPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000227" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&amp;#8217;s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000228" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;1&amp;#8212;Unadjusted quoted prices in active markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;2&amp;#8212;Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level&amp;#160;2 inputs include the following: &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.69%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;quoted prices for similar assets and liabilities in active markets; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.69%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;quoted prices for identical or similar assets or liabilities in markets that are not active; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.69%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;observable inputs other than quoted prices that are used in the valuation of the asset or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals); and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:7.69%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;inputs that are derived principally from or corroborated by observable market data by correlation or other means. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:2.62%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"&gt;Level&amp;#160;3&amp;#8212;Unobservable inputs for the assets or liability (i.e., supported by little or no market activity). Level&amp;#160;3 inputs include management&amp;#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000229" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, the Company does not allocate loss to participating securities because they have no contractual obligation to share in the losses of the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net income loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy id="F_000230" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Redeemable convertible preferred stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&amp;#8217;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. &lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock id="F_000231" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for stock-based awards at fair value, and measures fair value using the Black-Scholes option-pricing model. Stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period, on a straight-line basis for all time-vested awards. Forfeitures are recognized as they occur. &lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <dyn:SuccessFeeObligationPolicyTextBlock id="F_000232" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Success fee obligation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s loan and security agreement (the &amp;#8220;Loan Agreement&amp;#8221;) entered into in 2020 required the Company to pay a success fee of $0.5&amp;#160;million upon the occurrence of a specified liquidity event, as described in the Loan Agreement, which included the Company&amp;#8217;s IPO. The liability was initially deemed immaterial upon entering into the Loan Agreement and was subsequently remeasured to fair value at each reporting date. Following the completion of the IPO, the success fee of $0.5 million was paid in September 2020. &lt;/p&gt;</dyn:SuccessFeeObligationPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000233" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Comprehensive loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended December&amp;#160;31, 2020, the Company&amp;#8217;s only element of other comprehensive loss was unrealized gains (losses) on marketable securities. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000234" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;"&gt;Accounting pronouncements issued and not adopted &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The Company plans to adopt ASU 2016-02 on January 1, 2021 using the modified retrospective approach transition method as of the date of adoption such that prior periods will not be restated. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. The adoption of the new standard is expected to result in the recognition of material liabilities and right-of-use assets, however, the Company has not completed the assessment. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <dyn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock id="F_000235" contextRef="C_0001818794_20200101_20201231">Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furnitures and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of life of lease or 10&amp;nbsp;&amp;nbsp;years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;</dyn:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
  <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock id="F_000236" contextRef="C_0001818794_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities by security type at December&amp;#160;31, 2020 consisted of the following:&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,572&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,462&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="F_000237" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables set forth by level, within the fair value hierarchy (see Note 2), the assets carried at fair value on a recurring basis for the periods presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,545&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164,428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;207,787&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock id="F_000238" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the scheduled maturity for the Company&amp;#8217;s marketable securities at December 31, 2020:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing in one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing after one year through two years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing after two years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,770&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000239" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents a roll-forward of the aggregate fair values of the Company&amp;#8217;s liabilities for which fair value is determined by Level&amp;#160;3 inputs: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred Stock Tranche Obligations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Success Fee Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,375&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Settlement of Tranche Right I&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,323&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification of Tranche Right II to equity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,319&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Initial fair value of success fee obligation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;450&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Settlement of derivative instrument&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(450&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&amp;#8212;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000240" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,744&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,705&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in process&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&amp;#8212;at cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&amp;#8212;net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <dyn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock id="F_000241" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;540&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consulting services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;263&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,782&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Facility costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</dyn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000242" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions that the Company used to determine the grant-date fair value of options granted were as follows:&lt;font style="color:#000000;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.31% &amp;#8212; 1.67%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.46% &amp;#8212; 2.50%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000243" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the option activity: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except share and per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;311,303&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,252,967&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(110,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,421,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable&amp;#8212; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,282&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested or expected to vest&amp;#8212; December 31,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,421,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.97&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock id="F_000244" contextRef="C_0001818794_20200101_20201231">A summary of the Company&amp;#8217;s RSU activity and related information for the 2020 Plan for the year ended December&amp;#160;31, 2020 is as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Shares Underlying RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;403,355&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;403,355&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock id="F_000245" contextRef="C_0001818794_20200101_20201231">The following table summarizes the Company&amp;#8217;s restricted common stock award activity for the year ended December&amp;#160;31, 2020:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&amp;#160;of Restricted&amp;#160;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;652,482&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(282,153&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and unvested as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370,329&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000246" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its statements of operations: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,699&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,591&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000247" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&amp;#8212;net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of preferred stock tranche obligations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal &amp;amp; state R&amp;amp;D credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000248" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&amp;#8217;s net deferred tax assets at December&amp;#160;31, 2020 and 2019 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,349&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,858&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,848&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;580&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,607&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000249" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share was calculated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except share and per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(59,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,859&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average common shares outstanding&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,395,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,442,872&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.08&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000250" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,421,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;311,303&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370,329&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;652,482&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;403,355&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,798,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,195,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,762,083&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000251" contextRef="C_0001818794_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments under the non-cancelable operating leases consisted of the following as of December&amp;#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,603&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,883&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,728&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000252" contextRef="C_0001818794_20200101_20201231">2017-12-01</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="F_000253" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200921_20200921" decimals="INF" unitRef="U_xbrlishares">14089314</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <dyn:UnderwritersOptionToPurchaseAdditionalShares id="F_000254" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200921_20200921" decimals="INF" unitRef="U_xbrlishares">1837736</dyn:UnderwritersOptionToPurchaseAdditionalShares>
  <us-gaap:SaleOfStockPricePerShare id="F_000255" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200921" decimals="INF" unitRef="U_iso4217USD_xbrlishares">19.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000256" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200921_20200921" decimals="-5" unitRef="U_iso4217USD">246400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="F_000257" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_dynFollowOnPublicOfferingMember_20210125_20210125" decimals="INF" unitRef="U_xbrlishares">6000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockPricePerShare id="F_000258" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_dynFollowOnPublicOfferingMember_20210125" decimals="INF" unitRef="U_iso4217USD_xbrlishares">28.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000259" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_dynFollowOnPublicOfferingMember_20210125_20210125" decimals="-5" unitRef="U_iso4217USD">157300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <dyn:CashAndCashEquivalentsMaturityPeriod id="F_000260" contextRef="C_0001818794_20200101_20201231">P90D</dyn:CashAndCashEquivalentsMaturityPeriod>
  <us-gaap:RestrictedCash id="F_000261" contextRef="C_0001818794_20201231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash id="F_000262" contextRef="C_0001818794_20191231" decimals="-5" unitRef="U_iso4217USD">0</us-gaap:RestrictedCash>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000263" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynLaboratoryEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000264" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000265" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000266" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Shorter of life of lease or 10  years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:AssetImpairmentCharges id="F_000267" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:NumberOfOperatingSegments id="F_000268" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_dynSegment">1</us-gaap:NumberOfOperatingSegments>
  <dyn:SuccessFeePaid id="F_000269" contextRef="C_0001818794_us-gaapCreditFacilityAxis_dynPacificWesternBankMember_us-gaapDebtInstrumentAxis_dynLoanAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">500000</dyn:SuccessFeePaid>
  <dyn:SuccessFeePaid id="F_000270" contextRef="C_0001818794_20200901_20200930" decimals="-5" unitRef="U_iso4217USD">500000</dyn:SuccessFeePaid>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000271" contextRef="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" unitRef="U_iso4217USD">6412000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000272" contextRef="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCertificatesOfDepositMember_20201231" decimals="-3" unitRef="U_iso4217USD">1504000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000273" contextRef="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">36572000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000274" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">44489000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000275" contextRef="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000276" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000277" contextRef="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" unitRef="U_iso4217USD">6412000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000278" contextRef="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCertificatesOfDepositMember_20201231" decimals="-3" unitRef="U_iso4217USD">1504000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000279" contextRef="C_0001818794_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">36545000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000280" contextRef="C_0001818794_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AssetsFairValueDisclosure id="F_000281" contextRef="C_0001818794_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">155017000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000282" contextRef="C_0001818794_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">155017000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000283" contextRef="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">2999000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000284" contextRef="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">2999000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000285" contextRef="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">5309000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000286" contextRef="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">5309000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000287" contextRef="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">6412000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000288" contextRef="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">6412000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000289" contextRef="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">1504000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000290" contextRef="C_0001818794_us-gaapCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">1504000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000291" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">36545000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000292" contextRef="C_0001818794_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapInvestmentTypeAxis_dynMarketableSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">36545000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000293" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">164428000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000294" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">43359000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000295" contextRef="C_0001818794_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">207787000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000296" contextRef="C_0001818794_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231" decimals="-3" unitRef="U_iso4217USD">14420000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000297" contextRef="C_0001818794_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231" decimals="-3" unitRef="U_iso4217USD">14420000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000298" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231" decimals="-3" unitRef="U_iso4217USD">14420000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000299" contextRef="C_0001818794_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20191231" decimals="-3" unitRef="U_iso4217USD">14420000</us-gaap:AssetsFairValueDisclosure>
  <dyn:FairValueAssetsTransfersAmount id="F_000300" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_iso4217USD">0</dyn:FairValueAssetsTransfersAmount>
  <dyn:FairValueAssetsTransfersAmount id="F_000301" contextRef="C_0001818794_20191231" decimals="INF" unitRef="U_iso4217USD">0</dyn:FairValueAssetsTransfersAmount>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue id="F_000302" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">28623000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <dyn:AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue id="F_000303" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">24147000</dyn:AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000304" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">52770000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000305" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <dyn:FairValueLiabilityPaymentPercentage id="F_000306" contextRef="C_0001818794_20200921_20200921" decimals="INF" unitRef="U_xbrlipure">1.00</dyn:FairValueLiabilityPaymentPercentage>
  <us-gaap:DerivativeLiabilityMeasurementInput id="F_000307" contextRef="C_0001818794_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20200921" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:DerivativeLiabilityMeasurementInput>
  <us-gaap:DerivativeLiabilities id="F_000308" contextRef="C_0001818794_20200921" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:DerivativeLiabilities>
  <dyn:SuccessFeePaid id="F_000309" contextRef="C_0001818794_20200921_20200921" decimals="-5" unitRef="U_iso4217USD">500000</dyn:SuccessFeePaid>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000310" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynPreferredStockTrancheObligationsMember_20181231" decimals="-3" unitRef="U_iso4217USD">3375000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="F_000311" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynPreferredStockTrancheObligationsMember_us-gaapVestingAxis_dynTrancheRightOneMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1621000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000312" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynPreferredStockTrancheObligationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1323000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <dyn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity id="F_000313" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynPreferredStockTrancheObligationsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6319000</dyn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000314" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynSuccessFeeObligationMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">450000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="F_000315" contextRef="C_0001818794_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dynSuccessFeeObligationMember_us-gaapFinancialInstrumentAxis_us-gaapDerivativeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-450000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000316" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynLaboratoryEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">2744000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000317" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynLaboratoryEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">1705000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000318" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynOfficeAndComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">78000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000319" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_dynOfficeAndComputerEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">62000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000320" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000321" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000322" contextRef="C_0001818794_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" unitRef="U_iso4217USD">105000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000323" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">2941000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000324" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">1781000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000325" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">995000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000326" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">295000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000327" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">2105000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000328" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">540000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <dyn:AccruedConsultingServicesCurrent id="F_000329" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">263000</dyn:AccruedConsultingServicesCurrent>
  <dyn:AccruedConsultingServicesCurrent id="F_000330" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">60000</dyn:AccruedConsultingServicesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000331" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:AccruedProfessionalFeesCurrent>
  <dyn:AccruedResearchAndDevelopmentExpensesCurrent id="F_000332" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">4782000</dyn:AccruedResearchAndDevelopmentExpensesCurrent>
  <dyn:AccruedResearchAndDevelopmentExpensesCurrent id="F_000333" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">484000</dyn:AccruedResearchAndDevelopmentExpensesCurrent>
  <dyn:AccruedFacilityCostsCurrent id="F_000334" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">52000</dyn:AccruedFacilityCostsCurrent>
  <dyn:AccruedFacilityCostsCurrent id="F_000335" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">18000</dyn:AccruedFacilityCostsCurrent>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="F_000336" contextRef="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200220" decimals="INF" unitRef="U_iso4217USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityInterestRateDescription id="F_000337" contextRef="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200101_20201231">Interest on the outstanding loan balance accrued at a variable annual rate equal to the greater of (i) the lender&#8217;s prime rate plus 0.25% and (ii) 5.00%, and the Company was required to make interest-only payments on the loans on a monthly basis through August 2021</us-gaap:LineOfCreditFacilityInterestRateDescription>
  <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment id="F_000338" contextRef="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200101_20201231">interest-only payments on the loans on a monthly basis</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="F_000339" contextRef="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200220_20200220" decimals="INF" unitRef="U_xbrlipure">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod id="F_000340" contextRef="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200220_20200220" decimals="INF" unitRef="U_xbrlipure">0.0500</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentFeeAmount id="F_000341" contextRef="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200220" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:DebtInstrumentFeeAmount>
  <dyn:DebtInstrumentSuccessFeePaid id="F_000342" contextRef="C_0001818794_us-gaapCreditFacilityAxis_dynTermLoanMember_20200901_20200930" decimals="-5" unitRef="U_iso4217USD">500000</dyn:DebtInstrumentSuccessFeePaid>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000343" contextRef="C_0001818794_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="INF" unitRef="U_xbrlishares">28086375</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <dyn:PurchasesOfSharesValue id="F_000344" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20181129_20181129" decimals="-5" unitRef="U_iso4217USD">50000000</dyn:PurchasesOfSharesValue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000345" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20181129_20181129" decimals="INF" unitRef="U_xbrlishares">12500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000346" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20190401_20190430" decimals="INF" unitRef="U_xbrlishares">20000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000347" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200318_20200318" decimals="INF" unitRef="U_xbrlishares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000348" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200701_20200731" decimals="INF" unitRef="U_xbrlishares">17500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharePrice id="F_000349" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20181129" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000350" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20190430" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000351" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200318" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000352" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200731" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:SharePrice>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000353" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20181129_20181129" decimals="-5" unitRef="U_iso4217USD">7500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000354" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20190401_20190430" decimals="-5" unitRef="U_iso4217USD">20000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000355" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200318_20200318" decimals="-5" unitRef="U_iso4217USD">2000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000356" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20200701_20200731" decimals="-5" unitRef="U_iso4217USD">17500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000357" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20181129" decimals="INF" unitRef="U_xbrlishares">5000000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <dyn:PreferredStockFairValue id="F_000358" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20181129" decimals="-5" unitRef="U_iso4217USD">5000000</dyn:PreferredStockFairValue>
  <dyn:StockIssuanceCost id="F_000359" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20190401_20190430" decimals="-5" unitRef="U_iso4217USD">100000</dyn:StockIssuanceCost>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000360" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_20200801_20200831" decimals="INF" unitRef="U_xbrlishares">41159724</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharePrice id="F_000361" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_20200831" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.81</us-gaap:SharePrice>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000362" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassBMember_20200801_20200831" decimals="-5" unitRef="U_iso4217USD">115700000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="F_000363" contextRef="C_0001818794_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRightMember_20181129_20181129" decimals="INF" unitRef="U_xbrlishares">37500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="F_000364" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRightOneMember_20181129_20181129" decimals="INF" unitRef="U_xbrlishares">20000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="F_000365" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRighttwoMember_20181129_20181129" decimals="INF" unitRef="U_xbrlishares">17500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <dyn:PreferredStockFairValue id="F_000366" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRightMember_20181129" decimals="-5" unitRef="U_iso4217USD">3400000</dyn:PreferredStockFairValue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000367" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_us-gaapVestingAxis_dynTrancheRightOneMember_20190401_20190430" decimals="INF" unitRef="U_xbrlishares">20000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <dyn:PreferredStockFairValue id="F_000368" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapPreferredClassAMember_20190930" decimals="-5" unitRef="U_iso4217USD">6300000</dyn:PreferredStockFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000369" contextRef="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandEighteenStockIncentivePlanMember_20200915" decimals="INF" unitRef="U_xbrlishares">8267252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000370" contextRef="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandEighteenStockIncentivePlanMember_20200915" decimals="INF" unitRef="U_xbrlishares">1928487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000371" contextRef="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200916" decimals="INF" unitRef="U_xbrlishares">4884233</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000372" contextRef="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101" decimals="INF" unitRef="U_xbrlishares">2272345</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000373" contextRef="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200916_20200916" decimals="INF" unitRef="U_xbrlipure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000374" contextRef="C_0001818794_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">3237244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000375" contextRef="C_0001818794_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200916" decimals="INF" unitRef="U_xbrlishares">488414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000376" contextRef="C_0001818794_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">488414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <dyn:ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance id="F_000377" contextRef="C_0001818794_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200916_20200916" decimals="INF" unitRef="U_xbrlishares">1953656</dyn:ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000378" contextRef="C_0001818794_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200916_20200916" decimals="INF" unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000379" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000380" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000381" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000382" contextRef="C_0001818794_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.0146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000383" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000384" contextRef="C_0001818794_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000385" contextRef="C_0001818794_20200101_20201231">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000386" contextRef="C_0001818794_20190101_20191231">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000387" contextRef="C_0001818794_20191231" decimals="INF" unitRef="U_xbrlishares">311303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000388" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">6252967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000389" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">32197</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000390" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">110484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000391" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_xbrlishares">6421589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000392" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_xbrlishares">447925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000393" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_xbrlishares">6421589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000394" contextRef="C_0001818794_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000395" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000396" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000397" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000398" contextRef="C_0001818794_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000399" contextRef="C_0001818794_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000400" contextRef="C_0001818794_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000401" contextRef="C_0001818794_20190101_20191231">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000402" contextRef="C_0001818794_20200101_20201231">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000403" contextRef="C_0001818794_20200101_20201231">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000404" contextRef="C_0001818794_20200101_20201231">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000405" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000406" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">90112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000407" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">7282000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000408" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">90112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000409" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000410" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000411" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-5" unitRef="U_iso4217USD">20300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000412" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P2Y8M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <dyn:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable id="F_000413" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-5" unitRef="U_iso4217USD">2600000</dyn:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable>
  <dyn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting id="F_000414" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1</dyn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting>
  <dyn:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments id="F_000415" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_dynInstallment">4</dyn:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights id="F_000416" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200101_20201231">The Company grants RSUs with service conditions that vest in four equal annual installments provided that the employee remains employed with the Company. The Company also grants RSUs with performance conditions that vest upon the achievement of specified milestones</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000417" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">403355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000418" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">403355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000419" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">23.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000420" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_dynTwoThousandTwentyStockIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">23.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000421" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="-5" unitRef="U_iso4217USD">7700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000422" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">P2Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <dyn:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable id="F_000423" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="-5" unitRef="U_iso4217USD">600000</dyn:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000424" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">652482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000425" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">282153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000426" contextRef="C_0001818794_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">370329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000427" contextRef="C_0001818794_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2699000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000428" contextRef="C_0001818794_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000429" contextRef="C_0001818794_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3892000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000430" contextRef="C_0001818794_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000431" contextRef="C_0001818794_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6591000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000432" contextRef="C_0001818794_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000433" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000434" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000435" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000436" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <dyn:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations id="F_000437" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_xbrlipure">-0.02</dyn:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations>
  <dyn:EffectiveIncomeTaxRateReconciliationPermanentDifferences id="F_000438" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_xbrlipure">-0.01</dyn:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000439" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_xbrlipure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000440" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_xbrlipure">-0.04</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000441" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_xbrlipure">-0.27</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000442" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_xbrlipure">-0.28</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000443" contextRef="C_0001818794_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000444" contextRef="C_0001818794_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000445" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">1349000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000446" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000447" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">18858000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000448" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">4848000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000449" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">1155000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000450" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">612000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000451" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000452" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">580000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000453" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">161000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsGross id="F_000454" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">21942000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000455" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">5634000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000456" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">21899000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000457" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">5607000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet id="F_000458" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">43000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet id="F_000459" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="F_000460" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">43000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="F_000461" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000462" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">43000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000463" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_000464" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_000465" contextRef="C_0001818794_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:OperatingLossCarryforwards id="F_000466" contextRef="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" unitRef="U_iso4217USD">69100000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000467" contextRef="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" unitRef="U_iso4217USD">68900000</us-gaap:OperatingLossCarryforwards>
  <dyn:OperatingLossCarryforwardsExpirationYear id="F_000468" contextRef="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2038</dyn:OperatingLossCarryforwardsExpirationYear>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000469" contextRef="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" unitRef="U_iso4217USD">800000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000470" contextRef="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:TaxCreditCarryforwardAmount>
  <dyn:TaxCreditCarryforwardExpirationYear id="F_000471" contextRef="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">2039</dyn:TaxCreditCarryforwardExpirationYear>
  <dyn:TaxCreditCarryforwardExpirationYear id="F_000472" contextRef="C_0001818794_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">2033</dyn:TaxCreditCarryforwardExpirationYear>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000473" contextRef="C_0001818794_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">16300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000474" contextRef="C_0001818794_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">4200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000475" contextRef="C_0001818794_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000476" contextRef="C_0001818794_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:OpenTaxYear id="F_000477" contextRef="C_0001818794_20200101_20201231">2018</us-gaap:OpenTaxYear>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000478" contextRef="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">6421589</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000479" contextRef="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">311303</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000480" contextRef="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">370329</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000481" contextRef="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">652482</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000482" contextRef="C_0001818794_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">403355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000483" contextRef="C_0001818794_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">9798298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000484" contextRef="C_0001818794_20200101_20201231" decimals="0" unitRef="U_xbrlishares">7195273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000485" contextRef="C_0001818794_20190101_20191231" decimals="0" unitRef="U_xbrlishares">10762083</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <dyn:LeaseExecutedDate id="F_000486" contextRef="C_0001818794_20200101_20201231">2019-07-01</dyn:LeaseExecutedDate>
  <us-gaap:LeaseExpirationDate1 id="F_000487" contextRef="C_0001818794_20200101_20201231">2021-12-31</us-gaap:LeaseExpirationDate1>
  <dyn:FacilityAdditionalAreaLeased id="F_000488" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_utrsqft">68187</dyn:FacilityAdditionalAreaLeased>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000489" contextRef="C_0001818794_20201231">P8Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LesseeOperatingLeaseDescription id="F_000490" contextRef="C_0001818794_20200101_20201231">The Company&#8217;s obligation for the payment of base rent for the Premises begins six months after the commencement date and will be $0.4 million per month, increasing up to $0.5 million during the term of the Lease. The Company has two options to extend the term of the Lease, each for a period of an additional five years. The Company expects the Premises to be ready for occupancy in the second half of 2021.</us-gaap:LesseeOperatingLeaseDescription>
  <dyn:OperatingLeaseMonthlyRentExpense id="F_000491" contextRef="C_0001818794_20201201_20201231" decimals="-5" unitRef="U_iso4217USD">400000</dyn:OperatingLeaseMonthlyRentExpense>
  <dyn:OperatingLeaseIncreaseInMonthlyRentExpense id="F_000492" contextRef="C_0001818794_20201201_20201231" decimals="-5" unitRef="U_iso4217USD">500000</dyn:OperatingLeaseIncreaseInMonthlyRentExpense>
  <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend id="F_000493" contextRef="C_0001818794_20201201_20201231">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="F_000494" contextRef="C_0001818794_20200101_20201231">The Company has two options to extend the term of the Lease, each for a period of an additional five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <dyn:OperatingLeasePeriodOfExtension id="F_000495" contextRef="C_0001818794_20201201_20201231">P5Y</dyn:OperatingLeasePeriodOfExtension>
  <us-gaap:OperatingLeaseExpense id="F_000496" contextRef="C_0001818794_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">800000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000497" contextRef="C_0001818794_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:OperatingLeaseExpense>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000498" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000499" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">4603000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000500" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">4741000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000501" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">4883000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="F_000502" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">5029000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive id="F_000503" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">21672000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000504" contextRef="C_0001818794_20201231" decimals="-3" unitRef="U_iso4217USD">41728000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <dyn:CollaborativeAgreementUpfrontPayments id="F_000505" contextRef="C_0001818794_20200101_20201231" decimals="-5" unitRef="U_iso4217EUR">100000</dyn:CollaborativeAgreementUpfrontPayments>
  <dyn:ContractualAgreementsMilestonePayment id="F_000506" contextRef="C_0001818794_20201231" decimals="-5" unitRef="U_iso4217EUR">400000</dyn:ContractualAgreementsMilestonePayment>
  <dyn:ContractualAgreementsPossibleSecondMilestonePayment id="F_000507" contextRef="C_0001818794_20201231" decimals="-5" unitRef="U_iso4217EUR">200000</dyn:ContractualAgreementsPossibleSecondMilestonePayment>
  <dyn:AccruedMilestonePaymentObligation id="F_000508" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_iso4217USD">0</dyn:AccruedMilestonePaymentObligation>
  <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent id="F_000509" contextRef="C_0001818794_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>40
<FILENAME>dyn-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-02T07:22:25.4920071+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : ae64fadccf2840c0b084487bdd0b9296 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:dyn="http://www.dyne-tx.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dyne-tx.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.dyne-tx.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyn-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyn-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyn-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyn-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&apos; Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements" id="Role_DisclosureMarketableSecuritiesAndFairValueMeasurements">
        <link:definition>100090 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100110 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancing" id="Role_DisclosureDebtFinancing">
        <link:definition>100120 - Disclosure - Debt Financing</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100130 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureEquity" id="Role_DisclosureEquity">
        <link:definition>100140 - Disclosure - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100150 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100170 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100180 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" id="Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsTables">
        <link:definition>100220 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100230 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100240 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100250 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100260 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100270 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100280 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails">
        <link:definition>100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails" id="Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails">
        <link:definition>100320 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Security Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Marketable Securities and Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails" id="Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails">
        <link:definition>100340 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Assets Carried at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails">
        <link:definition>100350 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Scheduled Maturity for Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails" id="Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails">
        <link:definition>100360 - Disclosure - Marketable Securities and Fair Value Measurements - Roll-forward of Aggregate Fair Values of Liabilities Determined by Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100370 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100390 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancingAdditionalInformationDetails" id="Role_DisclosureDebtFinancingAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Debt Financing - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" id="Role_DisclosureEquityAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToDetermineGrantDateFairValueOfOptionsGrantedDetails" id="Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToDetermineGrantDateFairValueOfOptionsGrantedDetails">
        <link:definition>100440 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Determine Grant-Date Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetails">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
        <link:definition>100460 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails">
        <link:definition>100470 - Disclosure - Stock-Based Compensation - Summary of Restricted Common Stock Award Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100480 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Significant Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100520 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" id="Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails">
        <link:definition>100530 - Disclosure - Net Loss Per Share - Potential Dilutive Securities Excluded From Calculation Of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails">
        <link:definition>100550 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dyn_RestrictedCashAndOtherAssetsNoncurrent" name="RestrictedCashAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" name="ChangesInFairValueOfPreferredStockTrancheObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_ChangesInSuccessFeeObligation" name="ChangesInSuccessFeeObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_ReclassificationsOfTemporaryToPermanentEquityShares" name="ReclassificationsOfTemporaryToPermanentEquityShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" name="StockIssuedDuringPeriodSharesRestrictedStockVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_SettlementOfTrancheRightOne" name="SettlementOfTrancheRightOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_StockIssuanceCosts" name="StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" name="AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_PaymentsForSettlementOfSuccessFeeObligation" name="PaymentsForSettlementOfSuccessFeeObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_CashPaidForInterestAndIncomeTaxes" name="CashPaidForInterestAndIncomeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity" name="ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_SettlementsOfTrancheRightOne" name="SettlementsOfTrancheRightOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" name="MarketableSecuritiesAndFairValueMeasurementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" name="MarketableSecuritiesAndFairValueMeasurementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" name="ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_SuccessFeeObligationPolicyTextBlock" name="SuccessFeeObligationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" name="NatureOfBusinessAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_NatureOfBusinessAndBasisOfPresentationTable" name="NatureOfBusinessAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_UnderwritersOptionToPurchaseAdditionalShares" name="UnderwritersOptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_CashAndCashEquivalentsMaturityPeriod" name="CashAndCashEquivalentsMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_LoanAgreementMember" name="LoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_PacificWesternBankMember" name="PacificWesternBankMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_SuccessFeePaid" name="SuccessFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_FairValueAssetsTransfersAmount" name="FairValueAssetsTransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" name="AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" name="AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_FairValueLiabilityPaymentPercentage" name="FairValueLiabilityPaymentPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_PreferredStockTrancheObligationsMember" name="PreferredStockTrancheObligationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_SuccessFeeObligationMember" name="SuccessFeeObligationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_TrancheRightOneMember" name="TrancheRightOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_OfficeAndComputerEquipmentMember" name="OfficeAndComputerEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_AccruedConsultingServicesCurrent" name="AccruedConsultingServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_AccruedFacilityCostsCurrent" name="AccruedFacilityCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_TermLoanMember" name="TermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_DebtInstrumentSuccessFeePaid" name="DebtInstrumentSuccessFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_TrancheRightMember" name="TrancheRightMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_TrancheRighttwoMember" name="TrancheRighttwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_PurchasesOfSharesValue" name="PurchasesOfSharesValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_PreferredStockFairValue" name="PreferredStockFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_StockIssuanceCost" name="StockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_TwoThousandEighteenStockIncentivePlanMember" name="TwoThousandEighteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" name="ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" name="WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dyn_LeaseExecutedDate" name="LeaseExecutedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_FacilityAdditionalAreaLeased" name="FacilityAdditionalAreaLeased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="dyn_OperatingLeaseMonthlyRentExpense" name="OperatingLeaseMonthlyRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_OperatingLeaseIncreaseInMonthlyRentExpense" name="OperatingLeaseIncreaseInMonthlyRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_OperatingLeasePeriodOfExtension" name="OperatingLeasePeriodOfExtension" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dyn_CollaborativeAgreementUpfrontPayments" name="CollaborativeAgreementUpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dyn_ContractualAgreementsMilestonePayment" name="ContractualAgreementsMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_ContractualAgreementsPossibleSecondMilestonePayment" name="ContractualAgreementsPossibleSecondMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dyn_AccruedMilestonePaymentObligation" name="AccruedMilestonePaymentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>41
<FILENAME>dyn-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-02T07:22:25.4920071+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : ae64fadccf2840c0b084487bdd0b9296 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="dyn-20201231.xsd#TemplateLink" roleURI="http://www.dyne-tx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_RestrictedCashAndOtherAssetsNoncurrent" xlink:type="locator" xlink:label="dyn_RestrictedCashAndOtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="dyn_RestrictedCashAndOtherAssetsNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_ChangesInSuccessFeeObligation" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInFairValueOfPreferredStockTrancheObligations" xlink:type="locator" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther" xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeOther" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseOther" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="dyn_ChangesInSuccessFeeObligation" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_ChangesInSuccessFeeObligation" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInFairValueOfPreferredStockTrancheObligations" xlink:type="locator" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" xlink:type="locator" xlink:label="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PaymentsForSettlementOfSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_PaymentsForSettlementOfSuccessFeeObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dyn_PaymentsForSettlementOfSuccessFeeObligation" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dyn_ChangesInSuccessFeeObligation" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="10200.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" xlink:type="locator" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="dyn-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedFacilityCostsCurrent" xlink:type="locator" xlink:label="dyn_AccruedFacilityCostsCurrent" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="dyn_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedConsultingServicesCurrent" xlink:type="locator" xlink:label="dyn_AccruedConsultingServicesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="dyn_AccruedConsultingServicesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="dyn_AccruedResearchAndDevelopmentExpensesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="dyn_AccruedFacilityCostsCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" xlink:type="locator" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>42
<FILENAME>dyn-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-02T07:22:25.4930073+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : ae64fadccf2840c0b084487bdd0b9296 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="dyn-20201231.xsd#TemplateLink" roleURI="http://www.dyne-tx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_RestrictedCashAndOtherAssetsNoncurrent" xlink:type="locator" xlink:label="dyn_RestrictedCashAndOtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10200.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="dyn_RestrictedCashAndOtherAssetsNoncurrent" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" xlink:type="locator" xlink:label="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="locator" xlink:label="dyn_ReclassificationsOfTemporaryToPermanentEquityShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SettlementOfTrancheRightOne" xlink:type="locator" xlink:label="dyn_SettlementOfTrancheRightOne" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassBMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_SettlementOfTrancheRightOne" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_ReclassificationsOfTemporaryToPermanentEquityShares" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" order="13080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="13300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuanceCosts" xlink:type="locator" xlink:label="dyn_StockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassBMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassAMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="dyn_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dyn_SeriesARedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_StockIssuanceCosts" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_UnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="dyn_UnderwritersOptionToPurchaseAdditionalShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="dyn_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="dyn_NatureOfBusinessAndBasisOfPresentationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dyn_FollowOnPublicOfferingMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="dyn_UnderwritersOptionToPurchaseAdditionalShares" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10710.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeePaid" xlink:type="locator" xlink:label="dyn_SuccessFeePaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_CashAndCashEquivalentsMaturityPeriod" xlink:type="locator" xlink:label="dyn_CashAndCashEquivalentsMaturityPeriod" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PacificWesternBankMember" xlink:type="locator" xlink:label="dyn_PacificWesternBankMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LoanAgreementMember" xlink:type="locator" xlink:label="dyn_LoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dyn_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyn_LoanAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="dyn_PacificWesternBankMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dyn_CashAndCashEquivalentsMaturityPeriod" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dyn_SuccessFeePaid" order="10400.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="dyn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dyn_LaboratoryEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10490.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeePaid" xlink:type="locator" xlink:label="dyn_SuccessFeePaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueLiabilityPaymentPercentage" xlink:type="locator" xlink:label="dyn_FairValueLiabilityPaymentPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueAssetsTransfersAmount" xlink:type="locator" xlink:label="dyn_FairValueAssetsTransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dyn_FairValueAssetsTransfersAmount" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dyn_FairValueLiabilityPaymentPercentage" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dyn_SuccessFeePaid" order="10350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesMember" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="dyn_MarketableSecuritiesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" xlink:type="locator" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember" xlink:type="locator" xlink:label="us-gaap_DerivativeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRightOneMember" xlink:type="locator" xlink:label="dyn_TrancheRightOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeeObligationMember" xlink:type="locator" xlink:label="dyn_SuccessFeeObligationMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PreferredStockTrancheObligationsMember" xlink:type="locator" xlink:label="dyn_PreferredStockTrancheObligationsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="dyn_PreferredStockTrancheObligationsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="dyn_SuccessFeeObligationMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_VestingAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dyn_TrancheRightOneMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DerivativeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" order="10640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="dyn-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OfficeAndComputerEquipmentMember" xlink:type="locator" xlink:label="dyn_OfficeAndComputerEquipmentMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="dyn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dyn_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dyn_OfficeAndComputerEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancingAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureDebtFinancingAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancingAdditionalInformationDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_DebtInstrumentSuccessFeePaid" xlink:type="locator" xlink:label="dyn_DebtInstrumentSuccessFeePaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TermLoanMember" xlink:type="locator" xlink:label="dyn_TermLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="dyn_TermLoanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="dyn_DebtInstrumentSuccessFeePaid" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuanceCost" xlink:type="locator" xlink:label="dyn_StockIssuanceCost" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PreferredStockFairValue" xlink:type="locator" xlink:label="dyn_PreferredStockFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PurchasesOfSharesValue" xlink:type="locator" xlink:label="dyn_PurchasesOfSharesValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRighttwoMember" xlink:type="locator" xlink:label="dyn_TrancheRighttwoMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRightOneMember" xlink:type="locator" xlink:label="dyn_TrancheRightOneMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRightMember" xlink:type="locator" xlink:label="dyn_TrancheRightMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassBMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_VestingAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dyn_TrancheRightMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dyn_TrancheRightOneMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dyn_TrancheRighttwoMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dyn_PurchasesOfSharesValue" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharePrice" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dyn_PreferredStockFairValue" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dyn_StockIssuanceCost" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="11730.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" xlink:type="locator" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" xlink:type="locator" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" xlink:type="locator" xlink:label="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" xlink:type="locator" xlink:label="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TwoThousandTwentyStockIncentivePlanMember" xlink:type="locator" xlink:label="dyn_TwoThousandTwentyStockIncentivePlanMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="dyn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyn_TwoThousandEighteenStockIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyn_TwoThousandTwentyStockIncentivePlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11410.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TwoThousandTwentyStockIncentivePlanMember" xlink:type="locator" xlink:label="dyn_TwoThousandTwentyStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyn_TwoThousandTwentyStockIncentivePlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11050.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="dyn_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="dyn_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="dyn_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="dyn_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="dyn_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dyn_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dyn_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="dyn_OperatingLossCarryforwardsExpirationYear" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="dyn_TaxCreditCarryforwardExpirationYear" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="10670.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>43
<FILENAME>dyn-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-02T07:22:25.4930073+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : ae64fadccf2840c0b084487bdd0b9296 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_RestrictedCashAndOtherAssetsNoncurrent" xlink:type="locator" xlink:label="dyn_RestrictedCashAndOtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="dyn_RestrictedCashAndOtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and other assets noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_RestrictedCashAndOtherAssetsNoncurrent" xlink:to="dyn_RestrictedCashAndOtherAssetsNoncurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_RestrictedCashAndOtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and other assets</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_RestrictedCashAndOtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 200,000,000 and 68,000,000 shares authorized at December 31, 2020 and 2019, respectively; 45,446,903 and 3,239,017 shares issued and 45,076,574 and 2,586,535 shares outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInFairValueOfPreferredStockTrancheObligations" xlink:type="locator" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" />
    <link:label xml:lang="en-US" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in fair value of preferred stock tranche obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" xlink:to="dyn_ChangesInFairValueOfPreferredStockTrancheObligations_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_ChangesInSuccessFeeObligation" />
    <link:label xml:lang="en-US" xlink:label="dyn_ChangesInSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in success fee obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ChangesInSuccessFeeObligation" xlink:to="dyn_ChangesInSuccessFeeObligation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther" xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Other</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of preferred stock tranche obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Fair Value Of Preferred Stock Tranche Obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ChangesInSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in success fee obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ChangesInSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Success Fee Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other (expense) income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="locator" xlink:label="dyn_ReclassificationsOfTemporaryToPermanentEquityShares" />
    <link:label xml:lang="en-US" xlink:label="dyn_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassifications of temporary to permanent equity, shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:to="dyn_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" xlink:type="locator" xlink:label="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" />
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares restricted stock vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" xlink:to="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SettlementOfTrancheRightOne" xlink:type="locator" xlink:label="dyn_SettlementOfTrancheRightOne" />
    <link:label xml:lang="en-US" xlink:label="dyn_SettlementOfTrancheRightOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement of tranche right one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_SettlementOfTrancheRightOne" xlink:to="dyn_SettlementOfTrancheRightOne_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassAMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class A [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassBMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredClassBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredClassBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A redeemable convertible preferred stock, net of issuance costs of $0.1 million</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A redeemable convertible preferred stock, net of issuance costs of $0.1 million, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SettlementOfTrancheRightOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Settlement of Tranche Right I</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SettlementOfTrancheRightOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of Tranche Right One</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of redeemable convertible preferred stock and preferred stock tranche obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassifications Of Temporary To Permanent Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of redeemable convertible preferred stock and preferred stock tranche obligations, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassifications Of Temporary To Permanent Equity Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock, net of issuance costs, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon initial public offering, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted shares</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Vested</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gains on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuanceCosts" xlink:type="locator" xlink:label="dyn_StockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_StockIssuanceCosts" xlink:to="dyn_StockIssuanceCosts_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="dyn_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="dyn_SeriesARedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" xlink:type="locator" xlink:label="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization (accretion) of premium (discount) on marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" xlink:to="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PaymentsForSettlementOfSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_PaymentsForSettlementOfSuccessFeeObligation" />
    <link:label xml:lang="en-US" xlink:label="dyn_PaymentsForSettlementOfSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for settlement of success fee obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_PaymentsForSettlementOfSuccessFeeObligation" xlink:to="dyn_PaymentsForSettlementOfSuccessFeeObligation_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_CashPaidForInterestAndIncomeTaxes" xlink:type="locator" xlink:label="dyn_CashPaidForInterestAndIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="dyn_CashPaidForInterestAndIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for interest and income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_CashPaidForInterestAndIncomeTaxes" xlink:to="dyn_CashPaidForInterestAndIncomeTaxes_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity" xlink:type="locator" xlink:label="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity" />
    <link:label xml:lang="en-US" xlink:label="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of preferred stock tranche obligation liability to permanent equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity" xlink:to="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SettlementsOfTrancheRightOne" xlink:type="locator" xlink:label="dyn_SettlementsOfTrancheRightOne" />
    <link:label xml:lang="en-US" xlink:label="dyn_SettlementsOfTrancheRightOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlements of tranche right one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_SettlementsOfTrancheRightOne" xlink:to="dyn_SettlementsOfTrancheRightOne_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCashFlowsDirectMethodAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCashFlowsDirectMethodAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Cash Flows Direct Method [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_OperatingCashFlowsDirectMethodAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization (accretion) of premium (discount) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Accretion Of Premium Discount On Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value of preferred stock tranche obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ChangesInSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in success fee obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_PaymentsForSettlementOfSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Settlement of success fee obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_PaymentsForSettlementOfSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Settlement Of Success Fee Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of debt, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_CashPaidForInterestAndIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest and taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_CashPaidForInterestAndIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Interest And Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock tranche obligation liability to permanent equity</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Preferred Stock Tranche Obligation Liability To Permanent Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SettlementsOfTrancheRightOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of Tranche Right I</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SettlementsOfTrancheRightOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Settlements Of Tranche Right One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities and fair value measurements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:to="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities and fair value measurements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities And Fair Value Measurements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities and Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities And Fair Value Measurements [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and of Significant Suppliers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and manufacturing contract costs and accruals policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:to="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Manufacturing Contract Costs and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Manufacturing Contract Costs And Accruals Policy [Text Block]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="dyn_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dyn_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_PatentCostsPolicyTextBlock" xlink:to="dyn_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Redeemable Preferred Stock Issue Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeeObligationPolicyTextBlock" xlink:type="locator" xlink:label="dyn_SuccessFeeObligationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeeObligationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Success Fee Obligation Policy[Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_SuccessFeeObligationPolicyTextBlock" xlink:to="dyn_SuccessFeeObligationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeeObligationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Fee Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeeObligationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Success Fee Obligation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Pronouncements Issued and Not Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator" xlink:label="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment Estimated Useful Lives Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities by Security Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets Carried at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Scheduled Maturity for Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roll-forward of Aggregate Fair Values of Liabilities Determined by Level 3 Inputs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Determine Grant-Date Fair Value of Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity and Related Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Common Stock Award Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential Dilutive Securities Excluded From Calculation Of Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:label xml:lang="en-US" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business and basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="dyn_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:label xml:lang="en-US" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business and basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="dyn_NatureOfBusinessAndBasisOfPresentationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="dyn_FollowOnPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_FollowOnPublicOfferingMember" xlink:to="dyn_FollowOnPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_UnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="dyn_UnderwritersOptionToPurchaseAdditionalShares" />
    <link:label xml:lang="en-US" xlink:label="dyn_UnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriters option to purchase additional shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_UnderwritersOptionToPurchaseAdditionalShares" xlink:to="dyn_UnderwritersOptionToPurchaseAdditionalShares_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued and sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_UnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters option to purchase additional shares</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_UnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters Option To Purchase Additional Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_CashAndCashEquivalentsMaturityPeriod" xlink:type="locator" xlink:label="dyn_CashAndCashEquivalentsMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="dyn_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash And Cash Equivalents Maturity Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_CashAndCashEquivalentsMaturityPeriod" xlink:to="dyn_CashAndCashEquivalentsMaturityPeriod_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dyn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dyn_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LoanAgreementMember" xlink:type="locator" xlink:label="dyn_LoanAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_LoanAgreementMember" xlink:to="dyn_LoanAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PacificWesternBankMember" xlink:type="locator" xlink:label="dyn_PacificWesternBankMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_PacificWesternBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pacific Western Bank.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_PacificWesternBankMember" xlink:to="dyn_PacificWesternBankMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_PacificWesternBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pacific Western Bank</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_PacificWesternBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pacific Western Bank [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalent maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Maturity Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="dyn_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_LaboratoryEquipmentMember" xlink:to="dyn_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furnitures and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeePaid" xlink:type="locator" xlink:label="dyn_SuccessFeePaid" />
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Success fee paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_SuccessFeePaid" xlink:to="dyn_SuccessFeePaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success fee paid</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Success Fee Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificates of Deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Certificates Of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesMember" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_MarketableSecuritiesMember" xlink:to="dyn_MarketableSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueAssetsTransfersAmount" xlink:type="locator" xlink:label="dyn_FairValueAssetsTransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueAssetsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_FairValueAssetsTransfersAmount" xlink:to="dyn_FairValueAssetsTransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueAssetsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, transfers among level 1, level 2 or level 3</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueAssetsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Transfers Amount</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" />
    <link:label xml:lang="en-US" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available-for-sale debt securities maturity after year one through two years fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" xlink:to="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" xlink:type="locator" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" />
    <link:label xml:lang="en-US" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available-for-sale debt securities maturity after two years fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" xlink:to="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing in one year or less</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing after one year through two years</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Maturity After Year One Through Two Years Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing after two years</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Maturity After Year Two Years Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueLiabilityPaymentPercentage" xlink:type="locator" xlink:label="dyn_FairValueLiabilityPaymentPercentage" />
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueLiabilityPaymentPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value liability, payment percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_FairValueLiabilityPaymentPercentage" xlink:to="dyn_FairValueLiabilityPaymentPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueLiabilityPaymentPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liability, payment percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueLiabilityPaymentPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liability Payment Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of derivative liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" xlink:type="locator" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" />
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis reclassification of tranche right two to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" xlink:to="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" />
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis initial fair value of success fee obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" xlink:to="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PreferredStockTrancheObligationsMember" xlink:type="locator" xlink:label="dyn_PreferredStockTrancheObligationsMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_PreferredStockTrancheObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Stock Tranche Obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_PreferredStockTrancheObligationsMember" xlink:to="dyn_PreferredStockTrancheObligationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_PreferredStockTrancheObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Tranche Obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_PreferredStockTrancheObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Tranche Obligations [Member]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeeObligationMember" xlink:type="locator" xlink:label="dyn_SuccessFeeObligationMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeeObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Success fee obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_SuccessFeeObligationMember" xlink:to="dyn_SuccessFeeObligationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeeObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Fee Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_SuccessFeeObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Success Fee Obligation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRightOneMember" xlink:type="locator" xlink:label="dyn_TrancheRightOneMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRightOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche right one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_TrancheRightOneMember" xlink:to="dyn_TrancheRightOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRightOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Right I</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRightOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Right One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember" xlink:type="locator" xlink:label="us-gaap_DerivativeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeMember" xlink:to="us-gaap_DerivativeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance&#8212;January 1, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of Tranche Right II to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Reclassification Of Tranche Right Two To Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance&#8212;December 31, 2019</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial fair value of success fee obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Initial Fair Value Of Success Fee Obligation</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OfficeAndComputerEquipmentMember" xlink:type="locator" xlink:label="dyn_OfficeAndComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_OfficeAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and computer equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_OfficeAndComputerEquipmentMember" xlink:to="dyn_OfficeAndComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_OfficeAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OfficeAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment&#8212;at cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment&#8212;net</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedConsultingServicesCurrent" xlink:type="locator" xlink:label="dyn_AccruedConsultingServicesCurrent" />
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedConsultingServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued consulting services current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_AccruedConsultingServicesCurrent" xlink:to="dyn_AccruedConsultingServicesCurrent_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="dyn_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="dyn_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedFacilityCostsCurrent" xlink:type="locator" xlink:label="dyn_AccruedFacilityCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedFacilityCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued facility costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_AccruedFacilityCostsCurrent" xlink:to="dyn_AccruedFacilityCostsCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedConsultingServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting services</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedConsultingServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Consulting Services Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedFacilityCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility costs</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedFacilityCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Facility Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit Facility [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility [Table]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TermLoanMember" xlink:type="locator" xlink:label="dyn_TermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_TermLoanMember" xlink:to="dyn_TermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit Facility [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility, maximum borrowing capacity under loan agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility, interest rate description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Interest Rate Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, frequency of periodic payment of interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Frequency Of Periodic Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility, variable interest rate spread</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility, interest rate during period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Interest Rate During Period</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_DebtInstrumentSuccessFeePaid" xlink:type="locator" xlink:label="dyn_DebtInstrumentSuccessFeePaid" />
    <link:label xml:lang="en-US" xlink:label="dyn_DebtInstrumentSuccessFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument success fee paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_DebtInstrumentSuccessFeePaid" xlink:to="dyn_DebtInstrumentSuccessFeePaid_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success fee required to pay in the event of liquidation, including IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fee Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_DebtInstrumentSuccessFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success fee paid after IPO</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_DebtInstrumentSuccessFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Success Fee Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRightMember" xlink:type="locator" xlink:label="dyn_TrancheRightMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche Right [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_TrancheRightMember" xlink:to="dyn_TrancheRightMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Right</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Right [Member]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRighttwoMember" xlink:type="locator" xlink:label="dyn_TrancheRighttwoMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRighttwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche Right Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_TrancheRighttwoMember" xlink:to="dyn_TrancheRighttwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRighttwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Right II</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TrancheRighttwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Righttwo [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued upon conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PurchasesOfSharesValue" xlink:type="locator" xlink:label="dyn_PurchasesOfSharesValue" />
    <link:label xml:lang="en-US" xlink:label="dyn_PurchasesOfSharesValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases Of Shares Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_PurchasesOfSharesValue" xlink:to="dyn_PurchasesOfSharesValue_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PreferredStockFairValue" xlink:type="locator" xlink:label="dyn_PreferredStockFairValue" />
    <link:label xml:lang="en-US" xlink:label="dyn_PreferredStockFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred Stock Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_PreferredStockFairValue" xlink:to="dyn_PreferredStockFairValue_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuanceCost" xlink:type="locator" xlink:label="dyn_StockIssuanceCost" />
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issuance Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_StockIssuanceCost" xlink:to="dyn_StockIssuanceCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_PurchasesOfSharesValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of share</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_PurchasesOfSharesValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Shares Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_PreferredStockFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_PreferredStockFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_StockIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="dyn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_TwoThousandEighteenStockIncentivePlanMember" xlink:to="dyn_TwoThousandEighteenStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TwoThousandTwentyStockIncentivePlanMember" xlink:type="locator" xlink:label="dyn_TwoThousandTwentyStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="dyn_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_TwoThousandTwentyStockIncentivePlanMember" xlink:to="dyn_TwoThousandTwentyStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units ("RSUs")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total number of shares of common stock authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares initially reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares increased annually under the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" xlink:type="locator" xlink:label="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold limit for increase in common stock reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" xlink:to="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Limit For Increase In Common Stock Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable&#8212; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested or expected to vest&#8212; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable&#8212; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested or expected to vest&#8212; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="locator" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable&#8212; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested or expected to vest&#8212; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable&#8212; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested or expected to vest&#8212; December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" xlink:type="locator" xlink:label="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" />
    <link:label xml:lang="en-US" xlink:label="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee service share based compensation nonvested awards compensation cost not yet recognized performance conditions not probable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" xlink:to="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share based compensation expense, recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested stock-based awards with performance-based vesting conditions for which performance conditions not deemed probable</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Not Yet Recognized Performance Conditions Not Probable</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" xlink:type="locator" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" />
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, number of shares of common stock receivable upon vesting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" xlink:to="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" xlink:type="locator" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" />
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased compensation arrangement by sharebased payment award grant service conditions to vest number of annual installments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" xlink:to="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share of common stock receivable upon vesting</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Of Common Stock Receivable Upon Vesting</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement By Share-based Payment Award Grant Service Conditions to Vest Number of Annual Installments</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Grant Service Conditions To Vest Number Of Annual Installments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Issued and unvested as of January 1, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Issued and unvested as of December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Issued and unvested as of January 1, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Issued and unvested as of December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Restricted Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" xlink:type="locator" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" />
    <link:label xml:lang="en-US" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation, Change in Fair Value of Preferred Stock Tranche Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" xlink:to="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:label xml:lang="en-US" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation, Permanent Differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective income tax rate reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income tax expense at statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes&#8212;net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock tranche obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Fair Value Of Preferred Stock Tranche Obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal &amp; state R&amp;D credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets (liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="dyn_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards, Expiration Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_OperatingLossCarryforwardsExpirationYear" xlink:to="dyn_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="dyn_TaxCreditCarryforwardExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="dyn_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Credit Carryforward, Expiration Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_TaxCreditCarryforwardExpirationYear" xlink:to="dyn_TaxCreditCarryforwardExpirationYear_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="dyn_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="dyn_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="dyn_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="dyn_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="dyn_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_IncomeTaxDisclosureTable" xlink:to="dyn_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local Jurisdiction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Developments Tax Credit Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance for deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax positions, accrued interest or penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax returns open year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:type="locator" xlink:label="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" />
    <link:label xml:lang="en-US" xlink:label="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of shares outstanding basic and diluted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:to="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic And Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding&#8212;basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share&#8212;basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock (As Converted to Common Stock)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LeaseExecutedDate" xlink:type="locator" xlink:label="dyn_LeaseExecutedDate" />
    <link:label xml:lang="en-US" xlink:label="dyn_LeaseExecutedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease executed date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_LeaseExecutedDate" xlink:to="dyn_LeaseExecutedDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_LeaseExecutedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease executed date</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_LeaseExecutedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Executed Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FacilityAdditionalAreaLeased" xlink:type="locator" xlink:label="dyn_FacilityAdditionalAreaLeased" />
    <link:label xml:lang="en-US" xlink:label="dyn_FacilityAdditionalAreaLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Facility additional area leased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_FacilityAdditionalAreaLeased" xlink:to="dyn_FacilityAdditionalAreaLeased_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLeaseMonthlyRentExpense" xlink:type="locator" xlink:label="dyn_OperatingLeaseMonthlyRentExpense" />
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeaseMonthlyRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease monthly rent expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_OperatingLeaseMonthlyRentExpense" xlink:to="dyn_OperatingLeaseMonthlyRentExpense_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLeaseIncreaseInMonthlyRentExpense" xlink:type="locator" xlink:label="dyn_OperatingLeaseIncreaseInMonthlyRentExpense" />
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeaseIncreaseInMonthlyRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease increase in monthly rent expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_OperatingLeaseIncreaseInMonthlyRentExpense" xlink:to="dyn_OperatingLeaseIncreaseInMonthlyRentExpense_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLeasePeriodOfExtension" xlink:type="locator" xlink:label="dyn_OperatingLeasePeriodOfExtension" />
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeasePeriodOfExtension_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease period of extension.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_OperatingLeasePeriodOfExtension" xlink:to="dyn_OperatingLeasePeriodOfExtension_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_FacilityAdditionalAreaLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional leased office space</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_FacilityAdditionalAreaLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Facility Additional Area Leased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeaseMonthlyRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly rent expense</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeaseMonthlyRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Monthly Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeaseIncreaseInMonthlyRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in monthly rent expense</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeaseIncreaseInMonthlyRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Increase In Monthly Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Existence of option to extend lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeasePeriodOfExtension_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional period of lease</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_OperatingLeasePeriodOfExtension_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Period Of Extension</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases Future Minimum Payments Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_CollaborativeAgreementUpfrontPayments" xlink:type="locator" xlink:label="dyn_CollaborativeAgreementUpfrontPayments" />
    <link:label xml:lang="en-US" xlink:label="dyn_CollaborativeAgreementUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreement upfront payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_CollaborativeAgreementUpfrontPayments" xlink:to="dyn_CollaborativeAgreementUpfrontPayments_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ContractualAgreementsMilestonePayment" xlink:type="locator" xlink:label="dyn_ContractualAgreementsMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="dyn_ContractualAgreementsMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual agreements milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ContractualAgreementsMilestonePayment" xlink:to="dyn_ContractualAgreementsMilestonePayment_lbl" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ContractualAgreementsPossibleSecondMilestonePayment" xlink:type="locator" xlink:label="dyn_ContractualAgreementsPossibleSecondMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="dyn_ContractualAgreementsPossibleSecondMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual agreements possible second milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_ContractualAgreementsPossibleSecondMilestonePayment" xlink:to="dyn_ContractualAgreementsPossibleSecondMilestonePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_CollaborativeAgreementUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_CollaborativeAgreementUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreement Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ContractualAgreementsMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ContractualAgreementsMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Agreements Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ContractualAgreementsPossibleSecondMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory possible second milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_ContractualAgreementsPossibleSecondMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Agreements Possible Second Milestone Payment</link:label>
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedMilestonePaymentObligation" xlink:type="locator" xlink:label="dyn_AccruedMilestonePaymentObligation" />
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedMilestonePaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued milestone payment obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dyn_AccruedMilestonePaymentObligation" xlink:to="dyn_AccruedMilestonePaymentObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedMilestonePaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued milestone payment obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="dyn_AccruedMilestonePaymentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Milestone Payment Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued royalty obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties Current And Noncurrent</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>44
<FILENAME>dyn-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-02T07:22:25.4930073+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : ae64fadccf2840c0b084487bdd0b9296 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/role/TemplateLink" xlink:href="dyn-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="dyn-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_RestrictedCashAndOtherAssetsNoncurrent" xlink:type="locator" xlink:label="dyn_RestrictedCashAndOtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="dyn_RestrictedCashAndOtherAssetsNoncurrent" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_ChangesInSuccessFeeObligation" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInFairValueOfPreferredStockTrancheObligations" xlink:type="locator" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther" xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseOther" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="dyn_ChangesInSuccessFeeObligation" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" xlink:type="locator" xlink:label="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="locator" xlink:label="dyn_ReclassificationsOfTemporaryToPermanentEquityShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SettlementOfTrancheRightOne" xlink:type="locator" xlink:label="dyn_SettlementOfTrancheRightOne" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassBMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_SettlementOfTrancheRightOne" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_ReclassificationsOfTemporaryToPermanentEquityShares" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_StockIssuedDuringPeriodSharesRestrictedStockVested" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="13290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="13730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="13750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="13770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="13790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuanceCosts" xlink:type="locator" xlink:label="dyn_StockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassBMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassAMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="dyn_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dyn_SeriesARedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dyn_StockIssuanceCosts" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="dyn-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SettlementsOfTrancheRightOne" xlink:type="locator" xlink:label="dyn_SettlementsOfTrancheRightOne" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity" xlink:type="locator" xlink:label="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_CashPaidForInterestAndIncomeTaxes" xlink:type="locator" xlink:label="dyn_CashPaidForInterestAndIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PaymentsForSettlementOfSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_PaymentsForSettlementOfSuccessFeeObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_ChangesInSuccessFeeObligation" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ChangesInFairValueOfPreferredStockTrancheObligations" xlink:type="locator" xlink:label="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" xlink:type="locator" xlink:label="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCashFlowsDirectMethodAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dyn_ChangesInFairValueOfPreferredStockTrancheObligations" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dyn_ChangesInSuccessFeeObligation" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dyn_PaymentsForSettlementOfSuccessFeeObligation" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="dyn_CashPaidForInterestAndIncomeTaxes" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCashFlowsDirectMethodAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dyn_SettlementsOfTrancheRightOne" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="dyn-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="dyn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="dyn-20201231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="dyn-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancing" xlink:href="dyn-20201231.xsd#Role_DisclosureDebtFinancing" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancing">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="dyn-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureEquity" xlink:href="dyn-20201231.xsd#Role_DisclosureEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="dyn-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="dyn-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="dyn-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="dyn-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dyn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeeObligationPolicyTextBlock" xlink:type="locator" xlink:label="dyn_SuccessFeeObligationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="dyn_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyn_PatentCostsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyn_SuccessFeeObligationPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="dyn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator" xlink:label="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="dyn-20201231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="dyn-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="dyn-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="dyn-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="dyn-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_UnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="dyn_UnderwritersOptionToPurchaseAdditionalShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="dyn_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="dyn_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyn_NatureOfBusinessAndBasisOfPresentationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dyn_FollowOnPublicOfferingMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="dyn_UnderwritersOptionToPurchaseAdditionalShares" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeePaid" xlink:type="locator" xlink:label="dyn_SuccessFeePaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_CashAndCashEquivalentsMaturityPeriod" xlink:type="locator" xlink:label="dyn_CashAndCashEquivalentsMaturityPeriod" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PacificWesternBankMember" xlink:type="locator" xlink:label="dyn_PacificWesternBankMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LoanAgreementMember" xlink:type="locator" xlink:label="dyn_LoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="dyn_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dyn_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dyn_LoanAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="dyn_PacificWesternBankMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="dyn_SummaryOfSignificantAccountingPoliciesLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dyn_CashAndCashEquivalentsMaturityPeriod" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dyn_SuccessFeePaid" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="dyn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dyn_LaboratoryEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeePaid" xlink:type="locator" xlink:label="dyn_SuccessFeePaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueLiabilityPaymentPercentage" xlink:type="locator" xlink:label="dyn_FairValueLiabilityPaymentPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueAssetsTransfersAmount" xlink:type="locator" xlink:label="dyn_FairValueAssetsTransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dyn_FairValueAssetsTransfersAmount" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dyn_FairValueLiabilityPaymentPercentage" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="dyn_SuccessFeePaid" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesMember" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="dyn_MarketableSecuritiesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" xlink:type="locator" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" xlink:type="locator" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" xlink:type="locator" xlink:label="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeMember" xlink:type="locator" xlink:label="us-gaap_DerivativeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRightOneMember" xlink:type="locator" xlink:label="dyn_TrancheRightOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_SuccessFeeObligationMember" xlink:type="locator" xlink:label="dyn_SuccessFeeObligationMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PreferredStockTrancheObligationsMember" xlink:type="locator" xlink:label="dyn_PreferredStockTrancheObligationsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:type="locator" xlink:label="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="dyn_PreferredStockTrancheObligationsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="dyn_SuccessFeeObligationMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_VestingAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="dyn_TrancheRightOneMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DerivativeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialFairValueOfSuccessFeeObligation" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="dyn-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OfficeAndComputerEquipmentMember" xlink:type="locator" xlink:label="dyn_OfficeAndComputerEquipmentMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="dyn_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dyn_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dyn_OfficeAndComputerEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedFacilityCostsCurrent" xlink:type="locator" xlink:label="dyn_AccruedFacilityCostsCurrent" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="dyn_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedConsultingServicesCurrent" xlink:type="locator" xlink:label="dyn_AccruedConsultingServicesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dyn_AccruedConsultingServicesCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dyn_AccruedResearchAndDevelopmentExpensesCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="dyn_AccruedFacilityCostsCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancingAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureDebtFinancingAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancingAdditionalInformationDetails">
    <link:loc xlink:href="dyn-20201231.xsd#dyn_DebtInstrumentSuccessFeePaid" xlink:type="locator" xlink:label="dyn_DebtInstrumentSuccessFeePaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TermLoanMember" xlink:type="locator" xlink:label="dyn_TermLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="dyn_TermLoanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="dyn_DebtInstrumentSuccessFeePaid" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_StockIssuanceCost" xlink:type="locator" xlink:label="dyn_StockIssuanceCost" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PreferredStockFairValue" xlink:type="locator" xlink:label="dyn_PreferredStockFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_PurchasesOfSharesValue" xlink:type="locator" xlink:label="dyn_PurchasesOfSharesValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRighttwoMember" xlink:type="locator" xlink:label="dyn_TrancheRighttwoMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRightOneMember" xlink:type="locator" xlink:label="dyn_TrancheRightOneMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TrancheRightMember" xlink:type="locator" xlink:label="dyn_TrancheRightMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassBMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:type="locator" xlink:label="us-gaap_PreferredClassAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_VestingAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="dyn_TrancheRightMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="dyn_TrancheRightOneMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="dyn_TrancheRighttwoMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dyn_PurchasesOfSharesValue" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharePrice" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dyn_PreferredStockFairValue" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="dyn_StockIssuanceCost" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" xlink:type="locator" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" xlink:type="locator" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" xlink:type="locator" xlink:label="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" xlink:type="locator" xlink:label="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TwoThousandTwentyStockIncentivePlanMember" xlink:type="locator" xlink:label="dyn_TwoThousandTwentyStockIncentivePlanMember" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="locator" xlink:label="dyn_TwoThousandEighteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyn_TwoThousandEighteenStockIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyn_TwoThousandTwentyStockIncentivePlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToDetermineGrantDateFairValueOfOptionsGrantedDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToDetermineGrantDateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToDetermineGrantDateFairValueOfOptionsGrantedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="locator" xlink:label="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TwoThousandTwentyStockIncentivePlanMember" xlink:type="locator" xlink:label="dyn_TwoThousandTwentyStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dyn_TwoThousandTwentyStockIncentivePlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" xlink:type="locator" xlink:label="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="dyn_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="dyn_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="dyn_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="dyn_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dyn_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureTable" xlink:to="dyn_IncomeTaxDisclosureLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="dyn_OperatingLossCarryforwardsExpirationYear" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="dyn_TaxCreditCarryforwardExpirationYear" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:type="locator" xlink:label="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_AccruedMilestonePaymentObligation" xlink:type="locator" xlink:label="dyn_AccruedMilestonePaymentObligation" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ContractualAgreementsPossibleSecondMilestonePayment" xlink:type="locator" xlink:label="dyn_ContractualAgreementsPossibleSecondMilestonePayment" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_ContractualAgreementsMilestonePayment" xlink:type="locator" xlink:label="dyn_ContractualAgreementsMilestonePayment" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_CollaborativeAgreementUpfrontPayments" xlink:type="locator" xlink:label="dyn_CollaborativeAgreementUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLeasePeriodOfExtension" xlink:type="locator" xlink:label="dyn_OperatingLeasePeriodOfExtension" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLeaseIncreaseInMonthlyRentExpense" xlink:type="locator" xlink:label="dyn_OperatingLeaseIncreaseInMonthlyRentExpense" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_OperatingLeaseMonthlyRentExpense" xlink:type="locator" xlink:label="dyn_OperatingLeaseMonthlyRentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_FacilityAdditionalAreaLeased" xlink:type="locator" xlink:label="dyn_FacilityAdditionalAreaLeased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="dyn-20201231.xsd#dyn_LeaseExecutedDate" xlink:type="locator" xlink:label="dyn_LeaseExecutedDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_LeaseExecutedDate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_FacilityAdditionalAreaLeased" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_OperatingLeaseMonthlyRentExpense" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_OperatingLeaseIncreaseInMonthlyRentExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_OperatingLeasePeriodOfExtension" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_CollaborativeAgreementUpfrontPayments" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_ContractualAgreementsMilestonePayment" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_ContractualAgreementsPossibleSecondMilestonePayment" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="dyn_AccruedMilestonePaymentObligation" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="dyn-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038372857912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Dyne Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4883909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">830 Winter Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">786-8230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,457,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DYN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2021 Annual Meeting of Stockholders within 120 days of the end of the Registrant&#8217;s fiscal year ended December&#160;31, 2020. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038373009720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 300,852,000<span></span>
</td>
<td class="nump">$ 14,632,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">44,462,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,773,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">349,087,000<span></span>
</td>
<td class="nump">14,759,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,946,000<span></span>
</td>
<td class="nump">1,486,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_RestrictedCashAndOtherAssetsNoncurrent', window );">Restricted cash and other assets</a></td>
<td class="nump">2,301,000<span></span>
</td>
<td class="nump">191,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">353,334,000<span></span>
</td>
<td class="nump">16,436,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,440,000<span></span>
</td>
<td class="nump">1,256,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,527,000<span></span>
</td>
<td class="nump">1,102,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,967,000<span></span>
</td>
<td class="nump">2,358,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,967,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 and 68,000,000 shares authorized at December 31, 2020 and 2019, respectively; 45,446,903 and 3,239,017 shares issued and 45,076,574 and 2,586,535 shares outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">421,572,000<span></span>
</td>
<td class="nump">6,352,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(79,183,000)<span></span>
</td>
<td class="num">(19,746,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">342,367,000<span></span>
</td>
<td class="nump">14,036,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 353,334,000<span></span>
</td>
<td class="nump">16,436,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,429,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_RestrictedCashAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_RestrictedCashAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371742056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">68,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">45,446,903<span></span>
</td>
<td class="nump">3,239,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">45,076,574<span></span>
</td>
<td class="nump">2,586,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038377404792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 45,200<span></span>
</td>
<td class="nump">$ 11,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,447<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">58,647<span></span>
</td>
<td class="nump">13,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(58,647)<span></span>
</td>
<td class="num">(13,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="num">(396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ChangesInFairValueOfPreferredStockTrancheObligations', window );">Change in fair value of preferred stock tranche obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ChangesInSuccessFeeObligation', window );">Change in success fee obligation</a></td>
<td class="num">(450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(790)<span></span>
</td>
<td class="num">(1,033)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,437)<span></span>
</td>
<td class="num">$ (14,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (4.13)<span></span>
</td>
<td class="num">$ (6.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">14,395,955<span></span>
</td>
<td class="nump">2,442,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,437)<span></span>
</td>
<td class="num">$ (14,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized losses on marketable securities</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (59,464)<span></span>
</td>
<td class="num">$ (14,859)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ChangesInFairValueOfPreferredStockTrancheObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of preferred stock tranche obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ChangesInFairValueOfPreferredStockTrancheObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ChangesInSuccessFeeObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in success fee obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ChangesInSuccessFeeObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369524632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series B Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="num">$ (4,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,887)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,110,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A redeemable convertible preferred stock, net of issuance costs of $0.1 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A redeemable convertible preferred stock, net of issuance costs of $0.1 million, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_SettlementOfTrancheRightOne', window );">Settlement of Tranche Right I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of redeemable convertible preferred stock and preferred stock tranche obligations</a></td>
<td class="nump">33,748<span></span>
</td>
<td class="num">$ (27,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ReclassificationsOfTemporaryToPermanentEquityShares', window );">Reclassification of redeemable convertible preferred stock and preferred stock tranche obligations, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_StockIssuedDuringPeriodSharesRestrictedStockVested', window );">Vesting of restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,859)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">14,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,746)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,586,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="nump">246,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,467<span></span>
</td>
<td class="nump">$ 115,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,467<span></span>
</td>
<td class="nump">$ 115,319<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">246,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500,000<span></span>
</td>
<td class="nump">41,159,724<span></span>
</td>
<td class="nump">14,089,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (162,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">162,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,159,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,086,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">32,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 6,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_StockIssuedDuringPeriodSharesRestrictedStockVested', window );">Vesting of restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on marketable securities</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(59,437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,437)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 342,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 421,572<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">$ (79,183)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,076,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ReclassificationsOfTemporaryToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassifications of temporary to permanent equity, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ReclassificationsOfTemporaryToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_SettlementOfTrancheRightOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of tranche right one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_SettlementOfTrancheRightOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_StockIssuedDuringPeriodSharesRestrictedStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares restricted stock vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_StockIssuedDuringPeriodSharesRestrictedStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=120519210&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371750856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dyn_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dyn_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dyn_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038373009528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (59,437)<span></span>
</td>
<td class="num">$ (14,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,591<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities', window );">Amortization (accretion) of premium (discount) on marketable securities</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ChangesInFairValueOfPreferredStockTrancheObligations', window );">Changes in fair value of preferred stock tranche obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ChangesInSuccessFeeObligation', window );">Changes in success fee obligation</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,455)<span></span>
</td>
<td class="num">(284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="nump">8,567<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46,508)<span></span>
</td>
<td class="num">(11,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,161)<span></span>
</td>
<td class="num">(1,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(44,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(45,661)<span></span>
</td>
<td class="num">(1,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering of common stock, net of issuance costs</a></td>
<td class="nump">246,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_PaymentsForSettlementOfSuccessFeeObligation', window );">Settlement of success fee obligation</a></td>
<td class="num">(450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">134,786<span></span>
</td>
<td class="nump">19,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of debt, net of issuance costs</a></td>
<td class="nump">9,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">380,690<span></span>
</td>
<td class="nump">19,989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">288,521<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">14,632<span></span>
</td>
<td class="nump">8,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">303,153<span></span>
</td>
<td class="nump">14,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_CashPaidForInterestAndIncomeTaxes', window );">Cash paid for interest and taxes</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity', window );">Reclassification of preferred stock tranche obligation liability to permanent equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="nump">$ 162,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_SettlementsOfTrancheRightOne', window );">Settlement of Tranche Right I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization (accretion) of premium (discount) on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_AmortizationAccretionOfPremiumDiscountOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_CashPaidForInterestAndIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for interest and income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_CashPaidForInterestAndIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ChangesInFairValueOfPreferredStockTrancheObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of preferred stock tranche obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ChangesInFairValueOfPreferredStockTrancheObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ChangesInSuccessFeeObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in success fee obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ChangesInSuccessFeeObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_PaymentsForSettlementOfSuccessFeeObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for settlement of success fee obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_PaymentsForSettlementOfSuccessFeeObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of preferred stock tranche obligation liability to permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ReclassificationOfPreferredStockTrancheObligationLiabilityToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_SettlementsOfTrancheRightOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlements of tranche right one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_SettlementsOfTrancheRightOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038450014888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of business and basis of presentation </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dyne Therapeutics, Inc. (the &#8220;Company&#8221;) is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases that was incorporated in Delaware on December 1, 2017 and has a principal place of business in Waltham, Massachusetts.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, fluctuations in operating results, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes, the impact of the COVID-19 pandemic and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of a product. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 21, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold 14,089,314 shares of its common stock, including 1,837,736 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $19.00 per share, resulting in net proceeds of $246.4 million, after deducting underwriting discounts and commissions and offering expenses. Upon the closing of the IPO, all of the Company&#8217;s then outstanding convertible preferred stock automatically converted into shares of common stock.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 25, 2021, the Company completed a follow-on public offering of common stock pursuant to which it issued and sold 6,000,000 shares of its common stock at a public offering price of $28.00 per share, resulting in net proceeds of $157.3 million, after deducting underwriting discounts and commissions and offering expenses. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations with proceeds from the sales of preferred stock and common stock, including the IPO completed in September 2020 and the follow-on offering completed in January 2021. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance of these consolidated financial statements.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To continue its development efforts, the Company will need to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements in order to fund its research and development and ongoing operating expenses. The Company may not be able to obtain financing on acceptable terms, when needed or at all, and the Company may not be able to enter into collaborations, strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Any collaborations, strategic alliances or licensing arrangements may require the Company to relinquish rights to certain of its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to obtain funding, the Company could be forced to delay, limit, reduce or eliminate some or all of its research and development programs, pipeline expansion or future commercialization efforts or grant rights to develop and market product candidates, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has not experienced material business disruptions, including with its vendors, as a result of the COVID-19 pandemic. In March 2020, the Company implemented a remote working policy for many of its employees and began restricting non-essential travel, and on May 18, 2020, when Massachusetts began its staged reopening plan, the Company began implementing a return-to-work plan, in accordance with the guidance and requirements of federal and state authorities. The Company expects to continue to take actions as may be required or recommended by government authorities or as it determines are in the best interests of its employees and other business partners. The Company is continuing to monitor the potential impact of the pandemic, but cannot be certain what the overall impact will be on its business, financial condition, results of operations and prospects.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038452748424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of significant accounting policies </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements reflect the operations of the Company and the Company&#8217;s wholly owned subsidiary, Dyne Therapeutics Securities Corporation. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States of America. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentrations of credit risk and of significant suppliers</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company believes the depository institutions in which the cash and cash equivalents are held are of high-credit quality. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&#8217;s marketable securities as of December&#160;31, 2020 consisted of commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of any single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the development of its programs and future production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process.</p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash includes cash in readily available checking accounts and cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Restricted cash </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#8217;s leased facilities. Restricted cash totaled $2.3 million and $0.0 million at December 31, 2020 and 2019, respectively. These amounts are classified as restricted cash on the Company&#8217;s consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketable securities</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities as of December 31, 2020 consisted of commercial paper, certificates of deposit and corporate debt securities and are classified as available-for-sale and are reported at fair value. Unrealized losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#8220;other than temporary,&#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Deferred rent</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms.</p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnitures and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of life of lease or 10&nbsp;&nbsp;years</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. </p></div>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company has not recorded any impairment charges in the periods presented in these financial statements. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker is the chief executive officer (&#8220;CEO&#8221;). The CEO views the Company&#8217;s operations and manages the business as one operating segment. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are consumed or the services are performed. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and manufacturing contract costs and accruals</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent costs</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;2&#8212;Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level&#160;2 inputs include the following: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">quoted prices for similar assets and liabilities in active markets; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">quoted prices for identical or similar assets or liabilities in markets that are not active; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">observable inputs other than quoted prices that are used in the valuation of the asset or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals); and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">inputs that are derived principally from or corroborated by observable market data by correlation or other means. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs for the assets or liability (i.e., supported by little or no market activity). Level&#160;3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, the Company does not allocate loss to participating securities because they have no contractual obligation to share in the losses of the Company. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net income loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&#8217;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based awards at fair value, and measures fair value using the Black-Scholes option-pricing model. Stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period, on a straight-line basis for all time-vested awards. Forfeitures are recognized as they occur. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Success fee obligation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s loan and security agreement (the &#8220;Loan Agreement&#8221;) entered into in 2020 required the Company to pay a success fee of $0.5&#160;million upon the occurrence of a specified liquidity event, as described in the Loan Agreement, which included the Company&#8217;s IPO. The liability was initially deemed immaterial upon entering into the Loan Agreement and was subsequently remeasured to fair value at each reporting date. Following the completion of the IPO, the success fee of $0.5 million was paid in September 2020. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comprehensive loss </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended December&#160;31, 2020, the Company&#8217;s only element of other comprehensive loss was unrealized gains (losses) on marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Accounting pronouncements issued and not adopted </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The Company plans to adopt ASU 2016-02 on January 1, 2021 using the modified retrospective approach transition method as of the date of adoption such that prior periods will not be restated. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. The adoption of the new standard is expected to result in the recognition of material liabilities and right-of-use assets, however, the Company has not completed the assessment. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369622184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract', window );"><strong>Marketable Securities And Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3. Marketable securities and fair value measurements </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities by security type at December&#160;31, 2020 consisted of the following:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,572</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,489</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,462</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have marketable securities as of December&#160;31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth by level, within the fair value hierarchy (see Note 2), the assets carried at fair value on a recurring basis for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,017</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,017</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,309</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,309</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,359</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207,787</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of U.S. government money market funds and commercial paper were determined by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. Certificates of deposit and corporate debt securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the years ended December&#160;31, 2020 and 2019, there were no transfers between Level 1, Level 2 and Level 3. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the scheduled maturity for the Company&#8217;s marketable securities at December 31, 2020:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing in one year or less</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,623</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing after one year through two years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,147</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing after two years</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,770</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no sales of marketable securities during the year ending December&#160;31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the preferred stock tranche obligations in connection with the unfunded tranches associated with the Series A Preferred Stock Purchase Agreement (see Note 7) was determined based on significant inputs not observable in the market, which represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of the preferred stock tranche obligations was determined by considering as inputs the future value of the Series A Preferred Stock, the difference between the future value of the Series A Preferred Stock and the contract price, the number of shares underlying the contract, the probability of achieving the funding of the tranches, expected timing of the tranche closing and the discount rate. The future value of Series A Preferred Stock was estimated by calibrating, or backsolving, to the price of the Series A Preferred Stock as set forth in the Series A Preferred Stock Purchase Agreement. The contractual price of the shares to be issued in addition to the number of shares underlying the contract are both provided for by the Series A Preferred Stock Purchase Agreement. The probability of achieving the funding of the tranches and the expected timing of those closings were estimates made by the Company. The discount rate was equal to the risk-free rate for the estimated timing of each tranche closing. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the liability recognized in connection with the contingent success fee associated with the Loan Agreement (see Note 6) was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the liability was determined using the probability-weighted expected return method (&#8220;PWERM&#8221;), which considered as inputs the probability of occurrence of a specified liquidity event, the expected timing of a liquidity event, the amount of the success fee and a risk-adjusted discount rate. The initial fair value of the liability was de minimis due to the low probability of the events probable of triggering payment. As of September 21, 2020, the closing date of the IPO, the event occurred and the probability increased to 100% and the discount rate was assessed to be 0%. Based on these inputs, the Company determined that the fair value of the derivative liability was $0.5 million as of September 21, 2020. Following the completion of the IPO, the success fee of $0.5 million was paid in September 2020. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a roll-forward of the aggregate fair values of the Company&#8217;s liabilities for which fair value is determined by Level&#160;3 inputs: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock Tranche Obligations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Success Fee Obligation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;January 1, 2019</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of Tranche Right I</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,621</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,323</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of Tranche Right II to equity</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,319</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2019</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial fair value of success fee obligation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of derivative instrument</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Financial instruments not recorded at fair value </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of cash, cash equivalents, accounts payable and accrued expenses that are reported on the balance sheets approximate their fair value due to the short-term nature of these assets and liabilities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_MarketableSecuritiesAndFairValueMeasurementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038374493800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">4. Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,744</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,705</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment&#8212;at cost</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,941</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(295</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment&#8212;net</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,946</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,486</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense totaled $0.7 million and $0.3&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038449824008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">5. Accrued expenses and other current liabilities </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and benefits</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,105</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal services</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,782</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility costs</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038374326936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Financing<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Financing</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">6. Debt financing </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 20, 2020, the Company entered into a Loan Agreement pursuant to which the lender made term loans to the Company in an aggregate principal amount of $10.0 million. Borrowings under the Loan Agreement were collateralized by substantially all of the Company&#8217;s assets, excluding intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on the outstanding loan balance accrued at a variable annual rate equal to the greater of (i) the lender&#8217;s prime rate plus 0.25% and (ii) 5.00%, and the Company was required to make interest-only payments on the loans on a monthly basis through August 2021. The outstanding borrowings were repaid in October 2020.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Loan Agreement, a success fee of $0.5 million was required in the event of a liquidation event, including an IPO. The success fee represented an embedded derivative which the Company bifurcated from the debt arrangement and carried at fair value. In September 2020, the Company completed its IPO and paid the success fee of $0.5 million. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038373408104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">7. Convertible preferred stock </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company issued Series A convertible preferred stock (the &#8220;Series A Preferred Stock&#8221;) and Series B convertible preferred stock (the &#8220;Series B Preferred Stock&#8221;). Collectively the Series A Preferred Stock and the Series B Preferred Stock are referred to as the Preferred Stock. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO in September 2020, the Company&#8217;s Preferred Stock automatically converted into 28,086,375 shares of common stock.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Series A Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;29, 2018, the Company entered into the Series A Preferred Stock Purchase Agreement with its initial investors committing to purchase an aggregate of $50.0&#160;million in shares of Series A Preferred Stock. At the initial closing, 12,500,000 shares of Series A Preferred Stock were issued by the Company at a purchase price of $1.00 per share, for gross cash proceeds of $7.5&#160;million. Of the 12,500,000 shares issued, 5,000,000 shares were issued upon conversion of the then outstanding SAFEs, which had a fair value of $5.0&#160;million. In April 2019, the Company issued an additional 20,000,000 shares of Series A Preferred Stock under the terms of the Series A Preferred Stock Purchase Agreement at a purchase price of $1.00 per share for total gross proceeds of $20.0&#160;million. Issuance costs associated with each closing of the Series A Preferred Stock financing were $0.1&#160;million. On March&#160;18, 2020, the Company entered into a separate Series A Preferred Stock Purchase Agreement with an additional investor and issued 2,000,000 shares of Series A Preferred Stock at a purchase price $1.00 per share for gross cash proceeds of $2.0&#160;million. In July 2020, the Company issued and sold 17,500,000 shares of Series A Preferred Stock at a price of $1.00 per share, for gross proceeds of $17.5 million.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Series B Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company issued and sold 41,159,724 shares of Series B Preferred Stock at a price of $2.81 per share for gross proceeds of $115.7 million.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Tranche Rights</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in the terms of the November 2018 Series A Preferred Stock Purchase Agreement were certain rights (&#8220;Tranche Rights&#8221;) granted to the investors who purchased the Series A Preferred Stock purchased in November 2018. The Tranche Rights contingently obligated the investors to purchase, and the Company to sell, up to an aggregate of 37,500,000 shares of Series A Preferred Stock at $1.00 per share upon the satisfaction of specified research and development milestones by the Company. The Tranche Rights are also exercisable at the option of the holders of the Series A Preferred Stock. The Tranche Rights were divided into separate rights and obligations to purchase 20,000,000 shares (&#8220;Tranche Right I&#8221;) and 17,500,000 shares (&#8220;Tranche Right II&#8221;) based on the achievement of specified milestones for each tranche. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that the Tranche Rights met the definition of a freestanding financial instrument, as the Tranche Rights were legally detachable and separately exercisable from the Series A Preferred Stock. Therefore, the Company allocated the proceeds from the November 2018 issuance between the Tranche Rights and the Series A Preferred Stock. As the Series A Preferred Stock was redeemable upon a deemed liquidation event at the election of the holder-controlled Board, and therefore outside of the control of the Company, the Tranche Rights were initially classified as a liability and were initially recorded at their fair value of $3.4&#160;million. The Tranche Rights were then remeasured at fair value at each reporting period, with changes in fair value recorded in the statement of operations. The estimated fair value of the Tranche Rights was determined at each reporting date using a probability-weighted present value model that considers the probability of closing a tranche, the estimated future value of the Series A Preferred Stock to be issued at each closing, and the investment required at each closing. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, Tranche Right I was settled when the Company closed on the issuance of 20,000,000 shares Series A Preferred Stock. The fair value of the Tranche Right I as of the closing date was reclassified from a liability to Series A Preferred Stock within equity. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the size of the Board was increased from five to six members, including three independent members, which allowed the Company to conclude that the redemption rights of the holders of the Series A Preferred Stock was within the control of the Company. As a result, the Company concluded that Tranche Right II qualified for equity classification as of that date. The preferred stock tranche obligation liability, with a fair value of $6.3&#160;million, was reclassified into permanent equity and was no longer remeasured at fair value. In July 2020, Tranche Right II was settled when the Company closed on the issuance of 17,500,000 shares Series A Preferred Stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Preferred Stock had the followings rights and privileges: </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of the Preferred Stock were entitled to receive non-cumulative dividends when, as and if declared by the Board. The Company did not declare dividends on any class of preferred or common stock. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any liquidation, dissolution, or winding-up of the Company, which would include the sale of the Company, the Preferred Stock was senior to common stock. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Voting </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Preferred Stock were entitled to the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by each holder were then convertible. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Conversion </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Preferred Stock were able to convert, at any time, each share of Preferred Stock into shares of common stock at the stated conversion price. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038374326936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">8. Equity </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company&#8217;s restated certificate of incorporation authorized the Company to issue 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had authorized 68,000,000 shares of common stock. The voting,<font style="Background-color:#FFFFFF;color:#000000;"> dividend and liquidation rights of the holders of the Company&#8217;s common stock was subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock as set forth above.</font> </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038473792984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">9. Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2018 Stock incentive plan </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;) provided for the Company to sell or issue incentive stock options or nonqualified stock options, restricted stock, and other equity awards to employees, directors and consultants of the Company. The 2018 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of the board of directors.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total number of shares of common stock authorized under the 2018 Plan was 8,267,252 shares. Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under the 2018 Plan, and the 1,928,487 shares of common stock remaining under the 2018 Plan became available for future issuance under the 2020 Plan. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2020 Stock incentive plan </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020 the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2020 Plan (together with the 2018 Plan the &#8220;Plans&#8221;), which became effective on September 16, 2020. The 2020 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards to employees, directors, consultants and advisors of the Company. The 2020 Plan is administered by the Company&#8217;s board of directors or by a committee appointed by the board of directors. Upon the effectiveness of the 2020 Plan, the Company ceased granting awards under the 2018 Plan. The number of shares initially reserved for issuance under the 2020 Plan was 4,884,233. The number of shares of common stock reserved for issuance under the 2020 Plan automatically increases on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030, in an amount equal to the lower of (1) 5% of the shares of common stock outstanding on such date and (2) an amount determined by the Company&#8217;s board of directors. On January 1, 2021, 2,272,345 shares were added to the shares reserved for issuance under the 2020 Plan in the first of these annual increases.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, 3,237,244 shares remained available for future issuance under the 2020 Plan. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020 the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;), which became effective September 16, 2020. The 2020 ESPP is administered by the Company&#8217;s board of directors or by a committee appointed by the board of directors. The 2020 ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of 488,414 shares of common stock. The number of shares of common stock reserved for issuance under the 2020 ESPP will automatically increase on the first day of each fiscal year, beginning with the fiscal year commencing on January 1, 2021 and continuing for each fiscal year until, and including the fiscal year commencing on, January 1, 2030, in an amount equal to the lowest of (1) 1,953,656 shares of common stock, (2) 1% of the shares of common stock outstanding on such date, and (3) an amount determined by the board of directors. As of December&#160;31, 2020, no offering periods have commenced under the 2020 ESPP and 488,414 shares remained available for issuance.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock option valuation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company typically grants stock options at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time of grant. In the periods prior to the IPO, the fair value of the common stock was determined by the Board at each measurement date based on a variety of different factors, including the results obtained from independent third-party appraisals, the Company&#8217;s financial position and historical financial performance, the status of development of the Company&#8217;s programs, the current climate in the marketplace, the illiquid nature of the common stock, the effect of the rights and preferences of the preferred stockholders, and the prospects of a liquidity event, among others.&#160;&#160;In the periods following the IPO, the fair value is determined based upon the quoted price of the Company&#8217;s common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of options granted were as follows:<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75%</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74%</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% &#8212; 1.67%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46% &#8212; 2.50%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Stock option activity</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the option activity: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding January 1, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311,303</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.93</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,252,967</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,197</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.93</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110,484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding December 31, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.97</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,112</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable&#8212; December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,925</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,282</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested or expected to vest&#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.97</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,112</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of the options granted during the years ended December&#160;31, 2020 and 2019 was $4.50&#160;per share and $0.62 per share, respectively. As of December&#160;31, 2020 there was $20.3 million&#160;of unrecognized compensation expense, which the Company expects to recognize over&#160;a&#160;weighted-average&#160;period&#160;of&#160;2.71&#160;years. Additionally, as of December&#160;31, 2020, the Company has unrecognized compensation cost related to unvested stock-based awards with performance-based vesting conditions for which performance has not been deemed probable of $2.6 million.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Restricted stock units</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A restricted stock unit (&#8220;RSU&#8221;) represents the right to receive one share of common stock upon vesting of the RSU. The Company grants RSUs with service conditions that vest in four equal annual installments provided that the employee remains employed with the Company. The Company also grants RSUs with performance conditions that vest upon the achievement of specified milestones. The fair value of each RSU is based on the closing price of the Company&#8217;s common stock on the date of grant. A summary of the Company&#8217;s RSU activity and related information for the 2020 Plan for the year ended December&#160;31, 2020 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of January 1, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.60</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.60</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $7.7 million of unrecognized compensation costs &#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;related to unvested RSUs, which are expected to be recognized over a weighted-average period of 2.75 years. Additionally, as of December&#160;31, 2020, the Company has unrecognized compensation cost of $0.6 million related to unvested stock-based awards with performance-based vesting conditions for which performance has not been deemed probable.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Restricted common stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2018, the Company granted restricted common stock with service-based vesting conditions. Shares of unvested restricted common stock may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting conditions of each award. The grant date fair value of these shares was immaterial. The following table summarizes the Company&#8217;s restricted common stock award activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of Restricted&#160;Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of January 1, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,482</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(282,153</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,329</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense in the following expense categories of its statements of operations: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,699</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,892</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038373408104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">10. Income taxes </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no provision for income taxes because the Company has historically incurred net operating losses and maintains a full valuation allowance against its deferred tax assets. The reported amount of income tax expense/benefit for the years ended December&#160;31, 2020 and 2019 differs from the amount that would result from applying domestic federal statutory rates to pretax losses primarily because of changes in the valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax expense at statutory rate</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes&#8212;net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche obligations</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal &amp; state R&amp;D credits</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets at December&#160;31, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended&#160;December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,349</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,858</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,848</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">612</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,942</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,634</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,899</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,607</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets (liabilities)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had federal and state net operating loss carryforwards of $69.1 million and $68.9 million, respectively.&nbsp;&nbsp;The federal net operating loss carryforwards are indefinite lived and the state net operating loss carryforwards begin to expire in 2038. As of December 31, 2020, the Company also had federal and state research and development tax credit carryforwards $0.8 million and $0.4 million, respectively, which begin to expire in 2039 and 2033, respectively.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and concluded that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2020 and 2019. The increase in the valuation allowance for deferred tax assets during the years ended December 31, 2020 and 2019 totaled $16.3 million and $4.2 million, respectively, and related primarily to the increase in net operating loss carryforwards. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to record estimated interest and penalties related to uncertain tax positions in income tax expense. The Company has no amounts recorded for any unrecognized tax positions, accrued interest or penalties as of December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates, including the United States and the Commonwealth of Massachusetts. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#8217;s tax returns are open under statute from 2018 to the present. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038449925064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">11. Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,395,955</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,442,872</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.13</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.08</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311,303</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,329</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,482</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,798,298</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,195,273</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,762,083</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038450001448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">12. Commitments and contingencies </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Operating leases </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a sublease agreement for laboratory and office space in Waltham, Massachusetts. The term of the sublease commenced on July&#160;1, 2019 and expires on December&#160;31, 2021.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into a lease agreement (the &#8220;Lease&#8221;), pursuant to which the Company will lease approximately 68,187 square feet of additional office and laboratory space located in Waltham, Massachusetts (the &#8220;Premises&#8221;). The Lease will have a term of eight years and six months that will commence when the Premises are ready for occupancy. The Company&#8217;s obligation for the payment of base rent for the Premises begins six months after the commencement date and will be $0.4 million per month, increasing up to $0.5 million during the term of the Lease. The Company has two options to extend the term of the Lease, each for a period of an additional five years. The Company expects the Premises to be ready for occupancy in the second half of 2021.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense for the years ended December&#160;31, 2020 and 2019 totaled $0.8&#160;million and $0.7&#160;million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under the non-cancelable operating leases consisted of the following as of December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2021</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,603</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2023</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,741</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,883</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2025</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,728</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Legal proceedings </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any such legal proceedings. </p>
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Other contractual obligations </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancelable by the Company upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancelable obligations of the service providers, up to the date of cancellation and in the case of certain arrangements may include non-cancelable fees. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has also entered into a license agreement (the &#8220;UMONS Agreement&#8221;) with the University of Mons (&#8220;UMONS&#8221;) in April 2020, pursuant to which UMONS granted to the Company an exclusive, worldwide license to certain patents and patent applications and a non-exclusive, worldwide license to existing, related know-how. Each of the issued patents licensed to the Company under the UMONS Agreement is scheduled to expire in 2031. The licenses under the UMONS Agreement confer on the Company the right to research, develop and commercialize products (&#8220;licensed products&#8221;), and to practice processes, in each case, covered by the licensed patents and existing, related know-how. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UMONS Agreement, the Company is obligated to use commercially reasonable efforts to develop at least one licensed product and, to the extent regulatory approval is obtained in such jurisdictions, to commercialize at least one licensed product in the United States and the United Kingdom or a member country of the European Union. Unless terminated earlier, the UMONS Agreement will remain in effect until the last to expire of the licensed patent rights on a licensed product-by-licensed product and country-by-country basis. UMONS may terminate the UMONS Agreement in the event of a material breach by the Company and the Company&#8217;s failure to cure such breach within a specified time period. The Company may voluntarily terminate the UMONS Agreement with prior notice to UMONS. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entry into the UMONS Agreement, the Company paid UMONS an upfront payment of &#8364;0.1 million. The Company also agreed to make milestone payments to UMONS upon the achievement of specified development and regulatory milestones up to a maximum aggregate total of &#8364;0.4 million for the first licensed product to achieve such milestones and up to a maximum aggregate total of &#8364;0.2 million for each subsequent licensed product to achieve each such milestones, as well as a low single-digit percentage royalty on net sales of licensed products by the Company, its affiliates and sublicensees. These royalty obligations continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the last licensed patent rights covering such licensed product in such country. In addition, if the Company sublicenses rights under the UMONS Agreement, the Company is required to pay a low double-digit percentage of the sublicense revenue to UMONS. Additionally, if the Company chooses to file, prosecute or maintain any patents included in the licensed patent rights under the UMONS Agreement, it will be required to bear the full cost and expenses of preparing, filing, prosecuting and maintaining any such patents. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No amounts have been accrued under this arrangement with respect to potential milestone payment obligations or royalty obligations given the uncertainty of achieving the specified milestones and commercial sales of any licensed products. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038452761768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">13. Subsequent events </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2020, subsequent events were evaluated through March 4, 2021, the date on which the audited consolidated financial statements were issued. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038377270088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and of Significant Suppliers</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentrations of credit risk and of significant suppliers</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company believes the depository institutions in which the cash and cash equivalents are held are of high-credit quality. The Company maintains its cash equivalents in money market funds that invest in U.S. treasury securities. The Company&#8217;s marketable securities as of December&#160;31, 2020 consisted of commercial paper and corporate debt securities. The Company has adopted an investment policy that limits the amounts the Company may invest in the securities of any single issuer with the exclusion of the U.S. government. The Company has not experienced any credit losses.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on a small number of third-party suppliers for its drug substance and drug product. In particular, the Company relies, and expects to continue to rely, on third-party suppliers for certain materials and components required for the development of its programs and future production of any product candidates it may develop for its programs. These programs could be adversely affected by a significant interruption in the supply process.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash includes cash in readily available checking accounts and cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Restricted cash </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#8217;s leased facilities. Restricted cash totaled $2.3 million and $0.0 million at December 31, 2020 and 2019, respectively. These amounts are classified as restricted cash on the Company&#8217;s consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Marketable securities</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities as of December 31, 2020 consisted of commercial paper, certificates of deposit and corporate debt securities and are classified as available-for-sale and are reported at fair value. Unrealized losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#8220;other than temporary,&#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Deferred rent</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment escalations, rent holidays and other lease incentives that may be included in lease agreements are accrued or deferred as appropriate such that rent expense for each lease is recognized on a straight-line basis over the respective lease term. Adjustments for such items are recorded as deferred rent and amortized over the respective lease terms.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnitures and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of life of lease or 10&nbsp;&nbsp;years</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance which do not improve or extend the life of the respective assets are charged to expense as incurred. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. The Company evaluates the recoverability of its long-lived assets when circumstances indicate that an event of impairment may have occurred. The Company recognizes an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows. Impairment is measured based on the difference between the carrying value of the related assets and the fair value of such assets. The Company has not recorded any impairment charges in the periods presented in these financial statements. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker is the chief executive officer (&#8220;CEO&#8221;). The CEO views the Company&#8217;s operations and manages the business as one operating segment. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation and amortization, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities as well as the cost of licensing technology.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are consumed or the services are performed. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock', window );">Research and Manufacturing Contract Costs and Accruals</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Research and manufacturing contract costs and accruals</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development and manufacturing contracts. These agreements are generally cancelable, and related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the research studies and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Patent costs</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.<font style="color:#000000;"> </font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;2&#8212;Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level&#160;2 inputs include the following: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">quoted prices for similar assets and liabilities in active markets; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">quoted prices for identical or similar assets or liabilities in markets that are not active; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">observable inputs other than quoted prices that are used in the valuation of the asset or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals); and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">inputs that are derived principally from or corroborated by observable market data by correlation or other means. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.62%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs for the assets or liability (i.e., supported by little or no market activity). Level&#160;3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, the Company does not allocate loss to participating securities because they have no contractual obligation to share in the losses of the Company. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net income loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&#8217;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based awards at fair value, and measures fair value using the Black-Scholes option-pricing model. Stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period, on a straight-line basis for all time-vested awards. Forfeitures are recognized as they occur. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_SuccessFeeObligationPolicyTextBlock', window );">Success Fee Obligation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Success fee obligation </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s loan and security agreement (the &#8220;Loan Agreement&#8221;) entered into in 2020 required the Company to pay a success fee of $0.5&#160;million upon the occurrence of a specified liquidity event, as described in the Loan Agreement, which included the Company&#8217;s IPO. The liability was initially deemed immaterial upon entering into the Loan Agreement and was subsequently remeasured to fair value at each reporting date. Following the completion of the IPO, the success fee of $0.5 million was paid in September 2020. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Comprehensive loss </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended December&#160;31, 2020, the Company&#8217;s only element of other comprehensive loss was unrealized gains (losses) on marketable securities. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Issued and Not Adopted</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Accounting pronouncements issued and not adopted </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The Company plans to adopt ASU 2016-02 on January 1, 2021 using the modified retrospective approach transition method as of the date of adoption such that prior periods will not be restated. The Company will also elect a package of practical expedients, under which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, or initial direct costs for any existing leases. The adoption of the new standard is expected to result in the recognition of material liabilities and right-of-use assets, however, the Company has not completed the assessment. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and manufacturing contract costs and accruals policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_SuccessFeeObligationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success Fee Obligation Policy[Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_SuccessFeeObligationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038452741096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule Of Property Plant And Equipment Estimated Useful Lives</a></td>
<td class="text">Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furnitures and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of life of lease or 10&nbsp;&nbsp;years</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038377603112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract', window );"><strong>Marketable Securities And Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Marketable Securities by Security Type</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities by security type at December&#160;31, 2020 consisted of the following:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,572</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,489</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,462</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Assets Carried at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth by level, within the fair value hierarchy (see Note 2), the assets carried at fair value on a recurring basis for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,017</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,017</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,309</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,309</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,412</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,545</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,359</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207,787</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,420</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Scheduled Maturity for Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the scheduled maturity for the Company&#8217;s marketable securities at December 31, 2020:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing in one year or less</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,623</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing after one year through two years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,147</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing after two years</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,770</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Roll-forward of Aggregate Fair Values of Liabilities Determined by Level 3 Inputs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a roll-forward of the aggregate fair values of the Company&#8217;s liabilities for which fair value is determined by Level&#160;3 inputs: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock Tranche Obligations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Success Fee Obligation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;January 1, 2019</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of Tranche Right I</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,621</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,323</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of Tranche Right II to equity</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,319</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2019</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial fair value of success fee obligation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlement of derivative instrument</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(450</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance&#8212;December 31, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038377858872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,744</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,705</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment&#8212;at cost</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,941</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(295</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment&#8212;net</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,946</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,486</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038374429800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and benefits</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,105</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal services</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,782</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility costs</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,527</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371584936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Determine Grant-Date Fair Value of Options Granted</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of options granted were as follows:<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75%</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74%</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% &#8212; 1.67%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46% &#8212; 2.50%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity and Related Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the option activity: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding January 1, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311,303</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.93</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,252,967</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,197</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.93</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110,484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding December 31, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.97</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,112</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable&#8212; December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,925</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,282</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested or expected to vest&#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.97</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,112</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">A summary of the Company&#8217;s RSU activity and related information for the 2020 Plan for the year ended December&#160;31, 2020 is as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying RSUs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of January 1, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.60</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.60</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Restricted Common Stock Award Activity</a></td>
<td class="text">The following table summarizes the Company&#8217;s restricted common stock award activity for the year ended December&#160;31, 2020:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of Restricted&#160;Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of January 1, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,482</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(282,153</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued and unvested as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,329</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense in the following expense categories of its statements of operations: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,699</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,892</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038460261848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax expense at statutory rate</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes&#8212;net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock tranche obligations</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal &amp; state R&amp;D credits</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets at December&#160;31, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended&#160;December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,349</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,858</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,848</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">612</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,942</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,634</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,899</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,607</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets (liabilities)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369456792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,437</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,859</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,395,955</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,442,872</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.13</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.08</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Securities Excluded From Calculation Of Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,421,589</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311,303</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,329</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,482</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,355</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,798,298</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,195,273</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,762,083</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038374640456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under the non-cancelable operating leases consisted of the following as of December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2021</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,603</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2023</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,741</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,883</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2025</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,728</p></td>
<td valign="bottom" bgcolor="#DDEBF7" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038368441224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Sep. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  01,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,089,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_UnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters option to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,837,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dyn_FollowOnPublicOfferingMember', window );">Follow-on Public Offering | Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued and sold</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 157.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_NatureOfBusinessAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of business and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_NatureOfBusinessAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_UnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_UnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dyn_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dyn_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038368448824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 21, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_CashAndCashEquivalentsMaturityPeriod', window );">Cash and cash equivalent maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_SuccessFeePaid', window );">Success fee paid</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dyn_LoanAgreementMember', window );">Loan Agreement | Pacific Western Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_SuccessFeePaid', window );">Success fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_CashAndCashEquivalentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_CashAndCashEquivalentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_SuccessFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success fee paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_SuccessFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dyn_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dyn_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=dyn_PacificWesternBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=dyn_PacificWesternBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371811608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furnitures and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, plant and equipment, useful life</a></td>
<td class="text">Shorter of life of lease or 10  years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038370228440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Security Type (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 44,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">44,462,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">6,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">1,504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">36,572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total</a></td>
<td class="nump">$ 36,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369605240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 21, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,462,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_FairValueAssetsTransfersAmount', window );">Fair value assets, transfers among level 1, level 2 or level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_FairValueLiabilityPaymentPercentage', window );">Fair value liability, payment percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value of derivative liability</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_SuccessFeePaid', window );">Success fee paid</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_FairValueAssetsTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_FairValueAssetsTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_FairValueLiabilityPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value liability, payment percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_FairValueLiabilityPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_SuccessFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success fee paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_SuccessFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369795880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Summary of Assets Carried at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 207,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">164,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">43,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">155,017<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">155,017<span></span>
</td>
<td class="nump">$ 14,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Level 1 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents | Level 2 | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">36,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities | Level 1 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities | Level 2 | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">36,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities | Level 2 | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 1,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dyn_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dyn_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371692328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Summary of Scheduled Maturity for Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract', window );"><strong>Marketable Securities And Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 28,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue', window );">Maturing after one year through two years</a></td>
<td class="nump">24,147<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 52,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale debt securities maturity after year one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_MarketableSecuritiesAndFairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369610184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Roll-forward of Aggregate Fair Values of Liabilities Determined by Level 3 Inputs (Details) - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Preferred Stock Tranche Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance&#8212;January 1, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity', window );">Reclassification of Tranche Right II to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,319)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Preferred Stock Tranche Obligations | Tranche Right I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Success Fee Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Success Fee Obligation | Derivative Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement</a></td>
<td class="num">$ (450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis reclassification of tranche right two to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfTrancheRightTwoToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=dyn_PreferredStockTrancheObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=dyn_PreferredStockTrancheObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dyn_TrancheRightOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dyn_TrancheRightOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=dyn_SuccessFeeObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=dyn_SuccessFeeObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369734824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment&#8212;at cost</a></td>
<td class="nump">$ 2,941<span></span>
</td>
<td class="nump">$ 1,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(995)<span></span>
</td>
<td class="num">(295)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment&#8212;net</a></td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment&#8212;at cost</a></td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_OfficeAndComputerEquipmentMember', window );">Office and Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment&#8212;at cost</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment&#8212;at cost</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment&#8212;at cost</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dyn_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038450037400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038374650216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and benefits</a></td>
<td class="nump">$ 2,105<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_AccruedConsultingServicesCurrent', window );">Consulting services</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal services</a></td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development</a></td>
<td class="nump">4,782<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_AccruedFacilityCostsCurrent', window );">Facility costs</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 7,527<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_AccruedConsultingServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued consulting services current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_AccruedConsultingServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_AccruedFacilityCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued facility costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_AccruedFacilityCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371811416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Financing - Additional Information (Details) - Term Loan - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 20, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity under loan agreement</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Credit facility, interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest on the outstanding loan balance accrued at a variable annual rate equal to the greater of (i) the lender&#8217;s prime rate plus 0.25% and (ii) 5.00%, and the Company was required to make interest-only payments on the loans on a monthly basis through August 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt instrument, frequency of periodic payment of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">interest-only payments on the loans on a monthly basis<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility, variable interest rate spread</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Credit facility, interest rate during period</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Success fee required to pay in the event of liquidation, including IPO</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_DebtInstrumentSuccessFeePaid', window );">Success fee paid after IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_DebtInstrumentSuccessFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument success fee paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_DebtInstrumentSuccessFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=dyn_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=dyn_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038368951432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 18, 2020</div></th>
<th class="th"><div>Nov. 29, 2018</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,786<span></span>
</td>
<td class="nump">$ 19,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_PurchasesOfSharesValue', window );">Purchase of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Convertible preferred stock, price per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_PreferredStockFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_StockIssuanceCost', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Series A Convertible Preferred Stock | Tranche Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_PreferredStockFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Series A Convertible Preferred Stock | Tranche Right | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Series A Convertible Preferred Stock | Tranche Right I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Series A Convertible Preferred Stock | Tranche Right II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,159,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Convertible preferred stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,086,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,089,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_PreferredStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_PreferredStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_PurchasesOfSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases Of Shares Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_PurchasesOfSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_StockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_StockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dyn_TrancheRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dyn_TrancheRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dyn_TrancheRightOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dyn_TrancheRightOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dyn_TrancheRighttwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dyn_TrancheRighttwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038377814520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">68,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369884376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 16, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share based compensation expense, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable', window );">Unrecognized compensation cost related to unvested stock-based awards with performance-based vesting conditions for which performance conditions not deemed probable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units ("RSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share based compensation expense, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable', window );">Unrecognized compensation cost related to unvested stock-based awards with performance-based vesting conditions for which performance conditions not deemed probable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting', window );">Number of share of common stock receivable upon vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares of common stock authorized</a></td>
<td class="nump">488,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares increased annually under the plan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance', window );">Increase in common stock reserved for future issuance</a></td>
<td class="nump">1,953,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,267,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyn_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,237,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares initially reserved for issuance</a></td>
<td class="nump">4,884,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares increased annually under the plan</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyn_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Plan | Restricted Stock Units ("RSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments', window );">Share-based Compensation Arrangement By Share-based Payment Award Grant Service Conditions to Vest Number of Annual Installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company grants RSUs with service conditions that vest in four equal annual installments provided that the employee remains employed with the Company. The Company also grants RSUs with performance conditions that vest upon the achievement of specified milestones<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dyn_TwoThousandTwentyStockIncentivePlanMember', window );">2020 Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares initially reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,272,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost not yet recognized performance conditions not probable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPerformanceConditionsNotProbable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award grant service conditions to vest number of annual installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantServiceConditionsToVestNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, number of shares of common stock receivable upon vesting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockReceivableUponVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold limit for increase in common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ThresholdLimitForIncreaseInCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dyn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dyn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dyn_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dyn_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038377351304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used to Determine Grant-Date Fair Value of Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.31%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369750968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period</a></td>
<td class="nump">311,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">6,252,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(32,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled</a></td>
<td class="num">(110,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period</a></td>
<td class="nump">6,421,589<span></span>
</td>
<td class="nump">311,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable&#8212; December 31, 2020</a></td>
<td class="nump">447,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested or expected to vest&#8212; December 31, 2020</a></td>
<td class="nump">6,421,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period</a></td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled</a></td>
<td class="nump">1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period</a></td>
<td class="nump">6.97<span></span>
</td>
<td class="nump">$ 0.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable&#8212; December 31, 2020</a></td>
<td class="nump">4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested or expected to vest&#8212; December 31, 2020</a></td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable&#8212; December 31, 2020</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested or expected to vest&#8212; December 31, 2020</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 90,112<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable&#8212; December 31, 2020</a></td>
<td class="nump">7,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested or expected to vest&#8212; December 31, 2020</a></td>
<td class="nump">$ 90,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038452715240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Details) - Restricted Stock Units ("RSUs") - 2020 Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Underlying RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">403,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Issued and unvested as of December 31, 2020 | shares</a></td>
<td class="nump">403,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">$ 23.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Issued and unvested as of December 31, 2020 | $ / shares</a></td>
<td class="nump">$ 23.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dyn_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dyn_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038377146424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Common Stock Award Activity (Details) - Restricted Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Issued and unvested as of January 1, 2020</a></td>
<td class="nump">652,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(282,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Issued and unvested as of December 31, 2020</a></td>
<td class="nump">370,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371796152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,591<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,699<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,892<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038472368184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective income tax rate reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes&#8212;net of federal benefit</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations', window );">Change in fair value of preferred stock tranche obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Other permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal &amp; state R&amp;D credits</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in valuation allowance</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="num">(28.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Fair Value of Preferred Stock Tranche Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockTrancheObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038372942808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,349<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">18,858<span></span>
</td>
<td class="nump">4,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credit carryforwards</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">21,942<span></span>
</td>
<td class="nump">5,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21,899)<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371770504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance for deferred tax assets</a></td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax positions, accrued interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax returns open year</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 69,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal | Research and Developments Tax Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_TaxCreditCarryforwardExpirationYear', window );">Research and development tax credit carryforwards expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 68,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research and Developments Tax Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_TaxCreditCarryforwardExpirationYear', window );">Research and development tax credit carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiration Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038371644328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,437)<span></span>
</td>
<td class="num">$ (14,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">14,395,955<span></span>
</td>
<td class="nump">2,442,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share&#8212;basic and diluted</a></td>
<td class="num">$ (4.13)<span></span>
</td>
<td class="num">$ (6.08)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of shares outstanding basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038369756568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential Dilutive Securities Excluded From Calculation Of Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7,195,273<span></span>
</td>
<td class="nump">10,762,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock (As Converted to Common Stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,798,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">6,421,589<span></span>
</td>
<td class="nump">311,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">370,329<span></span>
</td>
<td class="nump">652,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">403,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038368889288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_LeaseExecutedDate', window );">Lease executed date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2019<span></span>
</td>
<td class="text">Jul.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_FacilityAdditionalAreaLeased', window );">Additional leased office space | ft&#178;</a></td>
<td class="nump">68,187<span></span>
</td>
<td class="nump">68,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s obligation for the payment of base rent for the Premises begins six months after the commencement date and will be $0.4 million per month, increasing up to $0.5 million during the term of the Lease. The Company has two options to extend the term of the Lease, each for a period of an additional five years. The Company expects the Premises to be ready for occupancy in the second half of 2021.<span></span>
</td>
<td class="text">The Company&#8217;s obligation for the payment of base rent for the Premises begins six months after the commencement date and will be $0.4 million per month, increasing up to $0.5 million during the term of the Lease. The Company has two options to extend the term of the Lease, each for a period of an additional five years. The Company expects the Premises to be ready for occupancy in the second half of 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_OperatingLeaseMonthlyRentExpense', window );">Monthly rent expense</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_OperatingLeaseIncreaseInMonthlyRentExpense', window );">Increase in monthly rent expense</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Existence of option to extend lease</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has two options to extend the term of the Lease, each for a period of an additional five years.<span></span>
</td>
<td class="text">The Company has two options to extend the term of the Lease, each for a period of an additional five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_OperatingLeasePeriodOfExtension', window );">Additional period of lease</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_CollaborativeAgreementUpfrontPayments', window );">Upfront payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ContractualAgreementsMilestonePayment', window );">Development and regulatory milestones payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_ContractualAgreementsPossibleSecondMilestonePayment', window );">Development and regulatory possible second milestones payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dyn_AccruedMilestonePaymentObligation', window );">Accrued milestone payment obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalty obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_AccruedMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payment obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_AccruedMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_CollaborativeAgreementUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_CollaborativeAgreementUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ContractualAgreementsMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual agreements milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ContractualAgreementsMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_ContractualAgreementsPossibleSecondMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual agreements possible second milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_ContractualAgreementsPossibleSecondMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_FacilityAdditionalAreaLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility additional area leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_FacilityAdditionalAreaLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_LeaseExecutedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease executed date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_LeaseExecutedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_OperatingLeaseIncreaseInMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease increase in monthly rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_OperatingLeaseIncreaseInMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_OperatingLeaseMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease monthly rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_OperatingLeaseMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dyn_OperatingLeasePeriodOfExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease period of extension.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dyn_OperatingLeasePeriodOfExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dyn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140038374583752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases Future Minimum Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">4,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">4,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">4,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">5,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">21,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 41,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $L[9%('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !+.V12V Q4M>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$Y&!R;-I:.G#@8K;.QF;+4UBQ-C:R1]^SE>FS*V!]C1TN]/
MGT"-]E(/ 9_#X#&0Q7@WN:Z/4OLU.Q%Y"1#U"9V*94KTJ7D8@E.4GN$(7ND/
M=42H.%^!0U)&D8(96/B%R-K&:*D#*AK"!6_T@O>?H<LPHP$[=-A3!%$*8.T\
MT9^GKH$;8(81!A>_"V@68J[^B<T=8)?D%.V2&L>Q'.N<2SL(>'O:O>1U"]M'
M4KW&]"M:26>/:W:=_%IO'O=;UE:\$@6O"WZ_YP^R6DE1O<^N/_QNPFXP]F#_
ML?%5L&W@UUVT7U!+ P04    " !+.V12F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M $L[9%*A!S<GH@8  -0:   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9E=4^,V%(:OM[]"D^YT=F<VQ)83$K; 3$B@37=A4\(N0SN]4&PEUF!;J20#
M^?<]LAT[,,ZQ>P/QQWG]^$AZCR2?/DOUJ$/.#7F)HT2?=4)C-I][/>V'/&;Z
M2&YX E=64L7,P*%:]_1&<19D07'4HXYSW(N92#KGI]FYN3H_E:F)1,+GBN@T
MCIG:7O!(/I]UW,[NQ*U8A\:>Z)V?;MB:+[CYOIDK..J5*H&(>:*%3(CBJ[/.
MV/T\]48V(+OCA^#/>N\WL:^RE/+1'LR"LXYCB7C$?6,E&/Q[XA,>158)./XM
M1#OE,VW@_N^=^E7V\O R2Z;Y1$;W(C#A66?4(0%?L30RM_+Y=UZ\T,#J^3+2
MV5_RG-_;[W>(GVHCXR(8"&*1Y/_92Y&(O8"1<R" %@'T38![Z E>$>"U#>@7
M ?TL,_FK9'F8,L/.3Y5\)LK>#6KV1Y;,+!I>7R2VW1=&P54!<>9\*OT4FM$0
ME@3D,C'";,DLR?N3;9<N^;Z8D@_O/Y[V##S.!O7\0OHBEZ8'I%U*KF5B0@VZ
M 0]>"_2 LX2E.]@+BBI.N7]$//<3H0YU:H F>/@57QX1>IR%NS7A4SS\CS2!
MISMU3W_U-EZ9>B_3\P[H3>035^3O\5(;!=W_'T2R7TKV,\E^4VO>;3>\KL7P
M<-?I?D$H!B7% )49 T*085Q%;%V'@<>O6*0YPG%<<ARWR\:<*R%M]PX(#)+:
MQ#0H%1WOIW?O&AI_6+(-V[%=">VSB#QPIL@5G-1U=+A6 ]*H1!K]+Z0B:P>A
M<+6K!P3II$0Z044FJ5)ODX2U(J[6[;JTZ[D(E^M4MNF@6H55WO*UL,,7&&]8
M7,O4(#3=)IS<A5RQ#4^-\/4G\%__"(/<\W:W#>0$4J@@?3.PX1?RA6]K,7$I
MQW'<D3L:GO0Q,EJ1T39D5R+BY":-EUS5,N$B@-3U3@;."894N;'KM4&"Y$NU
MD2HK?Y_(PD!7(U*1B4PABY!,&=0W,ZX^O<0@*W]W<8<N(._8"YD%T*QB)?R\
M4"-9Q"6]XVY_-/).\#16WN_BYET0CH- <0V=N?A!OL)]Y%M2GSM<<N0YY%XD
M!JHEG(:9#@9:%0<7]_2WH!-[! U])Y^36DA<[IY%)F0QAE;5!A<W]+=H92><
M*_DD$K\^B;CF]1A#JVJ$B]OZ6[2YU :LY2^Q.3PR<$6']@>H)U?%PFVH%AD9
MK'X.H^ "PQ$&0JOB0'%/_RJS^AG*!'.W!I'AZ+@[HAY6V6E5"6B[2E#4TUL.
M#F=$LLZZ5GUY;U!\X!HCJRH!;54)9G9XYXM 6]W9#K66#%=L(*L* FU5$&R-
M ON'$;B6JK9T-NC<R*3+?!^6NE!4>) +8H15-:"MJL$B9E%$+E(-EW5]6^(Z
M1J78?)M6YD];F?]ES-7:]J[?0,&$,!SC#4OJ<X<+-I%5;D];N?WE"[F#V9H6
M6<W,9[BU6+A:TPJ%5E9/6UD]9"@&H(61_B/X?<C 7<FWU("Y)@%DLG:QFRL/
M,F6[O_-T/G#[@^%@,#CM/=5152Y/6[G\(N30L;#6PV4:TU19.\6=N5R;C),D
M!6_-#:P6"1=JZ%!>Y?%>P[R]7&I7_>DP58-84Z*\RN@]W);OA($IM5P1EWY8
M?B0+[J<*FK*6"5=ZW27?.T=V"4 VL )[8E'*R09<4=N.BG%79<##31NR&&3U
M:!LO952+BPM,'VXPD+U-&=RM=QD#J_!#EJSYP85=@]#->#$=_XDQ53[OM?+Y
M>QB-W<<$YJ?0KDS#["(@,ZW3^NE%@^:-Q- JQ_=:.?X/&<'RB*FB7-86H08E
M'*@R>@^WYMGDZI:,TT 8F"^/C>%@H=G@/+07U:#7.#0KJ_=:6?T\74;"!QS)
MZJQB6J@<[]FZ4^_G7N7G7KNM';VWO(7.L[0;&"L.\ZSZ)46#ZEW(]S= [ HM
M"30QDJSLNI[9_7>1B&Q.MU'R94ML6_#,-3>ITJF-@KM!(XWR1G+[8Z*X/0 O
M@$L&'F%W:W>^?PVK/WL)#"XSIE!& 70W\BQ,*""<.B1@6VVOVU#@V?VL0'_Y
M>43=X:\:*+-=I:W=5>)VBYI,N<_M=+W<9#Z"!8ZR9)FD3OT0>RDP0\C"ZP2K
M78)M?B29,V7(;#;+L81^7="([:=2Q<3NQ.[>G[\8*YX])B AJ(FD=G^HM_<9
MP,[ LL\IFOAVYR+_(E">+3_9C+,/%;WJ]OQ[SS6S$SA-(KZ"4.=H"&-7Y9]0
M\@,C-]E'A:4T1L;9SY S: M[ UQ?26EV!_8!Y8>L\_\ 4$L#!!0    ( $L[
M9%*SY?J,. 4  'H4   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK5C;
M;N,V$/T5PET46\")1>IFY6)@XZ!H'[8(-MWVF9&9F(@D>DG*2?KU'=**9)<4
M[<7V(;$N,T=G1N2<&5V]"/FLUHQI]%I7C;J>K+7>7,QFJERSFJISL6$-W'D4
MLJ8:3N733&TDHROK5%<S$D79K*:\F2RN[+4[N;@2K:YXP^XD4FU=4_EVPRKQ
M<CW!D_<+7_C36IL+L\75ACZQ>Z:_;NXDG,UZE!6O6:.X:)!DC]>33_AB27+C
M8"W^XNQ%[1TC$\J#$,_FY/?5]20RC%C%2FT@*/QLV9)5E4$"'M\ZT$G_3..X
M?_R._JL-'H)YH(HM1?4W7^GU]60^02OV2-M*?Q$OO[$NH-3@E:)2]C]ZZ6RC
M"2I;I47=.0.#FC>[7_K:)6+/ 2<C#J1S(*<ZQ)U#; /=,;-AW5)-%U=2O"!I
MK '-'-C<6&^(AC?F-=YK"7<Y^.G%4C1*5'Q%-5NA&UK1IF3HWL I=(:^WM^B
MCQ]^N9II>)1QF)4=[,T.EHS WK+R',5XBDA$(H_[\F1W7!RZSR# /DK21TDL
M7CP692LE:S2B2D%@%P'$N$>,+6(RADC5&M%FA4ISP+ZU?$LK>(3RY6H'E5DH
MLZ^VBSB*YBEL-<C-=C\MKB5.LOC \(!NTM--@G0_4_G,-'VH&%*L;"77G'FI
M[F#2/0))DF0>IJ[A",6TIY@&*=Y)MJ%\A=@KE"C%E,VNT&LF81_LOSX?[=1A
M$^=Y[+)V[3#)1[.;]=2S(/4_A:;5"2PSEV521//<Y>E:XB1/BU&F><\T/Y)D
M$ "IWVQRS:K=0$G64]0P[2.<NS2*)'/I>NR2>3;*=MZSG0?9?F%*2UZ:TE2^
M[[?=BAC/\=RA0N((NY1=.US@4<9%S[@X826,LRO<%9#&<9RX_%Q+G"7Q>$YQ
M-%3\Z*1B6''ZP"M;"4(5$>])"0X&_ZDL10LE$&WHFRDU7MG GCU@PO]O_!Y#
M3-) _(,68'*,IFQ9L-#LI<8;!'&XY2GQ;&./(<;1>#G'@_S@L/X<EIQC?&.7
M1E1D/L*N)8G3^3CA08!P6(%NV2,#LBMD"'L[ H_T!#(UR H.Z\HN4\<RY!&&
MD0RYEL2NWS&B@XC@L(HL15US;>KQ;DF6HM&\>6)-":31QS^$9@@3?S,61#:C
MP(7:T))=3Z#75TQNV62!O"_AQX$.HQ^$">?!JG2O1?F\%M6*2?7S3W."\TLK
M4/HM!#\H"0Y+"707W?I3YD'>) 81OB>)/PYT&.6@/C@L/V8)P6QD0YRB#]$Y
M+$L,Y5@BZ$Y;=@G]=#2-=G]VC67S_E2MJ33%L-5K(?D_D"FJ$33BK'Z ROC>
MRULOTY5/82.K#;-36/5VB9)T"HWBM(AB:Q)/25Q,(YR_XW*E3-$U]\ TRK-I
MFB<[M&DZA[,X?3>%:5-IN .+_WLX>-^I*Z.I9T][Q'9T0Y-!:$D4%IK5BIM9
M%<J/Z6S/> -MS(9#.?)1[< .ZQ].<T_O[3'-XG2\6))!PLE1"6_KMK+38">)
MHH95NC:#^Y:A2BAO_22N6I\%&FNR-[@=%>N>$$SGO.3>1I6X0GN6%WCN&0%\
MIKC(D_'6@@RJ3$Y1975B*>NHNY(;)R3V:8_'%"=1H"DD@SR3L#P[*FDWV7=&
MDKAS[DAW2URQ#[>W9-![$M;[I6BV,.)P,^L.5?_>K?J'^(-,D^S_%RHRZ" Y
M-J$=$ZIEA["?9Y(GQ#,=SO8^#)FO<I^I?.*-0A5[!-?H/(=4RMV'KMV)%AO[
MK>A!:"UJ>[AF%$(U!G#_44 7TIV8ST_]Y\;%OU!+ P04    " !+.V12F?7.
M:*("  "D!P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)6576_:,!2&
M_XH5[6*3.N)\TRH@M535=C$-%6V[F'9AD@.QZMC,=F#;KY_MI!&%T (78#OG
M?<]S3HR=[X1\4A6 1G]JQM7$J[3>W/B^*BJHB1J)#7#S9"5D3;29RK6O-A)(
MZ40U\T.,4[\FE'O3W*W-Y307C6:4PUPBU=0UD7_O@(G=Q N\YX5'NJZT7?"G
M^8:L80'ZVV8NS<SO74I: U=4<"1A-?%N@YO9V,:[@.\4=FIOC&PE2R&>[.1S
M.?&P!0(&A;8.Q/QL80:,62.#\;OS]/J45K@_?G9_<+6;6I9$P4RP'[34U<0;
M>ZB$%6F8?A2[3]#5DUB_0C#EOM&NC4TR#Q6-TJ+NQ(:@IKS])7^Z/NP)@OB$
M(.P$X;F"J!-$KM"6S)5U3S29YE+LD+31QLT.7&^<VE1#N7V+"RW-4VIT>CH3
M7 E&2Z*A1'>$$5X 6E@[A=[/B02N*]"T(.P#^HC>(1^IRJRJW-<FN_7PBR[3
M79LI/)'I'HH1BH(K%.(0#\AG9\N#ZY=RW]3<%Q[VA8?.+SKAM]"F9+,=-?JZ
M0@^4F\(I86@N%'7[Z^?M4FEI=MFO5Y)%?;+()8M/))N;O0E2FA:;%UH\7:$-
MD6A+6 -#?6R],N=E_X7;*1YAC(/<WPXPQ#U#?!E#^R(1:70E)/T'Y1!+ZYGL
ML02X_0S3)#U-\BK-3-2UZ?(Y[4C>:D>[?=X,>\&9]ISI!9QGM2P]:EF(#WO6
M(A]'IN/7FIOUT-GET%2I9A@X.\*(DSA.KW%TP'L<&(71-0ZR8=QQCSN^'-?<
M.$H37E*^'F(>#S#C+$VR^(#Y.#!,QFD2)0?,_MX9:N^O+T2N*5>(P<HH\2@S
M%K*]$]J)%AMWK"Z%-H>T&U;F&@5I \SSE1#Z>6)/ZOYBGOX'4$L#!!0    (
M $L[9%+9'<BZ500  "0/   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
MG5?;<MLV$/T5C"8/R4QB$N!%I$?63"SWDIFF]=AQ\PR3*Y%CDE !2'+Z]5V0
M%"F+(*OV1;QH]^#L!8?8Q4'(%Y4!:/):%I6ZF65:;Z\=1R49E%Q=B2U4^,]:
MR))K?)0;1VTE\+1V*@N'N6[HE#RO9LM%_>Y>+A=BIXN\@GM)U*XLN?QQ"X4X
MW,SH[/CB(=]DVKQPEHLMW\ CZ*?MO<0GIT-)\Q(JE8N*2%C?S#[3ZQ6K'6J+
M/W,XJ)-[8D)Y%N+%/'Q);V:N800%)-I <+SL805%89"0QU\MZ*Q;TSB>WA_1
M?ZZ#QV">N8*5*+[GJ<YN9M&,I+#FNT(_B,.OT 84&+Q$%*K^)8?6UIV19*>T
M*%MG9%#F57/EKVTB3AQH..+ 6@=V[N"/.'BM@U<'VC"KP[KCFB\74AR(--:(
M9F[JW-3>&$U>F3(^:HG_YNBGERM1*5'D*=>0DD>-%ZR15D2LR1];D-SD6A%>
MI60E2FR4S%1P#^0WH13Y1)X>[\C[=Q_(.Y)7Y%LF=@I-U<+12,TLX"0MC=N&
M!ANA01GY*BJ=*?)3E4+Z%L#!F+K V#&P6S:)> ?)%?'H1\)<YEH(K2YVI_$$
M':_+LU?C>2-X;3*K#8%7W((*U/4$JM^A^C6J/X+Z  JX3+*Z0"GL<5=N3?UL
M!6B0PAK);.[]T@]PLR^<_6E6AE:4NGYO]89FT-$,)FG^ A5&7]0L>8I=G"MM
MLK$'&]$&*SBEX/G^_(SHT(K-H]#.,^QXAI,\OPF-+,6@5#:6X6#]( H'+(=6
MU(O8",UY1W,^2;/>>VLIRB-5W*(VBO/!XI]L'"UF$R2CCF0TW? Z TG>MRG\
M@/J0B!*FFC[ND./)\+]4&B0HW4+:(H^'Q0G/HAZ:L'BDS:G;BZE[&;4V;*L0
MNL-\>_%(MNF)CM/)I5<9KS9@9'C-<TGVO-B!47'4[#5(B>J.WY+DA>#&J_ L
M0,1SD6]&>V?5KG;6%<P;H<EZFNQ"FFJ7)& :&4[)6#/&AES\8*Q8O2)3[Y+=
M;NW3CZ0"JXJVF&^XS.-S%;594=<;RUXO]W1:[W_'<UV!N]_*;"C=GX+8]\ZW
MN\V.^E$0CY#K19Y.J_R1'$%1(BKC$K.()ZP\:;Y.>;'3YU_VEGF#&[VI[Q7U
MSHE;S,(K-QKAW8L^G5;][_51#S<(WZ.:8G-B Y1XPJQ#P)/03BN-$> 'X=)X
M+*KO>W$0!\%Y2$-+YOLLFK.1H/I/!)U/RN_;TYHIRY3TTE[5:?3_.S"ZL ,M
M=E,=V'\8:'S!-R?Y3Z&S7MS9M+@_53@G%?G?V"D&U+1&A4=Q^0*:/Q= %"0[
MF>O<?EY@%MEG<WO$K%=]]B^J/XC5NC:U%B;TSPICL[,5QCF9-TJ0FWH,4YCX
M7:6;$WKWMAOU/M<#SMG[6QP!FX&MAVGFQZ]<;G*</ I8(Z1[-<?$R68D:QZT
MV-93S;/0."/5MQF.L2"- ?Z_%D(?'\P"W6"\_ =02P,$%     @ 2SMD4B['
M@:56!@  41T  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6S%65M3VS@4
M_BN:3&>VG6F()=\[P$P)L(2RNPRTW6=ABT13VTHE!=K]]2LYQHXM683N=LH#
M\>6<X^_<=#[9AX^,?Q$K0B3X5A:5.)JLI%R_F\U$MB(E%@=L32IUYY[Q$DMU
MRI<SL>8$Y[526<R0YT6S$M-J<GQ87[OFQX=L(PM:D6L.Q*8L,?]^0@KV>#2!
MDZ<+-W2YDOK"[/APC9?DELA/ZVNNSF:ME9R6I!*458"3^Z/)>_CN"L5:H9;X
M3,FCV#D&VI4[QK[HDT5^-/$T(E*03&H36/T\D#DI"FU)X?C:&)VTS]2*N\=/
MUL]KYY4S=UB0.2O^IKE<'4V2"<C)/=X4\H8]7I#&H5#;RU@AZO_@L9'U)B#;
M",G*1EDA*&FU_<7?FD#L*$!_1 $U"FB@X*<C"GZCX \5XA&%H%$(]E4(&X5P
MH("2$86H48@&"E$PHA W"O&^"DFCD.P;UK112(<^C#D-O:?,>?O&";;)'F8;
MC9;'4[IAG>_9MK#JJCS%$A\?<O8(N)97]O1!7=JUOBI&6NDNO)5<W:5*3Q[/
M625807,L20YNI?I1+28%8/?@AN1$M?Q=08"2>B!<4GU\K=J$<%Z+L^P+P%5S
MM&)%3KCX#9Q]W5#Y';P^)?<TH_(-F()/MZ?@]:LWX!6@%?BX8ANAU,3A3"H7
M-)!9UL ]V<)%(W _,HD+B]K<K;:?*Q:[IVZ[MX13(L#[%UH]V\OJR0NMGKNM
MOLS8[S]L[ =C<O%?'_C2<"V>>V!9JBDQIGWIUGZ?YU1/&5R :TSSZ:("<[RF
M]N+]\(RM+-N4FZ+NT+_DBG#E:*E&[DK/P@<"KIBP==+5_E:;1NT;F:F5I%U.
M4+N<H-IJ,&+UA"QI5=%J"4YP@:N, "R5^>P ^/ M0!Y,;#V_M1G5-C5M>#B>
M!DF<'LX>=O-E2L&^Q*4I$?<EKJQ/2CJIGM-^Z[3_,J??@ML5YJHF]W!^L;4=
M[D!"$'J!%]A!!2VHX/_/Q#PPXI-Z$;0C"5LDX<\+SSPTP@-1Z.D_.ZJH114Y
M42V$V-1A49.N7;)X-R>RG<5DW2XF0B\';T&EZ+'2HT\V,B:V,_.5=P#5H"X*
MU?LV;R*SAM,T2>VNQ*TK\2]VY2EC-I=BLWX]SY&@I/4J<7JE-@"RJ-F(1O.1
M*W0K NIM EC8@"1F;\,(C11OVJ)(G2AN2%9@(:A:('&];5!8]@MM38R&UV3C
M!KLKZ+(V:"5!J1%3WX^#I+^8S5/3810':+!NGIMB%JE+\Y&1#T<*$WH=N_1^
M<?A<I=F VW5JZ@]7CX8[F:*&9#\&.PP;N@M90Y_JK6*N'"[5_EG4T*WL%YK=
M% TRY9;I@^SF-G0/[L]$2+U$U_D1DM-,$P,Q%MI%8VX71!!'T!]I-]C-4N@>
MIG^J]:BP,YH3:,[**0R2<%#+5\_+]<%U,Q6ZA^I9E3LF:FK%')@#+/#\:%A_
MYN2U=.G"(C8D098'1GZ(AB$RI:8PC8.Q0NJ&/71/^WZ(QD:]+53GT)SU]FY=
M6"11F$2A'X[ [U@!W)\6N":D-=61B2J(_&2P;I]"&PL(H@%7/;.)P7!W46YV
M:GN9N]C3W,(F-RRQ$4='>#3LB S<G\FXHN]8]'^')B&!J:V*+BR2@0I)&J-@
M&!.+S<!+4A^.L'38L1SHICG;3:MH9J-K(-)*,CU ]+9T>V6S5H>T4CM-M<]<
M;]10S)01I:0ZT-I@=HJ$8#CTUQ3TAS60F"'1IM!(0#K"!=V,ZV<%Q%$SY]!D
M/U.57&LIF*(H\9+(CT?6'M21)>0F2V??",^HZ*H?L/4H16QL]5(T*/!+9"$U
M(W0&=70&N>G,*$I'@$^0R5E\I.;-<(O_G%@?\\Y;"3>[>0D%0^8[@BA,C5<-
M)O_I2?6!=NP'N=G/2VD8LKP]2%0_^R- .J:#W$SG4\4)+N@_ZNE+3"NU(ZQ
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M:9QNY[NOYR,]\V&"?LC2K#3ZH\QX=CC &, W'I"=!_=D<,0'GGY%%%\@$I#
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MO/! X01XM^I/<GE+.Y2U$]?=*?6L28R?]G(H-D=R$]&.]A-N[;-SXTUV!#@
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M,E)N&\$XIL!JTO*&132IB8098[]3EB*(]G^N;8,/.2NCV(H@*<7T(<L]"2O
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MAQ4#Q6D6[7'EZH*85@J=B@;Q5HHALI6WEB <A1-H*EIGWGP-VP-;EN)'V%V
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MRXW*B8*"\F04K@KD,U</7#V#X;,,V!/$I1)&@&:\2-@=%XK]RK,2V -P72K
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MS:Q![L-"_;3^+'/MOD9LR=TWG0>N%NA@/'O.D;7?G8X[V#[L=Q)W8^32?IO
M"<[(W%ZF@%.1(@)<GTL<%/P-":@_5EW] 5!+ P04    " !+.V12SO:E//D"
M  !_!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RE55MKVS 4?O>O
M$%X9+90X=IPVZ9) ;V.#EH66;0]C#XI]'(O*DBL=-\U^_8[DQ$VAS1X&QI+.
MY3L7^7R>K+1YL"4 LN=**CL-2\3Z+(IL5D+%;4_7H$A3:%-QI*-91K8VP'/O
M5,DHZ?=/HHH+%<XF7C8WLXEN4 H%<\-L4U7<K"] ZM4TC,.MX$XL2W2":#:I
M^1+N ;_7<T.GJ$/)107*"JV8@6(:GL=G%ZFS]P8_!*SLSIZY2A9:/[C#UWP:
M]EU"("%#A\!I>8)+D-(!41J/&\RP"^D<=_=;],^^=JIEP2U<:OE3Y%A.PU'(
M<BAX(_%.K[[ IIZAP\NTM/[-5JUMV@]9UEC4U<:9,JB$:E?^O.G#CL/H/8=D
MXY#XO-M /LLKCGPV,7K%C+,F-+?QI7IO2DXH=RGW:$@KR ]G<T/W:W#-N,K9
M]6,C:NHX3B(D;&<191N<BQ8G>0<G3MBM5EA:=JURR%\#1)14EUFRS>PBV8MX
M!5F/#>)CEO23_AZ\05?IP.,-_E7I7'*%['RW7O;K?&'1T"?R>T^DM(N4^DCI
M?_=T+XZ;QS-;\PRF(0V<!?,$X2SML5?XT-7PCCC3-$$6(6>Z8%@"*[2D411J
M>190CZ%:@'%]#@Z%(KUN+/G;H\"UG5[Q.+CA"VTX:K-^@0T.@N3X-$UIC8]/
M^\/@6U&(#'SL3%=U@X3Z8GTZ"DZ2X 9H?DHM<R:JVN@G<#H;Q*E[+BE/-$T[
MK)0*&61@24O@'S^,DCCY%+Q=XD;+7:T6*:]Q&KNL1C%%M)8F/VNJ1G+7@QRH
ME9G@+240"J^T0?''"X+#\7@8' 6'B5_V1E. OO9Q>N+7='1"[=P!AV<B3@L,
M-7))D0_ZO5.:8"FWD4DPZ 1$K_YRUL"-9>!FB.W>CI\"[^:NY)CXT-;@&4VN
M>^RMCS;:(84*S-)3GZ46-0I;?NBD';N>MZ3R8MY2\RTW2Z$LDU"0*]4Q#)EI
MZ:X]H*X]Q2PT$F'Y;4E_"##.@/2%UK@]N #=/V?V%U!+ P04    " !+.V12
MBBLDHZ<"  #'!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RU5%MO
MVC 4?O>OL+)IVB1$$I,4U@$2T%:;U&JHW>5AVH-)#L2J8S/;*>V_W[$#*9-6
MI#WL);Z=[_O.)>>,=]K<VPK T<=:*CN)*N>VYW%LBPIJ;OMZ"PI?UMK4W.'1
M;&*[-<#+ *IES)+D+*ZY4-%T'.Z69CK6C9-"P=)0V]0U-T]SD'HWB=+H<'$K
M-I7S%_%TO.4;N /W=;LT>(H[EE+4H*S0BAI83Z)9>C[/O'TP^"9@9X_VU$>R
MTOK>'SZ5DRCQ#H&$PGD&CLL#+$!*3X1N_-IS1IVD!Q[O#^Q7(7:,9<4M++3\
M+DI73:)11$M8\T:Z6[W["/MX<L]7:&G#E^Y:VVP8T:*Q3M=[,'I0"]6N_'&?
MAR/ *'D!P/8 %OQNA8*7%]SQZ=CH'37>&MG\)H0:T.B<4+XH=\[@JT"<F\Z*
MPC10TLM'++,%2[DJZ6=7@:&+QAA0CEX+OA)2. %V'#O4],BXV///6W[V G_*
MZ(U6KK+T4I50_DD0H[.=Q^S@\9R=9+R HD\':8^RA"4G^ 9=!@:!;_ "WY(_
M\97$R&<8>4@'EY;^F*VL,_C/_#PAD74269#(_EN23_/G?7J0@&,)'22*O81\
MEOA7\T)C%UJ' +VF:$776F(["[4Y)U@/J%<(Q)J0MT+ANVXL\MEWQ)<(/^E[
M@EDVB DZ*U"P%LZ2UX3UTB3'-<\2LD 1["4DI1;,@RC $G8V(&<)N88-E\^W
M Y:3-Z]&+&4?R"U8X*:H G,)#SAFMC@T',EZPQ$CV2@C5[SP@3QA&!95<T;2
M$?FB'9>H/.SE;(AKBIZPO]4Z/FJN&LPFC!"?DD:YML^ZVVY*S=KF?#9O1]P-
M-QNA+)6P1FC2'^81->W8: ].;T.KKK3#Q@_;"B<M&&^ [VNMW>'@!;K9/?T-
M4$L#!!0    ( $L[9%*C4)])Y0,  $4(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;)U66T_D-AC]*Y_2;M5*-,D$6%9T9J0!BA:I*]#2RT/5!R?Y
MDE@X=K =ANFO[[$S,SN@71XJH8EOY_A\5S-?&_O@.F9/S[W2;I%TW@_G6>:J
MCGOA4C.PQDYC;"\\IK;-W&!9U!'4JZS(\_=9+Z1.EO.X=F>7<S-Z)37?67)C
MWPN[N6!EUHMDENP6/LNV\V$A6\X'T?(]^S^&.XM9MF>I9<_:2:/)<K-(5K/S
MBY-P/A[X4_+:'8PI6%(:\Q F-_4BR8,@5ESYP"#P>>)+5BH00<;CEC/97QF
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M1WHJA4I+Z<)8^!'"'8WQBL#W2M(:<@G9J\!IA9+_0GRY07- =*!4"J4VA)]
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M9QL.8+\QQN\FX8+]?P[+_P!02P,$%     @ 2SMD4L/ZLH7Q"   ;QL  !D
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&ULK5EK<]NX%?TK&#73V<XH>MF.
MG<3VC)W'K#M-X]GL;C]T^@$B(0D-2#  *"7[Z_?<"Y(B*4J)._U@F0_@XMS7
MN1?@]<ZZSWZC5!!?,Y/[F]$FA.+5=.J3C<JDG]A"Y7BSLBZ3 ;=N/?6%4S+E
M29F9+F:S%]-,ZGQT>\W/'MWMM2V#T;EZ=,*762;=MWME[.YF-!_5#W[1ZTV@
M!]/;ZT*NU2<5?BL>'>ZFC9149RKWVN;"J=7-Z&[^ZOZ<QO. W[7:^=:U($V6
MUGZFFX?T9C0C0,JH)) $B7];]4890X( XTLE<]0L21/;U[7T]ZP[=%E*K]Y8
M\R^=ALW-Z&HD4K62I0F_V-W/JM+G@N0EUGC^%;LX=H'!2>F#S:K)0)#I//Z7
M7RL[M"9<S8Y,6%03%HP[+L0HW\H@;Z^=W0E'HR&-+EA5G@UP.B>G? H.;S7F
MA=LW-M\J%_32*/$(@RCG5"H^!9M\OIX&+$##IDDE[#X*6QP1-E^(#S8/&R_>
MY:E*NP*F0-; 6]3P[A<G);Y5R42<S<=B,5O,3L@[:]0]8WEG1^2]^U+J\$W\
M^V[I@T-$_.>$S/-&YCG+//__F/"D,,K!5[Z0B;H9(<F\<ELUNKV<B/8B1;.(
MIT7$)YTG2M!/09$^%F&C,"$K9/Y-:.]+@J.<5E[<B>2$H)]HXE__<K58S%XW
M$WHJ\>OYZ[\)F3=2[Y\J]?Z85%+4<,9NE?G&BAP#P@!: PYD"NF4:!X%*Z3G
M\;UA$_%; 7J@-XFQ7N=K85=\^_#X$5:%_"*H;*D<!V''N@1[?OG:'RY=(G%E
MT(DT4*.R#M[J'#@65^/9U8OQV>6%\!N ]+1@8K,,,'R$=%3IC[GXI]U6<%Y2
M7LRON@Y7>5"N7NJD 1]+EVS :.)N[90"TP:03]@('3QFZZ"EP?^M B;G&: .
M@>P#P44]5X)9UYB_ED&1'L\N9I,9F,H8(EV8;Z_B,2 3<1<8:;UHY8>QF"_&
M%[/9>#:;_8 8L8/>=;POOW6,(H.0>\R%TTD$.Y] = %;LOBQ0)43:V<]U)5^
M@X$V42KE99]=3BYJO2;B8PR10X!Q_;&XH(?M%VUT)45<C JN;E7 X0_79? !
ML4V&_G3W_IT?B]U&)QNQD2F46$GMQ%::LK+VWM@3\9"+.^AF*"I>#M( >2M-
M-=&$I&%]D*?,6X+37<2I7.9KT$\)KQ]S WLAV "$T1<=-RQF'96AER3Z2ZQ'
MV$KO;:(EI1J'LI(P7"^MCP)>Z1RB:"3[ZMEL,F\Y/!<?)( +RK<#(NAFG11>
M%=)11CPY^;H>JM./R:[RX>(I3ANR^)"YCP7]HA=??R_!9X?J-^$%TK<F%?/+
MIR1N!/D#2=F!-N\DY-$J0$E1KM%)_0#L\_EX?O%R?+DX/X0]4%^ZL!>3J_F@
M5;NHYQ>3RSWL7QU"#HBX&_8 FY@RY3@ZS+0]\8/TGQ99%,\)2A"Z=.'B4C]5
M);F+H"GO:SP.L6Y&:J[KP&ZS9__T=$+MA^F\BQZ*8V)/>1 BE1< 1HS9I=%K
M3N3N\JW:,VY:@-J?>(F&WXQ!L%SP>[7I[*E1V<^4LNX4/&J[7\FXLX 07ZA$
MKS3F4M/&/$'84H4VQA;L [B<5,BQ5K<X#=J"5I/&6Z&^*I=H+ZFSDK%,VB*T
MBL8&@8LR\CUV&UR%XR+56YW6U-405Q4EI$7E"JS9,?] ^1B,*?'0Z1D/J>'(
MK/VT)<=097HPNH99V:8=R[<,3+G'U!^BR*A\'26(LRK+PJ8R:<\NF8J/L;WC
MGB1:&\47"=44YZI<,$MC-U$2HG'=9 X9VB 0J1U,50"VZ%%BGLKD>--V]LK9
M[/L>Q2-+'-EI=HRQ29,Z#?LT KL\HNL*NE1AIU0^!+_7:@]U</XT%>Q@%]R!
MCU@Y3B0IZ!Y#C,:V+.4($W!M;!1(7+-Y[\3Z<R(*1_N$5-Q;Z=*&"*(UN(5"
M2->SJN'U;66F\5$_56TH->X&#46,+N"7 "J7VM .DA;L#78JL8ZB*H)'F];K
MU<XFYRWB/[(X]X .9I&^=%%82PSN.*Z=*JSC7ASDI"TLP,T#H@K\2=U[>U(#
MK"HJB.#0Y(^%@)C;$1/B6V<</%WT0\:"31#+*%'8Q*8#V%(BDI)[+RJ4=EE9
M[_F.#TLPA_>X !*7R6RJ3$Q*^(Q<Z'P=P_5<WBM5#9VL\SOZL@6]##!>%_S1
MT 2E+9O.O%:BV8+4H1\K$%O-*82K.QP\$>];ZU;^W._]B#H[ZM:62;5/;$F"
MR5ZR@+;H*NB:>*QM-YG^%XT,9'&CMC)VYP^Z_AZ+LI>\"H&R9;>I\KNA0B#?
M4VM#!3#9(;F?KBS?B18 D4V-JOW'\1&9H95IS%/M7(/ACO,*PAYAK?A<AVW1
MWJ[7NR"O_VA@,6/PJCI/G.+2PDNN]%9Q!Z&_H@"0!&R]-)<*WO1N0/ZX3U6A
M\$,5O1X4]V=$NSMUT)#4U69?;(@'LUC#JRK[M%+.X"O%C_,;<[*D?J0TH5L@
M>@6P7W?%EU*:RA=42..96>VA)/)T[4W,)S?&(.@?_53IV>H@]FZM*.M@1_MB
M<E:SY/@P.+A) 65E,B<75-B8C3$TM\)8,* [RJ#]3<R![O]CNAQV-:?3I>]2
MVMR3S)6E*$*\^78'AO3>HKL!M;\2;[E=RU'0?^Z&R^!Q"(RD61>8#894%..Y
MS9\G958:2<=L5?]' DE?[F!XM[D"N</R;G^:PJG3[:52G4)>J(>VA%&,Y%78
M$,1];""FNJ==_VC5_X=HV]@&4-,%&:W^8$QLB;U:&6\@"L:B_'R.EK]?X&->
M[FQITBJ15=6]&S78#0PE&@A;\WE$#_3OEFO<KX=Y^UU'T*"\9(["E*T-B!-%
M27?X<OB ,*9!5(\5:D8=Q)4R[#ZN4Q%GJ\]H'=O61\Q\'O6C2G$O%SF.Y(QY
M2TRTIS/49%XS;IP&D,7MQK!Z%5%RHY*V#\IXMST10Z?VT]9'D$RY-7_JH4TE
M*FO\'M(\;;XFW<6/*/OA\5/4!^G6Z.G1L*\P=3:YO!C%;*QO@BWXD\K2AF S
MOMPH"7/1 +Q?6?BTNJ$%FF]LMW\"4$L#!!0    ( $L[9%+0?\.]NP(  %8&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;)55RV[;,!#\E85:]&3H
MY3S<U#9@)RG:0P CZ>-0]$!)*XN-2"HD9<7]^BXI6W6*Q$$/MKC4SNS,BEI-
M.Z7O385HX5'4TLR"RMKF(HI,7J%@)E0-2KI3*BV8I5"O(]-H9(4'B3I*X_@L
M$HS+8#[U>RL]GZK6UESB2H-IA6!ZN\1:=;,@"?8;MWQ=6;<1S:<-6^,=VJ_-
M2E,4#2P%%R@-5Q(TEK-@D5PL3UR^3_C&L3,':W!.,J7N7?"YF 6Q$X0UYM8Q
M,+IL\!+KVA&1C(<=9S"4=,##]9[]H_=.7C)F\%+5WWEAJUDP":# DK6UO57=
M)]SY.75\N:J-_X>NSTTH.6^-56(')@6"R_[*'G=]. !,XA< Z0Z0>MU](:_R
MBEDVGVK5@7;9Q.86WJI'DS@NW4.YLYKN<L+9^?5#R^UV&EGB<CM1OL,M>USZ
M BY)X49)6QFXE@463PDB$C$H2?=*ENE1QBO,0Q@G(TCC-#["-QZ<C3W?^*@S
M^+'(C-7T\'\>X3P9.$\\Y\E_=^LX;A+"3L["@"J!O*+(4 ]^1V KA$LE&B:W
M[]Y,TN3\@Z%#;RRS6$".VO*2YQ0X.)>YTHW2K#_8K:V4YK\I[X $K )N3(O$
M'X_B_@>F8D3J.'(E!('I@.7W(VB8A@VK*?MM'%)B @VI\]DC8+* Y#D.&@,E
M:DV%7Z<)G[>>O']B'2I6'!HZF[PB/80OA-XHR^5Z! 7?\ ))KI-<<VIYT?=(
MNY?3@UVQ2M4%ZB'\M^V'_- Q0Q,K^T53Q+74$3^TK*:G0?*RK2?HV<F^ZARM
MR^E;@S+'EZJNAN;=^4*N#@UAFK.V I:I#8;/G=CHX%T7J-=^HCG-K;3]:S_L
M#D-ST<^*O^G]Q+UA>LVE@1I+@L;A^6G06]D'5C5^<F3*TASRRXH&/VJ70/=+
MI>P^< 6&3\G\#U!+ P04    " !+.V12A^K/&" -  !!*0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6SE6NN/V[@1_^Z_@M@FQ0;0:BW9ZT=>P":Y
MNZ;H-8OLY0Y%T0^T1-M$)-$AJ75\?WUGAJ0LV;)O[W#7%B@"9&V1',[S-P_Y
MY5;ISV8MA&5?RZ(RKR[6UFZ>7U^;;"U*;F*U$16L+)4NN86O>G5M-EKPG Z5
MQ74Z'$ZN2RZKB]<OZ=F=?OU2U;:0E;C3S-1ER?7NC2C4]M5%<A$>?)2KM<4'
MUZ]?;OA*W O[:7.GX=MU0R67I:B,5!738OGJXC9Y_F:,^VG#CU)L3>LS0TD6
M2GW&+^_S5Q=#9$@4(K-(@<.?!_%6% 42 C:^>)H7S95XL/TY4/^69 =9%MR(
MMZKX2>9V_>IB=L%RL>1U83^J[5^$E^<&Z66J,/0_V[J]T_2"9;6QJO2'@8-2
M5NXO_^KUT#HP&YXXD/H#*?'M+B(NWW'+7[_4:LLT[@9J^(%$I=/ G*S0*/=6
MPZJ$<_;UO579YRN4*V=O50FV-AS5]?+: G7<<YUY2F\<I?0$I21EWZO*K@W[
MILI%WB5P#6PUO*6!MS?I68KO1!:S41*Q=)@.S] ;-;*.B-[H%#UILD*96@OV
M8=F1EGT4!;>D F,-NU]S+9Q.[O@.7!">_?-V8:P&)_K7&4[&#2=CXF3\.VC]
M/*5YS-K$LK90Z3"9N54FJPRD /]GFX)7[(>UH'MYM?OSGV9I,GUAVKO?-[OO
M</>EA>VX+QV^H%WXE+XG+YZQC58/$@S. "&8W1-F5C&(OH+!8VE,+5I,&+I&
M;9!-@QLJ57VI>2&7$@AU5B,(?5"\S&Q8B1BO<J;@*LW$EUK:'>-;KG.#-XIR
M4ZB=$' NEQI"7VE#^S.@!9'*T99JV68T)G4T@K$MAQ,YQ)HT5FBX=;&C[0L%
ME^#9/6&E@1E+JSDXEQ:D=T_^>'^$I#@:J936"G%ZI^-)?!4ZDP:,!O*C2 ^@
M"EFM6@H(RB%%;H%=@"3@&K@'QG\%:^Y"JRPO6%67"R -RP8#@?2%/,-Y9QI>
MV[72\F>XHH98=V;O*G 6I9-IE-ZDGD;,/FW@/&X4RZ4@+*Z$:6R!(4ZGHXX/
M98+<>J7!;B2X,W3/K<XK\%$2S=-9-)Y-3[&O!68K)-?'_4)DO!2,/W!9\$4A
MR*^7M4780#_FX,6=@Y[QV'WLC;?W%;NM5X#F;H_M";\>[^(YQ ":T0MV>(2D
M6:L"6('-&PQ$D7>9@MA5*T&>LI5V?2!J*Z[QNPDQ';'M6F;KH(K&8 Q4>"^
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MXZ7G(ZLU"9D5LD1E^&Q:<OU96.A@PA4 /1(Z[IQ5G+)@C_:C5@D:UEV]3J)
M%4\*S413F;I'.M3J/GWM^SE@U6R &AW@S'& T Q25C;"H,28Q;K>'#G04A4
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M+:]UP&HR)!/]H49NA&%%I>R3,41!RZMP\<DPGJ3[9S3QW+B6O-B=;#WP9B!
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M S46NT)#]G'MS]HH7R[OP_LY@ M_[!60;Z-LLK]@3"6IQ*%%W_R.XTE%20_
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M/QD)%V^ZXT.P-=\N;VP(MN*OA9+0G1;@?6YMZ![H@/Z_&R[_#U!+ P04
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M/",'H1N0#3<?'E-Y!'^ 7GDA*N.*2C=A^%\,2F/ONTOB'^W(1[W)(M#:AII
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MGXU#]-,/;QK^BK\RWIN*'S=* F3:@/7" ,KX@Q1T_ZUS_3]02P,$%     @
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M0R VF+=;5 @=UA/X6VVS@UXUZ+=I(@.3.TM#VX[6<>@OAEY_<Q_^&!SZ5MD
M&C<LS2<?3P7X80J'#;DV=?[:$<]16C;\XT(?'?A\XQSM-_&"\5=8_@)02P,$
M%     @ 2SMD4O\:\L"Z&0  @U$  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&ULM5QM<]LXDOZ>7\'R[5TE5;)B*Y-YRR15CI/LY2HSXXHGNQ^N[@-%
M0A(V%*D!2-O:7W_]=#= 4*(XWJG:#S.Q1!!H-/KEZ1?HI_O&??4;8]KL85O5
M_O79IFUW/SY_[HN-V>9^WNQ,34]6C=OF+7UTZ^=^YTQ>\DO;ZOGBXN+;Y]O<
MUF=O?N+O;MR;GYJNK6QM;ESFN^TV=_NWIFKN7Y]=GH4O/MOUIL47S]_\M,O7
MYM:T7W8WCCX]C[.4=FMJ;YLZ<V;U^NSJ\L>WBQ=X@4?\S9I[G_R=82O+IOF*
M#Q_+UV<7H,A4IF@Q14[_W)EK4U68B>CX72<]BVOBQ?3O,/L'WCQM9IE[<]U4
M?[=ENWE]]OU95II5WE7MY^;^OXUNZ"7F*YK*\_^S>QG[\H>SK.A\VVSU9:)@
M:VOY-W]01B0O?']QXH6%OK!@NF4AIO)=WN9O?G+-?>8PFF;#'[Q5?IN(LS5.
MY;9U]-32>^V;6SF-K%EEMW9=VY4M\KK-KHJBZ>K6UNOLIJEL88W/GH:_GOWT
MO*6E,<'S0I=Y*\LL3BQSN<A^;NIVX[/W=6G*X03/B>9(^"(0_G8Q.>,[4\RS
M%Y>S;'&QN)B8[T5DQ N>[\6)^<9V_+]72]\Z$IS_FUC@F[C -[S -R<6^.(-
MN/S>MY:$R?@Q)D[.  7]T>_RPKP^(PWTQMV9LS"M"=-FOVU,1H]WN<M9[NGA
MRM9Y7=B\RGQ+8TBI6I_9.BN:&GIMVSU)7;O)_GIU=4.J]GMG:7J2LIKT$H.S
MMJ%/7TVR2EZ76>Y)EW=8Q&?M)F^S?+4B9:._#<VR:UQK:- 6;/4@@\:;5EZM
M;+ZTE6V)RS,>7UI?5(WO'.^&",-)8.GQE[)<EBF)&+R OT=WB?=.T>/,G:D[
MPV/, ]DY3Q.7G8,,]._@T\XXVY1^/M"1T\P@PP*K0ZL1DVDF.B+:D2>Q KWE
MJ?,HJJXTLVS9T:Z)#W73TI;I=.B-MA$VY47A.GJ/J?<F=\6&5R]I*U6SX\.*
M6\$#,B#%UW/8K9)HV.*)B(6.FK.\7-.3O-ZS?2-*B)I^<S1V8VD:1[NN^#5G
M35T0H5_KYI[VYTQ=RF(-D>A(4MQ7TY[[G2G JJQQ^L"1+;X#YU:D4HU3H;%M
MMC25I0UXR-D2?,]]4^?+RF0=60O'.R^L*[HM\8N6IH/XE0PZR7:];G ^1+<E
M04HDEA:J.J9_L)L9G1.F(_:"Q<4F)RD374CGGS&)/DJ&['B>7??CD]-W(+EH
M7!D/7 4&G^XWELZ(OB/NTJ"M$;;-R<2V.$DZ1G(@T+8]*0$ID,M6KMG2&XU/
M%8ZXF(C8/)NP2"^C17HY:9&N&]I4W8J=8(VX=J:D\_AL_5<YT*%7N.UV.SHI
M-VJ[_M6U"EG+)6OY9"T?ULH^1&VQ-9GC3M2%96?7M/2!'E5[G!,XUB;B3.)4
M3*X+K239)GM)7':V8C]8Y'XSX_]G,(4D2-&2B&BS9'I3D*6 +3I0H2C+,$]D
M0;PE6=\S[;;MA(Q4+F0ES'Z\)$G6QE0E_T&4;0ABG"O]OY/PD.$>+@X8UM)_
M(O5'\]&RVZ8V>]U'MNJ@N:*%-=&,?[(O\]LYE#HG8[P_M<W_^H_O%Y??O?+C
M'(&2$;GDHLUV20(=W'3@MRG%R&^WQO'![G)2&.%!X\CHPJJ79MF>Y/*&5LC+
M9L<6O5;J6?%W<-Y[V11;3SF)8/;; ;?VR;[Q)-D"_!6-\61>:&^65(\H9"^)
M@>:!C+57]XHOF&OKYLZX&F0<4PMKWIN2DB?7HR2_YP\W:#V$ARPK]@3TFODM
MB7E6=\Q17M6Z\IS</'GO7EG(G_/9EZY;T]=+,6CB(_#5SC5E5Q!]'^L,[]JB
MJW(W&_#%081A*M7ZP1***I$S)'])?].0_0QTG::B, ZBF,%\.3IDK^>[W9$(
MXB@4:)0\6K2E=V*T06R#R%V[?"OOKKH6^$"WH,P'P?H-"7Q=LHN%_(M%E2DC
M6\)\S&QO^OD)_)&>D?/)2SI#BAKVBF:(ON4>[$]L$RF9<:YC4QQ%!YMG4LA_
M^/F$>?XVFN=OITUFL O\Q_M>C\>L[^14X\CQ^J3=X2>*1]2,6,1@>0D3F=_E
MMF*-IQ"Q^ K_FPMX]N/3Z4P9Y!<FC.:H+#TO$[V%)6D%>D'):+D?+@C=[7WP
MACW6VW6$>G) EPDF?Q>9_-TDDS_3^H1L<,S8]1AK'ST!;_Q*#8UNNA3.#<<0
ML,0I -WJZ%UERC6L B2QJJ R9!8AM95I6ZA4XKE2O5&+M0^NQHM2'AOJRC &
M)%RC$'J>'9+>-BV=6)G]93%_0;%F57'83"?ZEXOY1?]%.V+8,6IQ<?G##'N%
MQ:!0N]H'+0N[9,A5$8PA19+-'G+F!/$#]+S,*[9I'/1.:MKW40B^GSS#GWLG
M=AL]P)@H/'J:Q)'\F[WFC TM6Z96W)9*PK0[E9CEZ#RB;I^3<)U[$H<XL(^@
M ."MRX"P20F_U&08*OM/>B*.C-W5\3Q'! SFI,^];V"[7A <[RH^<0D?\-B9
M#3)"=X;7@FYQ@+-I*HH3O/*7C0^@T>= V)HQ$<>00B(6EZ!()2Y&*Q8>5]@)
M:=\: N)E9$+4ZF."A4@: (S_5,.K9[.L-A%>#,0X"?WP-AVE8M3@)H=['<*#
M87@S+DX,5KJCTUF%>.R<,%)]3C1 0H!0:6KK!+W\G9;FT-L# )U8X.1,I2F@
M&WP^+"5#?,'RC/,BITD8.$2#.2 'X=.ULA)>8$W?;4B94^\K4(%7B L +_&1
M$!N!]RD,#,B, M<U11 5+>M;F:UJ-,)7'"Q3Z/@$2P*W+0UQHB(^ %+6S.Z#
M&<<,EB0J]GR60 N20W&&$='!*F!C'B)&$&&W@!.K%9)0\B)Y3B*;!]:8E&";
MW;$4(? DP (@FVAE$JR V^0U0MBQ-C5<"^$_@4YY^8].Z:!UDADTAP&>)LP&
MZ:>XQ9![_)PEK@=W%A>OPND2-Z/(S/C9Y:L#'$JH3B.I=)T!G>W&-=UZ VW<
MY&[-Z)05.JC7([7KET:DL6<(:1#R!+4!H&.Q[E-#FA#*U(^;<LH-_1#=T ^3
M_N.=H>@?COTS33GF?A[YNL.N;_*])$)\0?Z2]SZ3)QLV0?LT9</@ +8+MD^"
MUUP ]-(,D(P,S-?.A/R:TZ043*E#/EQH@#+N" Q39 WOPZSE25V2HF*)-CD]
M4@(\RS.I^C_%,A/LIM =B?5SED#.\V00>$W0!:RA$Q!2VLZSJ^0(&2-A<4O2
M<)"KR7U/+Y/%5GZ+G!^O/[G,)/"XO.C3[Q>3AW;C()MJ*8#Q.?P93;!/3C0.
M\0>SFS![=N)K,(?5AGT\C)L8OM05EX"NA#[:@ V57_S%G,#+Q.-X[,-S[GS0
MJN%AJ^N-QQ!R87C#K+J*@HB5Y+XA09PGQI&N&AA+_^.3]W'\%QG_B<8_^90O
M 8B0DHD[?_(BVYO<^2<?.E=;!)D:<-H'_O#DI3Z'9>KH]$=>_03)  Z!'W5$
M-,O?D]L-  X'[(%<D2&2R\L+>9<,GE=1+?*=)1 >LMY(&NQI6[LJ+U@!R;CA
M:&VA^4L9SFS,!2:W3F+C<UN?<W3+)U@G)\>J11.,3$IH;L?5MI8"##&>I#Z$
MWF:*7WR;)/)+ZY%R*R4,#WEVD9-'RXRJY)8X5O:QWB"@%%^ -"D$!5@.9 D
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M[>D2;&1B%1%=$J8\OB0Z?@V-$Q6FZN]!M2<N4N*(DZN"<E_RJ6#K9UE3C]\
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M>&F(QT%8ECQ_T7H#OB^,H=W&$W03??H'4$L#!!0    ( $L[9%(RO^81;@4
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MH\!OM2T^/U1BB$?OKG9D'BGD#MEPXKF-[#RFV1IT1>[VAB(C+,1:!(_F!(_
MDF_U\^/0Z!U1W#"2VEK'$WN$L$X:_;?P#SEPGZ'N,@P[TG_[D%UA#Y>Q66%L
M^"XV^\J=^ZD7Q[ZS%YP(#^A7JE]3J(*WWT(O["Y.6N&D?P/=U-G59,/6TP:/
MN+5YP.&U@A>9*E\YS6SS1IR53Z.=>/G 1*Y<(UYDCA6J.J<!WHU$^6@K!XKG
MYJ&TY J?7>9OC.]<$%H UU<<+SC50#MH7LY7_P)02P,$%     @ 2SMD4C>:
M!E>] @  ZP4  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULA53;:MM
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MP6\KG,:@G0/:2Z7L\\$EZ.;[_!]02P,$%     @ 2SMD4F15%<*T @  J@4
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MHF<5G4LZDRBY)J<52LR$95-VS*XV7*X=5\BXT/"-YZ4O.QU,&6I-Y&CG)(]
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MPXE#XI]Q"#N'T/)N UF6=U33Y5R*/9'&&M',P*9JO9$<JTQ3-EKB+D,_O7S
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M.#Z/!&4RG$^];ZWG4]58SB2L-3&-$%0_+(&KW2Q,PKWCFFTKZQS1?%K3+=R
M_5:O-:ZB'J5@ J1A2A(-Y2Q<)!?+S,7[@.\,=N; )JZ2C5)W;O&IF(6Q$P0<
M<NL0*/[^P@HX=T HXT^'&?:4+O'0WJ-_\+5C+1MJ8*7X#U;8:A9.0E) 21MN
MK]7N(W3UC!Q>KKCQ7[+K8N.0Y(VQ2G3)J$ PV?[I?7<.KTE(NX34ZVZ)O,I+
M:NE\JM6.:!>-:,[PI?IL%,>DNY0;JW&789Z=KY00S.(I6T.H+,A*2<OD%F3.
MP)"36[KA8$ZGD44NEQ'E'>ZRQ4U?P$U2<H50E2'O90'%4X (1?9*T[W297H4
M\1+R,S),!B2-T_@(WK"O?.CQAJ^H?/%?Y9?,Y%R91@/YM=@8J_'Y_#["FO6L
MF6?-7F"]P:XJ&@Y$E>1#8QW^%9-,-()\!GQ=9$T?6DT-GILF7Y1\NZ(R!^YN
M@GRM05,GLXTVSUW,<0$=J>A(N2>MGY+:"HA$XOR16/7$/L.07&%C&@N%J\0E
ME(ICA[L(:IP/[PO$!M'V=W81_ 2JW7MP08?;P0F3B*$:@T_0G 88G01O@DD<
M.S,-LL%Y/'3F$,UQEC@S0W,R\=Y1,!K$Z;O@M@*<2Z4%':3)X'R<!K?*4HY(
M63(8IY/GKB\Z:!T!>NL'A*NND;;MHM[;SZ!%VWJ/X>T NZ)ZRZ3! RHQ-3X;
MCT*BVZ'0+JRJ?2-NE,6V]F:%<Q2T"\#]4BF[7SB"?C+/_P%02P,$%     @
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M>Y:":FAMIPS9^=P[U2V)NQ^\4]T]G=L!]6O[VBN)>__7U]Z_\5%O9WA><]L
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M9ETQ@09QU.Z]*>+>:">*0@SV4>"L:>?!"9+&?DW7X)RI)!%Z)7F,'OE>:!\
MT#(>=(4):L;#EC"'9Y#(:-0D0M \]HN^CI'05F[DBENW<+LE>2[VRDCK6[%
M\R3LB(J U ENAZJ(JZ**:-B BE266[\=U*#Z\TI&0/R$=D4#\B;^%;;1N8JX
M"Z5&P .(WP.:V5SK803D3?I=@8&$B7\];GZ7!I=Y6-'NPB6!@!\0OQ]XP5[A
M9@0<@8RZEI4@=^I?XIL+R_ *-Z-@"=1O"8VT2"M?H^ -M',M7BG&VU;C] I?
MHV 6U&\6]3NV[.W2>Z4=+4=J:2OW?+,$QZ!=2W<*3D!;%N_TO'JG_8A%#<C
M+JC?+IJ172Q("A9 NU;X%,1-6];X]+S([S-,&C9Z8 #,;P"-H*[6(@,38%VW
M  QTS=IM >Z*N+?K0L@:>('VF5_[3;Q:>3ZK;,B[;@<8")NUW ZP\S+?\XJ!
M^)E?_'YDI*61,? "UK7Z9R!UUK+Z9^?5O\?(&/@!\_O!!?"N5FH$[A!UW0U$
MH/JHY6Z@B.O[E1I4OGAFGYL=F*U,#8K%QH6%-P.'7I^^X)Y.K-KG'T&7REJ5
MY(<[P=="9PW<_8U2]O4D^ZY:?D>?_@=02P,$%     @ 2SMD4CK#2/!/ @
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M%IP7G<X8QG2SVQFD=WY>UIIX^ORRY.<.C0O@_4)K>C/<" X/:/H*4$L#!!0
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MKXN9L5A8M?5CUU)9&N+\XX;F;-3N!3I?*64/"^>@FMS'_P)02P,$%     @
M2SMD4D:IFS<L P  U@L  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
MM591;YLP$/XK%JNF5EH+)@22+HG4IIM6J=.B9MT>ICTXX#16 5/;).U^_<Y
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M$F'>IPF)Y3<KRB(LY"U[,7C""%YFH"@TD&D.C @'<6\\RIX]L/&(IB(,8O+
M $^C"+/OUR2DV\L>[.T?? U>UD(],,:C!+^0!1%/R0.3=T:A91E$).8!C0$C
MJ\O>%?Q\9]D*D$G\&9 MKUP#%<HSI:_J9KZ\[)G*(Q(27R@56'YLR(2$H=(D
M_?B6*^T5-A6P>KW7/LN"E\$\8TXF-/PK6(KU9<_M@259X3047^GV"\D#<I0^
MGX8\^P^VN:S9 W[*!8URL/0@"N+=)W[+$U$!0+L!@'( Z@JP<H#5%6#G +LK
MP,D!3E? ( <,N@*&.6#8%>#F +<KP,L!7E< -/>5,[,.VI4\ZY<I%G@\8G0+
MF)*7^M1%UG097K9)$*OUL1!,?AM(G!A/:+PA3 3/(0$/LC4)8V0)%H+ZK^ W
M<+5<!JJ-<0CF\6XQJJ;^."4"!R'_)$6>%E/P\<,G\ $8@*\Q(QP$,7B* \$O
MY$-Y_;BF*<?QDH\,(3U6=@T_]^YZYQUJ\.X>LSZ [@5 )C)KX!,]_ ^ZZ0/D
M*3AT:^!3/?PJ?>D#"S9:O]'#[])0"Y^U6$]D[):9.>_5P&_U\"GQM=:_=(;7
M6I_KX0N2[)VOM7[7&7YLW9 -7G0Y*KH<9?JL!GV/)$HHD_P/;KZE@?@._OY=
M2H"Y(!'_1Z/?*O1;F7Z[0?\#HSXA2PY6C$8@X#S%L4\ 70&_LKZ28GUQM;XN
M0"SGGY0IY'W*1=TJN=U9'V36U<3;C*%E#]W!R-A42UHCYGFN5T@=Q&87L=G:
MV!:$!7)17P$-56A2Z!1FG+.4:%#H'VC#F.@*L2<N60CY,$TDQ^T*I[8!=;RS
ML^54,NV8V5]]KH>%DT-]'Z7,7\MIK[HB\ZG.]O"DRDZS9;>P[.JK7,U '5&[
M)Q&CHXAWWIW*0>34"-[4" [K!&>-EAM"]HJ0O?=W1,("N2 3PAKK<.V=KK:C
M7+1*W+1*S'02!V%#LQSYYJ]DJ^O<_."H8D?)J9%2]3]*4(T4/!6;-9ALZ!!8
MV1U!;:IF.&!@@\.T=B7FX&,:./3M+I>J^C:P&ETK1QI$6M?F;768Y0H.<M=H
MMQQU4#_KNLP#\"]X9-*Y-0'9&Y>&OV$YAZ!]E@D!RQ$$G1^IMG.23LMNS&<Y
MEZ!^,+TGG_+^'K\%41KIXBZG#AR>)[/E=($MXP6'NZ%VNEO(DWO*\M;Q.#BT
M7=(\U//\NQ(\U^TZ2Z9%YED2BTJ"0GJ":IO;,W3*4?KQB2J;:CT#M18UQ_\/
MVR4+H9_/0F"NK6I)1.@\1(1*(D)Z(FK/K-.^>SJT7?(1ZL1'U^_<[Z.2==!Y
M6 >5K(-^;%,[1:>L8T/H>$-D-Z2Q9!UTUMWE-%?O5M=.WVW8^UDE(UF_=.\W
MM6KV:] 9-K6E51*=I2>Z"8TB^5K6UGY6R5[6F<X$*H<">H[ZJ:^<\]S8 9FZ
MICN08[(AMR6A62VO^"WKY#;'']"-;;J>!8_7B5$YBE0'[/>8O00Q!R%92:C9
M'TH=;'=FO;L1-,E.)Y^I$#3*+M<$+PE3 O+[%:5B?Z,./(M?#L;_ 5!+ P04
M    " !+.V12S/=ODD0"   F!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6R55=%NVC 4_14KVL,F=3@)A'95B$1AT_HP";7:]C#MP2078N'$J>U
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MU99$%SM4WS<C.[-\OB4B0K_]#"S1K:*I_-T!**@ !090OP701U,E:/2&;*B
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M"70 O0%^7W*N'E[TMY#J<]S97U!+ P04    " !+.V12!4_?K<P"   '"
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R=55UOVC 4_2M6I$F=5/+%
MUU8!$M!VVT-5!&KW,.W!)#?$PHF9[0SX][MV0D:[D%5] ?OFGN-S?&W?T5[(
MK4H!-#ED/%=C)]5Z=^-Y*DHAH\H5.\CQ2R)D1C5.Y<93.PDTMJ",>Z'O#[R,
MLMR9C&QL(2<C46C.<EA(HHHLH_(X R[V8R=P3H$EVZ3:!+S):$<WL +]M%M(
MG'DU2\PRR!43.9&0C)UI<#,?FGR;\,Q@K\[&Q#A9"[$UDV_QV/&-(. 0:<-
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M,M\;4Q$QDSE4<DN-=QOCS%)9T1L_E+957?I/ZOJ-NGYKZ9_]]T>2)EO4-$[
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M)6RO#?/E&I!EVR>BUN01#&J>8^LD[+/'D7G#=$'FKK(<7\B'6T#&*_/1HL]
MTA"M:A<[S#N%BU8A/:-P1,F]DE@:\D464/Q-$-IT^YSI(><%O<AX"_F0Q*-/
MA$8T,B738"ZPQGTE8\\:GV']48L5Z#?56OZ+?=RSCSW[^ S[G3&UY6.R(+7<
MVP#.,"[:=R9KUZ8NGU,%;JD33^VF=)]-$CJ>TC3<GY"4])*2BY*>O(I3\9)W
M\09T2D=)?#K@I \X^<\:V(Z"KWY\H0J3=ZKBJRBFG]^("H^&28#>^)5A2*YJ
MB>U<];?]5IJWP_C'O5UI]TQON#2D@K6%1L,K&URW:Z(U4.W\:*X4VD'WQ])N
M5M#.P;ZOE<*#X0+TNSI[!5!+ P04    " !+.V12#DT]8]T"  #6"   &0
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MN[K69T>43;2<*%[8/C3G2G<U.\STAP<($Z#?+SA7VXG9H/Z4B?\!4$L#!!0
M   ( $L[9%)\%PNX+@,  "H*   9    >&PO=V]R:W-H965T<R]S:&5E=#4P
M+GAM;)56;6_;-A#^*P<-+5)@M5[L.$YK&ZB=%NN'8H&S;I]IZ601H4B//-?I
MOQ])R8K3273[Q19)/<_=<W>ZX_RH]*.I$ F>:B'-(JJ(]N_BV.05ULR,U!ZE
M/2F5KAG9I=[%9J^1%1Y4BSA+DFE<,RZCY=SOW>OE7!U(<(GW&LRAKIG^OD*A
MCHLHC4X;&[ZKR&W$R_F>[? !Z>O^7MM5W+$4O$9IN)*@L5Q$'])WZS1Q /_&
MWQR/YNP9G)2M4H]N\;E81(GS" 7FY"B8_?N&:Q3",5D__FU)H\ZF YX_G]@_
M>?%6S)897"OQ#R^H6D2S" HLV4'01AW_P%;0M>/+E3#^%X[MNTD$^<&0JENP
M]:#FLOEG3VT@S@#I= "0M8#L1\!D #!N 6,OM/',R[ICQ)9SK8Z@W=N6S3WX
MV'BT5<.E2^,#:7O*+8Z6GV6N:H2_V!,:> L;S)7,N>#,!UF5\'7T,()/6*!F
M AZ(T8&4_@[/.-@P0B %'\L2?5+^=WAUA\2X,&_F,5F?G>4X;_U;-?YE _ZE
M&7Q1DBH#'V6!Q4N"V(KM%&<GQ:LLR'B'^0C&Z>^0)5G2X]#ZI^'I;<"=<9>
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M;+>ZF$Y5=>%J8N3:-;*%--@6W3#''Q<H&X#[2RG-;F(_T/P*1[\!4$L#!!0
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MC0"^7PBAMS=F@>($=OP74$L#!!0    ( $L[9%)+H50QC0(  ,(&   9
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M"Z(M!&H+LBT$;@O"+01R"](M!'8+XBT$>BOJK01Z*^JM!'KKZ&&;0&]%O95
M;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T.]C4!O0[V-0&]#O8U
M;QN]+"'0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU%O)]#;46\G
MT-M1;R?0VU%O)]#;1R^["?1VU-L)]';4VPGT=M3;"?1VU-L)]';4VPGTCJAW
M)- [HMZ10.^(>D<"O2/J'0GTCJAW)- [CCY6$N@=4>_XGWKG<MJE?.WY7N/U
M_Y/J<CXW72]_67[O'-WC%YP#_&_Q^ 502P,$%     @ 2SMD4H_AMVG3 0
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M2P$"% ,4    " !+.V12!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $L[9%+8#%2U[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M $L[9%*97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ 2SMD4J$'-R>B!@  U!H  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M $L[9%*SY?J,. 4  'H4   8              " @>4.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " !+.V12F?7.:*("  "D!P  &
M            @(%3%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ 2SMD4MD=R+I5!   ) \  !@              ("!*Q<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $L[9%(NQX&E5@8  %$=
M   8              " @;8;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " !+.V12J<N*W:,"  #>!P  &               @(%"(@
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 2SMD4LKBP#9[
M!@  *AD  !@              ("!&R4  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( $L[9%(.GECI70H  (,:   8              "
M@<PK  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !+.V12
M38)G^:(8  "D2   &               @(%?-@  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ 2SMD4D(B:DOI"   N!H  !D
M     ("!-T\  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M" !+.V12SO:E//D"  !_!@  &0              @(%76   >&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $L[9%***R2CIP(  ,<%   9
M              " @8=;  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!
M A0#%     @ 2SMD4J-0GTGE P  10@  !D              ("!95X  'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !+.V12P_JRA?$(
M  !O&P  &0              @(&!8@  >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;%!+ 0(4 Q0    ( $L[9%+0?\.]NP(  %8&   9              "
M@:EK  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 2SMD
M4H?JSQ@@#0  02D  !D              ("!FVX  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " !+.V12%#B$=3H)  !Z&   &0
M        @('R>P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( $L[9%*=>POWM ,  .L'   9              " @6.%  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 2SMD4NON2Y?L"0  XAD
M !D              ("!3HD  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " !+.V12ZD>W?D4"   6!0  &0              @(%QDP
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $L[9%+_&O+
MNAD  (-1   9              " @>V5  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ 2SMD4H0@$KW( @  W04  !D
M ("!WJ\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !+
M.V12,K_F$6X%  !%#P  &0              @('=L@  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( $L[9%(WF@97O0(  .L%   9
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M970R."YX;6Q02P$"% ,4    " !+.V12W/TIC:8"  "E!0  &0
M    @(&%S   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M $L[9%+K._JA<0,  .T*   9              " @6+/  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ 2SMD4HQEJQ3R @  .0D  !D
M             ("!"M,  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " !+.V12'LMS/]8"  "6"0  &0              @($SU@  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $L[9%+?4"F3( ,
M &L+   9              " @4#9  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ 2SMD4CX@*HDG P  00H  !D              ("!
ME]P  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !+.V12
M^N4T=F\$  !3%P  &0              @('UWP  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( $L[9%(ZPTCP3P(  $P%   9
M      " @9OD  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ 2SMD4L4<+42C P  Q0L  !D              ("!(><  'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !+.V121JF;-RP#  #6"P
M&0              @('[Z@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( $L[9%*BU!.+3P(  #X%   9              " @5[N  !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 2SMD4AI%6FR]
M @  G0<  !D              ("!Y/   'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " !+.V12:55Y39D#   ,"@  &0
M@('8\P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $L[
M9%(N(R1TX@0  $48   9              " @:CW  !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ 2SMD4LSW;Y)$ @  )@8  !D
M         ("!P?P  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M    " !+.V12O>GE@C &  ":&P  &0              @($\_P  >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( $L[9%(%3]^MS (   <(
M   9              " @:,% 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL
M4$L! A0#%     @ 2SMD4JT1_@!=!   I1$  !D              ("!I@@!
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !+.V128UZA
M49\"  #$!@  &0              @($Z#0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;%!+ 0(4 Q0    ( $L[9%(C!H=<6P(  +<%   9
M  " @1 0 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M2SMD4@Y-/6/= @  U@@  !D              ("!HA(! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " !+.V12?!<+N"X#   J"@  &0
M            @(&V%0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( $L[9%):8E!#4P,  #0+   9              " @1L9 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 2SMD4BT"[G_! P
M;0X  !D              ("!I1P! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " !+.V12#Q:'2L4"   6!P  &0              @(&=
M( $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( $L[9%*A
MV%HB1P,  )@+   9              " @9DC 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ 2SMD4H/>I-\J!0  C14  !D
M     ("!%R<! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $L[9%(,/Y#\Y0$  '\A   :
M          "  64W 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( $L[9%*/X;=ITP$  #8A   3              "  8(Y 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !  $  =Q$  (8[ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>138</ContextCount>
  <ElementCount>364</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Debt Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancing</Role>
      <ShortName>Debt Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfMarketableSecuritiesBySecurityTypeDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Summary of Marketable Securities by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Marketable Securities and Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Assets Carried at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfAssetsCarriedAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Summary of Assets Carried at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Scheduled Maturity for Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsSummaryOfScheduledMaturityForMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Summary of Scheduled Maturity for Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Marketable Securities and Fair Value Measurements - Roll-forward of Aggregate Fair Values of Liabilities Determined by Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsRollForwardOfAggregateFairValuesOfLiabilitiesDeterminedByLevel3InputsDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Roll-forward of Aggregate Fair Values of Liabilities Determined by Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Debt Financing - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureDebtFinancingAdditionalInformationDetails</Role>
      <ShortName>Debt Financing - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureEquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Determine Grant-Date Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToDetermineGrantDateFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used to Determine Grant-Date Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock-Based Compensation - Summary of Restricted Common Stock Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockAwardActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Common Stock Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Significant Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Significant Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerShareCalculationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Net Loss Per Share - Potential Dilutive Securities Excluded From Calculation Of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Potential Dilutive Securities Excluded From Calculation Of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dyn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyne-tx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dyn-20201231.xml</File>
    <File>dyn-20201231.xsd</File>
    <File>dyn-20201231_cal.xml</File>
    <File>dyn-20201231_def.xml</File>
    <File>dyn-20201231_lab.xml</File>
    <File>dyn-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001564590-21-010726-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-010726-xbrl.zip
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M\]._\X3#_/_A+'H'WP@=@-[F !2G+HV]:'()X=ST_<VF?_<_59-K8^?3OTY
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M?I'2RR!8B$4=M!V&5$LINQ8P.XR.NJ0EUX$%TS=>/*%0"8(GF!]")1XX)=C
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M,TZ4=E=(.Y^3NDABN:-&7RHTA\ Z&5&!F8"LL*(<GVD1'2"+I<1NH^(%%:F
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M(5. %+MAA)$JYHVE9[\P+0:"%U@?B?'GPWX/O2=D((ICP'<(078>P^A/BB;
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MQ9R"GG?^V^WME^*VL-2!OP>TCT>M0PC?M^"M 5M*9UROCU!.$6@I3AJ;3:?
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MZG&-?:_3OMB>7EI,<#2WU,^IY -+VO/WMCDP 6K=V&9=Z[0P7#O61,E'\H/
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M*I107%4MH7"4CJ5YQ8WU9^Y9-_XFSMRC.AW'(IFU-!0WFR!4JG&IBADRF\-
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MZIYD:Q6AIAYWO9,R0V\?;,L+-Z#V-?Z;1QGN[.UHOK6;#F\=?$Z=,%.)+B<
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MN#KC^RS=L1U+]VL:A,'_="L"  91N'V!P#3<'8<Y7\+$,IE-_@]F#F>7XS\
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M ^13>(N\KXX:H+J-#].FWD6-?2+8#[WNB,$"#/&AV&)'_;Z#'71@Z!)E4[9
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MD^+Q2Y52#Q?6!H<O;T#UN,;2$XF:-)XH2:0'/.=+,Y"U1.*I$/L2VL)UCW4
M8 W&:P4G8%ZC&TM.?/W]PQ^?V<O\^VH!AYP6@GV-0 HG,@ ] U/].V+W9/4>
MM5\"$"\721":DACK12ST8R_A78W8K:Y7'L&* M0D/+7#KN,D],'$%,7;(+D-
MW N>%G30?V,A#+C0+#%%$X7];7<4WP/%W4ZA#+Z!]?ET%E]WV1M4FV:U!E)F
MPB\>;.ZP]@ZE<EN98=2-TIL)/POUKW2-%)RR06_8UVK+W%7><!L@Z!2^BJ/:
M8_%OM>/!.^<RJ\-\<27">&'*^\SG(O%@5<)Z1=+Y&8JA*J#%2^7?UFN2*$D7
MPY<@OPQQ/:60D?;:QO!4M0DOOE*KT<BC\K85U&Z:=Y?I^74;<G6#*RCJDNC5
MD.7%=11"(-8+TTDP,84'IZKH1@%HJ@HA@)R.JO.K8</Y[>0+4]4%2>%VEUEH
M"@%AQ1BP]_08D$ZZYHNR?OX/U);T T_1J).W@RK7S<T/-L(9Y :^UN=4693<
ME"4QG_Y_ +H?S[4A.==9Z<J<2Y8YU]YD2;P0( [@)W'4A?^$J*ZQKDD0J1F#
M]1T&(NELI(BJPI*(.0H*7)C3J8"QH<$8ZO6(XR\9:!ZZLDHUG50)([[VHD\G
MRZ>;9CU_$?P^?Z<)!X7:-8-$S52\QF8QH:<0<-;U:7AIVT\2Q;$5+9]/[Z;2
M-U,>A%AN V'$_RJ(S6U0RJ/B9%A:))@&N Z#N3#U8>IF- [[*@[AA6#)A[>]
M@M(?H 8 86UUX//516Y3^YTRCR*AR%%JR4T3+Q3T2AO?*@H6//#-%;#DL\4T
M@1%42Q29.P_/1L][W7Y>+JB.D+("E+I7XF3.OV&1%:!-BD0M3+D<"&WYJ1V7
M-PM@L>7/*A>#$37J"[V7*R1(<6-I+#9<I-^5T<HO80R7:F6@FWEM^&59I+R(
MSC1(@(YK;,*[ZJ'I55MY)H[FKL\=U)ZK"""SB11_9_A^-SW=7%L;0@?WD]=@
ME^)_03S$UPR+.H7BJ1]<!BER" M/<-@:)_&2AVA @0DN4B9Y*)0%O*9K5W@-
M.A4UY70:A$$A1K$.F_Y=N:,H'E"QL/6.& S\PTBOBNQ4,E-;X[G<Y#7X:L)3
M&0)J&Z1VUAO4A?K"/*S+WI45J>#]IS6:E.\N\]MOM9+6=&T"0 >)Y@:0P6#F
MQUC7;AVS2M4[8R@F*(^SJB![653."I=K8_5F<6S*9 %^8!'!&TOA9;BG21@J
M)KUI4>S7-I'9KQ0;G"TS>L,K!VE1?ZSZNA,L Z.(EJG":C+-2_3IN<2=7B)@
M_ZN,,5QN^-]\P.6N5H]9_]NX2LS8W9;J?\3&M25UI;J)@-TR][P$S?U\N@-9
MW6%JV6^*<JDE5?C#UF1N?>>;;*3K)6Q/-.I99'8X>LNE95!@BL*5LGE%&)8F
M6BE?$*0U&5-%JJR>>G-9U'H)U<^%T'R#%HK<6#UUU/3JJ<,N*R="VVIN.]/>
M5BK:W5K0KE-5G>;EKV'#5WB1T2!-XNQRQGY7OK.1+OC9J7AVHDI52Y[Y:F>
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M'J$AKX7"IT!^>P66<)#B7U5)?]9L25^;!24$/#4-L)& >=#%P&'36I)<9NA
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M1V#I<4U&7+Q;"Q-A@>PK4_.IK(@/:@Y>Q%![$D>9*IV]K6Y1AXGY(HR7 HV
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M56.P,6DU-3%<ETAYDY1<E$=^7@YN:ZIQ@_)O5K=GHMK; W\19S>(A.VS612
M64G"V=1*IF-*?FNZE4)MA<E:I"?HK<+\OYHRJ4F=U1UYXLL"4FUJ%Y&<>:4[
MA;W)$\T-<9.  #+T[XQ[1;^ /(UHK=9B62.?A\O_"5,+!PW1TL]6:^^S8?HV
MZW(E;6?&I8UJ.Q1Y=1Y=$14OOHJ5*"JDJ,X&U&@H;:_>L%II\?\R_[+4'_7*
M>TIU@,CUA2Z_7\R&>7M3#:&H&"DB/R\6M%K?<:TFGRX%5*_*MZ6R?3ZF[3N1
M2A'%O(IC^2;*58,>!Y7VFA=*"I>%TR.MNFK5(/4\527X 01R*=D_JBK6ZO(;
MA/:]R@4V1FCKN=*(M$ 4OPQ#4^3\:2X+US<$JSTA= EUW9JH4D5]8YNB+9L4
MU9S+I!972X)KKT;%JUJ(0%$>1 "YRPHT^G;K522,T->ZU4=I(E61KBM1FF6(
M*LY-#FP=#S5!VJ["BXJCL@I%MS-KY;1!56/XPK_?P+^FE_O2<\!2_OWVJLRN
M%%0IS]I4+;KJ&Y;9A"8CL%+U>&ER"CMF%U/4:<X7/NC+7-D6:;APVVT5E//M
MEJ[K5[KE\2>X?U %PSU=F<64,U<'#F4[@$H:9+X3VE386+WD5LV)CTL$/!D/
M#E]7QFWT>Z[7=SP-V# "[?R'QYALYVV%J,WLBTC;(6I@NM1'T2W)O(<ZEJ^7
M("V'4\HOSW2QPCK3B:R7#]X%H8V%A?/FH&N+9Z7SC?*1FM41!M]$&,Q@>YB7
M7)8;!U VRLA[E2FCHUP8R@=L'KJAG5:EE'/'H%5TU-%T4K-?>),%=CA4I:3S
M2M!X^!,G9L1+7:0"S2)]U 6C,XU6DVJOE:VOH@TJEE=B ?.=E;YK5==#;?H#
M9;_!B (YJU3IKU:S*">Z+)S]L6AOH8^X2]6S:4#XD*(1P"3O_%H8[RMS##!/
M5>'J?!D9(UG5]%!Z,\G\?&U/!2QL_!4^;@'FKC*"E>82ET&#2J'6!&?5 E M
MS2IR=$?)-%%MWT)]O,G2ZQ@&*A9YY4[=6<Y(GTK56[7L4)QH_V/I%#*/[+*W
MV+Q)[[44)%C52ITY9%(MR$I'B-5'K%.U8*6$7^NV=(I4A4]2?.>J[5CE0 :>
MJM[)] U6%>W>3=<'I&K+"G04(>N>:M;IJD**=7'MN1O>2)^?Y"6+-KU0.6>5
M^2HFZR9XM$"KS/E,E/>HU-.H@FWDG3J=S:L(YFH+R^G -A?W5EJPG/9^K,ZW
M&J)V8)L('S7/& 4S5S4W1)J&8ONYS#9[K6[5O>5!\B<>0/^N#[G+H),;S+RF
M%[I\6Q[+S\MI<?LDYE7>@W>[<L?0A6"],%UE-A1!IXKTQK$DONNF!5AQ/>\!
M?IV7+"Y\*KI<E;$BL7DS^I!16:O1JT;FI5WY1+68#5)]RY]*4P-D:K#@2NG.
M58<L]))CC2_TM>45T(T963RJO&^@>S1@ "CJ<GPTUSO"W&(S]]#EI^%145FG
ML[(.5"':+ONS4-WJ4"  ^Q1M-BUTS.75  \E;54G/!0T:M.H^[S$$_2'&UMF
MD17'$M':E5FT=BU*]UQ6;8%V(ZP*<"U0JWM.]%/JUB=:5ZES8-//1-4"T09"
M(K!6SI4("Q]=Y<ZS #:MB3?#.MS3BDVJ>PB"6BO.!-!Z0!.Z?*D\,$;UJPMD
M]:KJRZ\5)/&#J[P0!\;<5@IKW+6<Q\'K=Y@;ZI\-NF>#'Y_#G*3B*8X"R7R=
M\,5=(\.+3/U'EB*KWH:CC"$/>SA[OL6Q<4/L.4*R[UP?[#5NC?8V61! L+)F
M3;_8IPZ>?XUT33J@Q=]9K+S_2:"#\;0K/*]IF'="TF6\L(RC,LQCLTO/'<ZX
M<4#/5;I1UNF]G8KJ\;:*F:H14IG_2EQX/2Q\+6*;*$P4;CB%!Q4*O].JOE+]
M\C8F[\+"DNX5I2H"]1 _ 'LLQ98XB0K:-?_2)?14/P[3>$<[ &"7AQNGXOAN
MS:#JLM77R^V7O.!_S6QXUA8!<=X]NSBH@'CD17O';"Z2D"0A]U]L=:&G9!%L
M>T*>;!-P:W+Q.<D5-Z FN4)RY8ARI32=UH5,Q:PQ,F9M^X0.:"UX2. XL@9(
MX)# >;3%MN[%W;JU*V1*)LL3P?(D>-N&"R73$]&]['9TGS\\4E(94V@B+0-L
M*^IE"1A&ZFE2UYV>SU7VI!F ^AT\2?[T7/V*!)D3:XL$&0FR1UML1GH50@HC
M/*ZT\-+G;^@S4B46$A56'JO4)AU%4A&"YBS-YRG';U0 >F@$7-Z!?2YX1(YC
M(B&1\!;'\;!V]K-N:M1.O67]V/M)T!5@,F#>H>X1-\'VJQ@[@M=%<<Y4DT*Q
M_&G-KSM<]>OJK&%59["66WRMCOBS^<($3A>!T-5/3:S,^DF[#ALP*6MH*M6#
M3U=>JDCR6'\B=H+_Z3YBI0RBV3D\IAY5\X8G&/0F/XKD\PR$Z VQ-$WO1?F'
M,%4\L >\Q,EP.HRF&O]GNJ/H,+3K^*D*I,A;K>A**:HP)ZY2W;E0]S/$Z?BI
M,A^\WK@>0\-41WI??Y]31HB\Z=TT*&.K"PJ93/V\J9@.5UL;5A$-)V\<4M&Y
M2?_8],LT><K;'JD"(A.=>14SX!*Z7'RIFL;Q1*=_5NM"K=P+"T\A5,K_HBJT
MI$DPR?!*8?BTY:6*V/,\%K@(Z55YT&K@U?Z6A;PTJ;@Z#B8O[^ 7\4"[O',]
MKCA(JE6AS.OH"$.,A*I,"H(\53'$9M K8YIQ7X>U5^:ARU[K=+>\PHLJ:R17
M\NC\6.AR,46]"L4_&,7VEQ >1\&K4I%-\E>1!(?97?$$5*B)=HK-&C$;U[Q9
MZ;0ZB*[3)/^-R\!3_%B17($TE-9J5*&9:ZD*G=2O3.RK'AFN=JQ$= G79:HK
M+=;[T>PNR:76* ,5AH>QZL;U10'X!Z%Z>#&VE1'IL)!<X.2X8P2I60J;>57/
M95@4D>188\A3T:X^/AA7<%7"K(UFMYGR5W_V %-530,MWZ=XB_PN^K;*A*B-
M3J58Z22+U6=6.MMO#KR]1?FO%$FJB*4WJM7N'S#:3P+CH%&"?4Q,\+ZZ\!VJ
MA;4"*<-[M8!TP(8HIP/?\PK[-.NLA#RQ02/CLLA9S[U670MW>N]Z8*=216@_
M<)7*@B0S"<;YAWE.<_69E2!0?5,=R:OJ6A2#"%9KOR'_0)^M"/_57O!I$H?5
M2X&AL(-0I3%,<^D_8I6$K+.S]4.+(/HB@SU"N:9^54G_TCG1EUK;2J&EG2_T
MAL!T:P55:-(*%DD\P3?94LEH7R[6*?VJ4A_FDTY(O25O>=CTOH^?MY3/:0QE
M:ZE U6)!_)JK,@I5BNJZ#2;*4M:X6R1<_A9RN,=G#Y8C\DPMYZ?YIG@>^R+L
MLJVS6A97JO,HKT=::7T*RUP&:5&2I=">.FP[D)7"$^J40LA*A8+.]B:N*N(?
M0\B"N7B*ORKFHLO>QLE4Y U6U@:I;%!5)G(S2W>D5UDZX'.F(E_?"O&AL&)O
MX&+3JZ*:Z6!3(:IF?4.86-,]8<SU[LT8K<NRJ@I[@LNY4D_O/5[[,O^Z6EJO
M7ML%="""G^\Y_=K62^VQEDB)ZB1/V0^][FGI3X/)"''*BV144Q055;.J9XH;
M2*V+PP">XN/(E=+KZ*;&T@,#OCPZK ^]X&Y>%WF;9G[W\8.V 4JWVK4J;Q"8
M.%"C-(-Y7@#$9/KA=* 04/.Q/@ UXW@GC"I5:=L89HJ^,U-&M=ZM'42C\C24
MT>@ZO^9M)=]$K%1OP4]@^'K?NV&N63[%. R5; 13]5DL4J$V% A@7;CL*"?6
M%7W1,UZGV]V6.C=L>HW3VISHW9W+DF7#ZQA>R7+[6BF?I\^UO#*QONIVJK#/
M6+[,]$S'^CZFHDZ9EF;*"\%RB>>!EUN]E:B"=!:#,E?E3*J/40JV* R %8:
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ML21!$51)7,]-%"S(H)R""NWJ;."(_LTC-75:-O0K&Q+8<VB3!';I25PV/EC
MFD+UK1 R=06T5YX73F&51(:6C:\W,KK2N9H7V-)@/K#Q9]?+9*C<^Y6Z=.H*
M'LH8!9.78O4-V"BALU#5O4?)Z:DB! OA![K$6P8+,C%&D:X_C9(W$L(W1=5-
M >?KF5 "3E7'_[X(S(F%^![H/4]1HD_GUR3J TRIUH#JE:8[J.3>%%U"RJ0_
M;[YK_F.5E!,8+R6FYIA=7/G;V@],-8)\0LU$UY9M(%?*OB@M8VS&E0H]A857
MRPG'ZH)J8Q=/GV8R7^ =K(>--63JQPYYD7ICJ1G#4\_M]BH%=Q7<E6V=-Q-^
M%HH/TZW=,XK.T[KQ-!:NEU]0"VW4 W>L^/GZQJXF^58[J/FR2CK5]\R&,<6^
MO"RTF.F6V7G;$64IFV),,C^ ?):'P>P?^6(B)'3/\0<(A&E3_[2JGOL2S(%(
ML,C9IWC.HXTJL6V]N"SLEU8TF'J\(":K(3I8NS0M4 [1+VW-;MX#QGM@5J@2
MIG4)>P\2>3M\UK; W:?O>B.ZW;TO2_ [TB6WM5 YTT9W'X0JPK%!O23=[;/;
M5!*]S9(H/V/#HHS!=_4/6RT.:@QNA<77&H%U>G"!]5@67%,Y\DJ'"R:NF&=-
MQ<$9ZZLULLI=X\HJ)\]C;SC13X]'LGDG:>74ME7_6^B4<TWNN>.5:Y!L_#S#
MI,9$MRO49R3Z""Y.6+]7P;3XZPZR](:DX]W7_M9#<714;EUY)B3I$&=<]4B)
MUV*2?BYB,%[FF5)OX^0SAQ]M/1U[T-9*>6^A6WNE''_!_;XIE 4S6(H8PW2Y
M4%%MVT-N\MZEPE\KKOQL6_#%?@V;=IM"-6%G*W[SC4=7#Y'-C3.S\M:VGF4>
M0>B?]KK#HY]F'N_<Y8F*5X@SR2-?_F2K9NYW!RW&:$?+"08%M 6 !B='Q:K7
M[=/99BU 4 >N@#;"1(HC<\R M*E02JO9XZAT:R)?2-ZYC=_7,E3]7QBJ3A+/
M2OZ0Q',-,7LDWF!_YW,3\:M(O/<J*X=$GI4$(I'G&F+VB#PR\NHYX7'*0UO$
MW$VXJ#=:\ 0FCL2AU0$X=5=LZ\)R7\7SN4A4I\D%7XC$UO"0FB9K'4KVA^_T
M=T#GT00A 78[8!<UV^*>F#4S#.&L,^H/;,7O,?=9QX?"?CZ1@K(<'U)0;@%&
M"FKGQ@G]@;4HDIJR# ]24W;C0VK*+< N:L=2I*9(33D"B-6L(C5E.3ZDIMP"
MC'93Y.YS!XH'.4I\I*R.IF+R"CN5J.J7NF>/+Q:Q#(X=67ZS!=%4+!R(/")Y
M914>6O^W6;WW.Z>]D:WP$%TLPX.T!]&!\"#M<3@?)I&F9:0A'4)T(#P6]8,R
MTB&D0^P"Q&K2D XA.A >M \A+Y9]4%B=[[9KG;%JHF)3@7H5)PML$R*8+R9I
MI<+?D0][=\S1;@-$]@=0W)+P2T$O%F)VL7/^?)M-BN%9Y_3\V($O]F;5'Q\@
M:XA&"LL^3$AA-0@S4EANY1.0UG* ;:2U[,.$M%:#,+O8N3)CF[76D\&Y'8*0
MM-4&=/;M0D!*JH4"CY24>YC1UFI77^#HU Y92'JJ89EQ;6Y$:$/EVINCC-J,
MCOV1+[LDW)--4@/U!UNQW#$7GVR5F_$=C3JC\<61029;Q6FI2HK/>HA(\9'B
M(\5G9QX):3^G12MI/^LA(NW7(.VW4Z50TGX/=8Y*6L_><U12=J3L2-DU2=G1
M5N] /LZS?7,S6JGO-!PY&NMP'?<X]N>43T)17.4'5_CW+S]G\NDEYXMGK\4D
M_5SD)[Z\XD&(/W@;)Y]Y*+[@WU]@@+^%L??MUW_^@[%?\E^^Y4'R)P\S\5)*
MD<K?!9=9(OP/T2>\70*0_L9E((M?L\!_<?+V+YBWP?#\A'GPBO#5)S%]<?(*
M/^V/^^/SB]%?@]X _M'KJS_Z@V'_Y-<[P(B=)FNH_;B1- \-TY>98-,X#.-K
MF >F,) ,I@D^3-(9FRQ9**Y$V&'703H+(I;B]3"A2*Y,L%D@$IYXLR5[(H5@
M?\2I8(.?.NHRKJ:;>1SF6/B,I]4?QA'C+,D!8!-$ )^I?KD021#[DBT2(;%!
MJ_^,E8OHCE39.L<(P-:5JAYBUJ 6)S@SAN4O3GJP+$2(K7 ]&'WQ;R,AU+^-
M[-$-9@M)8\0$L#/D"RF>Y7\\9WECVUZUJL7F&(6'EF<8DS Z=K1==?5_">:P
M*O\0U^Q3/.=1FTS"PD2W,?SQMI:Y1\'$RUM4]T='[5$].N^.J,=X%4!4Q$QI
M8F:4\!R&)D%18-7LU\(3\XE(V+#?8:A2;37@;8MQ/3*JAXF[.P*..ZBYA_5\
M'!FX)\J<BS/)(U_:[)TZJGO* 795E=[@J#JOW^OV#^7);XE2?(_;*]:WEGZN
M>1[=X*LU I4H2C*X]0!K&7QL9S+)8)+!1%&2P>T$6,O@H;6,)1E,,KCE%"49
MW'" [4[%)0E\_'SX!R]&L>*4WXIT4\/6=(S*LSU)^!C=YZG]O,W%7*C]O&.
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M$ JK,ZIJ)U-L$B>^2/+YEG$8^$Q?R-3K+G@"$]OH$ZPX6<0)3P7SQ22]?W7
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M0VGQ 7F1"P_0'R /@ ?HCRU((U63%AV0%CA./#HNMTZ G!>+UKR+$S*E=:>
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MR@F1C 72/'HK;3VSN84,9]M,YV$Y2=(^TXD^)+_Z5:KMH^!19ATWP4#,P(2
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MG7!.!#_#C%'BGHB4>!S<2R8,AC45MF_=_=DV; )D.8V[H1/4 J)80H1%OAJ
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MD=4MA%-"QEUO/>Y"J$\P<V1RX 8'T11JJ7A0)GHD"Q5&0:$Z(P8]JFZB6I:
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M9^H<GS.MX*CTF3N5)"_NR8B2(?&1?,G#9,KH_&B8+SC: ETV06%>5,V2$ 9
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M6US-'0BGDXW6J%+>9>G=9*^=JHWXXW@+V!8_R/\>09>?_@]02P,$%     @
M3#MD4GR]+#I<)0  &ZX" !0   !D>6XM,C R,#$R,S%?9&5F+GAM;.T]V7+C
M.)+O&['_H/6\S,2NRU?=,343\M7C#5?)8;MZ9IXZ:!*RN$T1'I"TK?GZ39 2
M04D\ )#$0:L?JFU+3&8F$IF)O/#GO[[.@]$S(I&/PV][1^\.]T8H=+'GAX_?
M]I)HWXE<W]_[ZU_^\S_^_%_[^Z/SRZL?H[$;^\_HW(_< $<)07^\^_ZGT3].
M;Z]'UW[X^X,3H=$Y=I,Y"N/1_F@6QT]?#PY>7E[>>5,_C'"0Q/"RZ)V+YP>C
M_?T5Z#."'/K!Z-R)T2C][^OH^/#X:/_P9/_P^/[PT]?CXZ_'']Z]_W)R>/CI
MY+\/#[\>'A8 _)I1,2K\]W7TX=WANZ-W'SX=%;YXX[B_.X]H='5>^**#/KZ?
M.I[K3H\_OS]T#Q\./[]___G3@^<=/GPY_O*QB"E^6A#_<1:/_NC^*441Z U#
M% 1H,;KT0R=T?2<8W:TH_9_15>B^&XV#8'1+'XM&MRA"Y!EY[Y90 ^#;UV#%
M/%B2,$I__;97X-[K PG>8?)X<'QX>'*P^O;>\NOT4R_.'RA^^<-!]F'^U2W0
M+R?I=X^^?/ERD'Z:?S7RR[X(0(\._O']^LZ=H;FS#ZL: ]$4E\C_&J5_O,9N
MNIP<)(PJOT%_VU]];9_^:?_H>/_DZ-UKY.T!XT:CC'4.<0D.T"V:CE+TO\:+
M)_1M+_+G3P'%*OW;C*!I)38K'M&7?*#@_^ $P=YH"?CG[=4V9_TP/O#\^<'R
M.P?I P<]8P4O1"$5\WT/39TDB,5P+'E<(<9X[OBA-,++IWO'-WW/_AS-'Q 1
M1';]T;XQG0$(XB8/:#_GDAB^I0"*6/.B["U"0.OX\.@XVYM_N$?P)=#CUZDN
MV40HM06+$.W'KZD56#UZD&*U_FP9.MSP8N<5AWB^R #?Q0"56J4S3,V0[\&O
MWJD34-5U-T,HCAJHN@4HO_%#6>=7D1#8?'[H4_5(B5S[.GJ-4>@A;P6$8MX#
MH2DR*W0"[)9)8"HW4R=Z2(4'G(%'QWE*WWF @CA:_27ET?[AT5(O_V'YY]^N
M?>?!#X!*%(U#[R[&[N\S''A@I2_^E?CQ8IU- ;47F*S^&#@/*$@]$$Y8!PHH
M:D>#+JQO40Q:"7D7#@G!K8O&+OAF"=UAWCG(H>O'(E3P0%-!5>&]DWB&R!F>
M/Q$THUKL&8&_A>?H&D?1#Q1/IO?.JPB)PJ"5T.MYJ<)P@AO']Z[",^?)CYU
MB*XJ$"KP!R;.<9CN@5^=($$BB&\_JP+C&X"%"$&>'-*EC^O14N.'*":.*[3/
MZZ"HDA<_ID:,:GPP9#%H&SB:@@40%9U*,"KH*%@N28.G!L_SI;3>4K<!_N_'
M/W#H)O"G4$ANZN$HYOB9./YE3RNR9R1!WKJCDYH?20GB!*B(-IS #KQQ%LY#
M@"16I0J"'GF2T:=U4!134>I!MZ2I :82*8NBK<-7@U0MGZC';NL8"'\ -QA(
M\UUP$<^<:+;:61E ,<4I DV-VX.?$(D7-W!<C $5NI1/U(""OROF_]3!42<0
M,MIF_4%%SN83..47KT]PS$#K$B!! 1<X)6OP[/@!5=F7F-PY ;I#(,RIQCA'
M#S'[36:51$$K<5NS_4O_1P7^&?"BKF=\YA"R -=3_.S#!U#Y?I*Q%Q4 U.$N
MC[3JPT_X#+K3!^%>/T9^7X:610Y #:"4T!,X4329IN\]7\;Q!4@H>=I&K'\[
M5A4 6(5_"RB,7WTAWZ@&B%(:[JF&ET)\^:12;*_]$%W!CW*L+CR]CC7+%XR)
MNP;9(>X*ZC*KPYFHS)Z9$CRO1V3Y,ES-8$S X_^V=P2L.7QW>+@W>B(^!M.[
M^+8' I]$@!%^RN*. "[-87UU<1BCU_@B2 %]VXO0XSPS_\O/ QPA[]M>3+:-
M6[?,*,V!U3)G72++&+.]91B/3IIYU">Y)0G@6F(K50ANTG2,Y/?&D+RFQ#NE
MN$CO1\WTKF>ARXBML6Q8P'5@)'\VGF0^W;;I[.44GAP93V&%B[M%W9;_S8C\
M8@F156<0+'QNRFE__VDXM N?C',N?+!%S#FXP!4#891_& [EE33:LK_KE[4N
MKIC3^E&WH]6&5I&8,*/8%@W6++H%JCZ9KY'X7 O^9 FCW7R=))Q6*N=(M4_R
MV?Q]S)$@+$IX12HSI_B+^1(O3#%/)IHQP"JQYV! 64T!H]9\H]QFD]?7@ZRX
M &>/07.A5-!!P0^:Z-K:JYP)1U:I.V$F\!CZHR/S-9X8U:7%CSFYVH.@79.[
M7:":TVI!X$B,ULHJ8D;RT*19N""<L<)\XR[&"I[R_YSZ]T/;YV4M'(S:85OS
MYA:<G!/\4<0_'VPP H[0O_?<\97_,9I,;Y&'T#P]AU4E.TJ)W6B<$>X7ZP$'
ML[K-NB1000(?5#?3XR*Y^XT'510;5)F@GR%!3N#_&WE_ RZ"<OX%U %%:Q*R
MD/^8^!%\= Z_AH\W"#:H)],BU1\.$K6XJ>1<15$"-J@ \V[F$!2Q,&KFGL&O
M3-R;ZG)E(*MI!ON_),I.5O>XPB%+D:1]\QY=)UBDM!W_%L'6BOP8W2'R[+LH
M(^@6N?@Q4Q'"!8K]XZ*L::IJI=,/)ZGIBBY>$7']B$^&VD#72'7*][Z(K@.N
M?:4S T6+12;3@K%BNJNS5>=XDVX)4,$,WA=IEXP?Z"7]J#L)*$#4O=)=$K<)
M4*JYQJ4%2CZX?ZFA !^2#H7 Q"&+>PROF3LAV)O,2\R8R6O1I4"KZ=(70$QD
MF00!R_A?*(ZS0DX 39S0G:%TSM$DY'(D&D%(H)13N%S(SG9V"^ JI(@/-?D]
M+P=?!^4I]R=)3"=3T8-(&RJW86F@:%6X-I[3]/$XAK/'0Q+34S7L8D>T>4H"
MN!(CU6;9-*V3G5-A\OA+6@M\*MY85 % />[CMKB/5>+.$0P3IT< J(V-4[NV
M*=E93S*B5 [!D)E.X@0) -4XQTF"KGI BF<ZR32F;CVL?JI3"].A'/.EIP;B
MB^F!35RQ5@"P%W?E#;4;6$32UJ$<T*ZQ=M=86]98>\B13W\3C;7EVX;QR9Q.
M4Z[FVEIU@CF4'Z-<=\F56(]M*\*+9)M?<E-O^2I+)K=:; _-KR3C)K7$]<OI
M/#*_9HR;S@87G=$\(#$6.&XQ^@<DVU7G9]8KK[D@6/' B_<<0T$,LDRMIS]8
M4//*-_U!(*;(B-?MAG1%?$6 F'52#V65*Z+X-K7%\QZNJ@N6#S^:/[*%D\KM
M%!CK)CX>")$2N4O63CR4237-.6K68:K;!/=%,U_U >NRLYT/+8I/&!-LUP*-
MY4*L^<IV4B5+N%@?CNYX6!=K+56QQU@P&,LNJ.P^#9SP:@WW>2C;OF7)](HA
MQSQS.6UF"'=!/>/(P#='78]%SH2/MEL'+K%HXL*GH6R._ONP<IY]MGW[R/;V
MK3AP<CB48V1_C9PYKTZ&LL,V>GUS C]P.QR6M[MGT909BL$5SRL==/:^ER(T
MV$;X=6I;]$G3>V#/<,1W65+5D[L"P^&5Z0VIT&W7X"#:X%#1W$>HI>^T;4$.
M[JYS8<B="[NZU%U=JK5UJ37U+P;5I"JI?[&@)+.^,D+..-E4I]E-"8P%<UN[
M*8'179&JH9#^R"ZEU54Y^9#J<&MKK,W740+QVT),@A79FA*2._<CZMHD!/UP
M8OAW,CU-(B IHD,T3YW(!_T$"B@"2M-8/ O<7X533.;I'\]I37&0<Z NXM;'
M^[0%U#HE1LFQ';L(>=$EB/)*,FDR,M^)8D?X1F!*3CI.@)8F](9DR:$T12)T
MWJF$(1&0^ E215Y@4R,297F]>WR3$'?F1(@)@-A4*#&8BMG^(Z%J$GY)7Y]E
MK*Y"6O84.6Y<\ 8$EX(#;C.ET8K4"+GO'O'S@8?\C$KX89,X^--O%V$,^ICF
M40BMX4EW**CZR73M3UP+)P!-R9(E#Q'Z5T+]D6?X1SQH5P%  ^[W@*UX^*L&
MB/TT*.LUWT9 .))7!4)"VU[B(, OD_ F>0A\=S*%DY(?/HJ%>NMA[/)(NSR2
MR7FDJYN)N,P4'E+M+3ASE!5%+ZVXA [D@#9$JE2J>-_S';(HX"2CY"N 2*AY
MOO,5=VI&&&1O*&^'#SI!^UI3XJ8-X5AB70:>ZI$5?<RU#TW, =7.)6G42UA4
MG=HVH*1;#MB5%A,PM[C4TS$F!Z9DW_.F4G372FM*I9B?8N@DE:)[FD?G^[KY
MP)[3?F)Z8K0C\UX:2V$S+W2W O ;][JX4CW-)1;]O>X=SFW1VY)='(=AP79O
M#(-6TVS3G).V1R&![ &;$V)N*TM+=LCEAQAC=+OW_<F)<'J0,<5<G[][:=E(
M[#(FZ#83O3.!(U'/9O"8<C,J*ZVX2^9S./#",OJ/83IE(8S'KDMGZ="N/@P>
M(*V%[*PNI;OW&5"7T@$Q$BT9B>N"J%XB1)M[>0.;FT^IB'2O3,@$''6'<N0N
MBP6*7;%:#43)P/XH0O'5_,GQ25H@#?KM4>S2I"H(:BZ$6#4RGSG13 3KS2<E
M0O3T05"H]'_TL/T,U@*6[3M5N:#[LH9A7O'E@R6!Y(WCTHW[=]KB3<)3)Q1L
M9*I^7DEFFR#0+9> 0T ;1<5;EDJ?MQ5S51F\]7>+IN[*GI80W&OLA.-'@M*X
MG9C,ECZJ@G'GZ"&^"D&Q)/3--!PEOO#5,&RG0)7XKK]?5'S+GI9I+.5RG812
MSD(@>T-Y^[#0"=K7&E/.LH1CB75Y REG&='']1O0MEQSC0JJI'1=45J66FY'
ML%V9Y$8;B6O<$+NRR"VW<IDKR'*HNJ/-?%NYQAFNI+1D&VOO)^7:QO+$&M11
MRM,Z6W<ZPTTG7T:I;MU<'_UMZ=?PQ208,W1GBGMC1E7,B)5)F"OQ'9%>%>1C
MU1*ZM7GO+*@)U#(N#%HA;,;8)6[!,2SO<^?.D)?0+-]%%/MS.M'N9X2F27#M
M/Z,T2X9AM4'9!?3QT*-Z\(DN>H^YH:YPLB9_U)I@-;W/Y3B4H2P2;A($K&8\
M6P5**TRF0NW17.!4T'6-G C1R9-@QPA^SL96BC<_U8)1U.[WE(!/FC-2JNFO
M'(0*_"\3 MH'U ,(PZ7_2G^26(8Z*#+I!N>!%D3A[.810;8V -"Z:>4:A;G
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M6<_%#<'@X<8+\#*HL#Q13MR!#'E) /24?2K5--'Z-09T/<C3H""/N7K]3>"
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MCN+-$K4[5;F>Y=_I/P].A/[R_U!+ P04    " !,.V1275("2D)P   /' <
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M0Z$!PML1C?\,_[C,[M"7U,CTQ:\[T'9-SK_9$UYDY42X!6;R$E!D!M_65H
MR(V=JGXYI'KGMDZ77\OL.D-/<;K2W$ETT7"@]!9-_Z9?[1I*EH'9?Q=0,B>0
M*B]44.3NP.!8JL#AW">N45Y$R?\7[_3WUG(*#E3?H.C?&Q@[@/D%M7ON!4CF
M"1*UA0F&W N487!R*4<&F,%(Q^J;WS&\^!%H>+APH_K$Y ,Q9*F649<F0M%H
MHJ=,%^9(7JPEUX\HU3RF/_Z>F1+;=-R;)N4 *(M@SEPZM8[ZM!*2AA-]Y3I\
MML+NEV_@#F5%G#Z098QZ.D\_#:M'+%*:_MZR\&OVBA]@#*>W;R68D*KJ0H4D
ML43#Y;T5-H^(/3N/BHB+HGMA):=A=^LAH^GQBJIB1W)-HA*34!QB ":DJKI0
M(6G?0.FBX3;O(#O#F]L'E&D^:VQ]U?9NO"+E-0$A R6;4&Q=CL!1&D)+/8%I
M^S@90471[LSX=ALER>D^CU.\3]4SX]97;13;(.7-C"D74+()Q8SE"* !]02F
M[<1(T>[,^,,69@]X1?13AKX4CV=HNXM2S:C<0<)&T5*2WLR[Y 88.\#YA6+G
M_1 A1;T%"D=BAX1#1_AZET5I'I-T _8.0-,+)-^WTOD1/7_V_Q74O/@CB&",
MOQL6I**N$"%(++3O\*0&;;<DWPVM?KU]C/ XEON"%D_#_J=Y7M-+R>J(H(>R
MO[,;RA10KB> \04"XU!<0PE I*?.L,%*.G'2@LGA)N 1)HG1HJGY3:M%J4#)
MWPZ , EM8235/NK735B:3DR4[/+A[2)-]U'"SD55#5C^7;MWGB(MCR]M&1M^
M#CR]&?>B@(8T%)K&$S-E.ZV55"VDS$SZ^/N6)7]:]'S64ZK7D*&9=R<J[4)+
M4FV%B$#;U#64[\+<;^%JG^$9X^V[^[NX2)2358Z_9Z;<-AWW9DW) K0!;]]]
M>_\'4#*<WJ8[58_Z5!.2FKGM"L0!I>[79+&'D$7Y[6%[CQ)5>VU]R4R+#2(>
M+)61!XS^] 8J5S3JU$4P2DWT].DRCG[XNGK$PX4Z)0GDW[5S=)&6>TLMN8"2
M32 E"7I10$,:"DWCB9FRW9U)_!UO(O\S15_26QCE*(7KRSS?Z[[L["1BLW_N
M(.KMT(+P>_4K80A*CH"QG-[HU;!"RNH+%I?D"!+PGWJ0N'.-GU&R3XLH8_D(
MFK?V1U^V47F+F#<7J/BP#(E@[NZ[D$"#2@I.ZXFAPEV8]>5JDRWVZQC;[:(H
M8%[0U](Z-7K[*)BININB>RN_/+NX 9P9$+@%4LQ7 1ZDIK0PH>"F3]@8H. N
MKE_O[Y-X=9&@2#.QMO%%F\@B$/(6RQD/0)E,;]O=FD>]B@E*RXF!@EMFNSZD
MU##?OBO-\I#^XP:[0!:O"K@^B_+'1;I>%H\P6^0Y+/)/6*\:2> :U Q4JTS=
MC;[7_,"4AH=O_E:S!BO,&T3I&B#"'424/4@K_M]-;/'ZH")]]0YWD2CC8W^3
M'/*;=K3DO_X'?5=,,%ANJGYOUX@=7NNT%=&CIV^:.O3=[MQ+AF"Y$5KBE3R#
M:5-B!"@R4>RH9GD7W:M=:'1]TX&I44H>#N JR_J%<@C-@)JJEYF*H)BPU'SD
MNX,:]FO%9PF>P98;FINT^!HK'34H$'&@]#91#P_."0=R=T=Y!&;CG<#(S%VN
MJV!!.'("AL22(X%G+LQJ;)<0AWJ.ME&L5%.J[]OF^C^F]C*LOP<#-*R=\/2=
MB*JNS9NQ&-W 4?H$LR+&T\TU)@OQ>GY-!?H(5:LV*).R@**?M <_J!F"BF-0
M3J&(&])48N 8)8/P@%\8O\D63U=Q"B_QCV:K)N';#F;JBIK7[0#A BB;T/8$
MQUC(%DHM+86G]^/]@9+*O=@Y._LQ.6MI?]-<STU*'MHJ4OIAV'*'OE&_-L+2
M;2*J5>D(RJ/I\F(1YA9\1,!6V2V"_KH6L7/I'T,R["XTCNQ;JJ0@-=^T]E+W
MDUD]/[@G__GPSWW\%"58G'Q1G$59=HC3AY^C9*]U9*E(T&(EJ<+ @Y>4ESCT
M-@?6G,/P%ST<D9$Z9X%9(L"%60+Z@\ 4+ I0L@64[]CSS%,4)^0 ]P)EMU@F
MGDT9P_P<WA?UOS2J:1F3MHB0>JS<^^/'*/L5%D0"D%?<PO!%4X21I7IGAF8Y
M$Y:\ 68."'=0,P2$O_AODV)>]CY[G<%=%*\_?-W!-(?-BVX#/U4B9XZF GGW
M_LB9 LBXYD+"PZJQP S#1W4010:JG0%Z21,XSI!.FI0E:*Y1I]R.&6_#G&T"
M'#D,*J*$.\P=^3E(WQCT J?V[L^R)[7?ZPSM8%8<KK$&"NQ39 FZ(\=SGZ#F
M7-%'QR;,=-/U,3LP;G16@"6K$Y#"B=,]M>!".NH+&9JDA0KE1"-_Q0M\&H(F
ML/Q+T=R&DB]G-;#D:$S5YK8Q3]=\)YFJ]>=H^UG#UZP<WFS</0V[F7\]3+PC
M6^%5'-W'"=TE8M>@M[V/*%GCJ$!B6G$P.=)7IVFN?U4>'EI4U)QIA!1Y__YW
MW[][^Y>_ B9#&)Z@C3 RU?)<T$R.@5RT@.0(3G?#( AG<;G61\4)6J-=LR4U
MST#NVA00DGN2XULWWVA(O&7R^[?%:D6Z8^?7T8&<@9J<=W10L%@12"EZ2*3@
M?,".,0K#&P8006IZ"E/[24OQG,=41WRK5;:'Z^:42;<TPJ\T74&%H!4VPPR\
M. IAVW>V+LPJP;B1!KC(2,>S #)I8MA>J[$M_)4*?",MS^R696X7 +Z/W8-S
MFQXX>M=@[M=>OM=<(]OY.<\#OR%/E/!_XT+OL;H:'7, ^NAZ**U:9L5/WZ=,
M"R"DH["0P4A:.-S0-VV4U70'N8;++D>+*_=+J*.P'W*X'XCS#@.\K\@^^N.T
M[38NMC23,%V?H91TOX3I2M-Z>\G8/'CJ).OC05K%C.6HBNS MY]0 <';=W\(
MP^95<$,:B@P8H^08'IJ3*G(:_26:BXL1/U<A8UY^R"X[8$"7'7K7&_XN-$:Z
MP@CJRJ+Y0E7["83TZU8)@6UR7M(W^4HT#^<9<Q\.2$%! >H\::N;/4N>XB&"
MT--*_Y7/T7?M9F&1EI_E$4J999^ __[FNS=OWKP%NR@#3X3A7P'^VLD;]O]T
M_?3G[ZM_YJSY5K0O'E$6_PLC%A7@'*[H,W+P_NT)(.JEWWKWYNT/)WA'G>\@
M;3^='/X*_OBGDS_^\<\G/[QY3S_R_N3=^Q].WKS]2TDW)@6"U_1O^*-O_O+G
MDS_]Y8^,VLF?OL?_>O^G\J.H[O^E(T,8KMQI;&C($$(SK*1A4].Y[V*]IO7,
MHN0ZBM>7Z5FTB_$>5^N^I(N$Q<&ZG*2'.Y&*$2#IZZ_B%*P8KS ,?@@>I*BS
M0*%(CE @3,!E"LZ&4/!UE[C?[I.H@.P:AW2:R^ C3',<!"_3%=K"*Y3GGV"Q
MW-Q%7S5O%?5(6UU+Z;#R<M-8"E!>,(HB@ 1-W2/=%G!DJ>V9@9L<X\IN'!O<
M 6,/"'^2^$T*3V$11O;A&UA$<0K7'Z(LQ8N<7!#Z'&[B5:QU1*%"S1S,8>I^
MG7/-F(3ABQK (7T5A@\2=[*2'2CY 1&Q\R'$1CKNLSOF<WN4Y.N>)Y_=X9[:
MH9[[PSS?AWB!/0(PO-;LH.4O37R$"U!Z7!"ZHRCCJ9'J[SO%?^S4_DD/QZ^C
M;)G1TG-K>@AR#3/:KM[\O+R;HJOCW"X.WD_53^HSQS#<2Q/+SC/W?HW. [>.
MDWG,%"PSP-BR@SZ &0/*>5+7HQ+DB^I@VMSECBFY@JQ->007.SJP#]'5.K'K
M=#&Y)L/&J<.E&#.P4$#(]\67B^E+B9R36XSQ)J[FC5E@LY8.?O+K)5_SU6A8
MR2ZA0IJI!$783%.]9)S Y'^":KI2H+.3"EYR5W(]+WG'1N8Z <U(3!3:-]C.
M54H2#J%@)$=R$989$:A[M/#I<PU1:8%BT>,2EP,HC.,.RSKUQ<HG&G0<@B'0
M'<D[A&2@0%U$AEF?GQSI,&1\>CQFJ8*,2J/5LT<\4.SHZ4449W0YM]PT=VUW
M692N'N'R/HD?:-M1M;;OQK3-FK":\/+2DI4+ N(4;+ H;$M#VEGMFF<(H&#R
M %0+%$"/5BM[0+98]#?*[#?@V_UJ!?/\ @IDM2U53L32)&5$?=M>SGB"#10M
M+"0#Z\6K;4G=*ARCMRI+7*EZWYB\9>DD83X!=9!TVYF>I>P(;7\":]X[! U2
MU-<89K3<P2PB;[)X%62C%D8]1,Q-J9.H^X5FQ:HJ-!)(@:IA=)"RPH)%(FF#
M4+*9[AW4#<PAAHG4-SV'3S!!M#(LETO',P8(V61X]1#V4E>6LJ.Y$^N:81AN
MH@87TM)>T- D+51(@H3 J_2@D;WF)YAB%TZP,(OU-DYCXKOD*8Z!WPR2,H=G
M@+1[W^$,J>M$#99A>(\J;$A3AX%#E#31(2[4Y#:1%QW-ME8K,:?SOJ_D/'2T
M_@K#,[JAZ%MV.5]N>5YF367?]<L/(PL7O^Y V34Y]U9.7Y<0TRHM':6A6;@$
M#)F-M[44H.*/[%QXXC.VJ9,'1Y]0BIIC+3L<F>RT%2E:X*+$P<,>G#[.^I9/
M '\ ,64;RCY<#TADILYY@):(>(D\2T<K^VE-MGN_3+%AP;Q@\E!!]8Y%)5^W
M.1(](N?>>THFW&W"\)H^')""@@+4>=)2-S=YRF$B*^?N9FSFS>_;ZURD9ZGT
M'YC24_A ,OO:I@Z'MF=3V+H4#8FQ'VLI*,UWF'L9V@?L/=S[<:E%,3F,;L?G
MJ(-6)@>_G[U, 1&!I\\N-Z"=O,[E $L?H_=P'3T M?PR.N@1=0+'>0',3( G
MJ,V.NTV.OW6RM^,MZ=8FH!Z0BM I;VO\;F?&W<:,[$6?8&%V+M;ZHKGR&X3<
MNP0ILA).,1VYNE&O-H)2;5)K=;ISKK+L1_G4YS3*XQ6Y_HR3?:&7S3](RES[
M Z3=;\I+4P<XM+#TY1-P3YBR6W3&-@P_4$40::HS<+2X]U1E:ZI78X"R8_?J
M0SAY<:F_P_CA$;-=/.%IZ0%^VI.*E\L-%4Y(M+;P-%,.YI":<73OEZ4<(&*"
MD%)O]*'!T0N#8/W5TCR0&U#F:0I)RPJX#( )0;:^+ 0(<DP>#B0E\\IR>2;7
M2$KDK)ZA#)'W\EJH5:\QD,LC'>R0@1)G@%,B@XBO5^NJB\J)W!/N9"3+NRG.
M609*:%ZCC)P +8HBB^_W!6EU>8>N(],>Q,Y86AX)V(O@Z][ZN%AL(,''M;6T
MSX!<0?),+*-QJJ12:19PT8 H&[A#@$DWW25ZEUH_IQF,$E(JX'^AA*R-?HKB
ME QJF=["U3YCY>&R.,=_.L?_3!_PIBI&:Y,"U/YD<&]NMC*YCTRU1#0@D9U-
M"K91]BMD1I978H4=JIQ9G$+L<H/B<[6NX>@FV!P7%!!)6=1;IJ 6%G!I 1,7
M,'FGJ\'=LQ9VM+/RM%)W?T1_O),*(T"H0*2V@?*X<1ISPV179N$&KI(HS^--
MO&+7^5A^N-VA+,H.>'4$LVV4DH=+M-8JJ_&@X@G&I,U>M!NP\O+._4@.DD%2
ME)*  I%; "8++S1<EC0)X &\C2D@2QP,ZBO0A!16H$><[!C5&X@7S/&J*%N8
MX7^J'8R;4C:S6WU.7LR6Y?;P9EQK-A7OV%3,C\.S2A:>!O5$I0G :BW, -F!
M8&*SL"@2^L@?.P9+I;HA!]#+5"DW9I"$H15VD_1C;A4_&AYY2EE&6.+="0S!
MJ!1P0HK*&Z. 0U4[8KEQU>%6B:!-+P8%!H[;,Y2E0LCECF'#U3%7NGJ@(B/=
MCFJ<3 "RG$4I[3K]-=;*;AH@Y, 8983=G\EP>ZO9!&9OO3C)[*Q;;4%C<A08
MCH#!,0%S&_O4M37B<[2-8J6*80,$+/)P9 3].T88?M$/!U+24I"J3^1:![\P
M)M/V'?](V_OJ6+W\^ZYZ!#!Z/C(6TB>8%3$YC&^]M@C#_'MAZ6S8(*HK1 BX
M[;??M_S">(QM^D+)5GV[EWS92?%8?Q9?EXT-P\2[U2\OV>O&N#VI.CG6\E1F
MW=&#6=_$!P@Y[Q+MR_1;#:-?J32,'M,1U  ;;M[MQD%& ">1XB(T\I[,=8;;
M)1NXD3I1KXV>O;G70)_G_E<QHSJ:-KQZG;L=.>"X4"9J*/(;T(D<L]U56=\+
MNRBXZ_0\AG\--G0>TYT&0.EIN^W&47P"P+WBN+WV9 ZPAG!+DL>$K:OMWEV#
MJ U*BDQ\E,XM68/@-_SZ "-C'<\&S$0'QZE<LQ+CC&1A+"R.T)H$'!S@B 3=
MN]<MS&@V8?C.U0^1[#CM6'-!PG%TH$998$B"\(536U\X=>T+IYY]X71NOM"&
MJ-,73GWX@E,X.GSA5,$7M&Y(VW?[;J1GF5^W1905W*1.X4.<INP)+)9K-78]
M%*LV>$Y[WWEJJ*:@\A/>82T,UU5J<N>\LYW?=G86'>S<F'F5*LOO?*,L.V I
M%ENT3PO9LS4=-S @;@Z4-K, (M>8[F..-+)6\NQ0Y>Y9<:_2=#A_P 3H>#PY
MK0];S5S#M)QA^=N\I@E?MQ\ZG_7&@:K+RT*;%3NR]6G%TD_P"_V+5E:I&7UW
M<*KP\U K'-,E[D<R\*O3DZP^W5H)F\=6"5Q:LY)\+RYIK%!>T*=.__W-=V_!
M-DZ2P2JJ4SFTEO7T.+DZ:G.TE,Y@0$\WF0RM-[NL9#"6@_U9O2"*]*&,VM!9
M;-+R>@OB9H]KC)AY>793H\F>'O*77'W/OE(,)_U[".\3[6P"6<,Q._S'C?=J
M"[FP-680]_CZ2"7P*8[?WW,\:37TYFN\LL [Y0@N QY,Z_"F'L6R/0K,:_0[
M<HUWT'KWY%J$;:Y7-1CYN"]OLB>FJ1:M:)E.ZZ8-X]VUFQ@*LL)I5D:1R.TA
MIUY>A6ERVE,55F#LK2/79#4EQO4#9]/V9/HR-I'!D7MZ#NOX ,/[B44 1Q1]
M"]$P(KGQR<(H1PGCGQWX."KPZH &APFZ%)WC-^JVL<\'PSK%US\:,-'S/- <
M=D>-'>SH$R++8<KQ=+[<"/E,=05!5Q.E B,_T7>0L:\GQSE?3O:M(>.T0%5C
M!/J;_0[_&*=8LB@!NSU>1ZXP$?REWHNA )Q?TYP4)VA%]&9M.JH3NF!6>.4M
M9A_>*A29'7^J'R.V*'/R-)D\H^@RHR6&RS"CA>.\K4AYJ3*?2$,C(_W;<D</
M)3Y\A=DJSO6Z-!D0]S/C2)EYJ /$25>[#H!V 1W:FF.MN*KH4?/L<%5=/; /
M<!E )408;LSBCB\_[J7N*:1/[<DSFLUM77I0X?.#6'FF#L.K%^O_N\\+<CF<
MWZ&.JB)4X/L("T>J#< TIY<(-R15)H\+O-;)GN(59*.[@2OTD%(J-'CIQ #_
MLM@47/$KFX?';L2^7E%Q:/NE4IXPPLIH=H?&QO"YVQ@/<(*PY *QITQ0+3(0
M90:5T(!+709(06ZV K)/M9FHF+SHCX0NF07H-75=,M[-#?-4 U2>[6H9^,3'
MI'#RVC/LID!X WZ/9$VG'K TICVG@G@'^R$M$^4^E%U@%1Z2!?6THW\@3A)
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MKR;4S6U7GYN'['9BPAMJPL1D *J,.ZJX_QB&$5M C^R5/C^8>;C"[%F@*@4
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MY4"V);%Z,3L^D$E%&5NDK>;@<4R.("1IT10LQA#4'.U[S'MO ME8^C22VLL
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MA,C:4WB06DH(B(C@+$I6^Z3:R89:3=BC"4JCDEMPGY^YR1+L! %[[*T6LB,
M!A'H+O;%/H,?XS3>[K>D,7B4\)2;_ )ERQW,(E(&YPI&N9O]D!5#%_9E(8#?
M!1(3#'#) !6@S'_*P3Y=8\OYA-)79Q&.(@F=*RMIV:>#VTNYL"YIV+(&\5E8
MDB0XM8R(255;$2G-T#8:FW67]+'$)_+6$^OG=)_'*<S)]I,^C")E:6!>)O=?
MX;]=%G";JSZ-T"9KEN>NR<;+LP<F PD*]UP*NDFZI\_+\&]W@B0!/'0P!1Q9
M:/RU+[NDWN#6)CE)G_9(6?QFBV8@:]FAH.F9 -KHHL+0Q#-%R9YNP=G#55JD
MJQ:!%[0;J&(7XH@3'X/ULQ+?W^=X-Q%E!U(Q:;FA]_Z+K['2K*A Q&*=TT74
MPRHX8BO@D#J&#.*"E%45+ ;E^K'BPLIV+<O$^5\(J]$]HA[IIVB+?[S+HC2/
M5L1)S]$VBE,MUU"@9H'/(/67X2SJD"%]Y84/3R(@4SD/X4C^)? $OS"NHY?(
MNEY^A-M[F.EXCO EBRI%)1$?S4MC>O1[O;]/XA76] :2&AQA>,2QQE&G4H+1
M+C?C2W -EN 71MGR*. ")0GZLDP92"5&ZL8X3,-L#=Y'T\LNBC%\A6/ CMDK
MXCP#V#(I@814%1<J((W>K14:6M$CB'$DXA!(^:'6$/0]U]U.!OYS3VI,/Y%R
M+WB )OL8*0F[%;2$I(_<[9(1H)P"*F<\A Q25%>@*"0] $RTA3D>KL'.I9N(
M4R"\[5-FY1 ]VY1^E06+1;];3+,1:0U9?U/20< 9"+X6'&T4@O2#[AU+CY:"
M5'V7[0\OC4*^)#0_QR>" "K)3(=N=*"O-&I)G,O+0)?#U7</Z.GU&L8LQN$?
MVJ$-_^H?'](B+@[DV4.V0QGE3DH@+3>-7RGM=S6H&6RTE*F[-UC&%\0B%[#&
MG"?>_^K#A_05&3Y420.E!@-6LAM[5^.W=N="GTDVTY<L)A;"ZJO<H6LL\V.4
MP\5Z'9/?1 E[9:UZ3J1'T^R80H>'EW,D40" 6&&C H$=EP%$E1 @IU($<+YD
M!#8R57A_8HC[.ZH]65'PJD8YZP1YF0J'_J:W5<-TW5R,#/'QL':A+,D=%C-1
M$-?],W.4A/((Q 3CCNLM-1W/"4_YE1<#MBRI535&O4S%6S#K%>CX05BT7NT(
M/,/Q)I*A\BIZ=PB4O$'-G ,^7:K =1:O8/D&P##DMF@X<<<&30\O8)J726!'
MV 47/^7@R&.E1&&A B&-@92/RJLB7]T=5A"N<_($A01?\E1@N6%EJJA\.JZA
M0,RJ3T _<0_K#EA@!V%L 3%6NO @C,E:9,5J>>7AI-6H@XFT]1H\<-RY2F[L
M457)C[B;6'O-;C-Z%N6/BW1-_D-Z1SQA?TZ+O.Q8Q0K=J&Y"U6B9;3Y5:'O9
M=!*.]*"-_B#PKMMZ,>[3[S6UL$2Z>C5X=,!K>N%9*'Y(XTV\(FU1ZN;VI(]\
M#/,KW<<PVF0-FS[HL?'3 X1712-3;"T%J,4 I1P:!]VC]/\PA!Y9Z-Z;A6H]
MB]$BZ=,R_3V+T;%*E6<4X1BD]&V,MKIG@JJL_*(K2$,<;^)^J%XV,J2[^&6:
M%QGU.=U$,MFW[5JL-ZFYMSW:3;UF$L8&I <$-*R>\!2>2'4]38Y8<XSDL8!^
MBE@W#5>ZKVEZ-_D3^F(B1,.7@--I_FV%A0I$ARO01RO:R6'29>45BM+%0P;A
M5BO3J_.K9@L*"2DORT'"!U2,%!.-QECS]<& !G04F,K%X-'4M_4ZS)O,B4S<
MJ5+TSS*XCHN+B-1B+0ZZBRK9M\W#VS$U]T;">("221AS2P\(:%@]X2D\D>IZ
MFD55<XSZ"RKY]UWIW-=":@9FWKU\ZE91B&KO,G8G*Z9K3 YOQ/].>HYDZ6F4
M_JJW;.K^OME$WD7/RP**,P.<&R#L LA=&\0$J>@J1/TWT@@DRK=>4_D5/^F6
MW%V:_R37'Z9'DE<.D_PG&;C!V:3+,8]WO=J8O,F5*LE\7)$?8,48;,NKU9W"
MU6I0PTN$D=G=&GM9)-;-O(A@.LO#]C?-5RA-2NZM2FA81NPJC"5AA^)1OUK"
M4G)RI-^S7OUZ+M][G2$<'K#[)B1 IVOB93NRJE*^KM6GZ:)T:C\/CW5VZ2,Q
MQAM0YC1"5>S#N*LUQEE:*U=%UW/!-'$-IZ\L3+DF3@\F93&4R%DE] V1]W%^
MFSZ\NHJ?:-N']"$F%8AIDY@P/$\'062@RAF@56ZP^MSK]#!AE8WN>&-4;T.)
MG ?<?-;@F*N7]5?D4%;E#-!2\3*SBAWR2]GHGKS?1=FA(J]Y-=M-P/"VL(N@
MGVO:BAO=:E-V 9PR#L."E+05) 2-@%3KO^)E?WGK5_ZD6_2I+G(O]ED:DU(8
M.%!<Q%_)3[E^,9T^*N:ALYNJASI^)2]6D[YD%\;LI@ 24E=;N( D+2SH[%4R
MFBS5@;9?@IG!-#=(PN)B4D[2PZDR9Z0:94>[%1Z !2GJ*E (DB[M3^4&M,//
M(TK6E]M=AIYH]I'!3-%+QAR+'K(>EAXE,R!R"\,M5&!"&GH+&)*D#XVIW*1S
MNW>E\RY/AYJ'K>F5OVOH_C/6JU >W1G J7*L<-7[Q"Y Z%0.%8RKXWGTML\Y
MW.R3JWBC=7.E1,X#:#5Y?PYW G84.[*[J0XL3L">L@8)YAVXQTD@57&YMFYG
M )^*TS&>X*H7MW%][D->Q-NH@.M2'T]J%?<,"7L 4L;H-X\T US%-[OU/2MP
M5?RUXEY[[M/H5:[HA0U>)4=Q1H0Z>XRR!ST?[:)@CI><HH<F/Q4+L&(\PO"N
M 4R0FJ;"U#]W#,H"" "<#0'@Q?K+>H95U^);^$#WBCH.T$/$'(-.HCXK9J*J
M>7/.N(7A#\,H(67%!8M(T@!CN1$Z:9>,[&YG;_>K%<SS"PBOHUBYY%3[6Z:5
M-T0JGDJF4!9@ R' 464=P,5KA\91MT["T6[SG4!3M0X> +@7.&G*BFF#ZUY9
MO15>N(4KDH >PWSQ%,4)R1&\0!DIY*B=-ZM$SJX*P !Y3Y49:JZ@8@LP7]8C
M-J@\61U(D8%N9P!?X@XY/QD+<1JEJSA*S(OZ=)*PN!J7D_20J% R"J[&SQ P
M2%%;@8*0=.M_FJQ56@A]@TUCD:YO8?84K_#Z<;F1*"$G>7^Y_$_ZZ:UN^9JC
M[5*.<?PTD",'+X:#? +SG(R$QY%*,'I06(E&-H-2TZ&YNWGWGR?JPT=J)\.,
M2',=X3VL46Z4C(!56LXQ02]Y49P-H'S"<.U^.)"2EH)4?2+7^F1)@3 KZ'/R
M@H2,<[A#>6R2&-A'Q@*';K(>'$%@1LX5.;M _$$!)Z2AN( Q221P+"LXILN>
M97W>8'/_:C)/]!*R"5H]A'W,&YP=:.VP W$8);R0EOJ"QB89@&4JQZE?0[?/
M>FK9KDQR"C4)NWC/K<#([T-]R>&5B/!5:&F'9N!+W^PKZWY60"=^,/:3==%2
M2NLD=XOPA/TON#Y#>4';#VOE8VC3ML@4T.3ER*51$27<I2L>@# )PU6-T46V
MFIT;DMQG)7YZ=-?0P)DUY0[+:5>K_7:?D'RNGS*4YY_3#$8)D?BG*$Y/X09E
M\"[ZZM"351EZ,PHU 7PTR2P9 <(ID&6R6_-0#P4Z*#P+4] (&K58@,H%6J8#
MF&@ RS:38'*%_S5J,&DQ'-^"&@)86M /S()2^$ 8'8<3PBN4;;=;"W$03R1
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M9N):%O:!J:T^BZ(6_H0)(H3+A?.ZEK@_LK? 0H%W^_.S.NB#\MG;FL_U@RQ
MZA;'D)ZI7.,_P0S+=5N@U:_\Q*;>DVDVF5&E9G:.H4;=RPE$Q1I0WH S!P+W
M $X*-,%$^FH-'S@QXBN@9GWE/^;8$N5A.6H[)3NFT8L(?13,C*F;HA?/OPWU
M6% !&Z2FL3!Q:*0W<A P,\'*K7W7]Q"2/NFG*N[S,\P+O/30/0)H?,U\+2>0
M<6\FG'@8:WF9GE&/(@+2:=)0YS1;<<Y<?]O<^J*U6GUM1T,TUNY-HD0906FV
M;;).-D?B!?8RA7HKGXXOFTVV4F)>UCMWC4P)E(:0QMR/ QI447 Z;]3(X@JG
M?,"E]:+&H]B)3&+RF'.BI4R=CJ9?HO/XNRX2[WP9B9!X=YGF148]-HRIHQ,$
M:;JCFVJ<?A1^G.0X=8UY^P//JSB%EP7<FEWW.>4?Q %P)<]<<A6(P(!*_/P2
M%HZ-T\^U1 OTYVB(7I,7E&QPM#Z]*OEG>1.+ZNY$NQR0)P'<-HJU%LB-#>[P
MQ(G6MT64%3PDGD9X0"OX^]]]_^[MN[_^1Y3NH^Q ZBWBC=8/@84S+Q8VT$[8
M$7#/TIJ.(YKX_(H(*0E=>2MVY4?AKKY&G:+,B)M\VFH,M[ H$M:O>8R@IB+%
M^+8X+)6'"XF*^+RCF(9=.0AEJD@]7QMR$M1Z8IH@\+PCVT]1G%ZA/+],5\E^
M#=>7Z8<H2_''I@QT?4(%8[/=0GIHV_B(1T>>W0AO:9YE0%0P1W_Q<0C1%V-Z
MOJ,GD1^0 8!R!/@'4([!77606;S5_8'I/(4/40'7W.';S,G#N=8%QF7]M/:%
M:<RKE1YI?MG6/*FB>(? !WO5SV!WR,X:/J2E839/&L[ABA[<@_=*9PW/\@VM
M.$]?:KQX?8&J\N.QI=(%LMAG=5/95/(4EAL<%4AENC.TQ9+!C,2 '1%>+V5A
MF([93?H072^)#(PI;2J^XFSIM$3Y!I#4H P:TE%BR ")$4E I^0)*J;6(6B<
M\22-H2RD0YGJ"OD,T32!%?&%R_0Z0P]XA :=3/OIF.\\^NAZV*<*W,ANE9;5
M#.71EQ)42$=U(<.22!"YI(A05E/Y"^:/EY3%X1KKJ,"N7#GP3QG>#^IXS! E
MJU*T/91]/)]A_&B4KJ9.OL2."CRMYH$<?RNBA_1T&39220LDRHO.0O7D0]F-
M74E_A9=A^X0<&IS#7097;'F,?TX@^0%+N-BBK(C_17_?J2H=GW/'TZ+ NR,9
M?!S;7)'(&M4"@K4@(77O2! M#)]V;D?(%U:SMYE6TP#!3D2I0"46C3*B8* O
M"CDYBNH<^B?HJCROT-NB=^9+H6T[S=4JV\,U60+M$_)<X19F3W@+D9_MLTPQ
M\JG1,6SB-T#73Y,^QA0O*DJN(.=LP8KQ#6#3K@P=TE&E22-)1O@&YA"+_H@]
MXISTK4744#]\W<$T-[4G19I6MJ7$PZN=95P"ZN+K6@8 N1#A69T>V,A4X>;6
M>!&M6&D-O#$P-#XY"2M;DY'T:EH;SI!ND *THUZ8D*+NQJC3^&&[2] !PAM(
M5R-"1K.&<6D0,U_(#1+WL#N/#OAW"8U?]S"%F[@OYV?,E;LZ;$A;@\%#Q!?1
M)3? V372\3E#^]Y_HRS4V@>IK=793$91;VYHC!8&4K(;AL77>0F1"&\Y-GB7
MCB>2*+F 1A%NB)+5/K6'LH<ZC? A2A0M;,3S"!6<D)[6PL:DY30B+W*![3R2
MC;@M$,WMIF,O,,-AM1"K1D9.9 3>H&3N&D%_B^WF4TMQA1V^["U4*O$I)R<0
MM**"L-K R"^+1Y@)OQJ]&:R7B?,J3N%R<Y;!=5R4&M4NQ]Y#Q#PT=Q+U4=$X
MI6E%C%EM64'5.!]&"BDK+UA4$DM E K2P&Q[A2+-&GSM;QF60VE0\5-[!K,
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MXGCI,E7)"OC)"I86$'%!4]X3P"0&<2H^_T4;4(G-+\JYX$"0?/I>4KX-%(V
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M1+<$ZGI5-+J3#>D(J9"DER/1W6+@'JBBT0'3].GJW;T0%>@V7CSSJU'[WW7
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M6Q7UP. Q6OCN!+ P5 R5NJ611SDJGPT5OK6A8PP=H^5P62 @@\9H&5P?VLE
M,EH2;P?L,E ,%<3E@=8Y+%\,E<35@?(,&D/%\'ZB X/$4/&[DY7"\#!4TI;G
M$#%8#)6UE_6)8#D^7PT5NI?E>7T,%T,E;EUN)@/'4-E[N9]@RS Q5/X"<J49
M5@J$\K]^W(/JAOQ 7FY_8ONG,S_'M+Z%ZR03MSQ:/H$H_BC*HS;K,OOYJ?28
MU\_!9&,PXB86<6:%S\GBQ>'[N64MTX!$Y$7AYB>[D8G9C_^X<:UGUR,*,@HG
MOI,\/5^P1[94>/F/F.PBGH!%?EK-X97M9]1N#GUQ?8\BRR6ZQ*45^$03#2<V
MD0 QK:GA7*"9:[M<H:,0:BIF51AW&KV@@#[; _2"R)-LA:AL6Z ;'(:W*)K.
M'JTWR!3!I)7,UW'<5-;>6:YS[9];2S>RN)+C&TFHX+]@@/K=\F*N(.KJ;U5P
M?+>YT<28+OV\'RD%"1'GH:)JO[A1HJD0B4\N,NI8(PH*N0&@6Z>2C(IY%&XN
MP0M/#9\7V6Z]IVH#^:\;W6+?YD]RYJ.C&'% DG;=UXKNLR FVO.6HI-</X([
MB).@HKG12+_PSEI;SQX26)4J"OWL)Q%Y6D=%\2Q*->B6<VJ@J627A>'>\ZMA
M5V5?U'.W]Q D/R!J,)F::Q,5\=P*7S8G*R4($YP0:FK4'KQ$0;2^(\_%I"(<
M6<HEO4")O@O3?^KHJ-L0(M)F^T-%RN:2*.67;TORS$#;.T!@!ESDE*S!RG(]
M*K*O</!@>2@S_Q.)<8&>(_8WD56"DE:BMJ;GE_Z';O@5X8NJGM&Y%01KHGK"
MWSY\!)6?)Y'[HH* .M[%F5;+;6[ NW%]=$W^"+K6RKY6\V3S5T3BN^1(;C]^
M?R+> A/<I)3,Q[/"<#I+QKW "\OE*OA2][72O5-D8/+FBFVA?2)*Y_!(Y;L0
MX]F72KF=SO+"TG<X#0T1,[WPT.O-Q20T;5R]1+HG-C5LZC)D]D\= ^G4#) J
MI1>N%[&Z)SQQ7$X8<(_JG@ E</@*6I/N&5 <^B:NUH19IL*QUNA4O!WVD-E[
MV#" OAL 4-7#$(,?LRSR^NN(FY"I@\53FG T.1#D,H@QU#Z/J)480AD^\N49
MCBQO6/C4;Z<ZXS8+G--;6:_&">+48&B9(.V;CUL!D6_RI?>0SAF?VLGO962X
MZ2V_P;[<<C2K]=7O>LLM#H]^\516Q![D:/W06\<"H\43=L+ ,^:H<H!7%GS$
MD-);Z6HCU.J#SC8(GAP;(];:7 M%P.1K9+ILN=K TAS $V.N!C" /(K<R8G>
MMP,,L=*(\APJ[1U#T-.YG3&0XZ2YL1J&4V5*"(-K/($M,H,8C'I[ & P\N20
MY<A]'N5:?0XA0VK4UCC4VXK\T1S%#CPF>R@.(-GY+L'[!46NS;((VV4^EY(<
M=!KT-L=JLR"%>K7RT5&<SYERD)0JX>K<VDBB%_XG<?1"#OQ?+>=0)*-X'F0W
M3X-DTSN)TGN'@H0GP?E4DU.??=MFB9HHJ9^-C(7BI3@&P XN )9WZ71O>247
MQ_V#K7LKJ+;X<<EZW3LC202Q9@=JVB1(.G@;#5#WECG2@2LOYZLBHZ*?MVS^
MPW ZFRY1VE0H]<043'+4&"?\MH4/,;2W+F &:EXJN\92D>I,M614:+M5EM\G
M/T"61P7_?V"/'L3?+->GX$Y]%J$["=R0_-,%^:L_3VN4BX#0'0]](EBTG=_1
M5AI$"$91X#['$8V\><2IO4;D22%M2$5O^JHM+C)W+G(JYO4WY,Y?B%R:K(@L
MFF==9*:SY 8K7&!G5NC:1$I=N%X<P=[ZHB.HF/W&V['1K5M,LY&4BOF0/<3.
M$(3[G0^529Q;<E^FMZ _3QG(T@' @J2&DD MF?.D$'9X[3_$MHW"\ JAZ;/G
MSI/KFH<W#B)MV+JRW"!Y%4YGVT]N6@'??BF,P]?X7IBVBIV2-"M"890M:++<
MD/U1_KU*SM,-*<SXUN?]GTWARYZ#HI+9;?, E96EGROE.T--C&OVL0J>?T,^
M&=<C%^'$6;A^TJ^9=AT3$/.-I-14[@V1%=@T=^8"K9"'DQ0C@=DT$.IE/PD=
M[&HB:B0L/8/YJUID!I4D>C=%-4T.<RT#,]SI';;3O)TQ]_%CYCJ]0Q-!F#4*
M8(::WA&*(-1*+EZ&D][Y(R+RJZA4L6(-\B77H>+$J4<SZ/3.X 6^5'##XXJ5
MN=!<@K6&;?LQS7"3)]%^I+CY:$X=)X>+G+AQA15WD"?_M$2UW,#&X),G W6!
MC]=VRBI!Z%WW ' %[]C*&4+RKXP#1:C1%\(PTSL'!X"9J)N,%=C0^W4/@)++
MN<IPTUM!ACBN.83<=[WU8D&TI(4R,)SU%HRRPTTXUJ)]' XK^S&*#)C8+=:O
MT#:7KQC:=X\<A!9);:*J<K^E28\[W1];!4A*XF'($91MIZ@B$:=-3N'>QW]X
M[K%WJL:U]H@6M!=QL$XQVQ2$G2QHZ:TRJ0R9&9AXCS-OM81-M%3.2W:S7)6\
M'UQHFZ'AR*5Q:\G621-)BC33P\"*DJ;%8<A?^4(O12FKZ0W\WW&8UJ)ZQ!4E
M71(FGZT0)<'_9)&2F_0>D;,5NA%Z0,'*M5$ZH7MDX[F?4 'WJ^J>%V7"JVJE
MDW^<)@ID>/F& ML-8>&[(M1[G'6">U>3KB/>^TJGBEY(V)K."DH?DUW25IUC
MI+YW@ HP> ?J?6?<HM?DG^3M@ +%OE=:YN1V"0KU6K5ILQN7/*-29R71#3:*
M+M'84;"P?!I/5=!Y>6]T(=)J0C\!C,%"04&$1?0O%$5>EM2:.9KOJ;MAZG,I
M$HTD!%C:?1=).]DMB/?QMI1]YL7HZ_:J-M%"HNB2DFK/.DR[Q]AQEJ.L4M(-
M[PS>9[:"@'K>)VUYGZCDG<,4#I\/@.C8_5?G[K^[Y6%%ME(Y!27&N.8:P? )
M 8BJ,3B6VO4$YE5/2'$!19$^Y7L?JR\GV.+J4,YYIE^2[8OI,Q,N6"L(*)6M
M.SR$PO*UG-#88;VFP"1'W6=8A<DZ@KU'Q\ FSM-D_5COR$U G^?RP\> ,J1D
M7ZTPPXV"E^&E=YQ:_<55695TK\_ZL=ZQEMPPE6A.IN2.<V/4H!TSO,:C!WTE
M,>S&\UC[9#:E. % <=BWBFPK#:?Z@U1I7<+U)C"6NJNWB*\Q'FZ=.6Z+IRFY
MXGS 59B^NTAAU@6DLWV0]-Y) (%>\%IUF6 [2'1NZEJOUS7*.OXJO:O",HV4
MB*P@.C"<:FJP?Y->@_U@81*(,F YBM(; >@"8]WF^RZ]:8<VJ/'%*K%40D/:
MGY1BV"+,C;5R-J2)426 M4&-K%&L/)B&63Z&[[0"PU19]TY#K/:5NTPHHIG!
M9TBGK&:M%W U?!M!X\]MR%'[;O)]P+/5.-)@-F">GIBLG7!M00B:I^.!%LK7
MRP'\:O(MS+4=&Q$<#[2*7.(<[^\F'WG1W/8->I^.#>G26+M;NZ\%]>E4NE0@
M]^ S/C2D*^K%??HRJI1UE5-RG+Y)OYY3J^"E?V!6!MYZ.0RYCGP>AXX<?TDE
M!F5'!OV#@Y)CUW5DQ=^%ZN!+V:5;[05%KDTQ2;'NLZY=*4,:%[G;GF^+VDV6
M;Q,.PH@["[_LRS%Q5J>DIS%U:!BI0V/2-33INJ),2D#??5)3J<7HCMG4.F=3
MCYE^8Z:?UM:0]@'[!H#4.F!?\_2^^I!JL7O5E)P_.3'[)WKG%\F)V=<\,U)R
M]K8!B5BRLK?'%%*.M&2]Q7C+A!E3\D-+;?E5%DB&C@+79/_F^W,K?+GR\&N.
M32O;^QZU(1O.&;-M*N:&$DKFEM%08U-F$7;I.R-Q!F9J,G).8#;F1F(2*DDW
M]L6]<:UGUR/G5:CFLO0AE2QCMI%OL6^3/UX3P$/:JW7B.U>N3YBE?[8C=Y7$
MK5RXH>WA, [V&[_RK'+KL00V 1V4AI!=X6#37YJ,EP:4/%IO_(6?.0@I,9G%
MRV5Z\BUO ^BU/\-D[R3WHXC1C)>DJ@U)_Y\>@I7E40G'XM'H/Q#0MW]0^$VR
M&EY,G>ID\RQQ:'F_!3A>)CU-0QO[9+/%R)FF_8B3-MBPS:N*+Y7-CT:\?55>
MV#8S2H,$R;P"9(7H J7_S>=Y^68G#<OOB8IR.9LAN&!6R9FBIEZ)Q [PRB7:
MX-GZ*42$RY*+!H(4A*H:#R>V$7+"*_)Z:=VSAX.8FH+ 2VN=J;87Z!FTD_>_
M5;T*FR?A=':#_?DCT>F@<^"AUM^L*NW@[:=80UI \;O+-@+1UXJYN ^Q;:,P
MO$(%)9Q7!021[&N)KFG*@^7=Q807>THD;@#LI  @.BQ!+J+[BE#O<=;LS23S
M^BJEJF3_9@?J$4]LHE$$Z*<5_(F22&*Q1F.<!'N9&T&=:)S1^LZS?/ITI#K4
MDOY*JPG64!W6/I5X.FNI]SCK[$4A^7264E4QRWV=?F+;U"X7DEU(CQ39;DD:
M5,[AQIH%G'C+@?K!@J@H2\MU+C)%Y?*-IB/FG$["$/&%,[<=H9_9YRN1)6:*
MG&X(51'+7_+N#*_]-BI? Y$V;%U9;I DIC8:B?EME$*T!28Q66"BJ/^5V@=M
MLGRYL7OAQHO$RD*.[]07O<_;CZ&D,4J!P_2]N>$J8Q)R&CB(J9C3!5H&R'83
M-LB?O01U(G.*[$&FQ4=/67NYL]W<<9"AO(*"\J[?-+6=/$\\M)4;^X@YU0<1
M8=W-^(H>R3,W2I.'0:_@_*MAJ902%>G>UZ9PX6<.]0ORIK&CGRAZP8[(3'DI
M]AYB IPZ;K>82D-3>D2UQ3'"Y8>?(:=WD18YR'5S3>1K\$GO /Y.+_G=)/02
M18;5G==;2JC"F4_Y9:CK799(%>H<+RD&N=Y"O6O(V[_368."4;2W70DQ\P];
M ;WK>BE=@7)S(>NF,-ZO,B0]Q(+<82>+06$O8*NO193/"\$:8,@3X\.L:"X;
M7Y"KB\&LMZR6\QB%.%19$PWYHAF333$49*6;G6J=\0Q5O85NBS"(HMD)$-R1
M(_M#=X';$;8-SY$?\@2LSK!"(LI8=YU1Q(+0K(U&9*@:*6)YXD"W+?N\P:VL
MEY'>EHEVP(+CHAFLADI8"3NV-E8^!]A,5Y\4>+>S+1BBHXAM1G0_!X?A)\_:
M;LJ1;V@=<J*Y1U0.H)"T/8:L?!.+'EJJZG31?$4Z\$J/*P)/EF;K84)/Z,-8
ME=TN B?R'=N#:[@@OC+<%2^,Z30*K"J"N6NBY AJ[O)L)R;:E<5A&.O]/I%6
MK*BB>VZK:DVL0:S>HD+F(N0TF^M_,7CU]GS*WN/UE>*4]N?MO&(A0^/6BLC_
M3F=G<>CZ* P)>F=6Z(;)"<]'WV!55[=0E&:/U0O!+"M(]-AP<(%".W"761QL
M"3./!($S#UA/1(2ZDJ2M-+:#-GG$GFN+IE[54.E=7G%,$;=;*%;E62\9]1 O
M%E:P)C>>._<3'<2/]M&$R2@8S4'(*$Z6522(UC$@))=X*8ZRJ =9Q+LXNLJ?
ML@ 8JF5N8L=_(HO^6J(ZPJ20".5!R"(0X_"J"1#R('G3@KA \0?(2! 9(TZ[
M-\G3&@[<:O%T%4V;N,>R*EE\(JB.PB!$32F#:JHAE(>4,M:$5!T8745U'\HY
M$M%[.(CUKO[P3QB+KINN H?F+<9Y<DNX2<(XCP,*>DE9,SXI!"8["-'$S[6Z
M9TN>'I/R5F!BPU[A1VPJ&<]"$DWVR(J*3E)>*6L)OY8G],JK)=._G..8).YN
M'765@316+W<QP.1<Z:>#D&7;G"FIG_;<5I6J)*&F_EMQ<!'A446A=[G1,#7,
ML0*ZGOW&JNY\<H"S.'S/,J&:2Y4]Z=,( [&G5@4)%?)!O#?WX)IP-W?;KD1:
M5SFPW>V,[]"7=4CK^81G+*GP&>UU;[_%$6JI  "(CD=>\I$'8*^K$$@@J"R4
MR^F(KJ4Q""%1P:(*'3OG@2;RL;'OD4>3F9)NLJQ$7YZY+O26:#N4DC<'+Y//
M12:%WB8M1^I=@$F""DO<(;J*P9(>H7RRK[*Y:,\"K\B7FJ81Z7 MM:%Z.HK:
M7^QR(-COHII,[Y*%9Y*8=U5TE0FW**D*?8>"1"0" XC+/QZ$;-CE3<6SP@I\
MUY_G8PH)AQHB2IY&.\,+/9(J:?0N$QJGA[E60E=I0-2EA9N6N9SX1%-*(@B1
M#P_;Y2 T""E1QZ>"TU88OJ5.T41)23_H:C#;Z1E PKU+&3$@,/]JZBI_'N+G
M$/TCIDF(*WB4;M77@Y T>\RIL.7NC"EFNZTFHJ3)U<[P(O*CFD;OHJ)Q>IAK
M)?05"#RY-%VF%AUPBI'*5*-;]%I@("!<Q[Z=AG<G;*S3_Q620'#:BK0=LN(O
MR _=56:):CU3?IH"60YEU0L%>.4FI6H1RNR[+=> BZ22VZ_4>7>/'(06UEZX
M!RWWEVV8]MY9KD'Z,$FT6-M&4BKF4Y8#TUIR (@J-3"WF%(U#0'A=T?.,:V_
M(28;FB@(,'1/E 6B)M*263\M/YX1G2^F97KI:Y$J@,E A8!@0:Y;#Z-BMQ28
MO$ KY.$D7R,+UX?+,RYR2J0WFM.1[]&2-I3*%+,VIYR3H)(3OE@2D9/410XV
M%=W2,K,W1'=QTC8J;4Z_$/U>T[!:S):?IIJ0Z?2^/R=WY!RU6<4F2BIF4Y:*
M"A<J=524:+II><6F\HN[Q4G!\VPW3G](M-'X^0BJ><^0ERV]F9/7AQO^>4X.
MCQO1/\'>,#5D5,SC*433V648N0NB-8':E.]^.582Z:&2R.XB*#4O'@Q*M:>,
M0:9W]40@9'RBEH&G=_U/&>#Q7LT,4[WK3<(PK5/K&&*:]U0&(=:DTN>HG8QW
MA<@#C^$W7AQMS0$,R_$> 5N1&'CCA0$T+C+HQIM#DATZAU3S)F#\D-8Y)!A:
MXR7"XU%B>(T7A9!3D0$X7A8 ?S.#;;PHI 0DY(!^&J\)@9@6!M]X;P!"G1AL
MX_4A$LW&\!MOCS9QCPQ'!=?)X,* 'Y,B>ET$ 6]3/J 0X(QQ@6!1^P4YL8=H
M$XL*R]7&/^0\A6@6>]0.DXX'#R>5,]CH*E1]-\I9-UV3%T UT 5DESC]04@P
M ?951N<6BJ=FG#A3HCP33JG=*NGP\^3CYQ %*\K<M;^,(_+/V+?)5^*=G[H9
M7TW,+^WLEBS7>=:%D':FWECX8LO[2;MWD7-]000"_*:0,X[2"._4+5&U?.WV
M!S=M5456"Z=X9;D>Q?T*!P^6UV*M873'UA]M[G\9K3_$UDWW\"*9R,+/O^Z1
M2#+1;7>WZ!ZVU,D^EJKG* URZKE_D,B3H9G.()X&-6SVF> A-[5C*&DK8_<@
MGC@M ^P5W&UR1"2/(/%!B",H[VW,K;"Q6IA:A0<:V_ZH;?LC:=ETE5KE5:^%
M?$$<E 8ACVH959'7G._&2X(#7B/R%@A6KHU86>4B8Q,O.:7D3],9U=SGOOL7
M<NX0V7]I&()8+G1W3*B0<+<X>6HBA^5O),N:<!].[,A=D;,I;CD3HZ\D*SY?
MN"H>GWPWD@!!RX'48E&^:Q,NIXE8E@J(^&A]H9+5:9^\6H%3Y)/:$-(#'H;Q
M(OV97(3:C#PV&QB$:5LR5+B[#:.[*5SM2D"%F^ZF<A7H"]VUNEO.NP->3,\S
M)1FXRXTN_=FA--^XG[XS(L_RRL\'\1;?YTZI@KS)QB8,I [AB>^T,A*V'D+M
M ^%R-D-4QK%UN+=HJLB6?U """+CC)U\^NGDTV[53-' A4$%R@.E.G5_G9-$
M;K9:$H.XW<HY5"KA)W[D.JX7TV/,0DXNWVPO)M.\(GN:ZEMQE"E94IHP=3&Z
MXGMQAQ$:1V/3F@5T+O3L2K@284.,W:M:BVQ(]RKA=3+E_A,#4YX\T/5>K&E^
M)')'<I,;Q'W9S*W26^ JCFBBC>N[BWAQ3S'P-C:.*QQ,EXC6+O3G-\@*Y;P5
M6PTX]BA3*/Y:]RB3M.BZAJ7<TCAQ LY9'+H^"BG(22PSS94L++;CN.GDKOT9
M#A;)#R]09+D>]"TA;;Q!"%()TU$34VLCY(3TWJ=E2"S?3@W-B\S?!(RI;2*F
MY UA)3XT.N!=X-JHO+MOPX5024,@1>N)[*K@E8@$<IQ3_]TCOHL#^X6($[8!
M4G\';Q@DC*9BV&_CQ3,*,C]FF)2W<:[]Q\#R0R*+"6>"2\%!MWFFX6:J(;(_
MS/'JHX/<=);D#[N3(S_ZXY+<+-&:6IN")4YK)=/<F>ELZT=<"P>@)K#/^$0.
MD7OH.D(+[JT&)MM#5\6?B.X,T+8J)] #[X^$VPN\L%S8L:@FTM,<)F\NJ%!^
M)0F!K7^%/0^_3OV[^-ES[>F,*%E$8>/?%<TT5.GVV54)W] E'RNQ6"7ES:C-
M /MD%>$;N8* FN9T1/(F13ZV>0C!6[F>D!(_VMT4OF<*'ZE6$:P%^6/AZA:0
M@!S45(E"UW&M8%W@2$085A#I3!-(7K)RM8",Y%C(2'$A(]#J,(O%J98&<M$3
M@+F.HRDAELUB#<-D,0/NJ][ \=]RN/0J9D!]UQ(H&>>S7N':/J.GVB$(4V!Q
MH[+-ROWKN>/X'BNX]C'%*ET?:XT13'PU/YQ92==1VZC1-DHM(=MR[+-VV/%:
MD^JQVI-B7S0_H8WVPVJ\]D[EE_%4[IQ*(9LWPU//&[2-?P'#/!\,2CU;2K2$
M4LPOEH/Z]?,(:LG^!+M4&:!ZOF;E[](=1SH#<)28-0!R!%7D2'Y3H/<,KFF"
MO @D>>,-(@))PG0$ZH#EW6;N+-?9QJ.FJ-?.5TKJUV279A[>EW65!+EM:H@H
M\8'0]"76633K: OR?U104,']=N-G"->[7PJXR,I[36^*XZ;YS;S;EX^6 )-\
M1WC__F@\;D"R JS?63:E_#>:VA_X9Y8/"&FH_UY)) :Y(-WHRJ))EM$:[ILN
M_UX]YU W=-G7 HM_@RU_,@]08IN&K7OIIZHZ %S[1*[$=&1J^H0O>S4-]3.
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M=PA9754G+6>^,-'+MR6B'H0+=^4Z!.I[,DDEJ8G\S"C+E'MNGL8S9!J/9/.
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M'3-R"*>Z0F@5=LA.!-,]HO'\Y.?GV$_F&5N>.DMQ!UP?PBH5I-X0ET.(O4/
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M              "  0    !D>6XM,C R,#$R,S$N>&UL4$L! A0#%     @
M3#MD4I4.:5[M$P  ?MD  !               ( !, D! &1Y;BTR,#(P,3(S
M,2YX<V102P$"% ,4    " !,.V12.YQ/+ $.   *Q@  %
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52P4&      8 !@"$ 0  %P8"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
